<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="ELECTROCARDIOGRAPHY
Approach (a systematic approach is vital)
  Rate (? tachy or brady), rhythm (? P waves, regularity, P & QRS relationship)"><title>→ periph blood plt count ~10,000 plt for every 1 plt seen at hpf 100×</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://htlin222.github.io/garden//icon.png><link href=https://htlin222.github.io/garden/styles.547fb332ce56cdc523146ba5ede80d7f.min.css rel=stylesheet><link href=https://htlin222.github.io/garden/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://htlin222.github.io/garden/js/darkmode.f852e6b434606ed577a6f145a9173070.min.js></script>
<script src=https://htlin222.github.io/garden/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://htlin222.github.io/garden/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://htlin222.github.io/garden/",fetchData=Promise.all([fetch("https://htlin222.github.io/garden/indices/linkIndex.2304afd31ca8836ff80b295953488b50.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://htlin222.github.io/garden/indices/contentIndex.5e2aad59e9517e52af48eb3fa1cb575e.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://htlin222.github.io/garden",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://htlin222.github.io/garden",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/htlin222.github.io\/garden\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://htlin222.github.io/garden/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://htlin222.github.io/garden/>🪴 3</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>→ periph blood plt count ~10,000 plt for every 1 plt seen at hpf 100×</h1><p class=meta>Last updated
Jan 9, 2023
<a href=https://github.com/jackyzha0/quartz/tree/hugo/content/pocket%20medicine%20fullText.md rel=noopener>Edit Source</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>Table of Contents</summary><nav id=TableOfContents><ol><li><a href=#gastroesophageal-reflux-disease-gerd>GASTROESOPHAGEAL REFLUX DISEASE (GERD)</a></li></ol></nav></details></aside><p>ELECTROCARDIOGRAPHY</p><p>Approach (a systematic approach is vital)</p><ul><li><p>Rate (? tachy or brady), rhythm (? P waves, regularity, P & QRS relationship)</p></li><li><p>Intervals (PR, QRS, QT), axis (? LAD or RAD), chamber abnl (? LAA, RAA, LVH, RVH)</p></li><li><p>QRST changes (? Q waves, poor R-wave progression V1–V6, ST ↑/↓ or T-wave ∆s)</p></li></ul><p>Figure 1-1 QRS axis</p><p>Left axis deviation (LAD)</p><ul><li><p>Definition: axis beyond –30° (S >R in lead II)</p></li><li><p>Etiologies: LVH, LBBB, inferior MI, WPW</p></li><li><p>Left anterior fascicular block (LAFB): LAD (–45 to –90°) and qR in aVL and QRS &lt;120 msec and no other cause of LAD (eg, IMI)</p></li></ul><p>Right axis deviation (RAD)</p><ul><li><p>Definition: axis beyond +90° (S >R in lead I)</p></li><li><p>Etiologies: RVH, PE, COPD (usually not >+110°), septal defects, lateral MI, WPW</p></li><li><p>Left posterior fascicular block (LPFB): RAD (90–180°) and rS in I & aVL and qR in III & aVF and QRS &lt;120 msec and no other cause of RAD</p></li></ul><p>Bundle Branch Blocks (Circ 2009;119:e235)</p><p>Normal</p><p>Initial depol. left to right across septum (r in V1 & q in V6; nb, absent in LBBB) followed by LV & RV free wall, with LV dominating (nb, RV depol. later and visible in RBBB).</p><p>RBBB</p><ol><li><p>QRS ≥120 msec (110–119 msec = IVCD or “incomplete”)</p></li><li><p>rSR′ in R precordial leads (V1, V2)</p></li><li><p>Wide S wave in I and V6</p></li><li><p>± ST↓ or TWI in R precordial leads</p></li></ol><p>LBBB</p><ol><li><p>QRS ≥120 msec (110–119 msec = IVCD or “incomplete”)</p></li><li><p>Broad, slurred, monophasic R in I, aVL, V5–V6 (± RS in V5–V6 if cardiomegaly)</p></li><li><p>Absence of Q in I, V5, and V6 (may have narrow q in aVL)</p></li><li><p>Displacement of ST & Tw opposite major QRS deflection</p></li><li><p>± PRWP, LAD, Qw’s in inferior leads</p></li></ol><p>Bifascicular block: RBBB + LAFB/LPFB. “Trifascicular block”: bifascicular block + 1° AVB.</p><p>Prolonged QT interval (NEJM 2008;358:169;
<a href=https://www.torsades.org rel=noopener>www.torsades.org</a>)</p><ul><li><p>Measure QT using threshold method (start of QRS to end of Tw at isoelectric line) or tangent (QRS to where tangent of Tw downslope intersects baseline) when long tail. Use longest QT (often V2 or V3) and omit U wave (Circ 2018;138:2345).</p></li><li><p>QT varies w/ HR → corrected w/ Bazett formula: (RR in sec), overcorrects at high HR, undercorrects at low HR (nl QTc &lt;450 msec ♂, &lt;460 msec ♀)</p></li><li><p>Fridericia’s formula preferred at very high or low</p></li><li><p>QT prolongation a/w ↑ risk TdP (espec >500 msec); establish baseline QT and monitor if using QT prolonging meds, no estab guidelines for stopping Rx if QT prolongs</p></li><li><p>Etiologies:</p></li></ul><p>Antiarrhythmics: class Ia (procainamide, disopyramide), class III (amio, sotalol, dofet)</p><p>Psych drugs: antipsychotics (phenothiazines, haloperidol, atypicals), Li, ? SSRI, TCA</p><p>Antimicrobials: macrolides, quinolones, azoles, pentamidine, atazanavir</p><p>Other: antiemetics (droperidol, 5-HT3 antagonists), alfuzosin, methadone, ranolazine</p><p>Electrolyte disturbances: hypoCa (nb, hyperCa a/w ↓ QT), ± hypoK, ? hypoMg</p><p>Autonomic dysfxn: ICH (deep TWI), Takotsubo, stroke, CEA, neck dissection</p><p>Congenital (long QT syndrome): K, Na, & Ca channelopathies (Circ 2013;127:126)</p><p>Misc: CAD, CMP, bradycardia, high-grade AVB, hypothyroidism, hypothermia, BBB</p><p>Bundle Branch Blocks (Circ 2009;119:e235)</p><p>ECG P-wave criteria</p><p>Left Atrial Abnormality (LAA)</p><p>Right Atrial Abnormality (RAA)</p><p>Left ventricular hypertrophy (LVH) (Circ 2009;119:e251)</p><ul><li><p>Etiologies: HTN, AS/AI, HCM, coarctation of aorta</p></li><li><p>Criteria (all w/ Se &lt;50%, Sp >85%; accuracy affected by age, sex, race, BMI)</p></li></ul><p>Sokolow-Lyon: S in V1 + R in V5 or V6 ≥35 mm or R in aVL ≥11 mm (↓ Se w/ ↑ BMI)</p><p>Cornell: R in aVL + S in V3 >28 mm in men or >20 mm in women</p><p>Romhilt-Estes point-score system (4 points = probable; 5 points = diagnostic): ↑ volt: limb lead R or S ≥20 mm or S in V1 or V2 ≥30 mm or R in V5 or V6 ≥30 mm (3 pts)</p><p>ST displacement opposite to QRS deflection: w/o dig (3 pts); w/ dig (1 pt)</p><p>LAA (3 pts); LAD (2 pts); QRS duration ≥90 msec (1 pt)</p><p>Intrinsicoid deflection (QRS onset to peak of R) in V5 or V6 ≥50 msec (1 pt)</p><p>If LAFB present: S in III + max (R+S) in any lead ≥30 mm in men or ≥28 mm in women</p><p>Right ventricular hypertrophy (RVH) (Circ 2009;119:e251; JACC 2014;63:672)</p><ul><li><p>Etiologies: cor pulmonale, congenital (tetralogy of Fallot, TGA, PS, ASD, VSD), MS, TR</p></li><li><p>Criteria [all insensitive, but specific (except in COPD); all w/ poor PPV in general population]</p></li></ul><p>R >S in V1, R in V1 ≥6 mm, S in V5 ≥10 mm, S in V6 ≥3 mm, R in aVR ≥4 mm</p><p>RAD ≥110° (LVH + RAD or prominent S in V5 or V6 → consider biventricular hypertrophy)</p><p>Ddx of dominant R wave in V1 or V2</p><ul><li><p>Ventricular abnl: RVH (RAD, RAA, deep S waves in I, V5, V6); HCM; Duchenne’s</p></li><li><p>Posterior MI: anterior R wave = posterior Q wave; often with IMI</p></li><li><p>Abnormal depolarization: RBBB (QRS >120 msec, rSR′); WPW (↓ PR, δ wave, ↑ QRS)</p></li><li><p>Other: dextroversion; counterclockwise rotation; lead misplacement; nl variant</p></li></ul><p>Poor R wave progression (PRWP) (Am Heart J 2004;148:80)</p><ul><li><p>Definition: loss of anterior forces w/o frank Q waves (V1–V3); R wave in V3 ≤3 mm</p></li><li><p>Etiologies: old anteroseptal MI (w/ R wave V3 ≤1.5 mm, ± persistent ST ↑ or TWI V2 & V3)</p></li></ul><p>LVH (delayed RWP w/ ↑ left precordial voltage); RVH; COPD (may also have RAA, RAD, limb lead QRS amplitude ≤5 mm, SISIISIII w/ R/S ratio &lt;1 in those leads)</p><p>LBBB; WPW; clockwise rotation of the heart; lead misplacement; CMP; PTX</p><p>Pathologic Q waves</p><ul><li><p>Definition: ≥30 msec (≥20 msec V2–V3) or >25% height of R wave in that QRS complex</p></li><li><p>Small (septal) q waves in I, aVL, V5 & V6 are nl, as can be isolated Qw in III, aVR, V1</p></li><li><p>“Pseudoinfarct” pattern may be seen in LBBB, infiltrative dis., HCM, COPD, PTX, WPW</p></li></ul><p>ST elevation (STE) (NEJM 2003;349:2128; Circ 2009;119:e241 & e262)</p><ul><li><p>Acute MI: upward convexity STE (ie, a “frown”) ± TWI (or prior MI w/ persistent STE)</p></li><li><p>Coronary spasm: Prinzmetal’s angina; transient STE in a coronary distribution</p></li><li><p>Pericarditis: diffuse, upward concavity STE (ie, a “smile”); a/w PR ↓; Tw usually upright</p></li><li><p>HCM, Takotsubo CMP, ventricular aneurysm, cardiac contusion</p></li><li><p>Pulmonary embolism: occ. STE V1–V3; classically a/w TWI V1–V4, RAD, RBBB, S1Q3T3</p></li><li><p>Repolarization abnormalities:</p></li></ul><p>LBBB (↑ QRS duration, STE discordant from QRS complex; see “ACS” for dx MI in LBBB)</p><p>LVH (↑ QRS amplitude); Brugada syndrome (rSR′, downsloping STE V1–V2); pacing</p><p>Hyperkalemia (↑ QRS duration, tall Ts, no P’s); epsilon waves (late afterdepol.) in ARVC</p><ul><li><p>aVR: STE >1 mm a/w ↑ mortality in STEMI; STE aVR > V1 a/w left main disease</p></li><li><p>Early repolarization: most often seen in V2–V5 in young adults (Circ 2016;133:1520)</p></li></ul><p>1–4 mm elev of notch peak or start of slurred downstroke of R wave (ie, J point); ± up concavity of ST & large Tw (∴ ratio of STE/T wave &lt;25%; may disappear w/ exercise)</p><p>? early repol in inf leads may be a/w ↑ risk of VF (NEJM 2009;361:2529; Circ 2011;124:2208)</p><ul><li>Post-ROSC: transient STE can be seen w/in 1st ~8 mins; not indicative of ACS</li></ul><p>ST depression (STD)</p><ul><li><p>Myocardial ischemia (± Tw abnl)</p></li><li><p>Acute true posterior MI: posterior STE appearing as anterior STD (± ↑ R wave) in V1–V3 ✓ posterior ECG leads; manage as a STEMI with rapid reperfusion (see “ACS”)</p></li><li><p>Digitalis effect: downsloping ST ± Tw abnl; does not correlate w/ dig levels</p></li><li><p>Hypokalemia (± U wave)</p></li><li><p>Repolarization abnl a/w LBBB or LVH (usually in leads V5, V6, I, aVL, called “LV strain”)</p></li></ul><p>T wave inversion (TWI; generally ≥1 mm; deep if ≥5 mm) (Circ 2009;119:e241)</p><ul><li><p>Ischemia or infarct; Wellens’ sign (deep, symm precordial TWI) → critical prox LAD lesion</p></li><li><p>Myopericarditis; CMP (Takotsubo, ARVC, apical HCM); MVP; PE (espec if TWI V1–V4)</p></li><li><p>Repolarization abnl in a/w LVH/RVH (“strain pattern”); BBB; nl variant if QRS predom. ⊖</p></li><li><p>Posttachycardia or postpacing (“memory” T waves)</p></li><li><p>Electrolyte, digoxin, PaO2, PaCO2, pH/core temp ∆’s, intracranial bleed (“cerebral Tw”)</p></li></ul><p>Low voltage</p><ul><li><p>QRS amplitude (R + S) &lt;5 mm in all limb leads & &lt;10 mm in all precordial leads</p></li><li><p>Etiol: COPD, pericardial/pleural effusion, myxedema, ↑ BMI, infiltrative CMP, diffuse CAD</p></li></ul><p>Electrolyte abnormalities</p><ul><li><p>↑ K: tented Tw, ↓ QT, ↑ PR, AVB, wide QRS, STE; ↓ K: flattened Tw, U waves, ↑ QT</p></li><li><p>↑ Ca: ↓ QT, flattened Tw & Pw, J point elevation; ↓ Ca: ↑ QT; Tw ∆s</p></li></ul><p>ECG in young athletes (JACC 2017;69:805)</p><ul><li><p>Normal patterns may include LVH, RVH, early repolarization</p></li><li><p>Evaluate if: arrhythmia, HR &lt;30, ↑ QT, ε/δ waves, LBBB, Brugada pattern, QRS >140 ms, PR >400 ms, Mobitz II, 3˚ AVB, ST depression, TWI</p></li></ul><p>CHEST PAIN</p><p>Disorder</p><p>Typical Characteristics & Diagnostic Studies</p><p>Cardiovascular Causes</p><p>Angina/ACS</p><p>(&lt;10% of</p><p>chest pain in ED)</p><p>Substernal “pressure” (⊕ LR 1.3) → neck, jaw, arm (⊕ LR 1.3–1.5)</p><p>Sharp, pleuritic, positional, or reprod. w/ palp all w/ ⊕ LR ≤0.35</p><p>Diaphoresis (⊕ LR 1.4), dyspnea (⊕ LR 1.2), a/w exertion (⊕ LR 1.5–1.8)</p><p>≈ prior MI (⊕ LR 2.2); ↓ w/ NTG/rest (but not reliable; Annals EM 2005;45:581)</p><p>± ECG ∆s: STE, STD, TWI, hyperacute Tw, Qw. ± ↑ Troponin.</p><p>Pericarditis & myo-pericarditis</p><p>Sharp pain → trapezius, ↑ w/ respiration, ↓ w/ sitting forward. ± Pericardial friction rub. ECG ∆s (diffuse STE & PR ↓, opposite in aVR) ± pericardial effusion. If myocarditis, same as above + ↑ Tn and ± s/s HF and ↓ EF.</p><p>Aortic dissection</p><p>Sudden severe tearing pain (absence ⊖ LR 0.3). ± Asymm (>20 mmHg) BP or pulse (⊕ LR 5.7), focal neuro deficit (⊕ LR >6), AI, widened mediast. on CXR (absence ⊖ LR 0.3); false lumen on imaging.</p><p>PE</p><p>Sudden onset pleuritic pain. ↑ RR & HR, ↓ SaO2, ECG ∆s (sinus tach, RAD, RBBB, SIQIIITIII, TWI V1–V4, occ STE V1–V3), + CTA or V/Q, ± ↑ Tn.</p><p>Pulm HTN</p><p>Exertional pressure, DOE. ↓ SaO2, loud P2, RV heave, right S3 and/or S4.</p><p>Pulmonary Causes</p><p>Pneumonia</p><p>Pleuritic; dyspnea, fever, cough, sputum. ↑ RR, crackles. CXR infiltrate.</p><p>Pleuritis</p><p>Sharp, pleuritic pain. ± Pleuritic friction rub.</p><p>PTX</p><p>Sudden onset, sharp pleuritic pain. Hyperresonance, ↓ BS. PTX on CXR.</p><p>GI Causes</p><p>Esoph reflux</p><p>Substernal burning, acid taste in mouth, ↑ by meals. See “GERD.”</p><p>Esoph spasm</p><p>Intense substernal pain. ↑ by swallowing, ↓ by NTG/CCB. Manometry.</p><p>Mallory-Weiss</p><p>Esoph tear precipitated by vomiting. ± Hematemesis. Dx w/ EGD.</p><p>Boerhaave</p><p>Esoph rupture. Severe pain, ↑ w/ swallow. Mediastinal air palpable & on CT.</p><p>PUD</p><p>Epigastric pain, relieved by antacids. ± GIB. EGD, ± H. pylori test.</p><p>Biliary dis.</p><p>RUQ pain, N/V. ↑ by fatty foods. RUQ U/S, CT, MRCP; ↑ LFTs.</p><p>Pancreatitis</p><p>Epigastric/back discomfort. ↑ amylase & lipase; abdominal CT.</p><p>Musculoskeletal and Miscellaneous Causes</p><p>Costochond</p><p>Localized sharp pain. ↑ w/ movement. Reproduced by palpation.</p><p>Zoster</p><p>Intense unilateral pain. Pain may precede dermatomal rash.</p><p>Anxiety</p><p>“Tightness,” dyspnea, palpitations, other somatic symptoms</p><p>(Braunwald’s Heart Disease, 12th ed, 2022; JAMA 2015;314:1955)</p><p>Initial diagnostic studies</p><ul><li><p>Focused history: quality, severity, location, radiation; provoking/palliating factors; intensity at onset; duration, freq, & pattern; setting; assoc sx; cardiac hx & risk factors</p></li><li><p>Targeted exam: VS (incl. BP in both arms); gallops, murmurs, rubs; signs of vascular dis. (carotid/femoral bruits, ↓ pulses) or CHF; lung & abd. exam; chest wall for reproducibility</p></li><li><ul><li>12-lead ECG: obtain w/in 10 min; comp to priors & obtain serial ECGs; consider posterior leads (V7–V9) if hx c/w ACS but stnd ECG unrevealing or ST ↓ V1–V3 & pain refractory</li></ul></li><li><p>Troponin: >99th %ile w/ rise and/or fall in approp. setting is dx of AMI (Circ 2018;138:e618)</p></li></ul><p>High-sens Tn (hsTn) detectable 1 h after injury, peaks ~24 h, can be elevated for >1 wk</p><p>✓ at presentation & 1–3 h later; repeat if clinical or ECG ∆s; assess absolute level & Δ</p><p>Ddx: MI (type 1 [plaque rupture] or 2 [supply-demand mismatch not due to Δ in CAD), non-ischemic cardiac (eg, myocarditis, ADHF, Takotsubo, defibrillation, contusion), systemic illness (eg, PE, PHT, stroke, SAH, critical illness)</p><ul><li>CXR; other imaging (echo, PE CTA, etc.) as indicated based on H&P and initial testing</li></ul><p>Initial approach (Circ 2021;144:e368)</p><ul><li><ul><li>R/o life-threatening causes (ACS, PE, AoD, myopericarditis, etc.)</li></ul></li><li><p>If possible ACS, risk stratify w/ clinician decision pathway (clinical factors + ECG + Tn)</p></li><li><p>Low prob ACS (eg, H&P unconcerning, ⊖ ECG & Tn): d/c to home; risk factor mgmt</p></li><li><p>Intermed prob ACS (neither low nor high clinical risk, ± borderline Tn): ✓ TTE and</p></li></ul><p>If no known CAD → CCTA or stress (former ↓ LOS c/w fxnal testing; NEJM 2012;366:1393)</p><p>If recent mildly ⊕ stress or known non-obstructive CAD → CCTA</p><p>If obstructive but not high-risk CAD → stress test</p><p>If recent mod-severely ⊕ stress or high-risk CAD (LM, prox LAD, MVD) → invasive angio</p><ul><li><p>High prob ACS (eg, ECG Δs, ⊕ Tn, new ↓ LVEF): invasive coronary angiography</p></li><li><p>Pts w/ acute CP: CCTA vs. stress testing → ↓ time to dx & LOS (less so in era of hsTn), but ↑ probability of cath/PCI (NEJM 2012;366:1393 & 367:299; JACC 2013;61:880)</p></li></ul><p>NONINVASIVE EVALUATION OF CAD</p><p>Stress testing (J Nucl Cardiol 2016;23:606; EHJ 2020;41:407)</p><ul><li><p>Indications: evaluate possible CAD sx or ∆ in clinical status in Pt w/ known CAD, risk stratify after chest pain, evaluate exercise tolerance, localize ischemia (imaging required)</p></li><li><p>Contraindications (Circ 2002;106:1883; & 2012;126:2465)</p></li></ul><p>Absolute: AMI w/in 48 h, high-risk UA, acute PE, severe sx AS, uncontrolled HF, uncontrolled arrhythmias, severe HTN (SBP >200), myopericarditis, acute AoD</p><p>Relative (discuss with stress lab): left main CAD, mod symptomatic valvular stenosis, HCM w/ LVOT obstruction, high-degree AVB, severe electrolyte abnl</p><p>Exercise tolerance test (w/ ECG alone)</p><ul><li><p>Generally preferred if Pt can meaningfully exercise; ECG ∆s w/ Se ~65%, Sp ~80%</p></li><li><p>Typically via treadmill w/ Bruce protocol (modified Bruce or submax if decond. or recent MI)</p></li><li><p>Hold anti-isch. meds (eg, nitrates, βB) if dx’ing CAD but give to assess adequacy of meds</p></li></ul><p>Pharmacologic stress test (nb, requires imaging because ECG not interpretable)</p><ul><li><p>Use if unable to exercise, low exercise tolerance, or recent MI. Se & Sp ≈ exercise.</p></li><li><p>Preferred if LBBB, WPW or V-paced, because higher prob of false ⊕ imaging with exercise</p></li><li><p>Coronary vasodilator: diffuse vasodilation → relative perfusion defect in vessels w/ fixed epicardial disease. Reveals CAD, but not if Pt ischemic w/ exercise. Regadenoson (↓ side effects), dipyridamole, adenosine. Side effects: flushing, ↓ HR, AVB, SOB, bronchospasm.</p></li><li><p>Chronotropes/inotropes (dobuta): more physiologic, but longer test; may precip arrhythmia</p></li></ul><p>Imaging for stress test</p><ul><li><p>Use if uninterpretable ECG (V-paced, LBBB, resting ST ↓ >1 mm, digoxin, LVH, WPW), after indeterminate ECG test, or if pharmacologic test</p></li><li><p>Use when need to localize ischemia (often used if prior coronary revasc)</p></li><li><p>Radionuclide myocardial perfusion imaging w/ images obtained at rest & w/ stress</p></li></ul><p>SPECT (eg, 99mTc-sestamibi): Se ~85%, Sp ~80%</p><p>PET (rubidium-82): Se ~90%, Sp ~85%; requires pharmacologic stress, not exercise</p><p>ECG-gated imaging allows assessment of regional LV fxn (sign of ischemia/infarction)</p><ul><li>Echo (exercise or dobuta): Se ~80%, Sp ~85%; no radiation; operator dependent</li></ul><p>Test results</p><ul><li><p>HR (must achieve ≥85% of max pred HR [220-age] for exer. test to be dx), BP response, peak double product (HR × BP; nl >20k), HR recovery (HRpeak – HR1 min later; nl >12)</p></li><li><p>Max exercise capacity achieved (METS or min); occurrence of symptoms</p></li><li><p>ECG ∆s: downsloping or horizontal ST ↓ (≥1 mm) 60–80 ms after QRS predictive of CAD (but does not localize ischemic territory); however, STE highly predictive & localizes</p></li><li><p>Duke treadmill score = exercise min – (5 × max ST dev) – (4 × angina index) [0 none, 1 nonlimiting, 2 limiting]; score ≥5 → &lt;1% 1-y mort; –10 to + 4 → 2–3%; ≤–11 → ≥5%</p></li><li><p>Imaging: radionuclide defects or echocardiographic regional wall motion abnormalities</p></li></ul><p>reversible defect = ischemia; fixed defect = infarct; transient isch dilation → ? severe 3VD</p><p>false ⊕: breast → ant defect; diaphragm → inf defect. False ⊖: balanced (3VD) ischemia.</p><p>High-risk test results (PPV ~50% for LM or 3VD, ∴ consider coronary angio)</p><ul><li><p>ECG: ST ↓ ≥2 mm or ≥1 mm in stage 1 or in ≥5 leads or ≥5 min in recovery; ST ↑; VT</p></li><li><p>Physiologic: ↓ or fail to ↑ BP, &lt;4 METS, angina during exercise, Duke score ≤–11; ↓ EF</p></li><li><p>Radionuclide: ≥1 lg or ≥2 mod. reversible defects, transient LV cavity dilation, ↑ lung uptake</p></li></ul><p>Myocardial viability (Circ CV Imaging 2020;13:e53)</p><ul><li><p>Goal: identify hibernating myocardium that could regain fxn after revascularization</p></li><li><p>Options: MRI (Se ~95%, Sp ~50%), PET (Se ~90%, Sp ~65%), dobutamine stress</p></li></ul><p>echo (Se ~80%, Sp ~80%); SPECT/rest-redistribution (Se ~85%, Sp ~65%)</p><ul><li>Pts w/ ischemic CMP (EF &lt;35%), viability predicts ↑ EF w/ CABG but not survival or benefit of CABG vs. medical Rx (NEJM 2011;364:1617 & 2019;381:739)</li></ul><p>Coronary CT angiography (JCCT 2021;15:192)</p><ul><li><p>Gated CT of heart timed during peak contrast enhancement in coronary arteries</p></li><li><p>NTG given to dilate coronary arteries. β-blockers commonly used to lower HR.</p></li><li><p>CT-FFR: uses computational fluid dynamics to estimate fxnal significance of focal lesions</p></li><li><p>CAD-RADS score in stable CP improves risk stratif. of CV events (JACC Img 2020;13:1534)</p></li><li><p>In stable outPt w/ CP: CCTA added to stnd of care → ↑ early but not overall angiography/revasc; ↑ use of preventive med Rx, and ↓ coronary death/MI by 5 y (NEJM 2018;379:924)</p></li></ul><p>Coronary artery calcium (CAC) score</p><ul><li><p>Quantifies extent of calcium; thus, estimates plaque burden (but not % coronary stenosis)</p></li><li><p>CAC sensitive (91%) but not specific (49%) for presence of CAD; high NPV to r/o CAD</p></li><li><p>In intermediate-risk or selected borderline-risk adults (ie, 10-year ASCVD risk of 5–20%), if decision about statin remains uncertain, reasonable to use CAC score to help guide</p></li></ul><p>CORONARY ANGIOGRAPHY & PCI</p><p>Precath checklist</p><ul><li><p>Peripheral arterial exam (radial, femoral, DP, PT pulses; bruits); palmar arch eval (eg, w/ pulse oximetry & plethysmography) not routinely done. ✓ can lie flat × hrs, NPO >6 h.</p></li><li><p>✓ CBC, PT-INR (ideally ≤2), Cr; hold ACEI/ARB if renal dysfxn. Blood bank sample.</p></li><li><p>↓ risk of contrast-induced kidney injury: hold ACEI/ARB/ARNI, NSAIDs, diuretics. PreRx w/ isotonic IVF: data mixed, but may be helpful if high risk (Lancet 2017;389:1312).</p></li><li><p>If iodinated contrast allergy, preRx w/ steroids & antihistamines</p></li></ul><p>Vascular access</p><ul><li><p>Radial access preferred for coronary angiography: ↓ major bleeding & vascular complications, and possibly mortality benefit (Circ CI 2018;11:e000035)</p></li><li><p>Femoral artery commonly used; high puncture ↑ risk of retroperitoneal bleed; low puncture ↑ risk of arterial complic. (eg, AV fistula, superficial femoral artery cannulation)</p></li></ul><p>Periprocedural pharmacotherapy for PCI</p><ul><li><p>ASA 325 mg × 1. P2Y12 inhibitor: ticagrelor or prasugrel preferred over clopidogrel in ACS. Outside of STEMI, preRx load not recommended when anatomy unknown. Cangrelor (IV P2Y12 inhib) ↓ peri-PCI events vs. clopi w/o PreRx (NEJM 2013;368:1303).</p></li><li><p>GP IIb/IIIa inhibitor: sometimes added if periprocedural thrombotic complication</p></li><li><p>Anticoagulant: UFH or bivalirudin (if HIT) typically given during case and stopped at end</p></li></ul><p>PCI and peri-PCI interventions</p><ul><li><p>Physiology: fractional flow reserve (FFR): ratio of max flow (induced by adenosine) distal vs. prox to stenosis to ID hemodyn. signif. lesions (≤0.80). Instantaneous wave-free ratio (iFR) similar, doesn’t require vasodilator; iFR threshold ≤0.89 (NEJM 2017;376:1813 & 1824).</p></li><li><p>Advanced imaging: intravascular U/S (IVUS) or optical coherence tomography (OCT)</p></li><li><p>Drug-eluting stents (DES): ↓ cardiac death, MI, repeat revasc, & stent thrombosis vs. BMS (Lancet 2019;393:2503). Balloon angioplasty alone reserved for lesions too narrow to stent.</p></li></ul><p>Peri-PCI complications</p><ul><li><p>No or slow reflow: Rx with local delivery of vasodilators</p></li><li><p>Coronary artery dissection: treat with stent</p></li><li><p>Coronary perforation: immediate balloon tamponade, ✓ for effusion, seal w/ covered stent</p></li></ul><p>Vascular access post-PCI complications</p><ul><li><p>Postprocedure ✓ vascular access site, distal pulses, ECG, CBC, Cr</p></li><li><p>Bleeding: reverse/stop anticoag (d/w interventionalist); IV fluids/PRBC/plts as required</p></li></ul><p>hematoma/overt bleeding: manual compression</p><p>retroperitoneal bleed: may p/w ↓ Hct ± flank or back pain. CT abd/pelvis (I–) or angio if unstable. If does not auto-tamponade, intravascular balloon and/or covered stent.</p><ul><li>Vascular damage (~1% of dx angio, ~5% of PCI; Circ 2007;115:2666)</li></ul><p>pseudoaneurysm: triad of pain, expansile mass, systolic bruit; diagnose w/ U/S;</p><p>Rx (if pain or >2 cm): U/S-directed thrombin injection, surgical repair if former fails</p><p>AV fistula: continuous bruit; Dx: U/S; Rx: surgical repair if large or sx</p><p>limb ischemia (emboli, dissection, clot): cool, mottled extremity, ↓ distal pulses; Dx: loss of pulses, ↓ pulse volume recording, angio; Rx: percutaneous or surgical repair</p><p>radial artery occlusion: if sx, consider 4 weeks LMWH</p><p>Other complications (NEJM 2017;377:1513)</p><ul><li><p>Contrast-induced AKI: w/in 48 h, peak 3–5 d; pre-hydration reasonable (see “CIAKI”)</p></li><li><p>Stroke: ~0.1–0.4% of cases. Usually ischemic from atheroembolic event during cath. Rx depends on sx/location/timing but includes thrombectomy, tPA, DAPT if ischemic.</p></li><li><p>Cholesterol emboli syndrome: typically in Pts w/ large burden Ao atheroma; mesenteric ischemia (abd pain, LGIB, pancreatitis); intact distal pulses but livedo and toe necrosis</p></li></ul><p>Stent post-PCI complications</p><ul><li><p>Stent thrombosis: acute clot formation in stent usually in 1st mo but can occur anytime. Typically p/w AMI. Often due to premature d/c antiplt Rx or mech prob. (stent underexpansion or unrecognized dissection, typically presents early).</p></li><li><p>In-stent restenosis: develops in previously stented segment mos after PCI. Typically p/w gradual ↑ angina. Due to elastic recoil and neointimal hyperplasia; ↓ w/ DES.</p></li></ul><p>Duration of dual antiplatelet therapy (JACC 2016;68:1082 & EHJ 2018;39:213)</p><ul><li><p>DAPT duration determined by patient presentation (ACS vs. SIHD), long-term ischemic risk (patient and procedural risk factors), and bleeding risk</p></li><li><p>Antiplt Rx: DAPT (ASA 81 + P2Y12 inhib) in SIHD for 4 wk (BMS) or ≥6 mo (DES); in ACS (qv) for 12 mo and possibly beyond (JAMA Cards 2016;1:627). Data emerging for DAPT 1–3 mo, followed by P2Y12 inhib monotherapy (Circ 2020;142:538).</p></li><li><p>If need long-term oral anticoag, consider clopi+DOAC and consider stopping ASA (? after ~1 wk) as ↓ bleed, but trend small ↑ ischemic risk (JAMA Cardiol. 2020;5:582)</p></li></ul><p>STABLE ISCHEMIC HEART DISEASE</p><p>Definition</p><ul><li>SIHD refers to asx and stably sx Pts as well as low-risk new-onset chest pain felt to be due to IHD, and excludes Pts w/ rapidly progressive sx or rest sx (ie, ACS)</li></ul><p>Noninvasive testing (Circ 2012;126:e354 & 2021;144;e368)</p><ul><li><p>Noninvasive dx testing most valuable when pretest probability is intermediate (variably defined as anywhere from 30–70% to 10–90%)</p></li><li><p>Several pretest probability scores that take into account age, sex, nature of sx, risk factors</p></li><li><p>Exercise ECG testing or CAC reasonable in some low-risk Pts</p></li><li><p>In intermediate/high-risk Pts, stress test w/ imaging or CCTA (see “Noninv Eval of CAD”)</p></li><li><p>If known nonobstructive CAD & stable chest pain: stress testing or CCTA ± FFR</p></li><li><p>If obstructive CAD & stable chest pain: stress testing or invasive angio if high-risk CAD</p></li></ul><p>Coronary angiography for SIHD (Circ 2014;130:1749)</p><ul><li><p>High-risk noninvasive testing results suggestive of left main or multivessel CAD</p></li><li><p>Angina that is refractory to optimal medical therapy</p></li><li><p>Uncertain dx after noninvasive testing, occupational need (eg, pilot)</p></li><li><p>Unexplained heart failure or ↓ EF</p></li></ul><p>Major risk factor modification (Circ 2012;126:e354)</p><ul><li><p>Lipids: statin (typically high-intensity) ± ezetimibe & PCSK9i (see “Dyslipidemia”)</p></li><li><p>BP &lt;130/80 (see “Hypertension”); in SIHD may opt for ACEI and βB (if angina)</p></li><li><p>Diabetes management (qv): HbA1c ≤7% and consider GLP1RA or SGLT2i</p></li><li><p>Smoking cessation; influenza vaccine</p></li><li><p>Diet (↑ vegetables, fruits, whole grains; ↓ saturated fat, trans fatty acids, sweets, red meat, Na); target BMI 18.5–24.9 kg/m2; 30–60 min mod-to-vigorous physical activity ≥5×/wk</p></li></ul><p>Optimal medical therapy (OMT) (Circ 2012;126:e354)</p><ul><li><p>ASA 75–162 mg/d; can substitute clopi if ASA-intolerant. ~12 mos after PCI, clopi monoRx ↓ risk of ischemic and bleeding events by ~30% c/w ASA monoRx (Lancet 2021;397:2487).</p></li><li><p>βB for 3 years post-MI or if ↓ EF; can consider in all Pts w/ SIHD</p></li><li><p>ACEI (or ARB if intolerant of ACEI) if HTN, DM, CKD, or ↓ EF (Lancet 2006;368:581)</p></li><li><p>Dual antiplatelet therapy (ASA + P2Y12 inhibitor): ↓ CV events by ~10% in Pts with known IHD w/o MI but w/ DM, but ↑ bleeding (THEMIS, NEJM 2019; 381:1309)</p></li><li><p>Rivaroxaban 2.5 mg bid + ASA 100 mg/d: 24% ↓ CV events and 18% ↓ death vs. ASA alone, but ↑ major bleeding in stable ASCVD (COMPASS, NEJM 2017;377:1319)</p></li><li><p>Colchicine (0.5 mg/d): ↓ CV events by 31%, but ? ↑ non-CV death (NEJM 2020;383:1838)</p></li></ul><p>Medical therapies for symptomatic relief (Circ 2014;130:1749)</p><ul><li><p>Beta-blockers 1st-line therapy; CCB (except short-acting dihydropyridines)</p></li><li><p>Long-acting nitrates</p></li><li><p>Ranolazine (↓ late inward Na+ current to ↓ myocardial demand): 2nd-line anti-anginal</p></li></ul><p>Revascularization (JAMA 2021;325:1765; Circ 2022;145:e18)</p><ul><li><p>OMT should be initial focus if stable & w/o evidence of critical anatomy & w/ normal EF</p></li><li><p>Goal of revasc should be to ↓ risk of CV morbidity & mortality or to relieve refractory sx</p></li><li><p>Older studies: survival benefit w/ revascularization (CABG) vs. medical Rx (pre-statin era) if: left main disease (≥50% stenosis); 3VD (≥70% stenoses) especially if ↓ EF, 2VD w/ critical proximal LAD, DM, ? 1–2 VD w/ large area of viable, ischemic myocardium</p></li><li><p>More recent studies: revascularization (largely if not exclusively PCI) vs. OMT did not Δ risk of death, ↑ peri-PCI MI, and ± ↓ spontaneous MI (NEJM 2007;356:1503 & 2020;382:1395)</p></li><li><p>In the most recent trial (ISCHEMIA, NEJM 2020;382:1395), which enrolled Pts w/ moderate-severe ischemia by noninvasive testing w/o LM disease and w/ preserved LVEF, revasc (~¾ PCI, ~¼ CABG) ↑ 5-yr rate of peri-procedural MI by ~2% and ↓ 5-yr rate of spontaneous MI by 3%. Nonsignificant ~1% lower rate of CV death by 5 yrs that appeared to start to emerge after 2 yrs. Magnitude of benefit tended to be greater in those with multivessel disease, proximal LAD disease, or diabetes.</p></li><li><p>In Pts w/ CAD, HF, & LVEF &lt;35%, CABG compared w/ medical Rx ↓ mortality by 16% and ↓ CV mortality by 21% after a median of 10 yrs (STICHES, NEJM 2016;374:1511)</p></li><li><p>Thus, recommendations (Circ 2012;126:e354 & EHJ 2019;40:87) for revascularization include:</p></li></ul><p>Indicated in: ≥50% left main stenosis, 3VD (≥70% stenoses), 2VD w/ proximal LAD, unacceptable angina despite OMT</p><p>Reasonable if: 2VD + extensive myocardial ischemia, MVD or proximal LAD disease + ↓ EF, proximal LAD disease + extensive ischemia, MVD + diabetes (if can get CABG)</p><ul><li>Trials of PCI vs. CABG in Pts w/ MVD or LM disease have shown CABG ↓ risk of spontaneous MI, repeat revascularization, ± death. These benefits appear greater in those with more complex coronary anatomy or with diabetes (Lancet 2018;391:939 & 2021;398:2247).</li></ul><p>ACUTE CORONARY SYNDROMES</p><p>Spectrum of Acute Coronary Syndromes</p><p>Dx</p><p>UA</p><p>NSTEMI</p><p>STEMI</p><p>Coronary thrombosis</p><p>Subtotal occlusion</p><p>Total occlusion</p><p>History</p><p>Angina that is new-onset, crescendo or at rest; usually &lt;30 min</p><p>Angina at rest</p><p>ECG</p><p>± ST depression and/or TWI</p><p>ST elevations</p><p>Troponin/CK-MB</p><p>⊖</p><p>⊕</p><p>⊕ ⊕</p><p>Ddx (causes of myocardial ischemia/infarction other than atherosclerotic plaque rupture)</p><ul><li><p>Ischemia w/o plaque rupture (“type 2” MI): ↑ demand (eg, ↑ HR), ↓ supply (eg, HoTN). More likely in older, ♀, non-CAD comorbidities (CKD, etc.) (JACC 2021;77:848). Distinguishing from ACS is clinical dx; angiography is gold standard.</p></li><li><p>Nonatherosclerotic coronary artery disease (JACC 2018;72:2231)</p></li></ul><p>Spasm: Prinzmetal’s variant, cocaine-induced (6% of chest pain + cocaine use r/i for MI)</p><p>Dissection: spontaneous (vasculitis, CTD, pregnancy), aortic dissection with retrograde extension (usually involving RCA → IMI) or mechanical (PCI, surgery, trauma)</p><p>Embolism (Circ 2015;132:241): AF, thrombus/myxoma, endocard., prosth valve thrombosis</p><p>Vasculitis: Kawasaki syndrome, Takayasu arteritis, PAN, Churg-Strauss, SLE, RA</p><p>Congenital: anomalous origin from aorta or PA, myocardial bridge (intramural segment)</p><ul><li>Direct myocardial injury: myocarditis; Takotsubo/stress CMP; toxic CMP; cardiac contusion</li></ul><p>Clinical manifestations (JAMA 2015;314:1955)</p><ul><li><p>Cardiac chest pain (“angina”): retrosternal pressure/pain/tightness ± radiation to neck, jaw, arms. Precipitated by exertion (physical or emotional), ↓ w/ rest or NTG. In ACS: new-onset, crescendo or at rest.</p></li><li><p>Associated symptoms: dyspnea, diaphoresis, N/V, palpitations or light-headedness</p></li><li><p>Nonclassic sx (incl N/V & epig pain) ? more common in ♀, elderly, diabetes, inf. ischemia</p></li></ul><p>Physical exam (may be seen, but often are not)</p><ul><li><p>Signs of ischemia: S4, new MR murmur 2° pap. muscle dysfxn, paradoxical S2, diaphoresis</p></li><li><p>Signs of HF (eg, if large MI or ischemic MR): ↑ JVP, crackles, ⊕ S3, HoTN, cool extremities</p></li><li><p>Signs of other vascular disease: asymmetric BP, carotid or femoral bruits, ↓ distal pulses</p></li></ul><p>Diagnostic studies (NEJM 2017;376:2053)</p><ul><li>ECG: ST ↓/↑, TWI, new LBBB, hyperacute Tw; Qw/PRWP may suggest prior MI & ∴ CAD</li></ul><p>✓ ECG w/in 10 min of presentation, with any ∆ in sx & at 6–12 h; compare w/ baseline</p><ul><li>STEMI dx challenging w/ old LBBB or ventricular pacing:</li></ul><p>Sgarbossa: ≥1 mm STE concordant w/ QRS (Se 73%, Sp 92%), STD ≥1 mm V1–V3 (Se 25%, Sp 96%), STE ≥5 mm discordant w/ QRS (Se 31%, Sp 92%)</p><p>Barcelona: ST deviation ≥1 mm concordant w/ QRS in any lead, or ST deviation ≥1 mm discordant w/ QRS in leads with max voltage (largest R or S) ≤6 mm (Se 93%, Sp 94%)</p><p>Localization of MI</p><p>Anatomic Area</p><p>ECG Leads w/ STE</p><p>Coronary Artery</p><p>Septal</p><p>V1–V2 ± aVR</p><p>Proximal LAD</p><p>Anterior</p><p>V3–V4</p><p>LAD</p><p>Apical</p><p>V5–V6</p><p>Distal LAD, LCx, or RCA</p><p>Lateral</p><p>I, aVL</p><p>LCx</p><p>Inferior</p><p>II, III, aVF ± aVR</p><p>RCA (~85%), LCx (~15%)</p><p>RV</p><p>V1–V2 & V4R (most Se)</p><p>Proximal RCA</p><p>Posterior</p><p>ST depression V1–V3 (= STE V7–V9 posterior leads, ✓ if clinical suspicion)</p><p>RCA or LCx</p><p>If ECG non-dx & suspicion high, ✓ leads V7–V9 (⊕ if ≥0.5 mm STE) to assess distal LCx/RCA territory. ✓ R-sided precordial leads in IMI to detect RV involvement (STE in V4R most Se). STE in III >STE in II and lack of STE in I or aVL suggest RCA rather than LCx culprit in IMI. STE in aVR suggests LM, prox LAD, or diffuse ischemia.</p><ul><li><p>Cardiac biomarkers: ✓ Tn (pref. over CK-MB) at presentation & 3–6 h if stnd assay or 1 h later if high-sens assay; repeat if clinical or ECG ∆s. Universal definition of MI: >99th %ile w/ rise and/or fall in appropriate clinical setting (eg, sx, ECG ∆s, WMA on TTE, thrombus on coronary angiography).</p></li><li><p>If low prob, stress test or CT angio to r/o CAD; new wall motion abnl on TTE suggests ACS</p></li><li><p>Coronary angio gold standard for epicardial CAD</p></li></ul><p>Prinzmetal’s (variant) angina</p><ul><li><p>Coronary spasm → transient STE usually w/o MI (but MI, AVB, VT can occur)</p></li><li><p>Pts usually young, smokers, ± other vasospastic disorders (eg, migraines, Raynaud’s)</p></li><li><p>Angiography: nonobstructive CAD (spasm can be provoked during cath but rarely done)</p></li><li><p>Treatment: high-dose CCB & standing nitrates (+SL prn), ? α-blockers/statins; d/c smoking; avoid high-dose ASA (can inhibit prostacyclin and worsen spasm), nonselect βB, triptans</p></li><li><p>Cocaine-induced vasospasm: CCB, nitrates, ASA; ? avoid βB, but labetalol appears safe</p></li></ul><p>MI in absence of obstructive CAD (MINOCA)</p><ul><li><p>Definition: MI but w/o coronary stenosis ≥50% in any major epicardial vessel</p></li><li><p>More common in younger Pts, women, Black/Pacific race or Hispanic</p></li><li><p>Advanced coronary imaging (eg, OCT) & cardiac MRI to exclude missed coronary obstruction, other causes of myocyte injury (eg, myocarditis), other causes of ↑ Tn (eg, PE)</p></li><li><p>~75% ischemic (ie, plaque disruption identified) and 25% alternative dx (eg, myocarditis)</p></li></ul><p>Likelihood of ACS (Circ 2007;116:e148; Circ 1994;90[1]:613-22)</p><p>Feature</p><p>High (any of below)</p><p>Intermediate (no high features, any of below)</p><p>Low (no high/inter. features, may have below)</p><p>History</p><p>Chest or L arm pain like prior angina, h/o CAD (incl MI)</p><p>Chest or arm pain, age >70 y, male, diabetes</p><p>Atypical sx (eg, pleuritic, sharp or positional pain)</p><p>Exam</p><p>HoTN, diaphoresis, HF, transient MR</p><p>PAD or cerebrovascular disease</p><p>Pain reproduced on palp.</p><p>ECG</p><p>New STD (≥1 mm) TWI in mult leads</p><p>Old Qw, STD (0.5-0.9 mm), TWI (>1 mm)</p><p>TWF/TWI (&lt;1 mm) in leads w/ dominant R wave</p><p>Biomarkers</p><p>⊕ Tn or CK-MB</p><p>Normal</p><p>Normal</p><p>Acute Anti-Ischemic and Analgesic Treatment</p><p>Nitrates (SL or IV) 0.3–0.4 mg SL q5min × 3, then consider IV if still sx</p><p>Use for relief of sx, Rx for HTN or HF. No clear ↓ in mortality.</p><p>Caution if preload-sensitive (eg, HoTN, AS, sx RV infarct); contraindicated if recent PDE5 inhibitor use.</p><p>β-blockers</p><p>eg, metop 25–50 mg PO q6h titrate slowly to HR 50–60 IV only if HTN and no HF</p><p>↓ ischemia & progression of UA to MI (JAMA 1988;260:2259)</p><p>STEMI: ↓ arrhythmic death & reMI, but high doses can ↑ cardiogenic shock early (espec if signs of HF) (Lancet 2005;366:1622)</p><p>Contraindic. PR >0.24 sec, HR &lt;60, 2°/3° AVB, severe bronchospasm, s/s HF or low output, risk factors for shock (eg, >70 y, HR >110, SBP &lt;120, late presentation STEMI)</p><p>CCB (nondihydropyridines)</p><p>If cannot tolerate βB b/c bronchospasm</p><p>Morphine</p><p>Relieves pain/anxiety; venodilation ↓ preload. Do not mask refractory sx. May delay antiplt effects of P2Y12 inhib.</p><p>Oxygen</p><p>Use prn to keep SaO2 >90% (NEJM 2017;377:1240)</p><p>Other early adjunctive therapy</p><ul><li><p>High-intensity statin therapy (eg, atorva 80 mg qd; PROVE-IT TIMI 22, NEJM 2004;350:1495); ↓ ischemic events w/ benefit emerging w/in wks (JAMA 2001;285:1711 & JACC 2005;46:1405); ↓ peri-PCI MI (JACC 2010;56:1099); ? ↓ contrast-induced nephropathy (NEJM 2019;380:2156)</p></li><li><p>Ezetimibe: ↓ CV events when added to statin (IMPROVE-IT, NEJM 2015;372:2387)</p></li><li><p>ACEI/ARB: start once hemodynamics and renal function stable (hold if anticipate CABG)</p></li></ul><p>Strong indication for ACEI/ARB if heart failure, EF &lt;40%, HTN, DM, CKD; ~10% ↓ mortality, greatest benefit in ant. STEMI or prior MI (Lancet 1994;343:1115 & 1995;345:669)</p><ul><li>IABP: can be used for refractory angina when PCI not available</li></ul><p>NSTE-ACS (Circ 2014;130:e344; EHJ 2021;42:1289)</p><p>Key issues are antithrombotic regimen and decision regarding angiography</p><p>Antiplatelet Therapy</p><p>Aspirin</p><p>162–325 mg × 1, then 81 mg qd</p><p>(non–enteric-coated, chewable)</p><p>50–70% ↓ D/MI (NEJM 1988;319:1105)</p><p>Low dose (~81 mg) pref long term (NEJM 2010;363:930)</p><p>If allergy, use clopi and/or desensitize to ASA</p><p>P2Y12 (ADP receptor) inhibitor (choose one of the following in addition to ASA).</p><p>Timing (on presentation or at angiography) remains controversial.</p><ul><li>Ticagrelor (preferred over clopi)</li></ul><p>180 mg × 1 → 90 mg bid</p><p>Reversible, but wait 3–5 d prior to surg. Antidote being developed (NEJM 2019;380:1825).</p><p>More rapid and potent plt inhib c/w clopi</p><p>16% ↓ CVD/MI/stroke & 21% ↓ CV death c/w clopi; ↑ non-CABG bleeding (NEJM 2009;361;1045)</p><p>Given upstream or at time of PCI</p><p>Dyspnea (but SaO2 & PFTs nl) & ventricular pauses</p><ul><li>Prasugrel (preferred over clopi)</li></ul><p>60 mg × 1 at PCI → 10 mg qd (consider 5 mg/d if &lt;60 kg)</p><p>Wait 7 d prior to surgery</p><p>Contraindicated if h/o TIA/CVA; caution if >75 y</p><p>More rapid and potent plt inhib c/w clopi</p><p>19% ↓ CVD/MI/stroke in ACS w/ planned PCI vs. clopi, but ↑ bleeding (NEJM 2007;359:2001), incl fatal bleeds</p><p>In NSTE-ACS, should be given at time of PCI and not upstream due to ↑ bleeding (NEJM 2013;369:999)</p><p>? ↓ MACE vs ticagrelor (NEJM 2019;381:1524)</p><ul><li>Clopidogrel</li></ul><p>300–600 mg × 1 → 75 mg qd</p><p>~6 h to steady state</p><p>Wait 5 d prior to surgery</p><p>ASA+clopi → 20% ↓ CVD/MI/stroke vs. ASA alone. ~30% pop has ↓ fxn CYP2C19 → ↑ CV events if PCI on clopi (NEJM 2009;360:354).</p><ul><li>Cangrelor*</li></ul><p>Only IV P2Y12 inhibitor</p><p>Rapid onset/offset; t½ 3–5 min</p><p>22% ↓ CV events (mostly peri-PCI MI and stent thrombosis) vs. clopi 300 mg at time of PCI; no significant ↑ bleeding (NEJM 2013;368:1303)</p><p>Consider for rapidly reversible P2Y12 inhib peri-PCI or as bridge to surgery in high-risk Pts who need to stop P2Y12</p><p>GP IIb/IIIa inhibitors (GPI)</p><p>abciximab; eptifibatide; tirofiban</p><p>Infusions given ≤24 h peri & post PCI; shorter (~2 h) as effective w/ ↓ bleeding (JACC 2009;53:837)</p><p>No clear benefit for routinely starting prior to PCI and ↑ bleeding (NEJM 2009;360:2176)</p><p>Consider if refractory ischemia despite optimal Rx while awaiting angio or in high-risk Pts (eg, large clot burden) at time of PCI, espec if using clopi and no preRx.</p><p>*Transition from cangrelor to oral P2Y12 inhib.: ticagrelor loading dose during infusion or immediately after d/c of infusion; prasugrel or clopidogrel loading dose only immediately after d/c of infusion.</p><p>Anticoagulant Therapy (choose one)</p><p>UFH: 60 U/kg IVB (max 4000 U) then 12 U/kg/h (max 1000 U/h initially) × 48 h or until end of PCI</p><p>24% ↓ D/MI (JAMA 1996;276:811)</p><p>Titrate to aPTT 1.5–2× control (~50–70 sec)</p><p>Hold until INR &lt;2 if already on warfarin</p><p>Enoxaparin (low-molec-wt heparin) 1 mg/kg SC bid (± 30 mg IVB) (qd if CrCl &lt;30) × 2–8 d or until PCI</p><p>~10% ↓ D/MI vs. UFH (JAMA 2004;292:45,89). Can perform PCI on enox (Circ 2001;103:658), but ↑ -bleeding if switch b/w enox and UFH.</p><p>Bivalirudin (direct thrombin inhibitor) 0.75 mg/kg IVB at PCI → 1.75 mg/kg/h</p><p>No diff in bleeding, MI, or death c/w UFH (NEJM 2017;377:1132). Use instead of UFH if HIT.</p><p>Fondaparinux (Xa inh) 2.5 mg SC qd</p><p>Rarely used; must supplement w/ UFH if PCI.</p><p>Coronary angiography (Circ 2014;130:e344)</p><ul><li><p>Immediate/urgent coronary angiography (w/in 2 h) if refractory/recurrent angina or hemodynamic or electrical instability</p></li><li><p>Routine angiography (aka “invasive strategy”) = coronary angiography for all</p></li></ul><p>Early (w/in 24 h) if: ⊕ Tn, ST ∆, GRACE risk score >140 (NEJM 2009;360:2165; Circ 2018;138:2741)</p><p>Delayed (ie, w/in 72 h) acceptable if w/o above features but w/: diabetes, EF &lt;40%, GFR &lt;60, post-MI angina, TRS ≥3, GRACE score 109–140, PCI w/in 6 mo, prior CABG</p><p>32% ↓ rehosp for ACS, nonsignif 16% ↓ MI, no ∆ in mort. c/w select angio (JAMA 2008;300:71)</p><p>↑ peri-PCI MI counterbalanced by ↓↓ in spont. MI. Mortality benefit seen in some studies, likely only if cons. strategy w/ low rate of angio.</p><ul><li>Selective angiography (“conservative strategy”): med Rx w/ pre-d/c stress test; angio only if recurrent ischemia or strongly ⊕ ETT. Indicated for: low TIMI Risk Score, Pt or physician pref in absence of high-risk features, or low-risk women (JAMA 2008;300:71).</li></ul><p>TIMI Risk Score (TRS) for UA/NSTEMI (JAMA 2000;284:835)</p><p>Calculation of Risk Score</p><p>Application of Risk Score</p><p>Characteristic</p><p>Point</p><p>Score</p><p>D/MI/UR by 14 d</p><p>Historical</p><p>0–1</p><p>5%</p><p>Age ≥65 y</p><p>1</p><p>2</p><p>8%</p><p>≥3 Risk factors for CAD</p><p>1</p><p>3</p><p>13%</p><p>Known CAD (stenosis ≥50%)</p><p>1</p><p>4</p><p>20%</p><p>ASA use in past 7 d</p><p>1</p><p>5</p><p>26%</p><p>Presentation</p><p>6–7</p><p>41%</p><p>Severe angina (≥2 episodes w/in 24 h)</p><p>1</p><p>Higher risk Pts (TRS ≥3) derive ↑ benefit from LMWH, GP IIb/IIIa inhibitors and early angiography (JACC 2003;41:89S)</p><p>ST deviation ≥0.5 mm</p><p>1</p><p>⊕ cardiac marker (troponin, CK-MB)</p><p>1</p><p>RISK SCORE = Total points</p><p>(0–7)</p><p>STEMI (Circ 2013;127:529; EHJ 2018;39:119)</p><p>Figure 1-2 Approach to UA/NSTEMI</p><p>Requisite STE (at J point)</p><ul><li><p>≥2 contiguous leads w/ ≥1 mm (except for V2–V3: ≥2 mm in ♂ and ≥1.5 mm in ♀), or</p></li><li><p>New or presumed new LBBB w/ compelling H&P, or</p></li><li><p>True posterior MI: ST depression V1–V3 ± tall Rw w/ STE on posterior leads (V7–V9)</p></li></ul><p>Reperfusion (“time is muscle”)</p><ul><li><p>In PCI-capable hospital, goal should be primary PCI w/in 90 min of 1st medical contact</p></li><li><p>In non–PCI-capable hospital, consider transfer to PCI-capable hospital (see below), o/w fibrinolytic therapy w/in 30 min of hospital presentation</p></li><li><p>Do not let decision regarding method of reperfusion delay time to reperfusion</p></li></ul><p>Primary PCI (JACC 2013;61:e78 & 2016;67:1235)</p><ul><li><p>Definition: immediate PCI upon arrival to hospital or transfer for immediate PCI</p></li><li><p>Indic: STE + sx onset w/in &lt;12 h; ongoing ischemia 12–24 h after sx onset; shock</p></li><li><p>Superior to lysis: 27% ↓ death, 65% ↓ reMI, 54% ↓ stroke, 95% ↓ ICH (Lancet 2003;361:13)</p></li><li><p>Transfer to center for 1° PCI superior to lysis (NEJM 2003;349:733), see below</p></li><li><p>PCI of non-culprit lesions (stenoses ≥70% or FFR ≤0.80 if 50–69%) early after event (during initial PCI, prior to or early after d/c) ↓ recurrent MACE, primarily recurrent MI vs. culprit alone (NEJM 2019;381:1411-21); may harm if cardiogenic shock (NEJM 2018;379:1699)</p></li></ul><p>Fibrinolysis vs. Hospital Transfer for Primary PCI: Assess Time and Risk</p><ol><li><p>Time required for transport to skilled PCI lab: door-to-balloon &lt;120 min & [door-to-balloon]–[door-to-needle] &lt;1 h favors transfer for PCI</p></li><li><p>Risk from STEMI: high-risk Pts (eg, shock) fare better with mechanical reperfusion</p></li><li><p>Time to presentation: efficacy of lytics ↓ w/ ↑ time from sx onset, espec >3 h</p></li><li><p>Risk of fibrinolysis: if high risk of ICH or bleeding, PCI safer option</p></li></ol><p>Adapted from ACC/AHA 2013 STEMI Guidelines (Circ 2013;127:529)</p><p>Fibrinolysis</p><ul><li><p>Indic: STE/LBBB + sx &lt;12 h (& >120 min before PCI can be done); benefit if sx >12 h less clear; reasonable if persist. sx & STE, hemodynamic instability or large territory at risk</p></li><li><p>Mortality ↓ ~20% in anterior MI or LBBB and ~10% in IMI c/w Ø reperfusion Rx</p></li><li><p>Prehospital lysis (ie, ambulance): further 17% ↓ in mortality (JAMA 2000;283:2686)</p></li><li><p>~1% risk of ICH; high risk incl elderly (~2% if >75 y), ♀, low wt. ? PCI more attractive</p></li></ul><p>Contraindications to Fibrinolysis</p><p>Absolute Contraindications</p><p>Relative Contraindications</p><ul><li><p>Any prior ICH</p></li><li><p>Intracranial neoplasm, aneurysm, AVM</p></li><li><p>Ischemic stroke or closed head trauma w/in 3 mo; head/spinal surg. w/in 2 mo</p></li><li><p>Active internal bleeding or known bleeding diathesis</p></li><li><p>Suspected aortic dissection</p></li><li><p>Severe uncontrollable HTN</p></li><li><p>For SK, SK Rx w/in 6 mo</p></li><li><p>H/o severe HTN, SBP >180 or DBP >110 on presentation (? absolute if low-risk MI)</p></li><li><p>Ischemic stroke >3 mo prior</p></li><li><p>CPR >10 min; trauma/major surg. w/in 3 wk</p></li><li><p>Internal bleed w/in 2–4 wk; active PUD</p></li><li><p>Noncompressible vascular punctures</p></li><li><p>Pregnancy</p></li><li><p>Current use of anticoagulants</p></li><li><p>For SK, prior SK exposure</p></li></ul><p>Nonprimary PCI</p><ul><li><p>Rescue PCI if shock, unstable, failed reperfusion, or persistent sx (NEJM 2005;353:2758)</p></li><li><p>Routine angio ± PCI w/in 24 h of successful lysis: ↓ D/MI/revasc (Lancet 2004;364:1045) and w/in 6 h ↓ reMI, recurrent ischemia, & HF compared to w/in 2 wk (NEJM 2009;360:2705);</p></li></ul><p>∴ if lysed at non-PCI-capable hosp., consider transfer to PCI-capable hosp.. ASAP espec if high-risk (eg, ant. MI, IMI w/ ↓ EF or RV infarct, extensive STE/LBBB, HF, ↓ BP or ↑ HR)</p><ul><li>Late PCI (median day 8) of occluded infarct-related artery: no benefit (NEJM 2006;355:2395)</li></ul><p>Antiplatelet Therapy</p><p>Aspirin 162–325 mg × 1</p><p>(crushed/chewed) then 81 mg qd</p><p>23% ↓ in death (Lancet 1988;ii:349)</p><p>Should not be stopped if CABG required</p><p>P2Y12 inhibitor</p><p>Give ASAP (do not wait for angio) b/c onset inhib delayed in STEMI Pts</p><p>Ticagrelor or prasugrel (if PCI) as detailed above</p><p>Clopidogrel: 600 mg pre-PCI; 300 mg if lysis (no LD if >75 y) → 75 mg qd</p><p>PCI: prasugrel and ticagrelor ↓ CV events c/w clopi (Lancet 2009;373:723 & Circ 2010;122:2131)</p><p>Prehospital ticagrelor may be safe & ? ↓ rate of stent thrombosis (NEJM 2014;371:1016)</p><p>Lysis: clopidogrel 41% ↑ in patency, 7% ↓ mort, no Δ major bleed or ICH (NEJM 2005;352:1179; Lancet 2005;366:1607); no data for pras or ticag w/ lytic</p><p>GP IIb/IIIa inhibitors</p><p>abciximab, eptifibatide, tirofiban</p><p>Lysis: no indication (Lancet 2001;357:1905)</p><p>Peri-PCI: 60% ↓ D/MI/UR (NEJM 2001;344:1895)</p><p>(Circ 2013;127:529; NEJM 2021;384:452; JAMA 2021;325:1545)</p><p>Anticoagulant Therapy (choose one)</p><p>UFH</p><p>60 U/kg IVB (max 4000 U)</p><p>12 U/kg/h (max 1000 U/h initially)</p><p>No demonstrated mortality benefit</p><p>↑ patency with fibrin-specific lytics</p><p>Titrate to aPTT 1.5–2× control (~50–70 sec)</p><p>Enoxaparin</p><p>Lysis: 30 mg IVB → 1 mg/kg SC bid (adjust for age >75 & CrCl)</p><p>PCI: 0.5 mg/kg IVB</p><p>Lysis: 17% ↓ D/MI w/ ENOX × 7 d vs. UFH × 2 d (NEJM 2006;354:1477)</p><p>PCI: ↓ D/MI/revasc and ≈ bleeding vs. UFH (Lancet 2011;378:693)</p><p>Bivalirudin</p><p>0.75 mg/kg IVB → 1.75 mg/kg/hr IV</p><p>PCI: similar bleeding, ± ↑ MI, ↑ stent thromb, ↓ mortality in some but not all trials (Lancet 2014;384:599; JAMA 2015;313:1336; NEJM 2015;373:997)</p><p>Fondaparinux can be used (if CrCl >30 mL/min) in setting of lysis, where superior to UFH w/ less bleeding (JAMA 2006;295:1519). Adapted from ACC/AHA 2013 STEMI Guidelines (Circ 2013;127:529; Lancet 2013;382:633).</p><p>LV failure (occurs in ~25%)</p><ul><li><p>Diurese to achieve PCWP ~14 → ↓ pulmonary edema, ↓ myocardial O2 demand</p></li><li><p>↓ Afterload → ↑ stroke volume & CO, ↓ myocardial O2 demand. Can use IV NTG or nitroprusside (although risk of coronary steal) → short-acting ACEI.</p></li><li><p>Inotropes if HF despite diuresis & ↓ afterload; use dopamine, dobutamine, or milrinone</p></li><li><p>Cardiogenic shock (~7%) = MAP &lt;60 mmHg, CI &lt;2.2 L/min/m2, PCWP >18 mmHg.</p></li></ul><p>If not done already, coronary revasc (NEJM 1999;341:625)</p><p>Support w/ inotropes or mechanical circulatory support to keep CI >2</p><p>Intraaortic balloon pump (IABP) counterpulsation offers ~0.5 L/min CO and ↑ coronary perfusion, but no survival benefit if early revasc (NEJM 2012;367:1287)</p><p>Axial flow pumps (eg, Impella) offer up to 3–5 L/min CO, but no data that improves clinical outcomes (JACC 2017;69:278)</p><p>IMI complications (Circ 1990;81:401; NEJM 1994;330:1211; JACC 2003;41:1273)</p><ul><li>Heart block: ~20%, occurs in part because RCA typically supplies AV node</li></ul><p>40% on present., 20% w/in 24 h, rest by 72 h; high-grade AVB can develop abruptly</p><p>Rx: atropine, epi, aminophylline (100 mg/min × 2.5 min), temp pacing wire</p><ul><li>RV infarct: proximal RCA occlusion → ↓ flow to RV marginals</li></ul><p>Angiographically present in 30–50% of cases, but only ~½ clinically significant</p><p>HoTN; ↑ JVP, ⊕ Kussmaul’s; ≥1 mm STE in V4R; RA/PCWP ≥0.8; RV dysfxn on TTE</p><p>Rx: optimize preload (RA goal 10–14 mmHg; BHJ 1990;63:98); ↑ contractility (dobutamine); maintain AV synchrony (pacing as necessary); reperfusion (NEJM 1998;338:933); mechanical support (IABP or RVAD); pulmonary vasodilators (eg, inhaled NO)</p><p>Mechanical complications (incid. &lt;1% for each; typically occur a few days post-MI)</p><ul><li><p>Free wall rupture: ↑ risk w/ lysis, large MI, ↑ age, ♀, HTN; p/w PEA or hypoTN, pericardial sx, tamponade; Rx: volume resusc., ? pericardiocentesis, inotropes, surgery</p></li><li><p>VSD: large MI in elderly; AMI → apical VSD, IMI → basal septum; 90% w/ harsh murmur ± thrill (NEJM 2002;347:1426); Rx: diuretics, vasodil., inotropes, IABP, surgery, perc. closure</p></li><li><p>Papillary muscle rupture: more common after IMI (PM pap m. supplied by PDA alone) than AMI (AL supplied by OMs & diags); 50% w/ new murmur; ↑ v wave in PCWP tracing; asymmetric pulmonary edema on CXR. Rx: diuretics, vasodilators, IABP, surgery.</p></li></ul><p>Arrhythmias post-MI (treat all per ACLS protocols if unstable or symptomatic)</p><ul><li><p>AF (10–16% incidence): βB or amio, ± digoxin (particularly if HF), heparin</p></li><li><p>VT/VF: lido or amio × 6–24 h, then reassess; ↑ βB as tol., replete K & Mg, r/o ischemia; VT &lt;48 h post-MI does not worsen prognosis; >48 h, consider ICD (see below)</p></li><li><p>Accelerated idioventricular rhythm (AIVR): slow ventricular rhythm (&lt;120 bpm), often after reperfusion; typically asx, gradual onset/offset, and does not require treatment</p></li><li><p>Backup transcutaneous or transvenous pacing if: 2° AVB type II; BBB + AVB</p></li><li><p>Transvenous pacing if: 3° AVB; new BBB + 2° AVB type II; alternating LBBB/RBBB</p></li></ul><p>Other Post-MI Complications</p><p>Complication</p><p>Clinical Features</p><p>Treatment</p><p>LV thrombus</p><p>~30% incid. (espec lg antero-apical MI)</p><p>AC×3-6 mo (? warfarin pref)</p><p>Ventricular aneurysm</p><p>Noncontractile outpouching of LV; 8–15% incid. (espec ant); persist STE</p><p>Surgery or perc repair if HF, thromboemboli, arrhythmia</p><p>Ventricular pseudoaneurysm</p><p>Rupture (narrow neck) → sealed by thrombus and pericardium (esp in inf).</p><p>Urgent surgery (or percutaneous repair)</p><p>Pericarditis</p><p>10–20% incid.; 1–4 d post-MI ⊕ pericardial rub; ECG Δs rare</p><p>High-dose ASA, colchicine, narcotics; minimize anticoag</p><p>Dressler’s syndrome</p><p>&lt;4% incid.; 2–10 wk post-MI fever, pericarditis, pleuritis</p><p>High-dose aspirin, NSAIDs</p><p>CHECKLIST AND LONG-TERM POST-ACS MANAGEMENT</p><p>Risk stratification</p><ul><li><p>Stress test if anatomy undefined; consider stress if signif residual CAD post-PCI of culprit</p></li><li><p>Assess LVEF prior to d/c; EF ↑ ~6% in STEMI over 6 mo (JACC 2007;50:149)</p></li></ul><p>Antiplatelet therapy</p><ul><li><p>Aspirin: 81 mg daily (no clear benefit to higher doses)</p></li><li><p>P2Y12 inhibitor: ticagrelor or prasugrel preferred over clopi. In landmark analyses, benefit over clopidogrel both early & late. De-escalation (ticag → clopi or pras 10 → 5 mg) after 1 mo ↓ bleeding w/o clear ↑ MACE, but wide CIs (Lancet 2020;396:1079 & 2021;398:1305).</p></li><li><p>Duration controversial. Traditionally ASA lifelong and P2Y12 inhib for 12 mos. Prolonged P2Y12 inhib >12 mos → ↓ MACE but ↑ bleeding (NEJM 2014;371:2155 & 2015;372:1791). Consider if high ischemic and low bleeding risk. Shorter duration (eg, 3–6 mo) if converse or if require major surgery. D/c ASA after 1–3 mos and continuing P2Y12 inhib monoRx (preferably ticagrelor) ↓ bleeding with no ↑ MACE (Circ 2020;142:538).</p></li></ul><p>Anticoagulation</p><ul><li><p>If need therapeutic a/c (eg, AF) in addition to anti-plt Rx, consider full-dose apixa + P2Y12 (typically clopi) and d/c ASA at time of hospital d/c (NEJM 2019;380:1509)</p></li><li><p>In Pts w/o indic. for anticoag, once DAPT completed, rivaroxaban 2.5 bid + ASA ↓ MACE & CV death and ↑ bleeding vs. ASA monoRx (NEJM 2017;377:1319)</p></li></ul><p>Other CV drugs</p><ul><li><p>β-blocker: 23% ↓ mortality after MI (benefit beyond 3 yrs less clear)</p></li><li><p>ACEI/ARB: lifelong if HF, ↓ EF, HTN, DM; 4–6 wk or at least until hosp. d/c in all STEMI. Trend toward ARNI better than ACEI in post-MI Pts w/ ↓ EF (NEJM 2021;385:1845).</p></li></ul><p>? long-term benefit of ACEI/ARB in CAD w/o HF (NEJM 2000;342:145)</p><ul><li><p>Aldosterone antag: 15% ↓ mort. if EF &lt;40% & either s/s of HF or DM (NEJM 2003;348:1309)</p></li><li><p>Nitrates: standing if symptomatic; SL NTG prn for all</p></li><li><p>Ranolazine: ↓ recurrent ischemia, no impact on CVD/MI (JAMA 2007;297:1775)</p></li><li><p>Low dose colchicine ↓ CV events post MI but ? ↑ PNA (NEJM 2019; 381:2497)</p></li></ul><p>Risk factors and lifestyle modifications (Circ 2019;139:e1082 & EHJ 2020;41:111)</p><ul><li>LDL-C: goal &lt;70 mg/dL (U.S) or &lt;55 (Europe) or even &lt;40 if recurrent events</li></ul><p>Statin: high-intensity (eg, atorva 80 mg, PROVE-IT TIMI 22, NEJM 2004;350:1495)</p><p>Ezetimibe: ↓ CV events when added to statin (IMPROVE-IT, NEJM 2015;372:1500)</p><p>PCSK9 inhibitor: ↓ CV events when added to statin (NEJM 2017;376:1713; 2018;379:2097)</p><ul><li><p>BP &lt;140/90 and &lt;130/80; quit smoking</p></li><li><p>If diabetic, GLP1-RA ↓ MACE & SGLT2i ↓ hospitalization for HF (Lancet D&E 2019;7:776 & Lancet 2019;393:31); further tailor HbA1c goal based on Pt (avoid TZDs and saxa if HF)</p></li><li><p>Exercise (30–60′ 5–7×/wk) 1–2 wk after revasc; cardiac rehab; BMI goal 18.5–24.9 kg/m2</p></li><li><p>Influenza & S. pneumo vaccines (Circ 2021;144:14764 NEJM 2018;378:345); ✓ for depression</p></li></ul><p>ICD (Circ 2018;138:e272)</p><ul><li><p>Sust. VT/VF >2 d post-MI w/o revers. isch; ? ↓ death w/ wearable defib (NEJM 2018;379:1205)</p></li><li><p>1° prevention of SCD if post-MI EF ≤30–40% (NYHA II–III) or ≤30–35% (NYHA I); wait 40 d after MI (NEJM 2004;351:2481 & 2009;361:1427)</p></li></ul><p>PA CATHETER AND TAILORED THERAPY</p><p>Rationale</p><ul><li><p>Cardiac output (CO) = SV × HR; optimize SV (and thereby CO) by manipulating preload/ LVEDV (w/ IVF, diuretics), contractility (w/ inotropes), & afterload (w/ vasodilators)</p></li><li><p>Balloon at catheter tip inflated → floats into “wedge” position. Column of blood extends from tip of catheter, through pulm venous circulation to a point just prox to LA. Under conditions of no flow, PCWP ≈ LA pressure ≈ LVEDP, which is proportional to LVEDV.</p></li><li><p>Situations in which these basic assumptions fail:</p></li></ul><p>(1) Catheter tip not in West lung zone 3 (and ? PCWP = alveolar pressure ≠ LA pressure); clues include lack of a & v waves and if PA diastolic pressure &lt; PCWP</p><p>(2) PCWP >LA pressure (eg, mediastinal fibrosis, pulmonary VOD, PV stenosis)</p><p>(3) Mean LA pressure >LVEDP (eg, MR, MS)</p><p>(4) ∆ LVEDP-LVEDV relationship (ie, abnl compliance, ∴ “nl” LVEDP may not be optimal)</p><p>Indications (NEJM 2013;369:e35; Circ 2017;136:e268)</p><ul><li>Diagnosis and evaluation</li></ul><p>Ddx of shock (cardiogenic vs. distributive; espec if trial of IVF failed or is high risk) and of pulmonary edema (cardiogenic vs. not; espec if trial of diuretic failed or is high risk)</p><p>Evaluation of CO, intracardiac shunt, pulm HTN, MR, tamponade, cardiorenal syndrome</p><p>Evaluation of unexplained dyspnea (PAC during provocation w/ exercise, vasodilator)</p><ul><li>Therapeutics (Circ 2017;136:e232)</li></ul><p>Tailored therapy to optimize PCWP, SV, SMVO2, RAP, PVR in heart failure or shock</p><p>Guide to vasodilator therapy (eg, inhaled NO, nifedipine) in PHT, RV infarction</p><p>Guide periop mgmt in some high-risk Pts, candidacy for mech circ support & transplant</p><ul><li>Contraindications</li></ul><p>Absolute: right-sided endocarditis, thrombus/mass or mechanical valve; proximal PE</p><p>Relative: coagulopathy (reverse), recent PPM or ICD (place under fluoroscopy), LBBB (~5% risk of RBBB → CHB, place under fluoro), bioprosthetic R-sided valve</p><p>Efficacy concerns (NEJM 2006;354:2213; JAMA 2005;294:1664)</p><ul><li><p>No benefit to routine PAC use in high-risk surgery (JACC 2014;62:e77), sepsis, ARDS</p></li><li><p>No benefit in decompensated HF (JAMA 2005;294:1625); untested in cardiogenic shock</p></li><li><p>But: ~½ of clinical CO & PCWP estimates incorrect; CVP & PCWP not well correl.; ∴ use PAC to (a) answer hemodynamic ? and then remove, or (b) manage cardiogenic shock</p></li></ul><p>Placement (NEJM 2013;369:e35)</p><ul><li><p>Insertion site: R IJ or L subclavian veins preferred for “anatomic” flotation into PA</p></li><li><p>Inflate balloon (max 1.5 cc, mindful of resistance) when advancing and to measure PCWP</p></li><li><p>Deflate the balloon when withdrawing and at all other times</p></li><li><p>CXR should be obtained after placement to assess for catheter position and PTX</p></li><li><p>If catheter cannot be floated (i.e., severe TR, RV dilatation), consider fluoroscopic guidance</p></li></ul><p>Complications</p><ul><li><p>Central venous access: pneumo/hemothorax (~1%), arterial puncture (if inadvertent cannulation w/ dilation → surgical/endovasc eval), air embolism, thoracic duct injury</p></li><li><p>Advancement: atrial or ventricular arrhythmias (3% VT; 20% NSVT and >50% PVC), RBBB (5%), catheter knotting, cardiac perforation/tamponade, PA rupture</p></li><li><p>Maintenance: infection (espec if catheter >3 d old), thrombus, pulm infarction (≤1%), valve/chordae damage, PA rupture/pseudoaneurysm (espec w/ PHT), balloon rupture</p></li></ul><p>Intracardiac pressures</p><ul><li><p>Transmural pressure (≈ preload) = measured intracardiac pressure – intrathoracic pressure</p></li><li><p>Intrathoracic pressure (usually slightly ⊖) is transmitted to vessels and heart</p></li><li><p>Always measure intracardiac pressure at end-expiration, when intrathoracic pressure closest to 0 (“high point” in spont. breathing Pts; “low point” in Pts on ⊕ pressure vent.)</p></li><li><p>If ↑ intrathoracic pressure (eg, PEEP), measured PCWP overestimates true transmural pressures. Can approx by subtracting ~½ PEEP (× ¾ to convert cm H2O to mmHg).</p></li><li><p>PCWP: LV preload best estimated at a wave; risk of pulm edema driven by avg PCWP</p></li></ul><p>Cardiac output</p><ul><li><p>Thermodilution: saline injected in RA or intermittent heating of prox thermal filament in some PA lines (“continuous CO”). ∆ in temp over time measured at thermistor (in PA) used to calc CO. Inaccurate if ↓ CO, severe TR, or shunt.</p></li><li><p>Fick method: O2 consumption (L/min) = CO (L/min) × ∆ arteriovenous O2 content ∴ CO = O2/C(a-v)O2</p></li></ul><p>O2 ideally measured (esp. if ↑ metab demands), but freq estimated (125 mL/min/m2)</p><p>C(a-v)O2 = [10 × 1.36 mL O2/g of Hb × Hb g/dL × (SaO2 – SMVO2)]. SMVO2 is key var that ∆s.</p><p>If SMVO2 >80%, consider if the PAC is “wedged” (ie, pulm vein sat), L→R shunt, impaired O2 utilization (severe sepsis, cyanide, carbon monoxide), ↑↑ CO or FiO2.</p><p>PCWP waveform abnormalities: large a wave → ? mitral stenosis; large v wave → ? mitral regurgitation; blunted y descent → ? tamponade; steep x & y descents → ? constriction.</p><p>Surrogates: RA ≈ JVP (1 mmHg = 1.36 cm H2O); pulmonary edema on CXR implies ↑ PCWP; UOP ∝ CO (barring AKI); delayed capillary refill (ie, >2–3 sec) implies ↑ SVR</p><p>Tailored therapy in cardiogenic shock (Circ 2009;119:e391)</p><ul><li>Goals: optimize both MAP and CO while ↓ risk of pulmonary edema</li></ul><p>MAP = CO × SVR; CO = HR × SV (which depends on preload, afterload, and contractility)</p><p>pulmonary edema when PCWP >20–25 (↑ levels may be tolerated in chronic HF/MS)</p><p>hepatic and renal congestion (↓ GFR) occur when CVP/RAP >15 mmHg</p><ul><li>Optimize preload = LVEDV ≈ LVEDP ≈ LAP ≈ PCWP (NEJM 1973;289:1263)</li></ul><p>goal PCWP ~14–18 in acute MI, 14 in acute decompensated HF</p><p>optimize in individual Pt by measuring SV w/ different PCWP to create Starling curve</p><p>↑ by giving crystalloid (albumin w/o clinical benefit over NS; PRBC if significant anemia)</p><p>↓ by diuresis (qv), ultrafiltration or dialysis if refractory to diuretics or ESRD</p><ul><li>Optimize afterload ≈ wall stress during LV ejection = [(~SBP × radius) / (2 × wall thick.)] and ∴ ∝ MAP and ∝ SVR = (MAP – CVP / CO); goals: MAP >60, SVR 800–1200</li></ul><p>MAP >60 (& ∴ SVR ↑): vasodilators (eg, nitroprusside, NTG, ACEI, hydral.) or wean pressors</p><p>MAP &lt;60 (& ∴ SVR low/nl, ie, inappropriate vasoplegia): start with inopressor (eg, norepinephrine [α > β], dopamine [β → α w/ ↑ doses], epi [β > α at low doses]); better outcomes w/ norepi than dopa even in cardiogenic shock (NEJM 2010;362:779)</p><ul><li>Optimize contractility ∝ CO for given preload & afterload; goal CI = (CO / BSA) >2.2 if too low despite optimal preload & vasodilators (as MAP permits):</li></ul><p>⊕ inotropes: eg, dobutamine (mod inotrope & mild vasodilator) or milrinone (strong inotrope & vasodilator, incl pulm), both proarrhythmic, or epi (strong inotrope & pressor)</p><p>mech circulatory support (L/min): IABP (0.5), Impella (3.7–5.5), TandemHeart (5), VAD (L-sided, R-sided or both; temp or perm; 10) or ECMO (6) (JACC 2021;77:1243)</p><p>HEART FAILURE</p><p>Definitions (Braunwald’s Heart Disease, 12th ed., 2022)</p><ul><li><p>Failure of heart to pump blood forward at rate sufficient to meet metabolic demands of peripheral tissues, or ability to do so only at abnormally high cardiac filling pressures</p></li><li><p>Low output (↓ cardiac output) vs. high output (↑ stroke volume ± ↑ cardiac output)</p></li><li><p>Left-sided (pulmonary edema) vs. right-sided (↑ JVP, hepatomegaly, peripheral edema)</p></li><li><p>Backward (↑ filling pressures, congestion) vs. forward (impaired systemic perfusion)</p></li><li><p>Systolic (inability to expel sufficient blood) vs. diastolic (failure to relax and fill normally)</p></li><li><p>Reduced (HFrEF, EF &lt;40%), mildly reduced (HFmrEF, EF 40–49%), & preserved (HFpEF, EF >50%); combination of systolic and diastolic dysfxn may occur regardless of EF</p></li></ul><p>Figure 1-3 Approach to left-sided heart failure</p><p>History</p><ul><li><p>Low output: fatigue, weakness, exercise intolerance, ∆ MS, anorexia</p></li><li><p>Congestive: left-sided → dyspnea, orthopnea, paroxysmal nocturnal dyspnea</p></li></ul><p>right-sided → peripheral edema, RUQ discomfort, bloating, satiety</p><p>Functional classification (New York Heart Association class)</p><ul><li>Class I: no sx w/ ordinary activity; class II: sx w/ ordinary activity; class III: sx w/ minimal activity; class IV: sx at rest</li></ul><p>Physical exam (“2-minute” hemodynamic profile; JAMA 1996;275:630 & 2002;287:628)</p><ul><li>Congestion (“dry” vs. “wet”): ↑ JVP (~80% of the time JVP >10 → PCWP >22)</li></ul><p>⊕ hepatojugular reflux: ≥3 cm ↑ in JVP for ≥10–15 sec w/ abdominal pressure Se/Sp 73/87% for RA >8 and Se/Sp 55/83% for PCWP >15 (AJC 1990;66:1002)</p><p>Abnl Valsalva response: square wave (↑ SBP w/ strain), no overshoot (no ↑ BP after strain)</p><p>S3 (in Pts w/ HF → ~40% ↑ risk of HF hosp. or pump failure death; NEJM 2001;345:574)</p><p>Rales, dullness at base 2° pleural effus. (often absent in chronic HF due to lymphatic compensation) ± hepatomegaly, ascites and jaundice, peripheral edema</p><ul><li>Perfusion (“warm” vs. “cold”)</li></ul><p>narrow pulse pressure (&lt;25% of SBP) → CI &lt;2.2 (91% Se, 83% Sp; JAMA 1989;261:884);</p><p>soft S1 (↓ dP/dt), pulsus alternans, cool & pale extremities, ↓ UOP, muscle atrophy</p><ul><li>± Other: Cheyne-Stokes resp., abnl PMI (diffuse, sustained or lifting depending on cause of HF), S4 (diast. dysfxn), murmur (valvular dis., ↑ MV annulus, displaced papillary muscles)</li></ul><p>Evaluation for the presence of heart failure</p><ul><li><p>CXR (see Radiology insert): pulm edema, pleural effusions ± cardiomegaly, cephalization, Kerley B-lines; lung U/S better than CXR (PPV & NPV 92% vs. 77%; Chest 2015;148:202)</p></li><li><p>BNP/NT-proBNP can help exclude HF; levels ↑ w/ age, renal dysfxn, AF; ↓ w/ obesity Se ≥95%, Sp: ~50%, PPV ~65%, NPV ≥ 94% for HF in Pts p/w SOB (BMJ 2015;350:h910)</p></li><li><p>Evidence of ↓ organ perfusion: ↑ Cr, ↓ Na, abnl LFTs</p></li><li><p>Echo (see inserts): ↓ EF & ↑ chamber size → systolic dysfxn; hypertrophy, abnl MV inflow, abnl tissue Doppler → ? diastolic dysfxn; abnl valves or pericardium; ↑ estimated RVSP</p></li><li><p>PA catheterization: ↑ PCWP, ↓ CO, and ↑ SVR (in low-output failure)</p></li></ul><p>Evaluation for the potential causes of heart failure</p><ul><li><p>ECG: evidence for CAD, LVH, LAE, heart block or low voltage (? infiltrative CMP/DCM)</p></li><li><p>TTE: LV & RV size & fxn, valve abnl (cause or consequence?), infiltrative or pericardial dis.</p></li><li><p>Cardiac MRI: distinguishes ischemic vs. nonischemic and can help determine etiol. of latter</p></li><li><p>Coronary angio (or noninvasive imaging, eg, CT angio); if no CAD, w/u for NICM</p></li></ul><p>Precipitants of acute heart failure</p><ul><li><p>Dietary indiscretion or medical nonadherence (~40% of cases)</p></li><li><p>Myocardial ischemia or infarction (~10–15% of cases); myocarditis</p></li><li><p>Renal failure (acute, progression of CKD, or insufficient dialysis) → ↑ preload</p></li><li><p>Hypertensive crisis (incl. from RAS), worsening AS → ↑ left-sided afterload</p></li><li><p>Drugs (βB, CCB, NSAIDs, TZDs), chemo (anthracyclines, trastuzumab), or toxins (EtOH)</p></li><li><p>Arrhythmias; acute valvular dysfxn (eg, endocarditis), espec mitral or aortic regurgitation</p></li><li><p>COPD/PE → ↑ right-sided afterload; extreme stress; anemia; systemic infxn; thyroid dis.</p></li></ul><p>Rx of acute decompens. HF (NEJM 2017;377:1964)</p><ul><li><p>Assess congestion & adequacy of perfusion</p></li><li><p>For congestion: “LMNOP”</p></li></ul><p>Lasix IV; 1–2.5× usual total daily PO dose Ø clear diff between gtt vs. q12h IV</p><p>Morphine (↓ sx, venodilator, ↓ afterload)</p><p>Nitrates (venodilator)</p><p>Oxygen ± noninvasive ventilation</p><p>Position (sitting up & legs dangling over side of bed → ↓ preload)</p><ul><li><p>For low perfusion, see below</p></li><li><p>Adjustment of home oral meds: prefer to continue, except:</p></li></ul><p>ACEI/ARB/ARNI: hold or ↓ dose if HoTN; ∆ to hydralazine & nitrates w/ AKI</p><p>βB: hold if evidence of hypoperfusion or HoTN</p><p>Treatment of acute advanced heart failure (Circ 2013;128:e240)</p><ul><li><p>Consider PAC if not resp to Rx, unsure re: vol status, HoTN, hypoperfusion, need inotropes</p></li><li><p>Tailored Rx w/ PAC (qv); goals of MAP >60, CI >2.2 (MVO2 >60%), SVR &lt;800, PCWP &lt;18</p></li><li><p>IV vasodilators: NTG, nitroprusside (risk of coronary steal if CAD)</p></li><li><p>Inotropes (properties in addition to ↑ inotropy listed below)</p></li></ul><p>dobutamine: vasodilation at doses ≤5 µg/kg/min; mild ↓ PVR; desensitization over time</p><p>dopamine: splanchnic vasodil. → ↑ GFR & natriuresis; vasoconstrictor at ≥5 µg/kg/min</p><p>milrinone: prominent systemic & pulmonary vasodilation; ↓ dose by 50% in renal failure</p><ul><li>Mechanical circulatory support (also see “Tailored Therapy;” JACC 2015;65:e7 & 2542)</li></ul><p>Temporary: bridge to recovery, transplant, or durable MCS; periprocedural support</p><p>Intra-aortic balloon pump (IABP): inflates in diastole & deflates in systole to ↓ impedance to LV ejection, ↓ myocardial O2 demand & ↑ coronary perfusion; +0.5 L/min CO</p><p>Axial flow pumps (eg, Impella): Archimedes screw principle in LV; +3.7–5.5 L/min</p><p>Extracorporeal centrifugal pumps: TandemHeart (+5 L/min, percutaneous) & CentriMag (10 L/min, surgical)</p><p>Extracorporeal membrane oxygenation (ECMO): 6 L/min (JACC HF 2018;6:503)</p><p>Durable: surgically placed LVAD ± RVAD as bridge to sufficient recovery (in 5–50% of niCMP; JACC 2017;69:1924), to transplant or as destination Rx (>50% ↓ 1-y mort. vs. med Rx; NEJM 2001;345:1435 & 2009;361:2241). Current preferred option is fully magnetically levitated centrifugal flow pump (HeartMate 3), ↓ stroke or re-op vs. axial flow models (NEJM 2019;380:1618).</p><ul><li>Cardiac transplantation: ~2200/yr in U.S. &lt;10% mort. in 1st y, median survival ~13 y</li></ul><p>Recommended Chronic Therapy by HF Stage (JACC 2021;77:772)</p><p>Stage (not NYHA Class)</p><p>Therapy</p><p>A</p><p>At risk for HF (eg, HTN); but asx & w/o struct. dis.</p><p>Rx HTN, lipids, DM; stop smoking, EtOH; ↑ exercise</p><p>ACEI/ARB if HTN/DM/CAD/PAD</p><p>B</p><p>⊕ Struct. heart dis.</p><p>(eg, CMP, LVH), but asx</p><p>As per stage A + ACEI/ARB + βB if MI/CAD or ↓ EF. ? ICD.</p><p>C</p><p>⊕ Struct. heart dis.</p><p>⊕ Any h/o Sx of HF</p><p>As per stage A + diuretics, ↓ Na.</p><p>If ↓ EF: ARNI, ACEI or ARB; βB; aldo antag; SGLT2i; ICD; ? CRT; ± nitrate/hydral; ± dig.</p><p>If preserved EF: ? ARNI; ? aldo antag; SGLT2i</p><p>D</p><p>Refractory HF requiring specialized interventions</p><p>All measures for stages A–C. Consider IV inotropes, VAD, transplant, end-of-life care (4-y mortality >50%)</p><ul><li><p>Utility of BNP-guided Rx (inPt and outPt) remains debated (Eur Heart J 2014;35:16)</p></li><li><p>Implantable PA pressure sensor in sx Pts: ~19–37% ↓ risk of hosp (Lancet 2016;387:453 & 2021;398:991)</p></li></ul><p>Treatment of Chronic HF with Reduced EF (Circ 2017;136:e137; JACC 2021;77:772)</p><p>Diuretics</p><p>Loop ± thiazides diuretics (sx relief; no mortality benefit)</p><p>RASi</p><p>Choose one of ARNI (ARB + neprilysin inhib),</p><p>ACEI or ARB</p><p>36-hr washout when transitioning ACEI to ARNI</p><p>ARNI preferred RASi in NYHA II–IV. Neutral endopeptidase (NEP, aka neprilysin) degrades natriuretic peptides, bradykinin & angiotensins. Valsartan + sacubitril (NEPi) ↓ CV mort & HF hosp c/w ACEi; ↑ HoTN, AKI (NEJM 2014;371:993 & 2019;380:539). Contraindicated if h/o angioedema.</p><p>ACEI: if unable to tolerate or afford ARNI. ↓ mortality vs. placebo. High-dose more effic. than low. Watch for ↑ Cr, ↑ K (ameliorate by low-K diet, diuretics, K binders), cough, angioedema.</p><p>ARB: consider if cannot tolerate ACEI (eg, b/c cough) as noninferior</p><p>β-blocker</p><p>(data for carvedilol, metoprolol, bisoprolol)</p><p>Add in concert w/ RASi</p><p>35% ↓ mort. & 40% ↓ rehosp. in NYHA II–IV (JAMA 2002;287:883)</p><p>EF will transiently ↓, then ↑. Contraindicated in ADHF.</p><p>Carvedilol superior to low-dose metop in 1 trial (Lancet 2003;362:7), but meta-analysis suggests no diff between βB (BMJ 2013;346:f55).</p><p>Aldosterone antagonists</p><p>Add after RASi and bB if adeq. renal fxn and w/o hyperkalemia</p><p>25–30% ↓ mort. in NYHA II–IV & EF ≤35% (NEJM 2011;364:11)</p><p>15% ↓ mort. in HF post-MI, EF ≤40% (EPHESUS, NEJM 2003;348:1309)</p><p>Watch for ↑ K. Do not use if GFR &lt;30 or K ≥5</p><p>SGLT2i</p><p>~25% ↓ death or HF hospitalization in NYHA II–IV (DAPA-HF, NEJM 2019; 381:1995, EMPEROR-Reduced; NEJM 2020;383:1413).</p><p>Hydralazine + nitrates</p><p>Consider if cannot tolerate ACEI/ARB or in black Pts w/ class III/IV</p><p>25% ↓ mort. (NEJM 1986;314:1547); infer. to ACEI (NEJM 1991;325:303)</p><p>40% ↓ mort. in blacks on standard Rx (A-HEFT, NEJM 2004;351:2049)</p><p>Ivabradine (If blocker w/o ⊖ ino)</p><p>Reasonable if EF ≤35%, NYHA II or III, HR ≥70, NSR on max bB.</p><p>18% ↓ CV mort or HF hosp (Lancet 2010;376:875)</p><p>Digoxin</p><p>23% ↓ HF hosp., no ∆ mort (NEJM 1997;336:525); ? ↑ mort w/ ↑ levels (NEJM 2002;347:1403); optimal 0.5–0.8 ng/mL (JAMA 2003;289:871)</p><p>Vericiguat</p><p>10% ↓ CV mort or HF hosp in NYHA II–IV (NEJM 2020;382:1883)</p><p>Cardiac resynch therapy (CRT, qv)</p><p>Consider if EF ≤35%, LBBB (QRS ≥130 ms) and symptomatic HF</p><p>36% ↓ mort. & ↑ EF in NYHA III–IV (CARE-HF, NEJM 2005;352:1539)</p><p>41% ↓ mort. if EF ≤30%, LBBB and NYHA I/II (NEJM 2014;370:1694)</p><p>ICD (see “Cardiac Rhythm Mgmt Devices”)</p><p>For 1° prevention if EF ≤30–35% or 2° prevention; not if NYHA IV</p><p>↓ mort. in ischemic CMP but perhaps only SCD in modern era in niCMP (NEJM 2005;352:225 & 2016;375:1221)</p><p>Iron supplementation</p><p>? IV (not PO) if NYHA II/III, EF ≤40%, Fe-defic (ferritin &lt;100 or 100– 300 & TSAT &lt;20%). ~20% ↓ HF hosp. (Lancet 2020;396:1895).</p><p>Anticoagulation</p><p>If AF, VTE, LV thrombus, ± if large akinetic LV segments.</p><p>Heart rhythm</p><p>If AF & NYHA II–IV w/ EF &lt;35%, catheter ablation ↓ D/HF hosp vs. med Rx (rate or rhythm; NEJM 2018;378:417)</p><p>BP</p><p>Goal &lt;130/80 (JACC 2018;71:127)</p><p>Diet, exercise</p><p>? Na &lt;2 g/d, fluid restriction, exercise training in ambulatory Pts</p><p>Meds to avoid</p><p>NSAIDs, nondihydropyridine CCB, TZDs</p><p>(Circ 2013;128:e240 & 2016;134:e282; EHJ 2016;37:2129)</p><p>Heart failure with preserved EF (HFpEF; “Diastolic HF”) (JACC 2022;epub)</p><ul><li><p>Epidemiology: ~½ of Pts w/ HF have normal (EF ≥50%); risk factors for HFpEF incl ↑ age, ♀, DM, AF. Mort ≈ to those w/ HFrEF.</p></li><li><p>Etiologies (impaired relaxation and/or ↑ passive stiffness): ischemia, prior MI, LVH, HCMP, infiltrative CMP, RCMP, aging, hypothyroidism</p></li><li><p>Precipitants of pulmonary edema: volume overload (poor compliance of LV → sensitive to small ↑ in volume); ischemia (↓ relaxation); tachycardia (↓ filling time in diastole), AF (loss of atrial boost to LV filling); HTN (↑ afterload → ↓ stroke volume)</p></li><li><p>Dx w/ clinical s/s of HF w/ preserved systolic fxn. Dx supported by evidence of diast dysfxn:</p></li></ul><p>(1) echo: impaired relaxation using tissue Doppler (eg, e′ &lt;9 cm/s), high filling pressures ± impaired relaxation (eg, E/e′ ≥15), large left atrium</p><p>(2) exercise-induced ↑ PCWP ± inadequate ↑ stroke volume or CO</p><ul><li>Treatment: diuresis, Rx HTN, tachycardia, and ischemia</li></ul><p>SGLT2i ↓ CV death or HF hosp (NEJM 2021;385:1451; DELIVER)</p><p>Nonsignficiant trends toward benefit for ARB vs. placebo. ARNI ↓ CV death or hosp for HF in HFpEF Pts w/ LVEF &lt;60% (NEJM 2019; 381:1609)</p><p>Spironolactone likely ↓ HF hospitalization (NEJM 2014;370:1383; Circ 2015;131:34)</p><p>CARDIOMYOPATHIES</p><p>Diseases with mechanical and/or electrical dysfunction of the myocardium</p><p>DILATED CARDIOMYOPATHY (DCM)</p><p>Definition and epidemiology (JACC 2016;67:2996; Lancet 2017;390:400)</p><ul><li>LV or biventricular dilatation and global ↓ contractility ± ↓ wall thickness in the absence of ischemia/infarct, valvular disease or HTN. Pts w/ prior MI complicated by LV dilation and ↓ EF are often termed “ischemic CMP.”</li></ul><p>Etiologies (JACC 2021;77:2551; can also be prior myocarditis, vide infra)</p><ul><li><p>Familial/genetic (>35%): Pt & ≥2 closely related family members w/ unexplained DCM; ~30 genes identified to date, encoding structural & nuclear proteins (eg, titin)</p></li><li><p>Idiopathic (&lt;20%): ? undx infectious, EtOH, or genetic cause; ¼ w/ e/o DCM in relative</p></li><li><p>Toxic: alcohol (~20%) typ. 7–8 drinks/d × >5 y, but variable; cocaine; XRT (usu RCMP);</p></li></ul><p>anthracyclines (risk ↑ >550 mg/m2, may manifest late), CYC, trastuzumab, TKIs.</p><ul><li><p>Infiltrative (5%): typically RCMP (qv), but can be DCMP with thickened walls; amyloidosis, sarcoidosis, hemochromatosis, tumor</p></li><li><p>Peripartum (onset last mo → 5 mo postpartum; JACC 2020;75:207): ~1:2000; ↑ risk w/ multip, ↑ age, Afr Am; stnd HF Rx (if preg, no ACEI or spironolact.); ~30% recur w/ next preg</p></li><li><p>Stress-induced (Takotsubo = apical ballooning): typically postmenopausal ♀; mimics MI (chest pain, ± STE & ↑ Tn; deep TWI & ↑ QT); mid/apex dyskinesis; ? Rx w/ βB, ACEI; usu. improves over wks (JAMA 2011;306:277). In-hosp morb/mort similar to ACS (NEJM 2015;373:929).</p></li><li><p>Tachycardia (JACC 2019;73:2328): likelihood ∝ rate/duration; often resolves w/ rate cntl</p></li><li><p>Arrhythmogenic right ventricular cardiomyopathy (ACM/ARVC): fibrofatty replacement of RV → dilation (dx w/ MRI); ECG: ± RBBB, TWI V1–V3, ε wave; VT risk (NEJM 2017;376:61)</p></li><li><p>LV noncompaction (Lancet 2015;386:813): prominent trabeculae, arrhythmias, cardioemboli</p></li><li><p>Metab/other: hypothyroid, acromegaly, pheo, OSA, Vit B1, selenium or carnitine defic.</p></li></ul><p>Clinical manifestations</p><ul><li>Heart failure: both congestive & poor forward flow sx; signs of L- & R-sided HF</li></ul><p>diffuse, laterally displaced PMI, S3, ± MR or TR (annular dilat., displaced pap. muscle)</p><ul><li>Embolic events (~10%), supraventricular/ventricular arrhythmias, & palpitations</li></ul><p>Diagnostic studies and workup (JACC 2016;67:2996)</p><ul><li><p>ECG: may see PRWP, Q waves, or BBB; low-voltage; AF (20%); may be normal</p></li><li><p>Echocardiogram: LV dilatation, ↓ EF, regional or global LV HK ± RV HK, ± mural thrombi</p></li><li><p>Cardiac MRI: high Se for myocarditis or infiltration; extent of scar correlated w/ mortality</p></li><li><p>Labs: TFTs, Fe panel, HIV, SPEP, ANA; viral sero not recommended; others per suspicion</p></li><li><p>Family hx (20–35% w/ familial dis.), genetic counseling ± genetic testing (JAMA 2009;302:2471)</p></li><li><p>Coronary CT angiography (or invasive) to r/o CAD if risk factors, h/o angina, Qw MI</p></li><li><p>Endomyocardial biopsy: consider if fulminant myocarditis or suspect infiltrative disease</p></li></ul><p>Treatment (see “Heart Failure” for standard HF Rx)</p><ul><li><p>Possibility of reversibility of CMP may temper implantation of devices</p></li><li><p>Prognosis differs by etiology (NEJM 2000;342:1077): postpartum (best), ischemic/GCM (worst)</p></li></ul><p>MYOCARDITIS</p><p>Etiologies</p><ul><li>Infectious (Lancet 2012;379:738; JACC 2012;59:779)</li></ul><p>Viruses (parvoB19, Coxsackie, adeno, HIV, SARS-CoV-2/vaccine, etc.)</p><p>Bacterial, fungal, rickettsial, TB, Lyme (mild myocarditis, often with AVB)</p><p>Chagas: apical aneurysm ± thrombus, RBBB, megaesophagus/colon (Lancet 2018;391:82)</p><ul><li>Autoimmune</li></ul><p>Idiopathic giant cell myocarditis (GCM): avg age 42, fulminant, AVB/VT (Circ HF 2013;6:15)</p><p>Eosinophilic (variable peripheral eos): hypersensitivity (mild HF but at risk for SCD) or acute necrotizing eosinophilic myocarditis (ANEM; STE, effusion, severe HF)</p><p>Collagen vasc. dis. (pericarditis >myocarditis): PM, SLE, scleroderma, PAN, RA, EGPA</p><p>Clinical manifestations</p><ul><li><p>Highly variable, ranging from incidental dx based on labs/imaging to fulminant HF w/ shock</p></li><li><p>Can present as ACS-like syndrome (chest pain, ECG Δs, ↑ Tn), acute HF, arrhythmias</p></li></ul><p>Diagnostic studies and workup</p><ul><li><p>Echo: systolic dysfxn (typically global but can be regional); ± ↑ LV wall thickness due to edema; LV size may be small in fulminant and dilated in chronic; ± pericardial effusion</p></li><li><p>Cardiac MRI: can show hyperemia, edema, and scar (JACC 2009;53:1475)</p></li><li><p>Endomyocardial biopsy: useful in GCM & eosinophilic; ∴ consider if rapidly progressive HF, high-grade AVB or sustained VT, suspected allergic rxn or eosinophilia</p></li></ul><p>Treatment</p><ul><li><p>Standard HF Rx if LV dysfxn (but do not start if e/o shock); temporary MCS as needed</p></li><li><p>Immunosuppression: for GCM (high-dose steroids + CsA or tacrolimus ± AZA), collagen vascular disease, peripartum (? IVIg), & eosinophilic; no proven benefit if viral</p></li></ul><p>HYPERTROPHIC CARDIOMYOPATHY (HCM)</p><p>Definition, epidemiology, pathology (Circ Res 2017;121:749)</p><ul><li><p>LV (usually ≥15 mm) and/or RV hypertrophy disproportionate to hemodynamic load</p></li><li><p>Due to gene mutations affecting proteins of or related to sarcomere; prev.: ~1/200-500</p></li><li><p>Myocardial fiber disarray with hypertrophy, which creates arrhythmogenic substrate</p></li><li><p>Many morphologic hypertrophy variants: asymmetric septal; concentric; midcavity; apical</p></li><li><p>Ddx: LVH 2° to HTN, AS, elite athletes (wall usually &lt;13 mm & symmetric and nl/↑ rates of tissue Doppler diastolic relaxation; Circ 2011;123:2723), Fabry dis. (↑ Cr, skin findings)</p></li></ul><p>Pathophysiology</p><ul><li><p>LV outflow tract obstruction (LVOTO) in ≥70%: narrowed tract 2° hypertrophied septum + systolic anterior motion (SAM) of ant. MV leaflet (may be fixed, variable, or nonexistent) and papillary muscle displacement. Gradient (∇) worse w/ ↑ contractility (digoxin, β- agonists, exercise, PVCs), ↓ preload (eg, Valsalva maneuver) or ↓ afterload.</p></li><li><p>Mitral regurgitation: due to SAM (mid-to-late, post.-directed regurg. jet) and/or abnl</p></li></ul><p>mitral leaflets and papillary muscles (pansystolic, ant.-directed regurg. jet)</p><ul><li><p>Diastolic dysfunction: ↑ chamber stiffness + impaired relaxation</p></li><li><p>Ischemia: small vessel dis., perforating artery compression (bridging), ↓ coronary perfusion</p></li></ul><p>Clinical manifestations (70% are asymptomatic at dx)</p><ul><li><p>Dyspnea (90%): due to ↑ LVEDP, MR, and diastolic dysfunction</p></li><li><p>Angina (25%) even w/o epicardial CAD; microvasc. dysfxn (NEJM 2003;349:1027)</p></li><li><p>Arrhythmias (AF in 20–25%; VT/VF): palpitations, syncope, sudden cardiac death</p></li></ul><p>Physical exam</p><ul><li><p>Sustained PMI, S2 paradoxically split if severe outflow obstruction, ⊕ S4 (occ. palpable)</p></li><li><p>Systolic murmur: crescendo-decrescendo; LLSB; ↑ w/ Valsalva & standing (↓ preload)</p></li><li><p>± mid-to-late or holosystolic murmur of MR at apex</p></li><li><p>Bifid (biphasic) carotid pulse (brisk rise, decline, then 2nd rise); JVP w/ prominent a wave</p></li><li><p>Contrast to AS, which has murmur that ↓ w/ Valsalva and ↓ carotid pulses</p></li></ul><p>Diagnostic studies (EHJ 2014;35:2733)</p><ul><li><p>ECG: LVH, anterolateral TWI and inferior pseudo-Qw, ± apical giant TWI (apical variant)</p></li><li><p>Echo: any LV wall segment ≥15 mm (or ? even ≥13 if ⊕ HFx), often but not necessarily involving septum; other findings include dynamic outflow obstruction, SAM, MR</p></li><li><p>MRI: hypertrophy + patchy delayed enhancement (useful for dx & prog) (Circ 2015;132:292)</p></li><li><p>Cardiac cath: subaortic pressure ∇; Brockenbrough sign = ↓ pulse pressure post-PVC (in contrast to AS, in which pulse pressure ↑ post-PVC); spike & dome Ao pressure pattern</p></li><li><p>Consider genotyping for family screening; pathogenic variant ID’d in &lt;½ (Circ 2020;142:e558)</p></li></ul><p>Treatment (Circ 2020;142:e558; Lancet 2021;398:2102; JACC 2022;79:390)</p><ul><li>Heart failure</li></ul><p>⊖ inotropes/chronotropes: β-blockers (JACC 2021;78:2505), CCB (verapamil), disopyramide</p><p>Careful use of diuretics, because may further ↓ preload. If LVOTO, avoid vasodilators. Avoid digoxin b/c ↑ contractility and ∴ outflow obstruction.</p><p>If sx refractory to drug Rx + obstructive physio. (∇ ≥30 mmHg at rest or w/ provocation):</p><p>(a) Surgical myectomy: long-term ↓ symptoms in 90% (Circ 2014;130:1617)</p><p>(b) Alcohol septal ablation (JACC 2018;72:3095): ∇ ↓ by ~80%, only 5–20% remain w/ NYHA III–IV sx; 14% require repeat ablation or myectomy. Good alternative for older Pts, multiple comorbidities. Complic: transient (& occ. delayed) 3° AVB w/ 10–20% req. PPM; VT due to scar formation.</p><p>Mavacamten (cardiac myosin inhibitor) ↓ HF sxs & LVOT ∇ (Lancet 2020;396,750)</p><p>If refractory to drug therapy and there is nonobstructive pathophysiology: transplant</p><ul><li><p>Acute HF: can be precip. by dehydration or tachycardia; Rx w/ fluids, βB, phenylephrine</p></li><li><p>AF: rate control w/ βB, maintain SR w/ disopyramide or amio; low threshold to anticoag</p></li><li><p>ICD if VT/VF. Reasonable for 1° prevention if ≥1 risk factor: ⊕ FHx SCD, unexplained syncope, LV wall ≥30 mm, LV aneurysm or EF &lt;50%; consider if NSVT, failure of SBP to ↑ or fall from peak ≥20 mmHg w/ exercise, ? extensive MRI delayed enhancement. EPS not useful. HCM Risk-SCD Score (
<a href=https://doc2do.com/hcm/webHCM.html%29 rel=noopener>https://doc2do.com/hcm/webHCM.html)</a>.</p></li><li><p>Counsel to avoid dehydration, extreme exertion</p></li><li><p>1st-degree relatives: screen w/ TTE q12–18m as teen or athlete then q5y as adult, ECG (because timing of HCMP onset variable). Genetic testing if known mutation.</p></li></ul><p>RESTRICTIVE & INFILTRATIVE CMP</p><p>Definition (JACC 2018;71:1130 & 1149)</p><ul><li><p>Restrictive CMP: ↓ ventricular filling with ↓ compliance in nonhypertrophied, nondilated ventricles; nl/↓ diastolic volumes, nl or near-nl EF; must r/o pericardial disease</p></li><li><p>Infiltrative CMP: myocardial deposition; ± ↑ wall thickness; may present as RCM or DCM</p></li></ul><p>Etiologies (JACC 2018;71:1130 & 1149)</p><ul><li>Amyloidosis: age at presentation ~60 y; ♂:♀ = 3:2</li></ul><p>AL (eg, MM, etc.); familial (transthyretin, ATTR-m); senile (ATTR-wt)</p><p>ECG: ↓ QRS amplitude (50%), pseudoinfarction pattern (Qw), AVB (10–20%), hemiblock (20%), BBB (5–20%)</p><p>Echo: biventricular wall thickening (yet w/ low voltage on ECG), granular sparkling (30%), biatrial enlargement (40%), valve thickening, small effusions</p><p>Normal ECG voltage & septal thickness has NPV ~90%</p><p>Cardiac MRI: distinct late gadolinium enhancement pattern (JACC 2008;51:1022)</p><ul><li>Sarcoidosis (can also be DCM): presents at age ~30 y; ↑ in blacks, N. Europe, ♀</li></ul><p>Cardiac involvement in 25–58% of sarcoid, many not overt; cardiac w/o systemic in 10%</p><p>ECG: AVB (75%), RBBB (20–60%), VT; PET: ↑ FDG uptake in affected area</p><p>Echo: regional WMA (particularly basal septum) w/ thinning or mild hypertrophy</p><p>Cardiac MRI: T2 early gad (edema); fibrosis/scar in basal septum; LGE prognostic</p><ul><li>Other myocardial processes</li></ul><p>Hemochromatosis: often middle-aged men (espec N. European); 15% w/ cardiac sx</p><p>Diabetes; radiation (also accelerated athero, valvular disease, constrictive pericarditis)</p><p>Autoimmune (scleroderma, polymyositis-dermatomyositis)</p><ul><li><p>Endomyocardial diseases: carcinoid heart disease (R-sided HF w/ TR/TS, PR/PS); Löffler’s endocarditis (↑ eos; mural thrombi that can embolize; fibrosis); endomyocardial fibrosis (tropical climates; resembles Löffler’s but w/o eos)</p></li><li><p>Storage diseases: Fabry (glycosphingolipids); Gaucher (glucocerebrosidase)</p></li></ul><p>Pathophysiology</p><ul><li><p>↓ myocardial compliance → nl EDV but ↑ EDP → ↑ systemic & pulm. venous pressures</p></li><li><p>↓ ventricular cavity size → ↓ SV and ↓ CO</p></li></ul><p>Clinical manifestations (JACC 2018;71:1130 & 1149)</p><ul><li><p>Right-sided >left-sided heart failure with peripheral edema >pulmonary edema</p></li><li><p>Diuretic “refractoriness”; thromboembolic events</p></li><li><p>Poorly tolerated tachyarrhythmias; VT → syncope/sudden cardiac death</p></li></ul><p>Physical exam</p><ul><li><p>↑ JVP, ± Kussmaul’s sign (JVP not ↓ w/ inspir., classically seen in constrict. pericarditis)</p></li><li><p>Cardiac: ± S3 and S4, ± murmurs of MR and TR</p></li><li><p>Congestive hepatomegaly, ± ascites and jaundice, peripheral edema</p></li></ul><p>Diagnostic studies</p><ul><li><p>CXR: normal ventricular chamber size, enlarged atria, ± pulmonary congestion</p></li><li><p>ECG: low voltage, pseudoinfarction pattern (Qw), ± arrhythmias</p></li><li><p>Echo: ± symmetric wall thickening, biatrial enlarge., ± mural thrombi, ± cavity oblit. w/ diast dysfxn: ↑ early diast (E) and ↓ late atrial (A) filling, ↑ E/A ratio; ↓ mitral annular velocity (e′) on tissue Doppler, ↑ E/e′ ratio</p></li><li><p>Cardiac MRI/PET: may reveal inflammation or evidence of infiltration (but nonspecific)</p></li><li><p>Amyloid (qv) workup: ✓ for plasma cell dyscrasia (immunofix. & serum free light chains). If ⊕ → fat pad bx. If ⊖ → PYP SPECT for TTR evaluation (not AL).</p></li><li><p>Endomyocardial biopsy if suspect amyloid (Se ~100%) & noninvasive tests non-dx. Se low for sarcoidosis b/c patchy disease infiltrative process.</p></li><li><p>Cardiac catheterization</p></li></ul><p>Atria: M’s or W’s (prominent x and y descents)</p><p>Ventricles: dip & plateau (rapid ↓ pressure at onset of diastole, rapid ↑ to early plateau)</p><p>Concordance of LV–RV pressure peaks w/ respiration (vs. discordance in constriction)</p><ul><li>Restrictive cardiomyopathy vs. constrictive pericarditis: see “Pericardial Disease”</li></ul><p>Treatment (in addition to Rx’ing underlying disease)</p><ul><li><p>Gentle diuresis. May not tolerate CCB or other vasodilators.</p></li><li><p>Control HR (but can ↓ CO); maintain SR (helps filling). Digoxin ↑ arrhythmias in amyloid.</p></li><li><p>Anticoagulation (particularly with AF or low CO)</p></li><li><p>Transplantation for refractory cases</p></li><li><p>AL amyloid: Rx targeted at plasma cell dyscrasia</p></li><li><p>ATTR amyloid: tafamidis (TTR binder) ↓ death and CV hosp, ↑QoL (NEJM 2018;379:1007)</p></li><li><p>Sarcoid: consider steroids/immunomodulators if FDG PET ⊕ for inflammation + AVB, VT or LV dysfxn; ↑ risk for VT; unique indications for ICD placement (Circ 2018;138:e272)</p></li></ul><p>VALVULAR HEART DISEASE</p><p>AORTIC STENOSIS (AS)</p><p>Etiology</p><ul><li><p>Calcific: predominant cause in Pts >70 y; risk factors: HTN, ↑ LDL-C, ↑ Lp(a), ESRD</p></li><li><p>Congenital (ie, bicuspid AoV w/ premature calcification): cause in 50% of Pts &lt;70 y</p></li><li><p>Rheumatic heart disease (AS usually accompanied by AR and MV disease)</p></li><li><p>AS mimickers: subvalvular (HCMP, subaortic membrane) or supravalvular stenosis</p></li></ul><p>Clinical manifestations (usually indicates AVA &lt;1 cm2 or concomitant CAD)</p><ul><li><p>Angina: ↑ O2 demand (hypertrophy) + ↓ O2 supply (↓ cor perfusion pressure) ± CAD</p></li><li><p>Syncope (exertional): peripheral vasodil. w/ fixed CO → ↓ MAP → ↓ cerebral perfusion</p></li><li><p>Heart failure: outflow obstruct + diastolic dysfxn → pulm. edema, esp. if ↑ HR/AF (↓ LV fill.)</p></li><li><p>Acquired vWF disease (~20% of sev. AS): destruction of vWF; GI angiodysplasia</p></li><li><p>Natural hx: usually slowly progressive (AVA ↓ ~0.1 cm2/y, but varies; Circ 1997;95:2262), until sx develop; mean survival based on sx: angina = 5 y; syncope = 3 y; CHF = 2 y</p></li></ul><p>Physical exam</p><ul><li><p>Midsystolic crescendo-decrescendo murmur at RUSB, harsh, high-pitched, radiates to carotids, apex (holosystolic = Gallavardin effect), ↑ w/ passive leg raise, ↓ w/ standing & Valsalva. Dynamic outflow obstruction (HCM) is the reverse.</p></li><li><p>Ejection click after S1 sometimes heard with bicuspid AoV</p></li><li><p>Signs of severity: late-peaking murmur, paradoxically split S2 or inaudible A2, small and delayed carotid pulse (“pulsus parvus et tardus”), LV heave, ⊕ S4 (occasionally palpable)</p></li></ul><p>Pathophys Heart Dis., 7th ed., 2021, for this et al.</p><p>Diagnostic studies</p><ul><li><p>ECG: may see LVH, LAE, LBBB, AF (in late disease)</p></li><li><p>CXR: cardiomegaly, AoV calcification, poststenotic dilation of ascending Ao, pulmonary congestion</p></li><li><p>Echo: valve morph., jet velocity → estimate pressure gradient (∇) & calculate AVA, dimensionless index (DI); LVEF</p></li><li><p>Cardiac cath: usually to r/o CAD (in ~½ of calcific AS); for hemodyn. if disparity between exam & echo: ✓ pressure gradient (∇) across AoV, calc AVA (underestim. if mod/sev AR)</p></li><li><p>Dobutamine challenge (echo or cath): if low EF and mean ∇ &lt;40, use to differentiate:</p></li></ul><p>Afterload mismatch: 20% ↑ SV & ∇, no ∆ AVA (implies contractile reserve, ↑ EF post-AVR)</p><p>Pseudostenosis: 20% ↑ SV, no ∆ in ∇, ↑ AVA (implies low AVA artifact of LV dysfxn)</p><p>Limited contractile reserve: no ∆ SV, ∇ or AVA (implies EF prob. will not improve w/ AVR)</p><p>aAVA indexed to BSA &lt;0.6 cm2/m2 also severe (use for smaller Pts); bDSE → max jet vel ≥4 & AVA ≤1.0; cSmall LV w/ ↓ stroke vol (LVSVi &lt;35 mL/m2), severe LVH with marked diastolic dysfunction, consider cardiac amyloid</p><p>Valve replacement (Circ 2021;143:e72)</p><ul><li><p>Based on symptoms: once they develop → AVR needed</p></li><li><p>Indicated in: sx severe (stage D1; D2; D3 if AS felt to be cause of sx); asx severe + EF &lt;50% (stage C2); or severe (stage C1) and undergoing other cardiac surgery</p></li><li><p>Reasonable if: asx severe (C1) but either sx or ↓ BP w/ exercise (can carefully exercise asx AS to uncover sx; do not exercise sx AS), very severe, ↑ BNP, rapid progression</p></li><li><p>Growing data to support AVR in asx severe AS (NEJM 2020;382:111; Circ 2021;143:e72)</p></li><li><p>Type of valve: mechanical reasonable if Pt &lt;50 yrs, bioprosthetic if >65 yrs or cannot tolerate long-term anticoagulation; individualize if 50–65 yrs</p></li><li><p>Transcatheter AoV implantation (TAVI, see below) attractive alternative to surgery</p></li><li><p>Medical (if not AVR candidate or to temporize): careful diuresis prn, control HTN, maintain</p></li></ul><p>SR; digoxin if ↓ EF & HF or if AF; avoid venodilators (nitrates) & ⊖ inotropes (βB/CCB) if</p><p>severe AS; avoid vigorous physical exertion once AS mod–severe</p><p>? nitroprusside (w/ PAC) in HF w/ sev. AS, ↓ EF/CO, & HTN (Circ 2013;128:1349)</p><ul><li><p>IABP: stabilization, bridge to surgery</p></li><li><p>Balloon valvotomy (now rare): ↑ AVA, but risk CVA/AR & restenosis; ∴ bridge or palliation</p></li></ul><p>TAVI (transcatheter AoV implantation) (JAMA 2021;325:2480; Circ 2021;143:e72)</p><ul><li><p>Valves: balloon-expandable or self-expanding.</p></li><li><p>Most commonly deployed retrograde via perc. transfemoral access (best outcomes)</p></li><li><p>Peri- & postprocedural complic.: CHB ~15% at 30d, more common if preexisting RBBB (JACC 2020;76:2391); annular rupture or coronary occlusion (both rare); stroke; local vascular; paravalvular leaks</p></li><li><p>Postprocedural antithrombotic Rx: ASA 75–100 mg/d superior to DAPT (NEJM 2020;383:1447). In Pts with indication for OAC: OAC alone superior to OAC + P2Y12 (NEJM 2020;382:1696; Circ 2021;143:e72); apixaban & edoxaban appear comparable to warfarin (ATLANTIS, ACC 2021; NEJM 2021;385:2150)</p></li><li><p>Outcomes w/ TAVI: In nonoperative Pts (ie, vs. med Rx): ↓ mortality but still ~72% 5 y mortality in TAVI reflective of comorbidities (NEJM 2012;366:1696; Lancet 2015;385:2485).</p></li></ul><p>TAVI noninferior to SAVR in terms of risk of death or disabling stroke for high,</p><p>intermediate, and low surgical risk Pts (NEJM 2014;370:1790; 2020;382:799; 2019;380:1695 &</p><p>2019;380:1706; JACC 2021;77:1149).</p><p>AORTIC REGURGITATION (AR)</p><p>Etiology (Circ 2006;114:422)</p><ul><li><p>Valve disease (43%): rheumatic (usually mixed AS/AR + MV disease); bicuspid AoV (natural hx: ⅓→ normal, ⅓→ AS, ⅙→ AR, ⅙→ endocarditis → AR); infective endocarditis; valvulitis (RA, SLE, certain anorectics & serotonergics, XRT)</p></li><li><p>Root disease (57%): HTN, aortic aneurysm/dissection, annuloaortic ectasia (ie, Marfan), aortic inflammation (GCA, Takayasu’s, ankylosing spond., reactive arthritis, syphilis)</p></li></ul><p>Clinical manifestations</p><ul><li><p>Acute: sudden ↓ forward SV and ↑ LVEDP (noncompliant ventricle) → pulmonary edema ± hypotension and cardiogenic shock</p></li><li><p>Chronic: clinically silent while LV dilates (to ↑ compliance to keep LVEDP low) more than it hypertrophies → chronic volume overload → LV decompensation → CHF</p></li><li><p>Natural hx: variable progression (unlike AS, can be fast or slow); once decompensation begins, prognosis poor w/o AVR (mortality ~10%/y)</p></li></ul><p>Physical exam</p><ul><li><p>Early diastolic decrescendo murmur at LSB (RSB if dilated Ao root); ↑ w/ sitting forward, expir, handgrip; severity of AR ∝ duration of murmur (except in acute and severe late); Austin Flint murmur: mid-to-late diastolic rumble at apex (AR jet interfering w/ mitral inflow)</p></li><li><p>Wide pulse pressure due to ↑ stroke volume, hyper-dynamic pulse; pulse pressure narrows in late AR with ↓ LV fxn; bisferiens (twice-beating) arterial pulse</p></li><li><p>PMI diffuse and laterally displaced; soft S1 (early closure of MV); ± S3 (≠ ↓ EF but rather just volume overload in AR)</p></li></ul><p>Classic Eponymous Signs in Chronic AR (South Med J 1981;74:459)</p><p>Sign</p><p>Description</p><p>Corrigan’s pulse</p><p>“water hammer” pulse (ie, rapid rise/fall or distention/collapse)</p><p>Hill’s sign</p><p>(popliteal SBP – brachial SBP) >60 mmHg</p><p>Duroziez’s sign</p><p>to-and-fro murmur heard over femoral artery w/ light compression</p><p>Pistol shot sounds</p><p>pistol shot sound heard over femoral artery</p><p>Traube’s sound</p><p>double sound heard over femoral artery when compressed distally</p><p>de Musset’s sign</p><p>head-bobbing with each heartbeat (low Se)</p><p>Müller’s sign</p><p>systolic pulsations of the uvula</p><p>Quincke’s pulses</p><p>subungual capillary pulsations (low Sp)</p><p>Diagnostic studies</p><ul><li><p>ECG: can see LVH, LAD, abnl repol; CXR: cardiomegaly ± ascending Ao dilatation</p></li><li><p>Echo: severity of AR (severe = regurg jet width ≥65% LVOT, regurg fraction ≥50%, effective regurg orifice ≥0.3 cm2, holodiastolic flow reversal in descend. Ao; moderate = jet width 25–64%, regurg fraction 30–49%, regurg orifice 0.1–0.29 cm2); LV size & fxn</p></li></ul><p>Treatment (Lancet 2016;387:1312; Circ 2021;143:e72)</p><ul><li><p>Acute decompensation (consider endocarditis as possible acute precipitant): surgery usually urgently needed for acute severe AR, which is poorly tolerated by LV IV afterload reduction (nitroprusside) and inotropic support (dobutamine) ± chronotropic support (↑ HR → ↓ diastole → ↓ time for regurgitation) pure vasoconstrictors and IABP contraindicated</p></li><li><p>In chronic AR, management decisions based on LV size and fxn (and before sx occur); low diastolic BP and high resting HR associated with mortality (JACC 2020;75:29)</p></li><li><p>Surgery (AVR, replacement or repair if possible):</p></li></ul><p>Severe and sx (if equivocal, consider stress test)</p><p>Asx and either EF ≤55%, LV dilation [LVESD >50 mm or LVESDi (indexed to BSA) ≥ 25 mm/m2 (JACC 2019;73:1741)], or undergoing cardiac surg</p><ul><li><p>Transcatheter AoV implantation (TAVI) being explored (JACC 2013;61:1577 & 2017;70:2752)</p></li><li><p>Medical therapy: vasodilators (nifedipine, ACEI/ARB, hydralazine) if severe AR w/ sx or LV dysfxn & not operative candidate or to improve hemodynamics before AVR.</p></li></ul><p>MITRAL REGURGITATION (MR)</p><p>Etiology (NEJM 2010;363:156 & 2020;383:1458)</p><ul><li>Primary (degeneration of valve apparatus)</li></ul><p>Leaflet abnl: myxomatous (MVP), endocarditis, calcific, RHD, valvulitis (collagen-vascular disease), congenital, anorectic drugs (phen-fen), XRT</p><p>Chordae tendineae rupture: myxomatous, endocarditis, spontaneous, trauma</p><p>Papillary muscle dysfxn b/c of ischemia or rupture during MI [usu. posteromedial papillary m. (supplied predominantly by PDA) vs. anterolateral (suppl. by diags & OMs)]</p><ul><li>Secondary (functional): inferoapical papillary muscle displacement due to ischemic LV remodeling or DCM; HCM (JACC 2015;65:1231)</li></ul><p>Clinical manifestations</p><ul><li><p>Acute: pulmonary edema, hypotension, cardiogenic shock (NEJM 2004;351:1627)</p></li><li><p>Chronic: typically asx for yrs, then as LV fails → progressive DOE, fatigue, AF, PHT</p></li><li><p>Prognosis: 5-y survival w/ medical therapy is 80% if asx, but only 45% if sx</p></li></ul><p>Physical exam</p><ul><li>High-pitched, blowing, holosystolic murmur at apex; radiates to axilla; ± thrill; ↑ w/ handgrip (Se 68%, Sp 92%),</li></ul><p>↓ w/ Valsalva (Se 93%)</p><p>ant. leaflet abnl → post. jet heard at spine</p><p>post. leaflet abnl → ant. jet heard at sternum</p><ul><li><p>± diastolic rumble b/c ↑ flow across valve</p></li><li><p>Lat. displ. hyperdynamic PMI, obscured S1, widely split S2 (A2 early b/c ↓ LV afterload, P2 late if PHT); ± S3</p></li><li><p>Carotid upstroke brisk (vs. diminished and delayed in AS)</p></li></ul><p>Diagnostic studies (Circ 2021;143:e72)</p><ul><li><p>ECG: may see LAE, LVH, ± atrial fibrillation</p></li><li><p>CXR: dilated LA, dilated LV, ± pulmonary congestion</p></li><li><p>Echo: MV anatomy (ie, etiol); MR severity: jet area, jet width at origin (vena contracta) or effective regurgitant orifice (ERO; predicts survival); LV fxn (EF should be supranormal if compensated, ∴ EF &lt;60% w/ sev. MR = LV dysfxn)</p></li><li><p>TEE or cardiac MR if TTE not sufficiently informative</p></li><li><p>Cardiac cath: prominent PCWP c-v waves (not spec. for MR), LVgram for MR severity & EF</p></li></ul><p>aInfluenced by LV function, etc. b1+ = LA clears w/ each beat; 2+ = LA does not clear, faintly opac. after several beats; 3+ = LA & LV opac. equal. cFor 2° MR, ERO ≥0.20 severe as underestimated & likely LV dysfxn.</p><p>Treatment (Circ 2021;143:e72)</p><ul><li><p>Acute severe MR: consider ischemia & endocarditis as precipitants; IV afterload reduction (nitroprusside), relieve congestion (diuresis & NTG), ± inotropes (dobuta), IABP, avoid vasoconstrictors; surgery usually needed b/c prognosis poor w/o (JAMA 2013;310:609)</p></li><li><p>Chronic severe primary MR: surgery (repair [preferred if feasible] vs. replacement) if sx; asx & either EF 60% or LVESD 40 mm; reasonable if low surgical risk + high prob successful repair; consider transcatheter repair if not surg candidate</p></li><li><p>For primary MR, surgery superior to percutaneous repair (NEJM 2011;364:1395)</p></li><li><p>If undergoing surgery & AF, MAZE ↓ AF recurrence, Ø ∆ stroke (NEJM 2015;372:1399); surgical LAA occlusion ↓ risk of stroke; nb, Pts remained on anticoag (NEJM 2021;384:2081)</p></li><li><p>Chronic sx severe secondary MR: if on optimal GDMT, EF 20–50%, LVESD ≤70 mm, & PASP ≤70 mmHg, transcatheter edge-to-edge repair (TEER) may ↑ survival & ↓ HF hosp., but conflicting trial data (NEJM 2018:379;2297 & 2307; JACC 2021;77:1029 & 78:2326); consider MV surgery if EF≥50% or EF≤50% but not meeting criteria for repair</p></li><li><p>Transcathether replacement (TMVR) remains under study (JACC Intv 2021;14:489)</p></li><li><p>If sx & EF&lt;60% but not operative candidate: Rx (βB, ACE/ARB ± MRA); ↓ preload w/ diuretics, NTG (espec. if ischemic MR) for sx relief ± ↓ ERO; maintain SR</p></li><li><p>Asymptomatic: Ø proven benefit of medical therapy; βB ↑ LV fxn (JACC 2012;60:833)</p></li></ul><p>MITRAL VALVE PROLAPSE (MVP)</p><p>Definition and Etiology</p><ul><li><p>Billowing of MV leaflet ≥2 mm above mitral annulus in parasternal long axis echo view</p></li><li><p>Primary: sporadic or familial myxomatous proliferation of spongiosa of MV apparatus</p></li><li><p>Secondary: trauma, endocarditis, congenital, CTD (eg, Marfan’s, OI, Ehlers-Danlos)</p></li></ul><p>Clinical manifestations (usually asymptomatic)</p><ul><li><p>MR, endocarditis, emboli, arrhythmias (rarely SCD from VT from papillary muscle)</p></li><li><p>High-pitched, midsystolic click (earlier w/ ↓ preload) ± mid-to-late systolic murmur</p></li><li><p>No Rx per se [endocarditis Ppx not rec. (Circ 2007;116:1736)]; Rx MR as above</p></li></ul><p>MITRAL STENOSIS (MS)</p><p>Etiology (Lancet 2012;379:953)</p><ul><li><p>Rheumatic heart disease (RHD): fusion of commissures → “fish-mouth” valve from autoimmune rxn to β strep infxn; seen largely in developing world (Circ 2020;142:e337)</p></li><li><p>Mitral annular calcification: encroachment upon leaflets → fxnal MS; espec in ESRD</p></li><li><p>Postsurgical repair or post-TEER w/ reduced mitral valve area (MVA)</p></li><li><p>Congenital, infectious endocarditis w/ large lesion, myxoma near MV, thrombus</p></li><li><p>Valvulitis (eg, SLE, amyloid, carcinoid) or infiltration (eg, mucopolysaccharidoses)</p></li></ul><p>Clinical manifestations (Lancet 2009;374:1271)</p><ul><li><p>Dyspnea and pulmonary edema (if due to RHD, sx usually begin in 30s) precipitants: exercise, fever, anemia, volume overload (incl. pregnancy), tachycardia, AF</p></li><li><p>Atrial fibrillation: onset often precipitates heart failure in Pts w/ MS</p></li><li><p>Embolic events: commonly cerebral, espec in AF or endocarditis</p></li><li><p>Pulmonary: hemoptysis, frequent bronchitis (due to congestion), PHT, RV failure</p></li><li><p>Ortner’s syndrome: hoarseness from LA compression of recurrent laryngeal nerve</p></li></ul><p>Physical exam</p><ul><li><p>Low-pitched mid-diastolic rumble at apex w/ presystolic accentuation (if not in AF); best heard in L lat decubitus position during expiration, ↑ w/ exercise; severity proportional to duration (not intensity) of murmur; loud S1</p></li><li><p>Opening snap (high-pitched early diastolic sound at apex) from fused leaflet tips; MVA proportional to S2–OS interval (tighter valve → ↑ LA pressure → shorter interval)</p></li><li><p>Loud S1 (unless MV calcified and immobile)</p></li></ul><p>Diagnostic studies</p><ul><li><p>ECG: LAE (“P mitrale”), ± AF, ± RVH</p></li><li><p>CXR: dilated LA (flat L heart border, R double density, displaced L mainstem bronchus)</p></li><li><p>Echo: estimate pressure gradient (∇), RVSP, valve area, valve echo score (0–16, based on leaflet mobility & thick, subvalvular thick., Ca++); exer. TTE (to assess ∆ RVSP and ∇) if sx & severity of MS at rest discrepant; TEE to assess for LA thrombus before PMBC</p></li><li><p>Cardiac cath: ∇, calculated MVA; LA tall a wave & blunted y descent; ↑ PA pressures</p></li></ul><p>Treatment (Lancet 2016;387:1324; Circ 2021;143:e72)</p><ul><li><p>Medical: Na restriction, cautious diuresis, βB, AF control, sx-limited physical stress</p></li><li><p>Antibiotic Ppx recommended if h/o RHD w/ valvular disease for 10 y or until age 40</p></li><li><p>Anticoag w/ warfarin (not DOAC) if: AF; prior embolism; LA clot</p></li><li><p>Mechanical intervention indicated if sx severe MS; reasonable if asx severe MS but PASP >50 mmHg and morphology favorable for PMBC; consider PMBC if non-severe MS but exertional sx and hemodyn signif w/ exercise, or if asx severe MS and new-onset AF</p></li><li><p>Percutaneous mitral balloon commissurotomy (PMBC): preferred Rx if RHD; ≈ MVR if valvuloplasty score &lt;8, Ø if mod-severe MR or LA clot</p></li><li><p>Surgical (MV repair if possible, o/w replacement) if PMBC contraindicated</p></li><li><p>Calcific MS: surgical MVR if severe & highly sx; use of transcatheter aortic prosthesis experimental and w/ high rate of complications (Circ CVI 2020;13:e008425)</p></li><li><p>Pregnancy: if NYHA class III/IV → PMBC, o/w medical Rx w/ low-dose diuretic & βB</p></li></ul><p>TRICUSPID REGURGITATION (Circ 2014;129:2440; Lancet 2016;388:2431)</p><ul><li><p>Fxnl etiol (90%): RV dilation, PHT (may be 2° to L-sided dis.), large L → R shunts</p></li><li><p>1° etiol: myxomatous, IE, pacemaker leads, RHD, CTD, XRT, Ebstein’s, carcinoid, tumors</p></li><li><p>Holosystolic murmur, 3rd/4th ICS, ↑ w/ insp (Carvallo’s sign); S3; prominent cv wave in JVP</p></li><li><p>Consider repair/replacement in severe TR (eg, ERO ≥0.40 cm2) undergoing L-sided surgery, R heart failure or ? progressive RV dysfxn; emerging transcatheter Rx (JACC 2018;71:2935)</p></li></ul><p>PROSTHETIC HEART VALVES</p><p>Mechanical</p><ul><li><p>Bileaflet (eg, St. Jude Medical); tilting disk; caged-ball</p></li><li><p>Very durable (20–30 y), but thrombogenic and ∴ require anticoagulation consider if age &lt;50 y or if anticoagulation already indicated (JACC 2010;55:2413)</p></li></ul><p>Bioprosthetic</p><ul><li><p>Bovine pericardial or porcine heterograft (eg, Carpentier-Edwards), homograft</p></li><li><p>Less durable, but min. thrombogenic; consider if >~65 y, lifespan &lt;20 y, or Ø anticoag</p></li><li><p>If 50–69 y, 2× reop but ½ bleeding or stroke vs. mech (JAMA 2014;312:1323 & 2015;313:1435)</p></li></ul><p>Physical exam</p><ul><li>Crisp sounds ± soft murmur during forward flow (normal to have small ∇)</li></ul><p>Anticoagulation & antiplatelet therapy (Circ 2021;143:e72)</p><ul><li>Mechanical: warfarin (not DOAC), INR 3 or 2.5 if low-risk mech AVR (none of following: prior thromboembolism, AF, EF &lt;30–35%, hypercoagulable).</li></ul><p>If thrombosis, ↑ intensity (eg, INR 2–3 → 2.5–3.5; 2.5–3.5 → 3.5–4.5; or + ASA if not on)</p><ul><li>Bioprosthetic:</li></ul><p>Surgical: ASA (75–100 mg/d) or warfarin INR 2.5 ×3–6 mo, then ASA (75–100 mg/d). DOAC reasonable alternative to warfarin if indication for anticoag (NEJM 2020;383:2117).</p><p>TAVI: ASA 75–100 mg/d. If need OAC, then no antiplt (vide supra).</p><p>Periprocedural “Bridging” of Anticoagulation in Pts with Mechanical Valve(s)</p><p>AVR w/o risk factors</p><p>d/c warfarin 2–4 d before surg; restart 12–24 h after surg</p><p>MVR or AVR w/ risk factors</p><p>Preop: d/c warfarin, start UFH (preferred to LMWH) when INR &lt;2 4–6 h preop: d/c UFH; postop: restart UFH & warfarin ASAP</p><p>JACC 2017;70:253. Procedures include noncardiac surgery, invasive procedures, and major dental work.</p><p>Correction of overanticoagulation (Circ 2021;143:e72)</p><ul><li><p>Risk from major bleeding must be weighed against risk of valve thrombosis</p></li><li><p>Not bleeding: if INR 5–10, withhold warfarin</p></li><li><p>Bleeding: PCC (or FFP); reversal agent for DOACs; ± low-dose (1 mg) vit K IV if on VKA</p></li></ul><p>Endocarditis prophylaxis: for all prosthetic valves (see “Endocarditis”)</p><p>Complications</p><ul><li><p>Structural failure (r/o endocarditis); mechanical valves: rare except for Bjork-Shiley; bioprosth: up to 30% rate w/in 10–15 y, mitral >aortic; consider TAVR (JACC 2017; 69:2253)</p></li><li><p>Paravalvular leak (r/o endocarditis); small central jet of regurg is normal in mech. valves</p></li><li><p>Obstruction from thrombosis (JACC 2013;62:1731) or pannus: ✓ TTE, TEE, CTA, or fluoro significantly symptomatic pannus ingrowth: remove w/ surgery</p></li></ul><p>thrombosis: surgery if sx or large L-sided mech valve obstruction; UFH ± low-dose lytic if small, not surgical candidate, or R-sided; OAC for sx bioprosthetic thrombosis</p><ul><li><p>Infective endocarditis ± valvular abscess and conduction system dis. (see “Endocarditis”)</p></li><li><p>Embolization (r/o endocarditis); risk highest 1st 90 d, ~1%/y w/ warfarin (vs. 2% w/ ASA, or 4% w/o meds); mech MVR 2× risk of embolic events vs. mech AVR (Circ 1994;89:635)</p></li><li><p>Bleeding (from anticoag), hemolysis (espec w/ caged-ball valves or paravalvular leak)</p></li></ul><p>PERICARDIAL DISEASE</p><p>Anatomy</p><ul><li>2-layered (parietal & visceral) tissue sac surrounding heart & proximal great vessels</li></ul><p>Disease states</p><ul><li><p>Inflammation (w/ or w/o fluid accumulation) → pericarditis</p></li><li><p>Fluid accumulation → effusion ± tamponade</p></li><li><p>Decrease in compliance (sequela of inflammation) → constrictive pericarditis</p></li><li><p>Tamponade and constriction characterized by increased ventricular interdependence</p></li></ul><p>PERICARDITIS AND PERICARDIAL EFFUSION</p><p>Etiologies of Acute Pericarditis (JACC 2020;75:76)</p><p>Idiopathic (~90%)</p><p>Most presumed to be undiagnosed viral etiologies</p><p>Infectious (&lt;5% can be confirmed infectious)</p><p>Viral: Coxsackie, Parvovirus B19, echo, adeno, EBV, VZV, HIV, influenza, SARS CoV-2</p><p>Bacterial (from endocarditis, pneumonia, or s/p cardiac surgery): S. pneumo, N. meningitidis, S. aureus, Borrelia (Lyme); TB</p><p>Fungi: Histo, Coccidio, Candida; Parasite: Entamoeba, Echino</p><p>Neoplastic (&lt;10%)</p><p>Common: metastatic (lung, breast, lymphoma, leukemia, RCC)</p><p>Rare: primary cardiac & serosal tumors (mesothelioma)</p><p>Autoimmune</p><p>Connective tissue diseases: SLE, RA, scleroderma, Sjögren’s</p><p>Vasculitides: PAN, ANCA ⊕ (EGPA, GPA)</p><p>Drug-induced: procainamide, hydralazine, inh, CsA</p><p>Uremia</p><p>~5–13% of Pts prior to HD; ~20% occurrence in chronic HD Pts</p><p>Cardiovascular</p><p>STEMI, late post-MI (Dressler’s syndrome), but rare in modern era; prox AoD; chest trauma/postpericardiotomy; PCI or EP complication</p><p>Radiation</p><blockquote><p>40 Gy to mediastinum; acute or delayed; may be transudative</p></blockquote><p>Effusion w/o pericarditis</p><p>HF (particularly R-sided as pericardial fluid drains into RA), cirrhosis, nephrotic syndrome, hypothyroidism, amyloidosis. Transudative.</p><p>Clinical manifestations (NEJM 2014;371:2410; JACC 2020;75:76)</p><ul><li><p>Pericarditis: retrosternal CP, pleuritic, positional (often ↓ by sitting forward), → trapezius; may be absent in TB, neoplastic, XRT, or uremic; ± fever; ± s/s of systemic etiologies</p></li><li><p>Effusion: present in 50–65% of Pts w/ pericarditis; ranges from asx to tamponade</p></li><li><p>Definitions: acute (&lt;4–6 wks), incessant (persistent sx >4–6 wks), recurrent (after a symptom-free interval of 4–6 wks), chronic (lasting >3 mos)</p></li></ul><p>Physical exam</p><ul><li><p>Pericarditis: multiphasic friction rub best heard at LLSB w/ diaphragm of stethoscope. Notoriously variable and evanescent leathery sound w/ up to 3 components: atrial contraction, ventricular contraction, ventricular relaxation (NEJM 2012;367:e20).</p></li><li><p>Effusion: distant heart sounds, dullness over left posterior lung field due to compressive atelectasis from pericardial effusion (Ewart’s sign)</p></li></ul><p>Diagnostic studies (JAMA 2015;314:1498; EHJ 2015;36:2921; JACC 2020;75:76)</p><ul><li><p>Need ≥2 of the following: chest pain (as noted above), friction rub, ECG findings, effusion</p></li><li><p>ECG: may show diffuse STE (concave up) & PR depression (except in aVR: ST ↓ & PR ↑), TWI; classically and in contrast to STEMI, TWI do not occur until STs normalize</p></li></ul><p>Stages: (I) STE & PR ↓; (II) ST & PR normalize; (III) diffuse TWI; (IV) Tw normalize</p><p>ECG may show evidence of large effusion w/ low-voltage & electrical alternans (beat-to-beat ∆ in QRS amplitude and/or axis due to swinging heart)</p><ul><li><p>CXR: if lg effusion (>250 mL) → ↑ cardiac silhouette w/ “water-bottle” heart & epicardial halo</p></li><li><p>Echocardiogram: presence, size, & location of effusion; presence of tamponade physiology; pericarditis itself w/o spec. abnl (∴ echo can be nl), although can see pericardial stranding (fibrin or tumor); can also detect LV/RV dysfxn (myocarditis?)</p></li><li><p>CT: effusion (often larger by CT than by echo) ± calcif.; pericard. enhancement w/ contrast</p></li><li><p>MRI: may reveal pericardial thickening/inflammation, as well as myocardial involvement</p></li><li><p>⊕ cTn in ~30%, indicative of concomitant myocarditis (JACC 2003;42:2144). Inflammatory biomarkers (ESR, CRP) elevated in 80% of presentations; CRP predicts recurrence.</p></li></ul><p>Workup for effusion</p><ul><li><p>r/o infxn: usually apparent from Hx & CXR; ? value of ✓ acute and convalescent serologies</p></li><li><p>r/o noninfectious etiologies: BUN, Cr, ANA, RF, HIV, screen for common malignancies</p></li><li><p>Pericardiocentesis if suspect infxn or malignancy or large effusion (>2 cm) or recurrent</p></li></ul><p>✓ cell counts, TP, LDH, glc, Gram stain & Cx, AFB, cytology</p><p>ADA, PCR for MTb, and specific tumor markers as indicated by clinical suspicion</p><p>“exudate”: TP >3 g/dL, TPeff/TPserum >0.5, LDHeff/LDHserum >0.6 or glc &lt;60 mg/dL; high Se (~90%) but very low Sp (~20%); overall low utility (Chest 1997;111:1213)</p><ul><li>Pericardial bx if suspicion for malignancy or TB; perform during every surgical drainage</li></ul><p>Treatment of pericarditis (JACC 2020;75:76)</p><ul><li><p>High-dose NSAID (eg, ibuprofen 600–800 mg tid) or ASA (eg, 650–1000 mg tid) × 7–14 d then taper over wks; ASA preferred over NSAID in acute MI; consider PPI to ↓ risk of GIB</p></li><li><p>Add colchicine 0.6 mg bid (qd if ≤70 kg) × 3 mo; 50% ↓ risk of refractory or recurrent pericarditis (NEJM 2013;369:1522). Amio, dilt, verap & atorva ↓ P-gp & ↑ risk of colchicine tox.</p></li><li><p>Avoid steroids except for systemic autoimmune disorder, uremia, preg., NSAIDs contra- indicated. Appear to ↑ rate of pericarditis recurrence; risk lower w/ low-dose wt-based (ie, prednisone 0.2–0.5 mg/kg) with slow taper (Circ 2008;118:667 & 2011;123:1092).</p></li><li><p>Avoid anticoagulants (although no convincing data that ↑ risk of hemorrhage/tamponade)</p></li><li><p>Infectious effusion → pericardial drainage (preferably surgically) + systemic antibiotics</p></li><li><p>Restrict activity until sx resolve/hsCRP ↓; athletes must also wait ~1–3 mos w/ nl TTE/ECG</p></li><li><p>Acute idiopathic pericarditis self-limited in 70–90% of cases</p></li><li><p>Recurrent pericarditis (Circ 2007;115:2739) risk factors: subacute, lg effusion/tamponade, T >38°C, no NSAID response after 7 d. Rx: colchicine 0.6 mg bid × 6 mo (Lancet 2014;383: 2232). IL-1 antagonists: anakinra (JAMA 2016;316:1906) or rilonacept (NEJM 2021;384:31).</p></li><li><p>Recurrent effusions: consider pericardial window (percutaneous vs. surgical)</p></li></ul><p>PERICARDIAL TAMPONADE</p><p>Etiology</p><ul><li><p>Any cause of pericarditis but espec malignancy, infectious, uremia, ascending AoD, myocardial rupture, periprocedural complication, trauma, post-cardiotomy</p></li><li><p>Rapidly accumulating effusions most likely to cause tamponade b/c no time for pericardium to stretch (eg, to ↑ compliance) and accommodate ↑ intrapericardial fluid volume</p></li></ul><p>Pathophysiology (NEJM 2003;349:684)</p><ul><li><p>↑ intrapericardial pressure, compression of heart chambers, ↓ venous return → ↓ CO</p></li><li><p>Diastolic pressures ↑ & equalize in all cardiac chambers → minimal flow of blood from RA to RV when TV opens → blunted y descent</p></li><li><p>↑ ventricular interdependence → pulsus paradoxus (pathologic exaggeration of nl physio) Inspiration → ↓ intrapericardial & RA pressures → ↑ venous return → ↑ RV size → septal shift to left. Also, ↑ pulmonary vascular compliance → ↓ pulm venous return. Result is ↓ LV filling → ↓ LV stroke volume & blood pressure & pulse pressure.</p></li></ul><p>Clinical manifestations</p><ul><li><p>Cardiogenic shock (hypotension, fatigue) without pulmonary edema</p></li><li><p>Dyspnea (seen in ~85%) may be due to ↑ respiratory drive to augment venous return</p></li></ul><p>Physical exam (EHJ 2014;35:2279)</p><ul><li><p>Beck’s triad (present in minority of cases): distant heart sounds (28%), ↑ JVP (76%) w/ blunted y descent, hypotension (26%); ± pericardial friction rub (30%)</p></li><li><p>Reflex tachycardia (77%), cool extremities</p></li><li><p>Pulsus paradoxus (Se 82%, Sp 70%) = ↓ SBP ≥10 mmHg during inspiration</p></li></ul><p>⊕ LR 3.3 (5.9 if pulsus >12), ⊖ LR 0.03</p><p>Ddx = PE, hypovolemia, severe COPD, auto-PEEP, periconstriction (~⅓), RV infarct</p><p>Can be absent if preexisting ↑ LVEDP, arrhythmia, severe AR, ASD, regional tamponade</p><ul><li>Tachypnea and orthopnea but clear lungs</li></ul><p>Diagnostic studies</p><ul><li><p>ECG: ↑ HR, ↓ voltage (seen in 42%), electrical alternans (20%), ± signs of pericarditis</p></li><li><p>CXR: ↑ cardiac silhouette (89%)</p></li><li><p>Echocardiogram: ⊕ effusion, IVC plethora, septal shift with inspiration</p></li></ul><p>diastolic collapse of RA (Se 85%, Sp 80%) and/or RV (Se &lt;80%, Sp 90%)</p><p>respirophasic ∆’s in transvalvular velocities (↑ across TV & ↓ across MV w/ inspir.)</p><p>postsurgical tamponade may be localized and not easily visible</p><ul><li>Cardiac cath (right heart and pericardial): elevation (15–30 mmHg) and equalization of</li></ul><p>intrapericardial and diastolic pressures (RA, RV, PCWP), blunted y descent in RA</p><p>↑ in stroke volume postpericardiocentesis = ultimate proof of tamponade</p><p>if RA pressure remains high after drainage, Ddx: effusive-constrictive dis. (visceral pericardium constriction), myocardial. dysfxn (eg, concomitant myocarditis)</p><p>Treatment (EHJ 2014;35:2279)</p><ul><li><p>Volume (but be careful b/c overfilling can worsen tamponade) and ⊕ inotropes (avoid βB)</p></li><li><p>Avoid vasoconstrictors b/c will ↓ stroke volume & potentially ↓ HR</p></li><li><p>Avoid positive pressure ventilation b/c it can further impair cardiac filling (Circ 2006;113:1622)</p></li><li><p>Pericardiocentesis (except if due to aortic/myocardial rupture, for which emergent surgery is treatment of choice; if too unstable, consider small pericardiocentesis to prevent PEA)</p></li><li><p>Surgical drainage considered if fluid rapidly reaccumulates, loculated, or hemorrhagic</p></li></ul><p>CONSTRICTIVE PERICARDITIS</p><p>Etiology (Circ 2011;124:1270)</p><ul><li><p>Any cause of pericarditis (~1–2% incidence overall after acute pericarditis)</p></li><li><p>Highest risk w/ TB, bacterial, neoplastic, XRT, connective tissue, postcardiac surgery</p></li><li><p>Viral/idiopathic, b/c most common cause of pericarditis, also account for signif proportion</p></li></ul><p>Pathophysiology</p><ul><li><p>Adhesion of visceral and parietal pericardial layers → rigid pericardium that limits diastolic filling of ventricles → ↑ systemic venous pressures</p></li><li><p>Venous return is limited only after early rapid filling phase; ∴ rapid ↓ in RA pressure with atrial relaxation and opening of tricuspid valve and prominent x and y descents</p></li><li><p>Kussmaul sign: JVP does not decrease with inspiration (↑ venous return with inspiration, but negative intrathoracic pressure not transmitted to heart because of rigid pericardium)</p></li></ul><p>Clinical manifestations (NEJM 2011;364:1350)</p><ul><li>Right-sided >left-sided heart failure (systemic congestion >pulmonary congestion)</li></ul><p>Physical exam</p><ul><li><p>↑ JVP with prominent y descent, ⊕ Kussmaul sign [Ddx: tricuspid stenosis, acute cor pulmonale, RV dysfxn (CMP, RV MI), SVC syndrome]</p></li><li><p>Hepatosplenomegaly, ascites, peripheral edema. Consider in Ddx of idiopathic cirrhosis.</p></li><li><p>PMI usually not palpable, pericardial knock, usually no pulsus paradoxus</p></li></ul><p>Diagnostic studies</p><ul><li><p>ECG: nonspecific, AF common (up to 33%) in advanced cases</p></li><li><p>CXR: calcification (MTb most common), espec in lateral view (although not specific)</p></li><li><p>Echocardiogram: ± thickened pericardium, “septal bounce” = abrupt displacement of septum during rapid filling in early diastole</p></li><li><p>Cardiac catheterization: atria w/ Ms or Ws (prominent x and y descents)</p></li></ul><p>ventricles: dip-and-plateau or square-root sign (rapid ↓ pressure at onset of diastole, rapid ↑ to early plateau)</p><p>discordance between LV & RV pressure peaks during respiratory cycle (Circ 1996;93:2007)</p><ul><li>CT or MRI: thickened pericardium (>4 mm; Se ~80%) w/ tethering (Circ 2011;123:e418)</li></ul><p>Constrictive Pericarditis vs. Restrictive Cardiomyopathy (JACC 2016;68;2329)</p><p>Evaluation</p><p>Constrictive Pericarditis</p><p>Restrictive Cardiomyopathy</p><p>Physical exam</p><p>⊕ Kussmaul sign</p><p>Absent PMI</p><p>⊕ Pericardial knock</p><p>± Kussmaul sign</p><p>Powerful PMI, ± S3 and S4</p><p>± Murmurs of MR, TR</p><p>ECG</p><p>± Low voltage</p><p>Low voltage if infiltrative myopathy</p><p>± Conduction abnormalities</p><p>Echocardiogram</p><p>Respirophasic variation (25–40%): inspir. → ↑ flow across TV and ↓ flow across MV</p><p>e′ (tissue velocity) nl/↑ (>12 cm/sec)</p><p>Expir. hepatic vein flow reversal</p><p>Septal bounce in early diastole</p><p>Normal wall thickness</p><p>&lt;10% respirophasic variation</p><p>Slower peak filling rate</p><p>Longer time to peak filling rate</p><p>e′ ↓ (&lt;8 cm/sec; Se & Sp ~95%)</p><p>Inspir. hepatic vein flow reversal</p><p>Biatrial enlargement</p><p>± ↑ wall thickness</p><p>CT/MRI</p><p>Usually w/ thickened pericardium</p><p>Normal pericardium</p><p>NT-proBNP</p><p>Variable</p><p>Typically ↑/↑↑ (JACC 2005;45:1900)</p><p>Cardiac catheterization</p><p>Prominent x and y descents (more so in constriction)</p><p>Dip-and-plateau sign (more so in constriction)</p><p>LVEDP = RVEDP</p><p>RVSP &lt;55 mmHg (Se 90%, Sp 29%)</p><p>RVEDP >⅓ RVSP (Se 93%, Sp 46%)</p><p>Discordance of LV & RV pressure peaks during respiratory cycle</p><p>Systolic area index (ratio of RV to LV pressure–time area in inspir vs. expir) >1.1 (Se 97%, Sp 100%)</p><p>LVEDP > RVEDP (esp. w/ vol.)</p><p>RVSP >55 mmHg</p><p>RVEDP &lt;⅓ RVSP</p><p>Concordance of LV & RV pressure peaks during respiratory cycle</p><p>Systolic area index ≤1.1 (JACC 2008;51:315)</p><p>Endomyocardial biopsy</p><p>Usually normal</p><p>± Specific etiology of RCMP (fibrosis, infiltration, hypertrophy)</p><p>Treatment</p><ul><li>Diuresis if intravascular volume overload; surgical pericardiectomy if infectious or advanced</li></ul><p>HYPERTENSION</p><p>ACC/AHA Classification for Office-Based BP (HTN 2018;71:e13)</p><p>Category</p><p>Systolic (mmHg)</p><p>Diastolic (mmHg)</p><p>Normal</p><p>&lt;120</p><p>&lt;80</p><p>Elevated</p><p>120–129</p><p>&lt;80</p><p>Stage 1 hypertension</p><p>130–139</p><p>80–89</p><p>Stage 2 hypertension</p><p>≥140</p><p>≥90</p><p>Average ≥2 measurements >1–2 minutes apart. If disparity in a category between systolic and diastolic, higher value determines stage. Elevated office BP should be confirmed with out-of-office (ABPM or home cuff) to confirm; can treat stage 2 immediately. White coat (≥Stage 1 in office but &lt;at home) at heightened risk of developing HTN. Masked (&lt;Stage 1 in office but ≥at home), if persistent, treat as HTN.</p><p>Epidemiology (Circ 2021;143:e254; Lancet 2021;398:957)</p><ul><li><p>Prevalence 47% in U.S. adults, higher in African-Americans; M = F</p></li><li><p>Of those with HTN, ~40% unaware of dx; of those dx w/ HTN, only ½ achieve target BP</p></li></ul><p>Etiologies (JACC 2017;71:127)</p><ul><li>Essential (95%): onset 25–55 y; ⊕ FHx. Unclear mechanism but ? additive microvasc renal injury over time w/ contribution of hyperactive sympathetics (NEJM 2002;346:913).</li></ul><p>↑ Age → ↓ art compliance → HTN. Genetics + environment involved (Nature 2011;478:103).</p><ul><li>Secondary: Consider if Pt &lt;20 or >50 y or if sudden onset, severe, refractory HTN</li></ul><p>Secondary Causes of Hypertension</p><p>Diseases</p><p>Suggestive Findings</p><p>Initial Workup</p><p>RENAL</p><p>Renal parenchymal</p><p>(2–3%)</p><p>h/o DM, polycystic kidney disease, glomerulonephritis</p><p>CrCl, albuminuria</p><p>See “Kidney Disease”</p><p>Renovascular (1–2%)</p><p>Athero (90%)</p><p>FMD (10%, young women)</p><p>PAN, scleroderma</p><p>ARF induced by ACEI/ARB</p><p>Recurrent flash pulm edema</p><p>Renal bruit; hypokalemia</p><p>(NEJM 2009;361:1972)</p><p>MRA (>90% Se & Sp, less for FMD), CTA, duplex U/S, angio,</p><p>plasma renin (low Sp)</p><p>ENDO</p><p>Hyperaldo or</p><p>Cushing’s (1–5%)</p><p>Hypokalemia</p><p>Metabolic alkalosis</p><p>See “Adrenal Disorders”</p><p>Pheochromocytoma (&lt;1%)</p><p>Paroxysmal HTN, H/A, palp.</p><p>Myxedema (&lt;1%)</p><p>See “Thyroid Disorders”</p><p>TFTs</p><p>Hypercalcemia (&lt;1%)</p><p>Polyuria, dehydration, ∆ MS</p><p>iCa</p><p>OTHER</p><p>Obstructive sleep apnea (qv); alcohol</p><p>Medications: OCP, steroids, licorice; NSAIDs (espec COX-2); Epo; CsA; TKI</p><p>Aortic coarctation: ↓ LE pulses, systolic murmur, radial-femoral delay; abnl TTE, CXR</p><p>Polycythemia vera: ↑ Hct</p><p>Standard workup (JAMA 2021;325:1650 & 326:339)</p><ul><li><p>Goals: (1) identify CV risk factors; (2) consider 2° causes; (3) assess for target-organ damage</p></li><li><p>History: CAD, HF, TIA/CVA, PAD, DM, renal insufficiency, sleep apnea, preeclampsia; ⊕ FHx for HTN; diet, Na intake, smoking, alcohol, prescription and OTC meds, OCP</p></li><li><p>Physical exam: ✓ BP in both arms; funduscopic exam, BMI, cardiac (LVH, murmurs), vascular (bruits, radial-femoral delay), abdominal (masses or bruits), neuro exam</p></li><li><p>Testing: K, BUN, Cr, Ca, glc, Hct, U/A, lipids, TSH, urinary albumin:creatinine (if ↑ Cr, DM, peripheral edema), ? renin, ECG (for LVH), CXR, TTE (eval for valve abnl, LVH)</p></li><li><p>Ambulatory BP monitoring (ABPM): consider for episodic, masked, resistant, or white coat HTN; stronger predictor of mortality than clinic BP (NEJM 2018;378:1509); 24 h target &lt;130/80</p></li></ul><p>Complications of HTN</p><ul><li><p>Neurologic: TIA/CVA, ruptured aneurysms, vascular dementia</p></li><li><p>Retinopathy: stage I = arteriolar narrowing; II = copper-wiring, AV nicking; III = hemorrhages and exudates; IV = papilledema</p></li><li><p>Cardiac: CAD, LVH, HF, AF</p></li><li><p>Vascular: aortic dissection, aortic aneurysm (HTN = key risk factor for aneurysms)</p></li><li><p>Renal: proteinuria, renal failure</p></li></ul><p>Treatment (J Clin HTN 2014;16:14; Circ 2018;138:e426; NEJM 2018;378:636)</p><ul><li><p>Every ↓ 5 mmHg → ~10% ↓ ischemic heart disease, stroke, and HF (Lancet 2021;397:1625)</p></li><li><p>Lifestyle modifications (each may ↓ SBP ~5 mmHg)</p></li></ul><p>weight loss: goal BMI 18.5–24.9; aerobic exercise: 90–150 min exercise/wk</p><p>diet: rich in fruits & vegetables, low in saturated & total fat (DASH, NEJM 2001;344:3)</p><p>limit Na: ideally ≤1.5 g/d or ↓ 1 g/d; ↑ K intake / use salt substitute (NEJM 2021;385:1067)</p><p>limit alcohol: ≤2 drinks/d in men; ≤1 drink/d in women & lighter-wt Pts; avoid NSAIDs</p><ul><li><p>ACC/AHA: initiate BP med if BP ≥130/80 & either clinical ASCVD, HF, CKD, T2DM, ≥65 yrs old or 10-y ASCVD risk ≥10%; otherwise if BP ≥140/90</p></li><li><p>In high CV risk w/o DM, SBP target &lt;120 (via unattended automated cuff) ↓ MACE & mortality vs. &lt;140 mmHg, but w/ ↑ HoTN, AKI, syncope, electrolyte abnl (NEJM 2021;384:1921 & 385:1268)</p></li><li><p>Pharmacologic options</p></li></ul><p>Pre-HTN: ARB prevents onset of HTN, no ↓ in clinical events (NEJM 2006;354:1685)</p><p>HTN: choice of therapy controversial, concomitant disease and stage may help guide Rx; ? improved control with nighttime administration (EHJ 2020;41:4564)</p><p>Uncomplicated: CCB, ARB/ACEI, or thiazide (chlorthalidone preferred) are 1st line; βB not.</p><p>For black Pts, reasonable to start with CCB or thiazide.</p><ul><li><p>CAD (Circ 2015;131:e435): ACEI or ARB; ACEI+CCB superior to ACEI+thiazide (NEJM 2008;359:2417) or βB+diuretic (Lancet 2005;366:895); may require βB and/or nitrates for anginal relief; if h/o MI, βB ± ACEI/ARB ± aldo antag (see “ACS”)</p></li><li><p>HF: ARNI/ACEI/ARB, βB, diuretics, aldosterone antagonist (see “Heart Failure”)</p></li><li><p>prior stroke: ACEI ± thiazide (Lancet 2001;358:1033)</p></li><li><p>diabetes mellitus: ACEI or ARB; can also consider thiazide or CCB</p></li><li><p>chronic kidney disease: ACEI or ARB (NEJM 2001;345:851 & 861)</p></li></ul><ul><li><p>Tailoring therapy: if stage 1, start w/ monoRx; if stage 2, consider starting w/ combo (eg, ACEI + CCB; NEJM 2008;359:2417); start at ½ max dose; after ~1 mo, uptitrate or add drug</p></li><li><p>Pregnancy: methyldopa, labetalol, & nifed pref. Hydral OK; avoid diuretics; Ø ACEI/ARB. Targeting DBP 85 vs. 105 safe and ↓ severe HTN (NEJM 2015;372:407).</p></li></ul><p>Resistant HTN (BP >goal on ≥3 drugs incl diuretic; HTN 2018;72:e53)</p><ul><li><p>Exclude: 2° causes (see table) and pseudoresistance: inaccurate measure (cuff size), diet noncomp (↑ Na), poor Rx compliance/dosing, white coat HTN (✓ ABPM)</p></li><li><p>Ensure effective diuresis (chlorthalidone or indapamide >HCTZ; loop >thiazide if eGFR &lt;30)</p></li><li><p>Can add aldosterone antagonist (Lancet 2015;386:2059), β-blocker (particularly vasodilators such as carvedilol, labetalol, or nebivolol), α-blocker, or direct vasodilator</p></li><li><p>Consider renal denervation therapy (Lancet 2018;391:2346; 2021;397:2476)</p></li></ul><p>HYPERTENSIVE CRISES</p><ul><li>Hypertensive emergency: ↑ BP (usually SBP >180 or DBP >120) → target-organ damage</li></ul><p>Neurologic damage: encephalopathy, hemorrhagic or ischemic stroke, papilledema</p><p>Cardiac damage: ACS, HF/pulmonary edema, aortic dissection</p><p>Renal damage: proteinuria, hematuria, acute renal failure; scleroderma renal crisis</p><p>Microangiopathic hemolytic anemia; preeclampsia-eclampsia</p><ul><li>Hypertensive urgency: SBP >180 or DBP >120 (? 110) w/o target-organ damage</li></ul><p>Precipitants</p><ul><li><p>Progression of essential HTN ± medical noncompliance (espec clonidine) or ∆ in diet</p></li><li><p>Progression of renovascular disease; acute glomerulonephritis; scleroderma; preeclampsia</p></li><li><p>Endocrine: pheochromocytoma, Cushing’s</p></li><li><p>Sympathomimetics: cocaine, amphetamines, MAO inhibitors + foods rich in tyramine</p></li></ul><p>Treatment – tailor to clinical condition (Circ 2018;138:e426)</p><ul><li><p>AoD, eclampsia/severe preeclampsia, pheo: target SBP &lt;140 (&lt;120 for AoD) in 1 hour</p></li><li><p>Emerg w/o above: ↓ BP by ~25% in 1 h; to 160/100–110 over next 2–6 h, then nl over 1–2 d</p></li><li><p>Acute ischemic stroke (w/in 72 hr from sx onset): &lt;185/110 before lysis initiated, o/w target &lt;220/120 (same SBP goal for ICH)</p></li><li><p>Watch UOP, Cr, mental status: may indicate a lower BP is not tolerated</p></li></ul><p>IV Drugs for Hypertensive Crises (Circ 2018;138:e426; Stroke 2018;49:46)</p><p>Drug</p><p>Dose</p><p>Preferred for</p><p>Labetalol</p><p>20–80 mg IVB q10min or 0.4–2 mg/min</p><p>AoD, ACS, Stroke, Eclampsia</p><p>Esmolol</p><p>0.5–1 mg/kg load → 50–200 µg/kg/min</p><p>AoD, ACS</p><p>Nitroprusside*</p><p>0.25–10 µg/kg/min</p><p>Pulm edema</p><p>Nitroglycerin</p><p>5–500 µg/min</p><p>Pulm edema, ACS</p><p>Nicardipine</p><p>5–15 mg/h (can ↑ 2.5 mg/h q 5 min)</p><p>Stroke, AKI, Eclampsia, Pheo</p><p>Clevidipine</p><p>1–32 mg/h (can titrate q 5–10 min)</p><p>Stroke, Pulm edema, AKI, Pheo</p><p>Fenoldopam</p><p>0.1–1.6 µg/kg/min</p><p>AKI</p><p>Hydralazine</p><p>10–20 mg q20–30min prn</p><p>Eclampsia</p><p>Phentolamine</p><p>5–15 mg bolus q5–15min</p><p>Pheo</p><p>*Metabolized to cyanide → ∆ MS, lactic acidosis, death. Limit use of very high doses (8–10 µg/kg/min) to &lt;10 min.</p><ul><li>HTN urgency: goal to return to normal BP over hrs to days. Reinstitute/intensify anti-HTN Rx. Additional PO options: labetalol 200–800 mg q8h, captopril 12.5–100 mg q8h, hydralazine 10–75 mg q6h, clonidine 0.2 mg load → 0.1 mg q1h.</li></ul><p>AORTIC ANEURYSMS</p><p>Definitions</p><ul><li><p>True (≥50% dilation of all 3 layers; &lt;50% = ectasia) vs. false (rupture w/in adventitia)</p></li><li><p>Location: root (annuloaortic ectasia), thoracic aortic aneurysm (TAA), thoracoabdominal aortic aneurysm (TAAA), abdominal aortic aneurysm (AAA)</p></li><li><p>Type: fusiform (circumferential dilation) vs. saccular (localized dilation of aortic wall)</p></li></ul><p>Epidemiology (Circ 2010;121:e266, 2011;124:2020; Nat Rev Cardiol 2011;8:92)</p><ul><li><p>TAA: ~10/100,000 Pt-yrs; ♂:♀ 2:1; ~60% root/ascending; 40% descending</p></li><li><p>AAA: ~4–8% prev in those >60 y; 5× more common in ♂; mostly infrarenal</p></li></ul><p>Pathophysiology & risk factors (JACC 2020:76:201 & 2021;78:201)</p><ul><li><p>Medial degen and/or ↑ wall stress; wall stress ∝ [(∆P × r) / (wall thickness)] (Laplace’s law)</p></li><li><p>TAA: medial degeneration (muscle apoptosis, elastin fiber weakening); a/w CTD, aortitis</p></li><li><p>AAA: long-standing HTN + athero/inflammation → medial weakening</p></li><li><p>Clinical risk factors: HTN, athero, smoking, age, ♂, presence of other aortic dilation</p></li><li><p>CTD (Marfan, Ehlers-Danlos type IV, Loeys-Dietz); congenital (bicuspid AoV, Turner’s) aortitis (Takayasu’s GCA, spondyloarthritis, IgG4); infection (eg, syphilis); FQ; trauma</p></li></ul><p>Screening (JAMA 2015;313:1156)</p><ul><li><p>TAA: if bicuspid AoV or 1° relative w/: (a) TAA or bicuspid AoV, (b) CTD as above</p></li><li><p>AAA: ✓ for pulsatile abd mass; U/S ♂ >60 y w/ FHx of AAA & ♂ 65–75 y w/ prior tobacco</p></li></ul><p>Diagnostic studies (JACC 2020;76:201)</p><ul><li><p>Contrast CT: quick, noninvasive, high Se & Sp for all aortic aneurysms</p></li><li><p>TTE/TEE: TTE most useful for root and proximal Ao; TEE can visualize other sites of TAA</p></li><li><p>MRI: favored over CT for AoRoot imaging; useful in AAA but time consuming; noncontrast “black blood” MR to assess aortic wall</p></li><li><p>Abdominal U/S: screening/surveillance test of choice for infrarenal AAA</p></li></ul><p>Treatment (Circ 2010;121:e266 & 2016;133:680; JACC 2020;76:201; NEJM 2021;385:1690)</p><ul><li><p>Goal is to prevent rupture (50% mortality prior to hospital) by modifying risk factors</p></li><li><p>Risk factor modification: smoking cessation; statins to achieve LDL-C &lt;70 mg/dL</p></li><li><p>BP control (goal SBP 100–120): βB (↓ dP/dt) ↓ aneurysm growth; ACEI a/w ↓ rupture risk (Lancet 2006;368:659); ARB may ↓ rate of aortic root growth in Marfan (NEJM 2008;358:2787)</p></li><li><p>Mod CV exercise OK, no burst activity requiring Valsalva maneuvers (eg, heavy lifting)</p></li><li><p>Indications for intervention (individualized based on FHx, body size, sex, anatomy)</p></li></ul><p>TAA: sxs; ascending Ao ≥5.5 cm (4–5 cm if Marfan, L-D, EDS, bicuspid AoV); descending Ao >6 cm; ≥4.5 cm and planned AoV surgery; ↑ >0.5 cm/y</p><p>AAA: sx; infrarenal ≥5.5 cm; consider ≥5.0 cm in ♀; ↑ >0.5 cm/y; inflam/infxn</p><p>Surgery (EHJ 2014;25:2873)</p><ul><li>Resection & replacement w/ graft. If involves root, need to address AoV & coronaries.</li></ul><p>Endovascular repair (EVAR) (Circ 2015;131:1291; NEJM 2019;380:2126)</p><ul><li><p>Requires favorable aortic anatomy</p></li><li><p>TEVAR (thoracic EVAR) for descending TAA ≥5.5 cm may ↓ periop morbidity and possibly mortality (Circ 2010;121:2780; JACC 2010;55:986; J Thorac CV Surg 2010;140:1001 & 2012;144:604)</p></li><li><p>AAA: guidelines support open repair or EVAR for infrarenal AAA in good surg candidates</p></li></ul><p>↓ short-term mort., bleeding, LOS; but long-term graft complic. (3–4%/y; endoleak, need for reintervention, rupture) necessitate periodic surveillance, with no difference in mortality long term, except ? in those &lt;70 y (Lancet 2016;388:2366; NEJM 2019;380:2126)</p><p>In Pts unfit for surgery or high periop risks: ↓ aneurysm-related mortality but no ∆ in overall mortality over med Rx (NEJM 2010;362:1872). EVAR noninferior (? superior) to open repair in ruptured AAA w/ favorable anatomy (Ann Surg 2009;250:818).</p><p>Complications (Circ 2010;121:e266; Nat Rev Cardiol 2011;8:92)</p><ul><li><p>Pain: gnawing chest, back, or abdominal pain; new or worse pain may signal rupture</p></li><li><p>Rupture: risk ↑ w/ diameter, ♀, current smoking, HTN</p></li></ul><p>TAA: ~2.5%/y if &lt;6 cm vs. 7%/y if >6 cm</p><p>AAA: ~1%/y if &lt;5 cm vs. 6.5%/y if 5–5.9 cm; ~80% mortality at 24 h</p><ul><li><p>Aortic insufficiency (TAA), CHF, acute aortic syndromes (qv)</p></li><li><p>Thromboembolic ischemic events (eg, to CNS, viscera, extremities)</p></li><li><p>Compression of adjacent structures (eg, SVC, trachea, esophagus, laryngeal nerve)</p></li></ul><p>Follow-up (Circ 2010;121:e266; Nat Rev Cardiol 2011;8:92; JAMA 2013;309:806)</p><ul><li><p>Expansion rate ~0.1 cm/y for TAA, ~0.3–0.4 cm/y for AAA</p></li><li><p>TAA: 6 mo after dx to ensure stable, and if stable, then annually (Circ 2005;111:816)</p></li><li><p>AAA: &lt;4 cm q2–3y; 4–5.4 cm q6–12mo; more often if rate of expansion >0.5 cm in 6 mo</p></li><li><p>Screen for CAD, PAD, & aneurysms elsewhere, espec popliteal. ~25% of Pts w/ TAA will also have AAA, and 25% of AAA Pts will have a TAA: consider pan-Ao imaging.</p></li></ul><p>ACUTE AORTIC SYNDROMES</p><p>Definitions (Circ 2010;121:e266; Eur Heart J 2012;33:26)</p><ul><li><p>Aortic dissection: intimal tear → blood extravasates into Ao media (creates false lumen)</p></li><li><p>Intramural hematoma (IMH): vasa vasorum rupture → medial hemorrhage that does not communicate with aortic lumen; 6% of aortic syndromes; clinically managed as AoD</p></li><li><p>Penetrating ulcer: atherosclerotic plaque penetrates elastic lamina → medial hemorrhage</p></li></ul><p>Classification (proximal more common than distal; JACC 2019;74:1494 & 2020;76:1703)</p><ul><li><p>Proximal: involves ascending Ao, regardless of origin (= Stanford A, DeBakey I & II)</p></li><li><p>Distal: involves descending Ao only, distal to L subclavian art. (= Stanford B, DeBakey III)</p></li></ul><p>Risk factors (Lancet 2015;385:800)</p><ul><li><p>Classic (in older Pts): HTN (h/o HTN in >70% of dissections); age (60s–70s), sex (~65% ♂); smoking; ↑ lipids. Acute ↑ BP: cocaine, Valsalva (eg, weightlifting).</p></li><li><p>Genetic: CTD (Marfan, Loeys-Dietz, Ehlers-Danlos type IV); congenital anomaly (bicuspid AoV, coarct [eg, Tuner’s syndrome], PCKD); FHx (AoD or aneurysm in 1st degree relative)</p></li><li><p>Acquired: aortitis (Takayasu’s, GCA, Behçet’s, syphilis); preg. (typically 3rd trim.); FQ use</p></li><li><p>Trauma: blunt, decel. injury (eg, MVA); IABP, cardiac/aortic surgery, Impella, cardiac cath</p></li></ul><p>Clinical Manifestations and Physical Exam* (JAMA 2000;283:897)</p><p>Feature</p><p>Proximal</p><p>Distal</p><p>“Aortic” pain (abrupt, severe, tearing or ripping quality, maximal at onset [vs. crescendo for ACS])</p><p>94%</p><p>(chest, back)</p><p>98%</p><p>(back, chest, abd)</p><p>Syncope (often due to tamponade)</p><p>13%</p><p>4%</p><p>HF (usually due to acute AI)</p><p>9%</p><p>3%</p><p>CVA</p><p>6%</p><p>2%</p><p>HTN</p><p>36%</p><p>70%</p><p>HoTN or shock (tamponade, AI, MI, rupture)</p><p>25%</p><p>4%</p><p>Pulse deficit (if involves carotid, subclavian, fem)</p><p>19%</p><p>9%</p><p>AR murmur</p><p>44%</p><p>12%</p><p>*S/S correlate w/ affected branch vessels & distal organs; may ∆ as dissection progresses</p><p>Initial evaluation & diagnostic studies (Circ 2010;121:e266; EHJ 2018;39:739)</p><ul><li><p>H&P, incl. bilat BP & radial pulses for symmetry; ECG w/ STE if propagates to cor</p></li><li><p>CXR: abnl in 60–90% [↑ mediast. (absence ⊖ LR 0.3), L pl effusion] but cannot r/o AoD</p></li><li><p>CT: quick and available, Se ≥93%, Sp 98%; facilitates “triple rule-out” ACS vs. PE vs. AoD</p></li><li><p>MRI: Se & Sp >98%, but time-consuming test & not readily available</p></li><li><p>TEE: Se >95% prox, 80% for distal; can assess cors/peric/AI; “blind spot” behind trachea</p></li><li><p>⊖ Initial imaging but high clinical suspicion → further studies (⅔ w/ AoD have ≥2 studies)</p></li><li><p>D-dimer &lt;500 ng/mL has Se/NPV ~97%, Sp ~50%, but not if high risk and not for IMH</p></li><li><p>Risk score (0–3 points): high-risk (eg, genetics, recent Ao manip); aortic pain; e/o perfusion deficit, AI or shock. Score >1 → imaging; ≤1 & DD &lt;500 has NPV >99% (Circ 2018;137:250)</p></li></ul><p>Treatment (Circ 2010;121:1544; EHJ 2018;39:739; JACC 2019;74:1494 & 2020;76:1703)</p><ul><li><p>↓ dP/dt targeting HR &lt;60 & central BP &lt;120 (or lowest that preserves perfusion; r/o pseudohypotension, eg, arm BP ↓ due to subclavian dissection; use highest BP reading)</p></li><li><p>First IV βB (eg, esmolol, labetalol) to blunt reflex ↑ HR & inotropy in response to vasodilators; verapamil/diltiazem if βB contraindic; then ↓ SBP w/ IV vasodilators (eg, nitroprusside)</p></li><li><p>If HoTN: urgent surgical consult, IVF to achieve euvolemia, pressors to keep MAP 60-65 mmHg; r/o complication (eg, tamponade, contained rupture, severe AI)</p></li><li><p>Proximal: surgery considered in all acute and in chronic if c/b progression, AI or aneurysm</p></li><li><p>Distal: med Rx unless complication (see below) or favorable TEVAR anatomy w/ high-risk imaging features (JACC 2019;74:1494); pre-emptive TEVAR may ↓ late complic. & mortality</p></li></ul><p>Complications (occur in ~20%; Circ 2010;121:e266; Lancet 2015;385:800)</p><ul><li><p>Freq assess (sx, BP, UOP), pulses, labs (Cr, Hb, lactic acid), imaging (~7 d or sooner if ∆s)</p></li><li><p>Uncontrolled BP or persistent pain may indicate complication/extension</p></li><li><p>Progression: propagation of dissection, ↑ aneurysm size, ↑ false lumen size</p></li><li><p>Rupture: pericardial sac → tamponade (avoid pericardiocentesis unless PEA); blood in pleural space, mediast., retroperitoneum; ↑ in hematoma on imaging portends rupture</p></li><li><p>Malperfusion (partial or complete obstruction of branch artery; can be static or dynamic) coronary → MI (usually RCA → IMI b/c dissection follows outer Ao curvature); innominate/carotid → CVA, Horner; intercostal/lumbar → spinal cord ischemia/paraplegia; innominate/subclavian → upper ext ischemia; iliac → lower ext ischemia; celiac/mesenteric → bowel ischemia; renal → AKI or slow ↑ Cr, refractory HTN</p></li><li><p>AI: due to annular dilatation or disruption or displacement of leaflet by false lumen</p></li><li><p>Mortality: 20–40% for proximal; 6% for uncomplicated and ~20% for complicated distal</p></li><li><p>Long-term serial imaging (CT or MRI; ↓ rad w/ MRI) at 1, 3, and 6 mo, and then annually</p></li></ul><p>ARRHYTHMIAS</p><p>BRADYCARDIAS, AV BLOCK, AND AV DISSOCIATION</p><p>Sinus bradycardia (SB, &lt;50–60 bpm) (NEJM 2000;342:703, Circ 2019;140:e382)</p><ul><li><p>Etiologies: meds (incl βB, CCB, amio, Li, dig), ↑ vagal tone (incl. athletes, sleep, IMI), metabolic (hypoxia, sepsis, myxedema, hypothermia, ↓ glc), OSA, ↑ ICP</p></li><li><p>Treatment: if no sx, none; atropine, β1 agonists (short-term) or pacing if symptomatic</p></li><li><p>Most common cause of sinus pause is blocked premature atrial beat</p></li></ul><p>Tachycardia-bradycardia (“tachy-brady”) syndrome</p><ul><li>Features may include: periods of unprovoked SB, SA arrest, paroxysms of SB and atrial</li></ul><p>tachyarrhythmias, chronotropic incompetence w/ ETT</p><ul><li>Treatment: meds alone usually fail (adeq. control tachy → unacceptable brady); usually need combination of meds (βB, CCB, dig) for tachycardia & PPM for bradycardia</li></ul><p>AV Block (Circ 2019;140:e382)</p><p>Type</p><p>Features</p><p>1°</p><p>Prolonged PR (>200 ms), all atrial impulses conducted (1:1).</p><p>2° Mobitz I (Wenckebach)</p><p>Progressive ↑ PR until impulse not conducted (→ ”grouped beating”).</p><p>AV node pathology: ischemia (IMI), inflammation (myocarditis, endocarditis, MV surgery), high vagal tone (athletes), drug induced.</p><p>Classically (~50%), absolute ↑ in PR decreases over time (→ ↓ RR intervals, duration of pause &lt;2× preceding RR interval); nl QRS.</p><p>AVB usually worsens w/ carotid sinus massage, improves w/ atropine.</p><p>Often paroxysmal/nocturnal/asx, no Rx required.</p><p>2° Mobitz II</p><p>Blocked impulses w/ consistent PR interval, often prolonged QRS</p><p>His-Purkinje pathology: ischemia (AMI), degeneration of conduction system, infiltrative disease, inflammation.</p><p>AVB may improve w/ carotid sinus massage, may worsen w/ atropine.</p><p>May progress to 3° AVB. Pacing pads; transven. pacing often required.</p><p>3° (complete)</p><p>No AV conduction. Escape, if present, narrow (jxnal) or wide (vent.)</p><p>Nb, if 2:1 block, cannot distinguish type I vs. II 2° AVB (no chance to observe PR prolongation); usually categorize based on other ECG & clinical data. High-grade AVB usually refers to block of ≥2 successive impulses</p><p>AV dissociation</p><ul><li><p>Default: slowing of SA node allows subsidiary pacemaker (eg, AV junction) to take over</p></li><li><p>Usurpation: acceleration of subsidiary pacemaker (eg, AV junctional tach, VT)</p></li><li><p>3° AV block: atrial pacemaker unable to capture ventricles, subsidiary pacemaker emerges; distinguish from isorhythmic dissociation (A ≈ V rate, some P waves nonconducting)</p></li></ul><p>Temporary pacing wires</p><ul><li><p>Consider w/ bradycardia with hemodyn instability or unstable escape rhythm when perm pacer not readily available. Risks: infxn, RV perf, VT, PTX, CHB if existing LBBB.</p></li><li><p>Consider instead of PPM for sx brady from reversible cause (βB/CCB O/D, Lyme, SBE, myocarditis, s/p cardiac surgery/trauma/TAVR), TdP, acute MI (sx brady/high-grade AVB)</p></li></ul><p>SUPRAVENTRICULAR TACHYCARDIAS (SVTS)</p><p>Arise above the ventricles, ∴ narrow QRS unless aberrant conduction or pre-excitation.</p><p>Common Etiologies of SVT (NEJM 2012;367:1438)</p><p>Type</p><p>Features</p><p>Atrial</p><p>Sinus tachycardia (ST)</p><p>Caused by pain, fever, hypovolemia, hypoxia, PE, anemia, anxiety, withdrawal, β-agonists, etc.</p><p>Atrial tachycardia (AT)</p><p>Originate at site in atria other than SA node. Seen w/ CAD, COPD, ↑ catechols, EtOH, dig.</p><p>Multifocal atrial tachycardia (MAT)</p><p>↑ automaticity at multiple sites in the atria; seen with underlying pulmonary disease</p><p>Atrial flutter (AFL)</p><p>Clockwise or counterclockwise macroreentry, usually w/in right atrium</p><p>Atrial fibrillation (AF)</p><p>Chaotic atrial activation with rapid, irregular AVN bombardment; often from pulmonary veins</p><p>AV Jxn</p><p>AV nodal reentrant tach (AVNRT)</p><p>Reentrant circuit using dual pathways w/in AVN</p><p>Atrioventricular reciprocating tachycardia (AVRT)</p><p>Reentry using AVN & access. path. May show pre-excitation (WPW) or not (concealed access. path.). Can be ortho or antidromic (vide infra).</p><p>Nonparoxysmal junctional tachycardia (NPJT)</p><p>↑ jxnal automaticity. May see retro. P, AV dissoc. A/w myo/endocarditis, cardiac surg, IMI, dig.</p><p>Diagnosis of SVT Type (NEJM 2012;367:1438)</p><p>Onset</p><p>Abrupt on/off argues against sinus tachycardia</p><p>Rate</p><p>Not dx b/c most can range from 140–250 bpm, but: ST usually &lt;150; AFL often conducts 2:1 → vent. rate 150; AVNRT & AVRT usually >150</p><p>Rhythm</p><p>Irregular → AF, AFL w/ variable block, or MAT</p><p>P wave</p><p>morphology</p><p>Before QRS (ie, long RP) → ST, AT (P ≠ sinus), MAT (≥3 morphologies)</p><p>None (ie, buried in or deforming terminal QRS, eg, pseudo RSR′ in V1) → typical AVNRT, NPJT</p><p>After QRS (ie, short RP) & inverted in inf. leads (ie, retrograde atrial) → AVNRT, AVRT (usually slightly after QRS; RP interval >100 ms favors AVRT vs. AVNRT), or NPJT</p><p>Fibrillation or no P waves → AF</p><p>Saw-toothed “F” waves (best seen in inferior leads & V1) → AFL</p><p>Response to vagal stim. or adenosine</p><p>Slowing of HR often seen with ST, AF, AFL, AT, whereas reentrant rhythms (AVNRT, AVRT) may abruptly terminate (classically w/ P wave after last QRS) or no response. Occ AT may terminate.</p><p>In AFL & AF, ↑ AV block may unmask “F” waves or fibrillation</p><p>Figure 1-4 Approach to SVT (adapted from NEJM 2012;367:1438)</p><p>Treatment of SVT (Circ 2016;133:e506)</p><p>Rhythm</p><p>Acute Treatment</p><p>Long-term Treatment</p><p>Unstable</p><p>Cardioversion per ACLS</p><p>n/a</p><p>ST</p><p>Treat underlying stressor(s)</p><p>n/a</p><p>AT</p><p>βB, CCB or adenosine; ? amiodarone</p><p>radiofrequency ablation (RFA); βB or CCB, ± class IC/III AAD</p><p>AVNRT</p><p>or AVRT</p><p>Vagal maneuvers</p><p>Adenosine (caution in AVRT*)</p><p>CCB or βB, DCCV if other Rx fail</p><p>For AVNRT (see next section for AVRT):</p><p>RFA. CCB, βB, or dig (chronic or prn)</p><p>± Class IC/III AAD (if nl heart)</p><p>NPJT</p><p>CCB, βB, amiodarone</p><p>Rx underlying dis. (eg, dig tox, ischemia)</p><p>AF</p><p>βB, CCB, digoxin, AAD</p><p>See “Atrial Fibrillation”</p><p>AFL</p><p>βB, CCB, AAD</p><p>RFA; βB or CCB ± class III AAD</p><p>MAT</p><p>CCB or βB if tolerated</p><p>Treat underlying disease. CCB or βB.</p><p>AVN ablation + PPM if refractory to meds</p><p>*Avoid adenosine & nodal agents if accessory pathway + pre-excited tachycardia, see below (Circ 2014;130:e199)</p><ul><li>Catheter ablation: high overall success rate (AFL/AVNRT ~95%, AVRT ~90%, AF ~70%)</li></ul><p>complications: stroke, MI, bleeding, perforation, conduction block</p><p>ACCESSORY PATHWAYS (WOLFF-PARKINSON-WHITE)</p><p>Definitions</p><ul><li><p>Accessory pathway (bypass tract) of conducting myocardium connecting atria & ventricles, allowing impulses to bypass normal AVN delay</p></li><li><p>Pre-excitation (WPW) pattern: ↓ PR interval, ↑ QRS width w/ δ wave (slurred onset, can be subtle). ST & Tw abnl (can mimic old IMI).</p></li></ul><p>Only seen w/ pathways that conduct antegrade (if pathway only conducts retrograde, then ECG will be normal during SR; “concealed” bypass tract).</p><ul><li><p>PAC can exaggerate pre-excitation if AV node conduction slowed</p></li><li><p>WPW syndrome: WPW accessory pathway + paroxysmal tachycardia</p></li></ul><p>Classic tachycardias of WPW accessory pathways</p><ul><li><p>Orthodromic AVRT: narrow-complex SVT (typically), conducting ↓ AVN & ↑ accessory pathway; requires retrograde conduction and ∴ can occur w/ concealed bypass tracts</p></li><li><p>Antidromic AVRT (rare): wide-complex SVT, conducting ↓ accessory pathway & ↑ AVN; requires antegrade conduction and ∴ should see pre-excitation pattern during SR</p></li><li><p>AF w/ rapid conduction down accessory pathway; ∴ wide-complex irregular SVT; requires antegrade conduction; ∴ should see pre-excitation in SR. Rarely can degenerate into VF.</p></li></ul><p>Treatment (Heart Rhythm 2012;9:1006, Circ 2014;130:e199 & 2016;133:e506)</p><ul><li><p>AVRT (orthodromic): vagal, βB, CCB; care w/ adenosine (can precip AF); have defib ready</p></li><li><p>AF/AFL w/ conduction down accessory pathway: need to Rx arrhythmia and ↑ pathway refractoriness. Use procainamide, ibutilide, or DCCV; avoid CCB, βB, amio, dig, &</p></li></ul><p>adenosine, b/c can ↓ refractoriness of pathway → ↑ vent. rate → VF (Circ 2016;133:e506).</p><ul><li>Long term: RFA if sx; if not candidate for RFA, then AAD (IA, III) or CCB/βB.</li></ul><p>Consider RFA if asx but AVRT or AF inducible on EPS (NEJM 2003;349:1803) or if rapid conduction possible (✓ w/ EPS if pre-excitation persists during exercise testing)</p><p>Risk of SCD related to how short RR interval is in AF (eg, &lt;250 ms) and if SVT inducible</p><p>WIDE-COMPLEX TACHYCARDIAS (WCTS)</p><p>Etiologies (Lancet 2012;380:1520)</p><ul><li><p>Ventricular tachycardia (VT): accounts for 80% of WCT in unselected population</p></li><li><p>SVT conducted with aberrancy: either fixed BBB, rate-dependent BBB (usually RBBB), conduction via an accessory pathway or atrially triggered ventricular pacing</p></li></ul><p>Monomorphic ventricular tachycardia (MMVT)</p><ul><li><p>All beats look similar; predominantly upward in V1 = RBBB-type vs. downward = LBBB-type</p></li><li><p>In obviously structurally abnormal heart: prior MI (scar); CMP</p></li><li><p>In apparently nl heart that is actually diseased: subtle HCM, infiltrative CMP, myocarditis,</p></li></ul><p>arrhythmogenic CMP (ACM): incomplete RBBB,</p><p>ε wave (terminal notch in QRS) & TWI in V1–V3 on resting ECG</p><p>LBBB-type VT, dx w/ MRI (Lancet 2009;373:1289)</p><ul><li>In structurally normal heart w/ normal resting ECG & cardiac MRI:</li></ul><p>RVOT VT: LBBB-type VT or PVCs w/ inferior axis; typically ablate</p><p>LVOT VT: RBBB-type VT or PVCs w/ superior axis; responds to verapamil</p><p>Polymorphic ventricular tachycardia (PMVT)</p><ul><li><p>QRS morphology changes from beat to beat</p></li><li><p>Etiologies: ischemia; CMP; catecholaminergic</p></li></ul><p>torsades de pointes (TdP = “twisting of the points,” PMVT + ↑ QT): ↑ QT acquired (meds, lytes, stroke, see “ECG”) w/ risk ↑ w/ ↓ HR, freq PVCs (pause dependent) or congenital (K/Na channelopathies) w/ resting Tw abnl & TdP triggered by sympathetic stimulation (eg, exercise, emotion, sudden loud noises) (Lancet 2008;372:750)</p><p>Brugada syndrome (Na channelopathy; JACC 2018;72:1046): ♂ > ♀; pseudo-RBBB w/ STE in V1–V3 (provoked w/ class IA or IC) on resting ECG</p><p>Diagnostic clues that favor VT (assume until proven o/w)</p><ul><li><p>Prior MI, CHF, or LV dysfunction best predictors that WCT is VT (Am J Med 1998;84:53)</p></li><li><p>Hemodynamics and rate do not reliably distinguish VT from SVT</p></li><li><p>MMVT is regular, but initially it may be slightly irregular, mimicking AF w/ aberrancy; grossly irregularly irregular rhythm suggests AF w/ aberrancy or pre-excitation</p></li><li><p>ECG features that favor VT (Circ 2016;133:e506)</p></li></ul><p>AV dissociation (independent P waves, capture or fusion beats) proves VT</p><p>Very wide QRS (>140 ms in RBBB-type or >160 in LBBB-type); extreme axis deviation</p><p>QRS morphology atypical for BBB (longest precordial RS >100 ms and R wider than S)</p><p>RBBB-type: absence of tall R′ (or presence of monophasic R) in V1, r/S ratio &lt;1 in V6</p><p>LBBB-type: onset to nadir >60 ms in V1, q wave in V6</p><p>Initial R wave in aVR; concordance (QRS in all precordial leads w/ same pattern/direction)</p><p>Long-term management (EHJ 2015;36:2793; Circ 2018;138:e272; NEJM 2019;380:1555)</p><ul><li><p>Workup: echo to ✓ LV fxn, cath or stress test to r/o ischemia, ? MRI and/or RV bx to look for infiltrative CMP or ARVC, ? EP study to assess for VT in Pts w/o ICD indication</p></li><li><p>ICD: 2° prevention for VT/VF arrest (unless due to reversible cause) or cardiac syncope with inducible VT on EP study. 1° prev. if high risk, eg, EF &lt;30–35% (>40 d after MI, >90 d after revasc), ? ARVC, ? Brugada, certain LQTS, severe HCMP. See “Cardiac Rhythm Mgmt Devices.” Wearable vest if reversible or waiting for ICD? (NEJM 2018;379:1205). Antitachycardia pacing (ATP = burst pacing faster than VT) can terminate VT w/o shock.</p></li><li><p>Meds: βB, AAD (amio, sotalol, mexiletine); verapamil if LVOT VT</p></li><li><p>If med a/w TdP → QT >500 ± PVCs: d/c med, replete K, give Mg, ± pacing (JACC 2010;55:934)</p></li><li><p>Ablate: if isolated VT focus or if recurrent VT triggering ICD firing (↓ VT storm by 34%; NEJM 2016;375:111); stereotactic radioablation under investigation (Circ 2019;139:313).</p></li></ul><p>ATRIAL FIBRILLATION</p><p>Classification (Circ 2014;130:e199)</p><ul><li><p>Paroxysmal (terminates spontaneously or within 7 d) vs. persistent (>7 d) vs. long-standing persistent (>1 y) vs. permanent (no plan for SR)</p></li><li><p>Nonvalvular vs. valvular (mechanical heart valve or moderate-severe MS)</p></li></ul><p>Epidemiology and etiologies (Circ A&E 2018;11:e006350)</p><ul><li><p>1–2% of pop. has AF (10% of those age ≥80); M >F; lifetime risk ~25%; mean age 75 y</p></li><li><p>Acute (up to 50% w/o identifiable cause)</p></li></ul><p>Cardiac: HF, new CMP, myo/pericarditis, ischemia/MI, HTN crisis, valve dis., cardiac surg</p><p>Pulmonary: acute pulmonary disease or hypoxemia (eg, COPD flare, PNA), PE, OSA</p><p>Metabolic: high catecholamine states (stress, infection, postop, pheo), thyrotoxicosis</p><p>Drugs: alcohol, cocaine, amphetamines, smoking, ibrutinib</p><p>Neurogenic: subarachnoid hemorrhage, ischemic stroke</p><ul><li><p>Chronic: ↑ age, HTN, ischemia, valve dis. (MV, TV, AoV), CMP, hyperthyroidism, obesity</p></li><li><p>Aggressive mgmt of HTN, OSA & EtOH (NEJM 2020;382:20) to ↓ risk</p></li></ul><p>Evaluation</p><ul><li><p>H&P, ECG, CXR, TTE (LA size, thrombus, valves, LV fxn, pericardium), K, Mg, Cr, TFTs</p></li><li><p>In acute AF &lt;48º, ~70% spont. convert to SR w/in 48 hrs (NEJM 2019;380:1499)</p></li></ul><p>Figure 1-5 Approach to acute AF (Adapted from Circ 2014;130:e199)</p><p>Lancet 2016;388:818. IV βB, CCB & dig contraindic. if evidence (ie, pre-excitation or WCT) of WPW (qv).</p><p>*Many meds incl. amio, verapamil, quinidine, propafenone, macrolides & azole antifungals ↑ digoxin levels.</p><p>Cardioversion</p><ul><li>Consider if: 1st AF, sx, tachycardia-mediated CMP, or difficult to rate control</li></ul><p>If AF >48 h 2–5% risk stroke w/ cardioversion (pharmacologic or electric) ∴ either TEE to r/o thrombus or ensure therapeutic anticoagulation ≥3 wk prior</p><p>If needs to cardiovert urgently, often anticoagulate acutely (eg, IV UFH)</p><ul><li><p>For AF &lt;36 hrs, no Δ in % in SR at 4 wks w/ early cardioversion vs. wait & see (βb + a/c), with spont cardioversion in 69% and cardioversion required in 28% (NEJM 2019;380:1499)</p></li><li><p>Likelihood of success ∝ AF duration & atrial size; control precipitants (eg, vol status, thyroid)</p></li><li><p>Before electrical cardiovert, consider pre-Rx w/ AAD (eg, ibutilide), esp. if 1st cardiovert failed</p></li><li><p>For pharmacologic cardioversion, class III and IC drugs have best proven efficacy</p></li><li><p>If SR returns (spont. or w/ Rx), atria may be mech. stunned; also, high risk of recurrent AF over next 3 mo. ∴ Anticoag postcardioversion ≥4 wk (? unless AF &lt;48 h and low risk).</p></li></ul><p>Rhythm control (Lancet 2016;388:829)</p><ul><li><p>Consider if sx w/ rate control (eg, HF), difficult to control rate, or tachycardia-mediated CMP</p></li><li><p>If minimally sx or asx, previously no clear benefit vs. rate control (NEJM 2008;358:2667)</p></li><li><p>For recent AF (~1 mo), rhythm-control w/ AAD (flecainide, amio) & cardioversion (if persist. AF) superior to usual care for achieving SR and ↓ adverse CV events (NEJM 2020;383:1305)</p></li></ul><p>Ablation (Heart Rhythm 2017;14:e445; JACC 2020;75:1689)</p><ul><li><p>Controlling triggers in pulm veins effective when little atrial fibrosis; as AF persists, substrate more complex</p></li><li><p>Pulm vein isolation (radiofreq or cryo; NEJM 2016;374:2235): ~70% success; superior to AAD (JAMA 2014;311:692; NEJM 2021;384:305 & 316) & ↑ QoL (JAMA 2019;321:1059)</p></li><li><p>If NYHA II–IV + EF &lt;35%, ablation ↓ D/HF hosp vs. rate/rhythm meds (NEJM 2018;378:417)</p></li><li><p>AV node ablation + PPM if other Rx inadequate (NEJM 2001;344:1043 & 2002;346:2062)</p></li></ul><p>Oral anticoagulation (Circ 2014;130:e199 & 2019;140:125; EHJ 2021;42:373)</p><ul><li><p>All valvular AF because stroke risk very high</p></li><li><p>Nonvalvular AF (NVAF): stroke risk ~4.5%/y but varies; a/c → 68% ↓ stroke but ↑ bleeding</p></li><li><p>CHA2DS2-VASc to guide Rx: CHF (1 point); HTN (1); Age ≥75 y (2); DM (1), Stroke/TIA (2); Vascular disease (eg, MI, PAD, Ao plaque) (1); Age 65–74 (1); ♀ Sex category (1)</p></li></ul><p>Annual risk of stroke (Lancet 2012;379:648): at low end, ~1% per point: 0 → ~0%, 1 → 1.3%, 2 → 2.2%, 3 → 3.2%, 4 → 4.0%; at higher scores, risk ↑↑ (5 → 6.7%, ≥6 → ≥10%)</p><ul><li><p>Score 2 in ♂ or 3 in ♀→ anticoagulate; scores 1 in ♂ or 2 in ♀ → consider anticoag or ASA or no Rx; score 0 → reasonable to not Rx</p></li><li><p>Rx options: DOAC (NVAF only) prefered over warfarin (INR 2–3); if Pt refuses anticoag, ASA + clopi or, even less effective, ASA alone (NEJM 2009;360:2066)</p></li><li><p>AF + CAD/ PCI: consider DOAC + clopi (not ticag or prasugrel) + ASA (d/c ~1–4 wks) (Circ 2021;143:583); consider DOAC only after 12 mos (JACC 2021;77:629)</p></li><li><p>If concern for procedural bleed, interrupt OAC (1–2 d DOAC, 4–5 d VKA). If CHA2DS2-VASc ≥7 (or ≥5 w/ h/o CVA/TIA), consider bridge w/ UFH/LMWH, otherwise do not (JACC 2017;69:735).</p></li></ul><p>Direct Oral Anticoagulants (DOACs) for NVAF (Lancet 2014;383:955)</p><p>Anticoag</p><p>Dosing</p><p>Efficacy & Safety vs. Warfarin</p><p>Apixaban</p><p>(FXa inhib)</p><p>5 mg bid (2.5 mg bid if ≥ 2 of: ≥80 y, ≤60 kg, Cr ≥1.5 mg/dL)</p><p>≈ ischemic stroke & ↓ major bleed incl ICH,</p><p>11% ↓ death. In Pts felt not cand for warfarin, apixa 55% ↓ stroke w/o ↑ bleed vs ASA alone.</p><p>Rivaroxaban</p><p>(FXa inhib)</p><p>20 mg qd (15 mg qd if CrCl 15–50) w/ pm meal</p><p>≈ ischemic stroke & major bleeds, but ↓ fatal bleed incl ICH</p><p>Edoxaban</p><p>(Fxa inhib)</p><p>60 mg qd if CrCl 51–95 (30 mg if CrCl 15–50)</p><p>≈ ischemic stroke & ↓ major bleed incl ICH, 14% ↓ CV death. ↑ ischemic CVA if CrCl >95.</p><p>Dabigatran</p><p>(Thromb inhib)</p><p>150 mg bid (75 mg bid if CrCl 15–30)</p><p>150 mg: ↓ ischemic stroke & ICH, but ↑ GIB</p><p>Risks: GI side effects, ↑ MI c/w warfarin</p><p>Onset w/in hrs. Reversal: andexanet for FXa inhib; idarucizumab for dabi; 4F-PCC.</p><p>Nonpharmacologic stroke prevent (JACC 2015;66:1497)</p><ul><li><p>If contraindic. to long-term OAC, consider perc. left atrial appendage (LAA) occlusion (JACC 2022;79:1). Nb, ideally warfarin + ASA × 45 d → DAPT out to 6 mo → ASA.</p></li><li><p>Consider surgical LAA occlusion if undergoing cardiac surgery (NEJM 2021;384:2081)</p></li></ul><p>Atrial flutter</p><ul><li><p>Macroreentrant atrial loop. Typical involves cavotricuspid isthmus (if counterclockwise, flutter waves ⊖ in inf leads, if clockwise, ⊕). Atypical: other pathways related to prior scar.</p></li><li><p>Risk of stroke similar to that of AF, ∴ anticoagulate same as would for AF</p></li><li><p>Ablation of typical (cavotricuspid isthmus) AFL has 95% success rate</p></li></ul><p>SYNCOPE</p><p>Definition</p><ul><li><p>Symptom of sudden transient loss of consciousness due to global cerebral hypoperfusion</p></li><li><p>If CPR or cardioversion required, then SCD and not syncope (different prognosis)</p></li><li><p>Presyncope = prodrome of light-headedness without LOC</p></li></ul><p>Etiologies (JACC 2017;70:e39; EHJ 2018;39:1883)</p><ul><li><p>Vasovagal (a.k.a. neurocardiogenic, ~25%): ↑ sympathetic tone → vigorous contraction of LV → LV mechanoreceptors trigger ↑ vagal tone (hyperactive Bezold-Jarisch reflex) → ↓ HR (cardioinhib.) and/or ↓ BP (vasodepressor). Cough, deglutition, defecation, & micturition → ↑ vagal tone and thus can be precipitants. Carotid sinus hypersensitivity (exag vagal resp to carotid massage) is related disorder.</p></li><li><p>Orthostatic hypotension (~10%)</p></li></ul><p>hypovolemia/diuretics, deconditioning; vasodilat. (esp. if combined w/ ⊖ chronotropes)</p><p>autonomic neuropathy [1° = Parkinson’s, MSA/Shy-Drager, Lewy body dementia, POTS (dysautonomia in the young); 2° = DM, EtOH, amyloidosis, CKD] (JACC 2018;72:1294)</p><ul><li>Cardiovascular (~20%, more likely in men than women)</li></ul><p>Arrhythmia (~15%): challenging to dx because often transient</p><p>Bradyarrhythmias: SB, SSS, high-grade AV block, ⊖ chronotropes, PPM malfunction</p><p>Tachyarrhythmias: VT, SVT (syncope rare unless structural heart disease or WPW)</p><p>Mechanical (5%)</p><p>Endocardial/Valvular: critical AS, MS, PS, prosthetic valve thrombosis, myxoma</p><p>Myocardial: outflow obstruction from HCMP (or VT); pericardial: tamponade</p><p>Vascular: PE (in ~25% w/o alt dx; NEJM 2016;375:1524), PHT, AoD, ruptured AAA</p><ul><li><p>Neurologic (~10%): vertebrobasil insuff, cerebrovasc dissection, SAH, TIA/CVA</p></li><li><p>Misc. causes of LOC (but not syncope): seizure, ↓ glc, hypoxia, narcolepsy, psychogenic</p></li></ul><p>Workup (etiology cannot be determined in ~40% of cases) (JAMA 2019;321:2448)</p><ul><li><p>H&P incl. orthostatic VS have highest yield and most cost effective</p></li><li><p>R/o life-threatening dx including: cardiac syncope, severe blood loss, PE, SAH</p></li><li><p>History (from Pt and witnesses if available)</p></li></ul><p>activity and posture before the incident</p><p>precipitating factors: exertion (AS, HCMP, PHT), positional ∆ (orthostatic HoTN), stressors such as sight of blood, pain, emotional distress, fatigue, prolonged standing, warm environment, N/V, cough/deglutition/micturition/defecation (neurocardiogenic), head turning or shaving (carotid sinus hypersens.); arm exercise (subclavian steal)</p><p>sudden onset → cardiac; prodrome (eg, diaphoresis, nausea, blurry vision) → vasovagal</p><p>associated sx: chest pain, palp., neurologic, postictal, bowel/bladder incontinence, (convulsive activity for &lt;10 sec may occur w/ transient cerebral HoTN & mimic seizure)</p><ul><li><p>PMH: prior syncope, previous cardiac or neuro dis.; cardiac more likely if >35 y, known structural heart dis., h/o AF, CV prodrome, syncope while supine or exertional, cyanosis</p></li><li><p>Medications that may act as precipitants</p></li></ul><p>vasodilators: α-blockers, nitrates, ACEI/ARB, CCB, hydralazine, phenothiazines, antidep.</p><p>diuretics; ⊖ chronotropes (eg, βB and CCB)</p><p>proarrhythmic or QT prolonging: class IA, IC or III antiarrhythmics (see “ECG”)</p><p>psychoactive drugs: antipsychotics, TCA, barbiturates, benzodiazepines, EtOH</p><ul><li><p>Family history: CMP, SCD, syncope (vasovagal may have genetic component)</p></li><li><p>Physical exam</p></li></ul><p>VS incl. orthostatics (⊕ if supine → standing results in ≥20 mmHg ↓ SBP or ≥10 ↓ DBP or SBP &lt;90 mmHg w/in 3 min; POTS if ≥30 bpm ↑ HR w/in 10 min), BP in both arms</p><p>Cardiac: HF (↑ JVP, displ. PMI, S3), murmurs, LVH (S4, LV heave), PHT (RV heave, ↑ P2)</p><p>Vascular: ✓ for asymmetric pulses, carotid/vert/subclavian bruits; carotid sinus massage to ✓ for carotid hypersens (if no bruits): ⊕ if asystole >3 sec or ↓ SBP >50 mmHg</p><p>Neurologic exam: focal findings, evidence of tongue biting</p><ul><li>ECG (abnormal in ~50%, but only definitively identifies cause of syncope in &lt;10%)</li></ul><p>Conduction: SB &lt;40 bpm, sinus pauses >3 sec or sinus arrhythmia, AVB, BBB/IVCD</p><p>Arrhythmia: ectopy, ↑ or ↓ QT, preexcitation (WPW), Brugada, ε wave (ACM), SVT/VT</p><p>Ischemic changes (new or old): atrial or ventricular hypertrophy</p><ul><li>Lab: glc, Hb, HCG (pre-menop ♀), ? D-dimer, ? troponin/NT-proBNP (↓ yield w/o other s/s)</li></ul><p>Other diagnostic studies (consider based on results of H&P and ECG)</p><ul><li>Ambulatory ECG monitoring: if suspect arrhythmogenic syncope</li></ul><p>Holter monitoring (continuous ECG 24–72 h): useful if frequent events</p><p>Event recorder (activated by Pt to record rhythm): limited role if LOC w/o prodrome</p><p>External loop recorder (continuously saves rhythm, ∴ can be activated after an event): useful for episodes (including w/o prodrome) likely to occur w/in 2–6 wks; can be coupled w/ mobile cardiac telemetry than can be auto-triggered for specific rhythms</p><p>External patch recorder (1-lead recording; saves for 1–4 wks): Pt-activated or auto-triggered; more comfortable for Pts</p><p>Implantable loop recorders (SC; can record 2–3 y; can be triggered): useful if episodes &lt;1/mo; dx in 55% of cases; recommended for recurrent syncope w/o prodrome</p><ul><li><p>Echo: consider to r/o structural heart disease (eg, CMP [incl HCMP & ARVC], valvular disease [incl AS, MS, MVP], myxoma, amyloid, PHT, ± anomalous coronaries)</p></li><li><p>ETT/CCTA/Cath: esp. w/ exertional syncope; r/o ischemia or catechol-induced arrhythmia</p></li><li><p>Electrophysiologic studies (EPS): consider in high-risk Pts in whom tachy or brady etiology is strongly suspected (eg, prior MI), but cannot be confirmed; avoid if ECG/Echo normal.</p></li></ul><p>50% abnl (inducible VT, conduction abnormalities) if heart disease, but ? significance</p><p>3–20% abnl if abnl ECG; &lt;1% abnl if normal heart and normal ECG</p><ul><li><p>Tilt table: debated utility due to poor Se/Sp/reproducibility; consider if suspected neuro- cardiogenic, orthostatic HoTN, POTS, or psychogenic, and initial eval unrevealing</p></li><li><p>Cardiac MRI: helpful to dx sarcoid or ARVC if suggestive ECG, echo (RV dysfxn) or ⊕ FHx</p></li><li><p>Neurologic studies (cerebrovascular studies, CT, MRI, EEG): if H&P suggestive; low yield</p></li></ul><p>Figure 1-6 Approach to syncope</p><p>(Adapted from JACC 2017;70:e39)</p><p>High-risk features (admit w/ tele; JACC 2017;70:620; EHJ 2018;39:1883)</p><ul><li><p>Age >60 y, h/o CAD, HF/CMP, valvular or congenital heart dis., arrhythmias, FHx SCD</p></li><li><p>Syncope c/w cardiac cause (⊖ prodrome, exertional, supine, trauma) or recurrent</p></li><li><p>Complaint of chest pain or dyspnea; abnl VS, cardiac, pulm, or neuro exam; low Hct</p></li><li><p>ECG suggesting conduction abnormality, arrhythmia, or ischemia; Pt w/ PPM/ICD</p></li><li><p>Canadian Syncope Risk Score (CMAJ 2016;188:e289) stratifies from &lt;1% to >20% risk of serious arrhythmias. If low-risk & no arrhythmia in ED × 2 h, 0.2% risk over 30 d.</p></li></ul><p>Treatment (JACC 2017;70:620 & 2019;74:2410; EHJ 2018;39:1883)</p><ul><li><p>Arrhythmia, cardiac mechanical or neurologic syncope: treat underlying disorder, ? ICD if Brugada pattern, sarcoid, ARVC, early repol + syncope</p></li><li><p>Vasovagal: avoidance of triggers; physical counterpressure; consider ↑ Na & fluid intake, fludrocortisone or midodrine (JACC 2016;68:1; Ann Intern Med 2021;174:1349); SSRI; ? βB;</p></li></ul><p>consider PPM if recurrent + pauses on recorder or tilt test (EHJ 2021;42:508)</p><ul><li>Orthostatic: 2–3 L fluid & 10 g Na per day; rise from supine to standing slowly, compression stockings; consider: midodrine, fludrocortisone, droxidopa, ? pyridostigmine, ? octreotide</li></ul><p>Prognosis (Ann Emerg Med 1997;29:459; NEJM 2002;347:878)</p><ul><li><p>22% overall recurrence rate if idiopathic, else 3% recurrence</p></li><li><p>Cardiac syncope has poor prognosis (20–40% 1-y SCD rate); vasovagal good prognosis</p></li><li><p>Unexplained syncope w/ 1.3-fold ↑ in mort., but noncardiac or unexplained syncope w/ nl</p></li></ul><p>ECG, no h/o VT, no HF, age &lt;45 → low recurrence rate and &lt;5% 1-y SCD rate</p><ul><li>✓ state driving laws and MD reporting requirements. Consider appropriateness of Pt involvement in exercise/sport, operating machinery, high-risk occupation (eg, pilot).</li></ul><p>CARDIAC RHYTHM MANAGEMENT DEVICES</p><p>Common Pacing Modes</p><p>VVI</p><p>Ventricular pacing on demand w/ single lead in RV. Sensed ventricular beat inhibits V pacing. Used in chronic AF with symptomatic bradycardia.</p><p>DDD</p><p>A & V sensing/pacing (RA & RV leads). Native A beat inhib A pacing & triggers V pacing → tracking of intrinsic atrial activity. Maintains AV synchrony, ↓ AF.</p><p>Mode Switch</p><p>In atrial tachyarrhythmia (eg, AF), PPM ∆s from DDD to nontracking mode (eg, VVI). Prevents PPM from pacing at max V rate in response to rapid atrial rate.</p><p>Magnet over generator</p><p>PPM: fixed rate pacing (VOO/DOO). ICD: no shock, pacing preserved.</p><p>Indic: ✓ capture; surgery; inapprop PPM inhib/ICD shock, PM-mediated tachy</p><p>Leadless intracardiac PPM for RV or AV synchronous pacing (JACC Clin EP 2020;6:94). His or L bundle pacing: more physiologic than RV pacing or even CRT (JACC 2018;72:927).</p><p>Indications for Permanent Pacing (JACC 2013;61:e6 & 2017;70:e39, Circ 2019;140:e382)</p><p>AV block</p><p>2° type II, high-grade or 3° AVB; symptomatic 1°, 2° type I AVB or asx with Lamin A/C or neuromuscular disease; bifasc or alter. L & RBBB</p><p>Sinus node</p><p>SB, pauses (SSS), chronotrop incompet a/w sx or ? if sx w/o clear assoc</p><p>Tachy-arrhythmia</p><p>AF w/ SSS; sx recurrent SVT term. by pacing after failing drugs/ablation; Sustained pause-dependent VT; ? high-risk congenital long QT</p><p>Syncope</p><p>Carotid sinus hypersensitivity with asystole >3 sec</p><p>Syncope with bi- or trifascicular block and HV>70 ms on EP study</p><p>? Recurrent vasovagal syncope w/ abnormal tilt test (JACC 2017;70:1720)</p><p>Pacemaker Complications</p><p>Issue</p><p>Manifestation</p><p>Description & etiologies</p><p>Perforation</p><p>Effusion/tamp/pain</p><p>Typically acute, consider if HoTN</p><p>Failure to pace</p><p>Bradycardia</p><p>↓ Battery, lead fx/dislodgment, ↑ pacing threshold due to tissue rxn/injury; oversense → inapprop. inhib</p><p>Failure to sense</p><p>Inapprop. pacing</p><p>Lead dislodgment or sensing threshold too high</p><p>PM-mediated tachycardia</p><p>WCT at device upper rate</p><p>Seen w/ DDD. V → A retrograde conduction; sensed by A lead → triggers V pacing → etc.</p><p>PM syndrome</p><p>Palpit, HF</p><p>Seen w/ VVI, due to loss of AV synchrony</p><p>Cardiac resynch therapy (CRT)/Biventricular (BiV) pacing (JACC 2013;61:e6)</p><ul><li><p>3-lead pacemaker (RA, RV, coronary sinus to LV); R >S in V1 suggests approp LV capture</p></li><li><p>Synch LV fxn (↑ CO/EF, ↓ adv remodeling); ↓ HF sx & hosp, ↑ survival (NEJM 2010;363:2385)</p></li><li><p>Indications: LVEF ≤35% + NYHA II–IV despite med Rx + SR + LBBB ≥150 ms (also reasonable if LBBB ≥120 ms, any non-LBBB ≥150 ms, or >40% V-pacing); mort. benefit w/ CRT-D only if LBBB (& QRS ≥130 ms) (NEJM 2014;370:1694)</p></li></ul><p>? benefit in NYHA I–III, EF ≤50% w/ PPM indication for AVB (NEJM 2013;368:1585)</p><p>Implantable cardiac defibrillator (ICD) (Circ 2019;140:e382)</p><ul><li><p>RV lead: defib & pacing (± antitachycardia pacing [ATP] = burst pacing > VT rate to stop VT); ± RA lead for dual-chamber PPM. Subcut-ICD (consider if young), but Ø pace/ATP.</p></li><li><p>2° prev: survivors of VT/VF arrest w/o revers cause; asx sustained VT + struct. heart dis.</p></li><li><p>1° prev: IHD (wait ≥40 d after MI): LVEF ≤30% or ≤35% & NYHA II–III or ≤40%, spont NSVT & inducible. NICM (wait ≥90 d after starting GDMT): LVEF ≤35% & NYHA II–III. High-risk CMP (w/o meeting above criteria): HCM, ACM, sarcoid, laminopathy, Chagas. Channelopathies: LQTS or Brugada if syncope or high-risk. ACHD: if SCD risk factors.</p></li></ul><p>More recently, for niCMP ICD ↓ SCD but not overall mortality (NEJM 2016;375:1221).</p><p>Life expectancy must be >1 y.</p><ul><li><p>Wearable vest as bridge while waiting for ICD, but no benefit in RCT (NEJM 2018;379:1205)</p></li><li><p>Subcutaneous ICD non-inferior in patients without PPM indication (NEJM 2020;383:526)</p></li><li><p>Risks: inapprop shock in ~15–20% at 3 y (commonly d/t misclassified SVT); infxn; lead fx</p></li><li><p>ICD discharge: ✓ device to see if approp; r/o ischemia; 6-mo driving ban (✓ state law)</p></li><li><p>MRI: new devices OK; older may be OK (NEJM 2017;377:2555). Consult prescan.</p></li></ul><p>Device infection (Heart Rhythm 2017;14:e503, NEJM 2019;380:1895)</p><ul><li><p>Presents as pocket infection (warmth, erythema, tenderness) and/or sepsis w/ bacteremia</p></li><li><p>~2% over 5 y; if S. aureus bacteremia, infxn in ≥35%; antibacterial envelope ↓ risk</p></li><li><p>TTE/TEE used to help visualize complic. (eg, vegetation), but even ⊖ TEE does not r/o</p></li><li><p>Rx: abx; system removal if pocket infxn or GPC bacteremia; Ø routine abx prior to inv. proc.</p></li></ul><p>CARDIAC RISK ASSESSMENT FOR NONCARDIAC SURGERY</p><p>Goal: characterize risk of Pt & procedure → appropriate testing (ie, results will ∆ management) and interventions (ie, reasonable probability of ↓ risk of MACE)</p><p>Preoperative evaluation (Circ 2014;130:e278, NEJM 2015;373:2258, JAMA 2020;324:279)</p><p>Figure 1-7 Approach to preop CV eval for non-CV surgery</p><p>(Modified with permission Circulation. 2014;130:2215-2245 © 2014 American Heart Association, Inc.)</p><p>Noninvasive Testing Result</p><p>High Risk</p><p>Intermediate Risk</p><p>Low Risk</p><p>Ischemia at &lt;4 METs manifested by ≥1 of:</p><ul><li><p>Horiz/down ST ↓ ≥1 mm or STE</p></li><li><p>≥5 abnl leads or ischemic ECG ∆s</p></li><li><p>lasting >3 min after exertion</p></li><li><p>SBP ↓ 10 mmHg or typical angina</p></li></ul><p>Ischemia at &lt;4–6 METs manifested by ≥1 of:</p><ul><li><p>Horiz/down ST ↓ ≥1 mm</p></li><li><p>3–4 abnl leads</p></li><li><p>1–3 min after exertion</p></li></ul><p>No ischemia or at &lt;7 METs w/</p><ul><li><p>ST ↓ ≥1 mm or</p></li><li><p>1–2 abnl leads</p></li></ul><p>Additional preoperative testing (Circ 2014;130:e278)</p><ul><li><p>ECG if known cardiac disease and possibly reasonable in all, except if low-risk surgery</p></li><li><p>TTE if any of following & prior TTE >12 mo ago or prior to ∆ in sx: dyspnea of unknown origin; hx of HF w/ ↑ dyspnea; suspect (eg, murmur) or known ≥moderate valvular dis.</p></li></ul><p>Coronary artery disease</p><ul><li><p>If possible, wait ~60 d after MI in the absence of revascularization before elective surgery</p></li><li><p>Coronary revasc guided by standard indications. Has not been shown to ∆ risk of death or postop MI when done prior to elective vasc. surgery (NEJM 2004;351:2795).</p></li></ul><p>Heart failure (Circ 2014;130:e278)</p><ul><li><p>Decompensated HF should be optimally Rx’d prior to elective surgery</p></li><li><p>30-d CV event rate: symptomatic HF >asx HFrEF >asx HFpEF >no HF</p></li></ul><p>Valvular heart disease</p><ul><li><p>If meet criteria for valve intervention, do so before elective surgery (postpone if necessary)</p></li><li><p>If severe valve disease and surgery urgent, intra- & postoperative hemodynamic monitoring reasonable (espec for AS, because at ↑ risk even if sx not severe; be careful to maintain preload, avoid hypotension, and watch for atrial fibrillation)</p></li></ul><p>Cardiac implantable electronic devices</p><ul><li><p>Discuss w/ surgical team need for device (eg, complete heart block) & consequences if interference w/ fxn, and likelihood of electromagnetic interference</p></li><li><p>Consider reprogramming, magnet use, etc. as needed</p></li></ul><p>Pre- & perioperative pharmacologic management</p><ul><li><p>ASA: continue in Pts w/ existing indication. Initiation prior to surgery does not ↓ 30-d ischemic events and ↑ bleeding (NEJM 2014;370:1494), but Pts w/ recent stents excluded.</p></li><li><p>Dual antiplatelet therapy: delay elective surg 14 d after balloon angioplasty, 30 d after BMS and ideally 6 mo (min 3 mo) after DES (JACC 2016; 68:1082) unless risk of bleeding > risk of stent thrombosis or ACS. If must discontinue P2Y12 inh, continue ASA and restart P2Y12 inh ASAP; can consider IV cangrelor if high-risk (JAMA 2012;307:265).</p></li><li><p>β-blockers (JAMA 2020;324:279)</p></li></ul><p>Continue βB in Pts on them chronically. Do not stop βB abruptly postop (may cause reflex sympathetic activation). Use IV if Pt unable to take PO.</p><p>Reasonable to initiate if intermed- or high-risk ⊕ stress test, or RCRI ≥3, espec if vasc surgery. Initiate ≥1 wk prior to surgery (not day of), use low-dose, short-acting βB, and titrate to achieve HR and BP goal (? HR ~55–65). Avoid bradycardia and HoTN.</p><ul><li><p>Statins: ↓ ischemia & CV events in Pts undergoing vascular surg (NEJM 2009;361:980). Consider if risk factors & non–low-risk surgery and in all Pts undergoing vascular surgery.</p></li><li><p>ACEI/ARB: holding 24 h preop to ↓ intraop HoTN (Anes 2017;126:16). Restart ASAP.</p></li><li><p>Amiodarone: ↓ incidence of postop AF if started prior to surgery (NEJM 1997;337:1785)</p></li></ul><p>Postoperative monitoring</p><ul><li><p>ECG if known CAD or high-risk surgery. Consider if >1 risk factor for CAD.</p></li><li><p>Routine troponin prognostic (JAMA 2017;317:1642) but ✓ only if sx/ECG ∆s suggestive of ACS</p></li></ul><p>PERIPHERAL ARTERY DISEASE (PAD)</p><p>Clinical features (NEJM 2016;374:861, Circ 2021;144:e171)</p><ul><li><p>Prev. ↑ w/ age: &lt;1% if &lt;40 y, ~15% if ≥70 y; risk factors incl. smoking, DM, HTN, chol</p></li><li><p>Claudication (ache/cramp, often in calves) precip by walking and relieved by stopping (vs. spinal stenosis, qv); Leriche synd = claudic., ↓ or Ø fem pulses, & erectile dysfxn</p></li><li><p>Critical limb ischemia (CLI): rest pain (↑ w/ elevation b/c ↓ perfusion), ulcer (typically at pressure foci, often dry; in contrast, venous ulcers are more often at medial malleolus, wet, and with hemosiderin deposition) or gangrene, due to PAD, and >2-wk duration (implies chronicity vs. acute limb ischemia; see below) (Circ 2019;140:e657)</p></li></ul><p>Diagnosis (Circ 2016;135:e686, JAMA 2021;325:2188)</p><ul><li><p>↓ peripheral pulses, bruits; signs of chronic PAD: hair loss, skin atrophy, nail hypertrophy</p></li><li><p>Ankle: brachial index (ABI): nl 1–1.4; borderline 0.91–0.99; abnl ≤0.90; if >1.4, non-dx possibly due to calcified noncompressible vessel → ✓ PVR, TBI (toe-brachial index). If ABI abnl → segmental ABI w/ PVR to localize disease. If ⊕ sx but nl ABI, ✓ for ↓ lower extrem BP after exercise (≥20% ↓ in ABI w/ exercise or ≥30 mmHg ↓ in ankle pressure).</p></li><li><p>Duplex arterial U/S; CTA w/ distal run-off; MRA or angio if dx in ? or possible intervention</p></li></ul><p>Treatment (JACC 2013;61:1555, Circ 2021;144:e171, JAMA 2021;325:2188)</p><ul><li><p>Risk factor modif. Screen for CAD/AAA. Structured high-intensity walking (JAMA 2021;325:1266).</p></li><li><p>If sx or if asx with ABI ≤0.90, ASA, clopi, or ticag to ↓ D/MI/stroke (NEJM 2017; 376:32). More intensive antiplt Rx ↓ both MACE & limb ischemic events (JACC 2016;67:2719). Adding riva 2.5 mg bid to ASA ↓ MACE but ↑ bleeding (Lancet 2018;391:219; NEJM 2020;382:1994).</p></li><li><p>Statins & PCSK9i ↓ MACE & limb ischemic events (Circ 2018;137:338). Cilostazol (if no HF).</p></li><li><p>Endovascular (angioplasty vs. stent) or surgical revasc if limiting/refractory sx or CLI</p></li></ul><p>Acute limb ischemia (ALI) (Circ 2016;135:e686)</p><ul><li><p>Sudden decrement in limb perfusion (ie, acutely cold & painful) that threatens viability</p></li><li><p>Etiologies: embolism > acute thrombosis (eg, athero, APS, HITT), trauma to artery</p></li><li><p>Clinical manifestations (6 Ps): pain (distal to proximal, ↑ in severity), poikilothermia, pallor, pulselessness, paresthesias, paralysis</p></li><li><p>Testing: pulse & neuro exam; arterial & venous Doppler; angiography, CTA or MRA</p></li><li><p>Urgent consultation w/ vascular medicine and/or vascular surgery</p></li></ul><p>DYSPNEA</p><p>Pathophysiology</p><p>Etiologies</p><p>Airway obstruction (↑ resistance to airflow)</p><p>Asthma, COPD, bronchiectasis, cystic fibrosis, tumor, foreign body, vocal cord dysfunction, anaphylaxis</p><p>Alveolar / Parenchymal disease</p><p>Pulmonary edema: cardiogenic or noncardiogenic</p><p>ILD; pneumonia; atelectasis</p><p>Vascular</p><p>(V/Q mismatch)</p><p>Large vessel: PE, tumor emboli</p><p>Small vessel: PHT, vasculitis, ILD, emphysema, PNA</p><p>Chest wall</p><p>(↑ resistance to expansion; weakness of respir. muscles)</p><p>Pleural disease: large effusion, fibrosis, pneumothorax</p><p>Chest wall/diaphragm: kyphoscoliosis, ↑ abd girth</p><p>Neuromuscular disorders (ALS, GBS, MG)</p><p>Hyperinflation (COPD, asthma)</p><p>Stimulation of receptors</p><p>Chemoreceptors: hypoxemia, metabolic acidosis</p><p>Mechanoreceptors: ILD, pulmonary edema, PHT, PE</p><p>↓ O2 carrying cap. (but nl PaO2)</p><p>Anemia, methemoglobinemia, CO poisoning</p><p>Psychological</p><p>Anxiety, panic attack, depression, somatization</p><p>Evaluation</p><ul><li><p>History: quality of sensation, tempo, positional dependence, exac./allev. factors, exertion</p></li><li><p>Cardiopulmonary exam, SaO2, CXR (see Appendix & Radiology inserts), ECG, ABG, U/S Predictors of CHF: h/o CHF, PND, S3, CXR w/ venous congestion, AF (JAMA 2005;294:1944) Dyspnea w/ nl CXR: CAD, asthma, PE, PHT, early ILD, anemia, acidosis, NM disease</p></li><li><p>Based on results of initial evaluation: PFT, chest CT, TTE, cardiopulmonary testing</p></li><li><p>BNP & NT-proBNP ↑ in CHF (also ↑ in AF, RV strain from PE, COPD flare, PHT, ARDS) BNP &lt;100 pg/mL to r/o CHF (90% Se), >400 to r/i (NEJM 2002;347:161) NT-proBNP &lt;300 pg/mL to r/o CHF (99% Se); age-related cut points to r/i: >450 pg/mL (&lt;50 y), >900 (50–75 y), >1800 (>75 y) (EHJ 2006;27:330)</p></li></ul><p>↑ in chronic HF, ∴ need to compare to known “dry BNP.” May be falsely low in obesity.</p><p>PULMONARY FUNCTION TESTS (PFTs)</p><ul><li>Spirometry: evaluate for obstructive disease</li></ul><p>Flow-volume loops: diagnose and/or localize obstruction</p><p>Bronchodilator: indicated if obstruction at baseline or asthma clinically suspected</p><p>Methacholine challenge: helps dx asthma if spirometry nl, >20% ↓ FEV1 → asthma</p><ul><li><p>Lung volumes: evaluate for hyperinflation or restrictive disease including NM causes</p></li><li><p>DLCO: evaluates functional surface area for gas exchange; helps differentiate causes of obstructive and restrictive diseases and screens for vascular disease & early ILD</p></li></ul><p>Figure 2-1 Approach to abnormal PFTs</p><p>ASTHMA</p><p>Definition and epidemiology (Lancet 2018;391:783)</p><ul><li><p>Chronic inflam disorder w/ airway hyperresponsiveness + variable airflow obstruction</p></li><li><p>Affects 5–10% population; ~85% of cases by age 40 y</p></li></ul><p>Clinical manifestations (NEJM 2013;369:549)</p><ul><li><p>Classic triad = wheezing, cough, dyspnea; others include chest tightness, sputum; symptoms typically chronic with episodic exacerbation</p></li><li><p>Precipitants (triggers)</p></li></ul><p>respiratory irritants (smoke, perfume, etc.) & allergens (pets, dust mites, pollen, etc.)</p><p>infections (URI, bronchitis, sinusitis)</p><p>drugs (eg, ASA & NSAIDs via leukotrienes, βB via bronchospasm, MSO4 via histamine)</p><p>emotional stress, cold air, exercise (increase in ventilation dries out airways)</p><p>Physical examination</p><ul><li><p>Wheezing and prolonged expiratory phase</p></li><li><p>Presence of nasal polyps, rhinitis, rash → allergic component</p></li><li><p>Exacerbation → ↑ RR, ↑ HR, accessory muscle use, diaphoresis, pulsus paradoxus</p></li></ul><p>Diagnostic studies (JAMA 2017;318:279)</p><ul><li>Spirometry: ↓ FEV1, ↓ FEV1/FVC, coved flow-volume loop; lung volumes: ± ↑ RV & TLC</li></ul><p>⊕ bronchodilator response (↑ FEV1 ≥12% & ≥200 mL) strongly suggestive of asthma</p><p>methacholine challenge (↓ FEV1 ≥20%) if PFTs nl: Se >90%</p><ul><li>Allergy suspected → consider checking serum IgE, eos, skin testing/RAST</li></ul><p>Ddx (“all that wheezes is not asthma…”)</p><ul><li><p>Hyperventilation & panic attacks</p></li><li><p>Upper airway obstruction or inh foreign body; laryngeal/vocal cord dysfxn (eg, 2° to GERD)</p></li><li><p>CHF (“cardiac asthma”); COPD; bronchiectasis; ILD (including sarcoidosis); vasculitis; PE</p></li></ul><p>“Asthma plus” syndromes</p><ul><li><p>Atopy = asthma + allergic rhinitis + atopic dermatitis</p></li><li><p>Aspirin-exacerbated respiratory disease (Samter’s syndrome) = asthma + ASA sensitivity + nasal polyps (J Allergy Clin Immunol 2015;135:676)</p></li><li><p>ABPA = asthma + pulmonary infiltrates + hypersensitivity to Aspergillus (Chest 2009;135:805)</p></li></ul><p>Dx: ↑ IgE to Asperg. & total (>1000), ↑ Asperg. IgG levels, ↑ eos, central bronchiectasis</p><p>Rx: steroids ± itra-/voriconazole for refractory cases (NEJM 2000;342:756)</p><ul><li>Eosinophilic granulomatosis w/ polyangiitis (EGPA, previously Churg-Strauss) = asthma + eosinophilia + granulomatous vasculitis</li></ul><p>CHRONIC MANAGEMENT</p><p>“Reliever” medications (used prn to quickly relieve sx)</p><ul><li><p>Low-dose inhaled corticosteroids (ICS) + long-acting inh β2-agonists (LABA): budesonide-formoterol (NEJM 2019;380:2020)</p></li><li><p>Short-acting inh β2-agonists (SABA): albuterol Rx of choice</p></li><li><p>Short-acting inh anticholinergics (ipratropium) ↑ β2-agonist delivery → ↑ bronchodilation</p></li></ul><p>“Controller” meds (taken daily to keep control) (JAMA 2020;324:2301)</p><ul><li><p>ICS Rx of choice. Superior to LAMA if sputum w/ ≥2% eos (NEJM 2019;380:2009). PO steroids may be needed for severely uncontrolled asthma; avoid if possible b/c of systemic side effects.</p></li><li><p>LABA (eg, salmeterol, formoterol) safe & ↓ exacerb. when added to ICS (NEJM 2018;378:2497)</p></li><li><p>Long-acting inh antimuscarinics (LAMA; eg, tiotropium, umeclidinium): may consider if sx despite ICS+LABA (JAMA 2018;319:1473)</p></li><li><p>Leukotriene receptor antagonists (LTRA): some Pts very responsive, esp. ASA-sens and exercise-induced. Warning for serious neuropsychiatric effects, including suicide.</p></li><li><p>Nedocromil/cromolyn: limited use in adults. Useful in young Pts, exercise-induced bronchospasm; ineffective unless used before trigger or exercise exposure.</p></li></ul><p>Immunotherapies (NEJM 2017;377:965)</p><ul><li><p>Allergen ImmunoRx (“allergy shots”) may help if sig. allerg. component (JAMA 2016;315:1715)</p></li><li><p>Anti-IgE (omalizumab) for uncontrolled mod-to-severe allergic asthma (w/ IgE >30) on ICS ± LABA (JAMA 2017; 318:279); ↓ exacerbations in severe asthma (Cochrane 2014;CD003559)</p></li><li><p>Anti-IL5 (mepolizumab, reslizumab) ↓ exacerb in severe asthma (NEJM 2014;371:1189 & 1198)</p></li><li><p>Anti-IL5Rα (benralizumab) ↓ steroid use, ↓ exac. in sev asthma w/ eos (NEJM 2017;376:2448)</p></li><li><p>Anti-IL4Rα (dupilumab) blocks IL-4 & IL-13; ↓ exacerb in severe asthma, ↓ steroid use, ↑ FEV1 (NEJM 2018;378:2475 & 2486)</p></li><li><p>Anti-TSLP (tezepelumab-ekko) ↓ exacerbations in severe asthma; can use in non-allergic/non-eosinophilic asthma (NEJM 2021;384:1800)</p></li></ul><p>Principles of treatment</p><ul><li><p>Education and avoidance of environmental triggers (Lancet 2015;386:1075); yearly flu shot</p></li><li><p>Use quick-relief rescue medication as needed for all Pts</p></li><li><p>Goal to achieve complete control = daily sx ≤2/wk, Ø nocturnal sx or limitation of activity, reliever med ≤2/wk, nl peak expiratory flow rate or FEV1; partly controlled = 1–2 of the above present in a wk; uncontrolled = ≥3 of the above present in a wk</p></li><li><p>Step up treatment as needed to gain control, step down as tolerated</p></li><li><p>Can abort exacerb by quadrupling ICS if deteriorating control (NEJM 2018;378:902)</p></li></ul><p>Category for sx determined by most severe day or nocturnal element</p><p>EXACERBATION</p><p>Evaluation</p><ul><li>History: baseline PEF, steroid requirement, ED visits, hospital admissions, prior intubation</li></ul><p>Current exacerbation: duration, severity, potential precipitants, meds used</p><p>Risk factors for life-threatening: prior intubation, h/o near-fatal asthma, ED visit/hosp for asthma w/in 1 y, current/recent PO steroids, not using ICS, overdependent on SABA, Ψ, h/o noncompliance</p><ul><li>Physical exam: VS, pulm, accessory muscle use, pulsus paradoxus, abdominal paradox</li></ul><p>Assess for barotrauma: asymmetric breath sounds, tracheal deviation, subcutaneous air → pneumothorax, precordial (Hamman’s) crunch → pneumomediastinum</p><ul><li>Diagnostic studies: peak expiratory flow (know personal best; &lt;80% personal best c/w poor control, &lt;50% c/w severe exacerbation); SaO2; CXR to r/o PNA or PTX; ABG if severe (low PaCO2 initially; nl or high PaCO2 may signify tiring)</li></ul><p>Severity of Asthma Exacerbation</p><p>Mild-Moderate</p><p>Severe</p><p>Life-Threatening</p><p>Symptoms</p><p>Talks in phrases</p><p>Talks in words, tripod positioning</p><p>Drowsy</p><p>Confused</p><p>Vitals/ Exam</p><p>RR >20, HR 100–120, Room air SaO2 90–95%</p><p>RR >30, HR >120</p><p>Room air SaO2 &lt;90%</p><p>Silent chest</p><p>Bradycardia</p><p>PEF</p><blockquote><p>50% predicted or best</p></blockquote><p>≤50% predicted or best</p><p>Not indicated</p><p>Initial Treatment</p><p>O2, SABA 4–10 puffs q20min, prednisone</p><p>Tx to acute facility,</p><p>SABA, ipratropium, methylpred, IV Mg</p><p>Tx to acute facility, prepare for intubation</p><p>SABA, ipratropium, methylpred, IV Mg</p><p>Initial treatment details (GINA 2021 Guidelines)</p><ul><li><p>Oxygen to keep SaO2 ≥93–95%</p></li><li><p>Inhaled SABA (eg, albuterol) by MDI (4–8 puffs) or nebulizer (2.5–5 mg) q20min</p></li><li><p>Corticosteroids: prednisone 40–60 mg PO if outPt; methylpred IV if ED or inPt</p></li><li><p>Ipratropium MDI (4–6 puffs) or nebulizer (0.5 mg) q20min if severe (Chest 2002;121:1977)</p></li><li><p>Reassess after 60–90 min of Rx</p></li></ul><p>Mild–mod exacerbation: cont SABA q1h</p><p>Sev exacerbation: SABA & ipratropium q1h or cont.; if refractory, consider Mg ± heliox</p><ul><li><p>Decide disposition within 4 h of presentation and after 1–3 h of Rx</p></li><li><p>High-dose steroids: methylpred 125 mg IV q6h (NEJM 1999;340:1941)</p></li></ul><p>Figure 2-2 Disposition of patients after initial treatment of asthma exacerbation</p><p>ICU-level care</p><ul><li>Invasive ventilation:</li></ul><p>Large ET tube, Pplat &lt;30 cm H2O (predicts barotrauma better than PIP), max exp time</p><p>PEEP individualized to patient physiology</p><p>Paralysis, inhalational anesthetics, bronchoalveolar lavage w/ mucolytic, heliox (60–80% helium) and ECMO have been used with success</p><p>IV ketamine: bronchodilating effects and can be used for refractory status asthmaticus</p><ul><li>NPPV likely improves obstruction (Chest 2003;123:1018), but controversial and rarely used</li></ul><p>ANAPHYLAXIS</p><p>Definition and pathophysiology (Ann Emerg Med 2006;47:373)</p><ul><li><p>Severe, rapid onset (mins to hrs), potentially life-threatening systemic allergic response</p></li><li><p>IgE-mediated mast cell degranulation with release of histamine, tryptase, and TNF</p></li><li><p>Precipitates systemic reactions (bronchospasm, tissue swelling, fluid shifts, vasodilation)</p></li><li><p>Common triggers: penicillins, cephalosporins, shellfish, nuts, insect stings, IV contrast (not truly an IgE-mediated mechanism, but clinically similar)</p></li></ul><p>Diagnosis: any of the three following criteria</p><ol><li>Acute illness with skin ± mucosal involvement (rash, flushing, hives), AND at least one of:</li></ol><p>Respiratory compromise (wheeze, stridor, dyspnea, hypoxemia)</p><p>Hypotension or hypoperfusion (syncope, incontinence)</p><ol start=2><li><p>Two or more of the following after exposure to a likely allergen: skin/mucosal involvement, respiratory compromise, ↓ BP or hypoperfusion, GI symptoms</p></li><li><p>Hypotension after exposure to known allergen for that Pt</p></li></ol><p>Treatment</p><ul><li><p>Epi: 0.5 mg IM (0.5 mL of 1 mg/mL solution) q5–15min as needed. For those who do not respond, IV infusion starting at 0.1 mcg/kg/min.</p></li><li><p>Airway: suppl O2 ± intubation or cricothyroidotomy (if laryngeal edema); β2-agonists</p></li><li><p>Fluid resuscitation w/ ≥1–2 L crystalloid (may extravasate up to 35% of intravasc volume)</p></li><li><p>Antihistamines relieve hives & itching, no effect on airway or hemodynamics; H1RA (diphenhydramine 50 mg IV/IM)</p></li><li><p>Methylprednisolone 1–2 mg/kg/d × 1–2 d for those who do not respond to epi</p></li><li><p>Avoid unopposed α-adrenergic vasopressors</p></li></ul><p>Disposition</p><ul><li><p>Mild rxn limited to urticaria or mild bronchospasm can be observed for ≥6 h; admit all others</p></li><li><p>Watch for biphasic reaction; occurs in 23%, typically w/in 8–10 h but up to 72 h</p></li></ul><p>Angioedema (J Allergy Clin Immunol 2013;131:1491)</p><ul><li><p>Localized swelling of skin/mucosa; involves face, lips, tongue, uvula, larynx, and bowels</p></li><li><p>Etiologies: mast cell-mediated (eg, NSAIDs); bradykinin-mediated (eg, ACEI, ARNi, hereditary angioedema, acquired C1 inhibitor deficiency); idiopathic</p></li><li><p>Diagnosis: C4 and C1 inhibitor level, tryptase (if suspect anaphylaxis), ESR/CRP</p></li><li><p>Rx: intubation if risk of airway compromise. Allergic angioedema: H1/H2 antihist., steroids.</p></li></ul><p>If 2° ACEI: d/c ACEI, antihist., icatibant (bradykinin-receptor antag; NEJM 2015;372:418).</p><p>Hereditary angioedema: plasma-derived C1 inhibitor, ecallantide (kallikrein inhibitor)</p><p>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</p><p>Definition and epidemiology (Lancet 2017;389:1931)</p><ul><li>Progressive airflow limitation caused by airway and parenchymal inflammation</li></ul><p>Emphysema vs. Chronic Bronchitis</p><p>Emphysema</p><p>Chronic Bronchitis</p><p>Definition</p><p>Dilation/destruction of parenchyma (path definition)</p><p>Productive cough >3 mo/y × ≥2 y (clinical definition)</p><p>Pathophysiology</p><p>Tissue destruction</p><p>V/Q: ↑ dead space fraction → hypercarbia, but only mild hypoxemia</p><p>Small airways affected</p><p>V/Q: ↑ shunt fraction → severe hypoxemia, hypercapnia PHT, cor pulmonale</p><p>Clinical manifestations</p><p>Severe, constant dyspnea</p><p>Mild cough</p><p>Intermittent dyspnea</p><p>Copious sputum production</p><p>Physical exam</p><p>“Pink puffer”</p><p>Tachypneic, noncyanotic, thin</p><p>Diminished breath sounds</p><p>“Blue bloater”</p><p>Cyanotic, obese, edematous</p><p>Rhonchi & wheezes</p><p>Pathogenesis (Lancet 2017;389:1931)</p><ul><li><p>Cigarette smoke (centrilobular emphysema, affects 15–20% of smokers)</p></li><li><p>Recurrent airway infections</p></li><li><p>α1-antitrypsin deficiency: early-onset panacinar emphysema or signif basilar disease, 1–3% of COPD cases. Suspect if age &lt;45, lower lungs affected, extrathoracic manifestations (liver disease [not if heterozygote MZ], FMD, pancreatitis). ✓ serum A1AT level (nb, acute phase reactant).</p></li><li><p>Low FEV1 in early adulthood associated w/ COPD (NEJM 2015;373:111)</p></li></ul><p>Clinical manifestations</p><ul><li><p>Chronic cough, sputum production, dyspnea; later stages → freq exacerb, AM HA, wt loss</p></li><li><p>Exacerbation triggers: infection, other cardiopulmonary disease, including PE</p></li></ul><p>Infxn: overt tracheobronchitis/pneumonia from viruses, S. pneumoniae, H. influenzae, M. catarrhalis or triggered by changes in strain of colonizers (NEJM 2008;359:2355)</p><ul><li><p>Physical exam: ↑ AP diameter of chest (“barrel chest”), hyperresonance, ↓ diaphragmatic excursion, ↓ breath sounds, ↑ expiratory phase, rhonchi, wheezes during exacerbation: tachypnea, accessory muscle use, pulsus paradoxus, cyanosis</p></li><li><p>Asthma-COPD overlap syndrome (ACOS; NEJM 2015;373:1241): features of both present. For example: reversibility of airway obstruction w/ bronchodilator in COPD; neutrophilic inflammation in asthma (more classic in COPD); eos in COPD.</p></li></ul><p>Diagnostic studies (JAMA 2019;321:786)</p><ul><li><p>CXR (see Radiology inserts): hyperinflation, flat diaphragms, ± interstitial markings & bullae</p></li><li><p>PFTs: obstruction: ↓↓ FEV1, ↓ FVC, FEV1/FVC &lt;0.7 (no sig Δ post bronchodilator), expiratory coving of flow-volume loop; hyperinflation: ↑↑ RV, ↑ TLC, ↑ RV/TLC; abnormal gas exchange: ↓ DLCO (in emphysema)</p></li><li><p>ABG: ↓ PaO2, ± ↑ PaCO2 (in chronic bronchitis, usually only if FEV1 &lt;1.5 L) and ↓ pH</p></li><li><p>Screen symptomatic Pts w/ spirometry; don’t screen if asx; screen for α1-AT deficiency</p></li></ul><p>Chronic treatment (Adapted from GOLD 2021 Report)</p><p>COPD Staging and Recommended Therapies by GOLD Criteria</p><p>Exacerbations/Yr</p><p>Mild Symptoms</p><p>Mod/Severe Symptoms</p><p>&lt;2</p><p>A Short-acting inh dilator prn</p><p>B LAMA</p><p>≥2</p><p>C LAMA</p><p>D LAMA + LABA ± ICS</p><p>Consider adding PDE-4 inhib to bronchodilator</p><p>Smoking cessation & vaccinations in all. Pulm rehab in groups B–D. O2 as indicated per SaO2.</p><ul><li>Bronchodilators (1st-line): long-acting muscarinic antag (LAMA), β2-agonists (LABA)</li></ul><p>LAMA (eg, tiotropium): ↓ exacerb, slows ↓ FEV1, ↓ admit, ↓ resp failure; better than ipratropium or LABA (NEJM 2008;359:1543; 2011;364:1093; 2017;377:923)</p><p>LABA: ~11% ↓ in exacerbations, no ↑ in CV events (Lancet 2016;387:1817)</p><p>LAMA + LABA: ↑ FEV1, ↓ sx vs. either alone (Chest 2014;145:981) and superior to LABA + inh steroid (NEJM 2016;374:2222)</p><ul><li><p>Corticosteroids (inhaled, ICS): ~11% ↓ in exacerbations & slows ↓ FEV1; no Δ in mortality (Lancet 2016;387:1817). Greatest benefit if eos >300 (Lancet Repir Med 2018;6:117).</p></li><li><p>“Triple Therapy” (LAMA+LABA+ICS) ↓ exac, ↓ hosp, ↑ PNA (NEJM 2020;383:35)</p></li><li><p>Roflumilast (PDE-4 inhib) + bronchodil: ↑ FEV1, ↓ exacerb in Pts with severe COPD, chronic bronchitis, and a hx of exacerbations (Lancet 2015;385:857)</p></li><li><p>Anti-IL5 (eg, mepolizumab, benralizumab): mixed data on ↓ exacerb in Pts w/ eos (NEJM 2017;377:1613 & 2019;381:1023)</p></li><li><p>Antibiotics: daily azithro ↓ exacerbations, but not routine (JAMA 2014;311:2225)</p></li><li><p>Oxygen: if PaO2 ≤55 mmHg or SaO2 ≤89% (during rest, exercise, or sleep) to prevent cor pulmonale; only Rx proven to ↓ mortality (Annals 1980;93:391; Lancet 1981;i:681); no benefit in Pts w/ moderate hypoxemia (SaO2 89–93%) (NEJM 2016;375:1617) or nocturnal O2 alone (NEJM 2020;383:1129); unknown benefit of isolated exertional O2 (AJRCCM 2020;202:121).</p></li><li><p>Night NPPV if recent exacerb & PaCO2 >53 ↓ risk of readmit or death (JAMA 2017;317:2177)</p></li><li><p>Prevention: Flu/Pneumovax; smoking cessation → 50% ↓ in lung function decline (AJRCCM 2002;166:675) and ↓ long-term mortality (Annals 2005;142:223)</p></li><li><p>Rehabilitation: ↓ dyspnea and fatigue, ↑ exercise tolerance, ↑ QoL (NEJM 2009;360:1329)</p></li><li><p>Surgery & bronchoscopic interventions</p></li></ul><p>Lung volume reduction surgery: ↑ exercise capacity, ↓ mortality if FEV1 >20%, upper lobe, low exercise capacity (NEJM 2003;348:2059)</p><p>Bronchoscopic lung reduction w/ endobronchial valves or coils: ↑ lung fxn but significant complications (PTX, PNA) (NEJM 2015;373:2325; Lancet 2015;386:1066; JAMA 2016;315:175)</p><ul><li>Lung transplant: ↑ QoL and ↓ sx (Lancet 1998;351:24), ? survival benefit (Am J Transplant 2009;9:1640)</li></ul><p>Staging and prognosis</p><ul><li><p>Assess breathlessness, cough, sputum, exercise capacity & energy (tools such as CAT and mMRC may be used as part of assessment)</p></li><li><p>Ratio of diam PA/aorta >1 associated with ~3× ↑ risk of exacerbations (NEJM 2012;367:913)</p></li><li><p>FEV1 stages: I = ≥80%; II = 50–79% (~11% 3-y mort.); III = 30–49% (~15% 3-y mort.); IV = &lt;30% (~24% 3-y mort.)</p></li></ul><p>EXACERBATION</p><p>COPD Exacerbation Treatment</p><p>Agent</p><p>Dose</p><p>Comments</p><p>Ipratropium</p><p>MDI 4–8 puffs q1–2h or</p><p>Nebulizer 0.5 mg q1–2h</p><p>First-line therapy (NEJM 2011;364:1093)</p><p>Albuterol</p><p>MDI 4–8 puffs q1–2h or</p><p>Nebulizer 2.5–5 mg q1–2h</p><p>Benefit if component of reversible bronchoconstriction</p><p>Corticosteroids</p><p>Prednisone 40 mg/d × 5d (JAMA 2013;309:2223); some Pts will benefit from higher dose/longer course if severe</p><p>Methylprednisolone 125 mg IV q6h × 72 h for more severe exacerbations</p><p>↓ treatment failure, ↓ hosp. stay</p><p>↑ FEV1 but no mortality benefit,</p><p>↑ complications (Cochrane 2009:CD001288)</p><p>OutPt Rx after ED visit ↓ relapse (NEJM 2003;348:2618)</p><p>Antibiotics</p><p>Amox, TMP-SMX, doxy, azithro, antipneumococcal FQ all reasonable (no single abx proven superior). Consider local flora and avoid repeat courses of same abx. ≤5d course likely enough for mild–mod exacerbation (JAMA 2010;303:2035).</p><p>H. flu, M. catarrhalis, S. pneumo</p><p>↑ PEF, ↓ Rx failure, ? ↓ short-term mort, ↓ subseq exacerb (Chest 2008;133:756 & 2013;143:82)</p><p>Consider if CRP >20 + ↑ sputum purulence or CRP >40 (NEJM 2019;381:111)</p><p>Oxygenation</p><p>↑ FiO2 to achieve PaO2 ≥55–60 or SaO2 88–92%</p><p>Watch for CO2 retention (due to ↑ V/Q mismatch, loss of hypoxemic resp drive, Haldane effect), but must maintain acceptable SaO2!</p><p>Noninvasive positive-pressure ventilation</p><p>Initiate early if moderate/severe dyspnea, ↓ pH / ↑ PaCO2, RR >25</p><p>Results in 58% ↓ intubation, ↓ LOS by 3.2 d, 59% ↓ mortality</p><p>Contraindications: Δ MS, inability to cooperate or clear secretions, hemodynamic instability, UGIB</p><p>(NEJM 1995;333:817; Annals 2003;138:861; Cochrane 2004;CD004104; ERJ 2005;25:348)</p><p>Endotracheal intubation</p><p>Consider if PaO2 &lt;55–60, ↑’ing PaCO2, ↓’ing pH, ↑ RR, respiratory</p><p>fatigue, Δ MS or hemodynamic instability</p><p>Other measures</p><p>Mucolytics overall not supported by data (Chest 2001;119:1190)</p><p>Monitor for cardiac arrhythmias</p><p>Post-exacerb care</p><p>Follow up w/in 1 mo; smoking cessation if current smoker; vaccinations (influenza, pneumococcal), referral to pulm rehab (AJRCCM 2007;176:532)</p><p>SOLITARY PULMONARY NODULE</p><p>Principles</p><ul><li><p>Definition: single, well-defined, &lt;3 cm, surrounded by nl lung, no LAN or pleural effusion</p></li><li><p>Often “incidentalomas,” esp with ↑ CT use, but may still be early, curable malignancy</p></li></ul><p>Etiologies</p><p>Benign (70%)</p><p>Malignant (30%)</p><p>Granuloma (80%): TB, histo, coccidio</p><p>Hamartoma (10%)</p><p>Bronchogenic cyst, AVM, pulm infarct</p><p>Echinococcosis, ascariasis, aspergilloma</p><p>GPA, rheumatoid nodule, sarcoidosis</p><p>Lipoma, fibroma, amyloidoma</p><p>Bronchogenic carcinoma (75%) periph: adeno (most common) & large cell central: squamous & small cell</p><p>Metastatic (20%): sarcoma, melanoma, breast, head & neck, colon, testicular, renal</p><p>Carcinoid, primary sarcoma</p><p>Initial evaluation</p><ul><li><p>History: h/o cancer, smoking, age (&lt;30 y = 2% malignant, +15% each decade >30)</p></li><li><p>CT: size/shape, Ca2+, LAN, effusions, bony destruction, compare w/ old studies</p></li></ul><p>Ø Ca → ↑ likelihood malignant; laminated → granuloma; “popcorn” → hamartoma</p><ul><li>High-risk features for malig: size (eg, ≥2.3 cm diameter), spiculated, upper lobe, ♀, >60 yo, >1 ppd current smoker, no prior smoking cessation (NEJM 2003;348:2535 & 2013;369:910)</li></ul><p>Diagnostic studies</p><ul><li><p>PET: detects metab. activity of tumors, 97% Se & 78% Sp for malig (esp if >8 mm). Useful for deciding which lesions to bx vs. serial CT & for surgical staging b/c may detect mets.</p></li><li><p>Transthoracic needle biopsy (TTNB): if tech feasible, 97% will obtain definitive tissue dx</p></li><li><p>Video-assisted thoracoscopic surgery (VATS): for percutaneously inaccessible lesions; highly sensitive and allows resection</p></li><li><p>Transbronchial bx (TBB): most lesions too small to sample w/o endobronchial U/S; bronch w/ brushings low-yield unless invading bronchus; navigational bronch 70% yield</p></li><li><p>PPD, fungal serologies, ANCA</p></li></ul><p>Management (JAMA 2022;327:264)</p><ul><li><p>Low risk (&lt;5%): serial CT (freq depending on risk); shared decision w/ Pt re: bx</p></li><li><p>High risk (and surgical candidate): TBB, TTNB, or VATS → lobectomy if malignant</p></li><li><p>Subsolid nodules: longer f/u (b/c if malignant can be slow-growing) & PET</p></li></ul><p>HEMOPTYSIS</p><p>Definition and pathophysiology</p><ul><li><p>Expectoration of blood or blood-streaked sputum</p></li><li><p>Massive hemoptysis: >100 mL/h or >500 mL in 24 h; massive hemoptysis usually from tortuous or invaded bronchial arteries</p></li></ul><p>Etiologies (Crit Care Med 2000;28:1642)</p><p>Infection/Inflammation</p><p>Bronchitis (most common cause of trivial hemoptysis)</p><p>Bronchiectasis incl CF (common cause of massive hemoptysis)</p><p>TB or aspergilloma (can be massive); pneumonia or lung abscess</p><p>Neoplasm</p><p>Usually primary lung cancer, sometimes metastasis (can be massive)</p><p>Cardiovasc</p><p>PE (can be massive), pulmonary artery rupture (2° to instrumentation), CHF, mitral stenosis, trauma/foreign body, bronchovascular fistula</p><p>Other</p><p>Vasculitis (GPA, anti-GBM, Behçet’s, SLE), AVM, anticoag (w/underlying lung disease), coagulopathy, cocaine, pulm hemosiderosis</p><p>Diagnostic workup</p><ul><li><p>Localize bleeding site (r/o GI or ENT source by H&P ± endo); determine whether unilateral or bilateral, localized or diffuse, parenchymal or airway by CXR/chest CT ± bronch</p></li><li><p>PT, PTT, CBC to rule out coagulopathy</p></li><li><p>Sputum culture/stain for bacteria, fungi and AFB; cytology to r/o malignancy</p></li><li><p>ANCA, anti-GBM, ANA, urinalysis to ✓ for vasculitis or pulmonary-renal syndrome</p></li></ul><p>Treatment</p><ul><li><p>Death is from asphyxiation not exsanguination; maintain gas exchange, reverse coagulopathy and Rx underlying condition; cough suppressant may ↑ risk of asphyxiation</p></li><li><p>Inhaled tranexamic acid promising (Chest 2018;154:1379)</p></li><li><p>Massive hemoptysis: put bleeding side dependent; selectively intubate nl lung if needed</p></li></ul><p>Angiography: Dx & Rx (vascular occlusion balloons or selective embol of bronchial art)</p><p>Rigid bronch: allows more options (electrocautery, laser) than flexible bronch</p><p>Surgical resection</p><p>BRONCHIECTASIS</p><p>Definition and epidemiology (NEJM 2002;346:1383)</p><ul><li>Obstructive airways disease of bronchi and bronchioles, chronic transmural inflammation w/ airway dilatation and thickening, collapsibility, mucus plugging w/ impaired clearance</li></ul><p>Initial workup</p><ul><li><p>H&P: cough, dyspnea, copious sputum production, ±hemoptysis, inspiratory “squeaks”</p></li><li><p>CXR: scattered or focal; rings of bronchial cuffing; “tram track” of dilated, thick airways</p></li><li><p>PFTs: obstructive; chest CT: airway dilation & thickening ± cystic Δs, infiltrates, adenopathy</p></li></ul><p>Etiology</p><p>Other Features</p><p>Evaluation</p><p>Chronic infxns (eg, MTb, ABPA)</p><p>Chronic cough, freq/persist infiltrate, refract asthma (ABPA)</p><p>Sputum cx (incl mycobact, fungal), ± bronch/BAL, IgE & eos (ABPA)</p><p>1° ciliary dyskin</p><p>Sinusitis, infertility, otitis</p><p>Dynein mutations</p><p>Immunodefic</p><p>Recurrent infxns often as child</p><p>IgA, IgG, IgM, IgG subclasses</p><p>RA, Sjogren, ANCA</p><p>Resp sx may precede joint sx</p><p>RF, CCP, SS-A, SS-B, ANCA</p><p>IBD</p><p>Not relieved by bowel resection</p><p>Colonoscopy, biopsy</p><p>α1-AT deficiency</p><p>Lower lobe emphysema</p><p>α1-AT level and genotype</p><p>Anatomic</p><p>R middle lobe synd. from sharp takeoff, foreign body aspiration</p><p>Bronchoscopy</p><p>Treatment</p><ul><li><p>Acute exacerbations: antibiotics directed against prior pathogens; if no prior Cx data → FQ</p></li><li><p>Chronic mgmt: treat underlying condition, chest PT, inhaled hypertonic saline, bronchodil.; prophylactic azithro shown to ↓ exacerb in non-CF bronchiectasis (JAMA 2013:1251)</p></li><li><p>Airway clearance: guaifenesin, instrumental devices (eg, Aerobika, Acapella), chest PT</p></li></ul><p>Non-tuberculous mycobacterium (NTM; eg, MAC, Mycobacterium kansaii)</p><ul><li><p>Chronic cough, ↓ wt; Lady Windermere syndrome: R middle lobe and lingula bronchiectasis in elderly ♀ who suppress expectoration</p></li><li><p>Dx: CT scan (tree-in-bud, nodules, cavities, bronchiect.), sputum ×3 or BAL, AFB stain + Cx</p></li><li><p>Treatment: susceptibility-based Rx pref over empiric Rx w/ [azithro or clarithro] + rifamycin & ethambutol for ≥12 mo (CID 2020;71:e1)</p></li></ul><p>CYSTIC FIBROSIS</p><p>Definition and pathophysiology (NEJM 2015;372:351)</p><ul><li><p>Autosomal recessive genetic disorder due to mutations in chloride channel (CFTR gene)</p></li><li><p>↑ mucus thickness, ↓ mucociliary clearance, ↑ infections → bronchiectasis</p></li></ul><p>Clinical features</p><ul><li><p>Recurrent PNA, sinus infections</p></li><li><p>Distal intestinal obstruction syndrome (DIOS), pancreatic insufficiency (steatorrhea, malabsorption, failure to thrive, weight loss), CF-related diabetes, infertility</p></li></ul><p>Treatment (Lancet 2021;397:2195)</p><ul><li><p>Acute exacerbations: may be assoc w/ persistent drop in FEV1 (AJRCCM 2010;182:627); continue aggressive airway clearance, target abx based on sputum cx (incl double coverage for PsA); common pathogens include PsA, S. aureus, non-typeable H. flu, Stenotrophomonas, Burkholderia, NTM</p></li><li><p>Chronic mgmt: airway clearance with chest PT, inhaled hypertonic saline, inhaled DNAse (dornase alfa), SABA; oral azithromycin if chronic respiratory symptoms, inhaled tobramycin or aztreonam if persistent PsA infection</p></li><li><p>CFTR potentiator (ivacaftor) or corrector (lumacaftor, tezacaftor) depending on mutation; combo (elexacaftor+tezacaftor+ivacaftor) if homozygous for ΔF508 (Lancet 2019;394:1940)</p></li><li><p>Lung transplantation; refer to lung transplant center when FEV1 &lt;30% predicted, rapidly declining FEV1, 6MWT &lt;400 m, evidence of PHT, significant clinical decline</p></li></ul><p>INTERSTITIAL LUNG DISEASE</p><p>WORKUP OF ILD (Thorax 2008;63:v1)</p><p>May present as incidental finding, subacute dyspnea, or rapidly progressive hypox. resp fail.</p><p>Broad categories</p><ul><li><p>(1) Sarcoid; (2) Exposures (eg, drugs, XRT, organic & inorganic dusts, vaping);</p></li><li><p>(3) Collagen vasc dis (eg, scleroderma, ANCA, myositis, RA); (4) Idiopathic PNAs (qv)</p></li></ul><p>Rule out mimickers of ILD</p><ul><li>Congestive heart failure (✓ BNP, trial of diuresis); infection: viral, atypical bacterial; malignancy: lymphangitic carcinomatosis, bronchoalveolar, leukemia, lymphoma</li></ul><p>History and physical exam</p><ul><li><p>Occupational, exposures (eg, birds), tobacco, meds, XRT, FHx, precipitating event</p></li><li><p>Tempo (acute → infxn, CHF, hypersens pneumonitis, eos PNA, AIP, COP, drug-induced)</p></li><li><p>Extrapulm signs/sx (skin Δs, arthralgias, arthritis, myalgias, sicca sx, alopecia, Raynaud’s)</p></li></ul><p>Diagnostic studies (see Appendix & Radiology inserts)</p><ul><li>CXR and high-resolution chest CT</li></ul><p>Upper lobe predom: hypersensitivty, coal, silica, smoking-related, sarcoidosis, Langerhan’s</p><p>Lower lobe predom: NSIP, UIP, asbestosis</p><p>Adenopathy: malignancy, sarcoidosis, berylliosis, silicosis</p><p>Pleural disease: collagen-vascular diseases, asbestosis, infections, XRT</p><ul><li>PFTs: ↓ DLCO (early sign), restrictive pattern (↓ volumes), ↓ PaO2 (esp. w/ exercise);</li></ul><p>If restrictive + obstructive, consider sarcoid</p><p>If combined pulmonary fibrosis and emphysema (CFPE) → near-nl lung vol on PFTs</p><ul><li><p>Serologies: ✓ ACE, ANA, RF, RNP, ANCA, CCP, SSA/SSB, Scl 70, CK, aldolase, myositis panel</p></li><li><p>Bronchoalveolar lavage: in select cases if suspect superimposed infection, hemorrhage, eosinophilic syndromes</p></li><li><p>Bx (transbronch w/ or w/o cryo vs. VATS depending on location) if unclear etiology</p></li></ul><p>SPECIFIC ETIOLOGIES OF ILD</p><p>Sarcoidosis (AJRCCM 2020;201:e26; JAMA 2022;327:856)</p><ul><li><p>Prevalence: African Americans, northern Europeans, and females; onset in 3rd-5th decade</p></li><li><p>Pathophysiology: depression of cellular immune system peripherally, activation centrally</p></li></ul><p>Clinical Manifestations of Sarcoidosis</p><p>Organ System</p><p>Manifestations</p><p>Pulmonary</p><p>Hilar LAN; fibrosis; pulm hypertension. Stages: I = bilat hilar</p><p>LAN; II = LAN + ILD; III = ILD only; IV = diffuse fibrosis.</p><p>Cutaneous (~15%)</p><p>Waxy skin plaques; lupus pernio (violaceous facial lesions)</p><p>Erythema nodosum (red tender nodules due to panniculitis, typically on shins). Ddx: idiopathic (34%), infxn (33%, strep, TB), sarcoid (22%), drugs (OCP, PCNs), vasculitis (Behçet’s), IBD, lymphoma.</p><p>Ocular (10–30%)</p><p>Anterior >posterior uveitis; ↑ lacrimal gland</p><p>Endo & renal (10%)</p><p>Nephrolithiasis, hypercalcemia (10%), hypercalciuria (40%) Due to vitamin D hydroxylation by macrophages</p><p>Neuro (10% clin, 25% path)</p><p>CN VII palsy, periph neuropathies, CNS lesions, seizures</p><p>Cardiac (5% clin, 25% path)</p><p>Conduction block, VT, CMP</p><p>Liver, spleen, BM</p><p>Granulomatous hepatitis (25%), splenic & BM gran. (50%)</p><p>Constitutional</p><p>Fever, night sweats, anorexia & wt loss (a/w hepatic path)</p><p>Musculoskeletal</p><p>Arthralgias, periarticular swelling, bone cysts</p><ul><li><p>Löfgren’s syndrome: erythema nodosum + hilar adenopathy + arthritis (good prognosis)</p></li><li><p>Diagnostic studies: LN bx → noncaseating granulomas + multinucleated giant cells Endobronchial ultrasonography superior to conventional bronch (JAMA 2013;309:2457) 18FDG PET can be used to identify extent and potentially targets for dx bx ↑ ACE (Se 60%, 90% w/ active dis., Sp 80%, false ⊕ in granulomatous diseases)</p></li><li><p>To assess extent: CXR, PFTs, full ophtho exam, ECG, CBC (lymphopenia, ↑ eos), Ca, LFTs; ± Holter, echo, cardiac MRI, brain MRI, etc., based on s/s</p></li><li><p>Rx: steroids if sx or extrathoracic organ dysfxn (eg, prednisone 20–40 mg/d), improves sx, but doesn’t Δ long-term course; hydroxychloroquine for extensive skin disease; MTX, AZA, mycophenolate, or anti-TNF for chronic/refractory disease</p></li><li><p>Prognosis: ~²∕³ spontaneously remit w/in 10 y (60–80% of stage I, 50–60% stage II, 30% stage III), w/ relapses uncommon; ~1∕³ have progressive disease</p></li></ul><p>Exposure</p><ul><li>Drugs/Iatrogenic</li></ul><p>Amiodarone: interstitial pneumonitis ↔ org. PNA ↔ ARDS; Rx: d/c amio; steroids</p><p>Other drugs: nitrofurantoin, sulfonamides, inh, hydralazine</p><p>Chemo: bleomycin, busulfan, cyclophosphamide, MTX, immunotherapy, XRT</p><ul><li>Pneumoconioses (inorganic dusts) (NEJM 2000;342:406; Clin Chest Med 2004;25:467)</li></ul><p>Coal worker’s: upper lobe coal macules; may progress to massive fibrosis</p><p>Silicosis: upper lobe opacities ± eggshell calcification of lymph nodes; ↑ risk of TB</p><p>Asbestosis: lower lobe fibrosis, calcified pleural plaques, DOE, dry cough, rales on exam. Asbestos exposure → pleural plaques, benign pleural effusion, diffuse pleural thickening, rounded atelectasis, mesothelioma, lung Ca (esp. in smokers)</p><p>Berylliosis: multisystemic granulomatous disease that mimics sarcoidosis</p><ul><li>Hypersensitivity pneumonitides (organic dusts): loose, noncaseating granulomas</li></ul><p>Antigens: farmer’s lung (spores of thermophilic actinomyces); bird fancier’s lung (proteins from feathers and excreta of birds or down); humidifier lung (thermophilic bacteria)</p><p>Collagen vascular diseases (Chest 2013;143:814)</p><ul><li>Rheumatologic disease</li></ul><p>Scleroderma: ILD in ~50%; PHT seen in ~10% of Pts with limited disease</p><p>PM-DM: ILD & skin/muscle findings; MCTD: PHT & fibrosis; Sjogren’s: ILD & sicca sx</p><p>SLE & RA: pleuritis and pleural effusions more often than ILD; SLE can cause DAH</p><ul><li>Vasculitis (can p/w DAH)</li></ul><p>Granulomatosis w/ polyangiitis (GPA): ⊕ c-ANCA w/ necrotizing granulomas</p><p>Eosinophilic GPA (EGPA): ⊕ c- or p-ANCA w/ eosinophilia & necrotizing granulomas</p><p>Microscopic polyangiitis: ⊕ p-ANCA w/o granulomas</p><ul><li><p>Goodpasture’s syndrome = DAH + RPGN; typically in smokers; ⊕ anti-GBM in 90%</p></li><li><p>Lymphangioleiomyomatosis (LAM): cystic, ↑ in ♀, Rx w/ sirolimus (NEJM 2011;364:1595)</p></li></ul><p>Idiopathic interstitial pneumonias (IIPs) (AJRCCM 2013;188:733)</p><ul><li>Definition: ILD of unknown cause; dx by radiographic, histologic, and clinical features</li></ul><p>IIPs</p><p>Type</p><p>Imaging/Histology</p><p>Clinical</p><p>IPF</p><p>UIP imaging pattern: reticular opacities, honeycombing, traction bronchiectasis; peripheral, subpleural, & basal</p><p>Sx >12 mo</p><p>5-y mort ~80%</p><p>NSIP</p><p>Homogenous ground-glass opacities or consolid., reticular irreg lines; subpleural sparing; symmetric, peripheral, basal. Cellular & fibrotic subtypes.</p><p>Sx mos–y</p><p>5-y mort 10%</p><p>COP</p><p>Patchy, migratory consolidations; subpleural & peribronchial. Excessive proliferation of granulation tissue in small airways and alveolar ducts.</p><p>Post-infxn, XRT, rxn to drug. 5-y mort &lt;5%</p><p>AIP</p><p>Diffuse ground-glass opacities, consolidations w/ lobular sparing. Path/imaging similar to DAD (diffuse, bilateral, central>periph ground glass or consolidative opacities).</p><p>Sx &lt;3 wk</p><p>6-mo mort 60%</p><p>DIP</p><p>Diffuse ground-glass opacities, reticular lines; lower zones. Peripheral macrophage in alveoli.</p><p>30–50 yo smokers</p><p>Sx wks–mos</p><p>Death rare</p><p>RB-ILD</p><p>Bronchial thickening, centrilobular nodules, patchy ground-glass opacities; upper lobe predom. Mφ in alveoli.</p><p>UIP, usual interstitial PNA (IP); IPF, idiopathic pulm fibrosis; NSIP, nonspecific IP; COP, cryptogenic organizing PNA; AIP, acute IP (Hamman-Rich syndrome); DIP, desquamative IP; RB-ILD, resp bronchiolitis-assoc ILD.</p><ul><li>Rx for IPF: suppl O2, pulm rehab, Rx for GERD, PHT screening, lung tx referral;</li></ul><p>pirfenidone (antifibrotic) or nintedanib (tyrosine kinase inhib mediating fibrogenic growth factors) ↓ rate of FVC decline (Lancet 2021;398:1450)</p><p>high-dose steroids may be used for acute exacerbations, but no RCT data</p><ul><li>Steroids for other IIPs: NSIP (esp. cellular type) and COP (AJRCCM 2000;162:571); ? benefit for AIP and DIP/RB-ILD (for which Pts should stop smoking)</li></ul><p>Pulmonary infiltrates w/ eosinophilia (PIE) = eos on BAL é peripheral blood</p><ul><li><p>Allergic bronchopulmonary aspergillosis (ABPA)</p></li><li><p>EGPA</p></li><li><p>Löffler’s syndrome: parasites/drugs → transient pulm infilt + cough, fever, dyspnea, eos</p></li><li><p>Acute eosinophilic PNA (AEP): acute hypox febrile illness; Rx: steroids, tobacco cessation</p></li><li><p>Chronic eosinophilic pneumonia (CEP): “photonegative” of CHF, typically in women</p></li></ul><p>Miscellaneous</p><ul><li><p>Pulm alveolar proteinosis (PAP): accumulation of surfactant-like phospholipids; white & gummy sputum; BAL milky fluid (NEJM 2003;349:2527); Rx w/ lung lavage & GMCSF</p></li><li><p>Langerhans cell granulomatosis (LCG): young ♂ smokers; apical cysts; PTX (25%)</p></li></ul><p>PLEURAL EFFUSION</p><p>Pathophysiology</p><ul><li><p>Systemic factors (eg, ↑ PCWP, ↓ oncotic pressure) → transudative effusion</p></li><li><p>Local factors (ie, Δ pleural surface permeability) → exudative effusion</p></li></ul><p>Transudates</p><ul><li><p>Congestive heart failure (40%): 80% bilateral, ± cardiomegaly on CXR occasionally exudative (especially after aggressive diuresis or if chronic)</p></li><li><p>Constrictive pericarditis (knock on exam, calcification or thickening on imaging)</p></li><li><p>Cirrhosis (“hepatic hydrothorax”): diaphragmatic pores allow passage of ascitic fluid often right-sided (²∕³) & massive (even w/o marked ascites)</p></li><li><p>Nephrotic syndrome: usually small, bilateral, asymptomatic (r/o PE b/c hypercoag)</p></li><li><p>Other: PE (usually exudate), malignancy (lymphatic obstruction), myxedema, CAPD</p></li></ul><p>Exudates</p><ul><li>Lung parenchymal infection (25%)</li></ul><p>Bacterial (parapneumonic): can evolve along spectrum of exudative (but sterile) → fibropurulent (infected fluid) → organization (fibrosis & formation of rigid pleural peel). Common causes: Strep pneumo, Staph aureus, Strep milleri, Klebsiella, Pseudomonas, Haemophilus, Bacteroides, Peptostreptococcus, mixed flora in aspiration pneumonia.</p><p>Mycobacterial: >50% lymphs 80% of the time, ADA >40, pleural bx ~70% Se</p><p>Fungal, viral (usually small), parasitic (eg, amebiasis, echinococcosis, paragonimiasis)</p><ul><li><p>Malignancy (15%): primary lung cancer most common, metastases (esp. breast, lymphoma, etc.), mesothelioma (✓ serum osteopontin levels; NEJM 2005;353:15)</p></li><li><p>Pulmonary embolism (10%): effusions in ~40% of PEs; exudate (75%) >transudate (25%); hemorrhagic—must have high suspicion b/c presentation highly variable</p></li><li><p>Collagen vascular disease: RA (large), SLE (small), GPA, EGPA</p></li><li><p>Abdominal diseases: pancreatitis, cholecystitis, esophageal rupture, abdominal abscess</p></li><li><p>Hemothorax (Hcteff/Hctblood >50%): trauma, PE, malignancy, coagulopathy, leaking aortic aneurysm, aortic dissection, pulmonary vascular malformation</p></li><li><p>Chylothorax (triglycerides >110): thoracic duct damage due to trauma, malignancy, LAM</p></li><li><p>Other:</p></li></ul><p>Post-CABG: left-sided; initially bloody, clears after several wks</p><p>Dressler’s syndrome (pericarditis & pleuritis post-MI), uremia, post-radiation therapy</p><p>Asbestos exposure: benign; ⊕ eosinophils</p><p>Drug-induced (eg, nitrofurantoin, methysergide, bromocriptine, amiodarone): ⊕ eos</p><p>Uremia; post-XRT; sarcoidosis</p><p>Meigs’ syndrome: benign ovarian tumor → ascites & pleural effusion</p><p>Yellow-nail syndrome: yellow nails, lymphedema, pleural effusion, bronchiectasis</p><p>Diagnostic studies (NEJM 2018;378:740)</p><ul><li>Thoracentesis (ideally U/S guided) (NEJM 2006;355:e16)</li></ul><p>Indications: all effusions >1 cm in decubitus view</p><p>if suspect due to CHF, can diurese and see if effusions resolve (75% do so in 48 h); asymmetry, fever, chest pain or failure to resolve → thoracentesis</p><p>parapneumonic effusions should be tapped ASAP (cannot exclude infxn clinically)</p><p>Diagnostic studies: ✓ total protein, LDH, glucose, cell count w/ differential, Gram stain & culture, pH; remaining fluid for additional studies as dictated by clinical scenario</p><p>Complications: PTX (5–10%), hemothorax (~1%), re-expansion pulm edema (if >1.5 L removed), spleen/liver lac.; post-tap CXR not routinely needed (Annals 1996;124:816)</p><p>↓ PTX w/ U/S and experienced supervisor; even with INR ~1.9, on DOAC, or on clopi, risk of bleed low w/ U/S & experienced operator (Mayo 2019;94:1535)</p><ul><li>Transudate vs. exudate (JAMA 2014;311:2422)</li></ul><p>Light’s criteria: exudate = TPeff/TPserum >0.5 or LDHeff/LDHserum >0.6 or LDHeff >²∕³ ULN of LDHserum; 97% Se, 85% Sp; best Se of all methods; however, will misidentify 25% of transudates as exudates; ∴ if clinically suspect transudate but meets criterion for exudate, confirm w/ test w/ higher Sp</p><p>Exudative criteria w/ better Sp: choleff >55 mg/dL (95–99% Sp); choleff >45 mg/dL and LDHeff >200 (98% Sp); choleff/cholserum >0.3 (94% Sp); serum-effusion alb gradient ≤1.2 (92% Sp); serum-effusion TP gradient ≤3.1 (91% Sp)</p><p>CHF effusions: TP may ↑ with diuresis or chronicity → “pseudoexudate”; alb gradient ≤1.2, choleff >60 mg/dL (Se 54%, Sp 92%) or clin judgment to distinguish (Chest 2002;122:1524)</p><ul><li>Complicated vs. uncomplicated parapneumonic (Chest 1995;108:299)</li></ul><p>complicated = ⊕ Gram stain or culture or pH &lt;7.2 or glucose &lt;60</p><p>complicated parapneumonic effusions usually require tube thoracostomy for resolution</p><p>empyema = frank pus, also needs tube thoracostomy (J Thorac CV Surg 2017;153:e129)</p><ul><li>Additional pleural fluid studies (NEJM 2002;346:1971)</li></ul><p>NT-proBNP ≥1500 pg/mL has 91% Se & 93% Sp for CHF (Am J Med 2004;116:417)</p><p>WBC & diff.: exudates tend to have ↑ WBC vs. transudates but nonspecific neutrophils → parapneumonic, PE, pancreatitis lymphocytes (>50%) → cancer, TB, rheumatologic eos (>10%) → blood, air, drug rxn, asbestos, paragonimiasis, Churg-Strauss, PE</p><p>RBC: Hcteff 1–20% → cancer, PE, trauma; Hcteff/Hctblood >50% → hemothorax</p><p>AFB: yield in TB 0–10% w/ stain, 11–50% w/ culture, ~70% w/ pleural bx</p><p>adenosine deaminase (ADA): seen w/ granulomas, >70 suggests TB, &lt;40 excludes TB</p><p>cytology: ideally ≥150 mL and at least 60 mL should be obtained (Chest 2010;137:68)</p><p>glucose: &lt;60 mg/dL → malignancy, infection, RA</p><p>amylase: seen in pancreatic disease and esophageal rupture (salivary amylase)</p><p>rheumatoid factor, CH50, ANA: limited utility in dx collagen vascular disease</p><p>triglycerides: >110 → chylothorax, 50–110 → ✓ lipoprotein analysis for chylomicrons</p><p>cholesterol: >60; seen in chronic effusions (eg, CHF, RA, old TB)</p><p>creatinine: effusion/serum ratio >1 → urinothorax</p><p>fibulin-3: ↑ plasma and/or effusion levels → mesothelioma (NEJM 2012;367:1417)</p><ul><li><p>Chest CT; pleural biopsy; VATS</p></li><li><p>Undiagnosed persistent pleural effusions (Clin Chest Med 2006;27:309)</p></li></ul><p>Transudative: most commonly CHF or hepatic hydrothorax. ✓ s/s CHF or cirrhosis, NT-proBNPeff; consider intraperitoneal injection of technetium-99m sulfur colloid</p><p>Exudative (ensure using Sp test listed above): most commonly malig, empyema, TB, PE. ✓ s/s malig, chest CT (I+), ADA or IFN-γ release assay; consider thoracoscopy.</p><p>Treatment</p><ul><li><p>Symptomatic effusion: therapeutic thoracentesis, treat underlying disease process</p></li><li><p>Parapneumonic effusion (Chest 2000;118:1158)</p></li></ul><p>uncomplicated → antibiotics for pneumonia</p><blockquote><p>½ hemithorax or complicated or empyema → tube thoracostomy (otherwise risk of organization and subsequent need for surgical decortication)</p></blockquote><p>loculated→ tube thoracostomy or VATS; intrapleural t-PA + DNase ↓ need for surgery</p><ul><li><p>Malignant effusion: serial thoracenteses vs. tube thoracostomy + pleurodesis (success rate ~80–90%) vs. indwelling pleural catheter, which ↓ hosp days but ↑ adverse events (JAMA 2017;318:1903); systemic steroids & pH &lt;7.2 a/w ↑ pleurodesis failure rate</p></li><li><p>TB effusions: effusion will often resolve spontaneously; however, treat Pt for active TB</p></li><li><p>Hepatic hydrothorax</p></li></ul><p>Rx: Δ pressure gradient (ie, ↓ ascitic fluid volume, NIPPV)</p><p>avoid chest tubes; prn thoracenteses, pleurodesis, TIPS or VATS closure of diaphragmatic defects if medical Rx fails; NIPPV for acute short-term management</p><p>spontaneous bacterial empyema (SBEM) can occur (even w/o SBP being present), ∴ thoracentesis if suspect infection</p><p>transplant is definitive treatment and workup should begin immediately</p><p>VENOUS THROMBOEMBOLISM (VTE)</p><p>Definitions</p><ul><li><p>Superficial thrombophlebitis: pain, tenderness, erythema along superficial vein</p></li><li><p>Deep venous thrombosis (DVT): Proximal = thrombosis of iliac, femoral, or popliteal veins (nb, “superficial” femoral vein part of deep venous system). Distal = calf veins below knee; lower risk of PE/death than proximal (Thromb Haem 2009;102:493).</p></li><li><p>Pulmonary embolism (PE): thrombosis originating in venous system and embolizing to pulmonary arterial circulation; 1 case/1000 person y; 250,000/y (Archives 2003;163:1711)</p></li></ul><p>Risk factors</p><ul><li>Virchow’s triad for thrombogenesis. Stasis: bed rest, inactivity, CHF, CVA w/in 3 mo, air travel >6 h. Injury to endothelium: trauma, surgery, prior DVT, inflam, central catheter.</li></ul><p>Thrombophilia: genetic disorders (qv), HIT, OCP, HRT, tamoxifen, raloxifene.</p><ul><li><p>Malignancy (12% of “idiopathic” DVT/PE; Circ 2013;128:2614)</p></li><li><p>History of thrombosis (greater risk of recurrent VTE than genetic thrombophilia)</p></li><li><p>Obesity, smoking, acute infection, postpartum (JAMA 1997;277:642; Circ 2012;125:2092)</p></li></ul><p>Thromboprophylaxis (Blood Adv 2018;2:3198)</p><p>Patient & Situation</p><p>Prophylaxis</p><p>Low-risk med; same-day surg & &lt;40 y</p><p>Early, aggressive ambulation ± mechanical</p><p>Moderate-risk (hosp., ≥1 risk factor) or high-risk medical (hosp., ICU, cancer, stroke)</p><p>LMWH or UFH (if renal failure) or fonda (if HIT ⊕). Pharmacologic favored vs. mechanical, but may personalize based on bleeding & thrombotic risk.</p><p>Low-risk surgery (minor surgery)</p><p>Mechanical Ppx</p><p>Moderate-risk surgery (eg, major surgery, trauma, immobilization)</p><p>If low bleeding risk: LMWH or UFH SC</p><p>If high bleeding risk: mech Ppx</p><p>High-risk nonorthopedic surgery (multiple risk factors), stroke or ICH</p><p>[LMWH or UFH SC] + mech. Stroke s/p lytic or ICH: mech 24 h or until bleed stable, then + pharm.</p><p>Ortho surgery (cont pharmacoRx up to 35 d [hip] or 10–14 d [knee])</p><p>LMWH or DOAC (or fonda, UFH, or warfarin [INR 2–3]) + mech Ppx.</p><p>UFH: 5000 U SC bid or tid. Enox: 30 mg bid for highest risk or 40 mg qd for moderate risk or spinal/epidural anesthesia. For riva 10 mg/d, apixa 2.5 mg/d, edox 30 mg/d, dabi 110 mg post-op and then 220 mg/d.</p><p>Clinical manifestations—DVT</p><ul><li><p>Calf pain, swelling (>3 cm c/w unaffected side), venous distention, erythema, warmth, tenderness, palpable cord, ⊕ Homan’s sign (calf pain on dorsiflexion, seen in &lt;5%)</p></li><li><p>50% of Pts with sx DVT have asx PE</p></li><li><p>Popliteal (Baker’s) cyst: may lead to DVT due to compression of popliteal vein</p></li></ul><p>“Simplified Wells” Pretest Probability Scoring of DVT (JAMA 2006;295:199)</p><p>+1 point each for: active cancer (Rx ongoing or w/in 6 mo or palliative); paralysis, paresis, or recent immobilization of lower extremities; recently bedridden for ≥3 d or major surgery w/in 12 wk; localized tenderness along distribution of deep venous system; entire leg swelling; calf ≥3 cm larger than asx calf (at 10 cm below tibial tuberosity); pitting edema confined to sx leg; collateral superficial veins (nonvaricose); previous DVT</p><p>–2 points if alternative dx at least as likely as DVT</p><p>Pretest Probability Assessment (useful if outPt, less so if inPt; JAMA IM 2015;175:1112)</p><p>Score ≤0</p><p>Score 1 or 2</p><p>Score ≥3</p><p>Low probability (5%)</p><p>Moderate probability (17%)</p><p>High probability (53%)</p><ul><li>For UE DVT, +1 point each for venous cath, local pain, & unilateral edema, –1 if alternative dx. ≤1 = unlikely; ≥2 = likely. U/S if likely or if unlikely but abnl D-dimer (Annals 2014;160:451)</li></ul><p>Diagnostic studies—DVT</p><ul><li><p>D-dimer: &lt;500 helps r/o; ? use 1000 as threshold if low risk (Annals 2013;158:93)</p></li><li><p>Compression U/S >95% Se & Sp for sx DVT (lower if asx); survey whole leg if ≥ mod prob</p></li></ul><p>Figure 2-3 Approach to suspected DVT</p><p>Clinical manifestations—PE</p><ul><li><p>Dyspnea (~50%), pleuritic chest pain (~40%), cough (~23%), hemoptysis (~8%)</p></li><li><p>↑ RR (>70%), crackles (51%), ↑ HR (30%), fever, cyanosis, pleural friction rub, loud P2</p></li><li><p>Massive: syncope, HoTN, PEA; ↑ JVP, R-sided S3, Graham Steell (PR) murmur</p></li></ul><p>Modified Wells Pretest Probability Scoring for PE (Annals 2011;154:709)</p><ul><li><p>Prior PE or DVT=1.5 points</p></li><li><p>Active cancer =1.0</p></li><li><p>Immobilization (bed rest ≥3 d) or surgery w/in 4 wk=1.5</p></li><li><p>Alternative dx less likely than PE=3</p></li><li><p>Clinical signs of DVT=3</p></li><li><p>HR >100 bpm=1.5</p></li><li><p>Hemoptysis=1.0</p></li></ul><p>Simplified Wells Probability Assessment</p><p>≤4 = ”Unlikely” (13% probability)</p><blockquote><p>4 “Likely” (39% probability)</p></blockquote><p>Diagnostic studies—PE (EHJ 2014;35:3033)</p><ul><li><p>CXR (limited Se & Sp): 12% nl, atelectasis, effusion, ↑ hemidiaphragm, Hampton hump (wedge-shaped density abutting pleura); Westermark sign (avascularity distal to PE)</p></li><li><p>ECG (limited Se & Sp): sinus tachycardia, AF; signs of RV strain → RAD, P pulmonale, RBBB, SIQIIITIII & TWI V1–V4 (McGinn-White pattern; Chest 1997;111:537)</p></li><li><p>ABG: hypoxemia, hypocapnia, respiratory alkalosis, ↑ A-a gradient (Chest 1996;109:78) 18% w/ room air PaO2 85–105 mmHg, 6% w/ nl A-a gradient (Chest 1991;100:598)</p></li><li><p>D-dimer: high Se, poor Sp (~25%); ELISA has >99% NPV ∴ use to r/o PE if “unlikely” pretest prob (JAMA 2006;295:172); cut-off 500 if &lt;50 y, 10× age if ≥ 50 y (JAMA 2014;311:1117)</p></li><li><p>Echocardiography: useful for risk stratification (RV dysfxn), but not dx (Se &lt;50%)</p></li><li><p>V/Q scan: high Se (~98%), low Sp (~10%). Sp improves to 97% for high-prob VQ. Use if pretest prob of PE high and CT not available or contraindicated. Can also exclude PE if low pretest prob, low-prob VQ, but 4% false (JAMA 1990;263:2753).</p></li><li><p>CT angiography (CTA; see Radiology inserts; JAMA 2015;314:74): Se ~90% & Sp ~95%; PPV & NPV >95% if imaging concordant w/ clinical suspicion, ≤80% if discordant (∴ need to consider both); ~1/4 of single & subseg may be false ⊕; CT may also provide other dx</p></li><li><p>Lower extremity compression U/S shows DVT in ~9%, sparing CTA</p></li></ul><p>Figure 2-4 Approach to suspected PE</p><p>Workup for idiopathic VTE (NEJM 2015;373:697)</p><ul><li><p>Thrombophilia workup: ✓ if ⊕ FH; may be helpful but consider timing as thrombus, heparin and warfarin Δ results. Useful for relatives, if dx APLAS (given requires warfarin), or if not planning lifelong anticoagulation for Pt.</p></li><li><p>Malignancy workup: 12% Pts w/ “idiopathic” DVT/PE will have malignancy; age-appropriate screening adequate; avoid extensive w/u</p></li></ul><p>Risk stratification for Pts with PE</p><ul><li><p>Clinical: Simplified PE Severity Index (sPESI) risk factors include age >80 y; h/o cancer; h/o cardiopulm. disease; HR ≥110; SBP &lt;100; SaO2 &lt;90%</p></li><li><p>Imaging: TTE for RV dysfxn; CTA for RV/LV dimension ratio >0.9. Biomarker: Tn & BNP.</p></li><li><p>Classification (EHJ 2020;41:543)</p></li></ul><p>High risk (“massive”): hemodyn unstable w/ arrest, obstructive shock, or persistent HoTN</p><p>Intermediate risk (“submassive”): sPESI ≥1</p><p>“Intermediate-high” if both RV dysfunction & elevated Tn</p><p>“Intermediate-low” if either or neither RV dysfunction or elevated Tn</p><p>Low risk: clinically stable, sPESI = 0, normal RV function, normal Tn</p><p>Whom to treat (JAMA 2020;324:1765; Chest 2021;160:e545)</p><ul><li><p>Superficial venous thrombosis: elevate extremity, warm compresses, compression stockings, NSAIDs for sx. Anticoag if high risk for DVT (eg, ≥5 cm, proximity to deep vein ≤5 cm, other risk factors) for 4 wk as ~10% have VTE w/in 3 mo (Annals 2010;152:218).</p></li><li><p>LE DVT: proximal → anticoag; distal → anticoag if severe sx, o/w consider serial imaging over 2 wk and anticoag if extends (although if bleeding risk low, many would anticoag).</p></li><li><p>UE DVT: anticoagulate (same guidelines as LE; NEJM 2011;364:861). If catheter-associated, need not remove if catheter functional and ongoing need for catheter.</p></li><li><p>PE: anticoagulate (unless isolated subsegmental and risk for recurrent VTE low)</p></li></ul><p>Initial anticoagulation options (EHJ 2020;41:543; Chest 2021;160:e545)</p><ul><li><p>Initiate immediately if high or intermed suspicion but dx test results will take ≥4 h</p></li><li><p>Either (a) initial parenteral → long-term oral or (b) solely DOAC if no interven. planned</p></li><li><p>LMWH (eg, enoxaparin 1 mg/kg SC bid or dalteparin 200 IU/kg SC qd)</p></li></ul><p>Preferred over UFH (especially in cancer) except: renal failure (CrCl &lt;25), ? extreme obesity, hemodynamic instability or bleed risk (Cochrane 2004;CD001100)</p><ul><li><p>IV UFH: 80 U/kg bolus → 18 U/kg/h → titrate to PTT 1.5–2.3 × cntl (eg, 60–85 sec); preferred option when contemplating thrombolysis or catheter-based Rx (qv)</p></li><li><p>IV direct thrombin inhibitors (eg, argatroban, bivalirudin) used in HIT ⊕ Pts</p></li><li><p>Fondaparinux: 5–10 mg SC qd (NEJM 2003;349:1695); use if HIT ⊕; avoid if renal failure</p></li><li><p>Direct oral anticoag (DOAC; NEJM 2010;363:2499; 2012;366:1287; 2013;369:799 & 1406)</p></li></ul><p>Preferred b/c as good/better than warfarin in preventing recurrent VTE w/ less bleeding</p><p>Apixaban (10 mg bid × 7 d → 5 bid) or rivaroxaban (15 mg bid for 1st 3 wk → 20 mg/d) can be given as sole anticoagulant w/ initial loading dose</p><p>Edoxaban or dabigatran can be initiated after ≥5 d of parenteral anticoag</p><ul><li><p>DVT & low-risk PE w/o comorbidities and able to comply with Rx can be treated as outPt</p></li><li><p>Generally safe to anticoagulate if platelets >50,000 but contraindicated if &lt;20,000</p></li></ul><p>Systemic thrombolysis (EHJ 2020;41:543; Chest 2021;160:e545)</p><ul><li><p>Typically TPA 100 mg over 2 h or wt-adjusted TNK bolus; risk of ICH ~2-5%, ↑ w/ age</p></li><li><p>Consider if low bleed risk w/ acute PE + HoTN or cardiopulm deterioration after anticoag</p></li><li><p>High-risk PE: ↓ death & recurrent PE each by ~50% (JAMA 2014;311:2414; EHJ 2015;36:605)</p></li><li><p>Intermediate-risk PE: ↓ hemodyn decompensation, ↑ ICH & major bleeding, ↓ mortality in short- but not long-term; ? consider if &lt;75 y and/or low bleed risk (JAMA 2014;311:2414)</p></li><li><p>Half-dose lytic (50 mg or 0.5 mg/kg if &lt;50 kg; 10-mg bolus → remainder over 2 h) in ~intermed. PE: ↓ pulm HTN & ? PE or death w/ ≈ bleeding vs. heparin alone (AJC 2013;111:273)</p></li><li><p>DVT: consider if (a) acute (&lt;14 d) & extensive (eg, iliofemoral), (b) severe sx swelling or ischemia, and (c) low bleed risk</p></li></ul><p>Mechanical intervention (JACC 2020;76:2117)</p><ul><li><p>Catheter-directed pharmacomech: low-dose lytic infused (eg, tPA 1 mg/h for 12–24 hr per catheter) + U/S or mech fragmentation of clot. Consider if hemodyn. compromise or high risk & not candidate for systemic lysis or surgical thrombectomy. Preferred to systemic lytic by some centers. Also consider if intermediate-high risk and evidence of early hemodynamic deterioration (Circ 2014;129:479). Lack of data on hard outcomes.</p></li><li><p>Catheter-based clot extraction (eg, AngioVac or FlowTriever): ↓ PA pressure</p></li><li><p>Surgical embolectomy: if large, proximal PE + hemodynamic compromise + contraindic. to lysis; consider in experienced ctr if large prox. PE + RV dysfxn</p></li><li><p>IVC filter: use if anticoag contraindic.; no benefit to adding to anticoag (JAMA 2015;313:1627)</p></li></ul><p>Complications: migration, acute DVT, ↑ risk of recurrent DVT & IVC obstruction (5–18%)</p><p>Duration of full-intensity anticoagulation</p><ul><li><p>Superficial venous thrombosis: 4 wk</p></li><li><p>1st prox DVT or PE 2° reversible/time-limited risk factor or distal DVT: 3–6 mo</p></li><li><p>1st unprovoked prox DVT/PE: ≥3 mo, then reassess; benefit to prolonged Rx. Consider clot, bleed risk, Pt preference, and intensity of Rx when crafting strategy.</p></li><li><p>2nd VTE event or cancer: indefinite (or until cancer cured) (NEJM 2003;348:1425)</p></li></ul><p>Long-term anticoagulation options</p><ul><li><p>For nonpregnant Pt without severe renal dysfunction or active cancer → DOAC</p></li><li><p>For severe renal insufficiency or APLAS → warfarin. Start w/ parenteral anticoag unless ? need for lytic, catheter-based Rx or surg; bridge to INR ≥2 × ≥24 h.</p></li><li><p>Pregnancy or unable to take oral therapy → LMWH or fondaparinux</p></li><li><p>Cancer → DOAC (but in Pts w/ UGI cancers, more GI bleeding w/ riva) or LMWH</p></li></ul><p>Extended DOAC strategies</p><ul><li><p>After ≥6 mo of anticoag, following regimens compared w/ no extended Rx (or ASA):</p></li><li><p>Full-dose DOAC: 80–90% ↓ recurrent VTE, 2–5× bleeding, but no signif excess in major bleeding (NEJM 2010;363:2499; 2013;368:699 & 709)</p></li><li><p>½ dose apixa or riva: ≥75% ↓ recur. VTE, w/o ↑ bleeding (NEJM 2013;368:699 & 2017;376:1211)</p></li></ul><p>Complications & prognosis</p><ul><li><p>Postthrombotic syndrome (23–60%): pain, edema, venous ulcers</p></li><li><p>Recurrent VTE: 1%/y (after 1st VTE) to 5%/y (after recurrent VTE)</p></li><li><p>Chronic thromboembolic PHT after acute PE ~2–3%, consider thromboendarterectomy</p></li><li><p>Mortality: ~10% for DVT and ~10–15% for PE at 3–6 mo (Circ 2008;117:1711)</p></li></ul><p>PULMONARY HYPERTENSION (PHT)</p><p>PHT defined as PA mean pressure ≥20 mmHg at rest (ERJ 2019;53:1801913)</p><p>PA mean = CO × PVR + PA wedge pressure. Trans pulm gradient = PA mean – PA wedge.</p><p>Etiologies (Revised WHO Classification) (JACC 2013;62:D34)</p><p>Primary pulmonary arterial HTN (PAH) (group 1)</p><p>Precapillary PHT</p><p>PCWP ≤15 mmHg</p><p>↑ transpulm grad</p><p>↑ PVR</p><ul><li><p>Idiopathic (IPAH): yearly incidence 1–2 per million; mean age of onset 36 y (♂ older than ♀); ♂: ♀ = ~2:1, usually mild ↑ in PAP</p></li><li><p>Familial (FPAH)</p></li><li><p>Associated conditions (APAH)</p></li><li><p>Connective tissue dis.: CREST, SLE, MCTD, RA, PM, Sjögren</p></li><li><p>Congenital L→R shunts: ASD, VSD, PDA</p></li><li><p>Portopulmonary HTN (? 2° vasoactive substances not filtered in ESLD; ≠ hepatopulmonary syndrome)</p></li><li><p>HIV; drugs & toxins: anorexic agents, SSRIs, l-tryptophan</p></li><li><p>Pulmonary veno-occlusive disease: ? 2° chemo, BMT; orthopnea, pl eff, CHF, nl PCWP; art vasodil. worsen CHF (AJRCCM 2000;162:1964)</p></li><li><p>Pulmonary capillary hemangiomatosis</p></li></ul><p>Left heart disease (group 2). ↑ PCWP</p><ul><li><p>Left atrial or ventricular (diastolic or systolic) dysfunction</p></li><li><p>Left-sided valvular heart disease (eg, MS/MR)</p></li></ul><p>Lung diseases and/ or chronic hypoxemia (group 3)</p><ul><li><p>COPD</p></li><li><p>Alveolar hypoventilation (eg, NM disease)</p></li><li><p>ILD</p></li><li><p>Chronic hypoxemia (eg, high altitude)</p></li><li><p>Sleep apnea</p></li><li><p>Developmental abnormalities</p></li></ul><p>Chronic thrombo- embolic dis (group 4)</p><ul><li><p>Prox or distal PEs; ~½ w/o clinical h/o PE (NEJM 2011;364:351)</p></li><li><p>Nonthrombotic emboli (tumor, foreign body, parasites)</p></li></ul><p>Miscellaneous/ Multifactorial (group 5)</p><ul><li><p>Sarcoidosis, histiocytosis X, LAM, schistosomiasis, ESRD</p></li><li><p>Compression of pulm vessels (adenopathy, tumor, fibrosing mediastinitis, histoplasmosis, XRT)</p></li><li><p>Other: thyroid dis., glycogen storage dis., Gaucher dis, HHT, sickle cell, etc., chronic myeloprolif d/o, splenectomy</p></li></ul><p>Clinical manifestations</p><ul><li><p>Dyspnea, exertional syncope (hypoxia, ↓ CO), exertional chest pain (RV ischemia)</p></li><li><p>Symptoms of R-sided CHF (eg, peripheral edema, RUQ fullness, abdominal distention)</p></li><li><p>WHO class: I = asx w/ ordinary activity; II= sx w/ ord. activ; III = sx w/ min activ.; IV = sx at rest</p></li></ul><p>Physical exam</p><ul><li><p>PHT: prominent P2, R-sided S4, RV heave, PA tap & flow murmur, PR (Graham Steell), TR</p></li><li><p>± RV failure: ↑ JVP, hepatomegaly, peripheral edema</p></li></ul><p>Diagnostic studies & workup (JAMA 2022;327:1379)</p><ul><li><p>High-res chest CT: dilat. & pruning of pulm arteries, ↑ RA & RV; r/o parenchymal lung dis.</p></li><li><p>ECG: RAD, RBBB, RAE (“P pulmonale”), RVH (Se 55%, Sp 70%)</p></li><li><p>PFTs: disproportionate ↓ DLCO, mild restrictive pattern; r/o obstructive & restrictive lung dis.</p></li><li><p>ABG & polysomnography: ↓ PaO2 and SaO2 (espec w/ exertion), ↓ PaCO2, ↑ A-a gradient; r/o hypoventilation and OSA</p></li><li><p>TTE: ↑ RVSP (but estimate over/under by ≥10 mmHg in ½ of PHT Pts; Chest 2011;139:988) ↑ RA, RV, & PA; ↑ pressure → interventricular septum systolic flattening (“D” shape) ↓ RV systolic fxn (TAPSE &lt;1.6 cm); TR, PR; r/o LV dysfxn, MV, AoV, congenital disease</p></li><li><p>RHC: ↑ RA, RV, & PA pressures; ✓ L-sided pressures and for shunt</p></li></ul><p>if PAH: nl PCWP, ↑ transpulmonary gradient (mean PAP-PCWP >12–15), ↑ diastolic pulmonary gradient (PA diastolic – PCWP >7), ↑ PVR, ± ↓ CO</p><p>if 2° to L-heart disease: PCWP (or LVEDP) >15; if PVR nl → “passive PHT”; PVR >240 suggests mixed picture: if ↓ PCWP → ↓ PVR, then “reactive” PHT; if no Δ, then “fixed”</p><ul><li><p>CTA (large/med vessel), V/Q scan (small vessel to r/o CTEPH), ± pulm angio if ↑ concern</p></li><li><p>Labs: ANA (~40% ⊕ in PAH), anti-Scl-70, anti-RNP; LFTs; HIV</p></li><li><p>6-min walk test (6MWT) or cardiopulmonary exercise testing to establish fxnl capacity</p></li></ul><p>Treatment (JAMA 2022;327:1379)</p><ul><li><p>Principles: 1) prevent & reverse vasoactive substance imbalance and vascular remodeling 2) prevent RV failure: ↓ wall stress (↓ PVR, PAP, RV diam); ensure adeq systemic DBP</p></li><li><p>Supportive</p></li></ul><p>Oxygen: maintain SaO2 >90–92% (reduces vasoconstriction)</p><p>Diuretics: ↓ RV wall stress and relieve RHF sx; gentle b/c RV is preload dependent</p><p>Anticoag: not routinely used; ↓ VTE risk of RHF; ? prevention of in situ microthrombi; ? mortality benefit even if in NSR, no RCTs (Chest 2006;130:545)</p><p>Supervised exercise training; aggressive apnea/hypoventilatory Rx w/ CPAP/BiPAP</p><ul><li>Vasodilators (ideally right heart catheterization prior to initiation; NEJM 2004;351:1425) acute vasoreactivity test: use inh NO, adenosine or prostacyclin to identify Pts likely to have long-term response to CCB (⊕ response = ↓ PAP ≥10 mmHg to &lt;40 mmHg w/ ↑ or stable CO); ~10% Pts acute responders; no response → still candidate for other vasodilators</li></ul><p>Vasoactive Agents</p><p>Comments (data primarily in Group 1)</p><p>PDE-5 inhibitor sildenafil, tadalafil, vardenafil</p><p>↑ cGMP → vasodilatation, ↓ smooth muscle proliferation, ↓ sx, ↑ 6MWT, no data on clinical outcomes. Often 1st line b/c minimal side-effect profile: HA, vision Δ’s, sinus congestion.</p><p>Endothelin receptor antagonists (ERAs) bosentan, ambrisentan, macitentan</p><p>↓ Smooth muscle remodeling, vasodilatation, ↓ fibrosis, ↓ sx, ↑ 6MWT, ↓ worsening PAH or need for prostanoids w/ trend for ↓ PAH mortality (w/ macitentan). Side effects: ↑ LFTs, HA, anemia, edema, teratogen (NEJM 2013;369:809).</p><p>IV prostacyclin epoprostenol (Flolan)</p><p>Vasodilatation, ↓ plt agg, ↓ smooth muscle prolif; benefits ↑ w/ time (? vasc remodeling). ↑ 6MWT, ↑ QoL, ↓ mortality. Side effects: HA, flushing, jaw pain, abd cramps, N/V, diarrhea, catheter infxn.</p><p>Prostacyclin analogs [iloprost (inh), treprostinil (IV, inh, SC)]</p><p>Same mech as prostacyclin IV, but easier admin, ↓ side effects, w/o risk of catheter infxn. ↓ sx, ↑ 6MWT. Inh Rx w/ improved V/Q matching. Inh trepostinil ↑ 6MWT in ILD-PH (NEJM 2021;384:325).</p><p>Prostacyclin receptor agonist (selexipag, PO)</p><p>Indicated for WHO Group I to delay disease progression and risk of hospitalization. Add in WHO FC II & III (NEJM 2015;373:2522).</p><p>Soluble guanylate cyclase stimulator riociguat</p><p>NO-independent ↑ cGMP → vasodilatation, ↓ smooth muscle -proliferation, ↓ sx, ↑ 6MWT in PAH; ↓ sx, ↓ PVR, ↑ 6MWT in CTEPH (NEJM 2013;369:319 & 330)</p><p>Oral CCB nifedipine, diltiazem</p><p>Consider if ⊕ acute vasoreactive response. Not 1st line b/c side effects: HoTN, lower limb edema.</p><ul><li><p>Upfront combination Rx (PDE-5 inhibitor + ERA vs. monotherapy): ↓ sx, ↓ NT-proBNP, ↑ 6MWT, ↓ hospitalizations (NEJM 2015;373:834)</p></li><li><p>Treat underlying causes of 2° PHT; can use vasodilators, although little evidence</p></li><li><p>CTEPH: riociguat. Pulm endarterectomy potentially curative (AJRCCM 2011;183:1605) vs. balloon pulmonary angioplasty in non-operative Pts (Circ Outcomes 2017;10:e004029).</p></li><li><p>Refractory PHT: balloon atrial septostomy: R→L shunt causes ↑ CO, ↓ SaO2, net ↑ tissue O2 delivery; lung txp (single or bilateral; heart-lung needed if Eisenmenger physiology)</p></li><li><p>PHT risk stratification based on CHF symptoms, syncope, WHO functional class, 6MWT, CPET, NTproBNP, imaging, hemodynamics (Eur Heart J 2016;37:67)</p></li></ul><p>Figure 2-5 Treatment of PAH (modified from ERJ 2019;53:1801889)</p><p>Management of ICU patient</p><ul><li><p>Avoid tachyarrhythmias & overly aggressive volume resuscitation</p></li><li><p>Caution w/ vasodilators if any L-sided dysfunction</p></li><li><p>Intubation can cause hemodynamic collapse</p></li><li><p>Dobutamine and inhaled NO or prostacyclin</p></li><li><p>Consider R-sided mechanical support (Circ 2015;132:536)</p></li><li><p>Consider fibrinolysis if acute, refractory decompensation (eg, TPA 100 mg over 2 h)</p></li></ul><p>Prognosis</p><ul><li><p>Median survival after dx ~2.8 y; PAH (all etiologies): 2-y 66%, 5-y 48% (Chest 2004;126:78–S)</p></li><li><p>Poor prognostic factors: clinical evidence of RV failure, rapidly progressive sx, WHO (modified NYHA) class IV, 6MWT &lt;300 m, peak VO2 &lt;10.4 mL/kg/min, ↑ RA or RV or RV dysfxn, RA >20 or CI &lt;2.0, ↑ BNP (Chest 2006;129:1313)</p></li></ul><p>RESPIRATORY FAILURE</p><ul><li><p>A-a gradient = PAO2 – PaO2: normal (on room air) = “4 + age/4” or “2.5 + (0.2 × age)”</p></li><li><p>Hypoxemia + nl A-a gradient: problem is ↓ PiO2/FiO2 or ↑ PaCO2 (ie, hypoventilation)</p></li><li><p>Hypoxemia + ↑ A-a gradient: problem is either</p></li></ul><p>R → L shunt, anatomic (congenital heart dis) or severe pathophys (alveoli filled w/ fluid; eg, PNA, pulm edema); cannot overcome w/ 100% O2 b/c of sigmoidal Hb-O2 curve</p><p>V/Q mismatch where “shunt-like” areas (↓ V & nl Q) cause unoxygenated blood to mix with oxygenated blood; can be overcome w/ ↑ O2 delivery</p><p>Diffusion limitation: generally seen with exercise/↑CO</p><p>Figure 2-6 Workup of acute hypoxemia</p><ul><li>Cyanosis: when >5 g/dL of deoxygenated Hb in vessels of skin/mucous membranes. Central: ↓ SaO2 (pulm disease, shunt); abnl Hb [metHb, sulfHb, COHb (not true cyanosis)] Peripheral: ↓ blood flow → ↑ O2 extraction (eg, ↓ CO, cold, arterial or venous obstruction)</li></ul><p>CO binds to Hb more avidly than does O2. Pulse oximeter (Ox) misreads COHb as HbO2 → falsely nl sat.</p><p>Oxidizing drugs Δ Hb (ferrous) to MetHb (ferric), which cannot carry O2. Pulse ox misreads MetHb as HbO2.</p><p>Etiologies of High ↑ PaCO2</p><p>“Won’t Breathe”</p><p>“Can’t Breathe”</p><p>↓ RR</p><p>↓ VT</p><p>↑ VD and/or ↓ VT</p><p>Respiratory Drive</p><p>NM System</p><p>CW/Pleura</p><p>Lung/Airways</p><p>Voluntary hypervent.</p><p>Nl PImax & A-a grad</p><p>↓ PImax</p><p>↓ PEmax</p><p>Abnl PEx</p><p>Abnl CT</p><p>Abnl PFTs</p><p>↓ End tidal CO2</p><p>Metabolic alkalosis</p><p>1° neurologic: brain-stem stroke, tumor, 1° alveolar hypovent</p><p>2° neurologic: sedatives, CNS infxn, hypothyroidism</p><p>Neuropathies: cervical spine, phrenic nerve, GBS, ALS, polio</p><p>NMJ: MG, LE</p><p>Myopathies: diaphragm PM/DM, ↓ PO4, musc dystrophies</p><p>Chest wall: obesity,</p><p>kyphosis,</p><p>scoliosis</p><p>Pleura: fibrosis effusion</p><p>Lung parenchyma: emphysema, ILD/fibrosis, CHF, PNA</p><p>Airways: asthma, COPD, OSA, CF bronchiectasis</p><p>↑ VCO2 typically transient cause of ↑ PaCO2; Ddx: exercise, fever, hyperthyroidism, ↑ work of breathing, ↑ carbs.</p><p>MECHANICAL VENTILATION</p><p>Indications</p><ul><li><p>Improve gas exchange: ↑ oxygenation, ↑ alveolar vent and/or reverse acute resp acidosis</p></li><li><p>Relieve respiratory distress: ↓ work of breathing (can account for up to 50% of total O2 consumption), ↓ respiratory muscle fatigue</p></li><li><p>Apnea, airway protection, pulmonary toilet</p></li></ul><p>SUPPORTIVE STRATEGIES PRIOR TO INTUB. OR AFTER EXTUB.</p><p>Oxygen Delivery Systems (Lancet 2016;387:1867)</p><p>System or Device</p><p>O2 Flowa</p><p>FiO2 Range & Comments</p><p>Low-flow nasal cannula</p><p>1–6</p><p>24–40%, 1L adds ~3% FiO2</p><p>Standard face mask</p><p>5–10</p><p>35–50%, minimum 5 L/min</p><p>Partial rebreather mask</p><blockquote><p>10</p></blockquote><p>40–70%</p><p>Nonrebreather mask</p><blockquote><p>10</p></blockquote><p>60–80% (not 100% b/c air leaks)</p><p>Air-entrainment mask</p><p>(Venturi or Venti mask)</p><p>10–15b</p><p>24–50%, FiO2 stays constant</p><p>High-flow nasal cannula (HFNC) (NEJM 2015;372: 2185; JAMA 2015;313:2331 & 2016;315:1354)</p><p>≤40</p><p>21–100%. In nonhypercapnic acute hypoxemic</p><p>resp failure, ± ↓ intub. (espec if PaO2/FiO2 ≤200) & ↓ 90-d mort vs. stnd O2 or NPPV.</p><p>Routine use after extub. ↓ need for reintub</p><p>aL/min. bTotal airflow >60L/min. (Adapted from Marino P. The ICU Book, 4th ed, Philadelphia: LWW, 2014:431)</p><p>Noninvasive Positive Pressure Ventilation (NPPV) (NEJM 2015;372:e30)</p><p>Indications (Lancet 2009;374:250)</p><p>Clinical: mod–severe dyspnea, RR >24–30, signs of ↑ work of breathing, accessory muscle use, abd paradox</p><p>Gas exchange: PaCO2 >45 mmHg (& significantly worse than -baseline), hypoxemia, PaO2/FiO2 &lt;200</p><p>Contraindications</p><p>(Crit Care Med 2007;35:2402)</p><p>Claustrophobia, poor mask fit, ΔMS, vomiting, cannot protect airway, extrapulm organ failure, HD instab, sev UGIB, ↑ secretions</p><p>Continuous positive airway pressure (CPAP)</p><p>≈ PEEP. Pt breathes spont. at own rate while vent maintains constant positive airway pressure throughout respiratory cycle.</p><p>No limit on O2 delivered (ie, can give hi-flow → FiO2 ≈1.0)</p><p>Used if primary problem hypoxemia (eg, CHF)</p><p>Bilevel positive airway pressure (BiPAP)</p><p>≈ PSV + PEEP. Able to set both inspiratory (usually 8–10 cm H2O) and expiratory pressures (usually &lt;5 cm H2O).</p><p>Used if primary problem hypoventilation; FiO2 delivery limited</p><p>Mask ventilation (? helmet better; JAMA 2016;315:2435)</p><p>Tight-fitting mask connecting patient to a standard ventilator</p><p>Can receive PS ~20–30 cm H2O, PEEP ~10 cm H2O, FiO2 ~1.0</p><p>Used for short-term support (&lt;24 h) for a reversible process</p><p>Conditions w/ strong evidence</p><p>Cardiogenic pulmonary edema: may ↓ intub. ± mortality (JAMA 2005;294:3124; Lancet 2006;367:1155; NEJM 2008;359:142)</p><p>COPD exac. w/ ↑ PaCO2: ↓ intub. & mort., but if pH &lt;7.3 → intubate</p><p>Acute hypoxemic resp failure: ↓ intub. & mortality (JAMA 2020;324:57)</p><p>High-risk extub. (age >65, CHF, APACHE II >12): NPPV × 24 h directly after extub. → ↓ reintub. and, if PaCO2 >45 mmHg during SBT, ↓ mortality. Does not Δ total # vent days (JAMA 2018;320:1881).</p><p>Hypoxemic resp failure after abdominal surgery: ↓ reintubation</p><p>Immunosupp. w/ infiltrates: ↓ complications & mortality</p><p>VENTILATOR MANAGEMENT</p><p>Ventilator Modes and Principles (NEJM 2001;344:1986; Chest 2015;148:340)</p><p>Cont mandatory ventilation (CMV), aka Assist control (AC)</p><p>Vent delivers a minimum number of supported breaths</p><p>Additional Pt-initiated breaths trigger fully assisted vent breaths</p><p>∴ Vent-triggered breaths identical to Pt-triggered breaths</p><p>Tachypnea → ? resp. alkalosis, breath-stacking, & auto-PEEP</p><p>May be pressure targeted or volume targeted (qv)</p><p>Pressure support</p><p>vent (PSV)</p><p>Support Pt-initiated breaths w/ a set inspiratory pressure & PEEP</p><p>A mode of partial vent support because no set rate</p><p>Other</p><p>Synch intermittent mand. vent: deliver min # supported breaths; VT of additional Pt-initiated breaths determined by Pt’s effort</p><p>Proportional assist ventilation (PAV): delivers variable pressure to achieve targeted % of work of breathing</p><p>Volume or Pressure Targeted</p><p>Volume targeted</p><p>Vent delivers a set VT; pressures depend on airway resist. & lung/CW compl.</p><p>Benefit: ↑ control over ventilation (ideal initial ventilator setting); benefit in ALI/ARDS; easy to measure mechanics (PIP, Pplat, airway resist., compl.)</p><p>Volume control (VC) ⊕: vent delivers variable pressure (depending on real- time lung compliance) to achieve set VT</p><p>Pressure</p><p>targeted</p><p>Vent delivers a fixed inspiratory pressure regardless of VT</p><p>VT depends on airway resistance and lung/chest wall compliance</p><p>Benefit: may ↑ Pt comfort (PSV) requiring less sedation</p><p>General</p><p>principles</p><p>Institutional/practitioner preference and Pt comfort usually dictate ventilator strategy; no strategy has proven superior</p><p>Alarms can be set for ↓ or ↑ volumes and ↑ airway pressures in pressure- targeted and volume-targeted strategies, respectively</p><p>Risks: volutrauma (ie, overdistention, if set volume too high; NEJM 2013;369:2126), barotrauma [can happen w/ relatively high set volumes (espec if stiff lungs) or if pressure target set too high; key is to monitor transpulmonary pressure (difference between Pplat and esophageal ≈ intrapleural), not just airway pressure]; can result in PTX, pneumomediastinum</p><p>Hypo-/hyperventilation: need to ✓ minute vent & pH/PaCO2</p><p>Variables on the Ventilator</p><p>FiO2</p><p>Fraction of inspired air that is oxygen</p><p>VT (tidal vol)</p><p>Volume of breath delivered; lung-protective ventilation: goal ≤6 mL/kg IBW</p><p>If no ARDS, similar # of vent days at higher VT (JAMA 2018;320:1872)</p><p>f (resp. rate)</p><p>Rate set by ventilator, f may be lower than RR if Pt triggering breaths.</p><p>Adjust to achieve desired PaCO2.</p><p>Positive end- expiratory pressure (PEEP)</p><p>Positive pressure applied during exhalation via resistor in exhalation port</p><p>Benefits: prevents alveolar collapse, ↓ shunt, ↑ O2 via alveolar recruitment and improved compliance, allows severely obstructed Pt to initiate breath</p><p>Cardiac effects: ↓ preload by ↑ intrathoracic pressure → ↓ venous return; ↓ afterload by ↓ cardiac transmural pressure; may ↑ or ↓ CO and may ↑ or ↓ oxygen delivery based on the above</p><p>Auto-PEEP or intrinsic PEEP (iPEEP): inadeq. exhalation time → lungs unable to completely empty before next breath (ie, “breath stacking”); if flow at end-expiration, there must be pressure = auto-PEEP. Will ↓ preload and may ↓ CO, espec if hypovolemic</p><p>Will ↑ work of breathing as must be overcome by Pt to trigger breaths; can prevent Pt from triggering ventilator, extrinsic PEEP helps</p><p>Can be detected if end-expiratory flow ≠ 0 before next breath</p><p>Can measure by occluding expiratory port of vent at end-expiration</p><p>Can ↓ by: ↑ exp time, ↓ RR, ↓ VT, Rx bronchospasm and secretions</p><p>If iPEEP >set PEEP, minimize iPEEP, then set PEEP to ~80% of iPEEP to ↓ ineffective triggering</p><p>Inspiratory time</p><p>Normally I:E ratio is ~1:2; however, can alter I time (and consequently flow rate, see later); use in pressure-control mode</p><p>Inspiratory flow rates</p><p>↑ flow rate → ↓ I time → ↑ E time → ∴ may improve ventilation in obstructive disease, but may affect resp rate and bronchodilation/constriction</p><p>Peak inspiratory pressure (PIP)</p><p>Dynamic measurement during inspiration; set in pressure-targeted mode</p><p>Determined by airway resistance and lung/chest wall compliance</p><p>↑ PIP w/o ↑ Pplat → ↑ airway resist (eg, bronchospasm, plugging)</p><p>↓ PIP → ↓ airway resistance or air leak in the system</p><p>Plateau pressure (Pplat)</p><p>Static measurement at the end of inspiration when there is no flow</p><p>Determined by resp system compliance (resist. not a factor since no flow)</p><p>↑ Pplat → ↓ lung or chest wall compliance (eg, PTX, pulmonary edema, pneumonia, atelectasis), ↑ PEEP or auto-PEEP</p><p>Pplat &lt;30 cm H2O ↓ barotrauma (↓ VT, ↓ PEEP or ↑ compl [eg, by diuresis])</p><p>Tailoring the ventilator settings</p><ul><li>To improve oxygenation: options include ↑ FiO2, ↑ PEEP</li></ul><p>SaO2 88–92% acceptable (AJRCCM 2016;193:43), do not exceed 96% (BMJ 2018;363:k4169)</p><p>First, ↑ FiO2. If >0.6 and oxygenation remains suboptimal, then try ↑ PEEP:</p><p>If ↑ PaO2/FiO2 and Pplat stable, suggests recruitable lung (ie, atelectasis). If PEEP 20 & FiO2 1.0 and oxygenation remains suboptimal, consider rescue/expt strategies (see “ARDS”).</p><p>If ↑ PEEP yields no Δ or ↓ PaO2/FiO2 or ↑ PaCO2, suggests additional lung not recruitable and instead overdistending lung → ↑ shunt & dead space; ∴ ↓ PEEP</p><p>If no ARDS, PEEP ≤5 (& SaO2 >92%) noninferior to PEEP 8 (JAMA 2020;324:2509)</p><ul><li>To improve ventilation: ↑ VT or inspiratory pressure, ↑ RR (may need to ↓ I time). Nb, tolerate ↑ PaCO2 (permissive hypercapnia) in ALI/ARDS (qv) as long as pH >7.2.</li></ul><p>Acute ventilatory deterioration (usually ↑ PIP)</p><ul><li>Response to ↑ PIP: disconnect Pt from vent, bag, auscultate, suction, ✓ CXR & ABG</li></ul><p>Figure 2-7 Approach to acute ventilatory deterioration</p><p>(Adapted from Marino PL. The ICU Book, 4th ed., Philadelphia: LWW, 2014)</p><p>Liberating from the ventilator (NEJM 2012;367:2233; Lancet 2016;387:1856)</p><ul><li><p>Perform daily assessment of readiness for spontaneous breathing trial (SBT)</p></li><li><p>Clinical screening criteria: VS stable, minimal secretions, adequate cough, cause of respiratory failure or previously failed SBT reversed</p></li><li><p>Vent parameters: PaO2/FiO2 >200, PEEP ≤5, f/VT &lt;105, VE &lt;12 L/min, VC >10 mL/kg; rapid shallow breathing index (f/VT) >105 predicts failure, NPV 0.95 (NEJM 1991;324:1445)</p></li><li><p>Daily awakening trial (d/c all sedation; Lancet 2008;371:126): open eyes & w/o: agitation, RR >35, SaO2 &lt;88%, resp distress or arrhythmias (if fail, restart sedation at ½ prior dose)</p></li><li><p>SBT = CPAP × 30 min superior to T-piece × 120 min (JAMA 2019;321:2175) failure if: deteriorating ABGs, ↑ RR, ↑ or ↓ HR, ↑ or ↓ BP, diaphoresis, anxiety</p></li><li><p>Tolerate SBT → extubation. Fail SBT → ? cause → work to correct → retry SBT qd</p></li><li><p>If high-risk, extubate to either NPPV or NPPV alternating w/ HFNC (JAMA 2019;322:1465)</p></li><li><p>? acetazolamide in Pts w/ COPD & metabolic alkalosis (JAMA 2016;315:480)</p></li></ul><p>Complications</p><ul><li><p>Oxygen toxicity (theoretical); proportional to duration + degree of ↑ oxygen (FiO2 >0.6)</p></li><li><p>Ventilator-induced lung injury (see “ARDS”)</p></li><li><p>Ventilator-associated pneumonia (~1%/d, mortality rate ~30%)</p></li></ul><p>typical pathogens: MRSA, Pseudomonas, Acinetobacter and Enterobacter species</p><p>preventive strategies (AJRCCM 2005;171:388): wash hands, HOB elevated, non-nasal intub., enteral nutrition rather than TPN?, routine suction of subglottic secretions, avoid unnecessary abx & transfusions; routine oral antiseptic controversial</p><ul><li><p>Stress ulcers/GIB: prophylaxis w/ PPI ↓ GIB, but no ∆ in overall course (NEJM 2018;379:2199)</p></li><li><p>Laryngeal</p></li></ul><p>edema: for Pts vent >36 h; ? predicted by ⊕ cuff leak test. Methylprednisolone 20 mg IV q4h starting 12 h pre-extub. → ↓↓ edema and 50% ↓ in reintubation (Lancet 2007;369:1003).</p><p>ulceration: consider tracheostomy for Pts in whom expect >14 d of mech vent → ↓ duration mech vent, ↓ # ICU days (BMJ 2005;330:1243); no benefit to performing at ~1 wk vs. waiting until ~2 wk (JAMA 2010;303:1483)</p><ul><li><p>Malnutrition (for all critically ill Pts): enteral nutrition initiated early is safe but not necessary (JAMA 2012;307:795), but bolus may ↑ risk of VAP & C diff. (JPEN 2002;26:174); no clear benefit to ✓ing gastric residuals (JAMA 2013;309:249); permissive enteral underfeeding (~½ of calculated caloric req) & standard enteral feeding w/ similar outcomes (NEJM 2015;372:2398); parenteral nutrition should be delayed until after day 8 to ↓ risk of infections, cholestasis, RRT, ventilator days (NEJM 2011;365:506)</p></li><li><p>Oversedation/delirium: BDZs and polypharmacy are risk factors</p></li></ul><p>propofol: HoTN in ~25%; propofol infusion syndrome (PRIS) ? espec w/ high (>5 mg/kg/h) & prolonged (>48 h) infusions & concom vasopressors → ↑ AG, cardiac dysfxn, rhabdomyolysis, ↑ triglycerides, & renal failure (Crit Care 2009;13:R169)</p><p>dexmedetomidine: no benefit on vent-free days (JAMA 2016;315:1460 & 2017;317:1321); similar outcomes to propofol when utilized as sole agent (NEJM 2021;384:1424)</p><p>ACUTE RESPIRATORY DISTRESS SYNDROME</p><p>Berlin definition (JAMA 2012;307:2526)</p><ul><li><p>Acute onset within 1 week of clinical insult or worsening respiratory status</p></li><li><p>Bilateral infiltrates without alternative explanation (eg, effusion, atelectasis, nodules)</p></li><li><p>Edema not fully explained by fluid overload or congestive heart failure</p></li><li><p>Hypoxemia: PaO2/FiO2 determined with 5 cm H2O of PEEP</p></li></ul><p>PaO2/FiO2 200–300 = mild ARDS (may be on NPPV), 100–200 = mod, &lt;100 = severe</p><p>Pathophysiology (Lancet 2016;388:2416)</p><ul><li><p>↑ intrapulmonary shunt → hypoxemia (∴ Rx w/ PEEP to prevent derecruitment)</p></li><li><p>↑ increased dead space fraction (see Appendix), predicts ↑ mort (NEJM 2002;346:1281)</p></li><li><p>↓ compliance: VT/(Pplat – PEEP) &lt;50 mL/cm H2O</p></li></ul><p>Pathology</p><ul><li><p>Diffuse alveolar damage (DAD) seen in 40% of autopsies (AJRCCM 2013;187:761)</p></li><li><p>If no clear inciting event and ILD considered as alt dx, consider bx (Chest 2015;148:1073)</p></li></ul><p>Etiologies</p><p>Direct Injury</p><p>Indirect Injury</p><ul><li><p>Pneumonia (~40%)</p></li><li><p>Aspiration (~15%)</p></li><li><p>Near drowning</p></li><li><p>Inhalation injury</p></li><li><p>Lung contusion</p></li></ul><p>*Sepsis (~25%)</p><p>*Shock</p><p>*DIC</p><p>*Pancreatitis</p><p>*Trauma/multiple fractures</p><p>*Transfusion (TRALI)</p><p>Treatment (Lancet 2021;398:622)</p><ul><li><p>Goal is to maintain gas exchange, sustain life, & avoid ventilator-induced lung injury (VILI)</p></li><li><p>In Pts on O2 for COVID-19 PNA, dexamethasone ↓ 28-day mortality (NEJM 2021;384:693)</p></li></ul><p>Mechanisms of VILI</p><p>Ventilator Strategies (see ARDSnet.org)</p><p>Barotrauma/volutrauma: alveolar dist → mech damage</p><p>VT ≤6 mL/kg, Pplat ≤30 cm H2O, tolerate ↑ PaCO2 (but keep pH >7.2), ↓ mortality (NEJM 2000;342:1301)</p><p>Biotrauma → SIRS</p><p>Low VT, open lung strategy w/ high PEEP</p><p>Atelectrauma: repetitive alveoli recruit & decruit</p><p>Titrate PEEP to prevent tidal alveolar collapse</p><p>See below for options</p><p>Hyperoxia: ? injury; worsened V/Q matching</p><p>↑ PEEP rather than FiO2 (keep &lt;0.60)</p><p>O2-induced injury only theoretical in humans</p><p>The 6 Ps</p><ul><li><p>PEEP (see below)</p></li><li><p>Proning: if PaO2/FiO2 &lt;150, prone positioning ≥16 h ↓ mort ~50% (NEJM 2013;368:2159)</p></li><li><p>Paralysis: no benefit routinely (NEJM 2019;380:1997); consider if Pt-vent dyssynchrony</p></li><li><p>Peeing (fluid balance): target CVP 4–6 cm H2O (if nonoliguric & normotensive) → ↑ vent/ICU-free days, but no Δ mortality (NEJM 2006;354:2564); PA catheter unproven (NEJM 2006;354:2213); consider BNP >200 to trigger diuresis (UOP goal 4.5–9 mL/kg/h × 3 h)</p></li><li><p>Pulm vasodilators: inhaled NO or prostacyclins ↑ PaO2/FiO2; no ↓ mort or vent-free days (BMJ 2007;334:779)</p></li><li><p>Perfusion (V-V ECMO): may be useful if refractory (NEJM 2018;378:1965)</p></li></ul><p>PEEP titration methods (best method unclear)</p><ul><li><p>No benefit at given VT if titrated to PaO2 alone (NEJM 2004;351:327; JAMA 2008;299:637)</p></li><li><p>Best PEEP trial: incremental PEEP titration using compliance, O2, hemodynamics</p></li></ul><p>If able to ↑ PEEP w/o ↑ Pplat, suggests “recruitability”</p><p>∴↑ PEEP if → ↑ SaO2 (target ≥88–90%) & Pplat ≤30 cm H2O → ↓ time on vent, better lung mechanics (JAMA 2008;299:646), ? ↓ mortality (JAMA 2010;303:865)</p><ul><li><p>ARDSnet “high” PEEP table for optimal FiO2/PEEP combo for goal SaO2 (ARDSnet.org)</p></li><li><p>Recruitment maneuvers: stepwise preferred over sustained inflation, evidence insufficient to recommend routine use (Resp Care 2015;60:1688); recruitment maneuvers at high pressures ? ↑ mortality (JAMA 2017;318:1335)</p></li><li><p>Esophageal balloon: used to estimate pleural pressure and thereby estimate trans-pulmonary pressure (ie, true airway distending pressure). Adjusting PEEP according to esoph pressure to maintain optimal transpulm. pressure does not ∆ ventilator-free days or mortality, although does ↓ need for advanced rescue Rx (see above) (JAMA 2019;321:846).</p></li><li><p>Driving pressure (ΔP = Pplateau–PEEP): ↓ ΔP a/w ↑ survival; target &lt;15 (NEJM 2015;372:747)</p></li></ul><p>Prognosis (JAMA 2016;315:788)</p><ul><li><p>Mortality ~40% overall in clinical trials; 9–15% resp. causes, 85–91% extrapulm (MODS)</p></li><li><p>Survivors: PFTs ~normal, ↓ DLCO, muscle wasting, weakness persists (NEJM 2003;348:683), ↓ exercise tolerance, ↓ QoL, ↑ psych morbidity (NEJM 2011;364:1293); 44% of previously employed Pts jobless at 12 mos (AJRCCM 2017;196:1012)</p></li></ul><p>SEPSIS AND SHOCK</p><p>Definitions (JAMA 2016;315:801; 2017;317:290 & 301)</p><p>Sepsis</p><p>Life-threatening organ dysfxn (SOFA ≥2) due to infection</p><p>Quick SOFA (qSOFA): ≥2 of the following: RR ≥22, ΔMS, SBP ≤100 mmHg</p><p>Septic shock</p><p>Sepsis-induced circulatory and cellular/metabolic abnormalities severe enough to ↑ mortality; hypotension requiring pressors for MAP ≥65 and lactate >2 despite adequate fluid resuscitation</p><p>Sequential Organ Failure Assessment (SOFA): ↑ points for worsening organ dysfxn: respiration (↓ P:F ratio); coag (↓ plt); liver (↑ bili); CV (↓ MAP or ↑ pressors); CNS (↓ GCS); renal (↑ Cr or ↓ UOP)</p><p>Shock (see “PA Catheter & Tailored Therapy” for subtypes; NEJM 2013;369:1726)</p><ul><li><p>Tissue hypoxia due to ↓ tissue perfusion and hence ↓ tissue O2 delivery and/or ↑ O2 consumption or inadequate O2 utilization</p></li><li><p>Typical signs include HoTN (SBP &lt;90 mmHg or drop in SBP >40 mmHg), tachycardia, oliguria (UOP &lt;0.5 cc/kg/h), Δ mentation, metabolic acidosis ± ↑ lactate</p></li><li><p>Hard to dx as ↑ SVR can maintain SBP, but tissue perfusion poor; shock index (HR/SBP) >0.9 and pulse pressure [(SBP – DBP)/SBP] &lt;25% clues to significant shock</p></li></ul><p>MANAGEMENT (Crit Care Med 2021;49:e1063)</p><p>Fluids</p><ul><li><p>Aggressive IV fluid resuscitation (30 mL/kg) admin in boluses w/in 3 h of presentation</p></li><li><p>Crystalloid as good as colloid for resuscitation (JAMA 2013;310:1809; NEJM 2014;370:1412)</p></li><li><p>No consistently seen benefit of balanced crystalloid (LR, Plasma-Lyte) vs. NS in terms of mortality, organ failure or need for RRT (NEJM 2018;378:829 & 2022:386:815)</p></li><li><p>NaHCO3 may ↓ mortality & need for RRT if AKI & pH &lt;7.2 (Lancet 2018;392:31)</p></li><li><p>Predictors of fluid responsiveness: pulse pressure variation >13% w/ respiration (Chest 2008;133:252); resp. variation in IVC diam, or >10% ↑ in pulse pressure w/ passive leg raise. Static CVP poor surrogate.</p></li><li><p>After early resuscitation, if ALI/ARDS, target CVP 4–6 mmHg because additional fluids may be harmful → ↑ ventilator/ICU days (NEJM 2006;354:2564; Chest 2008;133:252)</p></li></ul><p>Pressors & inotropes (also see “ICU Medications”)</p><ul><li><p>MAP target 65 mmHg as good as 80–85 and ↓ AF (NEJM 2014;370:1583; JAMA 2020;323:938)</p></li><li><p>Norepinephrine: ↓ arrhythmia & mortality c/w dopamine (NEJM 2010;362:779; Crit Care Med 2012;40:725) and ∴ is pressor of choice in septic shock</p></li><li><p>Vasopressin: adding to norepi (vs. using high-dose norepi) ↓ risk of AF & RRT by ~¼ (JAMA 2018;319:1889)</p></li><li><p>If refractory vasoplegia: angiotensin II (Giaprezza), methylene blue, steroids (vide infra)</p></li><li><p>If targets (see below) not reached after adequate fluids and pressors, consider inotropes</p></li></ul><p>Targets</p><p>Antibiotics</p><ul><li><p>Start empiric IV abx as soon as possible after recognition of severe sepsis or septic shock; every hr delay in abx admin a/w 7.6% ↑ in mortality (Crit Care Med 2006;34:1589), abx admin w/in 3 h of presentation in the ED a/w ↓ in-hospital mortality (NEJM 2017;376:2235)</p></li><li><p>If possible, obtain 2 sets of BCx before urgently starting abx (but do not delay abx)</p></li><li><p>Broad gram-positive (incl MRSA) & gram-neg (incl highly resistant) coverage, ± anaerobes</p></li><li><p>Procalcitonin-guided cessation (not initiation) ↓ mortality (Crit Care Med 2018;46:684)</p></li><li><p>Empiric micafungin in critically ill Pts w/ Candida colonization & sepsis of unknown etiology ↓ invasive fungal infxns & tended ↑ invasive fungal infxn-free survival, espec. in Pts w/ 1,3-b-D-glucan >80 (JAMA 2016;316:1555)</p></li></ul><p>TOXICOLOGY</p><p>Drug/Toxin</p><p>Signs/Sx and Diagnostics</p><p>Management Options</p><p>Acetaminophen</p><p>Salicylates</p><p>Opioids</p><p>Benzodiazepines</p><p>Calcium channel blockers</p><p>Beta blockers</p><p>Digoxin</p><p>Tricyclic antidepressants</p><p>Lithium</p><p>Ethylene glycol</p><p>Methanol (NEJM 2018;378:270)</p><p>CNS depression, blindness</p><p>↑ AG & OG met. acidosis</p><p>Ethanol or fomepizole, NaHCO3</p><p>Consider hemodialysis</p><p>Isopropanol</p><p>CNS depression, gastritis</p><p>Supportive care</p><p>Carbon monoxide</p><p>HA, dizziness, nausea, ΔMS</p><p>carboxyHb level, CO-oximetry</p><p>100% normobaric oxygen, hyperbaric O2 in severe cases</p><p>Organopho- sphate</p><p>Salivation, lacrimation, diaphoresis, miosis, emesis, bronchospasm, ΔMS</p><p>Endotracheal intubation for respiratory failure, atropine, pralidoxime, benzodiazepines</p><p>Cyanide</p><p>LUNG TRANSPLANT</p><p>Overview</p><ul><li><p>Indications: end stage, progressive decline despite max medical Rx, &lt;2-y life expectancy; COPD, ILD (IPF), pulmonary HTN, cystic fibrosis, alpha 1-antitrypsin</p></li><li><p>Contraindic: age >70, uncontrolled/unRx’d infxn, malig in prior 5 yrs, severe non-pulm dis., BMI ≥35 or &lt;16, active smoking, EtOH/drug depend., med nonadherence, psychosocial</p></li></ul><p>Posttransplant care</p><ul><li><p>Immunosuppression: no single best regimen. Calcineurin inhibitor (tacro >cyclosporine, ↓ incidence of graft failure (JHLT 2021;40:S165) + steroids + MMF or AZA</p></li><li><p>Monitoring: clinic visits, serial PFTs, chest X-ray, bronchoscopy w/ transbronchial biopsy</p></li></ul><p>Complications</p><ul><li><p>Primary graft dysfunction (PGD): acute lung injury following txp; assoc w/ early mortality</p></li><li><p>Anastomotic: vascular (stenosis, thrombosis) and airway (infection, necrosis, dehiscence, granulation tissue, tracheobronchomalacia, stenosis, fistula)</p></li><li><p>Acute rejection: ↓ lung fxn, cough, SOB, fever; Dx w/ trans-bronch bx; Rx immunosupp</p></li><li><p>Chronic rejection: bronchiolitis obliterans w/ obstruction; Dx w/ PFTs, trans-bronch bx; Rx limited (azithromycin, montelukast, Δ immunosuppressives)</p></li><li><p>Infection: ↑ bacterial, fungal, viral pneumonia, systemic infections, CMV, OI</p></li><li><p>Malignancy: 2× ↑ risk overall. 5.5× ↑ risk lung cancer. PTLD (assoc w/ EBV) common.</p></li><li><p>Misc: GVHD, CKD, DM, CAD, CHF, stroke, encephalopathy, drug toxicity</p></li></ul><p>ESOPHAGEAL AND GASTRIC DISORDERS</p><p>Dysphagia</p><ul><li><p>Oropharyngeal: inability to propel food from mouth through UES into esophagus</p></li><li><p>Esophageal: difficulty swallowing & passing food from esophagus into stomach</p></li></ul><p>Figure 3-1 Etiologies of and approach to dysphagia (NCP Gastrohep 2008;5:393; Neurogastro 2012;24:57)</p><p>Structural dysphagia (solids >liquids; JAMA 2015;313:18; Gastro 2018;155:1022)</p><ul><li>Oropharyngeal</li></ul><p>Zenker’s divertic. (pharyngeal pouch): in elderly, a/w aspir., dx w/ video fluoro, Rx endo/surg</p><p>Malignancy; proximal strictures/rings/webs; infection; radiation injury; goiter; osteophytes</p><ul><li>Esophageal</li></ul><p>Rings (intermittent dysphagia, concentric obstructing tissue, Schatzki ring): near GE jxn, a/w food impaction, linked to GERD; Rx w/ PPI, dilation</p><p>Webs: thin, partially occlusive structure, proximal, a/w Fe defic. (Plummer-Vinson synd.)</p><p>Peptic or XRT strictures, foreign body, tumor, vascular rings (dysphagia lusoria), compression from dilated left atrium compression</p><p>Infxn esophagitis: odynophagia >dysphagia; often immunosupp w/ Candida, HSV, CMV</p><p>Pill esophagitis: odynophagia >dysphagia; NSAID, KCl, bisphosp., doxy & tetracycline</p><p>Eosinophilic esophagitis (JAMA 2021;326:1310): often young/middle-aged ♂. Dx: >15 eos/hpf on bx, esoph dysfxn (ie, dysphagia, food impaction). Rx: 1st line is PPI (½ respond); alternative (or if fail PPI) is 3Ds: 1st elimination Diet (Ø milk, soy, eggs, wheat, nuts, fish); if no Δ, Drugs (swallow inh steroids); if ongoing sx & stricturing, Dilation (Gastro 2020;158:1776).</p><p>Neuromuscular dysphagia (solids & liquids; Neurogastero Motil 2021;33:e14058)</p><ul><li><p>Caused by aberrant motility or innervation of oropharynx/esophagus</p></li><li><p>Oropharyngeal: consider CNS disorders (eg, stroke, ALS, myopathies, CNS tumors)</p></li><li><p>Esophageal: motility disorder w/ dysphagia, chest pain, GERD; dx: conventional or high-res manometry w/ esophageal pressure topography. Chicago classification v4.0:</p></li></ul><ol><li><p>Disorders of EGJ Outflow: Isolated EGJ outflow obstruction or achalasia. Achalasia: simult. ↓ amp contractions & ↓ LES relaxation; barium swallow w/ dilated esophagus & distal “bird’s beak” narrowing; mostly idiopathic, although can be a/w Chagas; Rx: pneumatic dilation as effective as Heller myotomy (local expertise dependent) (Gut 2016;65:732); peroral endoscopic myotomy; CCB/nitrates/PDEi; botox if Ø surg cand.</p></li><li><p>Disorders of Peristalsis: Absent contractility (failed peristalsis); distal esophageal spasm (uncord. peristalsis w/ simult. contractions); hypercontractile esoph (high amp contract.; Rx w/PPI, nitrates/CCB/PDEi, TCA); ineffective esophageal motility (↓ amp of distal esoph contractions; seen in scleroderma, DM, hypothyroid.; Rx w/ underlying disorder & w/ PPI)</p></li></ol><a href=#gastroesophageal-reflux-disease-gerd><h2 id=gastroesophageal-reflux-disease-gerd><span class=hanchor arialabel=Anchor># </span>GASTROESOPHAGEAL REFLUX DISEASE (GERD)</h2></a><p>Pathophysiology (JAMA 2020;324:2536)</p><ul><li><p>↑ acid exposure in esophagus, caused by ↑ transient LES relaxations. Worsened by ↑ intraabd pressure (eg, obesity, pregnancy), ↓ esophagogastric motility, hiatal hernia. Rarely caused by ↑ secretory states (eg, Zollinger-Ellison).</p></li><li><p>Precipitants: supine, fatty foods, caffeine, alcohol, cigarettes, CCB, pregnancy, obesity</p></li></ul><p>Clinical manifestations</p><ul><li><p>Esophageal: heartburn, atypical chest pain, regurgitation, sour taste, dysphagia</p></li><li><p>Extraesophageal: dry cough, asthma (often poorly controlled), laryngitis, dental erosions</p></li></ul><p>Diagnosis (Annals 2015;163:ITC1; Nat Rev Gastro Hepatol 2016;13:501)</p><ul><li><p>Clinical diagnosis based on sx and response to empiric trial of PPI (“PPI test”)</p></li><li><p>EGD if: Ø response to PPI or alarm features: dysphagia, vomiting, ↓ wt, anemia, age >60</p></li><li><p>If dx uncertain & EGD nl → esoph manometry w/ 24-h pH monitoring ± impedance to dx:</p></li></ul><p>“Nonerosive reflux disease”: no erosion, ulceration or Barrett’s; ½ abnl pH. Unpredictable response to PPI. Most will not progress to erosive esophagitis or Barrett’s.</p><p>“Reflux hypersensitivity”: nl acid exposure on pH/impedance w/ symptom–reflux assoc.</p><p>“Functional heartburn”: nl acid exposure on pH/impedance w/o symptom–reflux assoc.</p><p>Treatment (World J Gastrointest Endosc 2018;10:175; Am J Gastro 2022;117:27)</p><ul><li><p>Lifestyle: avoid precipitants, lose weight, no eating 2 hrs before bed, exercise, Ø tobacco</p></li><li><p>Medical: start low-dose PPI, uptitrate up to 40 mg bid; H2 blockers for intermittent sx</p></li><li><p>Refractory (max dose ≥8 wks): confirm w/ pH testing on or off PPI, consider hernia repair</p></li></ul><p>If acidic or sx correlate w/ reflux episodes: surgical fundoplication (emerging Rx: LES sphincter augmentation w/ radiofrequency, implantable magnetic or electrical devices)</p><p>If nl pH or no sx correlation = “fxnal dyspepsia” (Gastro 2020;158:2286); Rx w/ TCA, SSRI</p><p>Complications (Gastro 2020;158:760)</p><ul><li><p>Reflux esophagitis (erosions/ulcers above GE jxn), strictures (caused by chronic inflamm)</p></li><li><p>Barrett’s esoph. (BE): metaplastic columnar mucosa above GE jxn replaces squam epithel.</p></li></ul><p>Screen if chronic (>5 y) and/or frequent GERD (≥1/wk) in ♂ w/ ≥2 risk factor for Barrett’s/esophageal adeno: >50 y, white, hiatal hernia, central adiposity, smoking, FHx of Barrett’s/esophageal adeno. In ♀, consider only if multiple RFs. 0.1–0.3%/y risk of esoph adenocarcinoma, ↑ if ↑ dysplasia (Am J Gastro 2016;111:30).</p><p>Mgmt: PPI. W/o dysplasia: surveillance EGD q3–5y. Low-grade dysplasia: EGD q12mo; possible endoscopic eradication. High-grade dysplasia: endoscopic eradication; consider chemoprophylaxis w/ high-dose PPI & ASA (Lancet 2018;392:400).</p><p>PEPTIC ULCER DISEASE (PUD)</p><p>Definition & etiologies (BMJ 2019;367:5495)</p><ul><li><p>Ulcers (break in mucosal lining >5 mm) & erosions (&lt;5 mm) in stomach and duodenum</p></li><li><p>Principal risk factors: H. pylori infection >ASA/NSAID use</p></li><li><p>H. pylori infection: causes ~80% of duodenal ulcers (DU) & ~30–40% of gastric ulcers (GU). ~50% of world colonized w/ H. pylori, but only 5–10% will develop PUD.</p></li><li><p>ASA/NSAIDs: damage to mucosa caused by ↓ prostaglandin synthesis. Cause majority of non–H. pylori-related DU & GU. Regular use a/w 5–6× ↑ odds of GIB.</p></li><li><p>Other: smoking, stress, excessive EtOH, gastric cancer/lymphoma, Crohn’s, viral infxn (eg, CMV/HSV in immunosupp), bisphosphonates, steroids (in combo w/ NSAIDs, but not risk factor alone); rarely gastrinoma (Zollinger-Ellison synd.), mastocytosis, idiopathic</p></li><li><p>Stress ulcer: risk factors = ICU & coagulopathic, mech vent, h/o GIB, steroid use; Rx w/ PPI</p></li></ul><p>Clinical manifestations</p><ul><li><p>Epigastric gnawing abdominal pain: relieved with food (DU) or worsened by food (GU)</p></li><li><p>Complic.: UGIB, perf. & penetration, gastric outlet obstruction (due to edema & dysmotility)</p></li></ul><p>Diagnostic studies</p><ul><li><p>Testing for H. pylori: stool Ag, urea breath testing (UBT) or EGD + rapid urease test (RUT) False ⊖ Ag, UBT, RUT if on abx, bismuth, PPI; ∴ stop prior to testing if possible Serology: ↓ utility, useful only to exclude infection in lower prevalence areas</p></li><li><p>EGD (definitive dx): if fail empiric Rx or alarm features (see “GERD”); bx GU to r/o malig & H. pylori; repeat EGD in 6–12 wk if >2 cm, malig features, risk factors for gastric cancer (ie, ⊕ FHx, ⊕ H. pylori, atrophic gastritis, metaplasia on bx, >50 y), or sx persist</p></li></ul><p>Treatment (Lancet 2016;388:2355; Gastro 2016;151:51; Gut 2017;66:6; AJG 2017;112:212)</p><ul><li>If H. pylori ⊕ → eradicate (“test and treat”); if ⊖ → gastric acid suppression w/ PPI</li></ul><p>1st line: Quad. Rx: 14d x [MNZ + TCN + bismuth + PPI] or [MNZ + amox + clarith + PPI]</p><p>Besides PUD, test & Rx if: gastric MALT lymphoma, s/p resection for early gastric ca, FHx gastric ca, unexplained iron def. anemia, ITP, uninvestigated dyspepsia in Pt &lt;60 y, or when initiating long-term NSAIDs</p><ul><li><p>“Test-of-cure”: 4 wk after Rx, off PPI x 1–2 wk. Use stool Ag, EGD + RUT, or UBT.</p></li><li><p>Lifestyle changes: d/c smoking and probably EtOH; diet does not seem to play a role</p></li><li><p>Surgery: if refractory to med Rx (1st r/o NSAID use) or for complic. (see above)</p></li></ul><p>GI prophylaxis if taking ASA/NSAID (Am J Gastro 2009;104:728)</p><ul><li><p>PPI if h/o PUD/UGIB and either (a) on P2Y12 inhib or anticoag, or (b) ≥2 of the following: >60 y, steroids or dyspepsia. Low bleeding risk Pts unlikely to benefit (Gastro 2019;157:403).</p></li><li><p>Consider Δ non-selective NSAID to selective COX-2 inhibitor (↓ PUD & UGIB but ↑ CV events), if low CV risk & not on ASA</p></li></ul><p>GASTROINTESTINAL BLEEDING</p><p>Definition</p><ul><li><p>Intraluminal blood loss anywhere from the oropharynx to the anus</p></li><li><p>Classification: upper = above the ligament of Treitz; lower = below the ligament of Treitz</p></li><li><p>“Severe” GIB: defined as having associated shock, orthostatic hypotension, ↓ Hct by 6% (or ↓ Hb by 2 g/dL), or requiring transfusion ≥2U PRBCs. Requires hospitalization.</p></li></ul><p>Clinical manifestations</p><ul><li><p>Hematemesis = blood in vomitus (UGIB)</p></li><li><p>Coffee-ground emesis = emesis of blood exposed to gastric acid (UGIB)</p></li><li><p>Melena = black, tarry stools from digested blood (usually UGIB, but can be SB or R colon)</p></li><li><p>Hematochezia = bloody or maroon-colored stools (LGIB or rapid UGIB)</p></li></ul><p>Initial management (Am J Gastro 2021;116:899)</p><ul><li><p>Assess severity: VS including orthostatic Δs, JVP. Tachycardia (can be masked by βB use) suggests 10% volume loss, orthostatic hypotension 20% loss, shock >30% loss. Scoring predicts rebleeding & mortality: AIMS65, ABC Score & Glasgow-Blatchford.</p></li><li><p>History: prior GIB, tempo of current bleed, specific bleeding manifestations (see above), other GI s/s (eg, abd pain, Δ in bowel habits, weight loss, N/V), ASA/NSAID or EtOH use, anticoag/antiplt drugs, h/o or risk factors for cirrhosis, radiation, prior GI or aortic surgery</p></li><li><p>Physical exam: localizable abd tenderness, peritoneal signs, masses, LAN, prior surgery, signs of liver disease (hepatosplenomegaly, ascites, jaundice, telangiectasias), rectal exam: masses, hemorrhoids, anal fissures, stool appearance, color</p></li><li><p>Resuscitation: placement of 2 large-bore (18-gauge or larger) intravenous lines. Volume replacement: NS or LR to achieve normal VS, UOP, & mental status.</p></li><li><p>Lab studies: Hct (may be normal in first 24 h of acute GIB before equilibration) 2–3% → 500 mL blood loss; low MCV → Fe deficient and chronic blood loss; plt, PT/INR,</p></li></ul><p>PTT; BUN/Cr (ratio >36 in UGIB b/c GI resorption of blood ± prerenal azotemia); LFTs</p><ul><li><p>Transfuse: type & cross; use O-neg if emerg; for UGIB (esp. w/ portal HTN) transfuse w/ more restrictive Hb goal (eg, >7 g/dL or >8 g/dL if CAD) (JAMA 2016;316:2025)</p></li><li><p>Reverse coagulopathy: consider FFP to normalize INR (however caution in ESLD where INR does not correlate with bleeding risk); plts >50k, ddAVP if uremic, consider reversal agents if on anticoagulants (qv)</p></li><li><p>Triage: alert endoscopist. Consider ICU if unstable VS or poor end organ perfusion.</p></li></ul><p>Intubation for: emergent EGD, ongoing hematemesis, shock, poor resp status, Δ MS</p><p>OutPt management if SBP ≥110, HR &lt;100, Hb ≥13 (♂) or ≥12 (♀), BUN &lt;18, Ø melena, syncope, heart failure, liver disease (Clin Gastro Hepatol 2015;13:115)</p><p>Diagnostic studies (JACR 2021;18:S139)</p><ul><li><p>UGIB: EGD w/in 24 h (NEJM 2020;382:1299). If severe bleed, ↑ dx/Rx yield if erythro 250 mg IV given 30 min prior to endoscopy to clear stomach contents.</p></li><li><p>LGIB: colonoscopy (identifies cause in >70%); early colo (w/in 24 h) unlikely to improve outcome vs. late (24-96 h) (Gastro 2020;158:168). If hematochezia a/w orthostasis, concern for brisk UGIB → exclude UGIB w/ EGD first. Push enteroscopy, anoscopy, capsule endoscopy in combo w/ urgent colo results in dx >95% of cases (GI Endo 2015;81:889).</p></li><li><p>Imaging: if too unstable for endo or recurrent bleeding, consider IR embolization or surgery</p></li></ul><p>tagged RBC scan: can identify general luminal location if bleeding rate ≥0.04 mL/min</p><p>CT angiography: faster to obtain than RBC scan, detects bleeding ≥0.3 mL/min</p><p>arteriography: can localize exact vessel if bleeding rates ≥0.5 mL/min, allows for IR Rx</p><ul><li>Emergent exploratory laparotomy (last resort) if no localization and life-threatening bleed</li></ul><p>Etiology UGIB</p><p>Comment & Treatment (GI Endosc Clin N Am 2015;25:415)</p><p>PUD (20–60%; duodenal>gastric)</p><p>(Am J Gastro 2021;116:899)</p><p>See “PUD”</p><p>Treatment: PPI: 40 mg PO or IV BID</p><p>Endoscopic therapy: epi inj + bipolar cautery or hemoclip. Bx for H. pylori and treat if ⊕.</p><p>High-risk (for rebleeding) ulcer: arterial spurting, adherent clot, visible vessel. Endo Rx, IV PPI × 72 h post EGD, then Δ to high-dose oral PPI. If fail, arteriography w/ embolization; surgery (last resort).</p><p>Intermediate-risk ulcer: oozing, in o/w stable Pt. Endo Rx, can Δ to oral PPI after EGD and observe 24–48 h.</p><p>Low-risk ulcer: clean-based or flat. Oral PPI & discharge.</p><p>Hold anticoag & antiplatelet Rx until hemostasis; can resume after hemostasis & PPI on board (Endoscopy 2015;47:a1)</p><p>Erosive gastropathy</p><p>(4–30%)</p><p>Precipitants: ASA/NSAID, EtOH, cocaine, gut ischemia, XRT</p><p>Stress-related mucosal injury in ICU Pts. Risk factors include severe coagulopathy, mech vent >48 h, high-dose glucocorticoids</p><p>Treatment: high-dose PPI</p><p>Esophagitis (15%)</p><p>Rx offending cause + high-dose PPI; repeat EGD to r/o Barrett’s.</p><p>Esophageal or gastric varices (4–20%)</p><p>(Clin Gastro Hepatol 2015;13:2109; J Gastro Hepatol 2016;31:1519; Hep 2017;65:310)</p><p>See “Cirrhosis”</p><p>2° to portal HTN. If isolated gastric → r/o splenic vein thrombosis.</p><p>Pharmacologic</p><p>Start octreotide pending EGD if suspect varices: Rx for 2–5 d</p><p>Abx: 20% cirrhotics p/w GIB have infxn, & ~50% develop infxn during hospitalization; Ppx w/ IV CTX, cipro, or levoflox × 7 d</p><p>Nonpharmacologic</p><p>Esophageal varices: endoscopic band ligation (>90% success). Covered esophageal stent placement or balloon tamponade if refractory as bridge to TIPS (consider early espec. if Child-Pugh C).</p><p>Gastric varices: arteriography w/ coiling, or if available, endoscopic injection of cyanoacrylate (glue). If refractory: TIPS or balloon-retrograde transvenous obliteration (BRTO).</p><p>Portal HTN gastropathy</p><p>↑ portal venous pressure → ectatic vessels, hyperemia in gastric antrum. Rx: reduce portal HTN (octreotide), βB, TIPS.</p><p>Vascular (5–10%)</p><p>Angioectasia AVMs, HHT (see below)</p><p>AVMs congenital. Angioectasia (ectatic submucosal vessels) a/w ↑ age, CKD, cirrhosis, CTD, severe CV dis. Heyde syndrome: GIB due to angioectasias + aortic stenosis. Rx: endoscopic Rx.</p><p>Dieulafoy’s lesion</p><p>Large (1–3 mm) submucosal artery protruding through fundal mucosa → sudden, massive UGIB. Difficult to identify. Endo Rx.</p><p>Gastric antral vasc. ectasia (GAVE)</p><p>“Watermelon stomach”; ectatic gastric vessels, often a/w cirrhosis, CTD, typically older ♂. Rx w/ EGD w/ thermal hemostasis, repeat q4–8wk to eradicate lesions. TIPS does not improve outcomes.</p><p>Aortoenteric fistula</p><p>AAA or aortic graft erodes into 3rd portion of duodenum. P/w “herald bleed.” If low suspicion → endoscopy; if high → CT angiography.</p><p>Malignancy (5%)</p><p>Endoscopic hemostasis of mass temporizing measure till cancer Rx</p><p>Mallory-Weiss tear (5–10%)</p><p>GE jxn lacerations due to vomiting → ↑ intraabd pressure & shearing Often self-resolve; Rx→ antiemetics, PPI, endoscopic therapy</p><p>Cameron’s lesions</p><p>Linear erosions in hiatal hernia due to mech trauma of diaphragm</p><p>Post-sphincter- otomy bleeding</p><p>Occurs in ~2% of ERCP w/ sphincterotomy; ↑ risk w/ more complic. procedure. Bleeding into duodenum. Rx w/ endo hemostasis.</p><p>Etiology LGIB</p><p>Comment & Treatment (NEJM 2017;376:1054)</p><p>Diverticular bleed (30%)</p><p>Pathophysiology: Intimal thickening and medial thinning of vasa recta as they course over dome of diverticulum → weakening of vascular wall → arterial rupture. Diverticula more common in left colon; but bleeding diverticula more often in right colon.</p><p>Clinical: older, ASA/NSAIDs, usually painless hematochezia ± abd cramping</p><p>Treatment: Usually stops spontaneously (~75%); ~20% recur. Can perform endoscopic hemostasis. Surgery (partial colectomy) last resort.</p><p>Polyp/Tumor (20%)</p><p>Typically slow ooze, p/w fatigue, weight loss, iron deficiency, anemia</p><p>Colitis (20%)</p><p>Infectious (see “Acute Diarrhea”), IBD, ischemic colitis, XRT</p><p>Anorectal disorders (20%)</p><p>Internal, external hemorrhoids; anal fissures, rectal ulcers, rectal varices (Rx by ↓ portal venous pressure in cirrhosis), XRT</p><p>Vascular (&lt;10%)</p><p>Angioectasia & AVMs. Hereditary hemorrhagic telangiectasia (Weber-Osler-Rendu): diffuse AVMs throughout GI mucosa (also involve lips, oral mucosa, fingertips).</p><p>Meckel’s diverticulum</p><p>Congenital intestinal pouch due to incomplete obliteration of vitelline duct. 2% of pop, w/in 2′ of IC valve, 2″ long, ♂:♀ 2:1, can present as obscure GIB in adults. Dx w/ 99mTc-pertechnetate scintigraphy. Rx w/ angioembo, surgical resection.</p><p>Obscure GIB (Am J Gastro 2015;110:1265; Gastro 2017;152:497)</p><ul><li><p>Definition: continued bleeding (melena, hematochezia) despite ⊖ EGD & colo; 5% of GIB</p></li><li><p>Etiologies: Dieulafoy’s lesion, GAVE, small bowel angiodysplasia, ulcer or cancer, Crohn’s disease, aortoenteric fistula, Meckel’s diverticulum, hemobilia</p></li><li><p>Diagnosis: repeat EGD w/ push enteroscopy/colonoscopy when bleeding is active</p></li></ul><p>If ⊖, video capsule to evaluate small intestine (contraindic. if stricture) (GIE 2015;81:889)</p><p>If still ⊖, consider 99mTc-pertechnetate scan (“Meckel’s scan”), enteroscopy (single-balloon, double-balloon, or spiral), tagged RBC scan and arteriography</p><p>DIARRHEA</p><p>ACUTE DIARRHEA (&lt;4 weeks’ duration)</p><p>Acute Infectious Etiologies (Am J Gastro 2016;111:602; JAMA 2019; 321:891)</p><p>NONINFLAMMATORY</p><p>Predom. disruption small intestine absorp. & secretion. Voluminous diarrhea, N/V. ⊖ Fecal WBC & FOB.</p><p>Preformed toxin</p><p>“Food poisoning,” &lt;24 h dur. S. aureus (meats & dairy),</p><p>B. cereus (fried rice), C. perfringens (rewarmed meats).</p><p>Viral (Lancet 2018; 392:175)</p><p>Rotavirus</p><p>Outbreak person to person (PTP), daycare; lasts 4–8 d.</p><p>Norovirus</p><p>~50% of all diarrhea. Winter outbreaks; PTP & food/water; no immunity. Lasts 1–3 d. Vomiting prominent.</p><p>Bacterial</p><p>E. coli (toxigenic)</p><blockquote><p>50% of traveler’s diarrhea; cholera-like toxin; &lt;7 d.</p></blockquote><p>Vibrio cholerae</p><p>Contam H2O, shellfish; “rice water” stools w/ dehydration</p><p>Parasitic</p><p>(± malab for mos after Rx)</p><p>Giardia</p><p>Streams/outdoor sports, travel, outbreaks. Bloating.</p><p>Acute (profuse, watery) → chronic (greasy, malodorous).</p><p>Cryptosporidia</p><p>In soil; water-borne outbreak; usually self-limited, can → chronic infxn if immunosupp. Abd pain (80%), fever (40%).</p><p>Cyclospora</p><p>Contaminated produce, intl travel (Latin America)</p><p>INFLAMMATORY</p><p>Predom. colonic invasion. Small-vol diarrhea. LLQ cramps, tenesmus, fever, typically ⊕ fecal WBC or FOB.</p><p>Bacterial</p><p>Campylobacter</p><p>Undercooked poultry, unpasteurized milk; carried by -puppies & kittens. Prodrome w/ abd pain, “pseudoappendicitis”; c/b GBS, reactive arthritis.</p><p>Salmonella</p><p>(nontyphoidal)</p><p>Eggs, poultry, milk, hamsters. Bacteremia in 5–10%. 10–33% of bacteremic Pts >50 y may develop aortitis.</p><p>Shigella</p><p>Abrupt onset; no N/V; gross blood & pus in stool; ↑↑ WBC</p><p>E. coli (O157:H7 & inv/hemorrhagic</p><p>non-O157:H7)</p><p>Undercooked beef, unpasteurized milk, raw produce; PTP.</p><p>O157 & non-O157 sp. (40%) produce Shiga toxin → HUS</p><p>(typically in children). Gross blood in stool.</p><p>C. difficile</p><p>Vide infra</p><p>Vibrio parahaem.</p><p>Undercooked seafood</p><p>Salmonella typhi</p><p>Travel to Asia, Africa, South America. Systemic toxicity, relative bradycardia, rose spot rash, ileus → ”pea-soup” diarrhea, bacteremia.</p><p>Other</p><p>Yersinia: undercooked pork; unpasteurized milk, abd pain → ”pseudoappendicitis” (aka mesenteric adenitis)</p><p>Aeromonas, Plesiomonas, Listeria (meats & cheeses)</p><p>Parasitic</p><p>E. histolytica</p><p>Contaminated food/water, travel (rare in U.S.); liver abscess</p><p>Viral</p><p>CMV</p><p>Immunosuppressed; dx by shell vial cx of colon bx</p><p>Evaluation (NEJM 2014;370:1532; Digestion 2017;95:293; PLOS One 2017;12:11)</p><ul><li><p>Ddx: hyperthyroid, adrenal insufficiency, meds (abx, antacids, immune checkpt inhibitors), appendicitis, diverticulitis, radiation, 1st presentation of bowel disorder (eg, IBD, celiac)</p></li><li><p>History: stool freq, blood, abd pain, duration of sxs [~1 wk for viral & bacterial (except C. diff), >1 wk for parasitic], travel, food, recent abx, immunocompromise</p></li><li><p>PEx: vol depletion (VS, UOP, axillae, skin turgor, MS), fever, abd tenderness, ileus, rash</p></li><li><p>Laboratory: calprotectin, stool cx, BCx, lytes, C. diff (if recent hosp/abx), stool O&P (if >10 d, travel to endemic area, exposure to unpurified H2O, community outbreak, daycare, HIV ⊕ or MSM); ± stool ELISAs (viruses, Crypto, Giardia), serologies (E. histolytica); PCR available (but high ⊕ rate & unclear if true vs. colonized; consider if immunocompromised)</p></li><li><p>Imaging/endoscopy: consider if warning signs (WS) of fever, severe abd pain, blood or pus in stool, >6 stools/d, severe dehydration, immunosupp, elderly, duration >7 d, hosp-acquired. CT/KUB if ? toxic megacolon; sig/colo if immunosupp or cx ⊖.</p></li></ul><p>Treatment (Am J Gastro 2016;111:602; Clin Infect Dis 2017;65:e45)</p><ul><li><p>If no WS, nl PO intake → supportive: hydrate, loperamide, bismuth subsalicylate (Ø antichol)</p></li><li><p>If mod. dehydration: 50–200 mL/kg/d of oral solution or Gatorade, etc. If severe: IV fluids.</p></li><li><p>If suspect traveler’s diarrhea → azithro 1 g x 1 d (due to FQ resistance in Asia), rifaximin, or rifamycin; if suspect protozoal → flagyl or nitazoxanide</p></li><li><p>Empiric abx for non–C. diff inflammatory diarrhea reasonable for severe disease (fever, >6 BMs/d, hospitalization, bloody or mucoid stools or high-risk Pt [> 70 yrs, immunosupp]: azithro 1 g x 1 d (preferred if fever or dysentery) or FQ × 3–5 d (↑ resistance)</p></li><li><p>Avoid abx if suspect E. coli O157:H7 (exposure hx, gross blood) as may ↑ risk of HUS</p></li></ul><p>CLOSTRIDIOIDES DIFFICILE INFECTION (CDI)</p><p>Pathogenesis & epidemiology (NEJM 2015;372:825)</p><ul><li><p>Ingestion of C. diff spores → colonization when colonic flora Δ’d by abx or chemo → release of toxin A/B → colonic mucosal necrosis & inflammation → pseudomembranes</p></li><li><p>Most frequently reported nosocomial infxn; community-acquired w/o abx ~⅓of new cases. A/w any abx during or up to 10 wks post Rx (esp. β-lactams, clinda, FQ).</p></li><li><p>Elderly, immunocompromised, and IBD Pts can develop CDI w/o recent abx exposure</p></li></ul><p>Clinical manifestations (a spectrum of disease)</p><ul><li><p>Asx colonization: &lt;3% healthy adults; ~20% in hospitalized patients on antibiotics</p></li><li><p>Acute watery diarrhea (>3 stool/d), occ bloody ± mucus, lower abd pain, fever, ↑↑↑ WBC</p></li><li><p>Pseudomembranous colitis: above sx + pseudomembranes + bowel wall thickening</p></li><li><p>Fulminant colitis (2–3%): toxic megacolon (colonic atony/absence of BMs, colon dilatation ≥6 cm on KUB, systemic toxicity) and/or bowel perforation</p></li></ul><p>Diagnosis (Ann Intern Med 2018;169:49)</p><ul><li><p>Only test if symptomatic (diarrhea, s/s of colitis); test liquid stool (unless concern for ileus)</p></li><li><p>Stool toxin immunoassay (high Sp) + glutamate dehydrogenase (GDH) (high Se)</p></li><li><p>Stool PCR: has ↑ Se, but ⊕ if colonized in absence of active infxn; should not necessarily Rx if ⊕ PCR w/ neg toxin assay (JAMA IM 2015;175;1792)</p></li><li><p>Obtain CT abdomen/pelvis if suspect complication (toxic megacolon). Consider flex sig if dx uncertain and/or evidence of no improvement on standard Rx.</p></li></ul><p>Initial treatment (CID 2021;73:5; Am J Gastro 2021;116:1124)</p><ul><li><p>If possible, d/c abx ASAP; stop antimotility agents & cholestyramine if using (binds vanco)</p></li><li><p>Fidaxomicin is now preferred over vancomycin regardless of severity; may be limited by $</p></li><li><p>Mild-mod: fidaxomicin 200 mg BID (↓ recurrence rate) or vanco 125 mg PO q6h × 10 d</p></li><li><p>Severe (any of the following: >12 BM/d, Temp >103°F, WBC >15, HoTN, ICU care required, ileus): as above; could consider PO+PR vanco</p></li><li><p>Fulminant disease: vanco 500 mg PO qid + MNZ 500 mg IV q8h; consider FMT</p></li><li><p>If worsening (ileus, ↑ WBC, ↑ lactate, shock, toxic megacolon, peritonitis): abd CT & urgent surgical consult - subtotal colectomy, diverting loop ileostomy or colonic lavage</p></li><li><p>If need to cont abx, cont C. diff. Rx for ≥7 d post-abx cessation (Am J Gastro 2016;111:1834)</p></li><li><p>Stool carriage 3–6 wk postcessation; retesting for C. diff of limited utility during this time</p></li></ul><p>Recurrent infection (15–30% risk after d/c of abx, most w/in 2 wk of stopping abx)</p><ul><li><p>1st recurrence: fidaxomicin 200 mg PO bid × 10 d or vanco 125 mg PO q6h × 10–14 d. Consider adding bezlotoxumab 10 mg/kg IV × 1 during abx Rx (mAb that binds toxin B) as ↓ recurrence; caution in CHF (NEJM 2017;376:305).</p></li><li><p>Subsequent recurrences: fidaxomicin or vanco PO pulse → taper. Consult ID. Fecal microbial transplant (JAMA 2017;318:1985) recommended after 3 CDI.</p></li><li><p>Prevention: vanco 125 mg PO QD ↓ risk of recurrence (CID 2016;65:651); consider for Pts needing abx w/ h/o severe or recurrent CDI. Avoid acid suppression/abx as able.</p></li></ul><p>CHRONIC DIARRHEA (>4 wk)</p><p>General evaluation (JAMA 2016;315:2712; Gastro 2019;157:3)</p><ul><li><p>Clinically can be classified as watery, fatty, inflammatory</p></li><li><p>Additional hx: timing (freq, relation to meals; nocturnal diarrhea a/w organic causes like IBD rather than IBS), abd pain, wt loss, prior surg, chemo/XRT, diet (incl caffeine or poorly absorbed carbs/sugars), infectious sxs, immunocompromise, travel, laxative use, stress</p></li><li><p>Hx offending meds: PPI, colchicine, abx, H2RA, SSRIs, ARBs, NSAIDs, chemo, caffeine</p></li><li><p>PEx: gen appearance (BMI), signs of systemic disease, surgical scars, rectal tone/DRE</p></li><li><p>Lab testing: CBC, metabolic profile, alb, TSH, Fe, fecal calpro; see under each category</p></li><li><p>Imaging/endoscopy: colonoscopy for chronic diarrhea of unknown cause. Abd CT/MRI usually warranted if systemic problem suspected.</p></li></ul><p>Osmotic (watery; ⊖ fecal fat, ↑ osmotic gap, ↓ diarrhea w/ fasting)</p><ul><li><p>Caused by ingestion of poorly absorbed cations/anions (Mg, sulfate, phos; found in laxatives) or poorly absorbed carbs (eg, mannitol, sorbitol [found in chewing gum]) or lactose if lactose intolerant. Diarrhea resolves w/ cessation of offending substance.</p></li><li><p>Dx: ↑ stool osmotic gap (see Figure); stool pH &lt;6 if unabsorbed carbohydrates</p></li><li><p>Lactose intolerance: can be acquired after gastroenteritis, med illness, GI surg. Clin: bloating, flatulence, discomfort, diarrhea. Dx: H+ breath test or empiric lactose-free diet. Rx: lactose-free diet & lactase tablets.</p></li></ul><p>Secretory (watery; nl osmotic gap, no Δ diarrhea w/ fasting, nocturnal, cramps)</p><ul><li><p>Caused by secretion of anions or K+ into lumen or inhib of Na absorption → ↑ H2O in stool. Most commonly caused by bacterial toxins from infxn (see above). Other causes:</p></li><li><p>Endocrine: Addison’s, VIPoma, carcinoid, Zollinger-Ellison, mastocytosis, hyperthyroid (↑ motility). ✓ serum peptide levels (eg, gastrin, calcitonin, VIP) & urinary histamine.</p></li><li><p>GI neoplasm: carcinoma, lymphoma, villous adenoma</p></li><li><p>Microscopic colitis: common cause of chronic diarrhea w/ obscure origin. Often seen in middle-aged women w/ autoimmune disorders. NSAIDs, SSRIs, PPIs notable triggers. Grossly normal on colo but bx shows lymphocytic & plasmacytic infiltration of mucosa ± thickened submucosal collagen. Rx: budesonide (1st line), antidiarrheals, cholestyramine, bismuth; consider anti-TNFs if refractory (Gastro 2016;150:242).</p></li><li><p>Bile acid-induced diarrhea: ileal resection or disease (eg, Crohn’s) → bile acids in colon → electrolyte & H2O secretion. Rx w/ empiric bile-acid binders (eg, cholestyramine).</p></li></ul><p>Functional/IBS (normal osmotic gap, ↓ diarrhea with fasting): see “Dysmotility”</p><p>Malabsorption (fatty; ↑ fecal fat, ↑ osmotic gap, ↓ diarrhea w/ fasting)</p><ul><li><p>Defective mucosal absorption of nutrients b/c Δs in: mucosal surface (surgical resection) or gen. mucosal dis. (celiac, IBD). Bloating, foul-smelling, floating stools (steatorrhea).</p></li><li><p>Celiac disease (JAMA 2017;318:647; Lancet 2018;391:70; Gastro 2019;156:4)</p></li></ul><p>Immune rxn in genetically predisposed Pts (~1% pop) to gliadin, a component of gluten (wheat protein) → small bowel inflammatory infiltrate → impaired absorption</p><p>Other s/s: Fe/folate/B12 defic anemia; osteoporosis; dermatitis herpetiformis; ↑ ALT/AST</p><p>Dx: best if eating gluten when tested; IgA anti-tissue transglutaminase Ab (most Se), IgA anti-deaminated gliadin peptide Ab; IgA α-endomysial Ab. Duodenal bx confirms dx (blunted villi, crypt hyperplasia, inflamm infiltrate); absence of HLA-DQ2/8 excludes dx.</p><p>Rx: gluten-free diet; 7–30% do not respond to diet → ? wrong dx or noncompliant</p><p>Complic: ~5% refractory sx, risk of T-cell lymphoma and small bowel adenocarcinoma</p><ul><li>Whipple’s disease: infxn w/ T. whipplei (Lancet 2016;16:13)</li></ul><p>Other s/s: fever, LAN, edema, arthritis, CNS Δs, gray-brown skin pigmentation, AI & MS, oculomasticatory myorhythmia (eye oscillations + mastication muscle contract).</p><p>Dx: bx/path, IHC, PCR. Rx: PCN + streptomycin or 3rd-gen ceph × 10–14 d → Bactrim ≥1 y.</p><ul><li><p>Small intestinal bacterial overgrowth (SIBO): colonic bacteria in SI → steatorrhea, B12/Fe defic, protein-losing enteropathy. A/w dysmotility (DM neuropathy, scleroderma), Δ’d anatomy (Crohn’s, surgery, fistulae), immune deficiency, celiac, CF. Dx w/ H+ or 14C -xylose breath testing or empiric abx. Rx w/ 7–10 d abx (rifaximin, MNZ, or FQ).</p></li><li><p>Other: s/p short bowel resection (short bowel syndrome), chronic mesenteric ischemia, eosinophilic gastroenteritis, intestinal lymphoma, tropical sprue, Giardia infection</p></li></ul><p>Maldigestion (fatty; ↑ fecal fat, ↑ osmotic gap, ↓ diarrhea w/ fasting)</p><ul><li><p>Defective intraluminal hydrolysis of nutrients, typ. 2/2 pancreatic/hepatobiliary pathology</p></li><li><p>Pancreatic insufficiency: most commonly from chronic pancreatitis or pancreatic cancer. Test w/ stool elastase, chymotrypsin levels, fecal fat, or empiric pancreatic enzyme Rx.</p></li><li><p>↓ bile acids due to ↓ synthesis (cirrhosis), cholestasis (PBC), or s/p ileal resection. Test w/ empiric bile acid replacement therapy.</p></li></ul><p>Inflammatory (⊕ fecal WBC, calprotectin, lactoferrin; ⊕ FOB; fever, abd pain)</p><ul><li><p>Infections: chronic C. diff, Entamoeba histolytica, Yersinia, CMV, TB especially in immunocompromised hosts. CMV, C. diff notorious for causing exacerbations of IBD.</p></li><li><p>Inflammatory bowel disease (Crohn’s, UC); fecal calprotectin helpful for ruling out IBD</p></li><li><p>Radiation enteritis, ischemic colitis, neoplasia (colon cancer, lymphoma)</p></li></ul><p>Figure 3-2 Workup of chronic diarrhea</p><p>DYSMOTILITY & NUTRITION</p><p>Functional GI disease (~30 types per Rome IV criteria; Gastro 2016;150:1257)</p><ul><li><p>Recurrent GI sx caused by disorders of gut-brain interaction rather than structural cause</p></li><li><p>Irritable bowel syndrome (IBS) (JAMA 2015;313:949; Gastro 2015;149:1399 & 2018;154:1140)</p></li></ul><p>Abd discomfort for 6+ mos a/w ≥2: improves w/ defecation, Δ stool frequency, Δ stool form</p><p>IBS-C (constipation predominant) vs. IBS-D (diarrhea predominant) vs. IBS-M (mixed) vs. IBS-U (unclassified). Sx may be affected by stress, diet, lifestyle, probably microbiome.</p><p>Treatment: cog. behavior Rx, probiotics, anti-spasmodics, exercise, neuromodulators (eg, TCA, SSRI), Δ diet (↓ fermentable carbs w/ low FODMAP diet, lactose-free diet)</p><p>IBS-C: ↑ fiber, laxatives (lubiprostone, linaclotide, tegaserod, tenapanor), biofeedback</p><p>IBS-D: loperamide, rifaximin, eluxadoline, bile acid sequestrants, alosetron</p><ul><li>Cyclic vomiting syndrome (CVS): acute recurrent vomiting; a/w marijuana use, personal or FHx of migraine. Acute Rx: antiemetics, IVF, sumatriptan (1st line, followed by aprepitant x 3 d), BDZs; prevention: TCAs/AEDs; avoid marijuana.</li></ul><p>Gastroparesis (Nat Rev Dis Primers 2018;4:41)</p><ul><li><p>Delayed gastric emptying w/o mechanical obstruction, typically p/w nausea (>90%), vomiting (>80%), early satiety (60%), postprandial fullness/pain</p></li><li><p>Etiol: DM, post-surg, post-viral, crit. illness, Parkinson’s, opiates, CCB, anti-cholin, idiopath</p></li><li><p>Dx: r/o mechanical cause then gastric emptying scintigraphy; (⊕ if retained solids >4 h)</p></li><li><p>Treatment: prokinetics (metoclopramide or erythromycin), antiemetics for sx; feeding tube if refractory; consider pyloromyotomy, botox injection, pyloroplasty, or gastric stimulator</p></li></ul><p>Paralytic ileus of the colon & small bowel (Dis Colon Rectum 2021;64:1046)</p><ul><li><p>Definition: loss of intestinal peristalsis in absence of mechanical obstruction</p></li><li><p>Abd discomfort & distention, ↓ or absent bowel sounds, ± N/V, hiccups</p></li><li><p>Typically in elderly, hospitalized, ill Pts; precipitated by: intra-abd process (surgery, pancreatitis, peritonitis, intestinal ischemia), severe illness (eg, sepsis), meds (opiates, CCB, anticholin.), metab/endo abnl (thyroid, DM, kidney failure, liver failure, hypoK), spinal cord compression/trauma, neurologic d/o (Parkinson’s, Alzheimer’s, MS)</p></li><li><p>KUB/CT w/ colonic dilatation (in ileus, dilated loops of SB) w/o mech obstruction; cecal diam >12 cm a/w high-risk perf in Ogilvie’s syndrome (colonic pseudo-obstruction)</p></li><li><p>Treatment: NPO, avoid offending meds, IV neostigmine (monitor for bradycardia), methylnaltrexone; bowel decompression w/ NGT, rectal tube, nutrition support. Ogilvie’s only: colonoscopic decompression; if refractory, colostomy or colectomy.</p></li></ul><p>Constipation (Annals 2015;162:ITC1, Nat Rev Dis Primers 2017;3:17095; JAMA 2019;322:2239)</p><ul><li><p>Defined as dissatisfaction w/ defecation or (per Rome IV): ≥2 of following during last 3–6 mos ≥25% of the time: straining, lumpy/hard stools, incomplete evacuation, sensation of anorectal obstruction, manual maneuvers to facilitate defecation, stool frequency &lt;3/wk</p></li><li><p>Primary etiologies: slow transit vs. pelvic floor dyssynergia</p></li><li><p>Secondary etiologies (4 Ms; JAMA 2016:315:185)</p></li></ul><p>Mech obstruction: malignancy, compression, rectocele, strictures</p><p>Meds: opioids, TCAs, anticholinergics, CCB, NSAIDs, diuretics, Ca2+, Fe, low fiber diet</p><p>Metabolic/endo: DM, hypothyroid, uremia, preg, panhypopit, porphyria, ↑ Ca, ↓ K, ↓ Mg</p><p>Myopathy/Neuro: Parkinson’s, Hirschsprung’s, amyloid, MS, spinal injury, dysautonomia</p><ul><li><p>Dx: H&P w/ DRE. Labs: consider CBC, electrolytes w/ Ca, TSH. Colonoscopy if alarm sx. Anorectal manometry/balloon expulsion test; colonic transit study; defecography.</p></li><li><p>Treatment: 1st line: ↑ fluid, fiber, & exercise; emollient laxative (docusate) to soften stool.</p></li></ul><p>2nd line: Bulk laxatives (psyllium, methylcellulose) to ↑ colonic residue, ↑ peristalsis. Stimulant laxatives (senna, castor oil, bisacodyl) to ↑ motility & secretion. Osmotic laxatives (Mg, NaPO4 [avoid in CKD], PEG) to ↑ H2O in colon.</p><p>3rd line: Enema/suppository (phosphate, mineral oil, tap water, soapsuds, bisacodyl)</p><p>After above failed: linaclotide ↑ stool freq, ↓ straining/bloating (Am J Gastro 2018;113:105).</p><p>Lubiprostone (↑ secretion); methylnaltrexone and alvimopan for opioid-induced.</p><p>Plecanitide (cGMP agonist) for chronic idiopathic constipation (Gastroenterol 2016;150:S317)</p><p>Nutrition in critical illness (also see “Mech Ventilation”) (Crit Care 2015;19:35)</p><ul><li><p>Enteral & parenteral with similar clinical outcomes (Lancet 2018;391:133)</p></li><li><p>Enteral (EN): starting w/in 48 h of ICU admit may ↓ infection & mortality. Contraindic. if bowel obstruction, major GIB, uncontrolled shock. Possible complic: ischemic bowel b/c ↑ demand for splanchnic blood, aspiration PNA, metabolic abnormality.</p></li><li><p>Parenteral (PN): start after 7 d if unable to tolerate EN; no clear benefit to early initiation. Contraindic: hyperosmolality, severe electrolyte disturbances, severe hyperglycemia; sepsis is relative contraindication. Complications: hyperglycemia, sepsis (↑ risk of fungal infections), catheter-associated thrombus, refeeding syndrome, abnl LFTs (steatosis, cholestasis, gallbladder sludge due to lack of enteric stimulation).</p></li></ul><p>DISORDERS OF THE COLON</p><p>DIVERTICULOSIS</p><p>Definition & pathophysiology (Aliment Pharm Ther 2015;42:664)</p><ul><li><p>Acquired herniations of colonic mucosa & submucosa in areas where vasa recta penetrate</p></li><li><p>Abnormal motility and ↑ intraluminal pressure cause protrusion of colonic wall</p></li></ul><p>Epidemiology</p><ul><li><p>Risk factors: ↓ fiber, chronic constipation, obesity, smoking, physical inactivity, EtOH, NSAIDs, ↑ age (10% if &lt;40 y; 50–66% if >80 y); ↑ red meat consumption</p></li><li><p>Left side (90%, mostly sigmoid) >R side of colon (except in Asia where 75–85% R-sided)</p></li></ul><p>Clinical manifestations</p><ul><li><p>Usually asx; 5–15% develop diverticular hemorrhage (see “GIB”) and 10–25% diverticulitis</p></li><li><p>Limited data for ↑ fiber diet or avoiding nuts/seeds (Thera Adv Gastro 2016;9:213)</p></li></ul><p>DIVERTICULITIS</p><p>Pathophysiology (NEJM 2007;357:2057; Gastro 2015;149:1944)</p><ul><li><p>Retention of undigested food and bacteria in diverticulum → fecalith formation → obstruction → compromise of diverticulum’s blood supply, infection, microperforation</p></li><li><p>Uncomplicated (75%): microperforation → localized infection, LLQ pain, fever, ↑ WBC</p></li><li><p>Complicated (25%): macroperf → abscess, peritonitis, fistula (65% w/ bladder), obstrxn</p></li></ul><p>Clinical manifestations</p><ul><li><p>LLQ abdominal pain, fever, nausea, vomiting, constipation or diarrhea</p></li><li><p>PEx ranges from LLQ tenderness ± palpable mass to peritoneal signs & septic shock</p></li><li><p>Ddx includes IBD, infectious colitis, PID, tubal pregnancy, cystitis, colorectal cancer</p></li></ul><p>Diagnostic studies</p><ul><li><p>Abdominal CT (I+O+): diverticula, bowel wall thickening, pericolic fat ± abscess, fistula</p></li><li><p>Colonoscopy contraindic. acutely as ↑ risk of perforation; for Pts w/o colonoscopy in the past year, perform 6–8 wks after to r/o neoplasm</p></li></ul><p>Treatment (JAMA 2017;318:291; NEJM 2018;379:1635; Gastro 2021;160:906)</p><ul><li>Mild: outPt Rx indicated if Pt has few comorbidities and can tolerate POs</li></ul><p>PO abx: (MNZ + FQ) or amox/clav for 7 d; liquid diet until clinical improvement</p><p>No abx is noninferior to abx in uncomplicated diverti (Clin Gastroenterol Hepatol 2021;19:503)</p><ul><li>Severe: inPt Rx if cannot take POs, narcotics needed for pain, or complications</li></ul><p>NPO, IVF, NGT (if ileus); IV abx (GNR & anaerobic coverage; eg, CTX/MNZ or pip-tazo)</p><ul><li><p>Abscesses >4 cm should be drained percutaneously or surgically</p></li><li><p>Surgery: if progression despite med Rx, undrainable abscess, free perforation</p></li></ul><p>After source control, 4 d abx may be sufficient (NEJM 2015;372:1996)</p><p>Resection for recurrent bouts of diverticulitis on a case-by-case basis</p><p>Consider lower threshold for urgent & elective surgery for immunocompromised Pts</p><p>Prevention (Gastro 2021;160:906)</p><ul><li><p>Avoid smoking and NSAIDs; insufficient evidence to recommend mesalamine or rifaximin</p></li><li><p>Risk of recurrence 10–30% w/in 10 y of 1st episode; nuts, seeds ∅ increase risk</p></li></ul><p>POLYPS</p><p>Pathophysiology & epidemiology (NEJM 2016;374:1065)</p><ul><li><p>Accumulation of mutations in colonic epithelial cell DNA affecting oncogenes & tumor suppressor genes → tumor initiation (formation of adenoma; APC loss of fxn) → tumor progression (adenoma → carcinoma; K-ras gain of fxn, DCC, p53 loss of fxn)</p></li><li><p>Risk factors: ↑ age, FHx (sporadic in 1° relatives, Lynch, FAP), IBD, ↑ dietary fat, central adiposity, ↑ EtOH, ↓ fiber, ↑ red meat, smoking, DM</p></li><li><p>Protective factors: ↑ physical activity, ASA/NSAIDs, Ca2+ intake, HRT, ↓ BMI; possibly ↑ fiber, vitamin D, fish oil, statins, selenium</p></li><li><p>Neoplastic polyps: adenomas (tubular, villous, tubulovillous dysplasia), sessile serrated adenomas/polyps (concern for interval CRC), carcinomas</p></li><li><p>Non-neoplastic polyps: hyperplastic, juvenile, Peutz-Jeghers (can undergo malignant transformation), inflammatory</p></li></ul><p>CRC screening (JAMA 2021;325:1978)</p><ul><li><p>Colonoscopy gold standard. Other options: FOBT/FIT yearly, flex sig q5y or flex sig q10y + FIT every year, fecal DNA testing (eg, Cologuard) q3y or CT colonography q5y</p></li><li><p>Start screening in average risk Pts at age 45 (typically q10y unless abnl found)</p></li><li><p>If ⊕ FHx, start age 40, or 10 y before age of dx in youngest family member, repeat q5y</p></li></ul><p>INFLAMMATORY BOWEL DISEASE</p><p>Definition (NEJM 2020;383:2652)</p><ul><li><p>Ulcerative colitis (UC): inflammation of the colonic mucosa; contiguous, starting at rectum</p></li><li><p>Crohn’s disease (CD): transmural inflammation anywhere along GI tract, skip lesions</p></li></ul><p>Epidemiology & pathophysiology (Lancet 2016;387:156 & 2017;390:2769)</p><ul><li><p>Age of onset 15–30 y; bimodal w/ 2nd peak at 50–70 y; 1:1 M:F in N America</p></li><li><p>Genetic predisposition (↑ Caucasian/Jewish) + environmental risk factors (smoking ↑ risk for CD, defective mucosal barrier) → T cell dysregulation → inflammation</p></li></ul><p>ULCERATIVE COLITIS (Lancet 2018;389:1756; Am J Gastro 2019:114:384)</p><p>Clinical manifestations</p><ul><li><p>Grossly bloody diarrhea, lower abdominal cramps, tenesmus, small, frequent BM</p></li><li><p>Extracolonic (>25%): erythema nodosum, pyoderma gangrenosum, aphthous ulcers, uveitis, episcleritis, thromboembolic events (esp. during a flare; Lancet 2010;375:657), AIHA, seroneg arthritis (most common), PSC (↑ risk cholangio CA, CRC)</p></li><li><p>Several scores for severity assessment: Truelove & Witts; Mayo Score/DAI; Montreal</p></li></ul><p>Diagnosis</p><ul><li><p>Colonoscopy: involves rectum (95%) & extends prox., circumfer., & contig. w/in colon</p></li><li><p>Location: proctitis (30–60%), L-sided (15–45%) and extensive (pancolitis; 15–35%)</p></li><li><p>Appearance: vascularity loss, friable mucosa, diffuse ulceration, pseudopolyps (chronicity)</p></li><li><p>Histology: superficial chronic inflammation; crypt abscesses & architectural distortion</p></li><li><p>Barium enema with featureless and tubular appearance of colon (leadpipe appearance)</p></li><li><p>Flares: ↑ ESR & CRP (not Se or Sp); ⊕ fecal calprotectin helpful in distinguishing IBD vs. IBS and monitoring for IBD flare (Gastro Hep 2017;13:53); must rule out infection</p></li></ul><p>Complications</p><ul><li><p>Toxic megacolon (5%): colon dilatation (≥6 cm on KUB), colonic atony, systemic toxicity, & ↑ risk of perf. Rx w/ IV steroids & broad-spectrum abx; surgery if needed.</p></li><li><p>Stricture (rectosigmoid), dysmotility, anorectal dysfxn after recurrent inflammation</p></li><li><p>↑ Risk of CRC and dysplasia (see below) after 8 years of active disease</p></li><li><p>For Pts s/p surgery w/ ileal pouch, may develop pouchitis (inflammation of ileal pouch, up to ½ of Pts). Rx w/ abx (MNZ, cipro), probiotics.</p></li></ul><p>Prognosis</p><ul><li><p>50% in remission at any given time. Intermittent exacerbations in 90%; continual active disease in ~18%. Prox progression in 25% at 10 y. Rate of colectomy at 10 y is 24%.</p></li><li><p>Mortality rate of severe UC flare is &lt;2%, & overall life expectancy in UC = non-UC Pts</p></li></ul><p>CROHN’S DISEASE (Lancet 2017;389:1741)</p><p>Clinical manifestations (Nat Rev Gastro Hep 2016;13:567)</p><ul><li><p>Abdominal pain, loose/frequent stools (up to 50% ⊕ FOBT), malaise, wt loss</p></li><li><p>Mucus-containing, often nonbloody diarrhea</p></li><li><p>N/V, bloating, obstipation if presence of obstruction; extracolonic manifestations as in UC</p></li><li><p>Several scoring systems: CD Activity Index (CDAI), Harvey-Bradshaw Index</p></li></ul><p>Diagnosis</p><ul><li><p>Ileocolonoscopy + bx along w/ small bowel assessment (eg, MR-enterography)</p></li><li><p>Small bowel/ileitis (~25%), ileocolonic (~50%), colonic (~25%); isolated upper tract rare</p></li><li><p>Appearance: nonfriable mucosa, cobblestoning, aphthous ulcers, deep & long fissures</p></li><li><p>Histology: transmural inflammation with mononuclear cell infiltrate, noncaseating granulomas (seen in &lt;25% of mucosal biopsies), fibrosis, ulcers, fissures, skip areas</p></li><li><p>Montreal classification: age at dx, disease location & behavior (stricturing vs. nonstricturing, penetrating vs. nonpenetrating), plus modifiers for upper tract & perianal disease</p></li></ul><p>Complications</p><ul><li><p>Perianal disease: fissures, fistulas, skin tags, perirectal abscesses (in 24% of Pts; perianal disease precedes intestinal symptoms)</p></li><li><p>Stricture: small bowel, postprandial abd pain; can lead to complete SBO & require surgery</p></li><li><p>Fistulas: perianal, enteroenteric, rectovaginal, enterovesicular, enterocutaneous</p></li><li><p>Abscess: fever, tender abd mass, ↑ WBC; steroids mask sx, ∴ need high level of suspicion</p></li><li><p>Malabsorption: ileal disease/resection: ↓ bile acids abs → gallstones; ↓ fatty acid abs → Ca oxalate kidney stones; ↓ fat-soluble vitamin abs → vit D deficiency → osteopenia</p></li></ul><p>Prognosis</p><ul><li><p>Variable at 1 y: ~50% in remission, ~20% flare, ~20% low activity, ~10% chronic active</p></li><li><p>At 20 y, majority will have required some surgery; overall life expectancy is slightly ↓</p></li></ul><p>MANAGEMENT (Lancet 2017;398:1756; Mayo 2017;92:1088)</p><p>Initial evaluation</p><ul><li><p>H&P (✓ for intestinal & extraintestinal manifestations) and dx studies as above</p></li><li><p>Lab: consider CBC/diff, LFTs, iron studies, B12, folate, vit D, ESR, CRP, fecal calprotectin</p></li><li><p>Exclude other etiologies: infectious (espec. TB), ischemic colitis, intestinal lymphoma, CRC, IBS, vasculitis, Behçet’s, celiac disease, small intestinal bacterial overgrowth</p></li><li><p>R/o infection (esp. TB, HBV, CMV, O&P) before treating with immunosuppressants and biologics (although not all acutely hospitalized Pts w/ IBD need infxn r/o prior to Rx)</p></li></ul><p>Goals of treatment (Ther Adv Gastro 2015;8:143)</p><ul><li><p>Induce remission of acute flare → maintain remission; mucosal healing 1° goal</p></li><li><p>Step-up Rx (least → most toxic) vs. top-down; (strongest → de-escalate) approach; consider early biologic if severe disease</p></li></ul><p>Medical Therapy for IBD (NEJM 2021;385:1302)</p><p>Ulcerative Colitis (Am J Gastrol 2019:114:384)</p><p>Mild</p><p>Rectal mesalamine or glucocorticoids as suppository or enema</p><p>Mild- moderate</p><p>Oral 5-ASA: many formulations (sulfasalazine, mesalamine, olsalazine, balsalazide) depending on disease location. Used for induction & maintenance of remission. Complications: pancreatitis, abd pain, diarrhea.</p><p>MMX-budesonide: PO budesonide released throughout colon for flare. 1st-pass metab ↓ systemic steroid adverse effects of steroid.</p><p>Moderate- severe</p><p>PO prednisone: 40–60 mg w/ taper over several wks to induce remission</p><p>AZA/6-MP: 0.5–1 mg/kg and uptitrate over several wks for maintenance</p><p>Complications: BM suppression, lymphoma, pancreatitis, hepatitis</p><p>✓ TPMT levels prior to dosing to ↓ risk of generation of toxic metabs.</p><p>In selected cases, add allopurinol to boost activity in non-responders.</p><p>Anti-TNF: ↑ remission rate when AZA combined w/ IFX (Gastro 2014;146:392)</p><p>Severe or refractory disease</p><p>(Lancet 2017; 389:1218; NEJM 2016; 374:1754 & 2017; 76:1723; JAMA 2019; 321:156)</p><p>IV steroids: 100 mg hydrocort q8h or 16–20 mg methylpred q8h to induce remission w/ plan to taper & switch to non-steroid maintenance.</p><p>Cyclosporine: for severe flares refractory to steroids, 2–4 mg/kg infusion × 7 d w/ goal to Δ to maintenance medication (eg, AZA/6-MP)</p><p>Anti-TNF (infliximab, adalimumab & golimumab): for steroid-refractory flares or to maintain remission. Complic: reactivation of TB (✓ PPD prior to Rx) or viral hepatitis; small ↑ risk NHL; lupus-like rxn, psoriasis, MS, CHF.</p><p>Alternative agents: vedolizumab (α4β7 integrin inhibitor); tofacitinib (JAK inhibitor); ustekinumab (IL-12/23 inhibitor); ozanimod (sphinosine-1- phosphate receptor agonist)</p><p>Investigational: fecal microbiota transplant; etrolizumab (α4β7 inhibitor)</p><p>Crohn’s Disease (JAMA 2021;325:69)</p><p>Mild</p><p>Oral 5-ASA: for colonic Crohn’s disease</p><p>Symptom control: loperamide/cholestyramine for diarrhea management.</p><p>Mild-mod</p><p>PO budesonide: enteric-coated for ileal release (taper over 3 mos)</p><p>Moderate- severe</p><p>PO prednisone: same as UC, for inducing remission, not maintenance</p><p>AZA/6-MP: same as UC; ↑ remission w/ AZA+IFX (NEJM 2010;362:1383)</p><p>MTX: 15–25 mg IM/SC or PO qwk for maintenance; 1–2 mo to take effect</p><p>Severe or refractory disease (NEJM 2016; 375:1946)</p><p>IV steroids: same as UC, for inducing remission, not maintenance</p><p>Anti-TNF: infliximab, adalimumab or certolizumab (pegylated); consider combination therapy with AZA/6-MP</p><p>Alternative agents: vedolizumab (α4β7 integrin inhibitor); ustekinumab (IL-12/23 inhibitor); natalizumab (α4 integrin inhibitor)</p><p>Investigational: tofacitinib (JAK inhibitor); ozanimod (S-1-P receptor agonist)</p><p>Surgery</p><ul><li><p>UC: colectomy if sx refractory to or intolerable side effects from meds, CRC, perforation, toxic megacolon, uncontrolled hemorrhage. Often ileal pouch-anal anastomosis (IPAA).</p></li><li><p>CD: resection if refractory; surgery for strictures; diverting ileostomy for perineal disease</p></li></ul><p>Cancer screening (NEJM 2015;372:1441)</p><ul><li><p>Colon cancer: risk in UC ~2% at 10 y, ~8% at 20 y, ~18% at 30 y. Similar for pancolonic CD, plus risk of small bowel cancer as well. Dysplasia best marker for risk. Other risk factors include: PSC, ⊕ FHx, greater extent of disease, stricture, & pseudopolyps.</p></li><li><p>Surveillance: colonoscopy w/ random bx 8 y after dx to eval for dysplasia, q1–3y thereafter based on risk factors. Chromoendoscopy using dye to stain high-risk lesions for targeted bx may be preferable. If high-grade dysplasia or dysplasia-assoc. lesion/mass → colectomy.</p></li></ul><p>INTESTINAL ISCHEMIA</p><p>ACUTE MESENTERIC ISCHEMIA</p><p>Definition and causes (NEJM 2016;374:959)</p><ul><li><p>Reduced or absent blood flow to small intestine, typically caused by arterial (ie, SMA or its branches) occlusion or transient hypoperfusion or less often by venous occlusion</p></li><li><p>Arterial embolism (~40–50%): embolic occlusion to SMA (has narrow take-off angle), often in setting of AF, valvular disease incl. endocarditis, atherosclerotic plaque in aorta</p></li><li><p>SMA thrombosis (~20–30%): typically due to atherosclerosis at origin of SMA; other risk factors incl. vascular injury from abd trauma, infxn, or mesenteric dissections/aneurysms</p></li><li><p>Nonocclusive mesenteric ischemia (~10%): transient intestinal hypoperfusion due to ↓ CO, athero, sepsis, drugs that ↓ gut perfusion (pressors, cocaine, amphetamines)</p></li><li><p>Mesenteric venous thrombosis (MVT, ~5%): a/w hypercoag. states, portal hypertension, IBD, malignancy, inflammation (pancreatitis, peritonitis), pregnancy, trauma, surgery</p></li><li><p>Focal segmental ischemia of small bowel (&lt;5%): vascular occlusion to small segments of small bowel (vasculitis, atheromatous emboli, strangulated hernias, XRT)</p></li></ul><p>Clinical manifestations</p><ul><li><p>Arterial occlusion: sudden intense abd pain out of proportion to tenderness on exam</p></li><li><p>Venous occlusion: often more insidious in onset, intermittent pain with peaks and valleys</p></li><li><p>Nonocclusive: abd distention & pain, n/v, lower GI bleeding due to mucosal sloughing; often occurring after episode of hypoperfusion (eg, cardiac event or shock)</p></li><li><p>Exam ranges: unremarkable ± abd distention to peritoneal (infarction); ⊕ FOBT ~75%</p></li></ul><p>Diagnostic studies</p><ul><li><p>Dx relies on high level of suspicion; rapid dx essential to avoid infarction (occurs w/in hrs)</p></li><li><p>Mortality 20 to >70% if bowel infarcted; dx prior to infarction strongest predictor of survival</p></li><li><p>Laboratory: often nl; ~75% ↑ WBC; ↑ amylase, LDH, PO4, D-dimer; ~50% ↑ lactate (late)</p></li><li><p>KUB: nl early before infarct; “thumbprinting,” ileus, pneumatosis in later stages</p></li><li><p>CT angiography (arterial phase): noninvasive test of choice; venous phase for dx MVT</p></li><li><p>Angiography: gold standard; potentially therapeutic; indicated if vasc occlusion suspected</p></li></ul><p>Treatment (NEJM 2016;374:959; World J Emerg Surg 2017;12:38)</p><ul><li><p>IVF, NPO, optimize hemodynamics (minimize pressors), broad-spectrum abx, anticoagulation w/ heparin ± tPA (for occlusive disease), IV papaverine (vasodilator; for non-occlusive mesenteric ischemia)</p></li><li><p>If evidence of peritonitis: to OR for surgical endovascular therapies & bowel resection</p></li><li><p>SMA thrombosis: percutaneous (stenting) or surgical revascularization</p></li><li><p>SMA embolism: embolectomy (catheter-based aspiration vs. surgical)</p></li><li><p>Nonocclusive: correct underlying cause (esp. cardiac)</p></li><li><p>Mesenteric venous thrombosis: 3–6 mo anticoag after initial heparinization. Fibrinolysis or thrombectomy typically reserved for Pts w/ hemodynamic instability or refractory sx.</p></li><li><p>Focal segmental ischemia: typically surgical resection</p></li></ul><p>CHRONIC MESENTERIC ISCHEMIA</p><ul><li><p>Pathophysiology: ↓ blood flow to gut typically because of mesenteric atherosclerosis</p></li><li><p>Sx: “intestinal angina” = postprandial abd pain, early satiety, & ↓ wt due to fear of eating. If pain becomes constant → could represent acute thrombosis (see above).</p></li><li><p>Dx: duplex U/S or CTA; angiography gold stnd; gastric tonometry exercise testing</p></li><li><p>Treatment: surgical revascularization (1st line); angioplasty ± stenting; TPN for nutrition</p></li></ul><p>ISCHEMIC COLITIS</p><p>Definition & pathophysiology</p><ul><li><p>Nonocclusive disease 2° to Δs in systemic circulation or anatomic/fxnal Δs in local mesenteric vasculature; often underlying etiology unknown, frequently seen in elderly</p></li><li><p>“Watershed” areas (splenic flexure & rectosigmoid) most susceptible; 25% involve R side; confers worse prognosis (Clin Gastroenterol Hepatol 2015;13:1969)</p></li></ul><p>Clinical manifestations, diagnosis, & treatment</p><ul><li><p>Usually p/w cramping LLQ pain w/ overtly bloody stool; fever and peritoneal signs should raise clinical suspicion for infarction</p></li><li><p>Disease spectrum: reversible colopathy (35%), transient colitis (15%), chronic ulcerating colitis (20%), resulting stricture (10%), gangrene (15%), fulminant colitis (&lt;5%)</p></li><li><p>Dx: flex sig/colonoscopy or CT abd/pelvis to make diagnosis; r/o IBD, infectious colitis</p></li><li><p>Treatment: bowel rest, IV fluids, broad-spectrum abx, serial abd exams; surgery for infarction, fulminant colitis, hemorrhage, failure of med Rx, recurrent sepsis, stricture</p></li><li><p>Resolution w/in 48 h w/ conservative measures occurs in >50% of cases</p></li></ul><p>PANCREATITIS</p><p>ACUTE PANCREATITIS (Lancet 2020; 396:726; JAMA 2021;325:382)</p><p>Pathogenesis</p><ul><li>Pancreatic duct and acinar injury via direct or indirect toxicity → impaired secretion and premature activation of digestive enzymes → autodigestion and acute inflammation</li></ul><p>Etiologies (JAMA 2021;325:382)</p><ul><li><p>Gallstones (40%): ♀ >♂; usually due to small stones (&lt;5 mm) or microlithiasis/sludge</p></li><li><p>Alcohol (30%): ♂ >♀; 4–5 drinks/day over ≥5 yrs; usually chronic w/ acute flares</p></li><li><p>Metabolic: hypertrig. (2–5%; TG >1000; type I & V familial hyperlipemia); hyperCa</p></li><li><p>Drugs (&lt;5%): 5-ASA, 6-MP/AZA, ACEI, cytosine, didanosine, dapsone, estrogen, furosemide, isoniazid, MNZ, pentamidine, statins, sulfa, thiazides, tetracycline, valproate</p></li><li><p>Anatomic: divisum, annular pancreas, duodenal duplication cysts, Sphincter of Oddi dysfxn</p></li><li><p>Autoimmune (vide infra)</p></li><li><p>Familial: suspect if age &lt;20 y; (often a/w mutation in PRSS1, SPINK1 or CFTR gene)</p></li><li><p>Infections: ascaris, clonorchis, coxsackie, CMV, EBV, HIV, mumps, mycoplasma, TB, toxo</p></li><li><p>Ischemia: shock, vasculitis, cholesterol emboli</p></li><li><p>Neoplastic: panc/ampullary tumors, mets (RCC most common, breast, lung, melanoma)</p></li><li><p>Post ERCP (5%): Ppx w/ PR indomethacin can ↓ sx; temporary panc duct stent if high risk</p></li><li><p>Trauma: blunt abdominal trauma, post-pancreatic/biliary surgery</p></li></ul><p>Clinical manifestations</p><ul><li><p>Epigastric abdominal or LUQ pain (90%), only ½ w/ bandlike pain radiating to back</p></li><li><p>10% pain-free (due to analgesic/steroid use, immunosuppressed, ΔMS, ICU); ∴ ✓ lipase in unexplained shock, periumbilical or flank (Cullen or Grey Turner signs) bruising</p></li><li><p>N/V (90%), abd tenderness/guarding, ↓ bowel sounds, jaundice if biliary obstruction</p></li><li><p>Ddx: acute cholecystitis, perforated viscus, SBO, mesenteric ischemia, IMI, AAA leak, distal aortic dissection, ruptured ectopic pregnancy</p></li><li><p>Early phase (&lt;1 wk): possible SIRS ± organ failure; late (>1 wk): local complications (qv)</p></li></ul><p>Diagnostic studies (Am J Gastro 2013;108:1400)</p><ul><li><p>Dx requires 2 of 3: characteristic abd pain; lipase or amylase >3× ULN; ⊕ imaging</p></li><li><p>Laboratory: levels of amylase & lipase do not correlate w/ severity of disease</p></li></ul><p>↑ amylase: rises w/in hrs, normalizes w/in 3–5 d (faster than lipase)</p><p>false ⊖: 20% EtOH pancreatitis; 50% hypertriglyceridemia (assay interference)</p><p>false ⊕: other abd or salivary gland process, acidemia, ↓ GFR, macroamylasemia</p><p>↑ lipase: longer t½ than amylase</p><blockquote><p>3× ULN 99% sensitive, 99% specific for acute pancreatitis</p></blockquote><blockquote><p>10k has 80% PPV for biliary dx, 99% NPV for EtOH (Dig Dis Sci 2011;56:3376)</p></blockquote><p>false ⊕: renal failure, other abd process, DKA, HIV, macrolipasemia</p><p>ALT >3× ULN has 95% PPV for gallstone pancreatitis (Am J Gastro 1994;89:1863)</p><ul><li>Imaging studies (Am J Gastro 2013;108:1400)</li></ul><p>Abd U/S: bowel gas often obscures pancreas visualization; however should be ordered to r/o biliary etiology (ie, gallstones, BD dilatation)</p><p>Abd CT: not rec for first 3 days (local complic. not yet visible & concern for AKI w/ IV contrast). However, if persistent pain and/or clinical deterioration after 48–72 h, CT(I+) useful to r/o local complications (necrosis, fluid collections).</p><p>MRI/MRCP: Can detect necrosis, assess for stones & ductal disruption earlier than CT</p><p>Endoscopic U/S (EUS): useful for occult biliary disease (microlithiasis)</p><p>Severity (Gut 2013;62:102; Gastro 2018;154:1096)</p><ul><li>Severity defined by presence of organ failure (AKI, resp failure, GIB, shock) & local or systemic complic. (panc necrosis, fluid collections, gastric outlet obstrxn, splenic & PVT).</li></ul><p>Mild: 80% of cases; no organ failure or local/systemic complications; low mortality</p><p>Moderate: transient (&lt;48 h) organ failure ± local/systemic complications, high morbidity</p><p>Severe: persistent (>48 h) organ failure, very high mortality</p><p>Prognosis (NEJM 2016;375:1972)</p><ul><li><p>Ranson’s, APACHE II: predict severity at 48 h using multiple physiolog. criteria; poor PPV</p></li><li><p>BISAP: simple 5-point scoring system (BUN >25, impaired MS, SIRS, age >60 y, pleural effusion) used w/in first 24 h; score ≥3 predicts ↑ risk of organ failure, mortality</p></li><li><p>CTSI: CT data at 48–72 h (fluid collect., necrosis) to predict mortality; lags behind clinical sx</p></li></ul><p>Treatment (Am J Gastro 2017;112:797; JAMA 2020;323:2331)</p><ul><li><p>Fluid resusc.: aggressive in 1st 24 hrs, even if mild. 20 mL/kg IVB → 3 mL/kg/hr. Goal ↓ BUN & Hct over 12–24 h. ✓ UOP (goal 0.5–1 cc/kg/hr); LR superior to NS (↓ SIRS; avoid if ↑ Ca).</p></li><li><p>Nutrition (NEJM 2014;317:1983)</p></li></ul><p>Early enteral feeding encouraged, though not superior to oral feeding at 72 h</p><p>Mild: Start feeding once without N/V or ileus; may not need to be completely pain free. Low-fat low-residue diet as safe as liquid diet and a/w shorter LOS.</p><p>Severe: early (w/in 48–72 h) enteral nutrition indicated and preferred over TPN b/c ↓ infectious complications. Nasogastric non-inferior to nasojejunal feeding.</p><ul><li><p>Analgesia: IV opioids (monitor respiratory status, adjust dosing if ↑ renal impairment)</p></li><li><p>Gallstone pancreatitis: urgent (w/in 24 h) ERCP w/ sphincterotomy if cholangitis, sepsis, or Tbili ≥5. If mild, CCY during initial hosp. to ↓ risk of recurrence (Lancet 2015;386:1261); defer surgery if necrotizing panc. until improvement in inflam. & fluid collections.</p></li><li><p>Hypertriglyceridemia: insulin gtt (activates lipoprotein lipase), fibrates, ± apheresis</p></li><li><p>No role for Ppx abx in absence of infectious complications (World J Gastro 2012;18:279)</p></li></ul><p>Complications</p><ul><li><p>Systemic: ARDS, abdominal compartment syndrome, AKI, GIB (pseudoaneurysm), DIC</p></li><li><p>Metabolic: hypocalcemia, hyperglycemia, hypertriglyceridemia</p></li><li><p>Fluid collections:</p></li></ul><p>Acute fluid collection: seen early; not encapsulated; asymptomatic; resolve in 1–2 wk</p><p>Pseudocyst: ~4 wk after initial attack, encapsulated. No need for Rx if asx (regardless of size/location). If sx → endoscopic (Gastro 2013;145:583) vs. perc/surg drainage.</p><ul><li>Pancreatic necrosis: Nonviable pancreatic tissue. CT-guided FNA if infection suspected.</li></ul><p>Sterile necrosis: if asx, can be managed expectantly, no role for Ppx abx</p><p>Infected necrosis: most often GN gut organism; high mortality. Rx w/ carbapenem, pip/tazo, or [(3rd gen ceph or FQ) + MNZ]. If stable, defer drainage to >4 wk to allow liquefication & WOPN (qv). If sx or unstable, perc. drainage & minimally invasive surgical debridement or endoscopic necrosectomy superior to open necrosectomy.</p><p>WOPN (walled off panc. nec.): fibrous wall surrounds necrosis over ≥4 wk; endoscopic or perc. drainage (preferred over open necrosectomy) if infected or symptomatic</p><ul><li>Peripancreatic vascular complications: pseudoaneurysm, abdominal compartment syndrome, splanchnic venous thrombosis (splenic vein most common site)</li></ul><p>CHRONIC PANCREATITIS (Lancet 2020;396:499)</p><p>Pathogenesis & etiology (Gastro 2013;144:1292; JAMA 2019;322:2422)</p><ul><li><p>Often recurrent acute attacks → inflam infiltrate → fibrosis → loss of exocrine & endocrine tissue. Pancreatic insufficiency (DM, fat/protein malabsorption) when 90% panc fxn lost.</p></li><li><p>TIGAR-O: Toxins (60–80% due to EtOH; smoking), Idiopathic, Genetic (PRSS1, SPINK1, CFTR, CTRC, CASR), Autoimmune, Recurrent panc., Obstruction</p></li></ul><p>Clinical manifestations</p><ul><li>Epigastric pain, N/V; over time can be painless; signs of exocrine insuff (steatorrhea, wt loss) or endocrine insuff (DM: polydipsia, polyuria); 13× ↑ risk of pancreatic cancer</li></ul><p>Diagnostic studies (Pancreas 2014;43:1143; Am J Gastro 2020;115:322)</p><ul><li><p>Labs: amylase/lipase ↑ early, may be nl later. ⊕ fecal fat, ↓ stool elastase & A1AT. Mixed TG breath test alternative to stool elastase. ✓A1c, consider IgG4/ANA & genetic testing if young or ⊕ FHx. If dx w/ CP, measure baseline fat-soluble vitamins (ADEK).</p></li><li><p>Imaging: Ca2+ on KUB/CT. ERCP/MRCP/EUS: high sens for dx; may show stricture, dilated ducts. IV secretin stim w/ MRI may ↑ dx yield. Panc fxn testing not widely available.</p></li></ul><p>Treatment (JAMA 2019;322:2422; Lancet 2020;396:499)</p><ul><li><p>Pancreatic enzyme replacement (may ↓ pain by reducing CCK). Rx routine vitamin D & Ca.</p></li><li><p>Pain control: smoking & EtOH cessation, analgesics (start with non-opioids; eg, pregabalin), endoscopy (stone removal or stenting strictures), celiac nerve plexus block, surgery</p></li></ul><p>AUTOIMMUNE PANCREATITIS</p><p>Pathogenesis (Am J Gastro 2018;113:1301)</p><ul><li><p>Type 1: lymphoplasmacytic sclerosing panc. w/ dense fibrosis; ↑ IgG4; high relapse</p></li><li><p>Type 2: idiopathic duct-centric pancreatitis; minimal ↑ IgG4; a/w IBD; fewer relapses</p></li></ul><p>Clinical manifestations</p><ul><li><p>Abdominal pain, can p/w obstructive jaundice and panc mass mimicking panc Ca</p></li><li><p>Can be primary, or in a/w IgG4 cholangiopathy, salivary gland disease (eg, Sjögren’s), mediastinal or RP fibrosis, interstitial nephritis, autoimmune thyroiditis, UC/PSC, RA</p></li></ul><p>Diagnosis</p><ul><li><p>Labs: cholestatic LFTs (↑ Aϕ >AST/ALT), ↑ γ-globulins and IgG4, ⊕ ANA, RF</p></li><li><p>HISORt criteria: Histology, Imaging (“sausage pancreas,” bile duct stricture), Serology, other Organ involvement, Response to therapy</p></li></ul><p>Treatment</p><ul><li>Glucocorticoids 1st-line; immunomod. (AZA, MMF, cyclophosphamide, rituximab) if relapse</li></ul><p>ABNORMAL LIVER TESTS</p><p>Tests of hepatocellular injury or cholestasis (J Clin Transl Hepatol 2017;5:394)</p><ul><li>Aminotransferases (AST, ALT): intracellular enzymes released 2° necrosis/inflammation</li></ul><p>ALT more specific for liver than is AST (heart, skeletal muscle, kidney, brain, RBC/WBC)</p><p>↑ levels seen w/ most types of hepatocellular injury; AST >ALT → MSK injury, MI</p><ul><li><p>Alkaline phosphatase (Aϕ): enzyme bound in hepatic canalicular membrane ↑ levels seen w/ biliary obstrxn, intrahepatic cholestasis or infiltration of the liver also found in bone, intestines, kidney, placenta; confirm from liver w/: ↑ GGT (or ↑ 5′-NT)</p></li><li><p>Bilirubin: product of heme metab (unconjugated, “indirect”) carried by alb to liver where taken up for conjugation (“direct”) to make soluble, then excreted into bile.</p></li></ul><p>↑ indirect hyperbili seen with hemolysis, enzymatic disorders (eg, Crigler-Najjar, Gilbert’s)</p><p>↑ direct hyperbili seen with cholestasis, enzymatic disorders (eg, Dubin-Johnson, Rotor’s)</p><p>jaundice seen when bili >2.5 mg/dL (esp. in sclera or under tongue); direct ↑ urine bili</p><p>Tests of hepatic function</p><ul><li><p>Albumin: marker for liver protein synthesis, can help differentiate acute vs. chronic liver failure, may be normal in acute hepatocellular injury (t1/2 ~15–18 d)</p></li><li><p>Prothrombin time (PT): depends on synthesis of coag factors by liver (except FVIII); b/c t1/2 of some factors (eg, V, VII) is short, ↑ PT can occur w/in hrs of liver dysfxn</p></li><li><p>R-value = ratio of ALT:Aϕ normalized to ULN for each = (ALT/ULN) ÷ (Aϕ/ULN)</p></li></ul><p>R >5 suggests hepatocellular injury, &lt;2 suggests cholestatic injury, 2–5 suggests mixed</p><p>Acute mild-to-moderate elevation in ALT/AST (&lt;15× ULN)</p><ul><li><p>Assess risk of EtOH/drug/toxin: H&amp;P; in EtOH AST:ALT ratio >2:1</p></li><li><p>Obtain abdominal imaging to r/o cirrhosis, congestion, or biliary obstruction (mixed LFTs)</p></li><li><p>Other infectious etiologies: tick borne illnesses, CMV/EBV, COVID-19, others</p></li><li><p>Can be initial manifestation of chronic etiologies noted below</p></li></ul><p>Chronic mild-to-moderate elevation in ALT/AST (&lt;15× ULN)</p><ul><li><p>Viral hepatitis: ✓ HBsAg, anti-HBs, anti-HBc, anti-HCV, IgM anti-HAV</p></li><li><p>NAFLD: consider BMI, ✓ lipid panel, HbA1c, liver U/S or elastography</p></li><li><p>Other etiologies of cirrhosis (qv)</p></li></ul><p>Hemochromatosis: ✓ TIBC, serum iron, serum ferritin</p><p>Wilson disease: serum ceruloplasmin, urine Cu</p><p>α-1 antitrypsin (can cause liver disease w/o lung involvement)</p><ul><li><p>Chronic autoimmune hepatitis ✓ ANA, ASMA, anti-LKMA, IgG, SPEP</p></li><li><p>TSH (both hypo & hyperthyroidism associated with abnormal LFTs), celiac disease</p></li><li><p>If workup negative, consider biopsy</p></li></ul><p>Acute severe elevation in ALT/AST (>1000)</p><ul><li><p>Massive elevations (>5000) usually due to ischemic injury or drug-induced hepatitis</p></li><li><p>Ischemia: hypotension, shock or severe HF (often >50× ULN), Budd-Chiari: usually diagnosed based on clinical hx, U/S w/ Doppler; ratio ALT:LDH &lt;1.5 if ischemic because of concomitant ↑ LDH (vs. ratio >1.5 w/ toxins, viruses)</p></li><li><p>Meds/toxins: acetaminophen, meds (eg, INH, amio, nitrofuratonin), OTC/herbal, cocaine (nb, EtOH should not produce this degree of elevation). Obtain acet. level, tox screen.</p></li><li><p>Acute viral infection: hepatitis A–E or reactivation of HBV, EBV/CMV</p></li><li><p>Acute autoimmune hepatitis (qv): ✓ IgG, ANA, ASMA</p></li><li><p>Acute biliary obstruction (often with sig drop in ALT/AST the next day, Aϕ takes longer to rise & fall): start w/ liver U/S, if unrevealing obtain CT or MRCP</p></li><li><p>Rhabdomyolysis and heat stroke</p></li></ul><p>Figure 3-3 Approach to abnormal liver tests with cholestatic pattern</p><p>Figure 3-4 Approach to abnormal liver tests with infiltrative pattern</p><p>HEPATITIS</p><p>VIRAL</p><p>Hepatitis A (ssRNA; 30–45% of acute viral hepatitis in U.S; MMWR 2018;67:1208)</p><ul><li><p>Transmission & RFs: fecal–oral route; contam. food, water, shellfish; daycare ctr; intl travel</p></li><li><p>Incubation: 2–6 wk; no chronic carrier state; once antibody forms → lifelong immunity</p></li><li><p>Sx: ↓ appetite, malaise, fever, N/V, RUQ pain, jaundice; rarely ALF (↑ w/ chronic HCV)</p></li><li><p>Diagnosis: acute hepatitis = ⊕ IgM anti-HAV; past exposure = ⊕ IgG anti-HAV (⊖IgM)</p></li><li><p>Rx for acute HAV: supportive care; refer to liver txplnt center if acute liver failure</p></li><li><p>Vaccinate if: MSM, IVDU, chronic liver disease, international travel; Havrix (2 doses)</p></li></ul><p>Hepatitis B (dsDNA; ~45% of acute viral hepatitis in U.S.; JAMA 2020;324:2452)</p><ul><li><p>Transmission: blood (IVDU, transfusion), sexual, perinatal (vertical)</p></li><li><p>Incubation: 6 wk–6 mo (mean 12–14 wk)</p></li><li><p>Acute infxn: 70% subclinical, 30% jaundice, &lt;1% acute liver failure (up to 60% mortality)</p></li><li><p>Chronic infxn: HBsAg ⊕ >6 mo in &lt;5% of adult-acquired (↑ if immunosupp), >90% of perinatal; ~40% chronic HBV → cirrhosis (↑ risk w/ HCV, HDV, or HIV coinfxn, EtOH)</p></li><li><p>HCC: ↑ risk if cirrhosis, ⊕ FHx HCC, African >20 y old, Asian ♂ >40 y old or ♀ >50 y old, or >40 y old w/ ↑ ALT ± HBV DNA >2000. Screen w/ AFP & U/S q6mo.</p></li><li><p>Extrahepatic syndromes: PAN (&lt;1%), membranous nephropathy, MPGN, arthritis</p></li><li><p>Serologic and virologic tests (screening guidelines: Hepatology 2018:67:1560)</p></li></ul><p>HBsAg: appears before sx; used to screen blood donors; persists >6 mo = chronic HBV</p><p>HBeAg: evidence of viral replication and ↑ infectivity</p><p>IgM anti-HBc: 1st Ab to appear; indicates acute infection window period = HBsAg becomes ⊖, anti-HBs not yet ⊕, anti-HBc only clue to infxn</p><p>IgG anti-HBc: indicates previous (HBsAg ⊖) or ongoing (HBsAg ⊕) HBV infection</p><p>anti-HBe: indicates waning viral replication, ↓ infectivity</p><p>anti-HBs: indicates resolution of acute disease & immunity (sole marker after vaccination)</p><p>HBV DNA: presence in serum correlates w/ active viral replication in liver</p><p>*Precore mutant: HBeAg not made, but anti-HBe can develop due to x-reactivity w/ HBcAg; a/w ↑ HBV DNA</p><ul><li>Treatment for acute HBV: supportive; hospitalize for Δ MS or ↑ INR (liver transplant center); consider antiviral therapy if severe or protracted course</li></ul><p>*ALT ULN &lt;35 U/L for ♂, &lt;25 U/L for ♀. Adapted from Hepatology 2018;67:1560</p><ul><li><p>When to treat chronic HBV with anti-virals? (1) immune active phase; (2) HBeAg ⊖ chronic hepatitis B; (3) cirrhosis w/ HBV DNA ≥2K; (4) decomp. cirrhosis due to hep B; (5) acute liver failure due to acute hepatitis B; (6) special pop: preg (3rd trimester w/ HBV DNA ≥200k), inactive carriers treated w/ immunosuppression, HCC, HCV co-infection</p></li><li><p>Entecavir or tenofovir: nucleo(s/t)ide analogs, well tolerated, low resistance; at 5 y, HBeAg seroconversion is 30–40% & loss of HBsAg is 5–10% (Lancet Gastro Hep 2016;1:185). Tenofovir preferred if h/o lamivudine resistance; no known tenofovir resistance to date.</p></li><li><p>Rx duration: (1) HBeAg ⊕ immune active w/o cirrhosis: if seroconversion (HBeAg ⊖, anti- HBe ⊕), can stop after 1 y if ALT nl & HBV DNA suppressed or until HBsAg clears; (2) HBeAg ⊖ immune reactivation: indefinite; (3) cirrhosis: indefinite</p></li><li><p>If undergo liver transplant: HBIG + nucleo(s/t)ide analogue effective in preventing reinfection</p></li><li><p>HIV/HBV coinfection: Rx w/ 2 drugs active against both HBV & HIV (
<a href=https://aidsinfo.nih.gov rel=noopener>https://aidsinfo.nih.gov</a>)</p></li><li><p>Immunosuppression: prior to initiating chemoRx, anti-TNF, rituximab, steroids (>20 mg/d >1 mo), screen for HBV; Rx if mod-to-high risk of reactive (incl anti-HBs ⊕ getting rituximab)</p></li><li><p>Postexposure (risk infxn ~30%) Ppx: HBIG → vaccine (if unvac or known nonresponder)</p></li></ul><p>Hepatitis C (ssRNA; ~10% of acute viral hepatitis in U.S.; Lancet 2015;385:1124)</p><ul><li><p>Transmission: blood (IVDU, transfusion before 1992) >sexual; 20–30% w/o clear precipitant</p></li><li><p>Incubation: 1–5 mo; mean 6–7 wk</p></li><li><p>Acute infxn: 80% subclinical; 10–20% sx hepatitis w/ jaundice; acute liver failure rare; prob of spont clearance a/w IL28B & HLA class II genotypes (Annals 2013;158:235)</p></li><li><p>Chronic: up to 85% → chronic hepatitis, 20–30% of whom develop cirrhosis (after ~20 y)</p></li></ul><p>↑ risk of cirrhosis in men, EtOH, HIV; HCC in 1–4% of Pts w/ cirrhosis per year</p><ul><li><p>Extrahepatic syndromes: mixed cryoglobulinemia, porphyria cutanea tarda, lichen planus, leukocytoclastic vasculitis, thyroiditis, MPGN, IPF, NHL and monoclonal gammopathies</p></li><li><p>Serologic, virologic, & genetic tests (screen all adults [✓ anti-HCV] JAMA 2020;323:970)</p></li></ul><p>anti-HCV (ELISA): ⊕ in 6 wk, does not = recovery or immunity; can be ⊖ after recovery</p><p>HCV RNA: ⊕ w/in 2 wk, marker of active infection</p><p>HCV genotype (1–6): guides duration & predicts response to Rx; geno. 3 a/w ↑ risk HCC</p><ul><li><p>Dx: acute hepatitis = ⊕ HCV RNA, ± anti-HCV; resolved = ⊖ HCV RNA, ± anti-HCV; chronic = ⊕ HCV RNA, ⊕ anti-HCV</p></li><li><p>Treatment indications (
<a href=https://www.hcvguidelines.org rel=noopener>www.hcvguidelines.org</a>) (Lancet 2019;393:1453; Hepatology 2020;71:686)</p></li></ul><p>Acute: if no spont. clearance at 12–16 wk, can Rx w/ same regimens for chronic HCV</p><p>Chronic: ↓ HCC & mortality. Recommended for all except if ↓ life expectancy.</p><p>Recommended First-Line Oral Direct-Acting Antiviral (DAA) Regimens</p><p>Regimen (simplified)</p><p>Indication</p><p>Sofosbuvir & velpatasvir</p><p>Genotypes 1–6, 12 weeks Rx</p><p>Glecaprevir & pibrentasvir</p><p>Gentotypes 1–6; 8 weeks Rx</p><p>Simplified treatment: adults w/ HCV w/o cirrhosis or w/ compensated cirrhosis & no prior HCV treatment; cannot have HIV, HBsAg ⊕, pregnancy, HCC, ESRD, or liver transplant; if decompensated or previously treated, refer to GI for assistance.</p><p>Based on Hepatology 2020;71:686. Antiviral classes: RNA polymerase inhibitor (“…buvir”); NS5a inhibitor (“…asvir”); NS3/4A protease inhibitor (“…previr”).</p><ul><li><p>Monitoring on Rx: CBC, INR, LFTs, GFR, HCV VL prior to starting Rx. PIs contraindicated if decomp. liver dx (ascites, encephalopathy) or CPS ≥7. D/c Rx if jaundice, N/V, weakness, 10x ↑ in ALT, or significant ↑ in bili, Aϕ, INR after 4 wks.</p></li><li><p>Goal is sustained virologic response (SVR) = Ø viremia 12 wks after completion of Rx. Success depends on genotype but SVR rates >90% with current regimens.</p></li><li><p>Special populations (HCV/HIV coinfection, decompensated cirrhosis, s/p liver transplant, renal impairment):
<a href=https://www.hcvguidelines.com rel=noopener>www.hcvguidelines.com</a> for updated recs on mgmt</p></li><li><p>Vaccinate all chronic HCV patients against HBV and HAV if not immune</p></li><li><p>Postexposure (needlestick risk ~3%) Ppx: none, although sofosbuvir-velpatasivir under investigation in clinical trial; if HCV RNA → ⊕, consider Rx w/in 3 mos</p></li></ul><p>Hepatitis D (RNA; Gastro 2019:156;461)</p><ul><li><p>Transmission: blood or sexual; endemic in Africa & E. Europe. Generally requires host to already have HBV infxn in order to cause co-infection or superinfection; in rare cases (immunosupp s/p liver transplant) can replicate autonomously.</p></li><li><p>Natural hx: acute HBV–HDV coinfection resolves in >80% of cases; however, acute HDV superinfection leads to chronic HBV–HDV in most cases (↑ progression to cirrhosis, HCC)</p></li><li><p>Dx: ✓ total anti-HDV once in all HBV-infected patients, if antibody ⊕, confirm w/ HDV RNA</p></li></ul><p>Hepatitis E (ssRNA; World J Gastro 2016;22:7030; Gastro Clin N Am 2017;46:393)</p><ul><li><p>Most common cause of acute viral hepatitis in endemic areas</p></li><li><p>Transmission: fecal–oral; travelers to central & SE Asia, Africa and Mexico, exposure to swine. ↑ rates of cases in Europe.</p></li><li><p>Natural hx: often asx, sometimes causes acute hepatitis w/ ↑ mort. (10–20%) if pregnant; rarely can become chronic in transplant Pts</p></li><li><p>Dx: IgM anti-HEV (through CDC), HEV RNA; treatment is generally supportive only</p></li><li><p>Extrahepatic sx: arthritis, pancreatitis, anemia, neuro (GBS, meningoencephalitis)</p></li></ul><p>Other viruses (human pegivirus, CMV, EBV, HSV, VZV)</p><p>AUTOIMMUNE HEPATITIS (AIH)</p><p>Classification (J Hep 2015;62:S100, World J Gastro 2015;21:60)</p><ul><li><p>Type 1: anti-smooth muscle Ab (ASMA), ANA; anti-soluble liver antigen (anti-SLA), a/w more severe disease and relapsing disease (found in 10–30% Pts), IgG often ↑</p></li><li><p>Type 2: anti-liver/kidney microsome 1 (anti-LKM1); anti-liver cytosol type 1 (anti-LC-1)</p></li><li><p>Overlap syndrome: AIH + PBC (suspect if ⊕ AMA or ⊕ histology → “autoimmune cholangitis”)</p></li><li><p>Drug-induced: minocycline, nitrofurantoin, infliximab, hydralazine, α-methyldopa, statins</p></li></ul><p>Diagnosis and treatment (J Hepatol 2015;63:1543, Clin Liver Dis 2015;19:57)</p><ul><li><p>70% female; bimodal presentation in the second and fifth decades of life</p></li><li><p>40% present w/ severe AIH (3% ALF) w/ ALT >10 × ULN; 34–45% asx</p></li><li><p>Extrahepatic syndromes: thyroiditis, arthritis, UC, Sjögren’s, Coombs’ ⊕ anemia, celiac</p></li><li><p>Dx: scoring system combining serologies, ↑ IgG, Ø viral hepatitis, & liver bx (interface hepatitis & lymphoplasmacytic infiltrate) has high Sp & mod Se (Dig Dis 2015;33[S2]:53)</p></li><li><p>Rx: (1) ALT or AST >10× ULN (2) IgG >2× ULN + ALT >5× ULN (3) bridging/multiacinar necrosis (4) cirrhosis w/ inflammation on biopsy (5) AST/ALT >2x ULN + symptoms</p></li><li><p>Induction Rx: (1) prednisone monoRx; (2) prednisone + AZA, or (3) budesonide (if non-cirrhotic) + AZA → 65–80% remission (asx, nl LFTs, bili, & IgG, none-to-minimal interface hepatitis); taper steroids as able; relapse rate of 50–80% (J Hep 2015;62:S100)</p></li><li><p>Nonresponders or AZA intolerant: cyclosporine, tacrolimus, MMF, rituximab, infliximab</p></li></ul><p>OTHER CAUSES OF HEPATITIS OR HEPATOTOXICITY</p><p>Alcohol-associated hepatitis (J Hepatol 2016;69:154; Am J Gastro 2018;113:175)</p><ul><li><p>Sx: progressive jaundice, tender hepatomegaly, fever, ascites, GIB, encephalopathy</p></li><li><p>Labs: ALT usually &lt;300–500 w/ AST:ALT > 2:1, ↓ plt, ↑ Tbili & INR indicate severe hepatitis</p></li><li><p>Prognosis: scoring systems include Maddrey’s discriminant fxn (MDF), Lille model, MELD</p></li></ul><p>MDF (4.6 × [PT – control] + Tb) ≥32 w/ 30–50% 1-mo mortality if unRx’d (Gastro 1996;110:1847)</p><p>Lille model: predicts nonresponse to steroids after 1st week of Rx; score >0.45 predicts poor response to further steroid Rx and a/w ↓ in 6-mo survival (Hep 2007;45:1348)</p><p>Combination of Lille + MELD scores best predictor of mortality (Gastro 2015;149:398)</p><ul><li>Rx: consider if MDF ≥32, MELD >18, or presence of encephalopathy</li></ul><p>Glucocorticoids (eg, methylprednisolone 32 mg/d or prednisolone 40 mg/d × 4 wk → 4–6 wk taper) may ↓ 1-mo but not 6-mo mortality, a/w ↑ infection (NEJM 2015;372:1619, CD001511)</p><p>Contraindic: active GIB, pancreatitis, untreated HBV, uncontrolled bact/fungal/TB infxn</p><p>Addition of NAC to steroids ↓ 1-mo but not 6-mo mortality (NEJM 2011;365:1781)</p><ul><li>Consider early transplantation in carefully selected Pts (Gastro 2018;155:422)</li></ul><p>Acetaminophen hepatotoxicity (Clin J Transl Hepatol 2016;4:131; BMJ 2016;353:i2579)</p><ul><li><p>Pathophysiology: >90% of acetaminophen (N-acetyl-p-aminophenol, APAP) metab into nontoxic metab, but ~5% metab by CYP2E1 into NAPQI, a hepatotoxic metab detoxified by glutathione conjugation; APAP overdose (>10 g) depletes glutathione stores → injury</p></li><li><p>CYP2E1 induced by fasting, alcohol, certain anticonvulsants and anti-TB drugs, resulting in injury with even low doses (2–6 g) of acetaminophen</p></li><li><p>Liver dysfunction may not be apparent for 2–6 d; nausea, vomiting & abdominal pain 1st sx</p></li><li><p>Rx: NG lavage, activated charcoal if w/in 4 h. Consider early transfer to transplant ctr</p></li></ul><p>N-acetylcysteine: administer up to 72 h after ingestion, if time of ingestion unknown or chronic ingestion >4g/d; low threshold to start NAC w/ low or undetectable APAP levels</p><p>PO NAC (preferred): 140 mg/kg loading dose → 70 mg/kg q4h × 17 additional doses</p><p>IV NAC: 150 mg/kg × 1 h → 50 mg/kg × 4 h → 100 mg/kg × 16 h; risk of anaphylaxis (↓ w/ 12-h regimen; Lancet 2014;383:697); use if unable to tolerate POs, GIB, pregnancy, liver injury</p><p>Ischemic hepatitis</p><ul><li><p>“Shock liver” w/ AST & ALT >1000 + ↑↑ LDH (ALT:LDH ratio often &lt;1:5); delayed ↑↑ Tbili</p></li><li><p>Seen in HoTN & CHF; often requires ↑ venous + ↓ portal/arterial pressure + hypoxia</p></li></ul><p>Nonalcoholic fatty liver disease (NAFLD) (JAMA 2020;323:1175; Lancet 2021;397:2212)</p><ul><li>Definition: fatty infiltration of liver + absence of EtOH or other cause of steatosis (HCV, etc.)</li></ul><p>NAFL = steatosis, Ø inflam; NASH = steatosis + inflam ± fibrosis on bx</p><ul><li><p>NAFLD: 25% of U.S. pop. & over 60% in T2DM & obesity</p></li><li><p>NASH: 2–5% of NAFLD & risk of cirrhosis in NASH w/ fibrosis on bx is 30% at 10 y</p></li><li><p>Clinical: 80% asx, ↑ ALT > AST, but nl ALT/AST does not exclude poss. of NASH on bx</p></li><li><p>Dx: liver bx remains gold standard. VCT elastography emerging alternative (J Hepatol 2017;66:1022). FIB-4/NAFLD fibrosis score predicts NASH w/ advanced fibrosis w/ PPV >80%.</p></li><li><p>Rx (Gastro 2021;161:1657): wt loss (≥10%), exercise, DM control, liraglutide (Lancet 2016;387:679), statins (Metabolism 2017;71:17), vit E in Pts w/o DM (Hepatol 2018;67:328), bariatric surgery (World J Hepatol 2019;11:138). New therapies (eg, PPAR agonist lanifibranor, NEJM 2021;385:1547) emerging. HCC a complication of NAFLD, usually in setting of NASH cirrhosis.</p></li></ul><p>ACUTE LIVER FAILURE (ALF)</p><p>Definition</p><ul><li><p>Acute liver injury + coagulopathy + encephalopathy w/o preexisting liver dis. (&lt;26 wks)</p></li><li><p>Fulminant if encephalopathy &lt;8 wks from jaundice onset, subfulminant if 8–26 wks</p></li><li><p>Acute on chronic liver failure: acute insult to liver in Pt w/ underlying chronic liver disease</p></li></ul><p>Etiology (J Hepatol 2015;62:S112)</p><ul><li>Drugs/toxins (nearly 80% of cases in U.S.; Gastro 2015;148:1353, Clin Liver Dis 2017;21:151)</li></ul><p>Dose-dependent: acetaminophen (most common cause; >40% of cases in U.S.)</p><p>Idiosyncratic, not dose related: anti-TB drugs (INH, RIF, PZA); AEDs (phenytoin, valproate, carbamazepine); NSAIDs; abx (eg, fluoroquinolones, macrolides, nitro-furantoin); drugs of abuse (MDMA & cocaine); others (amiodarone, TCAs)</p><p>Toxins: Amanita phalloides (mushroom sp. in West Coast), certain herbal preparations</p><ul><li><p>Viral: HAV, HBV, HCV (rare), HDV + HBV, HEV (esp. if pregnant). In immunosupp: HSV (50% have skin lesions), EBV, VZV, CMV, HHV6</p></li><li><p>Vascular: Budd-Chiari, ischemic hepatitis, hepatic sinusoidal obstruction syndrome</p></li><li><p>Other: Wilson disease, pregnancy-related ALF (acute fatty liver, preeclampsia, HELLP), initial presentation of autoimmune hepatitis; idiopathic</p></li></ul><p>Clinical manifestations</p><ul><li><p>Initial presentation: N/V, malaise, RUQ pain, jaundice, encephalopathy, multiorgan failure</p></li><li><p>Neurologic: encephalopathy: grade 1 = attn deficit, disordered sleep; grade 2 = asterixis, confusion; grade 3 = somnolence, rigidity; grade 4 = coma; ↑ ICP w/ bradycardia & HTN</p></li></ul><p>cerebral edema: astrocyte swelling related in part to ↑ ammonia levels</p><ul><li><p>Cardiovascular: hypotension with low SVR, shock</p></li><li><p>Pulmonary: respiratory alkalosis, impaired peripheral O2 uptake, pulm edema, ARDS</p></li><li><p>GI: GI tract bleed common (need PPI Ppx), pancreatitis (due to ischemia, drugs, infxn)</p></li><li><p>Renal: ATN, hepatorenal syndrome, hyponatremia, hypokalemia, hypophosphatemia</p></li><li><p>Hematology: bleeding diathesis w/ thrombocytopenia, ↑ PT/PTT, ↓ fibrinogen, ↓ synthesis of coag factors balanced by ↓ protein C/S; bleeding mostly due to low platelet count, DIC</p></li><li><p>Infection: espec. with Staph, Strep, GNRs, and fungi (↓ immune fxn, invasive procedures); fever and ↑ WBC may be absent, most common sites are respiratory, urinary & blood</p></li><li><p>Endocrine: hypoglycemia (↓ glc synthesis), metabolic acidosis (↑ lactate), adrenal insuf.</p></li></ul><p>Workup (Clin Liver Dis 2017;21:769)</p><ul><li><p>CBC, PT/PTT, LFTs, lytes, BUN/Cr, NH3, pH, arterial lactate, acetaminophen level, HIV, amylase/lipase, viral serologies (qv) in all Pts, with additional labs as below if suspected</p></li><li><p>Autoimmune hep serologies & IgG levels, ceruloplasmin & serum/urine copper, preg test</p></li><li><p>Imaging studies (RUQ U/S or abd CT, Doppler studies of portal and hepatic veins)</p></li><li><p>Liver biopsy if underlying etiology remains elusive after initial testing</p></li></ul><p>Management (J Clin Exp Hepatol 2015;5:S104; Gastro 2017;152:644)</p><ul><li><p>ICU care at liver transplant center for hemodynamic & ventilatory support; CVVH for AKI</p></li><li><p>Early listing for liver transplantation in selected Pts (see below)</p></li><li><p>Cerebral edema: consider ICP monitoring if grade 3/4 enceph; if ↑ ICP → mannitol 0.5–1.0 mg/kg; if arterial NH3 >150, grade 3/4 enceph, AKI or on vasopressors → prophylactic 3% saline with goal Na 145–155 mEq/L; barbiturates & hypothermia if refractory ↑ ICP</p></li><li><p>Encephalopathy: intubate for grade 3 or 4; lactulose is of little benefit & may be detrimental</p></li><li><p>Coagulopathy: vit K, FFP/plts/cryo only if active bleeding (↑ risk of volume overload)</p></li><li><p>Infection: low threshold for abx (broad spectrum, eg, vancomycin & 3rd-gen ceph.) if suspect infection; anti-fungal coverage in high-risk Pts (TPN, CVVH)</p></li><li><p>Rx of specific causes: NAC if acetaminophen; antiviral for HBV; plasma exchange can be temporizing measure for Wilson disease; IV acyclovir for HSV; PCN-G for A. phalloides; delivery of child for pregnancy-related; TIPS, anticoag for Budd-Chiari. Lack of data for use of steroids in autoimmune, but often given (Hepatology 2014;59:612).</p></li><li><p>NAC may benefit Pts w/ non-APAP ALF but data inconclusive (Clin Drug Investig 2017;37:473)</p></li><li><p>King’s College Criteria for Liver Transplantation consideration:</p></li></ul><p>Acetaminophen ALF: arterial pH &lt;7.30 or Grade III/IV enceph + INR >6.5 + Cr >3.4</p><p>Non-acetaminophen ALF: PT >100 or any 3: age &lt;10 or >40 y, jaundice >7 d prior to onsent of encephalopathy, PT >50 or INR >3.5, Tbili >18, unfavorable disease (viral hepatitis, DILI, Wilson’s disease, or low factor V level)</p><p>Prognosis (Ann Intern Med 2016;164:724; World J Gastro 2016;22:1523)</p><ul><li><p>Non-acetaminophen ALF mortality ~70%, acetaminophen-induced ALF mortality ~25–30%</p></li><li><p>HBV, Wilson’s, AIH, DILI, Budd-Chiari ~ associated with ↓ prognosis</p></li><li><p>Factor V level &lt;20% in Pts &lt;30 yrs or &lt;30% in >30 yrs associated w/ poor prognosis</p></li></ul><p>CIRRHOSIS</p><p>Definition (Dig Dis 2016;34:374; NEJM 2016;375:767; J Hep 2016;64:717)</p><ul><li><p>Definition fibrosis & regenerative nodules causing distortion of hepatic architecture</p></li><li><p>Decompensated = complication due to ↑ portal pressure such as: variceal bleed, HCC, SBP, encephalopathy, ascites, hepatorenal or hepatopulmonary syndrome</p></li></ul><p>Etiologies</p><ul><li><p>Alcohol, toxins (eg, arsenic)</p></li><li><p>Nonalcoholic fatty liver disease (NAFLD) is the cause of most “cryptogenic cirrhosis”</p></li><li><p>Viral hepatitis: chronic HBV, HCV, HDV infection</p></li><li><p>Autoimmune hepatitis: ♀, ↑ IgG, ⊕ ANA, ASMA, anti-LKM-1, anti-LC1</p></li><li><p>Metabolic diseases: hemochromatosis, Wilson disease, α1-AT deficiency</p></li><li><p>Biliary tract diseases: primary biliary cholangitis, secondary biliary cirrhosis (calculus, neoplasm, stricture, biliary atresia), primary sclerosing cholangitis</p></li><li><p>Vascular diseases: Budd-Chiari syndrome, R-sided CHF, constrictive pericarditis, SOS</p></li><li><p>Medications: amiodarone, methotrexate, vitamin A, valproic acid, isoniazid</p></li></ul><p>Clinical manifestations</p><ul><li>Nonspecific sx (anorexia, fatigue) or jaundice, encephalopathy, ascites, variceal bleeding</li></ul><p>Physical exam</p><ul><li><p>Liver: initially enlarged, palpable (L lobe predom), firm; eventually shrunken, nodular</p></li><li><p>Signs of liver failure: jaundice (bili >2.5), spider angiomata & palmar erythema (↑ estra- diol), Dupuytren contractures, white nail lines (Muehrcke lines) & proximal nail beds (Terry nails), ↑ parotid & lacrimal glands, gynecomastia, testicular atrophy, asterixis, encephalopathy, clubbing, hypertrophic osteoarthropathy, anovulation in women</p></li><li><p>Signs of portal HTN: splenomegaly, ascites, dilated superficial abd veins (caput medusae), epigastric Cruveilhier-Baumgarten venous hum (flow through recanalized umbilical vein)</p></li></ul><p>Laboratory studies</p><ul><li><p>LFTs: ↑ bili, ↑ PT/INR (poor correlation w/ bleeding; factor VIII nl b/c not synthesized by liver), ↓ alb, ± ↑ aminotransferases (AST >ALT if late) and ↑ Aϕ (variable)</p></li><li><p>Hematologic tests: anemia (marrow suppress., hypersplenism, Fe ± folate defic.), neutro-penia (hypersplenism), thrombocytopenia (hypersplenism, ↓ Tpo production, EtOH tox)</p></li><li><p>Chem: ↓ Na (↑ ADH due to ↓ EAV); ↑ Fe/TIBC, ↑ ferritin (released from hepatocytes)</p></li><li><p>Lab indices predictive of cirrhosis: AST/plt >2; Lok index; Bonacini score (JAMA 2012;307:832)</p></li><li><p>Indirect markers of fibrosis: FibroTest/FibroSURE, Hepascore (good at differentiating significant fibrosis F2 to F4), FIB-4 index (NAFLD, HCV), NAFLD fibrosis score, APRI (HCV), non-invasive imaging (eg, U/S or MR elastography)</p></li></ul><p>Workup (Am J Gastro 2017;112:18; Lancet 2021;398:1359)</p><ul><li><p>Abd U/S w/ Doppler: liver size & echotexture, r/o HCC, ascites, ✓ patency of vasculature</p></li><li><p>Determine etiology: hepatitis serologies (HBsAg, anti-HBs, anti-HCV), autoimmune hepatitis studies (IgG, ANA, ASMA), Fe and Cu studies, α1-AT, AMA</p></li><li><p>Assess fibrosis: biomarkers (FibroSURE = panel of 5 markers validated in HCV, ↑ score predictive of fibrosis); elastography (U/S or MR-based; measurement of liver stiffness)</p></li><li><p>Liver bx (gold standard): percutaneous or transjugular (consider if ascites or coagulopathy), used to confirm presence of cirrhosis and dx etiology, not always needed</p></li></ul><p>Prognosis (
<a href=https://www.mdcalc.com/child-pugh-score-cirrhosis-mortality rel=noopener>www.mdcalc.com/child-pugh-score-cirrhosis-mortality</a>)</p><ul><li><p>Modified Child-Turcotte-Pugh (CPS) score based on ascites, enceph., & labs (bili, alb & INR; see Appendix). CPS A (5–6 pts): 1-y survival 100%, B (7–9): 80%; C (10–15): 45%.</p></li><li><p>MELD-Na (Model for End-Stage Liver Disease; Gastro 2011;14:1952): used to stratify liver Tx list & predict 3-mo survival in cirrhosis and some acute forms of liver dis. Based on Cr, INR, total bili, Na. Calculator:
<a href=https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/ rel=noopener>https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/</a>.</p></li></ul><p>If MELD &lt;21, additional predictors of mortality include refractory ascites, ↑ HVPG & ↓ QoL.</p><p>MELD-Plus includes alb, chol, LOS, age, WBC (PLOS One 2017;12:e0186301).</p><p>Ascites (see “Ascites” for diagnostic eval; Dig Dis 2017;35:402; Hepatology 2021;74:1014)</p><ul><li><p>Due to portal HTN (defined as hepatic venous pressure gradient [HVPG] >5 mmHg)</p></li><li><p>Develops in 60% w/in 10 y; often first decompensating event</p></li><li><p>Treatment: ↓ Na intake (1–2 g/d); restrict intake of free water if Na &lt;125</p></li></ul><p>Diuretics: goal diurese ~1 L/d. Use spironolactone ± furosemide in 5:2 ratio (uptitrate as able); urine Na/K >1 implies effective natriuresis if Pt compliant w/ low-Na diet</p><p>Avoid NSAIDs/ACEI/ARBs in cirrhosis because interfere w/ diuretic action</p><p>Long-term albumin infusions ↓ mortality (Lancet 2018;391:2417), but not widely adopted</p><ul><li>Refractory ascites: seen in 5–10% of Pts; 2-y survival 25%</li></ul><p>Defined as diuretic-resistant if on 2-g Na diet w/ minimal weight loss on max diuretics, or diuretic-induced complications (AKI, Na &lt;125, ↑ K, encephalopathy)</p><p>Conflicting evid. for d/c’ing βB (Hep 2016;63:1968; J Hepatol 2016;64:574). Discontinue if SBP &lt;90 or MAP ≤82 mmHg, serum Na &lt;120 mEq/L, AKI, HRS, SBP, sepsis, severe alcohol-assoc hepatitis, or poor follow-up. If limited by HoTN, can add midodrine.</p><p>Large-volume paracenteses (LVP; >5 L fluid removal): give 6–8 g albumin per L fluid removed (above 5 L) as colloid replacement a/w ↓ risk of post-para circulatory dysfxn & possibly ↓ mortality (Hep 2012;55:1172). Avoid LVP if SBP present because ↑ risk of AKI.</p><p>Transjugular intrahepatic portosystemic shunt (TIPS) (Gastro 2017;152:157)</p><p>↓ ascites in 75%; ↑ CrCl, ↑ enceph, survival benefit over LVP remains controversial</p><p>Contraindic: grade II enceph, CHF or pulm HTN, active infxn or biliary obstruction</p><p>Complications: bleeding, fistula; stent thrombosis (1-y patency w/ coated stents ~80%); infxn (“endotipsitis”); new or ↑ enceph in 20–30% (Am J Gastro 2016;111:523), hemolysis</p><p>Consider for liver transplant if above fail</p><ul><li>Hepatic hydrothorax: 2° diaphragmatic defect; often unilateral, R >L, ± ascites</li></ul><p>Treatment: avoid chest tube (↑ complications); Rx same as ascites (TIPS if refractory). Indwelling pleural catheter potential option if refractory for palliation (Chest 2019;155:307)</p><p>Spontaneous empyema can occur (even w/o SBP) → dx thoracentesis; Rx abx</p><p>Spontaneous bacterial peritonitis (SBP; see “Ascites”; Hepatology 2021;74:1014)</p><ul><li><p>High mortality rate; risk factors include ascitic TP &lt;1 g/dL, hx of SBP, current GIB</p></li><li><p>Can p/w encephalopathy, abd pain, fever, but often (25%) asx; perform diagnostic paracentesis in all hospitalized patients with cirrhosis and ascites</p></li><li><p>Micro: typically, monobacterial GNRs (E. coli, Klebs) >GPCs (S. pneumo, enterococcus)</p></li><li><p>Rx: 3rd-gen. ceph is 1st line; consider pip/tazo or mero if ↑ risk of MDRO; vanc if prior MRSA ⊕; IV albumin 1.5 g/kg at time of dx & 1 g/kg on day 3 → ↑ survival (NEJM 1999;341:403)</p></li><li><p>Repeat paracentesis at 48 h: expect 25% ↓ in PMNs if Rx working.</p></li><li><p>Indefinite Ppx if (1) h/o SBP or (2) ascitic TP &lt;1.5 plus: Na ≤130 or Cr ≥1.2 or BUN ≥25 or [CPS ≥9 + Tbili ≥3] (Am J Gastro 2009;4:993) → cipro 500 mg qd or Bactrim DS qd. Short-term Ppx: CTX 1 g IV × 7d if GIB (Δ to cipro 500 bid/Bactrim DS bid when eating).</p></li></ul><p>Gastroesophageal varices  UGIB (see also “GIB”; Hepatology 2017;65:310)</p><ul><li><p>Presence of varices correlates w/ severity of liver dis (40% of Child A Pts → 85% Child C)</p></li><li><p>↑ varix size, child B/C, & red wale marks assoc w/ ↑ risk of bleeding</p></li><li><p>UGIB 1° prevention: screen at time of dx w/ EGD; data best for Pts w/ med-large varices</p></li></ul><p>Nonselective β-blockers: ~50% ↓ risk of bleeding & ↓ mortality if med-large varices. Nadolol, propranolol, or carvedilol; latter ↓ MAP & HVPG more than propranolol; delays progression of varices (Gut 2017;66:1838); may use in Pts w/ HTN. Titrate to max tolerated dose; EGD not req. to document improvement. Hold for criteria listed above.</p><p>Endoscopic variceal ligation (EVL): superior to βB in ↓ risk of 1st bleed but no diff in mortality (Ann Hep 2012;11:369); risk of serious complications (esoph perf, ulcers). Repeat q1–4wk until varices gone, w/ f/u EGD at 3 mo then q6–12mo.</p><p>βB vs. EVL: choice based on Pt/physician preference; βB often 1st for small varices; larger varices may benefit more from EVL; both for 1° Ppx currently not recommended</p><ul><li>2° prevention: for all Pts after 1st bleed, given ~50% risk of rebleed & ~30% mortality; βB + EVL >either alone; TIPS if refractory, or consider in child B/C w/in 72 h of admission for EV bleed (↓ rebleeding, ↑ enceph., Ø Δ mort.) (Hepatology 2017;65:310)</li></ul><p>Hepatic encephalopathy (HE) (NEJM 2016;375:1660; Hepatology 2014; 60:715)</p><ul><li><p>Pathogenesis: failure of liver to detoxify NH3 + other substances (eg, ADMA; J Hepatol 2013;58:38) that cause cerebral edema, ↓ O2 consumption, ↑ ROS → brain dysfxn</p></li><li><p>Precipitants: bleeding, infxn, med nonadherence, ↓ K, ↓ Na, dehydration, hypoxia, portosystemic shunt (eg, TIPS), meds (eg, sedatives), acute insult to liver (eg, PVT)</p></li><li><p>Stages: see section in “Acute Liver Failure”</p></li><li><p>Dx: serum NH3 levels have poor Se for dx & monitoring Rx; remains a clinical dx</p></li><li><p>Rx: identify/correct precipitants; lactulose (acidification of colon: NH3 → NH4+) w/ goal 2–4 stools/d (PEG may be as effective; JAMA IM 2014;174:1727); add rifaximin 550 mg bid (↓ gut bacteria → ↓ NH3 prod) if refractory or after 2nd recurrence HE on lactulose (NNT=3) (Am J Gastro 2013;108:1458); FMT, oral branched-chain AAs, probiotics may have a role (Cochrane Reviews 2017;2; Gastro 2019;156:1921); maintain K >4, avoid alkalosis as able</p></li></ul><p>Hepatorenal syndrome (HRS) (Hepatology 2021;74:1014, Gastro 2016;150:1525)</p><ul><li><p>Pathophys: splanchnic vasodilation and renal vasoconstriction w/ ↓ renal blood flow</p></li><li><p>Criteria: (1) cirrhosis w/ ascites; (2) acute kidney injury (serum Cr ↑ ≥0.3 mg/dL w/in 48 h or ≥50% ↑ in serum Cr from baseline; Gut 2015;64:531); (3) Ø improvement in Cr after d/c diuretic & volume expansion (1 g/kg/d of albumin × 2 d); (4) Ø shock (prerenal azotemia/ATN); (5) Ø nephrotoxic meds; (6) Ø intrinsic kidney disease</p></li></ul><p>HRS-AKI: development in &lt;2 wk; usually occurs in severe liver failure, often following precipitating event (see later); median survival 2 wk</p><p>HRS-CKD: more indolent, median survival 6 mo; liver failure present &lt;than in HRS-AKI</p><ul><li><p>Precipitants: GIB, overdiuresis, infection, serial LVP, drugs (aminoglycosides, NSAIDs)</p></li><li><p>Rx: if critically ill → vasopressor (eg, norepinephrine or vasopressin) + albumin (1 g/kg, max 100 g, bolus daily) to ↑ MAP 10 mmHg. If not critically ill → octreotide (100–200 mcg SC tid) + midodrine (max 15 mg PO tid) + 1 g/kg (max 100 g) albumin on day of presentation followed by 20–60 g albumin qd to ↑ MAP. Terlipressin + albumin ↑ 10 d survival (not yet approved in U.S. but now recommended by AASLD) (NEJM 2021;384:818). May need dialysis or TIPS as bridge to liver transplant.</p></li></ul><p>Hepatocellular carcinoma (HCC; qv in Heme-Onc) (Nature Reviews 2021;7:6)</p><ul><li><p>↑ risk w/ cirrhosis of any type (leading cause of death in cirrhosis, 1–6%/y) but esp. ↑ w/ viral (Hep B/C~3–8%/y), concomitant EtOH use, obesity related NASH, HFE or diabetes</p></li><li><p>Clinical: asx vs. hepatic decompensation (eg, ascites, HE), PVT w/ tumor thrombus</p></li><li><p>Dx: screen Pts w/ cirrhosis q6mo w/ U/S ± AFP; alternative is dual-phase CT/MRI</p></li><li><p>Rx: see “HCC” in Heme-Onc</p></li></ul><p>Other complications</p><ul><li>Hepatopulmonary syndrome (HPS) (Dig Dis Sci 2015;60:1914, Hepatology 2021;74:1014)</li></ul><p>Abnl gas exchange (A-a gradient ≥15 or PaO2 &lt;80) caused by intrapulmonary vascular dilatations leading to intrapulmonary shunting (improves with O2)</p><p>S/S: platypnea-orthodeoxia (dyspnea & hypoxia w/ sitting up), clubbing, spider angiomas</p><p>Dx w/ contrast echo showing “late” A-V shunting (contrast in LA 3–6 cycles after RA)</p><p>Rx: O2; potential embolization if large vessel on CT, TIPS, liver tx only definitive Rx</p><ul><li>Portopulmonary hypertension (POPH) (Expert Rev Gastro Hepatol 2015;9:983)</li></ul><p>Pulm HTN in Pt w/ portal HTN w/o other cause. ESLD→ ↑ endothelin→ pulm vasoconst.</p><p>Rx w/ same therapies as for idiopathic PAH, incl prostacyclin analogs, endothelin receptor antagonists, sildenafil; liver transplant is often curative</p><ul><li><p>Cirrhotic cardiomyopathy: ↓ inotropic & chronotropic response, ↓ systolic & diastolic fxn, ↑ QT, hyperkinetic circulation, high output; ↑ troponin & BNP</p></li><li><p>Infxns: unless immune, vaccinate for HAV, HBV, PCV13, PPSV23, COVID-19; flu yearly. Cellulitis in ~20% of Pts hospitalized w/ cirrhosis, often in abd or LE a/w edema.</p></li><li><p>Endocrine: diabetes (15–30%), ↑ frequency of adrenal insuffic. (Dig Dis Sci 2017;62:1067)</p></li><li><p>Coagulopathy: balanced defects w/ ↓ synth of coag factors, hyperfibrinolysis, ↓ plt balanced by ↓ synthesis anticoag factors (protein C/S), defic. of profibrinolytic factors, ↑ levels of vWF. No support for routine administration of FFP, plt, cryo unless DIC.</p></li><li><p>Nutrition: monitor and supplement fat-soluble vitamins, zinc, screen for malnutrition, sarcopenia & fraility; ensure protein intake 1.2–1.5 g/kg/d (Hepatology 2021;74:1611)</p></li><li><p>Meds: acetaminophen can be used up to 2 g/d; avoid ASA/NSAIDs; aminoglycosides contraindicated; oral hypoglycemics if compensated but insulin if decompensated</p></li></ul><p>Liver transplantation (Hepatology 2014;59:1144)</p><ul><li><p>Undertake evaluation when MELD ≥15. Exception points added if HCC, HPS</p></li><li><p>Indic: recurrent/severe enceph, refractory ascites, recurrent variceal bleeding, HRS, HPS, PPH, HCC (if no single lesion is >5 cm or ≤3 lesions with largest ≤3 cm), ALF</p></li><li><p>Contraindic: inadequate social support, active substance abuse (some exception), sepsis, advanced cardiopulm dis., extrahepatic Ca, cholangio Ca, hemangiosarcoma, persistent noncompliance, AIDS, ALF w/ sustained ICP >50 mmHg or CPP &lt;40 mmHg</p></li><li><p>Survival: 1-y up to 90%, 5-y up to 80%, though lower with autoimmune liver disease, such as AIH/PBC/PSC may recur in 10–30% (or more) of allografts</p></li></ul><p>OTHER ETIOLOGIES OF CIRRHOSIS</p><p>Hemochromatosis & iron overload syndromes (Am J Gastro 2019;114:1202)</p><ul><li><p>Recessive disorder of iron sensing or transport leading to tissue iron deposition</p></li><li><p>HFE mutations (85% of cases): typically C282Y homozyg. (~0.5% of N. Europeans), rarely C282Y/H63D compound heterozyg. C282Y homozygotes: 28% of ♂ & 1% of ♀ develop sx (delayed since menses ↓ Fe load). C282Y/H63D: only 1.5% manifest dis.</p></li><li><p>Non-HFE mutations: hemojuvelin, hepcidin, transferrin receptor 2, & ferroportin</p></li><li><p>2° causes of iron overload: iron-loading anemias (eg, thalassemia major, sideroblastic anemia, aplastic anemia), parenteral iron overload (RBC transfusions, long-term HD), chronic liver disease (due to EtOH, HBV, HCV, NASH, etc.), dietary iron overload</p></li><li><p>Sx: fatigue & arthralgias, loss of libido in ♂. In advanced disease (rare): bronze skin (melanin + iron), hypogonadism (esp. in juvenile onset), DM, arthropathy (MCP), CHF, infxns (↑ risk Vibrio, Listeria, Yersinia), cirrhosis (↑ risk if EtOH/fatty liver disease; 15% risk of HCC). Disease also a/w ALS (H63D homozygotes) & porphyria.</p></li><li><p>Dx: iron sat >45% (iron/TIBC × 100%); ↑ ferritin (acute phase reactant, so poor Sp; often nl in young Pts). If ↑ iron sat. → ✓ HFE to confirm dx, imaging by MRI (black liver). If HFE ⊕ & ferritin >1000 ng/mL or ↑ LFTs → liver bx for quant Fe index & to stage fibrosis</p></li><li><p>Treatment: phlebotomy (250 mL = 1 unit, ~250 mg of Fe) qwk until Fe sat &lt;50% & ferritin 50–100 µg/L, then q3–4mo; PPI ↓ intestinal Fe absorption & may ↓ need for phlebotomy; avoid vit C & uncooked seafood; deferoxamine if phleb. contraindic.; genetic counseling</p></li></ul><p>Wilson disease (World J Hepatol 2015;7:2859)</p><ul><li><p>Recessive disorder of copper transport (mutation in ATP7B) → copper overload</p></li><li><p>Epidemiology: 1 in ~30,000 w/ age of presentation generally ranging from 3 to 55 y</p></li><li><p>Extrahepatic s/s: neuro ψ disease, parkinsonism, movement disorder (hepatolenticular disease), Kayser-Fleischer rings (⊕ in 99% w/ neuro ψ but in &lt;50% w/ hepatic disease), Coombs ⊖ hemolytic anemia, renal disease</p></li><li><p>Dx: ↑ 24-h urine Cu, ↓ serum ceruloplasmin (Se 90%), liver bx w/ hepatic Cu content, genetic testing for ATP7B gene helpful if unclear dx. In acute liver failure, Aϕ/bili &lt;4 + AST/ALT >2.2 better Se & Sp than urine Cu or ceruloplasmin (Hepatology 2008;4:1167).</p></li><li><p>Treatment: chelation w/ D-penicillamine (supplement B6 as D-pen inactivates); alternative is trientine (↓ toxicity w/ ≈ efficacy, but $$), ammonium or bis-choline tetrathiomolybdate (investigational) may ↓ neurologic deterioration compared to trientine. Zinc: ↓ intestinal Cu transport & can help delay disease; best used in conjunction w/ chelation (give 5 h after chelators). Eliminate Cu-rich foods. Transplant for ALF or unresponsive to Rx.</p></li></ul><p>α1-antitrypsin deficiency (α1-AT) (J Hepatol 2016;65:413; NEJM 2020;382:1443)</p><ul><li><p>Abnl α1-AT → polymerization in liver (cirrhosis) & uninhibited protease activity in lung (emphysema). Affects 1/3000 of European ancestry. Varied presentations: neonatal hepatitis; cholestatic jaundice in children; ↑ AST/ALT or cirrhosis in children/adults.</p></li><li><p>Extrahepatic disease: panlobular emphysema, necrotizing panniculitis, ANCA vasculitis</p></li><li><p>Dx: serum α1-AT (acute phase reactant) w/ CRP level (to ensure not ↑ due to inflamm.)</p></li></ul><p>gold standard = phenotyping of protease inhibitor (Pi). Alleles most a/w hepatic dis.: Z (63% of ZZ adults have chronic liver dis. and liver fibrosis, may be present in 35% of ZZ individuals w/o overt liver disease) & M (malton) (J Hepatol 2018;69:1357). Liver bx shows characteristic PAS ⊕ cytoplasmic inclusion bodies.</p><ul><li>Treatment: ↓ risk by avoiding EtOH, maintaining a normal BMI; liver transplant if severe</li></ul><p>Primary biliary cholangitis (PBC) (Hep 2019;69:394; Nat Rev 2020;17:93; Lancet 2020;396:1915)</p><ul><li><p>Autoimmune destruction of intrahepatic bile ducts</p></li><li><p>Epi: ♀ 40–60 y; a/w Sjögren’s (50%), Raynaud’s, scleroderma, celiac & thyroid disease; may be triggered by infxns or toxins; a/w X monosomy, variants in IL12α & IL12R genes</p></li><li><p>Sx: fatigue/sleep disturbance, pruritus, jaundice, 50% asx w/ only LFT abnormalities</p></li><li><p>Ddx: PSC, AIH, hepatic sarcoidosis, meds, idiopathic adult ductopenia, biliary stricture/Ca</p></li><li><p>Dx: ↑ Aϕ, ↑ bili, ↑ IgM, ↑ chol (mainly HDL-C), ⊕ (AMA) in 95%. If ⊕ AMA, liver bx not needed due to high Se & Sp. 0.5% gen pop ⊕ AMA & nl LFTs → 10% develop PBC at 6 y. If AMA ⊖, liver bx (Pts often ⊕ ANA, smooth muscle Ab; same prognosis as ⊕ AMA).</p></li><li><p>Rx: ursodeoxycholic acid (UDCA) (13–15 mg/kg bid), monitor for 3–6 mos → ~25% complete response, ↑ survival & ↓ histologic change & ↓ complications (varices). Biochemical response predicts clinical outcome.</p></li></ul><p>Obeticholic acid (FXR agonist): monoRx if cannot tolerate UDCA (but not in decompen cirrhosis) or if no Δ w/ UDCA after 1 y; found to ↓ Aφ, ↑ pruritus (NEJM 2016;375:631)</p><p>Bezafibrate (not available in U.S. but fenofibrate similar) appears to be effective 2nd-line agent in combo w/ UDCA if inadequate response to UDCA (NEJM 2018;378:2171)</p><p>Pruritus: cholestyramine (give 2–4 h after UDCA); if refractory sx: naltrexone, rifampin</p><p>If ESLD: liver tx; ~20% recur but no impact on long-term survival</p><p>Primary sclerosing cholangitis (PSC) (NEJM 2016;375:1161; Clin Liver Dis 2020;15:125)</p><ul><li><p>Diffuse inflammation of intrahepatic and extrahepatic bile ducts leading to fibrosis & stricturing of biliary system. A/w HLA-B8 and -DR3 or -DR4, frequent ⊕ autoantibodies.</p></li><li><p>Epi: ♂ >♀ (20–50 y) ~70% Pts w/ PSC have IBD (usually UC); only 1–4% w/ UC have PSC. ⊕ prognostic factors: ♂, absence of IBD, small duct PSC (Gastro 2017;152:1829).</p></li><li><p>Symptoms: fatigue, pruritus, jaundice, fevers, RUQ pain, IBD; 50% of Pts asymptomatic</p></li><li><p>Ddx: extrahepatic obstruction, PBC, overlap w/ AIH, IgG4 autoimmune cholangitis, etc.</p></li><li><p>Dx: cholangiography (MRCP ± ERCP) → multifocal beaded bile duct strictures; exclude 2° cause; may miss dx if confined to small intrahepatic ducts (“small duct PSC”).</p></li></ul><p>Liver bx if unclear: “onion-skin” fibrosis around bile ducts + some findings similar to PBC.</p><ul><li>Treatment: supportive care, fat-soluble vitamins; no meds have improved survival</li></ul><p>UDCA may ↓ Aϕ & improve Sx, but unclear if beneficial</p><p>If dominant stricture → endoscopic dilation, stenting or surgical resection can help</p><p>Cholangiocarcinoma: 15% lifetime risk; annual surveillance w/ MRCP or U/S & CA19-9</p><p>Liver transplantation: ~30% recurrence, though if UC, colectomy may ↓ recurrence</p><p>HEPATIC VASCULAR DISEASE</p><p>Figure 3-5 Normal hepatic vasculature</p><p>(Modified from The Nature of Disease Pathology for the Health Professions, 2007. Hepatology 2009;49:1729.)</p><p>Portal vein thrombosis (PVT) (Clin Liver Dis 2017;10:152; Gastro 2019;156:1582)</p><ul><li><p>Definition: thrombosis of portal vein often w/ extension into mesenteric vein/splenic vein</p></li><li><p>Etiologies: commonly due to cirrhosis or hypercoaguable state (cancer, infection, OCP, collagen vascular diseases, Behçet’s, IBD, surgery, trauma, OCPs, preg)</p></li><li><p>Clinical manifestations</p></li></ul><p>acute: abd pain, fever, variceal bleed or asx w/ incidental finding on U/S or CT. If mesenteric vein involved may p/w intestinal infarct. If fever, consider pylephlebitis.</p><p>chronic: asx/incidental finding; may p/w s/s of portal HTN → hematemesis 2° variceal bleeding, splenomegaly, encephalopathy; ascites uncommon unless cirrhosis</p><ul><li><p>Dx: LFTs usually nl; begin w/ U/S w/ Doppler, confirm w/ MRA or CT (I+), angio; consider hypercoag w/u. “Portal cavernoma”: network of hepatopetal collaterals in chronic PVT—can rarely cause biliary obstruction & cholestatic LFTs = portal cholangiopathy.</p></li><li><p>Treatment: Acute: If noncirrhotic, LMWH → warfarin or DOAC × 6 mo, or indefinitely if irreversible cause. If cirrhotic, anticoag ↑ recanalization w/o ↑ bleeding (Gastro 2017;153:480); screen for high-risk varices prior to Rx (Nat Rev Gastro Hep 2014;11:435).</p></li></ul><p>Chronic: Anticoag if noncirrhotic or hypercoag state. If cirrhotic, consider txp if sx or progression. In all, screen for varices; if present, variceal bleed Ppx prior to anticoag.</p><p>Splenic vein thrombosis</p><ul><li>Can occur 2/2 local inflam. (eg, panc.). Can p/w isol. gastric varices. Splenectomy curative.</li></ul><p>Budd-Chiari syndrome (World J Hepatol 2016;8:691)</p><ul><li><p>Hepatic outflow obstruction 2/2 occlusion of hepatic vein(s) or IVC → sinusoidal congestion and portal HTN. Can be 1° (eg, thrombosis) or 2° (eg, extravascular compression).</p></li><li><p>Etiol.: ~50% due to myeloprolif. d/o a/w JAK2 mutations (P. vera, etc.), hypercoag states (systemic, OCP, pregnancy), tumor invasion (HCC, renal, adrenal), trauma, idiopathic</p></li><li><p>Symptoms: hepatomegaly, RUQ pain, ascites, dilated venous collaterals, acute liver failure</p></li><li><p>Dx: ± ↑ AST, ALT & Aϕ; Doppler U/S of hepatic veins (85% Se & Sp); CT (I+) or MRI/MRV → vein occlusion or ↑ caudate lobe (separate venous drainage); hepatic venography gold standard w/ “spider- web” pattern + assess venous pressure; biopsy only if unclear</p></li><li><p>Treatment: Rx underlying condition, anticoag (LMWH → warfarin); consider thrombolysis if acute; angioplasty & stent if short stenosis; consider TIPS or DIPS (U/S-guided direct intrahepatic portosystemic shunt) (if other methods fail to treat sx of portal HTN); liver transplant if ALF or failed other options</p></li></ul><p>Sinusoidal obstruction syndrome (SOS) (Bone Marrow Transplant 2020:55:485)</p><ul><li><p>Occlusion of hepatic venules & sinusoids (formerly veno-occlusive disease) 2/2 toxic insult</p></li><li><p>Etiologies: post HSCT (15%), chemo (cyclophosphamide, cytarabine), XRT, bush tea</p></li><li><p>Clinical manifestations: painful hepatomegaly, RUQ pain, ascites, weight gain, ↑ bilirubin</p></li><li><p>Dx: U/S w/ reversal of portal flow; dx made clinically (early weight gain, ↓ plt refractory to transfusion, ↑ bili, hx of recent toxins); if necessary, liver bx or HVPG (>10 mmHg)</p></li><li><p>Rx: supportive, diuretics; if severe → early defibrotide ↑ survival, but side effects & expensive</p></li><li><p>Ppx: defibrotide; ursodeoxycholic acid for high-risk HSCT pop; ? use of low-dose heparin</p></li></ul><p>ASCITES</p><p>Pathophysiology (Hepatology 2021;74:1014)</p><ul><li><p>Portal HTN → ↑ NO & prostaglandins → splanchnic vasodilatation→ ↓ effective arterial volume → ↑ RAAS & ADH → renal Na & H2O retention → volume overload and ascites</p></li><li><p>In malignant or inflammatory ascites, leaking of proteinaceous material occurs from tumor or from inflamed/infected/ruptured intraabdominal structures</p></li></ul><p>Symptoms</p><ul><li>↑ abd girth, wt gain, new abd hernia, abd pain, dyspnea, nausea, early satiety</li></ul><p>Evaluation (World J Hepatol 2013;5:251; JAMA 2016;316:340)</p><ul><li><p>Physical exam: flank dullness (>1500 mL needed), shifting dullness (Se ~83%)</p></li><li><p>Radiologic: U/S detects >100 mL fluid; MRI/CT (also help with Ddx)</p></li><li><p>Paracentesis: perform in all Pts w/ new ascites, suggested in all hosp. Pts w/ cirrhosis + ascites. Low complic. rate (~1% hematoma formation). Prophylactic FFP or plts does not ↓ bleeding complic. Most useful tests: cell count, alb, total protein (for SAAG), & culture</p></li><li><p>Serum-ascites albumin gradient (SAAG): serum alb (g/dL) – ascites alb (g/dL)</p></li></ul><p>SAAG ≥1.1 diagnoses portal HTN with ~97% accuracy (Ann Intern Med 1992;117:215)</p><p>If portal HTN + another cause (seen in ~5% of cases) SAAG still ≥1.1</p><p>Etiologies</p><p>Portal HTN Related (SAAG ≥1.1)</p><p>Non–portal HTN Related (SAAG &lt;1.1)</p><p>Presinusoidal obstruction portal or splenic vein thrombosis, schisto- somiasis, sarcoidosis</p><p>Sinusoidal obstruction: cirrhosis, acute hepatitis (including EtOH), malignancy (HCC or mets)</p><p>Postsinusoidal obstruction right-sided CHF (ex: constriction, TR), Budd-Chiari syndrome, SOS</p><p>Malig: peritoneal carcinomatosis; chylous ascites from malignant lymphoma (↑ TG); Meigs’ syndrome (ovarian tumor)</p><p>Infection: TB, chlamydia/gonorrhea (ie, Fitz-Hugh-Curtis syndrome)</p><p>Inflam: pancreatitis, ruptured pancreatic/biliary/lymph duct; bowel obstrxn, serositis (SLE)</p><p>Hypoalbuminemic states: nephrotic syndrome, protein-losing enteropathy</p><ul><li><p>Ascites fluid total protein (AFTP): useful when SAAG ≥1.1 to distinguish cirrhosis (AFTP &lt;2.5 g/dL) from cardiac ascites (AFTP ≥2.5 g/dL). Low AFTP (&lt;1 g/dL) assoc. w/ ↑ risk of SBP (see “Cirrhosis” for guidelines on SBP Ppx based on AFTP).</p></li><li><p>Cell count: normal limit of PMNs in ascitic fluid up to 250 PMNs/mm3. Bloody tap (typically from traumatic para) can skew cell count; subtract 1 PMN for every 250 RBCs to correct PMN count. Ascitic PMNs ≥250 suggest infection.</p></li><li><p>Other tests: amylase (pancreatitis, gut perforation); bilirubin (test in dark brown fluid, suggests bile leak or proximal intestinal perf); TG (chylous ascites); BNP (HF); cytology (peritoneal carcinomatosis, ~95% Se w/ 3 samples). SBP a/w ↓ glc & ↑ LDH. Ascites culture (prior to abx if possible, should have both aerobic & anerobic w/ 10 cc per bottle)</p></li></ul><p>Treatment (see “Cirrhosis” for details)</p><ul><li><p>If 2° to portal HTN: ↓ Na intake (&lt;2 g/d) + diuretics; if refractory → LVP (serial) or TIPS</p></li><li><p>If non–portal HTN related: depends on underlying cause (TB, malignancy, etc.)</p></li></ul><p>Bacterial peritonitis (Gut 2012;61:297; Hepatology 2021;74:1014)</p><p>Ascites PMN</p><p>⊕ Ascites Culture</p><p>⊖ Ascites Culture</p><p>≥250/µL</p><p>Spontaneous bacterial peritonitis (SBP): gut bacterial translocation to ascites. In cirrhosis, ↓ ascites opsonins (esp. if ↓AFTP) ↑ risk of infxn. Infection usually monomicrobial: most common → E. coli, Klebs, S. pneumo; rarely Staph & Pseudo. Rx 3rd-gen ceph; carbapenem if critically ill.</p><p>2° bacterial peritonitis: 2/2 intra-abd abscess, perf. Runyon’s criteria: AFTP >1 g/dL, glc &lt;50 mg/dL, LDH >ULN for serum. Cx polymicrobial. Rx 3rd-gen ceph. + MNZ; urgent abd imaging ± ex lap.</p><p>Culture-⊖ neutrocytic ascites (CNNA): cell counts suggest infxn but cx ⊖. No recent abx, w/o other explan. for counts. Often do have SBP and should be treated with empiric regimen.</p><p>&lt;250/µL</p><p>Nonneutrocytic bacterascites (NNBA): ⊕ cx w/o ↑ PMNs. Natural course may resolve w/o Rx. Start abx if symptomatic; if asymptomatic repeat para in 48 hrs.</p><p>Cx w/ 1 org.: Misc. GPC, E. coli, Klebs, misc. GNR.</p><p>(Normal)</p><p>Peritoneal dialysis-associated: cloudy fluid, abd pain, fever, nausea. Dx can be made with >50 PMNs. Culture most often GPC (50%) or GNR (15%).</p><p>Rx: vanc + gent (IV load, then administer in PD).</p><p>BILIARY TRACT DISEASE</p><p>CHOLELITHIASIS (GALLSTONES)</p><p>Epidemiology & pathogenesis (J Hepatol 2016;65:146; Gastro 2016;151:351)</p><ul><li><p>Affects ~10% of Western populations, 15–25% of people develop sx over 10–15 y</p></li><li><p>Bile = bile salts, phospholipids, cholesterol; ↑ cholesterol saturation in bile + accelerated nucleation + gallbladder hypomotility → gallstones</p></li><li><p>Risk factors: ♀; South, Central, Native American; ↑ age (>40 y); obesity, TPN, rapid ↓ wt; dyslipidemia; preg., drugs (OCPs, estrogen, clofibrate, octreotide); ileal dis., genetics</p></li><li><p>Statin use ↓ risk of sx gallstones & cholecystectomy (Hepatol Res 2015;45:942)</p></li></ul><p>Types of gallstones (J Hepatol 2016;65:146)</p><ul><li>Cholesterol (90%): 2 subtypes</li></ul><p>mixed: contain >50% cholesterol; typically smaller, multiple stones</p><p>pure: 100% cholesterol; larger, yellow, white appearance</p><ul><li>Pigment (10%)</li></ul><p>Black: unconjugated bili & calcium; seen w/ chronic hemolysis, cirrhosis, CF, Gilbert synd</p><p>Brown: stasis & infxn in bile ducts → bacteria deconjugate bilirubin → precipitates w/ Ca; found pred in bile ducts; seen w/ biliary strictures, parasites, post-cholecystectomy</p><p>Clinical manifestations</p><ul><li><p>Asx in ~80%. Biliary pain develops in 1–4%/y. Once sx, rate of complications ~1–3%/y.</p></li><li><p>Biliary pain = episodic RUQ or epigastric pain; begins abruptly, continuous, resolves slowly and lasts 30 min–3 h; ± radiation to scapula; precip by fatty foods; nausea</p></li><li><p>Physical exam: afebrile, ± RUQ tenderness or epigastric pain</p></li></ul><p>Diagnostic studies</p><ul><li><p>Labs normal in most</p></li><li><p>RUQ U/S: Se & Sp >95% for stones >5 mm; should be performed after ≥8 h fast for distended, bile-filled gallbladder. If ⊖, repeat in 1 mo to detect missed stones</p></li><li><p>Endoscopic U/S (EUS): Se 94–98% in Pts w/ biliary pain but nl U/S (J Hepatol 2016;65:146)</p></li><li><p>CT scan/KUB is less Se; stones often isodense w/o enough calcium & will be missed</p></li></ul><p>Treatment (Am Fam Physician 2014;89:795; J Hepatol 2016;65:146)</p><ul><li><p>Cholecystectomy (CCY), usually laparoscopic, if symptomatic (earlier is better)</p></li><li><p>CCY in asx Pts if: GB calcification (↑ risk of cancer), GB polyps >10 mm, stones >3 cm; Pts undergoing bariatric surgery, cardiac Tx candidates, hemolytic anemia (sickle cell)</p></li><li><p>Options if ↑ risk for surgery: percutaneous drainage, endoscopic transpapillary drainage</p></li><li><p>UDCA can be trialed for cholesterol stones w/ biliary pain or if poor surgical candidate, but takes ~3 mo to work; ↓ risk of gallstone formation that occurs w/ rapid wt ↓</p></li><li><p>Pain: NSAIDs drugs of choice, efficacy ≈ opiates & avoids ↑ sphincter of Oddi pressure</p></li></ul><p>Complications</p><ul><li><p>Cholecystitis: 20% of Pts with symptomatic biliary pain progress to cholecystitis w/in 2 y</p></li><li><p>Choledocholithiasis → cholangitis or gallstone pancreatitis</p></li><li><p>Mirizzi syndrome: hepatic duct compression by GB stone → jaundice, biliary obstruction</p></li><li><p>Cholecystenteric fistula: stone erodes through gallbladder into bowel, ~15% w/ colon</p></li><li><p>Gallstone ileus: SBO (usually at term ileum) due to stone in intestine that passed thru fistula</p></li><li><p>Gallbladder carcinoma: ~1% in U.S., often found late stage, a/w poor prognosis</p></li></ul><p>CHOLECYSTITIS (JAMA 2022;327:965)</p><p>Pathogenesis</p><ul><li><p>Acute cholecystitis: stone impaction in cystic duct → inflammation behind obstruction → GB swelling ± secondary infection (50%) of biliary fluid</p></li><li><p>Acalculous cholecystitis: GB stasis & ischemia (w/o cholelithiasis) → necroinflammation. Occurs in critically ill. A/w postop major surgery, TPN, sepsis, trauma, burns, opiates, immunosuppression, infxn (eg, CMV, Candida, Crypto, Campylobacter, typhoid fever).</p></li></ul><p>Clinical manifestations</p><ul><li><p>History: RUQ/epigastric pain ± radiation to R shoulder/back, nausea, vomiting, fever</p></li><li><p>Physical exam: RUQ tenderness, Murphy’s sign = ↑ RUQ pain and inspiratory arrest with deep breath during palpation of R subcostal region, ± palpable gallbladder</p></li><li><p>Laboratory evaluation: may see ↑ WBC, ± mild ↑ bilirubin, Aϕ, ALT/AST, amylase; if AST/ALT >500 U/L, bili >4 mg/dL or amylase >1000 U/L → choledocholithiasis</p></li></ul><p>Diagnostic studies</p><ul><li><p>RUQ U/S: high Se & Sp for stones, but need specific signs of cholecystitis: GB wall thickening >4 mm, pericholecystic fluid and a sonographic Murphy’s sign</p></li><li><p>HIDA scan: most Se test (80–90%) for acute cholecystitis. IV inj of HIDA (selectively secreted into bile). ⊕ if HIDA enters BD but not GB. 10–20% false ⊕ (cystic duct obstructed 2/2 chronic cholecystitis, lengthy fasting, liver disease).</p></li></ul><p>Treatment (Ann Surg 2013;258:385; NEJM 2015;373:357)</p><ul><li><p>NPO, IV fluids, nasogastric tube if intractable vomiting, analgesia</p></li><li><p>Antibiotics (E. coli, Klebsiella and Enterobacter sp. are usual pathogens) ([2nd- or 3rd-generation cephalosporin or FQ] + MNZ) or piperacillin-tazobactam</p></li><li><p>CCY (typically laparoscopic) w/in 24 h ↓ morbidity vs. waiting 7–45 d</p></li><li><p>If unstable for surgery, EUS-guided transmural, ERCP-guided transcystic duct drainage, or percutaneous cholecystotomy (if w/o ascites or coagulopathy) are alternatives to CCY</p></li><li><p>Intraoperative cholangiogram or ERCP to r/o choledocholithiasis in Pts w/ jaundice, cholangitis or stone in BD on U/S (see below)</p></li></ul><p>Complications</p><ul><li><p>Gangrenous cholecystitis: necrosis w/ risk of empyema and perforation</p></li><li><p>Emphysematous cholecystitis: infection by gas-forming organisms (air in GB wall)</p></li><li><p>Perforation: ~10% of cases, due to delay in diagnosis; pericholecystic abscess forms</p></li><li><p>Post CCY: bile duct leak, BD injury or retained stones, cystic duct remnant, sphincter of Oddi dysfxn</p></li></ul><p>CHOLEDOCHOLITHIASIS</p><p>Definition</p><ul><li>Gallstone lodged in common bile duct (CBD)</li></ul><p>Epidemiology</p><ul><li>Occurs in 15% of Pts w/ gallbladder stones; can form de novo in CBD due to biliary stasis</li></ul><p>Clinical manifestations</p><ul><li><p>RUQ/epigastric pain 2° obstrxn of bile flow → ↑ CBD pressure, jaundice, pruritus, nausea</p></li><li><p>Rarely asymptomatic</p></li></ul><p>Diagnostic studies (J Hepatol 2016;65:146; Gastrointest Endosc 2019;89:1075)</p><ul><li><p>Labs: ↑ bilirubin, Aϕ; transient spike in ALT or amylase suggests passage of stone</p></li><li><p>RUQ U/S: BD stones seen ~50–80% of cases; usually inferred from dilated CBD (>6 mm)</p></li><li><p>ERCP preferred modality when likelihood high (eg, visualized stone, cholangitis, bili >4, or dilated CBD on U/S + bili 1.8–4 mg/dL); cholangiogram (percutaneous, operative) if ERCP unavailable or unsuccessful; EUS/MRCP to exclude BD stones if suspicion intermediate (eg, no stone, dilated ducts on U/S, bili 1.8–4 mg/dL, gallstone panc., age >55, or abnl non-bili LFT)</p></li></ul><p>Treatment</p><ul><li><p>ERCP & papillotomy w/ stone extraction (± lithotripsy)</p></li><li><p>CCY w/in 6 wk unless contraindication (>15% Pts develop indication for CCY if unRx’d)</p></li></ul><p>Complications</p><ul><li>Cholangitis, cholecystitis, pancreatitis, stricture</li></ul><p>CHOLANGITIS</p><p>Definition & etiologies (World J Gasrointest Pathophysiol 2018:9:1)</p><ul><li><p>Bile duct obstruction causes stasis → infection proximal to the obstruction</p></li><li><p>Etiologies: BD stone (~85%); malignant (biliary, pancreatic) or benign stricture; infection w/ fluke (Clonorchis sinensis, Opisthorchis viverrini); recurrent pyrogenic cholangitis</p></li></ul><p>Clinical manifestations</p><ul><li><p>Charcot’s triad: RUQ pain, jaundice, fever/chills; present in ~70% of Pts</p></li><li><p>Reynolds’ pentad: Charcot’s triad + shock and Δ MS; present in ~15% of Pts</p></li></ul><p>Diagnostic studies</p><ul><li><p>RUQ U/S: often demonstrates dilation of bile ducts</p></li><li><p>Labs: ↑ WBC (with left shift), bilirubin, Aφ, amylase; may see ⊕ BCx</p></li><li><p>ERCP; percutaneous transhepatic cholangiogram if ERCP unsuccessful</p></li></ul><p>Treatment</p><ul><li><p>Antibiotics (broad spectrum) to cover common bile pathogens (see above) ampicillin + gentamicin (or levofloxacin) ± MNZ (if severe); carbapenems; pip/tazo</p></li><li><p>~80% respond to conservative Rx and abx → biliary drainage on elective basis</p></li><li><p>~20% require urgent biliary decompression via ERCP (papillotomy, stone extraction, and/or stent insertion). If sphincterotomy cannot be performed (larger stones), decompression by biliary stent or nasobiliary catheter can be done; otherwise, percutaneous transhepatic biliary drainage or surgery.</p></li></ul><p>ACID-BASE DISTURBANCES</p><p>GENERAL</p><p>Definitions</p><ul><li><p>Acidemia → pH &lt;7.36, alkalemia → pH >7.44; pH = 6.10 + log([HCO3]/[0.03xPCO2])</p></li><li><p>Acidosis → process that ↑ [H+] or ↓ pH by ↓ HCO3 or ↑ PaCO2</p></li><li><p>Alkalosis → process that ↓ [H+] or ↑ pH by ↑ HCO3 or ↓ PaCO2</p></li><li><p>Primary disorders: metabolic acidosis or alkalosis, respiratory acidosis or alkalosis</p></li><li><p>Compensation</p></li></ul><p>Respiratory: hyper/hypoventilation alters PaCO2 to counteract 1° metabolic process</p><p>Renal: excretion/retention of H+/HCO3– to counteract 1° respiratory process</p><p>Respiratory compensation occurs in mins-hrs; renal compensation takes days</p><p>Compensation usually never fully corrects pH; if pH normal, consider mixed disorder</p><p>Consequences of Severe Acid-Base Disturbances (NEJM 1998;338:26 & 107)</p><p>Organ System</p><p>Acidemia (pH &lt;7.20)</p><p>Alkalemia (pH >7.60)</p><p>Cardiovascular</p><p>↓ contractility, arteriolar vasodilation</p><p>↓ MAP & CO; ↓ response to catecholamines</p><p>↑ risk of arrhythmias</p><p>Arteriolar vasoconstriction</p><p>↓ coronary blood flow</p><p>↑ risk of arrhythmias</p><p>Respiratory</p><p>Hyperventilation, ↓ resp. muscle strength</p><p>Hypoventilation</p><p>Metabolic</p><p>↑ K (resp. > metab.), insulin resistance</p><p>↓ K, Ca, Mg, PO4</p><p>Neurologic</p><p>Δ MS</p><p>Δ MS, seizures, tetany</p><p>Workup (NEJM 2014;371:1434)</p><ul><li>Traditional or physiologic approach (Brønsted-Lowry definition of acids & bases)</li></ul><p>Determine primary disorder: ✓ pH, PaCO2, HCO3</p><p>Determine if degree of compensation is appropriate</p><p>Compensation for Acid-Base Disorders (NEJM 2014;371:1434)</p><p>Primary Disorder</p><p>Expected Compensation</p><p>Metabolic acidosis</p><p>↓ PaCO2 = 1.2 × ΔHCO3</p><p>or PaCO2 = (1.5 × HCO3) + 8 ± 2 (Winters’ formula)</p><p>(also, PaCO2 ≈ last 2 digits of pH)</p><p>Metabolic alkalosis</p><p>↑ PaCO2 = 0.7 × ΔHCO3</p><p>or PaCO2 = 0.7 (HCO3–24) + 40 ± 2 or HCO3 + 15</p><p>Acute respiratory acidosis</p><p>↑ HCO3 = 0.1 × ΔPaCO2</p><p>(also, ↓ pH = 0.008 × ΔPaCO2)</p><p>Chronic respiratory acidosis</p><p>↑ HCO3 = 0.35 × ΔPaCO2</p><p>(also, ↓ pH = 0.003 × ΔPaCO2)</p><p>Acute respiratory alkalosis</p><p>↓ HCO3 = 0.2 × ΔPaCO2</p><p>(also, ↑ pH = 0.008 × ΔPaCO2)</p><p>Chronic respiratory alkalosis</p><p>↓ HCO3 = 0.4 × ΔPaCO2</p><ul><li>Alternative approaches</li></ul><p>Base excess/deficit (NEJM 2018;378:1419)</p><p>Strong ion difference or “Stewart Method” (NEJM 2014;371:1821)</p><p>Mixed disorders (more than one primary disorder at the same time)</p><ul><li>If compensation less or greater than predicted, may be two disorders:</li></ul><p>PaCO2 too low → concomitant 1° resp. alk.; PaCO2 too high → concomitant 1° resp. acid.</p><p>HCO3 too low → concomitant 1° met. acid.; HCO3 too high → concomitant 1° met. alk.</p><ul><li>Normal pH, but&mldr;</li></ul><p>↑ PaCO2 + ↑ HCO3 → resp. acid. + met. alk.</p><p>↓ PaCO2 + ↓ HCO3 → resp. alk. + met. acid.</p><p>Normal PaCO2 & HCO3, but ↑ AG → AG met. acid. + met. alk.</p><p>Normal PaCO2, HCO3, & AG → no disturbance or non-AG met. acid. + met. alk.</p><ul><li>Cannot have resp. acid. (hypoventilation) and resp. alk. (hyperventilation) simultaneously</li></ul><p>Figure 4-1 Acid-base nomogram</p><p>(Adapted from Brenner BM, ed., Brenner & Rector’s The Kidney, 8th ed., 2007; Ferri F, ed. Practical Guide to the Care of the Medical Patient, 7th ed., 2007)</p><ul><li>ABG vs. VBG: concordant for pH (~0.04), HCO3 (~2 mEq) but not PCO2 (~8±17 mmHg)</li></ul><p>VBG can be used to screen for hypercarbia w/ PCO2 cutoff ≥45 mmHg (100% Se),</p><p>but may not accurately assess degree of hypercarbia (Am J Emerg Med 2012;30:896)</p><p>METABOLIC ACIDOSIS</p><p>Initial workup (NEJM 2014;371:1434)</p><ul><li>✓ anion gap (AG) = Na+ – (Cl– + HCO3–) = unmeasured anions – unmeasured cations</li></ul><p>If ↑ glc, use measured not corrected Na</p><p>Expected AG is [albumin] × 2.5 (ie, 10 if albumin is 4 g/dL, 7.5 if albumin is 3 g/dL)</p><p>↑ AG → ↑ unmeasured anions such as organic acids, phosphates, sulfates</p><p>↓ AG → ↓ alb or ↑ unmeasured cations (Ca, Mg, K, Li, Ig), bromide/iodine toxicity</p><ul><li>If ↑ AG, ✓ delta-delta (Δ/Δ = ΔAG/ΔHCO3) to assess if there is an additional metabolic</li></ul><p>acid-base disturbance; ΔAG = (calculated AG – expected AG), ΔHCO3 = (24 – HCO3)</p><p>Δ/Δ = 1–2 → pure AG metabolic acidosis</p><p>Δ/Δ &lt;1 → AG metabolic acidosis and simultaneous non-AG acidosis</p><p>Δ/Δ >2 → AG metabolic acidosis and simultaneous metabolic alkalosis</p><p>For pure lactic acidosis Δ/Δ 1.6 b/c of slow lactate clearance</p><p>Etiologies of AG Metabolic Acidosis</p><p>Ketoacidosis</p><p>Diabetes mellitus, alcoholism, starvation (NEJM 2015;372:546)</p><p>Lactic acidosis (NEJM 2014; 371:2309)</p><p>Type A: hypoxic (eg, shock, mesenteric ischemia, CO poisoning, cyanide)</p><p>Type B: nonhypoxic. ↓ clearance (eg, hepatic dysfxn) or ↑ generation [eg, malig, EtOH, thiamine def., meds (metformin, NRTIs, salicylates, propylene glycol, propofol, isoniazid, linezolid)]</p><p>D-lactic acidosis: short bowel syndrome → precip by glc ingest → metab by colonic bacteria to d-lactate; not detected by standard lactate assay</p><p>Renal failure</p><p>Accumulation of organic anions (eg, phosphates, sulfates, etc.)</p><p>Ingestions</p><p>(NEJM 2020; 382:2544)</p><p>Glycols: Ethylene (antifreeze) → metab to glycolic and oxalic acids</p><p>Propylene (pharmaceutical solvent, eg, IV diazepam, lorazepam, and phenobarbital; antifreeze) → lactic acidosis</p><p>Diethylene (brake fluid) → diglycolic acid</p><p>5-oxoproline (pyraglutamic acid): acetaminophen → ↑ organic acid 5- oxoproline in susceptible Pts (malnourished, female, renal failure)</p><p>Methanol (windshield fluid, antifreeze, solvents, fuel): metab to formic acid</p><p>Aspirin: early resp alkalosis (CNS stim) + late metab acidosis (impairs oxidative phosphorylation → inorganic acids (eg, ketones, lactate)</p><p>“GOLD MARK” = Glycols, Oxoproline, Lactic, D-Lactic, Methanol, ASA, Renal, Ketoacidosis</p><p>Workup for AG metabolic acidosis (AJKD 2021;78:A16)</p><ul><li>✓ for ketonuria (dipstick acetoacetate) or plasma β-hydroxybutyrate (βOHB)</li></ul><p>nb, urine acetoacetate often not present in early ketoacidosis due to shunting to βOHB; ∴ acetoacetate may later turn ⊕ but does not signify worsening disease</p><ul><li><p>If ⊖ ketones, ✓ renal function, lactate, toxin screen, and osmolal gap</p></li><li><p>If obtunded or ↑↑ AG, check osmolal gap (OG) = measured osmoles – calculated osmoles</p></li></ul><p>Calculated osmoles = (2 × Na) + (glucose/18) + (BUN/2.8) (+ [EtOH/4.6] if ↑ EtOH level and want to test if other ingestions)</p><p>OG >10 → suggests ingestion (see below) but lacks specificity (can be elevated in lactic acidosis, DKA, and alcoholic ketoacidosis due to acetone)</p><p>High-dose lorazepam (>10 mg/h) a/w propylene glycol intoxication</p><p>OG & AG vary based on timing, initially OG ↑, then ↓ w/ metabolism as AG ↑</p><p>Ingestions (NEJM 2018;378:270) Call poison control for guidance (800-222-1222)</p><p>AG</p><p>OG</p><p>Ingestion</p><p>Other Manifestations</p><p>↑</p><p>nl</p><p>Acetaminophen</p><p>Hepatitis</p><p>Salicylates</p><p>Fever, tachycardia, tinnitus; met. acid. + resp. alkalosis</p><p>↑</p><p>↑</p><p>Methanol</p><p>ΔMS, blurred vision, pupillary dilation, papilledema</p><p>↑</p><p>↑</p><p>Ethylene glycol</p><p>ΔMS, cardiopulm. failure, hypoCa. Ca oxalate crystals → AKI. Urine fluoresces under UV light.</p><p>nl/↑</p><p>↑</p><p>Propylene glycol</p><p>AKI, liver injury</p><p>↑</p><p>nl/↑</p><p>Diethylene glycol</p><p>AKI, N/V, pancreatitis, neuropathy, lactic acidosis</p><p>nl/↑</p><p>↑</p><p>Isopropyl alcohol</p><p>ΔMS, fruity breath (acetone), pancreatitis, lactic acidosis</p><p>Ethanol</p><p>Alcoholic fetor, ΔMS, hepatitis; keto + lactic acidosis ± met. alk. (vomiting)</p><p>Etiologies of Non-AG Metabolic Acidosis</p><p>GI losses of HCO3</p><p>Diarrhea, intestinal or pancreatic fistulas or drainage</p><p>RTAs</p><p>See section on renal tubular acidoses below</p><p>Early renal failure</p><p>Impaired generation of ammonia</p><p>Ingestions</p><p>Acetazolamide, sevelamer, cholestyramine, toluene</p><p>Dilutional</p><p>Due to rapid infusion of bicarbonate-free IV fluids</p><p>Posthypocapnia</p><p>Respiratory alkalosis → renal wasting of HCO3; rapid correction of resp. alk. → transient acidosis until HCO3 regenerated</p><p>Ureteral diversion</p><p>Colonic Cl–/HCO3– exchange, ammonium reabsorption</p><p>Workup for non-AG metabolic acidosis</p><ul><li><p>Evaluate history for causes (see above)</p></li><li><p>✓ urine anion gap (UAG) = (UNa + UK) – UCl</p></li></ul><p>UAG = unmeasured anions – unmeasured cations; NH4+ is primary unmeasured cation (represented by UCl). UAG is indirect assay for renal H+ excretion.</p><ul><li>⊖ UAG → ↑ renal NH4+ excretion → appropriate renal response to acidemia</li></ul><p>Ddx: GI causes (diarrhea, fistulas, ureteral diversion), IV NS, ingestions</p><ul><li>⊕ UAG → failure of kidneys to generate NH4+</li></ul><p>Ddx: distal (type 1, usually ↓ K) or hypoaldo (type IV, usually ↑ K) RTA, early renal failure</p><ul><li>UAG unreliable in AKI/CKD, polyuria, Na depletion (UNa &lt;20), UpH >6.5 & HAGMA (causes ⊕ UAG b/c excretion of organic anions) and less useful in prox RTA as variable. Then use UOsm gap = measured UOsm – [2×(Na+ + K+) + BUN + glc (mmol/L)]. UOsm gap &lt;40 mmol/L indicates impaired NH4+ excretion</li></ul><p>Renal tubular acidoses (RTAs) (Adv Ther 2021;38:949)</p><ul><li>Proximal (Type II): ↓ proximal reabsorption of HCO3</li></ul><p>1° (Fanconi’s syndrome) = ↓ proximal reabsorption of HCO3, PO4, glc, amino acids</p><p>Acquired: paraprotein (MM, amyloidosis), metals (Pb, Cd, Hg, Cu), ↓ vit D, PNH, renal Tx</p><p>Meds: acetazolamide, aminoglycosides, ifosfamide, cisplatin, topiramate, tenofovir</p><ul><li>Distal (Type I): defective distal H+ secretion</li></ul><p>1°, autoimmune (Sjögren’s, RA, SLE), hypercalciuria, meds (ampho, Li, ifosfamide); normally a/w ↓ K; if with ↑ K → sickle cell, obstruction, renal transplant</p><ul><li>Hypoaldo (Type IV): hypoaldo → ↑ K → ↓ NH3 synthesis → ↓ urine acid-carrying capacity</li></ul><p>↓ renin: diabetic nephropathy, NSAIDs, chronic interstitial nephritis, calcineurin inh, HIV</p><p>↓ aldo production: 1° AI, ACEI/ARBs, heparin, severe illness, inherited (↓ 21-hydroxylase)</p><p>↓ response to aldosterone</p><p>Meds: K-sparing diuretics, TMP-SMX, pentamidine, calcineurin inhibitors</p><p>Tubulointerstitial disease: sickle cell, SLE, amyloid, DM</p><ul><li>Combined (Type III): rarely discussed or clinically relevant, also called juvenile RTA, has distal & proximal features, can be due to carbonic anhydrase II deficiency</li></ul><p>aUrine pH will rise above 5.3 in the setting of HCO3 load</p><p>bFeHCO3 should be checked after an HCO3 load</p><p>cSee above for causes of distal RTA (Type I) associated with hyperkalemia</p><p>Figure 4-2 Approach to metabolic acidosis</p><p>Treatment of severe metabolic acidoses (pH &lt;7.2) (Nat Rev Nephrol 2012;8:589)</p><ul><li><p>DKA: insulin, IVF, K repletion (NEJM 2015;372:546); AKA: dextrose, IVF, replete K, Mg, PO4</p></li><li><p>Lactic acidosis: treat underlying condition, avoid vasoconstrictors, avoid “Type B” meds</p></li><li><p>Renal failure: hemodialysis</p></li><li><p>Methanol & ethylene glycol: fomepizole (20 mg/dL), vit. B1 & B6 (ethylene glycol), folate (methanol), dialysis (if AKI, VS unstable, vision Δ or >50 mg/dL) (NEJM 2018;378:270)</p></li><li><p>Alkali therapy: if pH &lt;7.1 or &lt;7.2 and co-existing AKI (may ↓ mortality; Lancet 2018;392:31)</p></li><li><p>NaHCO3: amps by IV push or infusion of three 50-mmol amps in 1 L D5W if less urgent</p></li></ul><p>Can estimate mmol of HCO3 needed as [desired-current HCO3]serum × wt (kg) × 0.4</p><p>Side effects: ↑ volume, ↑ Na, ↓ ICa, ↑ PaCO2 (& ∴ intracellular acidosis; ∴ must ensure adequate ventilation to blow off CO2)</p><p>METABOLIC ALKALOSIS</p><p>Pathophysiology (CJASN 2020;15:1848)</p><ul><li><p>Saline-responsive etiologies require initiating event and maintenance phase</p></li><li><p>Initiating event: net HCO3− reabsorption (due to loss of volume, Cl-, and/or K+) or loss of H+</p></li></ul><p>Loss of H+ (± Cl-) from GI tract, kidneys, or transcellular shift in hypokalemia</p><p>Contraction alkalosis: loss of HCO3&ndash;poor fluid → extracellular fluid “contracts” around fixed amount of HCO3- → ↑ HCO3- concentration</p><p>Exogenous alkali: iatrogenic HCO3- (with renal impairment), milk-alkali syndrome</p><p>Posthypercapnia: resp. acidosis → compensation with H+ excretion and HCO3- retention; rapid correction of hypercapnia (eg, intubation) → transient excess HCO3-</p><ul><li>Maintenance phase</li></ul><p>Volume depletion → ↑ ATII → ↑ PCT reabsorption of HCO3- & ↑ aldosterone (see below)</p><p>Cl- depletion → ↓ Cl- uptake in macula densa → ↑ RAS & ↑ CCD Cl-/HCO3- exchanger</p><p>Hypokalemia → transcellular K+/H+ exchange; intracellular acidosis → HCO3- reabsorption and ammoniagenesis & ↑ distal H+-K+-ATPase activity → HCO3- retention</p><p>Hyperaldosteronism (1° or 2°) → ↑ CCD α-intercalated H+ secretion w/ HCO3- retention & Na+ reabsorption in principal cell → H+ secretion (for electrical neutrality)</p><p>Etiologies of Metabolic Alkalosis</p><p>Saline responsive</p><p>UCl &lt;25</p><p>GI loss of H+: emesis, NGT suction, villous adenoma, chloridorrhea</p><p>Renal loss: loop/thiazide, ↓ Cl intake, milk-alkali, Pendred syndrome</p><p>Posthypercapnia, sweat losses in cystic fibrosis</p><p>Saline resistant</p><p>UCl >40</p><p>Hypertensive (mineralocorticoid excess)</p><p>1° hyperaldosteronism (eg, Conn’s)</p><p>2° hyperaldosteronism (eg, renovascular dis., renin-secreting tumor)</p><p>Non-aldo (Cushing’s, Liddle’s, exogenous mineralocorticoids, licorice)</p><p>Normotensive</p><p>Severe hypokalemia (K&lt;2); exogenous alkali load (w/ AKI or ↓ vol)</p><p>Bartter’s syndrome (loop-like); Gitelman’s syndrome (thiazide-like)</p><p>Workup</p><ul><li>Check volume status and UCl</li></ul><p>UCl &lt;25 mEq/L → saline responsive</p><p>UCl >40 mEq/L → saline resistant (unless currently receiving diuretics)</p><p>(UNa unreliable determinant of volume status in alkalemia → ↑ HCO3- excretion → ↑ Na excretion; negatively charged HCO3- w/ Na+ maintaining electrical neutrality)</p><p>If UCl >40 and volume replete, ✓ UK; UK &lt;20 laxative abuse; UK >30, ✓ blood pressure</p><p>Figure 4-3 Approach to metabolic alkalosis</p><p>Treatment of severe metabolic alkalosis (pH >7.6) (JASN 2012;23:204)</p><ul><li><p>If saline responsive: resuscitate with Cl-rich solution (NS), replete K, d/c diuretics cardiopulmonary disease precludes hydration, can use KCl, acetazolamide, HCl</p></li><li><p>Hyperaldosteronism: treat underlying condition, K-sparing diuretic, resect adenoma if 1o</p></li></ul><p>RESPIRATORY ACIDOSIS (NEJM 1989;321:1223; Crit Care 2010;14:220)</p><p>Etiologies (also see “Hypercapnia”; PaCO2 = VCO2/VE(1-VD/VT); VE = RR x VT)</p><ul><li><p>↑ CO2 production (↑ VCO2): fever, thyrotoxicosis, sepsis, steroids, overfeeding (carbs)</p></li><li><p>CNS depression (↓ RR and/or VT): sedatives (opiates, benzos, etc.), CNS trauma, central sleep apnea, obesity, hypoventilation, hypothyroidism</p></li><li><p>Neuromuscular disorders (↓ VT): Guillain-Barré, poliomyelitis, ALS, MS, paralytics, myasthenia gravis, muscular dystrophy, severe ↓ P & K, high spinal cord injury</p></li><li><p>Chest wall (↓ VT): PTX, hemothorax, flail chest, kyphoscoliosis, ankylosing spondylitis</p></li><li><p>Upper airway (↓ VT): foreign body, laryngospasm, OSA, esophageal intubation</p></li><li><p>Lower airway (gas exchange) (↑ VD and/or ↓ VT): asthma, COPD, pulm edema, IPF</p></li></ul><p>Often hypoxia → ↑ RR → resp. alk., but muscle fatigue → resp. acid</p><ul><li>Post infusion of bicarbonate in acidemic Pt w/ limited ability to ↑ minute ventilation</li></ul><p>RESPIRATORY ALKALOSIS</p><p>Etiologies (NEJM 2002;347:43; Crit Care 2010;14:220)</p><ul><li><p>Hypoxia → hyperventilation: pneumonia, CHF, PE, restrictive lung disease, anemia</p></li><li><p>Primary hyperventilation</p></li></ul><p>CNS stimulation, pain, anxiety, trauma, stroke, CNS infection, pontine tumors</p><p>drugs: salicylates toxicity (early), β-agonists, progesterone, methylxanthines, nicotine</p><p>pregnancy, sepsis, hepatic failure, hyperthyroidism, fever</p><ul><li>Pseudorespiratory alkalosis: ↓ perfusion w/ preserved ventilation (eg, CPR, severe HoTN) → ↓ delivery of CO2 to lungs for excretion; low PaCO2 but ↑ tissue CO2</li></ul><p>SODIUM AND WATER HOMEOSTASIS</p><p>OVERVIEW</p><p>General (NEJM 2015;372:55 & 373:1350)</p><ul><li><p>Disorders of serum sodium are generally due to Δs in total body water, not sodium</p></li><li><p>Hyper- or hypo-osmolality → rapid water shifts → Δs in brain cell volume → Δ MS, seizures</p></li></ul><p>Key hormones</p><ul><li>Antidiuretic hormone (ADH): primary hormone that regulates sodium concentration</li></ul><p>Stimuli: hyperosmolality (290–295 mOsm), ↓↓ effective arterial volume, angiotensin II</p><p>Action: insertion of aquaporin-2 channels in principal cells → passive water reabsorption</p><p>urine osmolality is an indirect functional assay of the ADH-renal axis</p><p>Uosm range: 50 mOsm/L (no ADH) to 1200 mOsm/L (maximal ADH)</p><ul><li>Aldosterone: primary hormone that regulates total body sodium (and ∴ volume)</li></ul><p>Stimuli for secretion: hypovolemia (via renin and angiotensin II), hyperkalemia</p><p>Action: iso-osmotic principal cell reabsorption of Na via epithelial Na channel (ENaC) in exchange for K+ or H+</p><p>HYPONATREMIA</p><p>Pathophysiology (JASN 2008;19:1076; NEJM 2015;372:1349)</p><ul><li><p>Excess H2O relative to Na, usually due to ↑ ADH</p></li><li><p>↑ ADH may be appropriate (eg, hypovolemia or hypervolemia with ↓ EAV)</p></li><li><p>↑ ADH may be inappropriate (SIADH)</p></li><li><p>Rarely, ↓ ADH (appropriately suppressed), but kidneys unable to maintain nl [Na]serum</p></li></ul><p>at steady state, solute intake = solute excretion; urine output = solute excretion/Uosm</p><p>nl dietary solute load ~750 mOsm/d, min Uosm = 50 mOsm/L, ∴ UOP can be up to ~15 L</p><p>↑ H2O intake (1° polydipsia): ingestion of massive quantities (usually >15 L/d) of free H2O overwhelms diluting ability of kidney → H2O retention</p><p>↓ solute intake (“tea & toast” & beer potomania): ↓↓ daily solute load → insufficient solute to excrete H2O intake (eg, if only 250 mOsm/d, minimum Uosm = 50 mOsm/L → excrete in ~5 L; if H2O ingestion exceeds this amount → H2O retention)</p><p>Workup (JASN 2012;23:1140 & 2017;28:1340; Crit Care 2013;17:206; NEJM 2015;372:55)</p><ul><li><p>History: (1) acute vs. chronic (>48 h); (2) sx severity; (3) risk for neuro complications (alcoholism, malnourished, cirrhosis, older women on thiazides, hypoxia, hypoK)</p></li><li><p>Measure plasma osmolality</p></li></ul><p>Hypotonic (Posm &lt;280) most common scenario; true excess of free H2O relative to Na</p><p>Isotonic (Posm 280–295): rare lab artifact from hyperlipidemia or hyperproteinemia</p><p>Hypertonic (Posm >295): excess of another effective osmole (eg, glucose, mannitol) that draws H2O intravascularly; for each 100 mg/dL ↑ glc >100 mg/dL → ↓ [Na] by ~2 mEq/L</p><ul><li><p>For hypotonic hyponatremia, ✓ volume status (JVP, skin turgor, dry axilla, mucous membranes, edema, ascites), effusions, vital signs, orthostatics, BUN/Cr, FEUricAcid, UNa</p></li><li><p>Measure Uosm, although useful for dx in limited circumstances, b/c almost always >300</p></li></ul><p>Uosm &lt;100 in ↑ H2O intake (1o polydipsia) or ↓ solute intake (beer potomania, “tea & toast”)</p><p>Uosm >300 does not mean SIADH; must determine if ↑ ADH appropriate or inappropriate</p><p>however, Uosm can be important when deciding on treatment (see below)</p><ul><li><p>If euvolemic and ↑ Uosm, evaluate for glucocorticoid insufficiency and hypothyroidism</p></li><li><p>If available, consider FEUricAcid as >12% suggests SIADH (J Clinc Endo 2008;93:2991)</p></li></ul><p>Figure 4-4 Approach to hyponatremia</p><p>Hypovolemic hypotonic hyponatremia (ie, ↓↓ total body Na, ↓ TBW)</p><ul><li>Renal losses (UNa >20 mEq/L, FENa >1%): diuretics (esp. thiazides, because loop diuretics</li></ul><p>↓ tonicity of medullary interstitium, Δ for H2O absorption, & ∴ urine concentrating ability), salt-wasting nephropathy, cerebral salt wasting, mineralocorticoid deficiency</p><ul><li>Extrarenal losses (UNa &lt;10 mEq/L, UCl &lt;10 mEq/L if alkalemia, FENa &lt;1%): hemorrhage, GI loss (diarrhea or vomiting), third-spacing (pancreatitis), ↓ PO intake, insensible losses</li></ul><p>Euvolemic hypotonic hyponatremia (ie, ↑ TBW relative to total body Na)</p><ul><li>SIADH (euvolemia or mild hypervolemia, typically inapprop Uosm >100, UNa >20 mEq/L)</li></ul><p>Malignancy: lung (SCLC), brain, GI, GU, lymphoma, leukemia, thymoma, mesothelioma</p><p>Pulmonary: pneumonia, TB, aspergillosis, asthma, COPD, PTX, mechanical ventilation</p><p>Intracranial: trauma, stroke, SAH, seizure, infxn, hydrocephalus, Guillain-Barré</p><p>Drugs: antipsychotics, antidepress. (SSRI, TCA, MAOi), haloperidol, chemo (vincristine, cisplatin), AVP, MDMA, NSAIDs, opiates, amiodarone (Am J Kidney Dis 2008;52:144)</p><p>Miscellaneous: pain, nausea, postoperative state</p><ul><li><p>Endocrinopathies: ↑ ADH activity seen in glucocorticoid deficiency (co-secretion of ADH & CRH) and severe hypothyroidism/myxedema coma (↓ CO/SVR → ADH release & ↓ GFR)</p></li><li><p>Psychogenic polydipsia (Uosm &lt;100, ↓ FEUric Acid): usually intake >15 L/d</p></li><li><p>Low solute (↓ UNa, ↓ Uosm) “tea & toast”; beer potomania</p></li><li><p>Reset osmostat: chronic malnutrition (↓ intracellular osmoles) or pregnancy (hormonal</p></li></ul><p>effects) → ADH physiology reset to regulate a lower [Na]serum</p><p>Hypervolemic hypotonic hyponatremia (ie, ↑ total body Na, ↑ ↑ TBW)</p><ul><li><p>↓ EAV → ↑ RAAS → ↑ aldosterone & ↑ adrenergic tone → ↑↑ ADH (Am J Med 2013;126:S1)</p></li><li><p>CHF (↓ CO & renal venous congestion → ↓ EAV; UNa &lt;10 mEq/L, FENa &lt;1%)</p></li><li><p>Cirrhosis (splanchnic arterial vasodilation + ascites → ↓ EAV; UNa &lt;10 mEq/L, FENa &lt;1%)</p></li><li><p>Nephrotic syndrome (hypoalbuminemia → edema → ↓ EAV; UNa &lt;10 mEq/L, FENa &lt;1%)</p></li><li><p>Advanced renal failure (diminished ability to excrete free H2O; UNa >20 mEq/L)</p></li></ul><p>Treatment (NEJM 2015;372:55; JASN 2017;28:1340; CJASN 2018;13:641 & 984)</p><ul><li>Approach: depends on volume status, acuity of hyponatremia, and if symptomatic</li></ul><p>Acute sx: initial rapid correction of [Na]serum (2 mEq/L/h for the first 2–3 h) until sx resolve</p><p>Asx or chronic symptomatic: correct [Na]serum at rate of ≤0.5 mEq/L/h</p><p>Rate ↑ Na should not exceed 6 (chronic) to 8 (acute) mEq/L/d to avoid central pontine myelinolysis/osmotic demyelination (CPM/ODS: paraplegia, dysarthria, dysphagia)</p><p>If severe (&lt;120) or neuro sx: consider 3% NaCl. dDAVP 1-2 µg q8h in consultation with nephrology (to prevent rapid overcorrection) (AJKD 2013;61:571; CJASN 2018; 13:641)</p><ul><li><p>Frequent lab draws and IVF rate adjustments are cornerstones of treatment</p></li><li><p>Rapid correction: can lead to CPM/ODS (esp if chronic or Na &lt;120 mEq/L). Should be emergently reversed w/ dDAVP ± D5W; partial neuro recovery possible (CJASN 2014;9:229).</p></li><li><p>Effect of IV fluids: complex as depends not only on [Na]infusate but also UOP and Uosm</p></li></ul><p>Scenario</p><p>Formula to estimate new [Na]serum after 1 L infusion</p><p>If minimal UOP and none of infused Na excreted</p><p>If euvolemic (eg, in SIADH) & all infused Na excreted</p><p>In SIADH “fixed” high Uosm. ∴ in SIADH w/ Uosm 616, 1 L NS (154 mEq Na or 308 mOsm solute in 1 L H2O) will be excreted in 0.5 L H2O → net gain 0.5 L H2O. ∴ NS worsens [Na]serum if Uosm >infusateosm. In contrast, 1 L 3% NaCl (1026 mOsm) would be excreted in ~1.7 L urine → net loss 0.7 L H2O. ∴ 3% saline ↑ [Na]serum.</p><p>Effect of 1 L infusion in 70-kg male w/ [Na]serum 110 mEq/L & Uosm 616 mOsm/kg</p><p>IVF Type</p><p>[Na]content</p><p>No UOP</p><p>Infused Na excreted</p><p>0.9% NaCl</p><p>154 mEq/L</p><p>+1.0 mEq/L</p><p>-1.3 mEq/L</p><p>3% NaCl</p><p>513 mEq/L</p><p>+9.4 mEq/L</p><p>+1.8 mEq/L</p><ul><li><p>Hypovolemic hyponatremia: volume repletion with isotonic 0.9% saline at a slow rate. Once volume replete → stimulus for ADH removed (w/ very short ADH t½) → kidneys excrete free H2O → serum Na will correct rapidly (D5W ± dDAVP if overcorrection)</p></li><li><p>SIADH (NEJM 2007;356:2064; AJKD 2020;76:203): fluid restrict + treat underlying cause</p></li></ul><p>hypertonic saline (± loop diuretic; AJKD 2020;76:203) if sx or Na fails to ↑ w/ fluid restriction Intermittent bolus of 3% saline (~2 mL/kg q6h) vs. continuous infusion (~0.5 mL/kg/h) similar (JAMA IM 2021;181:81) when moderate symptoms. Must recheck serum Na frequently during hypertonic use (at least q2h).</p><p>NaCl tabs if chronic and no CHF. Consider urea 0.25–0.5 g/kg/d (CJASN 2018;13:1627)</p><p>aquaresis: vaptans (vasopressin receptor antag) for refractory SIADH (NEJM 2015;372:23)</p><ul><li>Hypervolemic hyponatremia: free water restrict (1st line), diurese w/ loop diuretics (avoid thiazides) & ↑ EAV (vasodilators to ↑ CO in CHF, colloid infusion in cirrhosis)</li></ul><p>vaptans sometimes used; however, no mortality benefit, hypoNa recurs after stopping drug, high risk of overcorrection, contraindicated in cirrhosis (NEJM 2015;372:2207)</p><p>HYPERNATREMIA</p><p>Pathophysiology (Crit Care 2013;17:206; NEJM 2015;372:55)</p><ul><li><p>Deficit of water relative to sodium; by definition, all hypernatremic Pts are hypertonic</p></li><li><p>Usually loss of hypotonic fluid (ie, “dehydration”); occasionally infusion of hypertonic fluid, post-ATN diuresis w/ loss of low or electrolyte-free water (Am J Neph 2012;36:97)</p></li><li><p>And impaired access to free water (eg, intubation, Δ MS, elderly): hypernatremia is a powerful thirst stimulus, ∴ usually only develops in Pts w/o access to H2O or ill</p></li></ul><p>Workup</p><ul><li>✓ Uosm, UNa, volume status (vital signs, orthostatics, JVP, skin turgor, BUN, Cr)</li></ul><p>Figure 4-5 Approach to hypernatremia</p><p>Extrarenal H2O loss (Uosm >700–800)</p><ul><li><p>GI H2O loss: vomiting, NGT drainage, osmotic diarrhea, fistula, lactulose, malabsorption</p></li><li><p>Insensible loss: fever, exercise, ventilation, burns</p></li></ul><p>Renal H2O loss (Uosm &lt;700–800)</p><ul><li><p>Diuresis: osmotic (glucose, mannitol, urea), loop diuretics</p></li><li><p>Diabetes insipidus (Nature Reviews Nephrology 2015;11:576)</p></li></ul><p>ADH deficiency (central) or resistance (nephrogenic)</p><p>Central: hypothalamic or posterior pituitary disease (congenital, trauma/surgery, infiltrative/IgG4); also idiopathic, hypoxic/ischemic encephalopathy (shock, Sheehan’s syndrome), anorexia, sarcoidosis, histiocytosis, drugs: EtOH, phenytoin, snake venom, tumors: craniopharyngioma, germinoma, lymphoma, leukemia, meningioma, pituitary</p><p>Nephrogenic (Annals 2006;144:186)</p><p>congenital (ADH receptor V2 mutation, aquaporin-2 mutation; Pediatric Clinics 2019;66:227)</p><p>drugs: lithium, amphotericin, demeclocycline, foscarnet, cidofovir, ifosfamide</p><p>metabolic: hypercalcemia, severe hypokalemia, protein malnutrition, congenital</p><p>tubulointerstitial: postobstruction, recovery phase of ATN, PKD, sickle cell, Sjögren’s, amyloid, pregnancy (placental vasopressinase)</p><p>DI usually presents as severe polyuria and mild hypernatremia</p><p>Other (Uosm >700–800)</p><ul><li><p>Na overload: hypertonic saline (eg, resuscitation w/ NaHCO3), mineralocorticoid excess</p></li><li><p>Seizures, ↑ exercise: ↑ intracellular osmoles → H2O shifts → transient ↑ [Na]serum</p></li></ul><p>Treatment (NEJM 2015;372:55)</p><ul><li><p>Restore access to H2O or supply daily requirement of H2O (≥1 L/d)</p></li><li><p>Replace free H2O deficit (also replace concurrent volume deficit if appropriate):</p></li></ul><p>eg, 1 L D5W given to 70-kg man w/ [Na] = 160 mEq/L will ↓ [Na]serum by 3.7 mEq</p><p>nb, do not forget to correct Na if hyperglycemia also present</p><ul><li>Rate of correction depends on acuity of onset and risk:</li></ul><p>chronic (>48 hr): ~12 mEq/d appears safe w/o risk of cerebral edema (CJASN 2019;14:656)</p><p>acute (&lt;48 hr): may ↓ Na by 2 mEq/L/h until Na 145</p><p>hyperacute (min-hrs) & life threatening (ICH, seizure): rapidly infuse D5W ± emergent HD</p><ul><li><p>Estimate: in 70-kg man, 125 mL/h of free H2O will ↓ [Na] by ~0.5 mEq/L/h</p></li><li><p>½ NS (77 mEq/L) or ¼ NS (38 mEq/L) provides both volume & free H2O (500 or 750 mL of free H2O per L, respectively); can give free H2O via NGT/OGT</p></li><li><p>Formulas provide only estimates; ∴ recheck serum Na frequently</p></li><li><p>DI and osmotic diuresis: see “Polyuria” section below</p></li><li><p>Na overload: D5W + diuretic. Consider HD if life threatening (ICH, hypertonia, seizures).</p></li></ul><p>POLYURIA</p><p>Definition and pathophysiology</p><ul><li><p>Polyuria defined as >3 L UOP per day</p></li><li><p>Due to an osmotic or a water diuresis; almost always due to osmotic diuresis in inpatients</p></li></ul><p>Workup</p><ul><li><p>Perform a timed urine collection (6 h sufficient) and measure Uosm</p></li><li><p>24-h osmole excretion rate = 24-h UOP (actual or estimate) × Uosm</p></li></ul><blockquote><p>1000 mOsm/d → osmotic diuresis; &lt;800 mOsm/d → water diuresis</p></blockquote><p>Osmotic diuresis</p><ul><li>Etiologies</li></ul><p>Hyperglycemia (>180 exceeds PCT reabsorption), mannitol, propylene glycol</p><p>Na: NaCl IVF, recovering AKI (eg, post obstruction)</p><p>Urea: ↑ protein feeds, hypercatabolism (burns, steroids), GI bleed, resolving azotemia</p><p>Water diuresis</p><ul><li>Etiologies: DI (Naserum >143) or 1° polydipsia (Naserum &lt;136)</li></ul><p>see “Hypernatremia” above for list of causes of central and nephrogenic DI</p><ul><li>Workup of DI: Uosm &lt;300 (complete) or 300–600 (partial)</li></ul><p>water deprivation test (rarely used)</p><p>hypertonic saline-stimulated plasma copeptin >4.9 pmoL/L indicates 1° polydipsia (97% accuracy vs. 77% for water deprivation; NEJM 2018;379:428)</p><p>Figure 4-6 Approach to polyuria</p><p>Treatment</p><ul><li><p>1° polydipsia: treat psychiatric illness, check meds, restrict access to free H2O</p></li><li><p>Osmotic diuresis: address underlying cause, replace free H2O deficit (see “Hypernatremia” for formula to calculate) and ongoing losses</p></li><li><p>DI:</p></li></ul><p>Central DI: desmopressin (dDAVP, 1st line), low Na/protein diet + HCTZ, chlorpropamide</p><p>Nephrogenic DI: treat underlying cause if possible; Na restriction + HCTZ (mild volume depletion → ↓ delivery of filtrate for free H2O absorption), consider amiloride for Li- induced DI (Kid Int 2009;76:44), indomethacin (NEJM 1991;324:850) or trial desmopression</p><p>Pregnancy-induced DI: due to vasopressinase from placenta, ∴ Rx w/ dDAVP</p><p>POTASSIUM HOMEOSTASIS</p><p>Overview (NEJM 2015;373:60)</p><ul><li>Renal: K excretion regulated at distal nephron (CCD) by principal & α-intercalated cells</li></ul><p>Distal Na delivery & urine flow: Na absorption → lumen electronegative → K secretion</p><p>Metabolic alkalemia and aldosterone: increase Na absorption and K secretion</p><p>nb, diurnal urinary K excretion (day >night), ∴ 24-h sample preferred over spot</p><ul><li>Transcellular shifts: most common cause of acute ∆ in serum K (98% intracellular)</li></ul><p>Acid-base disturbance: K+/H+ exchange across cell membranes</p><p>Insulin → stimulates Na-K ATPase → hypokalemia (mitigates postprandial ↑ K)</p><p>Catecholamines → stimulate Na-K ATPase → hypokalemia; reversed by β-blockers</p><p>Massive necrosis (eg, tumor lysis, rhabdo, ischemic bowel) → release of intracellular K</p><p>Hypo- or hyperkalemic periodic paralysis: rare disorders due to channel mutations</p><ul><li>Diet: alone rarely causes ↑ or ↓ K (total body store ~3500 mEq, daily intake ~100 mEq)</li></ul><p>HYPOKALEMIA</p><p>Transcellular shifts (UK:Cr &lt;13 mEq/g)</p><ul><li>Alkalemia, insulin, catecholamines, β2-agonists, hypothermia, hypokalemic/thyrotoxic periodic paralysis, acute ↑ hematopoiesis (megaloblastic anemia Rx w/ B12, AML crisis), chloroquine; overdose: Ba/Cs, antipsychotics (risperidone, quetiapine), theophylline</li></ul><p>GI potassium losses (UK:Cr &lt;13 mEq/g)</p><ul><li><p>GI losses plus metabolic acidosis: diarrhea, laxative abuse, villous adenoma</p></li><li><p>Vomiting & NGT drainage usually manifest as renal losses due to 2° hyperaldo & met. alk.</p></li></ul><p>Renal potassium losses (UK:Cr >13 mEq/g)</p><ul><li>Hypotensive or normotensive</li></ul><p>acidosis: DKA, RTA [distal RTAs (type I) >proximal RTAs (type II)]</p><p>alkalosis: diuretics (thiazide >loop), vomiting/NGT drainage (via 2° hyperaldosteronism)</p><p>Bartter’s syndrome (loop of Henle dysfxn→ furosemide-like effect; JASN 2017;28:2540)</p><p>Gitelman’s syndrome (DCT dysfxn→ thiazide-like effect (KI 2017;91:24)</p><p>drugs: acetaminophen overdose, PCN, gent., ampho, foscarnet, cisplatin, ifosfamide</p><p>↓ Mg: less Mg to inhibit principal cell ROMK channel, ∴ ↑ K secretion (JASN 2010;21:2109)</p><ul><li>Hypertensive: mineralocorticoid excess</li></ul><p>1° hyperaldosteronism (eg, Conn’s syndrome, glucocorticoid-remediable aldosteronism)</p><p>2° hyperaldosteronism (eg, renovascular disease, renin-secreting tumor)</p><p>Nonaldosterone mineralocorticoid (eg, Cushing’s, Liddle’s [↑ ENaC], exogenous, licorice)</p><p>Clinical manifestations</p><ul><li><p>Nausea, vomiting, ileus, weakness, muscle cramps, rhabdomyolysis, ↓ insulin secretion</p></li><li><p>Renal: ammoniagenesis, phosphaturia, hypocitraturia, NaCl & HCO3 retention, polyuria</p></li><li><p>ECG: may see U waves, ↑ QT, flat Tw, ST depression, ventricular ectopy (PVCs, VT, VF)</p></li></ul><p>Workup (JAMA 2021;12:1216)</p><ul><li><p>Identify transcellular shifts & treat. TTKG validity questioned (Curr Op Nephro 2011;20:547).</p></li><li><p>✓ UK:Cr: >13 mEq/g → renal loss; &lt;13 mEq/g → extrarenal loss (AJKD 2019;74:682)</p></li><li><p>If renal losses, ✓ BP, acid-base, UCl (UNa unreliable), UCa/Cr, renin, aldosterone, cortisol</p></li></ul><p>Figure 4-7 Approach to hypokalemia</p><p>Treatment (JAMA 2000;160:2429)</p><ul><li>If true potassium deficit: potassium repletion (↓ 1 mEq/L ≈ 200 mEq total body loss)</li></ul><p>Dosage: 40 mEq PO q4h, 10 mEq/h (IV), 20 mEq/h (central line), 40 mEq in 1 L IVF</p><ul><li><p>Replete K+ to >3 or >4 mEq/L if high-risk (HTN, CHF, arrhythmias, MI, digoxin, cirrhosis)</p></li><li><p>Beware of excessive potassium repletion if transcellular shift cause of hypokalemia</p></li><li><p>Treat underlying cause (if ↓ vol: avoid dextrose as ↑ insulin → intracellular potassium shifts)</p></li><li><p>Consider Rx that ↓ K loss: ACEI/ARB, K+-sparing diuretics, βB</p></li><li><p>Replete Mg if &lt;2 mEq/L: IV Mg-SO4 1–2 g q2h and oral Mg-oxide (limited by diarrhea).</p></li></ul><p>Causes of low Mg: GI loss (diarrhea, bypass, pancreatitis, malnutrition, PPI); renal loss (diuretics, nephrotoxic drugs, EtOH, ↑ Ca, 1° wasting syndromes, volume expansion)</p><p>HYPERKALEMIA</p><p>Transcellular shifts (BMJ 2009;339:1019)</p><ul><li>Acidemia, ↓ insulin (DM), cell lysis (tumor, rhabdo, ischemic bowel, hemolysis, transfusions, resorbing hematomas, hyperthermia, rewarming), hyperkalemic periodic paralysis, ↑ osmolality. Drugs: succinylcholine, aminocaproic acid, digoxin, β-blockers.</li></ul><p>Decreased GFR</p><ul><li>Any cause of oliguric or anuric AKI or any cause of end-stage renal disease</li></ul><p>Normal GFR but with ↓ renal K excretion</p><ul><li>Normal aldosterone function</li></ul><p>↓ EAV (K excretion limited by ↓ distal Na delivery & urine flow): CHF, cirrhosis</p><p>Excessive K intake: in conjunction with impairment in K excretion or transcellular shift</p><p>Ureterojejunostomy (absorption of urinary K in jejunum)</p><ul><li>Hypoaldosteronism: same as etiologies of hypoaldo RTA (type IV)</li></ul><p>↓ renin: DM, NSAIDs, chronic interstitial nephritis, HIV, multiple myeloma, Gordon’s</p><p>Normal renin, ↓ aldo synthesis: 1° adrenal disorders, ACEI, ARBs, heparin, ketoconazole</p><p>↓ response to aldosterone</p><p>Meds: K-sparing diuretics, TMP-SMX, pentamidine, calcineurin inhibitors</p><p>Tubulointerstitial disease: sickle cell, SLE, amyloid, diabetes</p><p>Clinical manifestations</p><ul><li><p>Weakness, nausea, paresthesias, palpitations; Renal: ↓ NH4+ secretion → acidosis</p></li><li><p>ECG: ST depression, peaked T waves, ↓ QT, ↑ PR interval, ↑ QRS width, loss of P wave, sine wave pattern, PEA/VF (ECG: low sens., cardiac arrest can be first manifestation!)</p></li></ul><p>Workup (Crit Care Med 2008;36:3246)</p><ul><li>Rule out pseudohyperkalemia (IVF w/ K, tourniquet, hemolysis, ↑ plt or WBC), rule out transcellular shift</li></ul><p>Treatment of Hyperkalemia</p><p>Intervention</p><p>Dose</p><p>Onset</p><p>Comment</p><p>Ca gluconate Ca chloridea</p><p>1–2 amps IV</p><p>&lt;3 min</p><p>Transient effect (30–60 min)</p><p>Stabilizes cell membrane</p><p>Insulin</p><p>reg insulin 5–10 U IV</p><ul><li>1–2 amps D50W</li></ul><p>15–30 min</p><p>Peak 30–60 min, lasts 4–6 h</p><p>↓ K 0.5–1.2 mEq/L</p><p>Bicarbonate (esp. if acidemic)</p><p>1–2 amps IV</p><p>150 mEq in 1 L D5W</p><p>15–30 min</p><p>Exchange K for H+ in cells</p><p>Lasts 5–6 h; ↓ K 0.7 mEq/L</p><p>β2 agonists</p><p>albuterol 10–20 mg inh.</p><p>or 0.5 mg IV</p><p>30–90 min</p><p>Peak 90 min, lasts 2–6 h</p><p>↓ K 0.5–1.4 mEq/L (IV >inh)</p><p>K-binding resins</p><p>SPSb 15–60 g PO/PR</p><p>patiromer 8.4–25.2 g/d PO</p><p>Na zirconium 5–10 g PO</p><p>4–24 hrs</p><p>hrs-d</p><p>hrs</p><p>Exchange K for cations in gut</p><p>(Na, Ca, H); ↓ K 0.8–1 mEq/L/d.</p><p>Edema & HTN w/ Na zirconium.</p><p>Diuretics</p><p>furosemide ≥40 mg IV</p><p>30 min</p><p>↓ total body K</p><p>Hemodialysis</p><p>Most rapid in 1st hr (1 mEq/L)</p><p>↓ total body K (JASN 2017;28:3441)</p><p>aCaCl contains more calcium and is typically reserved for codes (↑ risk of tissue necrosis) or via central line</p><p>b~0.4% intestinal necrosis esp. postop, ileus, SBO/LBO, bowel disease (UC), renal txp (Clin Nephro 2016;85:38)</p><ul><li><p>Assess GFR, if normal, then ✓UK, UNa (&lt;25 mEq/d ↓ distal Na delivery). ✓ UK:Cr (&lt;13 favors ↓ renal K excretion).</p></li><li><p>Rate of onset important to note when establishing a treatment plan (Mayo Clinic 2020;96:744)</p></li><li><p>Stabilize (initial): 10% CaCl (central) or gluconate (IV). ↑ memb. potential → ↓ excitability</p></li><li><p>Redistribute: insulin + dextrose (continuous if NPO), HCO3, β2-agonists</p></li><li><p>Eliminate: SPS, patiromer, Na zirconium, diuretics (w/ saline if preserved renal fxn), consider emergent HD in life-threatening situations</p></li><li><p>Patient information for diet education:
<a href=http://www.kidney.org/atoz/content/potassium rel=noopener>http://www.kidney.org/atoz/content/potassium</a></p></li></ul><p>KIDNEY DISEASE</p><p>ACUTE KIDNEY INJURY (AKI)</p><p>Definition (KDIGO 2012;2:1)</p><ul><li>Stages in ICU correspond to ↑ hospital mortality and LOS (Crit Care Med 2009;37:2552)</li></ul><p>Stage 1: Cr ≥0.3 mg/dL in 2d or ↑ Cr ≥50%, or UOP &lt;0.5 mL/kg/h for ≥6h</p><p>Stage 2: ↑ Cr 2–3x baseline in 7d or UOP &lt;0.5 mL/kg/h for ≥12h</p><p>Stage 3: ↑ 3x baseline in 7d, UOP &lt;0.3 mL/kg/h for ≥24h, anuria ≥12h, or Cr >4</p><ul><li>Cannot estimate GFR using Cr in setting of AKI or ∆’ing Cr (requires steady state)</li></ul><p>Workup (NEJM 2014;371:55)</p><ul><li><p>H&P: meds, contrast, or other nephrotoxins; ↓ PO intake, HoTN, infxn/sepsis; trauma, myalgias; BPH/retention. Search for insult 24–48 hr prior ↑ Cr. VS, vol status, rash.</p></li><li><p>Urine evaluation: output, urinalysis, sediment, electrolytes, and osmolality</p></li><li><p>Fractional excretion Na (FENa) = (UNa/PNa)/(UCr/PCr); if diuretic, ✓ FEUN=(UUN/PUN)/(UCr/PCr)</p></li><li><p>Renal U/S or CT: r/o obstruction & cortical atrophy in chronic kidney disease</p></li><li><p>Serologies (if indicated): see “Glomerular Disease”</p></li><li><p>Renal biopsy (microscopy, IF, and EM): if etiology unclear (esp. if proteinuria/hematuria). Relative contraindic.: SBP>150, ASA/NSAID, anticoag, cirrhosis. DDAVP if GFR &lt;45.</p></li></ul><p>Etiologies and Diagnosis of Acute Kidney Injury (Ann Inter Med 2017;9:66)</p><p>Etiologies</p><p>UA, Sediment, Indices</p><p>Prerenal</p><p>↓ Effective arterial volume (NEJM 2007;357:797) Hypovolemia, ↓ CO (CHF), ↓ oncotic pressure (cirrhosis, nephrotic), vasodilation (sepsis)</p><p>Δ local renal perfusion: NSAIDs, ACEI/ARB, contrast, calcineurin inhib, HRS, hyperCa</p><p>Large vessel: RAS (bilateral + ACEI), VTE, dissection, abd compart. synd. (renal vs. compress), vasculitis</p><p>Bland</p><p>Transparent hyaline casts</p><p>FENa &lt;1%, BUN/Cr >20</p><p>FEUN ≤35%</p><p>Intrinsic</p><p>Acute tubular necrosis (ATN)</p><p>Severe ischemia, sepsis, CIN (↓ RBF + toxin)</p><p>Toxins</p><p>Drugs: vanc, AG, cisplatin, foscarnet, HES (starch), IVIG, pentamidine, amphotericin, tenofovir</p><p>Pigments: Hb, myoglobin (NEJM 2009;361:62)</p><p>Monoclonal: Ig light chains (Blood 2010;116:1397)</p><p>Crystals: UA, ACV, MTX, indinavir, oral NaPO4</p><p>Pigmented granular muddy brown casts</p><p>± RBCs & protein from tubular damage</p><p>FENa >2%, BUN/Cr &lt;20 (except pigment, CIN)</p><p>FEUN >50%</p><p>Acute interstitial nephritis (AIN)</p><p>Allergic: β-lactams, sulfa drugs, NSAIDs, PPIs</p><p>Infection: pyelo, viral, legionella, TB, leptospirosis</p><p>Infiltrative: sarcoid, lymphoma, leukemia</p><p>Autoimmune: Sjögren’s, TINU, IgG4, SLE, ICIs</p><p>WBCs, WBC casts, ± RBCs w/ neg UCx</p><p>⊕ urine eos in abx</p><p>⊕ lymphs in NSAIDs</p><p>Small-med vessel: chol emboli, PAN, TMAs (TTP, HUS, atypical HUS, DIC, preeclampsia, APS, malignant HTN, scleroderma renal crisis)</p><p>± RBCs</p><p>⊕ urine eos in chol emboli</p><p>Glomerulonephritis (see “Glomerular Disease”)</p><p>Dysmorphic RBCs, RBC casts</p><p>Post</p><p>Bladder neck: BPH, prostate cancer, neurogenic bladder, anticholinergic meds</p><p>Ureteral (bilateral or unilateral in single kidney): malig, LAN, retroperitoneal fibrosis, nephrolithiasis</p><p>Bland ± non-dysmorphic RBCs, WBC, crystals</p><p>General treatment (CJASN 2008;3:962)</p><ul><li><p>Prerenal: isotonic IVF ≈ alb (NEJM 2004;350:22). No clear benefit of balanced crystalloids (eg, LR) over normal saline (NEJM 2018;378:829 & 2022;386:815).</p></li><li><p>Avoid nephrotoxic insults (meds and contrast); renally dose medications</p></li><li><p>Optimize hemodynamics (both MAP & CO) and maintain euvolemia (NEJM 2007;357:797)</p></li><li><p>No benefit to dopamine (Annals 2005;142:510), diuretics (JAMA 2002;288:2547), or mannitol</p></li></ul><p>Managing complications</p><ul><li><p>May take 1–3 wk to recover from ATN; anticipate volume overload, ↑ K, ↑ PO4, acidosis</p></li><li><p>Episodes of AKI ↑ risk of CKD progression, even after recovery (NEJM 2014;371:58)</p></li><li><p>Indications for urgent dialysis (when condition refractory to conventional therapy)</p></li></ul><p>Acid-base disturbance: refractory acidemia</p><p>Electrolyte disorder: hyperK; hyperCa, hyperPO4, tumor lysis syndrome</p><p>Intoxications (
<a href=http://www.extrip-workgroup.org/%29 rel=noopener>http://www.extrip-workgroup.org/)</a>: Poison Control (1-800-222-1222)</p><p>Indicated for: methanol, ethylene glycol, metformin, Li, valproic acid, salicylates, barbiturates, theophylline, thallium</p><p>Consider for: carbamazepine, APAP, dig (Rx Digibind), dabigatran (Rx idarucizumab)</p><p>Overload: refractory hypervolemia → hypoxemia (eg, CHF)</p><p>Uremia: pericarditis, encephalopathy, bleeding</p><ul><li>In stage 3 AKI, wait until above indication or oliguria >72 hrs (NEJM 2016;375:122; Lancet 2020;395:1506). If oliguria >72 hrs, further delaying until urgent indication ↑ mortality (Lancet 2021;397:1293).</li></ul><p>DISEASE-SPECIFIC MANAGEMENT</p><p>Acute interstitial nephritis (AIN) (CJASN 2017;12:2046 & JASN 2020;31:435)</p><ul><li><p>Commonly drug-induced: β-lactams, sulfa drugs, NSAIDs, PPIs, quinolones, allopurinol</p></li><li><p>If suspected, prompt removal of offending drug; ? early steroids w/in 7d of dx</p></li><li><p>Rechallenging after suspected ICI-induced AIN may depend on oncology natural history</p></li></ul><p>Cardiorenal syndrome (CRS) (CJASN 2017;12:1624)</p><ul><li><p>Multifactorial pathophys including: 1) ↓ CO, 2) ↑ renal venous congestion, 3) ↑ RAAS</p></li><li><p>Bidirectionality: acute CHF → AKI, and oliguric AKI can worsen CHF (JACC 2008;52:1527)</p></li><li><p>Rx: IV loop diuretics (bypass gut edema; dosing below); no diff. between high vs. low dose and bolus vs. gtt (NEJM 2011;364:797). No clinical benefit: dopa, nesiritide, ultrafilt.</p></li><li><p>Prognosis: 7% ↑ mortality a/w each 10 mL/min ↓ eGFR in ADHF (JACC 2006;47:1987)</p></li></ul><p>Contrast-induced acute kidney injury (CIAKI) (NEJM 2019;380:2146)</p><ul><li><p>Risk factors: CKD, DM, CHF, age, hypotension, ↑ contrast volume (JACC 2004;44:1393)</p></li><li><p>AKI 24–48 h post contrast, peaks 3–5 d, resolves 7–10 d (consider chol emboli if does not)</p></li><li><p>Prevention: consider if eGFR &lt;60 (espec. w/ proteinuria), DM, MI, HoTN (CJASN 2013;8:1618)</p></li></ul><p>Isotonic IV fluids: may be helpful if high risk (Lancet 2017;389:1312)</p><p>Outpatients: 3 mL/kg/h × 1 h prior, 1–1.5 mL/kg/h × 6 h after (JAMA 2004;291:2328)</p><p>Inpatients: 1 mL/kg/h × 6–12 h pre, intra, post-procedure (Lancet 2014;383:1814)</p><p>Hold ACEI/ARB (AJKD 2012;60:576), NSAIDs, diuretics. Min. contrast & use iso-osmolar.</p><ul><li>Nephrogenic systemic fibrosis: fibrosis of skin, joints, internal organs ~2–4 wk post gado exposure in CKD 4–5 (JACC 2009;53:1621). Postgado HD encouraged, though limited data.</li></ul><p>Hepatorenal syndrome (HRS; see “Cirrhosis”; AJKD 2013;62:1198)</p><ul><li>Albumin + either IV vasopressors (norepi, terlipressin) or octreotide & midodrine</li></ul><p>Obstructive diseases</p><ul><li><p>Dx: renal U/S if undifferentiated or CT abd/pelvic (I–) if suspect nephrolithiasis</p></li><li><p>Rx: Foley if urethra vs. perc. nephrostomy if above ureters (eg, stones), tamsulosin/finasteride</p></li><li><p>Watch for post-obstructive diuresis after relieving blockage, replace ½ UOP w/ ½ NS.</p></li></ul><p>Hemorrhagic cystitis (rapid ∆ in size of bladder vessels); avoid by decompressing slowly.</p><p>Polycystic kidney disease (NEJM 2008;359:1477; 2017;377:1988)</p><ul><li><p>Mostly AD PKD1/PKD2 mutations → renal cysts. PKD1 (85%) younger-onset ESRD.</p></li><li><p>Rx: hydration, low-salt diet; tolvaptan reduces GFR decline. Family genetic screening.</p></li></ul><p>Rhabdomyolysis (NEJM 2009;361:62)</p><ul><li><p>Pathophys: myoglobin-induced oxidant injury, vasoconstriction, myoglobin precipitation & pre-renal (extravasation). Can lead to ↓ Ca, ↑ K, and ↑ PO4.</p></li><li><p>Diagnosis: UA ⊕ for heme but 0 RBCs (ie, myoglobinuria)</p></li><li><p>Risk of AKI when CK >20,000. Rhabdo and mortality risk score: JAMA Int Med 2013;173:1821.</p></li><li><p>Aggressive IVF (tailor IVF to target UOP ~3 mL/kg). If urine pH &lt;6.5, consider NaHCO3 ✓ K & Ca frequently, trend CK. Monitor for compartment syndrome.</p></li></ul><p>Scleroderma renal crisis (Nature Neph 2016;12:678)</p><ul><li>5–20% diffuse cutaneous SSc w/ narrowing glomerular vessels. Sx: renal failure, severe HTN, encephalopathy. Rx: max ACEi for BP control.</li></ul><p>COVID-19 associated AKI (Am J Physiol Renal Physiol 2021;4:403)</p><ul><li>17% of inPts. ATN >collapsing FSGS (high-risk APOL1 genotype). ↑ clotting risk w/ RRT</li></ul><p>Thrombotic microangiopathies (TMAs): see “Hematology”</p><p>CHRONIC KIDNEY DISEASE (CKD)</p><p>Definition and etiologies (Lancet 2021;10302:786)</p><ul><li><p>GFR &lt;60 for ≥3 mo and/or kidney damage (albuminuria, structural abnormality)</p></li><li><p>Prevalence 15% in U.S.</p></li><li><p>Albuminuria predicts all-cause & CV mortality, CKD progression (NEJM 2004;351:1296)</p></li><li><p>Cr poor estimate of GFR, use equation (
<a href=https://www.kidney.org/professionals/kdoqi/gfr rel=noopener>https://www.kidney.org/professionals/kdoqi/gfr</a> calculator)</p></li></ul><p>Cystatin-C–based formula less influenced by race than Cr-based (NEJM 2021;385:1737)</p><ul><li><p>Etiologies: DM (45%), HTN/RAS (27%), glomerular (10%), interstitial (5%), PKD (2%), congenital, drugs, myeloma, repeated insults (eg, Mesoamerican nephropathy)</p></li><li><p>Progression to ESRD: kidney failure risk equation (JAMA 2016;315:164; kidneyfailurerisk.com)</p></li></ul><p>Stages of CKD (Kid Int 2013;3[Suppl]:5)</p><p>GFR Stage</p><p>GFR mL/min/1.73 m2</p><p>Goals</p><p>1 (nl or ↑ GFR)</p><blockquote><p>90</p></blockquote><p>Dx/Rx of underlying condition & comorbidities, slow progression; cardiovascular risk reduction</p><p>2 (mild)</p><p>60–89</p><p>Estimate progression</p><p>3a (mild-mod)</p><p>45–59</p><p>Evaluate and treat complications</p><p>3b (mod-severe)</p><p>30–44</p><p>Evaluate and treat complications</p><p>4 (severe)</p><p>15–29</p><p>Prepare for renal replacement therapy (RRT)</p><p>5 (kidney failure)</p><p>&lt;15 or dialysis</p><p>Dialysis if uremic/volume overload; Tx</p><p>Albuminuria stage based on albuminuria (mg/d) or spot urine alb (mg) to Cr (g) ratio</p><p>Stages: A1 = &lt;30 (normal/mild); A2 = 30–300 (moderate); A3 = >300 (severe)</p><p>Signs and Symptoms of Uremia (NEJM 2018;379:669)</p><p>General</p><p>Nausea, anorexia, malaise, uremic fetor, metallic taste, hypothermia</p><p>Skin</p><p>Uremic frost (white crystals in & on skin), pruritus, calciphylaxis</p><p>Neurologic</p><p>Encephalopathy (Δ MS, ↓ memory & attention), seizures, neuropathy, impaired sleep, restless leg syndrome</p><p>Cardiovascular</p><p>Pericarditis, atherosclerosis, HTN, CHF, cardiomyopathy (LVH)</p><p>Hematologic</p><p>Anemia, bleeding (due to platelet dysfunction and Epo deficiency)</p><p>Metabolic</p><p>↑ K, ↑ PO4, acidosis, ↓ Ca, 2° hyperparathyroidism, osteodystrophy</p><p>Complications & treatment (JAMA 2019;322:1294; KI 2021;99:S1)</p><ul><li><p>General: renal referral when GFR &lt;30 or proteinuria, access planning (avoid subclavian lines, preserve an arm by avoiding phlebotomy, BP measurements, IVs)</p></li><li><p>CV risk reduction: consider usual preventive Rx including statin, βB, etc.</p></li><li><p>Dietary restrictions: Na (if HTN), K (if oliguric or hyperkalemic), PO4, mod protein.</p></li><li><p>Diabetes: strict glc control; ACEI/ARB, SGLT2i and MRA (NEJM 2020;383:2219) slow CKD progression (↓ glomerular pressure)</p></li><li><p>SGLT2i: in proteinuric CKD (min eGFR 25-30) w/ or w/o DM, transient ↓ in eGFR (&lt;5) but then 30-40% ↓ risk of CKD progression & ↓ mortality (NEJM 2019;380:2295 & 2020;383:1436)</p></li><li><p>BP control: goal ideally &lt;120/80, a/w ↓ mortality. ACEI or ARB, not both. For outPts, ✓ Cr & K in 1–2 wk, d/c if Cr ↑ 30% or K >5.4 (after dietary Δ & loop diuretic).</p></li><li><p>Metabolic acidosis: sodium bicarbonate or sodium citrate if low HCO3 (JASN 2015;26:515)</p></li><li><p>Hyperkalemia: 2-g K diet, see “Potassium Homeostasis”</p></li><li><p>Anemia: goal Hb 10–11.5 g/dL, worse outcomes if target higher (NEJM 2009;361:2019)</p></li></ul><p>epoetin (start 80–120 U/kg SC, divided 3×/wk) or darbepoetin (0.75 mg/kg q 2 wk)</p><p>iron supplementation to keep transferrin sat >20% (often given IV in HD Pts).</p><p>HIF inhib. ↑ endogenous EPO production, not yet approved (NEJM 2021;385:2313 & 2325).</p><ul><li><p>Uremic bleeding: desmopressin (dDAVP) 0.3 μg/kg IV or 3 μg/kg intranasally</p></li><li><p>2° hyperPTH: ↑ PO4, ↑ FGF-23, ↓ calcitriol, & ↓ Ca → ↑ PTH → renal osteodystrophy</p></li></ul><p>CKD stage</p><p>3</p><p>4</p><p>5</p><p>Target PTH (pg/mL)</p><p>35–70</p><p>70–110</p><p>150–600</p><p>Phosphorus binders (take with meals!) (NEJM 2010;362:1312). Non-Ca–based binders (eg, sevelamer) a/w ↓ mort. compared to Ca-based (Lancet 2013;382:1268).</p><p>If PTH above goal then start vit. D (if 25-(OH)D &lt;30) or 1,25-(OH)D analogue (calcitriol); stop if ↑ Ca (AJKD 2009;53:408)</p><p>Cinacalcet (parathyroid Ca-sensing receptor agonist) if ↑ PTH despite phosphorus binders ± vit. D analogue (CJASN 2016;11:161); consider parathyroidectomy</p><ul><li>Calciphylaxis (calcific uremic arteriopathy, NEJM 2018;378:1704)</li></ul><p>Pathophys: calcification of media in dermal small- to med-sized blood vessels & SC fat → ischemia and skin necrosis w/ painful lesions (NEJM 2007;356:1049)</p><p>Risk factors: ESRD, ♀>♂, DM, vit K def, obesity, warfarin, local trauma, thrombophilias</p><p>Dx: skin bx, but limitations (Kidney Int 2018;94:390); bone scan used in support of dx</p><p>Rx: ↓ risk factors, wound care/surgical debridement, manage hyperPTH, d/c vit D, Ca, & warfarin (DOAC okay). Pain control, palliative care, ? Na thiosulfate.</p><p>Prognosis: 60% 1-y mortality in ESRD Pts (AJKD 2015;66:133)</p><ul><li><p>Anticoag: ESRD at ↑ bleed risk; if using DOAC, consider apixiban >rivaroxaban >dabigatran due to protein binding/renal clearance (JASN 2017;28:2241)</p></li><li><p>Transplant evaluation</p></li></ul><p>DIURESIS</p><p>General considerations</p><ul><li><p>↑ Na & H2O excretion for treatment of HTN or edema in CHF, renal failure, and cirrhosis</p></li><li><p>Daily wt most effective method of documenting successful diuresis</p></li></ul><p>Loop diuretics (NEJM 2017;377:1964)</p><ul><li><p>Drugs: furosemide (Lasix), torsemide, bumetanide (Bumex), ethacrynic acid</p></li><li><p>Mech: inhib NaK2Cl cotransporter in thick ascending limb (ThAL, site of 25% Na reabsorp) → ↓ medullary osmotic gradient & ↓ free H2O reabsorption via ADH</p></li></ul><p>Transient venodilation may aid in pulmonary congestion (NEJM 1973;288:1087)</p><p>Response is fxn of amt of drug excreted; ∴ ↑ dose needed in renal insufficiency, CHF</p><p>Sigmoidal dose response curve; ∴ ↑ dose until induce diuresis, ↑↑ dose beyond that point yields diminishing returns compared with ↑ frequency of dosing</p><ul><li>Dosing: bioavailability PO furosemide ~50%, PO torsemide & bumetanide ~90%</li></ul><p>40 mg IV = 80 mg PO Lasix = 20 mg PO/IV torsemide = 1 mg IV/PO bumetanide</p><p>Dose furosemide bid-qid; qd dosing can yield initial diuresis, but then anti-natriuresis. Cont. vs. bolus IV similar in acute CHF (NEJM 2011;364:797). Ethacrynic acid if sulfa allergy.</p><p>? ↑ diuresis w/ co-administration of albumin if ↓ serum albumin (Crit Care Med 2005;33:1681)</p><ul><li>Adverse effects: ↑ Na, ↓ K, ↓ Mg, ↓ Ca, hyperuricemia, ototoxicity, hypersensitivity (sulfa)</li></ul><p>Thiazide diuretics (JASN 2017;28:3414)</p><ul><li><p>Drugs: hydrochlorothiazide (HCTZ), chlorothiazide (Diuril), metolazone (Zaroxolyn)</p></li><li><p>Mech: inhib Na-Cl cotransporter in the distal convoluted tubule (DCT); 5% Na reabsorp</p></li></ul><p>synergistic with loop diuretic, esp. if chronic loop use</p><p>↓ effect when GFR &lt;30, except metolazone, which is still effective in renal insufficiency</p><ul><li><p>Dosing: give 30 min prior to loop diuretic</p></li><li><p>Adverse effects: ↓ Na, ↓ K, ↓ Mg, ↑ Ca, HLD, pancreatitis, ↑ glc, hypersensitivity</p></li></ul><p>K-sparing diuretics (NEJM 2017;377:1964)</p><ul><li><p>Drugs: spironolactone (Aldactone), amiloride, triamterene, eplerenone</p></li><li><p>Mech: ↓ Na reabsorption (~1%) in collecting duct (amiloride/triamterene inhibit principal cell Na channel [ENaC]; spironolactone/eplerenone inhibit mineralocorticoid receptor).</p></li></ul><p>Relatively weak natriuretic activity, useful in combination with thiazide or in cirrhosis.</p><ul><li>Adverse effects: ↑ K (esp. w/ ACEI), metabolic acidosis, gynecomastia (spironolactone)</li></ul><p>Approach to Diuresis (if inadequate diuresis, go to next step)</p><p>Step</p><p>Action</p><p>1</p><p>Loop diuretic PO: ✓ response at 1–3 h, redose at 2× prior dose if needed</p><p>2</p><p>Add thiazide diuretic PO (potentiates response to loop diuretic)</p><p>3</p><p>Loop diuretic IV: bolus bid–qid ± thiazide (may start here if inPt) ↑ dose w/ ↑ Cr; initial effective IV Lasix dose ≈ 30 × Cr (ie, if Cr = 4 → 120 mg IV)</p><p>4</p><p>Loop diuretic infusion: bolus + continuous IV infusion ± thiazide (PO or IV)</p><p>5</p><p>RRT: consider ultrafiltration, CRRT, or HD</p><p>Disease state specific regimens</p><ul><li><p>Renal insufficiency: loop diuretic (↑ dose to achieve effective delivery to ThAL) ± thiazide</p></li><li><p>CHF: loop diuretic (↑ frequency over ↑ dose), IV for gut edema + thiazide (watch K & Mg)</p></li><li><p>Nephrotic syndrome: urinary albumin binds secreted loop diuretic, use 2–3× normal dose</p></li><li><p>Cirrhosis: spironolactone (blocks 2° hyperaldosteronism) + Lasix in 2.5:1 ratio</p></li><li><p>Severe metabolic alkalosis: acetazolamide & treat underlying cause</p></li></ul><p>RENAL REPLACEMENT AND DIALYSIS</p><p>General</p><ul><li><p>Acute indications: see “AKI”; choices CVVH vs. HD</p></li><li><p>Chronic indications: timing of RRT initiation should factor in Pt QoL, uremic sx, risk of development of urgent/acute indications; modalities PD vs. HD (no clear diff in outcomes)</p></li><li><p>Outcomes of ESRD: death from CVD (50%), infxn (30%), withdrawal of care (20%)</p></li></ul><p>Modalities</p><p>HD</p><p>CVVH</p><p>PD</p><p>Physiology</p><p>Diffusion</p><p>Convection</p><p>Diffusion</p><p>Access</p><p>AV fistula/graft or CVC</p><p>CVC</p><p>Peritoneal catheter</p><p>Prescription</p><p>Duration, volume goal; K, Na, Ca, HCO3 in bath, anticoag</p><p>Volume goal, K & Ca in replacement fluid (HCO3 vs. citrate)</p><p>PD fluid (dextrose, icodextrin), dwell time, # cycles</p><p>Complic.</p><p>HoTN, arrhythmia, disequilibrium syndrome* if very high BUN, ↑ CO HF</p><p>HoTN, ↓ PO4, ↓ iCa (citrate toxicity in hepatic dysfxn)</p><p>Peritonitis, ↑ glc, ↓ albumin, R pleural effusion</p><p>*Disequilibrium syndrome: sx cerebral edema due to H2O shifts after urea removal</p><p>Hemodialysis (HD) (NEJM 2010;363:1833)</p><ul><li>Solute removal across semipermeable membrane, countercurrent blood & dialysate flow</li></ul><p>Volume removal: Na/H2O ultrafiltered via transmembrane pressure (TMP) gradient</p><p>Solutes: Cr, urea, K diffuse from blood → dialysate, HCO3 from dialysate → blood</p><p>Solute removal inversely proportional to size ∴ effective removal of K, urea, Cr, not PO4</p><ul><li><p>6× vs. 3×/wk improved HTN, LV mass, QoL, but ↑ vasc issues (NEJM 2010;363:2287); w/ 3×/wk HD, ↑ mortality risk during 2-d interval (Sa–Tu or Fri–Mo) (NEJM 2011;365:1099)</p></li><li><p>Fever w/ catheter: empiric abx (vanc + GNR coverage qHD). GPC >GNR >mixed/fungal. Remove/replace catheter (depends on organism), “lock” abx (JASN 2014;25:2927).</p></li><li><p>Central vein stenosis: assoc. with longer HD duration, tunneled catheters. HeRO grafts bypass subclavian stenosis with flow into central vein (J Vasc Access 2016;17:138).</p></li></ul><p>Vascular Access</p><p>Advantages</p><p>Disadvantages</p><p>AV fistula</p><p>Highest patency</p><p>Lowest risk of bacteremia</p><p>Lowest mortality (JASN 2013;24:465)</p><p>Long maturation time (2–6 mo)</p><p>Primary nonfunction (20%)</p><p>AV graft</p><p>Easier to create than AVF</p><p>Maturation time (2–3 wk)</p><p>Poor 1° patency, often requiring thrombectomy or angioplasty</p><p>Catheter</p><p>Immediate use</p><p>Use as bridge to AVF/AVG</p><p>Highest risk of bacteremia</p><p>↓ blood flow → ↓ HD efficiency</p><p>Continuous veno-venous hemofiltration (CVVH) (NEJM 2012;367:26)</p><ul><li><p>Hemofiltration rather than dialysis. Blood under pressure passes down one side highly permeable membrane filtering H2O and solutes via TMP gradient (convective clearance); filtrate discarded. Replacement fluid infused (solute concentration similar to plasma, except no urea, Cr, PO4). Fluid balance by adjusting filtrate/replacement fluid.</p></li><li><p>Replacement fluid rate determines clearance. Choice of replacement fluid buffer:</p></li></ul><p>HCO3 (+ heparin to prevent clotting, although can be run heparin-free)</p><p>citrate: hepatically metabolized to HCO3, ∴ cannot be given in cirrhosis/liver failure. Provides anticoag w/in machine via Ca chelation. Citrate toxicity: ↓ iCa but nl/ ↑ serum Ca and AG met acidosis.</p><p>Dose adjust for solute and volume removal (AJKD 2016;68:645)</p><ul><li><p>Other CRRT modalities: CVVHD (dialysis), CVVHDF (filtration & dialysis) (AJKD 2016;68:645)</p></li><li><p>Benefits compared w/ HD: ↓ gross fluid shift (preferred in HoTN), but slower clearance of solutes and toxins</p></li></ul><p>Peritoneal dialysis (PD) (JAMA 2017;317:1864)</p><ul><li><p>Fluid removed via convection using oncotic pressure (eg, dextrose). ↑ concentrations and dwell times removes more fluid (less as glc equilibrates).</p></li><li><p>PD fluid: dextrose (1.5%, 2.5%, or 4.25%), buffer (lactate), Na+, Ca2+, Mg2+</p></li><li><p>Infuse 10 min, dwell 90 min–5.5 h, drain 20 min; exchanges done manually or using cycler at night (automated or cont. ambulatory peritoneal dialysis APD, CAPD)</p></li><li><p>PD peritonitis: abd pain & cloudy drainage (WBC >100 & >50% PMNs). 60–70% GPC, 15–20% GNR. Rx: abx IV or in PD, catheter removal for certain org (yeast, Pseudomonas).</p></li><li><p>Sclerosing peritonitis, a rare long-term complication (NEJM 2002; 347:737)</p></li><li><p>Hyperglycemia: exacerbated by inflammation, long dwell times, and higher [glucose]</p></li><li><p>Benefits: lower cost, independence, preservation of residual kidney function. No Δ mortality vs. HD (AJKD 2018;71:344).</p></li></ul><p>Kidney transplantation (Med Clin N Am 2016;100:435)</p><ul><li><p>Refer when GFR &lt;20. Contraindic: active malig, infxn, ischemia, noncompl, subst use</p></li><li><p>5-yr survival: living donor 91%; deceased donor 70–84% (AJKD 2016;23:281). Donors have minor ↑ risk of ESRD (Am J Transplant 2014;14:2434).</p></li><li><p>Immunosuppression: calcineurin inhib (tacrolimus>CsA) or CTLA4 inhib (belatacept) (NEJM 2016;374:333), antimetabolite (MMF>AZA), prednisone, mTOR inhib (sirolimus) if others contraindicated</p></li><li><p>Rejection: Ab (ABMR) or T-cell mediated (TCMR), a/w poor graft survival; BANFF criteria (Am J Transplant 2018;18:293). Rx options: ↑ immunosupp., pulse steroids, IVIG, rituximab.</p></li><li><p>Late renal dysfxn: usual AKI causes + calcineurin tox, rejection (NEJM 2010;363:1451), BK virus, recurrence of 1° disease; usual w/u + immunosupp levels, donor-specific antigen (DSA), BK virus load, U/S, then bx if no other cause (CJASN 2008;3:S56; CJASN 2011;6:1774)</p></li><li><p>↑ infxn (incl opportunistic such as CMV, JC, BK viruses; CJASN 2012;7:2058) & cancer (PTLD)</p></li><li><p>↑ CVD risk due to HTN (calcineurin inhib, RAS), DM & dyslipidemia (immunosupp meds)</p></li></ul><p>GLOMERULAR DISEASE</p><p>GLOMERULONEPHRITIS (GN)</p><p>Definition (Lancet 2016;387:2036; JASN 2016;27:1278)</p><ul><li><p>↑ glomerular inflammation → endothelial & podocyte injury</p></li><li><p>Histology: proliferative (↑ cells), sclerosing (scar), necrotizing (areas cell death). Focal (&lt;50% of glomeruli) to diffuse to crescentic. Segmental (&lt;50% tuft) to global (100%).</p></li><li><p>Clinically: hematuria w/ dysmorphic RBCs or RBC casts, ± subnephrotic proteinuria often w/ AKI, HTN, edema</p></li><li><p>Progression: acute ≈ days; rapidly progressive (RPGN) ~6 wk; chronic ≈ mos; can be asx</p></li></ul><p>aPredominant type; can see either type (NEJM 2012;367:214); bGPA (Wegener’s); EGPA (Churg-Strauss)</p><p>Anti-GBM Disease (linear staining) &lt;15% of total (CJASN 2017;12:1162)</p><p>Disease</p><p>Glomerulonephritis</p><p>Pulm Hemorrhage</p><p>Anti-GBM</p><p>Goodpasture’s</p><p>⊕</p><p>⊕</p><p>⊕</p><p>Anti-GBM disease</p><p>⊕</p><p>—</p><p>⊕</p><p>Immune Complex (IC) Disease (granular staining) ~40–45% of total (CJASN 2018;13:128)</p><p>Renal-Limited Diseases</p><p>Systemic Diseases</p><p>Infection-Related GN</p><p>(Staph & Strep; ↓ C3, ± ASLO)</p><p>SLE (CJASN 2017;12:825)</p><p>(⊕ ANA, ⊕ anti-dsDNA, ⊕ anti-Sm, ↓ C3, ↓ C4)</p><p>Membranoproliferative GN (MPGN) (↓ C3)</p><p>Cryoglobulinemia</p><p>(⊕ cryocrit, ⊕ RF, ⊕ HCV, SPEP, ↓ C3, ↓ C4)</p><p>Fibrillary and immunotactoid GN (normal C3/C4)</p><p>Endocarditis</p><p>(fever, ⊕ BCx, valvular disease, ↓ C3)</p><p>IgA nephropathy (normal C3, ±↑ IgA)</p><p>(NEJM 2013;368:2402; CJASN 2017;12:677)</p><p>Henoch-Schönlein purpura (IgA nephropathy + syst. vasculitis w/ IgA deposits, nl C3, ±↑ IgA)</p><p>Oncology-related glomerulopathy (CJASN 2016;11:1681)</p><ul><li><p>Associations between malig (solid tumors & heme) and/or their Rx (HSCT & chemo- therapeutics) and GN, nephrotic syndrome, and thrombotic microangiopathies (TMA)</p></li><li><p>Most common associations: membranous (solid tumors, HSCT), MCD (Hodgkin’s, solid tumors), MPGN (CLL, MM), TMA (HSCT, VEGF, anti-EGFR, CNIs, TKIs, mTOR)</p></li><li><p>Monoclonal glomerulopathy of renal significance: Ig-mediated kidney disease by nonmalignant B or plasma cells. Workup: SPEP, sFLC, flow cytometry, IFE, BMBx.</p></li></ul><p>Workup (JAMA 2017;318:1276)</p><ul><li><p>Acute GN/RPGN ± lung hemorrhage is an emergency → requires early Dx and Rx</p></li><li><p>UA + sediment (dysmorphic RBCs) ✓ ANCA, anti-GBM, C3/C4, SPEP, serum FLC</p></li><li><p>Depending on hx: ANA, anti-dsDNA/Sm, RF, Hep B&C, HIV, ASLO, BCx, cryocrit, skin bx</p></li><li><p>Consider GN mimics: thrombotic microangiopathies (qv), myeloma, AIN, cholesterol emboli</p></li><li><p>Renal biopsy with immunofluorescence (IF) + electron microscopy (EM)</p></li></ul><p>Figure 4-8 Approach to glomerulonephritis based on immunofluorescence pattern</p><p>Treatment (AJKD 2020;75:124 & 2020;76:265)</p><ul><li><p>If acute GN/RPGN suspected, give 500–1000 mg methylpred. IV qd × 3d ASAP while awaiting bx results.</p></li><li><p>SLE nephritis: induction w/ steroids + cyclophosphamide (CYC) or MMF (CJASN 2017;12:825)</p></li><li><p>ANCA ⊕ or anti-GBM: pulse steroids + CYC (or rituximab). Plasma exchange if ⊕ anti-GBM. Controversial in ANCA ⊕ only, even w/ GN or pulm hemor. (NEJM 2020;382:622).</p></li><li><p>See “Vasculitis” for further disease-specific Rx details (eg, eculizumab for atypical HUS)</p></li></ul><p>ASYMPTOMATIC GLOMERULAR HEMATURIA</p><p>Definition and etiologies</p><ul><li><p>Hematuria ± proteinuria of glomerular origin w/o renal insufficiency or systemic disease (nonglomerular more common; see “Hematuria”)</p></li><li><p>Ddx: any cause of GN (esp. IgA); also consider Alport’s (X-linked, deafness, renal failure), thin basement membrane nephropathy (autosomal dominant, benign; JASN 2013;23:364)</p></li></ul><p>IgA nephropathy (CJASN 2017;12:677; AJKD 2021;78:429)</p><ul><li><p>Most common cause of GN; ♂ pred; peak incidence 20–30s; can also be post-infectious</p></li><li><p>Wide range of clinical presentations: asx hematuria (30–40%), gross hematuria ~1–3 d after URI (10–15%), chronic GN (10%), nephrotic syndrome (5%), RPGN (&lt;5%)</p></li><li><p>Though clinical presentation can be highly suggestive, definitive dx only w/ bx</p></li><li><p>Prognosis: ↑Cr, HTN, proteinuria a/w poor prog. (AJKD 2012;59:865). 20–40% ESRD w/in 20 y.</p></li><li><p>Rx: ACEI/ARB; if persistent proteinuria (> 1g/d), clinical trial enrollment or shared decision for steroids, consider SGLT2i (NEJM 2020;383:1436); ± cytotoxic Rx for GN; ? fish oil</p></li></ul><p>NEPHROTIC SYNDROME</p><p>Definition (JASN 2014;25:2393)</p><ul><li><p>Podocyte injury (effacement) → loss of proteins (albumin, ATIII, Ig)</p></li><li><p>Clinically: proteinuria >3.5 g/d, albumin &lt;3 g/dL, edema, ↑ chol., VTE (25%), infection</p></li></ul><p>Primary glomerular diseases (grouped by pathology)</p><ul><li><p>Focal segmental glomerulosclerosis (40%; CJASN 2017;12:502). Primary: permeability factor. Secondary: adaptive (hyperfiltration, sickle cell, obesity, anabolic steroids, OSA, ↑ protein, vesico-ureteral reflux); meds/toxins (IFN, bisphosphonates, NSAIDs, heroin), viral (COVID-19, HIV) or genetic (ApoL1 mutation in AA; JASN 2015;26:1443).</p></li><li><p>Membranous nephropathy (30%; CJASN 2017;12:938, JASN 2021;32:268): Primary: Ab to PLA2R [70%], THSD7A [5%], other (EXT1-2, NELL1, Sema3B). Secondary: infxn (HBV, HCV, HIV, syphilis); autoimmune (eg, SLE); carcinomas; drugs (NSAIDs, penicillamine).</p></li><li><p>Minimal change disease (20%, more common in children; CJASN 2017;12:332) allergies, NSAIDs, ampicillin, Hodgkin’s disease, SLE, DM, MG, celiac disease</p></li><li><p>Membranoproliferative GN (5%, mixed nephrotic/nephritic features; CJASN 2014;9:600)</p></li></ul><p>Immune complex mediated: infection (esp. HCV ± cryos, IE, HBV, “shunt” nephritis, other chronic infxns), SLE, cryos, Sjögren’s, lymphomas, dysproteinemia, idiopathic</p><p>Complement mediated (rare); dense deposit disease (DDD), C3GN</p><ul><li><p>Fibrillary-immunotactoid glomerulopathy (1%; JASN 2008;19:34)</p></li><li><p>Mesangial proliferative GN (? atypical forms of MCD/FSGS, 5%) IgM, C1q nephropathy</p></li></ul><p>Systemic diseases with secondary glomerular involvement</p><ul><li><p>Diabetes mellitus (CJASN 2017;12:2032): nodular glomerulosclerosis (Kimmelstiel-Wilson lesion); glomerular hyperfiltration → microalbuminuria → dipstick ⊕ → nephrotic range (10–15 y). Proliferative retinopathy seen in 90% of type 1 and 60% of type 2.</p></li><li><p>Amyloidosis: AL or light-chain amyloid or AA amyloid secondary to inflammation</p></li><li><p>SLE (CJASN 2017;12:825): typically membranous nephropathy (WHO class V)</p></li><li><p>Cryoglobulinemia (AJKD 2016;67): a/w HCV, monoclonal gammopathy. Typically MPGN.</p></li></ul><p>Workup (BMJ 2008;336:1185)</p><ul><li><p>U/A + sediment: usually benign; ± oval fat bodies (“Maltese crosses”; NEJM 2007;357:806)</p></li><li><p>Measure proteinuria: 24-h urine or spot urine protein/Cr ratio (not accurate in AKI), renal bx</p></li><li><p>2° causes: ↑ HbA1C + retinop. → DM; ✓ ANA, anti-dsDNA, tox screen, C3/C4, SPEP/light chains, fat pad bx, cryocrit, HBV/HCV, HIV, RPR, APLA2R Ab, age-approp. CA screen</p></li></ul><p>Treatment (NEJM 2013;368:10)</p><ul><li><p>General: protein suppl.; diuretics for edema; treat hyperlipidemia, Na restriction (&lt;2 g/d)</p></li><li><p>ACEI or ARB: ↓ proteinuria → slow nonimmunologic progression of renal disease</p></li><li><p>1° glomerular: steroids ± rituximab or cytotoxic therapy (CJASN 2014;9:1386; NEJM 2019;381:36)</p></li><li><p>Secondary causes: treat underlying disease</p></li><li><p>Watch for malnutrition (protein loss), consider anticoag if albumin &lt;2.5 in membranous (KI 2014;85:1412), infection (esp. encapsulated organisms b/c loss of Ig)</p></li></ul><p>URINALYSIS</p><p>Urine Dipstick</p><p>Metric</p><p>Significance and Uses</p><p>Specific</p><p>gravity</p><p>Estimate Uosm: each 0.001 above 1 ≈ 30 osm (SG 1.010 → Uosm ≈ 300)</p><p>SG and Uosm useful in evaluating AKI, dysnatremias, polyuria Heavy substances (glucose, contrast) ↑ SG more than Uosm</p><p>pH</p><p>Range: 4.5–8.5; useful in evaluation of stones, RTAs, infection (urease UTI)</p><p>Protein</p><p>Detects albuminuria (>300 mg/d); see “Proteinuria.” False ⊖: dilute urine</p><p>Blood</p><p>See “Hematuria”; ⊕ from RBCs, free Hgb, or free myoglobin (eg, rhabdo)</p><p>False ⊕: semen, dilute urine (→ osmotic cell lysis), ↑ pH, vaginal blood</p><p>False ⊖: vit C</p><p>WBC</p><p>Suggests inflammation (UTI, interstitial nephritis, GN)</p><p>Ketones</p><p>Detects acetoacetate (ie, ketoacidosis) but not β-hydroxybutyrate</p><p>Leuk est</p><p>Lysed PMNs. Se 80% for UTI. FN: proteinuria, glycosuria FP: ↓ pH or SG</p><p>Nitrite</p><p>Suggests presence of nitrate reductase ⊕ bacteria (most enteric GNRs)</p><p>Bilirubin</p><p>↑ in biliary or hepatic disease</p><p>Glucose</p><p>⊕ in hyperglycemia (>180 mg/dL), pregnancy, Fanconi’s syndrome, SGLT2i</p><p>Urine Sediment (microscopic examination) (Am J Kidney Dis 2008;51:1052)</p><p>Method: Centrifuge fresh sample (prox. port if Foley) × 3–5 min at 1500–3000 rpm; pour off supernatant in one motion; resuspend pellet by agitating base of tube; pour suspension onto slide w/ coverslip; view under “high dry” power; phase contrast for RBC morphology</p><p>Cells</p><p>RBCs: assess amount & morphology (many dysmorphic → glomerular)</p><p>WBCs: PMNs (UTI) vs. eosinophils (AIN; may require special stain)</p><p>Epithelial cells: tubular (ATN), transitional (bladder or ureters), squamous</p><p>Casts (see urinalysis photo inserts in appendix)</p><p>Proteins molded in lumen of renal tubule ± entrapped cellular elements RBC → GN</p><p>WBC → AIN, pyelonephritis, GN</p><p>Granular (“muddy brown”): degenerating cellular casts → ATN</p><p>Tubular cell → ATN</p><p>Hyaline: Tamm-Horsfall protein (nonspecific)</p><p>Waxy and broad → advanced chronic kidney disease</p><p>Crystals</p><p>(see urinalysis photo inserts in appendix)</p><p>Calcium oxalate monohydrate: spindle, oval, or dumbbell shaped</p><p>Calcium oxalate dihydrate: envelope shaped or octahedral</p><p>Uric acid: variable shape; polychromatic under polarized light</p><p>Cystine: hexagon shaped</p><p>Struvite: coffin-lid shaped; seen in chronic UTI with urea-splitting organisms</p><p>Drugs: sulfa, protease inhibitors: “shocks of wheat”; acyclovir: fine needles</p><p>PROTEINURIA</p><p>Etiologies of Proteinuria</p><p>Category</p><p>Description</p><p>Etiologies</p><p>Glomerular</p><p>(can be >3.5 g/d)</p><p>Disruption of filtration</p><p>barrier → lose albumin</p><p>Glomerulonephritis</p><p>Nephrotic syndrome</p><p>Tubulointerstitial</p><p>(usually &lt;1–2 g/d)</p><p>↓ reabsorption of freely filtered proteins → lose globulins</p><p>ATN; AIN</p><p>Fanconi’s syndrome</p><p>Overflow</p><p>↑ production of freely filtered proteins</p><p>Multiple myeloma</p><p>Myoglobinuria</p><p>Isolated</p><p>By def’n: asx, normal</p><p>renal fxn, sed, & imaging, no</p><p>h/o renal disease</p><p>Functional (fever, exercise, CHF) Orthostatic (only when upright) Idiopathic (transient or persistent)</p><ul><li>Urine dipstick</li></ul><p>1+ ≈30 mg/dL, 2+ ≈100 mg/dL, 3+ ≈300 mg/dL, 4+ >2 g/dL; interpretation depends on SG; eg, 3+ in very concentrated urine might not indicate heavy proteinuria</p><p>Insensitive for microalbuminuria and myeloma light chains (Bence-Jones protein)</p><ul><li>Spot urine: protein (mg/dL)/creatinine (mg/dL) ≈ g/d of proteinuria (NEJM 1983;309:1543) unlike urine dipstick, will accurately measure myeloma light chains</li></ul><p>reliable surrogate for 24-hr urine, esp. 1st morning void (JASN 2009;20:436); inaccurate if AKI depends on Cr production, ∴ underestimates if muscular, overestimates if cachectic</p><ul><li><p>Moderate albuminuria (30–300 mg/d or mg/L or mg/g Cr): early sign of glomerular vascular disease; marker for ↑ risk of CV adverse outcomes (KI 2013;3:19)</p></li><li><p>Orthostatic proteinuria: typically in adolescents; ~90% of young ♂ with isolated proteinuria have orthostatic proteinuria; typically resolves spontaneously</p></li></ul><p>HEMATURIA</p><p>Etiologies of Hematuria</p><p>Extrarenal (far more common)</p><p>Intrarenal</p><p>Nephrolithiasis</p><p>Neoplasm: transitional cell, prostate</p><p>Infxn: cystitis, urethritis, prostatitis</p><p>Foley trauma</p><p>BPH</p><p>Schistosoma haematobium</p><p>Nephrolithiasis or crystalluria</p><p>Neoplasm</p><p>Trauma/exercise</p><p>Vascular: renal infarcts, renal v. thromb., sickle cell</p><p>Glomerular: IgA, thin BM, others</p><p>PKD (NEJM 2008;359:1477)</p><ul><li>Wide, overlapping ages for various etiologies, but general guide for common causes:</li></ul><p>&lt;20 y: GN, UTI, congenital; 20–60 y: UTI, nephrolithiasis, cancer</p><blockquote><p>60 y ♂: prostatitis, cancer, UTI; >60 y ♀: UTI, cancer</p></blockquote><p>Workup (NEJM 2021;385:153)</p><ul><li><p>Urine dipstick: ⊕ if ≥3 RBCs; ⊕ dipstick and ⊖ sediment → myo- or hemoglobinuria</p></li><li><p>Urine sediment: dysmorphic RBCs or RBC casts → GN → consider renal bx</p></li><li><p>If suggestive sx, r/o UTI or nephrolithiasis</p></li><li><p>Low cancer risk: repeat U/A in 4–6 wks; if still ⊕ → cystoscopy + imaging</p></li><li><p>Intermediate risk (eg, ♂ 40–59 yrs or ♀ 50–59 yrs or 10–30 pack-yrs): cystoscopy + U/S</p></li><li><p>High risk (eg, age ≥60 or >30 pack-yrs): CT urography (Se 96%, Sp 98%) + cystoscopy</p></li><li><p>Rx: if obstruction: bladder irrigation and 3-way Foley on CBI</p></li></ul><p>NEPHROLITHIASIS</p><p>Types of stones and risk factors (Nat Rev Dis Prim 2016;2:16008)</p><ul><li>Calcium (Ca oxalate >Ca phosphate): 70–90% of kidney stones (NEJM 2010;363:954)</li></ul><p>Urine findings: ↑ Ca, ↑ oxalate (Ca-ox only), ↑ pH (Ca-phos only), ↓ citrate, ↓ volume</p><p>2° hypercalciuria: 1° hyperparathyroidism, distal RTA, sarcoid, Li use</p><p>2° hyperoxaluria: Crohn’s, ileal disease w/ intact colon, gastric bypass, pancreatic insuffic.</p><p>Diet: ↑ animal protein, ↑ sucrose, ↑ Na, ↓ K, ↓ fluid, ↓ fruits/vegetables, ↑ vit. C, ↓ Ca</p><ul><li>Uric acid: 5–10% of kidney stones, radiolucent on plain film</li></ul><p>Urine findings: ↑ uric acid, ↓ pH (eg, from chronic diarrhea)</p><ul><li>Magnesium ammonium phosphate (“struvite” or “triple phosphate”)</li></ul><p>Chronic upper UTI w/ urea-splitting organisms (eg, Proteus, Klebs) → ↑ urine NH3, pH >7</p><ul><li>Cystine: inherited defects of tubular amino acid reabsorption</li></ul><p>Clinical manifestations</p><ul><li><p>Hematuria (absence does not exclude diagnosis), flank pain, N/V, dysuria, frequency</p></li><li><p>Ureteral obstruction (stones >5 mm unlikely to pass spont.) → AKI if solitary kidney</p></li><li><p>UTI: ↑ risk of infection proximal to stone; urinalysis of distal urine may be normal</p></li></ul><p>Workup</p><ul><li><p>Non-contrast CT 97% Se, 96% Sp (ureteral dilation w/o stone suggests recent passage); U/S (Se 57%, Sp 98%) may serve as initial test in stable patient (NEJM 2014;371:1100)</p></li><li><p>Strain urine for stone to analyze; U/A & UCx; electrolytes, BUN/Cr, Ca, PO4, PTH</p></li><li><p>24-h urine × 2 (>6 wk after acute setting) for Ca, PO4, oxalate, citrate, Na, Cr, pH, K, vol.</p></li></ul><p>Acute treatment (JAMA 2020;323:1961)</p><ul><li><p>Analgesia (narcotics ± NSAIDs; combination superior, Ann Emerg Med 2006;48:173), ensure adequate fluid repletion, antibiotics if UTI</p></li><li><p>α-blocker >CCB to pass stone if ≤10 mm (Cochrane; 2014:CD008509, Lancet 2006;368:1171)</p></li><li><p>Indications for immediate urologic eval and/or hosp: obstruction (esp. solitary or transplant kidney), urosepsis, intractable pain or vomiting, significant AKI</p></li><li><p>Urologic Rx: lithotripsy (NEJM 2012:367:50), ureteroscopic removal, lap/perc nephrolithotomy</p></li></ul><p>Chronic treatment (CJASN 2016;11:1305 & 2017;12:1699)</p><ul><li><p>Increase fluid intake (>2 L/d) for goal UOP 2 L/d (J Nephrol 2016;29:211)</p></li><li><p>Calcium stones: 24-h urine identifies specific urinary risk factors to treat</p></li></ul><p>Diet: ↓ Na and meat (NEJM 2002;346:77), ↓ oxalate foods & sucrose/fructose</p><p>Meds: thiazides (↓ urine Ca), K-citrate if low urine citrate, allopurinol if high urine uric acid</p><p>Avoid low dietary Ca as ↑ oxalate absorp (NEJM 2002;346:77), unclear role of Ca suppl.</p><ul><li><p>Uric acid: fluid intake, urine alkalinization (K-citrate) to pH 6.5–7, allopurinol</p></li><li><p>Magnesium ammonium phosphate (struvite): antibiotics for UTI; urologic intervention; acetohydroxamic acid; urease inhibitor reserved for experienced clinician, poorly tolerated</p></li><li><p>Cystine: fluid, urine alkaliniz (K-citrate) to 7–8, d-penicillamine, tiopronin (KI 2006;69:1041)</p></li></ul><p>ANEMIA</p><p>↓ in RBC mass: Hct &lt;41% or Hb &lt;13.5 g/dL (men); Hct &lt;36% or Hb &lt;12 g/dL (women)</p><p>Clinical manifestations</p><ul><li><p>Symptoms: ↓ O2 delivery → fatigue, exertional dyspnea, angina (if CAD)</p></li><li><p>Signs: pallor (mucous membranes, palmar creases), tachycardia, orthostatic hypotension</p></li><li><p>Other findings: jaundice (hemolysis), splenomegaly (thalassemia, neoplasm, chronic hemolysis), petechiae/purpura (bleeding disorder), glossitis (iron, folate, vitamin B12 defic.), koilonychia (iron defic.), neurologic abnormalities (B12 defic.)</p></li></ul><p>Diagnostic evaluation</p><ul><li><p>History: bleeding, systemic illness, drugs, exposures, alcohol, diet (including pica), FHx</p></li><li><p>CBC w/ diff.; RBC params incl. retics, MCV (nb, mixed disorder can → nl MCV), RDW</p></li><li><p>Reticulocyte index (RI) = [reticulocyte count × (Pt’s Hct/nl Hct)]/maturation factor maturation factors for a given Hct: 45% = 1, 35% = 1.5, 25% = 2, 20% = 2.5 RI >2% → adequate marrow response; RI &lt;2% → hypoproliferation</p></li><li><p>Peripheral smear: select area where roughly ⅓ RBCs touch each other; ✓ RBC size, shape, inclusions (see “Appendix” & “Peripheral Smear”), WBC morphology, plt count</p></li><li><p>Additional labs as indicated: hemolysis labs (if RI >2%, see below), iron/TIBC, ferritin, folate, B12, LFTs, BUN, & Cr, TFTs, Hb electrophoresis, enzyme/gene mutation screens</p></li><li><p>Bone marrow (BM) aspirate and biopsy (bx) with cytogenetics as indicated</p></li></ul><p>Figure 5-1 Approach to anemia and common causes</p><p>MICROCYTIC ANEMIAS</p><p>Figure 5-2 Approach to microcytic anemias (NEJM 2014;371:1324)</p><p>Iron deficiency (Lancet 2021;397:233)</p><ul><li><p>↓ marrow iron & depleted body iron stores → ↓ heme synthesis → microcytosis → anemia</p></li><li><p>Special clinical manifestations: angular cheilosis, atrophic glossitis, pica (consumption of nonnutritive substances such as ice, clay), koilonychia (nail spooning)</p></li></ul><p>Plummer-Vinson syndrome (iron deficiency anemia, esophageal web & atrophic glossitis)</p><ul><li><p>Etiologies: chronic bleeding (GI—incl. cancer, menstrual, parasites, NSAIDs, etc.), ↓ supply (malnutrition; ↓ absorp. due to celiac sprue, Crohn’s, ↑ gastric pH, subtotal gastrectomy), ↑ demand (preg; Blood 2017;129:940). Iron-refractory iron-defic. anemia (IRIDA; rare genetic disorder due to hepcidin dysregulation; Nat Genet 2008;40:569).</p></li><li><p>Diagnosis (eval ideally before Rx): ↓ Fe, ↑ TIBC, ↓ ferritin (esp. &lt;15), ↓ transferrin sat (Fe/TIBC; esp. &lt;15%), ↑ soluble transferrin receptor; ↑ plt. Unless hx c/w other etiology, initiate workup for GIB, incl. H. pylori serology. ? Celiac labs (anti-TTG, anti-endomysial IgA Abs). Cytogenetics & molecular testing as indicated (eg, MDS, leukemia).</p></li><li><p>Treatment: oral Fe TID (~6 wks to correct anemia; ~6 mo to replete Fe stores; nb, oral Fe does not give ⊕ Hemoccult). With severe anemia, persistent losses, prior to Epo Rx, or while inpatient, use IV iron (Fe-sucrose, -gluconate, -dextran).</p></li></ul><p>Thalassemias (Lancet 2018;391:155)</p><ul><li><p>↓ synthesis of α- or β-globin chains of Hb → ≠ subunits → destruction of RBCs and erythroid precursors; ∴ anemia from hemolysis and ineffective erythropoiesis</p></li><li><p>α-thalassemia (NEJM 2014;371:1908): deletions in α-globin gene complex (nl 4 α genes), seen w/ Southeast Asian, Mediterranean, African, Middle East ancestry</p></li></ul><p>3 α → silent carrier; 2 α → α-thal minor = mild anemia, α-thal-1 (&ndash;/αα, milder) or</p><p>α-thal-2 (-α/-α); 1 α → HbH (β4) disease = severe anemia, hemolysis, and splenomegaly</p><p>0 α genes → Hb Barts (γ4) = intrauterine hypoxia and hydrops fetalis</p><ul><li>β-thalassemia: mutations in β-globin gene → absent or ↓ gene product seen w/ Mediterranean (espec. Greek or Italian), African, or Asian ancestry</li></ul><p>1 mutated β gene → thal minor (or trait) = mild anemia (no transfusions)</p><p>2 mutated β genes → thal intermedia (occasional transfusions) or thal major (= Cooley’s anemia; transfusion dependent) depending on severity of mutations</p><ul><li><p>Special clinical manifestations: chipmunk facies, pathologic fractures, hepatosplenomegaly (due to extramedullary hematopoiesis), high-output CHF, bilirubin gallstones, Fe overload</p></li><li><p>Dx: MCV &lt;70, normal Fe, ferritin, MCV/RBC count &lt;13 [Mentzer Index, 60% Se, 98% Sp; (Ann Hem 2007;86:486)], ± ↑ retics, basophilic stippling; Hb electrophoresis: ↑ HbA2 (α2δ2) in β-thal; normal pattern in α-thal trait, ∴ PCR or supravital stain for dx</p></li><li><p>Treatment: folate; transfusions + Fe chelator [either deferoxamine (IV) or deferasirox (PO)]; ? splenectomy if ≥50% ↑ in transfusions; gene therapy in development (NEJM 2018;378:1479); luspatercept (↓ SMAD signaling) in β-thal major (NEJM 2020;382:1219)</p></li></ul><p>Anemia of chronic inflammation (see below)</p><p>Sideroblastic anemia</p><ul><li><p>Defective heme biosynthesis within RBC precursors</p></li><li><p>Etiologies: hereditary/X-linked (ALAS2 mutations), idiopathic, MDS-RARS, reversible (alcohol, lead, isoniazid, chloramphenicol, copper deficiency, hypothermia)</p></li><li><p>Special clinical manifestations: hepatosplenomegaly, iron overload syndromes</p></li><li><p>Dx: social, work, & TB hx; can be micro-, normo-, or macrocytic; variable populations of hypochromic RBCs; ↑ Fe, nl TIBC, ↑ ferritin, basophilic stippling, RBC Pappenheimer bodies (Fe-containing inclusions), ring sideroblasts (w/ iron-laden mitochondria) in BM</p></li><li><p>Treatment: treat reversible causes; trial of pyridoxine, supportive transfusions for severe anemia with chelation therapy; high-dose pyridoxine for some hereditary cases</p></li></ul><p>NORMOCYTIC ANEMIAS</p><p>Anemia of chronic inflammation (ACI; NEJM 2012;366:4)</p><ul><li><p>↓ RBC production due to impaired iron utilization and functional iron deficiency from ↑ hepcidin; cytokines (IL-6, TNF-α) cause ↓ Epo responsiveness/production</p></li><li><p>Etiologies: autoimmune disorders, chronic infection, inflammation, HIV, malignancy</p></li><li><p>Dx: ↓ Fe, ↓ TIBC (usually normal or low transferrin sat), ± ↑ ferritin; usually normochromic, normocytic (~70% of cases) but can be microcytic if prolonged</p></li><li><p>Coexisting iron deficiency common. Dx clues include ↓ serum ferritin levels, absence of iron staining on BM bx, ⊕ response to a trial of oral iron and/or ↑ soluble transferrin receptor/ferritin index (Am J Clin Pathol 2012;138:642).</p></li><li><p>Treatment: treat underlying disease ± iron and/or erythropoiesis-stimulating agent (ESA; eg, Epo). Iron if ferritin &lt;100 or Fe/TIBC &lt;20%. Consider ESA if Epo &lt;500. Avoid ESA in cancer if treatment goal is cure (Lancet 2009;373:1532). Transfuse PRBCs only if symptomatic & insufficient time to wait for response to Epo or underlying disease Rx.</p></li></ul><p>Anemias of other chronic disorders</p><ul><li><p>Anemia of CKD: ↓ Epo; treat w/ Epo & iron (see “Chronic Kidney Disease”)</p></li><li><p>Endocrine deficiencies: hypometabolism and ↓ O2 demand with thyroid, pituitary, adrenal, or parathyroid disease → ↓ Epo; can be normocytic or macrocytic</p></li></ul><p>Sideroblastic anemia (see above)</p><p>Pure red cell aplasia</p><ul><li><p>Destructive antibodies or lymphocytes → ineffective erythropoiesis</p></li><li><p>Associated with thymoma, CLL, parvovirus infection, autoimmunity, drugs</p></li><li><p>Diagnostic studies: lack of erythroid precursors on BM bx, other lines normal</p></li><li><p>Treatment: thymectomy if thymus enlarged; IVIg if parvovirus and immunosuppressed (Clin Infect Dis 2013;56:968); immunosuppression/chemoRx if CLL or idiopathic; supportive care w/ PRBC transfusions; ? erythropoietin receptor agonist if due to antierythropoietin Ab (NEJM 2009;361:1848); consider hematopoietic cell transplantation.</p></li></ul><p>MACROCYTIC ANEMIAS</p><p>includes megaloblastic and nonmegaloblastic causes</p><p>Megaloblastic anemia</p><ul><li><p>Impaired DNA synthesis → cytoplasm matures faster than nucleus → ineffective erythropoiesis and macrocytosis; due to folate or B12 deficiency; also in MDS</p></li><li><p>✓ folate and vitamin B12; ↑ LDH & indirect bilirubin (due to ineffective erythropoiesis)</p></li><li><p>Smear: neutrophil hypersegmentation, macro-ovalocytes, anisocytosis, poikilocytosis</p></li></ul><p>Folate deficiency</p><ul><li><p>Folate present in leafy green vegetables and fruit; total body stores sufficient for 2–3 mo</p></li><li><p>Etiologies: malnutrition (alcoholics, anorectics, elderly), ↓ absorption (sprue), impaired metabolism (methotrexate, pyrimethamine, trimethoprim; NEJM 2015;373:1649), ↑ requirement (chronic hemolytic anemia, pregnancy, malignancy, dialysis)</p></li><li><p>Diagnosis: ↓ folate; ↓ RBC folate, ↑ homocyst. but nl methylmalonic acid (unlike B12 defic.)</p></li><li><p>Treatment: folate 1–5 mg PO qd for 1–4 mo or until complete hematologic recovery; critical to r/o B12 deficiency first (see below)</p></li></ul><p>Vitamin B12 deficiency (NEJM 2013;368:149)</p><ul><li><p>B12 present only in foods of animal origin; total body stores sufficient for 2–3 y</p></li><li><p>Binds to intrinsic factor (IF) secreted by gastric parietal cells; absorbed in terminal ileum</p></li><li><p>Etiologies: malnutrition (alcoholics, vegans), pernicious anemia (PA, autoimmune disease against gastric parietal cells, a/w polyglandular endocrine insufficiency and ↑ risk of gastric carcinoma), other causes of ↓ absorption (gastrectomy, sprue, Crohn’s disease), ↑ competition (intestinal bacterial overgrowth, fish tapeworm)</p></li><li><p>Clinical manifestations: neurologic changes (subacute combined degeneration) affecting peripheral nerves, posterior & lateral columns of the spinal cord and cortex → numbness, paresthesias, ↓ vibratory & positional sense, ataxia, dementia, mood</p></li><li><p>Dx: ↓ B12 (even low nl); ↑ homocysteine & methylmalonic acid; anti-IF Ab; ↑ gastrin in PA</p></li><li><p>Treatment: 1 mg B12 IM qd × 7 d → q wk × 4–8 wk → q month for life</p></li></ul><p>neurologic abnormalities are reversible if treated w/in 6 mos</p><p>folate can reverse hematologic abnormalities of B12 deficiency but not neurologic changes (and can “steal” B12 stores → worsening of neuro complications)</p><p>oral supplementation (2 mg qd) appears feasible as well (Cochrane Rev CD004655) even w/o IF</p><p>Nonmegaloblastic macrocytic anemias</p><ul><li><p>Liver disease: often macrocytic, may see target cells, or spur cell anemia w/ hemolysis</p></li><li><p>Alcoholism: BM suppression & macrocytosis independent of folate/B12 defic. or cirrhosis</p></li><li><p>Other causes: reticulocytosis; hypothyroid; MDS; meds impairing DNA synth (zidovudine, 5-FU, hydroxyurea, Ara-C); hereditary orotic aciduria; Lesch-Nyhan syndrome</p></li></ul><p>PANCYTOPENIA</p><p>Etiologies</p><ul><li><p>Hypocellular bone marrow (nl cellularity ~100 – age): aplastic anemia, hypoplastic MDS</p></li><li><p>Cellular bone marrow: MDS, aleukemic leukemia, PNH, severe megaloblastic anemia</p></li><li><p>Myelophthesis (marrow replacement, PMF); systemic dis. (hypersplen, sepsis, EtOH/toxin)</p></li></ul><p>Clinical manifestations</p><ul><li>Anemia → fatigue; neutropenia → recurrent infections; thrombocytopenia → mucosal bleeding & easy bruisability</li></ul><p>Aplastic anemia (stem cell failure) (NEJM 2015;373:35)</p><ul><li><p>Epidemiology: 2–5 cases/106/y; biphasic (major peak in adolescents, 2nd peak in elderly)</p></li><li><p>Diagnosis: pancytopenia w/ ↓ retics, BM bx w/ hypocellularity, usually nl cytogenetics</p></li><li><p>Etiologies: idiopathic (½ – ⅔ of cases)</p></li></ul><p>Stem cell destruction: radiation, chemotherapy, chemicals (eg, benzene)</p><p>Med rxn (eg, chloramphenicol, NSAIDs, sulfa drugs, gold, carbamazepine, antithyroid)</p><p>Viruses (HHV-6, HIV, EBV, parvovirus B19); post-viral hepatic failure (not Hep A/B/C)</p><p>Immune disorders (SLE, GVHD post-HSCT, thymoma)</p><p>PNH (see below); Fanconi’s anemia (congenital disorder w/ pancytopenia, macrocytic anemia, ↑ risk of MDS, AML, & SCC of head & neck, and multiple physical anomalies)</p><p>Shortened telomeres: seen w/ telomerase (TERT, TERC) mut. (10% of aplastic anemia), dyskeratosis congenita/DKC1 mut; a/w IPF, cirrhosis (NEJM 2009;361:2353)</p><p>Somatic mutations: PNH clones in ~50% of aplastic anemia (Haematologica 2010;95:1075)</p><ul><li>Treatment and prognosis</li></ul><p>Immunosuppression (CsA/tacrolimus, ATG): 70–80% respond, with 80–90% 5-y survival in responders (96% vs. 76% w/ horse vs. rabbit ATG; NEJM 2011;365:430); 15–20% 10-y incidence of clonal disorders (mostly MDS, AML, PNH)</p><p>TPO mimetics (eg, eltrombopag): use 1st-line w/ immunosuppression (NEJM 2022;386:11)</p><p>Supportive care: transfusions, abx, possible utility of G-CSF & Epo (if Epo &lt;500)</p><p>Allogeneic HSCT: for young Pts → ~80% long-term survival and significantly ↓ risk of malignant evolution, but has risk of transplant-related morbidity & mortality; if possible, avoid transfusions (risk of alloimmunization) pretransplant</p><p>Myelodysplastic syndromes (MDS) (qv)</p><p>Paroxysmal nocturnal hemoglobinuria (PNH) (Blood 2009;113:6522)</p><ul><li><p>Acquired clonal stem cell disorder = inactivating somatic mutation of PIG-A gene → deficiency of GPI-anchor for CD55 & CD59 (inhib of complement) → complement-mediated RBC lysis, plt aggregation, & hypercoagulability</p></li><li><p>Clinical: intravascular hemolytic anemia, hypercoagulability (venous >arterial; esp. intraabdominal, cerebral), smooth muscle dystonias, deficient hematopoiesis (cytopenias); a/w aplastic anemia, MDS and evolution to AML</p></li><li><p>Dx: flow cytometry (↓ CD55 & CD59) on RBCs and granulocytes; urine hemosiderosis</p></li><li><p>Treatment: supportive care (iron, folate, transfusions); consider anticoagulation.</p></li></ul><p>Allogeneic HSCT for hypoplasia or severe thrombosis.</p><p>Pegcetacoplan (binds C3, prevents complement cascade activation) superior to eculizumab (Ab inactivates terminal complement C5s) in ↓ hemolysis & stabilizing Hb levels (NEJM 2021;384:1028). Eculizumab effective in pregnancy (NEJM 2015;373:1032); must have meningococcal vaccination.</p><p>Myelophthisic anemia (see also “Primary Myelofibrosis”)</p><ul><li>Infiltration of bone marrow by cancer (commonly metastatic solid tumors), leukemia, infection, fibrosis (primary myelofibrosis), granulomas, lysosomal storage disorders</li></ul><p>HEMOLYTIC ANEMIAS</p><p>Causes of Hemolytic Anemia by Mechanism (Lancet 2000;355:1169 & 1260)</p><p>Cause</p><p>Mechanism</p><p>Examples</p><p>Mode</p><p>Intrinsic</p><p>Enzyme deficiency</p><p>G6PD deficiency</p><p>Hereditary</p><p>Hemoglobinopathies</p><p>Sickle cell anemia, thalassemia</p><p>Membrane abnormalities</p><p>Hereditary spherocytosis</p><p>PNH, spur cell anemia in liver disease</p><p>Acquired</p><p>Extrinsic</p><p>Immune-mediated</p><p>Autoimmune; drug-induced, tx rxn</p><p>Traumatic</p><p>MAHA; prostheses (valves, TIPS)</p><p>Direct infections, toxins</p><p>Malaria, babesiosis; snake & spider venoms; Wilson’s; hypotonic infusions</p><p>Entrapment</p><p>Hypersplenism</p><p>Diagnostic evaluation</p><ul><li><p>↑ retic count (RI >2%), ↑ LDH, ↓ hapto (83% Se, 96% Sp), ↑ indirect bili, ✓ vit C & Cu</p></li><li><p>Autoimmune hemolysis: Coombs’ test = direct antiglobulin test (DAT) → ⊕ if agglutination occurs when antisera against Ig or C3 are applied to patient RBCs</p></li><li><p>Location of hemolysis (many conditions can include components of both)</p></li></ul><p>Intravascular: RBC destruction in vessels (shear by mech valve, DIC, toxins); assoc. w/ hemoglobinemia, hemoglobinuria, hemosiderinuria, ↑↑ LDH, ↓ haptoglobin.</p><p>Extravascular: more common cause. Mϕ clear damaged/opsonized RBC; splenomegaly (reticuloendothelial expansion in spleen, liver, BM, LNs); ↑ LDH ↓ hapto</p><ul><li>Family h/o anemia; personal or family h/o cholelithiasis</li></ul><p>Glucose-6-phosphate dehydrogenase (G6PD) deficiency (Lancet 2008;371:64)</p><ul><li><p>X-linked defect of metabolism (G6PD mutations) w/ ↑ susceptibility to oxidative damage</p></li><li><p>Most common in ♂ of African or Mediterranean descent (malaria-endemic areas)</p></li><li><p>Hemolysis precipitated by drugs (sulfonamides, dapsone, nitrofurantoin, rasburicase, primaquine, doxorubicin, methylene blue), infxn, DKA, foods (favism, NEJM 2018;378:60)</p></li><li><p>Diagnosis: smear may show RBC Heinz bodies (oxidized Hb) that result in bite cells once removed by spleen; ↓ G6PD levels (may be normal after acute hemolysis because older RBCs have already lysed and young RBCs may still have near-normal levels)</p></li></ul><p>Sickle cell anemia (NEJM 2017;376:1561 & Lancet 2017;390:311)</p><ul><li><p>Recessive β-globin mutation → structurally abnl hemoglobin (HbS). ~8% African Americans heterozygotes (“sickle trait”; usually w/o sx); ~1/400 homozygotes (sickle cell disease).</p></li><li><p>↓ O2 → HbS polymerizes → RBC sickles, ↓ RBC deformability → hemolysis & microvascular occlusion due to endothelial activ. & PMN adhesion (Blood 2013;122:3892)</p></li><li><p>Anemia: chronic hemolysis ± acute aplastic (parvo. B19) or splenic sequestration crises</p></li><li><p>Vaso-occlusion & infarction: acute chest syndrome & stroke (high mortality), pulmonary HTN, painful crises, splenic sequestration, renal papillary necrosis, avascular necrosis, dactylitis (hand–foot syndrome), priapism</p></li><li><p>Infection: splenic infarction → overwhelming infection by encapsulated organisms; infarcted bone → osteomyelitis (Salmonella, Staph. aureus), can be life threatening</p></li><li><p>Diagnosis: sickle-shaped RBCs and Howell-Jolly bodies on smear; Hb electrophoresis</p></li><li><p>Treatment: hydroxyurea, folic acid; voxelotor (Hgb S polymerization inhibitor) ↓ hemolysis & ↑ Hgb (NEJM 2019;381:509)</p></li><li><p>Vaccines: pneumo, meningo, H flu, HBV</p></li><li><p>Pain & vaso-occlusive crises: analgesia (consider PCA; ask Pt what worked prev.), IVF, transfusion only if sx & Hgb below Pt’s baseline (often low) given alloimmunization & Fe accumulation (need chelation); Ppx w/ crizanlizumab (anti-P-selectin; NEJM 2017;376:429)</p></li><li><p>Acute chest (fever, ↑ WBC, pulm. infilt., r/o other causes): O2, abx, IVF, exchange txfusion</p></li><li><p>TIA/stroke: often exchange transfusion (goal Hgb 10) ± thrombolytics</p></li><li><p>Gene therapy in development (NEJM 2021;384:205)</p></li></ul><p>Hereditary spherocytosis (HS) (Lancet 2008;372:1411)</p><ul><li><p>Defect in cytoskeleton of RBC membrane (ankyrin, α- and β-spectrin, band 3, & pallidin)</p></li><li><p>Most common in N. European populations (1/5000 births); ⊕ FHx (75% of Pts)</p></li><li><p>Anemia, jaundice (mostly neonates), splenomegaly, pigmented gallstones</p></li><li><p>Diagnosis: spherocytes on smear, ⊕ osmotic fragility test (~80% Se), ↓ eosin-5-maleimide (EMA) binding (93% Se; 99% Sp; Haemat 2012;97:516), acidified glycerol lysis test (Se 95%)</p></li><li><p>Treatment: folate, transfusions, splenectomy for moderate and severe HS (balance w/ ↑ risk of future thrombosis and infection; J Thromb Haemost 2008;6:1289)</p></li></ul><p>Paroxysmal nocturnal hemoglobinuria (see above)</p><p>Autoimmune hemolytic anemia (AIHA)</p><ul><li><p>Acquired, antibody-mediated RBC destruction</p></li><li><p>Warm AIHA: IgG Abs opsonize RBCs at body temp → removal by spleen</p></li></ul><p>Etiologies: idiopathic, lymphoproliferative (CLL, NHL), autoimmune (SLE), drugs, HIV, babesiosis (NEJM 2017;376:939)</p><ul><li>Cold AIHA: IgM Ab binds to RBCs at temp &lt;37°C → complement fixation → intravascular hemolysis and acrocyanosis on exposure to cold</li></ul><p>Etiologies: idiopathic, lymphoprolif. disorders (eg, Waldenström’s; monoclonal), Mycoplasma pneumoniae infxn and infectious mononucleosis (polyclonal)</p><ul><li><p>Diagnosis: spherocytes on smear, ⊕ Coombs’; ✓ cold agglutinin titer, splenomegaly</p></li><li><p>Treatment (Blood 2017;129:2971): treat underlying disease</p></li></ul><p>Warm AIHA: corticosteroids ± splenectomy, IVIg, cytotoxic agents, rituximab</p><p>Cold AIHA: avoid cold; steroids ineffective; rituximab (Blood 2004;103:2925); complement inhibitors (sutimlimab) approved for cold agglutinin disease (NEJM 2021;384:1323)</p><p>Drug-induced hemolytic anemia</p><ul><li><p>Acquired, Ab-drug mediated destruction vs. direct drug effect. Abx: ceph., sulfa drugs, rifampin, ribavirin. CV: methyldopa, procainamide, quinidine, thiazides. TCAs, phenothiazines, NSAIDs, sulfonylureas, MTX, 5-FU, rasburicase (G6PD defic.)</p></li><li><p>Diagnosis: Coombs’ usually negative, ↑ LDH; Treatment: discontinue offending agent</p></li></ul><p>Microangiopathic hemolytic anemia (MAHA; NEJM 2014;371:654)</p><ul><li><p>Intra-arteriolar fibrin damages RBCs → acquired intravascular hemolysis</p></li><li><p>Etiologies: hemolytic-uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC), malignancy, malignant HTN, eclampsia/HELLP, mech. cardiac valves, infected vascular prostheses</p></li><li><p>Diagnosis: schistocytes ± ↓ plts ± ↑ PT in DIC, ↑ Cr in HUS, ↑ LFTs in HELLP</p></li><li><p>Rx: see “DIC” section in “Coagulopathies” and “TTP/HUS” sections in “Platelet Disorders”</p></li></ul><p>Hypersplenism</p><ul><li>Stasis/trapping in spleen → Mϕ attack/remodel RBCs → spherocytosis → hemolysis</li></ul><p>Causes of Splenomegaly</p><p>Etiology</p><p>Comments*</p><p>RES hyperplasia</p><p>Hemolytic anemia, sickle cell disease, thalassemia major</p><p>Immune hyperplasia</p><p>Infxn [HIV, EBV, CMV, TB, malaria, kala azar (“black water fever” from visceral leishmaniasis), Mycobacterium avium complex], autoimmune disorders (SLE, RA w/ Felty’s syndrome), sarcoidosis, serum sickness</p><p>Congestion</p><p>Cirrhosis, CHF, portal/splenic vein thrombosis, schistosomiasis</p><p>Infiltration (nonmalignant)</p><p>Lysosomal storage disorders (Gaucher’s, Niemann-Pick), glycogen storage diseases, histiocytosis X, splenic cysts</p><p>Neoplasm</p><p>MPN (CML, PMF, PV, ET), CMML, leukemia, lymphoma (NHL, HL, hairy cell leukemia, CLL, PLL, WM), T-LGL, myeloma, amyloid</p><p>RES = reticuloendothelial system; *boldface = causes of massive splenomegaly.</p><p>DISORDERS OF HEMOSTASIS</p><p>Clinical Characteristics of Bleeding Disorders</p><p>Feature</p><p>Platelet/Vascular Defect</p><p>Coagulation Defect</p><p>Site</p><p>Skin, mucous membranes</p><p>Deep in soft tissues (muscles, joints)</p><p>Lesions</p><p>Petechiae, ecchymoses</p><p>Hemarthroses, hematomas</p><p>Bleeding</p><p>After minor cuts: yes</p><p>After surgery: immediate, mild</p><p>After minor cuts: unusual</p><p>After surgery: delayed, severe</p><p>Figure 5-3 Approach to abnormal hemostasis (NEJM 2014;370:847)</p><p>Figure 5-4 Coagulation cascade and sites of action for anticoagulants (NEJM 2008;359:938)</p><p>See “Coagulopathies” for reversal agents for anticoagulants. APC, activated protein C; AT, antithrombin; PrC, protein C; PrS, protein S; TF, tissue factor; TFPI, tissue factor pathway inhib.</p><p>Purpura (nonblanching purple/red lesions due to extravasation of RBCs into dermis)</p><ul><li>Nonpalpable (macular; ≤3 mm in diameter = petechiae; >3 mm = ecchymoses)</li></ul><p>platelet disorder: thrombocytopenia, defect in platelet fxn</p><p>thromboemboli: DIC, TTP, cholesterol or fat emboli, other thrombotic microangiopathies</p><p>trauma or vascular fragility: amyloidosis, Ehlers-Danlos, scurvy</p><ul><li><p>Palpable (papular); vasculitis: leukocytoclastic, HSP, PAN, RMSF; infectious emboli: meningococcemia, bacterial endocarditis</p></li><li><p>Purpura fulminans (aka retiform purpura): purpura + hypotension + DIC; typically due to infxn/sepsis, protein C or S deficiency or APS (see section on DIC)</p></li></ul><p>PLATELET DISORDERS</p><p>THROMBOCYTOPENIA (Plt count &lt;150,000/μL)</p><p>Thrombocytopenia and Risk of Bleeding</p><p>Platelet Count (cells/µL)</p><p>Risk</p><p>50,000–100,000</p><p>Risk with major trauma; can proceed with general surgery</p><p>&lt;50,000</p><p>Risk with minor trauma or surgery</p><p>&lt;20,000</p><p>Risk of spontaneous bleeding (less so with ITP)</p><p>&lt;10,000</p><p>Risk of severe, life-threatening bleeding</p><p>Etiologies</p><ul><li>↓ production</li></ul><p>Hypocellular bone marrow: aplastic anemia (qv), rarely MDS, drugs (eg, thiazides, antibiotics, chemotherapy), alcohol, cirrhosis, viral infection</p><p>Hypercellular bone marrow: MDS, leukemia, severe megaloblastic anemia</p><p>Marrow replacement: myelofibrosis, hematologic and solid malignancies, granulomas</p><ul><li>↑ destruction</li></ul><p>Immune-mediated (distinguish primary from secondary; Blood 2009;113:2386)</p><p>1° (idiopathic): immune thrombocytopenic purpura (ITP, see below)</p><p>2°: infxn (HIV, HCV, HSV), collagen vascular dis. (SLE), APS, lymphoprolif. (CLL, lymphoma), drugs (many, including heparin, abciximab, quinidine, sulfonamides, vanco), alloimmune (posttransfusion), vaccine-induced</p><p>Non–immune-mediated: MAHA (DIC, HUS, TTP), ticlopidine/clopidogrel, vasculitis, preeclampsia/HELLP, cardiopulm bypass, CVVH, IABP, cavernous hemangioma, viral</p><ul><li><p>Abnormal distribution or pooling: splenic sequestration, dilutional, hypothermia</p></li><li><p>Critical illness: multifactorial (Hematology Am Soc Hematol Educ Program 2017;1:660)</p></li><li><p>Unknown: ehrlichiosis/anaplasmosis, babesiosis, RMSF</p></li></ul><p>Diagnostic evaluation</p><ul><li><p>H&P: meds, infxns, underlying conditions, splenomegaly, lymph nodes, bleeding hx</p></li><li><p>CBC with differential: isolated thrombocytopenia vs. multilineage involvement</p></li><li><p>Peripheral smear (r/o pseudothrombocytopenia due to platelet clumping)</p></li></ul><p>↑ destruction → look for large plts, ↑ MPV, schistocytes (see “Peripheral Smear” inserts)</p><p>↓ production → rarely limited to platelets → look for blasts, hypersegmented PMNs, leukoerythroblastic Δs; can see inclusion bodies (anaplasma), parasites (Babesia)</p><p>Figure 5-5 Approach to thrombocytopenia</p><ul><li>Additional laboratory evaluations as indicated (eg, viral titers, flow cytometry, ANA, APLA)</li></ul><p>if anemia: ✓ reticulocyte count, LDH, haptoglobin, bilirubin to detect hemolysis</p><p>if hemolytic anemia: ✓ PT, PTT, fibrinogen, D-dimer, Coombs, ANA</p><p>BM bx for unexplained thrombocytopenia, esp. if associated with splenomegaly</p><p>Primary immune thrombocytopenic purpura (ITP) (Blood 2010;115:168)</p><ul><li><p>Isolated thrombocytopenia due to immune plt destruction (auto-Ab to plts) & ↓ production (auto-Ab to megakaryocytes) without precipitant</p></li><li><p>Clinical manifestations: insidious onset of mucocutaneous bleeding; ♀:♂ = 3:1</p></li><li><p>Diagnosis of exclusion (r/o 2° ITP); no robust clinical or lab parameters, but typically:</p></li></ul><p>CBC: isolated ↓ plt (&lt;100,000/µL); 10% have ITP + AIHA = Evans syndrome</p><p>Peripheral smear: large platelets (not specific), r/o pseudothrombocytopenia</p><p>BM bx: ↑ megakaryocytes, nl cellularity. Consider if other CBC or smear abnl or diagnostic uncertainty (Blood 2011;117:4910).</p><p>✓ HBSAg & anti-HBc prior to rituximab (and before IVIg, which could alter results)</p><ul><li>Treatment: rarely indicated if plt >50,000/µL unless bleeding, trauma/surgery, anticoag.</li></ul><p>Treatment of Primary ITP in Adults</p><p>Approach</p><p>Treatment</p><p>Notes</p><p>First-line or upfront therapy</p><p>Steroids: prednisone 0.5–2 mg/kg/d PO tapered ~4 wk, or dexamethasone 40 mg PO × 4 d</p><p>↓ Mϕ FcR & ↓ anti-plt Ab</p><p>70–90% have initial response</p><p>~20% sustained remission</p><p>IVIg (1 g/kg/d IV × 2–3 d)</p><p>Consider if need rapid ↑ in plt in 24–48 hrs; lasts 2–6 wks</p><p>Blocks Mϕ FcR, ↓ anti-plt Ab</p><p>Interferes w/ Mϕ uptake Ab-coated plts; 80% have initial response</p><p>Anti-Rh(D) Ig: alternative to IVIg if RBC Rh(D) ⊕; 50–75 mcg/kg/d</p><p>Ab-coated RBCs overwhelm Mϕ FcR</p><p>Avoid if h/o hemolysis; not often used</p><p>Second-line or maint. therapy</p><p>Romiplostim, el/avatrombopag</p><p>TPO-R agonists → ↑ plt prod</p><p>Rituximab (anti-CD20) ± dex</p><p>anti–B-cell Ab</p><p>Splenectomy* (less common)</p><p>~65% long-term remission</p><p>AZA, CYC, MMF</p><p>Immunosuppressants</p><p>Danazol: 600 mg/d</p><p>Androgen (hirsutism) ↓ plt clearance</p><p>Chronic/ refractory</p><p>Romiplostim or eltrombopag</p><p>Allows splenectomy to be deferred</p><p>Fostamatinib: 75–150 mg BID</p><p>Spleen tyrosine kinase (SYK) inhibitor</p><p>Vinca alkaloids</p><p>Good initial response, less durable</p><p>Bleeding</p><p>Aminocaproic acid</p><p>Inhibits plasmin activation</p><p>Methylprednisolone 1 g/d IV × 3 d</p><p>See above</p><p>IVIg</p><p>See above</p><p>Platelet transfusion</p><p>Given w/ IVIg or anti-Rh(D)</p><p>*Post-splenectomy vaccinations needed. (Blood Adv 2019;3:3829; Eur J Haem 2018;100:304)</p><p>Secondary immune thrombocytopenic purpura (2° ITP)</p><ul><li>Diagnosis: viral serologies (HIV, HCV, HBV, EBV), H. pylori Ab, ANA, pregnancy test, APLA, TSH, parvovirus, & CMV PCR. Anti-plt Ab tests often sent but less useful.</li></ul><p>Heparin-Induced Thrombocytopenias (Chest 2012;141:e495S; NEJM 2015;373:252)</p><p>Feature</p><p>Type I (not clin. signif)</p><p>Type II (clinically significant HIT)</p><p>Mechanism</p><p>Direct effect of heparin (non-immune)</p><p>Immune (Ab)-mediated</p><p>IgG against plt factor 4—heparin complex</p><p>Incidence</p><p>10–20%</p><p>1–3% with UFH, 0–0.8% LMWH</p><p>Onset</p><p>After 1–4 d of heparin therapy</p><p>After 4–10 d, but can occur in &lt;24 h if prior exposure w/in 100 d (persistent Ab). Postop highest risk. Can occur after heparin d/c.</p><p>Platelet nadir</p><blockquote><p>100,000/µL</p></blockquote><p>~60,000/µL, ↓ >50%</p><p>Sequelae</p><p>None</p><p>Thrombotic events (HITT) in 30–50%</p><p>Management</p><p>Can continue heparin and observe</p><p>Discontinue heparin</p><p>Alternative anticoagulation</p><ul><li><p>Treat underlying etiology</p></li><li><p>Pathophysiology (type II): Ab binds heparin-PF4 → immune complex binds to plt → plt activation, further PF4 release → plt aggregates removed from circulation → thrombocytopenia; procoagulants released by plts and tissue factor released by endothelial cells damaged by HIT Abs → prothrombotic state</p></li><li><p>Diagnosis (need clinical + pathologic)</p></li></ul><p>Clinical: plt &lt;100k or ↓ 50% from baseline; or venous (DVT/PE) or arterial (limb ischemia, CVA, MI) thrombosis (4:1 ratio); skin necrosis; ? ↑ heparin resistance</p><p>Pathologic: ⊕ HIT Ab using PF4-heparin ELISA (≥90% Se, IgG-specific ELISA Sp 94%), may confirm w/ functional plt assay (serotonin-release) (>95% Se/Sp)</p><p>Clinical context important: HIT Ab (esp. IgM ELISA) may be ⊕ in 10–20% of Pts on UFH/LMWH (Am J Hem 1996;52:90), up to 50% of cardiac bypass Pts (Circ 1997;95:1242)</p><p>Pretest prob w/ “4 T’s” criteria (Blood 2012;120:4160): ≤3 points → 99% NPV, investigate other causes; 4–5 points 22% PPV & 6–8 points 64% PPV, ✓ lab test & replace UFH</p><p>Evaluation of Suspected HIT (“4T’s”)</p><p>Factor</p><p>2 Points</p><p>1 Point</p><p>0 Points</p><p>Thrombo-cytopenia</p><p>↓ >50% and nadir ≥20k</p><p>↓ 30–50% or nadir 10–19k</p><p>↓ &lt;30% or nadir &lt;10k</p><p>Timing</p><p>5–10 d or ≤1 d if heparin w/in 30 d</p><p>? 5–10 d (but not clear), >10 d or ≤1 d if hep w/in 30–100 d</p><p>≤4 d w/o recent hep</p><p>Thrombosis</p><p>New thromb, skin necrosis, acute rxn after IV UFH</p><p>Prog/recurrent thromb, suspect thromb or non-nec skin lesion</p><p>None</p><p>Other cause</p><p>None apparent</p><p>Possible</p><p>Definite</p><ul><li>Treatment of HIT (type II) (NEJM 2015;373:252; Blood Adv 2018;2:3360)</li></ul><p>Discontinue heparin (incl. flushes, LMWH Ppx, heparin lines). Avoid plts (anecdotal link w/ thrombosis); if given warfarin, give vit K to reverse, prevent warfarin skin necrosis.</p><p>Nonheparin anticoag (argatroban, bivalirudin; NEJM 2013;368:737) regardless of thrombosis; start warfarin when plt >150k, overlap ≥5 d or DOAC (Blood 2017;130:1104)</p><p>⊕ thrombosis (HITT): anticoagulate for ≥3–6 mo</p><p>⊖ thrombosis (HIT): screen for DVT; unclear duration of subsequent anticoag (until plt count recovers, often ~2–3 mo if no clot); 25–50% thrombosis rate w/in 30 d</p><ul><li>H/o HIT: if PF4 Ab ⊖ or SRA ⊖ (typically >100 d after dx) → may consider re-exposure to UFH (eg, for surgery); HIT recurrence low but can be seen (Blood 2014;123:2485)</li></ul><p>Thrombotic microangiopathies (TMA; NEJM 2014;371:654; Lancet 2017;390:681)</p><ul><li><p>Endothelial injury → plt aggreg. & microvasc. thrombosis → ↓ plt & RBC hemolysis (MAHA)</p></li><li><p>Dx: unexplained thrombocytopenia (typically &lt;20k) + MAHA → sufficient for dx ⊕ schistocytes (>2–3/hpf), ⊖ Coombs, normal PT/PTT & fibrinogen ↑↑ LDH (tissue ischemia + hemolysis), ↑ indirect bili., ↓↓ haptoglobin, ↑ Cr (esp. in HUS)</p></li></ul><p>Biopsy: arterioles filled with platelet hyaline thrombi</p><p>Ddx: DIC, vasculitis, malignant hypertension, preeclampsia/HELLP syndrome</p><ul><li>Thrombotic thrombocytopenic purpura (TTP)</li></ul><p>Pathophys: ↓↓ ADAMTS13 protease activity (hereditary [Upshaw Schulman Syn.] or autoAb) → vWF multimers persist on endothelial surface → plt adhesion/aggregation → thrombosis</p><p>Clinical: pentad (all 5 in only ~5%) = ↓ plts + MAHA (100%) ± Δ MS (65%) ± renal failure (50%, late feature) ± fever (25%)</p><p>PLASMIC score to discriminate TTP from other TMAs (Lancet Haematol. 2017;4:157)</p><p>Rx: urgent plasma exchange ± glucocorticoids; FFP if delay to plasma exchange, caplacizumab (NEJM 2019;380:335), rituximab for 2° prevention (Blood Adv. 2017;1:1159),</p><p>plt transfusions contraindic. → ↑ microvascular thromb (J Thromb Haemost. 2020;18:2496)</p><ul><li>Hemolytic-uremic syndrome (HUS)</li></ul><p>Pathophys: (1) Shiga toxin damages renal endothelial cells → intrarenal thrombi; or (2) complement dysregulation (hereditary or acquired), so-called “atypical HUS”</p><p>Clinical: triad = thrombocytopenia + MAHA + renal failure (bloody diarrhea if Shiga)</p><p>Rx: supportive care; eculizumab (J Nephrol 2017;30:127); plasma exchange if CNS sx</p><ul><li>Drug-induced TMA (clinically similar to TTP; Blood 2017;129:2857)</li></ul><p>Immune-mediated (Ab reacts w/ plts & endothelial cells): eg, quinine, gemcitabine?</p><p>Direct toxicity mediated: eg, gemcitabine, mitomycin, tacrolimus, CsA, bevacizumab</p><p>Disseminated intravascular coagulation (DIC): see “Coagulopathies”</p><p>DISORDERS OF PLATELET FUNCTION</p><p>Mechanisms and Etiologies of Platelet Function Abnormalities</p><p>Function</p><p>Inherited</p><p>Acquired</p><p>Adhesion</p><p>Bernard-Soulier; vWD</p><p>Uremia; acquired vWD</p><p>Aggregation</p><p>Afibrinogenemia</p><p>Glanzmann’s thrombasthenia</p><p>P2Y12 inhibitors, GP IIb/IIIa inhibitors</p><p>Dysproteinemias (myeloma)</p><p>Granule</p><p>release</p><p>Chediak-Higashi syndrome</p><p>Hermansky-Pudlak syndrome</p><p>Drugs (ASA, NSAIDs); liver disease; MPN; cardiopulmonary bypass</p><p>Tests of platelet function</p><ul><li>Platelet aggregation tests: measure aggregation in response to agonists (eg, ADP)</li></ul><p>von Willebrand’s disease (vWD) (NEJM 2016;375:2067)</p><ul><li><p>von Willebrand’s factor (vWF) function = platelet glue & plasma carrier of factor VIII</p></li><li><p>vWD most common inherited bleeding disorder; ~85% (type 1) have partial quantitative vWF defic., ~15% (type 2) qualitative defic., &lt;1% (type 3) total/near-total absence of vWF</p></li><li><p>Acquired vWD: a/w many disorders (malig, MPN w/ ↑ plt count; autoimmune; hypo-thyroidism; drugs) and caused by different mechanisms (anti-vWF Abs, ↑ clearance, ↓ synthesis); Heyde’s syndrome = vWF destruction by severe AS, a/w GI AVMs/bleed</p></li><li><p>Diagnosis: ↓ vWF:Ag, ↓ vWF activity (measured by ristocetin cofactor assay), ↓ factor VIII, ± ↑ PTT, ± ↓ platelets; confirm with vWF multimer analysis</p></li><li><p>Clinical condition, factor VIII levels and ristocetin cofactor assay useful to guide Rx decision</p></li><li><p>Rx: desmopressin (dDAVP, IV/IN; tachyphylaxis) → ↑ endothelial cell release of vWF; efficacy depends on type (avoid in type 2), ∴ ✓ response before use w/ bleeding or procedures; vWF replacement: cryo, vWF-rich factor VIII concentrates, recomb. vWF</p></li></ul><p>Uremic bleeding</p><ul><li><p>Uremia → platelet dysfunction including ↓ aggregation, impaired adhesiveness</p></li><li><p>Treatment: dDAVP, cryoprecipitate, correct anemia (improves plt aggregation and adhesion by increasing plt interactions with endothelium), consider holding anti-plt agents</p></li></ul><p>COAGULOPATHIES</p><p>Further coagulation tests (JAMA 2016;316:2146)</p><ul><li>Mixing study: useful if ↑ PT or PTT; mix Pt’s plasma 1:1 w/ normal plasma and retest</li></ul><p>PT/PTT normalizes → factor deficiency; PT/PTT remains elevated → factor inhibitor</p><ul><li>Coagulation factor levels: useful if mixing study suggests factor deficiency</li></ul><p>DIC → all factors consumed; ∴ ↓ factors V and VIII</p><p>Liver disease → ↓ all factors except VIII; ∴↓ factor V, normal factor VIII</p><p>Vitamin K deficiency → ↓ factors II, VII, IX, X (and protein C, S); ∴ normal V and VIII</p><ul><li>DIC screen: ↓ fibrinogen (consumed), fibrin degradation products (FDPs, ⊕ from intense fibrinolysis), ↑ D-dimer (more specific FDP test that detects degradation of X-linked fibrin)</li></ul><p>Hemophilias (Lancet 2016;388:187)</p><ul><li><p>X-linked recessive factor VIII (hemophilia A) or factor IX (hemophilia B) deficiency</p></li><li><p>Classification: mild (5–25% normal factor activity), moderate (1–5%), or severe (&lt;1%)</p></li><li><p>Clinical manifestations: hematomas, hemarthroses, bruising, bleeding (mucosal, GI, GU)</p></li><li><p>Diagnosis: ↑ PTT (normalizes w/mixing study), normal PT & vWF, ↓ factor VIII or IX</p></li><li><p>Prophylaxis indicated if &lt;1% activity of factor VIII or IX</p></li><li><p>Rx: purified/recomb. factor VIII or IX; desmopressin (mild disease); anti-fibrinolytics (aminocaproic acid; tranexamic acid); cryo (FVIII); emicizumab (bridges factor IX and X), effective for hemophilia A w/ and w/o inhibitors (NEJM 2017;377:809 & 2018;379:811)</p></li></ul><p>Coagulation factor inhibitors (anti-factor antibodies; anti-factor VIII most common)</p><ul><li><p>Etiologies: hemophilia; postpartum; lymphoproliferative & autoimmune disorders; cancers</p></li><li><p>Diagnosis: ↑ PTT (does not normalize w/ mixing study); Bethesda assay quantitates titer</p></li><li><p>Rx: if high titer → recomb. factor VIIa, porcine factor concentrates, activated prothrombin complex; for others → high-purity human factor, plasmapheresis, immunosuppression</p></li></ul><p>Disseminated intravascular coagulation (DIC) (NEJM 2014;370:847)</p><ul><li><p>Etiologies: trauma, shock, infection, malignancy (esp. APL), obstetric complications</p></li><li><p>Pathogenesis: massive activation of coagulation that overwhelms control mechanisms</p></li></ul><p>Thrombosis in microvasculature → ischemia + microangiopathic hemolytic anemia</p><p>Acute consumption of coagulation factors and platelets → bleeding</p><p>Chronic DIC → able to compensate by ↑ factors and platelets → thrombosis</p><ul><li><p>Diagnosis: ↑ PT, ↑ PTT, ↓ fibrinogen (may be nl b/c acute phase), ⊕ FDP/D-dimer, ↓ plts, ⊕ schistos, ↑ LDH, ↓ hapto; chronic DIC: ⊕ FDP/D-dimer, variable plts, other labs nl</p></li><li><p>Treatment: Rx underlying process; support w/ FFP, cryo (goal fbgn >100 mg/dL) & plts</p></li></ul><p>Vitamin K deficiency</p><ul><li>Etiologies: malnutrition, ↓ absorption (antibiotic suppression of vitamin K-producing intestinal flora or malabsorption), liver disease (↓ stores), warfarin</li></ul><p>Properties and Antidotes for Anticoagulants & Fibrinolytics (Circ 2016;134:248)</p><p>Anticoag.</p><p>t1/2</p><p>Labs</p><p>Rx for O/D w/ Serious Bleeding (+ d/c anticoag)</p><p>UFH</p><p>60–90′, RES</p><p>↑ PTT</p><p>Protamine IV 1 mg/100 U UFH (max 50 mg). For infusions, dose to reverse 2× UFH given per h.</p><p>LMWH</p><p>2–7°, K</p><p>anti-Xa*</p><p>Protamine reverses ~60%. 1 mg per 1 mg enox.</p><p>Bivalirudin</p><p>25′, K</p><p>↑ PTT</p><p>Dialysis</p><p>Argatroban</p><p>45′, L</p><p>↑ PTT</p><p>? Dialysis</p><p>Warfarin</p><p>36°, L</p><p>↑ PT</p><p>No bleeding: vit K 2.5 mg PO if INR >9, o/w no e/o clinical benefit (Blood Adv 2019;3:789)</p><p>Bleeding: vit. K 10 mg IV + either 4F-PCC (KCentra, 25, 35, or 50 U/kg for INR 2–4, 4–6, or >6) or FFP 2–4 U IV q6–8h (slower, more volume)</p><p>Fibrinolytic</p><p>20′, LK</p><p>↓ fbgn</p><p>Cryo, FFP, ± tranexamic or aminocaproic acid</p><p>Rivaroxaban</p><p>Apixaban</p><p>Edoxaban</p><p>8–12°,</p><p>K >L</p><p>↑ PT*</p><p>anti-Xa*</p><p>Andexanet alfa (factor Xa decoy receptor): 800 mg bolus (30 mg/min) → 8 mg/min infusion (½ of above if taking ½ dose DOAC or ≥8 hrs since last dose; NEJM 2019;380:1326); 4F-PCC if andexanet not available</p><p>Dabigatran</p><p>~12°, K</p><p>↑ PTT*</p><p>Idarucizumab: mAb binds drug (NEJM 2017;377:431)</p><p>*Routine monitoring not performed. Mode of excretion: K, kidney; L, liver; RES, reticuloendothelial system. 4F-PCC: prothrombin complex concentrate (FII, VII, IX, X; Protein C & S). Anti-fibrinolytics: tranexamic, aminocaproic acid.</p><p>HYPERCOAGULABLE STATES</p><p>Suspect in Pts with venous or arterial thrombosis at young age or unusual locations, recurrent thromboses or pregnancy loss, or ⊕ FHx</p><p>Inherited Hypercoagulable States</p><p>Risk Factor</p><p>Prevalence</p><p>VTE*</p><p>Comments</p><p>Factor V Leiden</p><p>3–7%</p><p>2.65</p><p>Activated protein C (APC) resistance</p><p>Prothrombin mutation</p><p>2%</p><p>1.45</p><p>G20210A → ↑ prothrombin level</p><p>Hyperhomocysteinemia</p><p>5–10%</p><p>Inherited or acquired (vitamin defic., hypothyroid, renal insufficiency)</p><p>Protein C deficiency</p><p>0.02–0.05%</p><p>2.8</p><p>Warfarin-induced skin necrosis risk</p><p>Protein S deficiency</p><p>0.01–1%</p><p>2.8</p><p>Antithrombin III def.</p><p>0.04%</p><p>2.8</p><p>May be heparin resistant</p><p>*Relative risk of recurrent VTE compared to patient w/o respective thrombophilia (JAMA 2009;301:2472)</p><p>Vascular Beds Affected by Inherited and Acquired Hypercoagulable States</p><p>Venous</p><p>Venous and Arterial</p><p>Inher.</p><p>Factor V Leiden</p><p>Prothrombin mutation ↓ protein C, S or AT III</p><p>Hyperhomocysteinemia (inherited or acquired)</p><p>Dysfibrinogenemia</p><p>Acquired</p><p>Stasis: immobilization, surgery, CHF</p><p>Malignancy</p><p>Hormonal: OCPs, HRT, tamoxifen, pregnancy</p><p>Nephrotic syndrome</p><p>Platelet defects: myeloproliferative disorders, HIT, PNH (although venous >arterial)</p><p>Hyperviscosity: polycythemia vera, Waldenström’s -macroglobulinemia, sickle cell, acute leukemia</p><p>Vessel wall defects: vasculitis, trauma, foreign bodies</p><p>Others: antiphospholipid syndrome, IBD</p><p>Diagnostic evaluation (not routinely required for initial VTE; NEJM 2017;377:1177)</p><ul><li><p>APC resistance screen; prothrombin PCR test; functional assays for proteins C and S, ATIII; homocysteine level; factor VIII levels; anticardiolipin and lupus anticoagulant Ab. Also consider nephrotic syndrome, PNH (esp. if mesenteric thrombus).</p></li><li><p>Consider JAK2 mutation testing if suspect MPN or splanchnic thrombosis</p></li><li><p>Proteins C & S and ATIII levels unreliable during acute thrombosis and anticoagulation ∴ levels best assessed ≥2 wk after completing anticoagulation course</p></li><li><p>Age-appropriate malignancy screening (occult cancer in ~4% of initial unprovoked VTE; no benefit of routine abd/pelvis CT; NEJM 2015;373:697)</p></li></ul><p>Treatment</p><ul><li><p>Asx w/ inherited risk factor: consider prophylactic anticoag. if develops acquired risk factor</p></li><li><p>Thrombosis w/ inherited risk factor: see “Venous Thromboembolism”</p></li></ul><p>Antiphospholipid syndrome (APS) (NEJM 2018;398:2010)</p><ul><li>Definition: dx requires ≥1 clinical & ≥1 laboratory criteria</li></ul><p>Clinical: thrombosis (any) or complication of pregnancy (≥3 spont. abortions before 10 wk or ≥1 fetal loss after 10 wk or premature birth before 34 wk)</p><p>Laboratory: ⊕ lupus anticoagulant (LA), or ⊕ moderate–high titer anticardiolipin (ACL), or ⊕ β2-glycoprotein-I (β2-GP-I) Ab, on ≥2 occasions, at least 12 wk apart</p><ul><li><p>Features: DVT/PE/CVA, recurrent fetal loss, ↓ plts, hemolytic anemia, livedo reticularis</p></li><li><p>“Catastrophic APS”: ≥3 organ systems in &lt;1 wk w/ ⊕ APLA & tissue microthrombi; 44% mortality (Arth Rheum 2006;54:2568); Rx w/ plasmapheresis, rituximab</p></li><li><p>Antiphospholipid antibodies (APLA)</p></li></ul><p>✓ if: SLE, age &lt;40 y & arterial thromb, recurrent venous thromb, spontaneous abortion</p><p>ACL: Ab against cardiolipin, a mitochondrial phospholipid; IgG more specific than IgM</p><p>LA: Ab that prolongs phospholipid-dependent coagulation reactions; ∴ ↑ PTT that does not correct with mixing study but does correct with excess phospholipids or platelets; PT not affected b/c the reaction contains much more phospholipid</p><p>β2-GP-I: Ab against β2-glycoprotein-I, IgG or IgM (uncertain role of Abs in pathogenesis)</p><p>False ⊕ VDRL nontreponemal test for syphilis (cardiolipin is part of Ag complex)</p><p>Risk of thromboembolic phenomena may increase with titer of APLs</p><ul><li><p>Etiologies: primary (idiopathic) or secondary due to autoimmune syndromes (eg, SLE), malignancy, infections, drug reactions</p></li><li><p>Treatment: UFH/LMWH → warfarin (lifelong for most Pts)</p></li></ul><p>Rivaroxaban inferior to warfarin in triple positive (⊕ ACL, LA, & β2-GP) (Blood 2018;132:1365)</p><p>Initial venous thrombosis: INR 2–3 (NEJM 2003;349:1133; J Thromb Haemost 2005;3:848)</p><p>Initial arterial thrombosis: typically INR 2–3 + ASA 81 mg/d</p><p>Recurrent thrombosis on warfarin: consider INR 3–4 vs. LMWH or fondaparinux</p><p>DISORDERS OF LEUKOCYTES</p><p>Neutrophilia (>7500–10,000/µL)</p><p>Infection</p><p>Usually bacterial; ± toxic granulations, Döhle bodies</p><p>Inflammation</p><p>Burn, tissue necrosis, MI, PE, collagen vascular disease</p><p>Drugs and toxins</p><p>Corticosteroids, β-agonists, lithium, G-CSF; cigarette smoking</p><p>Stress</p><p>Release of endogenous glucocorticoids and catecholamines</p><p>Marrow stimulation</p><p>Hemolytic anemia, immune thrombocytopenia</p><p>Asplenia</p><p>Surgical, acquired (sickle cell), congenital (dextrocardia)</p><p>Neoplasm</p><p>Can be 1° (MPN) or paraneoplastic (eg, carcinomas of lung, GI)</p><p>Leukemoid reaction</p><blockquote><p>50,000/µL + left shift, not due to leukemia; unlike CML, ↑ LAP</p></blockquote><p>Neutropenia (&lt;1000/µL)</p><p>Congenital</p><p>Myelokathexis, Shwachman-Diamond-Oski, Chédiak-Higashi, retic dysgen., WHIM syndrome, cyclic neutropenia, monoMAC syndrome (↓ monos, NKs)</p><p>Infection</p><p>Viral (CMV, EBV, HIV); bacterial (Brucella, Rickettsia, TB); malaria</p><p>Nutritional</p><p>Vitamin B12 or copper deficiency</p><p>Drugs and toxins</p><p>Chemotherapeutics, clozapine, methimazole, TMP-SMX, NSAIDs, sulfasalazine, phenytoin (Am J Hem 2009;84:428), alcohol</p><p>Neoplasm</p><p>MDS, leukemia (AML, ALL, hairy cell, LGL, others)</p><p>Monocytosis (>500/µL)</p><p>Infection</p><p>Usually TB, SBE, Listeria, Brucella, Rickettsia, fungi, parasites, syphilis</p><p>Inflammation</p><p>IBD, sarcoidosis, collagen vascular diseases</p><p>Stress</p><p>MI, splenectomy, exercise (Cytokine 2013;61:364)</p><p>Neoplasm</p><p>Hodgkin lymphoma, leukemias, MPNs, carcinomas</p><p>Eosinophilia (>500/µL)</p><p>Infection</p><p>Usually parasitic (helminths)</p><p>Allergic</p><p>Drugs; asthma, hay fever, eczema; ABPA</p><p>Collagen vasc dis.</p><p>RA, EGPA (Churg-Strauss), eosinophilic fasciitis, PAN</p><p>Endocrine</p><p>Adrenal insufficiency</p><p>Neoplasm</p><p>HL, CML, mycosis fungoides, carcinomas, systemic mastocytosis</p><p>Atheroembolic dis.</p><p>Cholesterol emboli syndrome</p><p>Hypereosinophilic syndrome</p><p>Multiorgan involvement incl. heart & CNS, a/w FIP1L1-PDGFRA fusion (NEJM 2003;348:1201); often steroid resistant</p><p>Basophilia (>200/µL)</p><p>Neoplasm</p><p>MPN, CML, AML, Hodgkin lymph.</p><p>Infection</p><p>TB, smallpox, parasites</p><p>Alteration in BM or reticuloendothelial compartment</p><p>Hemolytic anemia, splenectomy</p><p>Inflammation or allergy</p><p>IBD, chronic airway inflammation</p><p>Lymphocytosis (>4000–5000/µL)</p><p>Infection</p><p>Usually viral; “atypical lymphocytes” with mononucleosis syndromes Other: pertussis, toxoplasmosis</p><p>Hypersensitivity</p><p>Drug-induced, serum sickness</p><p>Autoimmune</p><p>Rheumatoid arthritis (large granular lymphocytes), malignant thymoma</p><p>Neoplasm</p><p>Leukemia (eg, CLL, hairy cell, LGL), lymphoma (eg, mantle cell, folic.)</p><p>Lymphadenopathy</p><p>Viral</p><p>HIV, EBV, CMV, HSV, VZV, hepatitis, measles, rubella</p><p>Bacterial</p><p>Generalized (brucellosis, leptospirosis, TB, atypical mycobacteria, syphilis)</p><p>Localized (streptococci, staphylococci, cat-scratch disease, tularemia)</p><p>Fungal/parasitic</p><p>Histo, coccidio, paracoccidioidomycosis, toxoplasmosis</p><p>Immunologic</p><p>Collagen vascular disease, drugs (eg, phenytoin), serum sickness, histiocytosis X, Castleman’s and Kawasaki disease</p><p>Neoplasm</p><p>Lymphoma, leukemia, amyloidosis, metastatic carcinoma</p><p>Other</p><p>Sarcoidosis; lipid storage diseases</p><p>Factors that favor biopsy</p><p>Pt >40 y, >2 cm, location (supraclavicular always abnl), duration >1 mo</p><p>Consistency (hard vs. rubbery vs. soft) & tenderness are not reliable</p><p>Exicisional biopsy preferred over fine needle aspiration (FNA)</p><p>TRANSFUSION THERAPY</p><p>Blood Products and Indications (Lancet 2013;381:1845)</p><p>Packed red blood cells (PRBCs)</p><p>For acute blood loss or to ↑ O2-carrying capacity if end organ ischemia. 1 U PRBC → ↑ Hb by ~1 g/dL. Hb goal >7 g/dL adequate for UGIB & critically ill (NEJM 2013;368:11 & 2014;371:1381), ≥8 in acute MI and peri-cardiac surgery (NEJM 2018;379;1224; JAMA 2021;325:552).</p><p>Platelets (plts) (Annals Int Med 2015;162:205)</p><p>For plts &lt;10k (NEJM 2010;362:600) due to chemo/abx. If &lt;20k or if &lt;50k w/ active bleeding. Variable pre-procedure.100k for neurosurgery. 1 U → ↑ plt ~30–60k. Single donor plt apheresis ↓ alloimmunization.</p><p>Contraindic: TTP/HUS, HELLP, HIT.</p><p>Refractory if ↑ &lt;5k 30–60′ post-plts. Suggests consumption such as ITP, DIC, or alloimmunization → trial ABO-matched plts & give more. If still refractory ✓ panel reactive Abs to assess utility of HLA-matched plts.</p><p>Fresh frozen plasma (FFP)</p><p>Contains all coagulation factors. For bleeding due to defic. of multiple coag factors (eg, DIC, TTP/HUS, liver disease, dilution). Nb, reverse warfarin w/ Kcentra = 4 factor PCC (JACC 2020;76:594).</p><p>Cryoprecipitate</p><p>Enriched for fibrinogen, vWF, VIII, and XIII. 1st line for fibrinogen &lt;100 mg/dL. For bleeding in vWD factor XIII deficiency, use if other products not available.</p><p>Irradiated</p><p>Prevents donor T-cell engraftment and risk of transfusion-assoc. GVHD (HSCT, heme malignancy, congenital immunodeficiency).</p><p>CMV-negative</p><p>From CMV-negative donors. For CMV-seronegative pregnant women, transplant candidates/recipients, SCID, AIDS Pts.</p><p>Leuko- reduced</p><p>WBCs cause HLA alloimmunization & fever (cytokines) and carry CMV. For chronically transfused Pts, potential Tx recip., h/o febrile nonhemolytic transfusion rxn, cases in which CMV-neg products desired but unavailable.</p><p>IV immune globulin (IVIg)</p><p>Polyvalent IgG from >1000 donors. For postexposure prophylaxis (eg, HAV), certain autoimmune disorders (eg, ITP, Guillain-Barré, MG, CIDP), congenital or acquired hypogammaglobulinemia (CVID, CLL).</p><p>Therapeutic apheresis</p><p>Removes plasma large molec wt subst. (eg, cryoglobulinemia, Goodpasture’s, Guillain-Barré, hyperviscosity syndrome), or cells (eg, leukemia w/ hyperleukocytosis, sx thrombocytosis) from plasma. TTP: replace ADAMTS13. RBC exchange for SCD acute chest or stroke.</p><p>Massive transfusion</p><p>Large-vol. PRBC → ↓ Ca, ↑ K, ↓ plt, ↑ coags; initial ratio of 1 PRBC: 1 plt:1 FFP accepted but controversial, follow labs (JAMA Surg 2017;152:574).</p><p>Transfusion Complications (NEJM 2017;377:1261)</p><p>Noninfectious</p><p>Risk (per unit)</p><p>Infectious</p><p>Risk (per unit)</p><p>Febrile</p><p>1:100</p><p>CMV</p><p>Common</p><p>Allergic</p><p>1:100</p><p>Hepatitis B</p><p>1:220,000</p><p>Delayed hemolytic</p><p>1:50–75,000</p><p>Hepatitis C</p><p>1:1,600,000</p><p>Acute hemolytic</p><p>1:200,000</p><p>HIV</p><p>1:1,800,000</p><p>Febr. non-hemolytic</p><p>1:200</p><p>Bacteria (PRBCs)</p><p>1:500,000</p><p>TRALI</p><p>1:5000</p><p>Bacteria (platelets)</p><p>1:12,000</p><p>Transfusion reactions</p><ul><li><p>Reason why blood products (unless massive txfusion) run 1 at a time. For all rxns (except minor allergic): stop txfusion; send remaining blood product + fresh blood draw to blood bank.</p></li><li><p>Acute hemolytic: fever, HoTN, flank pain, AKI w/in 24 h. Due to ABO incompatibility → preformed Abs vs. donor RBCs. Rx: IVF, ↑ UOP w/ diuretics, mannitol, or dopamine.</p></li><li><p>Delayed hemolytic: generally less severe than acute hemolytic; 5–7 d after transfusion, but can be severe → hyperhemolysis. Due to undetected allo-Abs vs. minor antigens → anamnestic response. Rx usually not required; dx important for future transfusion.</p></li><li><p>Febrile nonhemolytic: fever, rigors 0–6 h post transfusion. Due to Abs vs. donor WBCs and cytokines in blood product. Rx: acetaminophen ± meperidine; r/o infection, hemolysis.</p></li><li><p>Allergic: urticaria; rarely, anaphylaxis due to rxn to txfused proteins, especially in IgA-deficient Pts w/ anti-IgA Abs (use washed products). Rx: urticaria → diphenhydramine; anaphylaxis → epinephrine ± steroids. Washed products ↓ rxns in chronic txfusions.</p></li><li><p>Transfusion-associated circulatory overload (TACO): ↑ volume → pulm. edema, ↑ BP. Rx: slow transfusion rate, diuretics, O2, ± nitrates, ± positive pressure ventilation.</p></li><li><p>Transfusion-related acute lung injury (TRALI): non-cardiogenic pulm. edema due to donor allo-Abs (from multiparous ♀ plasma) binding recipient WBCs, which then aggregate in pulmonary vasculature and release mediators causing ↑ capillary permeability. Rx: see “ARDS.” No longer seen in US as plasma only from ♂ donors.</p></li></ul><p>MYELODYSPLASTIC SYNDROMES (MDS)</p><p>Myeloid neoplasm overview (Blood 2016;127:2391)</p><ul><li>Categories based on clinical features, morphology, immunophenotyping, and genetics</li></ul><p>WHO 2016 Classification of Myeloid Neoplasms & Acute Leukemia</p><p>Acute myeloid leukemia</p><p>Clonal myeloid stem cell (SC) disorder w/ ≥20% blasts</p><p>Myelodysplastic syndromes</p><p>Dysplastic clonal myeloid SC disorder → cytopenias; &lt;20% blasts, risk of leukemic transformation</p><p>Myeloproliferative neoplasms</p><p>Nondysplastic multipotent myeloid SC clonal expansion</p><p>MDS/MPN neoplasms</p><p>Features of MDS & MPN (eg, CMML, atypical CML)</p><p>Myeloid/lymphoid malig. w/ eos & rearrangements of PDGFR or FGFR1 or w/ PCM1-JAK2</p><p>May be responsive to TKI therapy (eg, imatinib) for PDGFR rearrangement</p><p>Mastocytosis</p><p>Clonal mast cell disorder, assoc w/ KIT mutations</p><p>Myeloid neoplasms w/ germ line predisposition</p><p>MDS, MDS/MPN, acute leukemias in background of predisposing germline mutations (eg, DDX41)</p><p>Myelodysplastic syndromes (MDS) overview (Lancet 2014;383:2239)</p><ul><li><p>Acquired clonal stem cell disorder → ineffective hematopoiesis → cytopenias, dysmorphic blood cells and precursors, variable risk of leukemic transformation</p></li><li><p>Epidemiology: 20–30,000 cases/y; median age ~70 y; male predominance (1.8×)</p></li><li><p>Idiopathic or 2° to chemo w/ alkylating agents; ↑ risk w/ radiation, benzene</p></li><li><p>Clinical manifestations: anemia (85%), neutropenia (50%), thrombocytopenia (40–65%)</p></li><li><p>Diagnosis: dysplasia (usually multilineage) in peripheral smear (oval macrocytes, pseudo-Pelger-Huët anomaly) and bone marrow (≥10% dysplasia with blasts ± RS)</p></li><li><p>Both cytogenetic [eg, del(5q), mono 7, del(7q), trisomy 8, del(20q)] and molecular abnl (TP53, EZH2, ETV6, RUNX1, ASXL1, SF3B1, DNMT3A) may carry prognostic signif</p></li><li><p>Prior to dx MDS: exclude AML (≥20% blasts) and CMML (monos >1 × 109/L); r/o 2° BM Δs (defic. of B12, folate, copper); viral infxn (eg, HIV); EtOH; lead, arsenic exposures</p></li></ul><p>WHO 2016 Classification Systems for MDS (Blood 2016;127:2391)</p><p>Classification</p><p>WHO 2008</p><p>Features</p><p>MDS w/ single lineage dysplasia (MDS-SLD)</p><p>RCUD</p><p>(RA/RN/RT)</p><p>1 dysplastic lineage, 1–2 cytopenias, &lt;15% RS*, &lt;5% BM/ &lt;1% PB blasts, no Auer rods</p><p>MDS w/ multilineage dysplasia (MDS-MLD)</p><p>RCMD</p><p>2–3 dysplastic lineages, 1–3 cytopenias, &lt;15% RS*, &lt;5% BM/ &lt;1% PB blasts, no Auer rods</p><p>MDS w/ ring sideroblast (MDS-RS)</p><p>RARS</p><p>≥15% RS or ≥5% RS if SF3B1 mut. is present, &lt;5% BM/&lt;1% PB blasts, no Auer rods</p><p>MDS w/ isolated del(5q)</p><p>Del(5q)</p><p>Del(5q) alone or w/ 1 abnl except –7 or del(7q)</p><p>MDS w/ excess blasts (MDS-EB)</p><p>RAEB-1</p><p>RAEB-2</p><p>EB-1: 5–9% BM/2–4% PB blasts, no Auer rods</p><p>EB-2: 10–19% BM/5–19% PB blasts or Auer rods</p><p>MDS, unclassifiable (MDS-U)</p><p>MDS-U</p><p>w/ 1% PB blasts, single lineage dysplasia & pancytopenia, or defining cytogenetic alteration</p><p>Certain cytogenetics [eg, t(15;17), t(8;21), inv16, t(16;16), or MLL rearrangement] classified as AML, regardless of BM blast count. BM, bone marrow; PB, peripheral blood; RS, ring sideroblast. * &lt;5% RS if SF3B1 mutation.</p><ul><li>Rx (Am J Hematol 2012;87:692): intensity based on IPSS-R (qv), age, performance status (PS)</li></ul><p>Poor PS, any risk → supportive care (transfusions, G-CSF, Epo, TPO-mimetic, abx prn)</p><p>Very low/low risk (IPSS-R) → ESA if Epo &lt;500; lenalidomide (esp. for 5q synd.; Blood 2011;118:3765); luspatercept (MDS-RS). TPO-mimetic agents, transfusions.</p><p>Interm/high risk (IPSS-R) → allogeneic HSCT if medically fit, DNA methyltransferase inh azacitadine or decitabine (Lancet Oncol 2009;10:223) or oral decitabine/cedazuridine</p><p>Hypoplastic MDS (rare) → consider immunosuppression (CsA, ATG), HSCT</p><ul><li>Prognosis: mutations inTP53, ASXL1, EZH2, RUNX1, ETV6 (NEJM 2011; 364:2496) ↓ survival</li></ul><p>MYELOPROLIFERATIVE NEOPLASMS (MPN)</p><p>General (NEJM 2017;376:2168)</p><ul><li><p>Results from clonal expansion of multipotent hematopoietic stem cell</p></li><li><p>Categories of MPN: polycythemia vera (PV); essential thrombocythemia (ET); primary myelofibrosis (PMF); chronic myelogenous leukemia (CML; BCR-ABL1 ⊕); atypical CML (aCML); chronic neutrophilic leukemia (CNL); systemic mastocytosis; chronic eosinophilic leukemia; MPN-NOS/unclassifiable</p></li><li><p>MDS/MPN neoplasms: proliferative and dysplastic features</p></li><li><p>Mutations useful as clonal markers & dx tools:</p></li></ul><p>Gain of fxn mutations in JAK2 V617F (Janus kinase) frequently present (PV ~95%, ET ~50%, PMF ~50%; NEJM 2005;352:1779)</p><p>BCR-ABL1 fusion in all cases of CML; SETBP1 in aCML</p><p>CALR exon 9 mutation, type I and II (most MPNs w/o JAK2 or MPL mutation, including ~25% of ET, ~35% of myelofibrosis Pts; NEJM 2013;369:2379 & 2391)</p><p>Type I has better prognosis.</p><p>MPL, TET2, & ASXL1 mutation w/ lower frequency</p><p>CSF3R mutation present in ~60% of CNL; KIT D816V in 90% of systemic mastocytosis</p><p>POLYCYTHEMIA VERA (PV)</p><p>Definition</p><ul><li>↑ in RBC mass ± ↑ granulocytes and platelets in the absence of physiologic stimulus</li></ul><p>Etiologies of erythrocytosis (absolute ↑ RBC)</p><ul><li><p>Acquired 1°: PV (usually JAK2+) or other MPN</p></li><li><p>Germline 1°: Chuvash (hypoxia-sensing disorder due to VHL mutation), EGLN mutations</p></li><li><p>Secondary: carboxyhemoglobinemia; hypoxia (OSA, COPD); inappropriate erythropoietin (renal, hepatic); Cushing’s syndrome</p></li><li><p>Mimics: relative ↑ RBC (↓ plasma) due to dehydration; “stress” erythrocytosis (Gaisböck’s syndrome)</p></li></ul><p>Clinical manifestations (common between PV and ET)</p><ul><li>Symptoms (often termed “vasomotor”)</li></ul><p>Hyperviscosity (erythrocytosis): headache, dizziness, tinnitus, blurred vision</p><p>Thrombosis (hyperviscosity, thrombocytosis): ↑ risk of DVT, MI, stroke; transient visual disturbances (amaurosis, ocular migraine); Budd-Chiari syndrome; erythromelalgia = intense burning, pain and erythema of extremities due to microvascular ischemia</p><p>Bleeding (abnormal platelet function): easy bruising, epistaxis, GI bleeding</p><p>↑ histamine from basophils → pruritus, peptic ulcers; ↑ uric acid (cell turnover) → gout</p><ul><li>Signs: plethora, splenomegaly, hypertension, engorged retinal veins</li></ul><p>Diagnostic evaluation</p><ul><li><p>Men: Hb >16.5 g/dL or Hct >49%, women: Hb >16 g/dL or Hct >48%</p></li><li><p>± ↑ WBC, platelets, basophils; ↑ uric acid, leukocyte alkaline phosphatase, vit B12</p></li><li><p>Peripheral smear → no morphologic abnormalities</p></li><li><p>✓ Epo to rule out secondary causes of erythrocytosis; if Epo ↓, PV more likely If Epo ↑, then ✓ SaO2 or PaO2, carboxyhemoglobin, BM exam</p></li><li><p>BM bx → hypercellularity for age, trilineage growth, pleomorphic mature megakaryocytes</p></li><li><p>JAK2 V617F mutation in ~95% of PV; other Pts typically harbor JAK2 exon 12 mutations</p></li></ul><p>Treatment for JAK2 + PV</p><ul><li><p>Phlebotomy to goal Hct &lt;45% (NEJM 2013;368:22), consider &lt;42% in women</p></li><li><p>Low-dose ASA in all Pts (NEJM 2004;350:114)</p></li><li><p>Hydroxyurea if high risk of thrombosis (age ≥60, prior thrombosis) or if inadequate Hct by phlebotomy alone</p></li><li><p>PEG IFNα preferred in younger Pts and pregnancy (Lancet Haematol 2017;4:e165)</p></li><li><p>Ruxolitinib (JAK1/2 inhibitor) if refractory to or intolerant of hydroxyurea (NEJM 2015;372:426)</p></li><li><p>Supportive: allopurinol (gout), H2-blockers/antihistamines (pruritus). Avoid iron supp.</p></li><li><p>Data for optimal mgmt of other types of PV (secondary, germline, etc.) currently lacking</p></li></ul><p>Prognosis</p><ul><li><p>Median survival w/ Rx ~13.5 y (Blood 2014;124:2507); ↑ age, WBC, additional acquired somatic mutations → worse prognosis (Haematol 2013;160:251)</p></li><li><p>Post-PV myelofibrosis (spent phase) occurs in 10–20% of cases, usually after 10 y</p></li><li><p>Risk of transformation into acute leukemia (&lt;2–5% lifetime)</p></li></ul><p>ESSENTIAL THROMBOCYTHEMIA (ET)</p><p>Definition</p><ul><li>Sustained ↑ in platelets (>450,000/µL) ± ↑ RBC and granulocytes</li></ul><p>Etiologies of thrombocytosis</p><ul><li><p>1° = ET or other MPN; myelodysplastic syndromes (5q-syndrome); RARS-T</p></li><li><p>2° = reactive thrombocytosis: inflammation (RA, IBD, vasculitis), infection, trauma, acute bleed, iron deficiency, postsplenectomy, neoplasms (eg, Hodgkin lymphoma)</p></li><li><p>Of patients with plt >1,000,000/µL, &lt;1 in 6 will have ET</p></li></ul><p>Clinical manifestations (also see “Polycythemia Vera”)</p><ul><li>Thrombosis with erythromelalgia (risk of thrombosis highest in Pts with leukocytosis), bleeding (acquired vWD), pruritus; mild splenomegaly; migraine, TIA; early fetal loss</li></ul><p>Diagnostic evaluation</p><ul><li><p>Peripheral smear: large hypogranular platelets</p></li><li><p>BM bx: megakaryocytic hyperplasia; ⊖ Phil chr; rarely minor reticulin fibrosis; nl Fe; if atypical megakaryoctyes or ↑ reticulin, consider pre-PMF (Rx same as ET, but ↑ risk MF)</p></li><li><p>Mutations: JAK2 V617F in ~50%; CALR in ~45%; MPL in 5–10%; triple negative &lt;5%</p></li><li><p>Patients should not meet WHO criteria for diagnosis of CML, PV, PMF, or MDS</p></li><li><p>Check vWF in pts w/ plt>1,000,000 and hold ASA (vide infra) if acquired vWD</p></li></ul><p>Prognosis</p><ul><li><p>Low-risk Pts have overall survival ≈ control population</p></li><li><p>Risk of transformation into acute leukemia &lt;2–3% lifetime; risk of progression to MF ~10%</p></li></ul><p>PRIMARY MYELOFIBROSIS (PMF)</p><p>Definition</p><ul><li><p>Clonal myeloproliferation with reactive marrow fibrosis & extramedullary hematopoiesis</p></li><li><p>Prefibrotic stage (pre-PMF): megakaryocyte prolif, grade 1 reticulin fibrosis, ↑ BM cellularity. Compared w/ ET, pre-PMF has ↑ thrombosis, ↑ progression, ↓ survival (Blood 2012;120:569).</p></li></ul><p>Etiologies of myelofibrosis</p><ul><li><p>1° myelofibrosis (PMF): myeloproliferative neoplasm</p></li><li><p>2° myelofibrosis: post-PV/ET myelofibrosis, other hematologic (CML, AML, ALL, MDS) and solid cancers (breast, prostate), autoimmune (eg, SLE), toxin (benzene), radiation, granulomas (TB, fungal, sarcoid), deposition diseases (eg, Gaucher’s)</p></li></ul><p>Clinical manifestations (BJH 2012;158:453)</p><ul><li><p>Ineffective erythropoiesis → anemia; extramedullary hematopoiesis → massive splenomegaly (abdominal pain, early satiety) ± hepatomegaly</p></li><li><p>Tumor bulk and ↑ cell turnover → fatigue, weight loss, fever, sweats</p></li></ul><p>Diagnostic evaluation (Blood 2010;115:1703 & 2016;127:2391)</p><ul><li><p>Anemia with variable WBC and platelet counts</p></li><li><p>Peripheral smear → “leukoerythroblastic” (teardrop cells, nucleated RBCs, immature WBCs); large abnormal platelets</p></li><li><p>BM aspirate → “dry” tap; BM bx → severe fibrosis, replacement by reticulin & collagen</p></li><li><p>JAK2 V617F in 45–50%; CALR mut in 45–50%, MPL mut in 7–10%, triple neg in 1–2%</p></li><li><p>No BCR-ABL translocation; Pts should not meet criteria for PV or MDS</p></li><li><p>DIPSS score for prognosis. High-risk factors: age >65, WBC >25k, Hgb &lt;10, peripheral blasts >1%, symptoms, complex cytogenetics, absence of CALR type 1.</p></li></ul><p>Treatment (Am J Hematol 2021;96:145)</p><ul><li><p>In absence of adverse prognostic factors (eg, anemia or sx) → no treatment</p></li><li><p>Allogeneic HSCT only potential cure → consider in young Pts w/ high-risk disease</p></li><li><p>Supportive care: transfusions; ESA if Epo &lt;500 (risk ↑ splenomegaly); consider androgens vs. immunomodulatory agents (eg, lenalidomide) + prednisone; hydroxyurea; ? splenectomy if refractory to transfusions, failed chemoRx, painful splenomegaly</p></li><li><p>JAK inh: ruxolitinib (JAK1/2) ↓ sx, ↓ splenomegaly, ↑ survival; preferred (NEJM 2012;366:787 & 799); fedratinib (JAK2; JAMA Oncol 2015;1:643); pacritinib & momelotinib under study</p></li><li><p>Median survival ~6 y (JCO 2012;30:2981); transformation into AML occurs at a rate of ~8%/y</p></li></ul><p>LEUKEMIA</p><p>ACUTE LEUKEMIA</p><p>Definition</p><ul><li>Clonal proliferation of hematopoietic progenitor with failed differentiation into mature elements → ↑ blasts in bone marrow and periphery → ↓ RBCs, platelets, and neutrophils</li></ul><p>Epidemiology and risk factors</p><ul><li><p>Acute myelogenous (AML): ~20k cases/y in U.S.; median age 68 y</p></li><li><p>Acute lymphocytic (ALL): ~6k cases/y in U.S.; median age 15 y but 2nd peak in older adults</p></li><li><p>Risk factors: radiation, chemo (alkylating agents, topo II inhib), benzene, smoking, ? rising from acquired somatic mutations and clonal hematopoiesis (NEJM 2014;371:2477)</p></li><li><p>Secondary to acquired hematopoietic dis.: MDS, MPN (esp. CML), aplastic anemia, PNH</p></li><li><p>Inherited: Down’s, Klinefelter’s, Fanconi’s anemia, Bloom synd., ataxia telangiectasia, germline mut. in TP53 (Li-Fraumeni syndrome), DDX41, RUNX1, CEBPa, & GATA2</p></li></ul><p>Clinical manifestations</p><ul><li><p>Cytopenias → fatigue (anemia), infection (neutropenia), bleeding (thrombocytopenia)</p></li><li><p>Leukostasis (more in AML): blast >50k, ↓ SaO2, HA, blurry vision, confusion, TIA/CVA</p></li><li><p>Tumor lysis syndrome (TLS) from rapid turnover of cells</p></li><li><p>Disseminated intravascular coagulation (DIC; especially with APL)</p></li><li><p>Other: leukemic infiltration of skin, gingiva (esp. with monocytic subtypes); chloroma (myeloid sarcoma): extramedullary tumor of leukemic cells, any location; anterior mediastinal mass and SVC syndrome (T-ALL/LBL); hepatosplenomegaly (ALL and monocytic leukemias); CNS (~10% of ALL; also in monocytic >myeloid leukemias): cranial neuropathies, HA</p></li></ul><p>Diagnostic evaluation (Blood 2009;114:937)</p><ul><li><p>Peripheral smear: thrombocytopenia, blasts (seen in >95%; ⊕ Auer Rods in AML)</p></li><li><p>Bone marrow: >20% blasts; mostly hypercellular; test for cytogenetics and flow cytometry for immunophenotype (AML/ALL)</p></li><li><p>Cytogenetic anomalies: eg, in AML, t(15;17), t(8;21), inv(16) or t(16;16), complex; in ALL, Ph-chromosome [t(9;22)], hyper or hypodiploid, complex</p></li><li><p>Molecular mutations in AML: esp FLT3 (ITD and TKD), TP53, NPM1; ALL: BCR-ABL1</p></li><li><p>Evaluate for complications: TLS (↑ uric acid, ↑ LDH, ↑ K, ↑ PO4, ↓ Ca), DIC (PT, PTT, fibrinogen, D-dimer, haptoglobin, bilirubin), check for G6PD (prior to giving rasburicase)</p></li><li><p>LP (w/ co-admin of intrathecal chemotherapy to avoid seeding CSF w/ circulating blasts) for all Pts w/ ALL (CNS is sanctuary site) and for Pts w/ AML w/ CNS sx</p></li><li><p>TTE before use of anthracyclines</p></li><li><p>HLA typing of Pt, siblings >parents/children for potential allogeneic HSCT candidates</p></li></ul><p>ACUTE MYELOGENOUS LEUKEMIA (AML)</p><p>Classification (WHO; Blood 2016;127:2391)</p><ul><li><p>Features used to confirm myeloid lineage and subclassify AML to guide treatment: morphology: blasts, ⊕ granules, ± Auer rods (eosinophilic needle-like inclusions)</p></li><li><p>Immunophenotype: precursor: CD34, CD45, HLA-DR; myeloid: CD13, CD33, CD117; monocyte: CD11b, CD64, CD14, CD15</p></li><li><p>Histochem.: myeloperoxidase (myeloid), non-specific esterase, and lysozyme (monocytic)</p></li><li><p>Prognosis: age, prior antecedent MPN/MDS and genetics (cytogenetics + molecular mutation status) are key independent risk factors of poor prognosis</p></li></ul><p>ENL 2017 Genetic Risk Classification (Blood 2017;129:424)</p><p>Risk Category</p><p>Genetic Abnormality</p><p>Favorable</p><p>APL: t(15;17); PML-RARa;</p><p>t(8;21): RUNX1-RUNX1T1; inv(16): CBFB-MYH1;</p><p>mutated NPM1 w/o FLT3-ITD or w/ FLT3-ITDlow*;</p><p>biallelic mutation in CEBPA</p><p>Intermediate</p><p>FLT3-ITDlow*; mutated NPM1 & FLT3-ITDhigh*; t(9;11): MLL-MLLT3;</p><p>cytogenetic abnl not classified as favorable or adverse, including normal karyotype w/o mutations in FLT3-ITD & NPM1</p><p>Adverse</p><p>-5 or del(5q); -7; -17/abn(17p); complex or monosomal karyotype;</p><p>t(6;9): DEK-NUP214; t(9;22) BCR-ABL1; inv(3): GATA2-MECOM;</p><p>wildtype NPM1 & FLT-ITDhigh*; mutated TP53, RUNX1, ASXL1</p><ul><li>low/high: FLT3-ITD variant allele frequency (VAF); reflects burden of mut. leukemic cells</li></ul><p>Upfront treatment</p><ul><li><p>Induction chemo “7+3”: 7d cont. infusion cytarabine (Ara-C) + 3d bolus anthracycline (daunorubicin or idarubicin)</p></li><li><p>Ability to tolerate 7+3 regimen key determinant in subsequent Rx received (vide infra)</p></li><li><p>Obtain BM bx 14–21 days after start of induction chemo to assess response</p></li><li><p>Regimens for fit (generally age &lt;75 y)</p></li></ul><p>FLT3-ITD/TKD mutation: 7+3+midostaurin (early generation FLT3 inhib; NEJM 2017;377:454)</p><p>Core-binding factor ⊕: t(8;21) or inv(16): 7+3 ± gemtuzumab ozogamicin (mAb targ. CD33)</p><p>2° AML or w/ MDS-related changes: CPX-351 (liposomal Ara-C & daunorubicin)</p><p>Other: age &lt;60 y: 7+3 (high-dose daunorubicin 90 mg/m2); >60 y: dauno 60 mg/m2</p><ul><li>Regimens for unfit (may include age ≥75 y or &lt; 75y w/ ECOG ≥3 or severe cardiac or pulmonary comorbidity; Leukemia 2013;27:997)</li></ul><p>Azacitadine + venetoclax (Bcl2 inhibitor) (NEJM 2020;383:617)</p><p>IDH1/2 mutation: ivosidenib or enasedinib</p><p>Consolidation therapy</p><ul><li><p>If complete remission (CR) = ANC >103, plt >100, no RBC Rx, &lt;5% BM blasts; CR ≠ cure</p></li><li><p>Favorable risk: high-dose cytarabine (HiDAC); Intermediate/Poor risk: Allo-HSCT</p></li><li><p>Consider maintenance azacitadine if cannot complete curative intent Rx (NEJM 2020;383:2526)</p></li></ul><p>Refractory/relapsed disease</p><ul><li><p>Repeating mutation analysis key b/c clonal evolution common and may affect Rx</p></li><li><p>FLT3-ITD/TKD mutation: gilteritinib (potent FLT3 inhibitor)</p></li><li><p>IDH1 mutation: ivosidenib; IDH2 mutation: enasidenib (small-molecule inhib of IDH1 or 2)</p></li><li><p>Chemo: MEC (mitoxantrone, etoposide, Ara-C); FLAG-Ida (fludarabine, Ara-C, G-CSF, & idarubicin); CLAM (clofarabine, Ara-C, mitoxantrone), gemtuzumab</p></li></ul><p>Prognosis</p><ul><li><p>CR achieved in 70–80% of Pts &lt;60 y and in 40–50% of Pts >60 y</p></li><li><p>Overall survival variable, depends on prognostic factors: ranges from &lt;10% of older Pts w/ poor-risk tumor genetics to >65% of younger Pts w/ favorable prognostic factors</p></li></ul><p>Acute promyelocytic leukemia (APL) (Blood 2009;113:1875)</p><ul><li><p>Rare, ~8% of AML in U.S.; >90% cure rates</p></li><li><p>Atypical promyelocytes (large, granular cells; bilobed nuclei) in blood and bone marrow</p></li><li><p>Defined by translocation of retinoic acid receptor: t(15;17); PML-RARA (>95% of cases)</p></li><li><p>Medical emergency with DIC and bleeding common</p></li><li><p>Remarkable responses to all-trans-retinoic acid (ATRA) & arsenic trioxide (ATO) which induce differentiation of leukemic blasts. ∴ early initiation of ATRA if APL suspected</p></li><li><p>Non-high-risk APL: ATRA + ATO (induction + 4 cycles consolidation) → CR ~100%; event-free survival 97% and overall survival 99% at 2 y (NEJM 2013;362:111)</p></li><li><p>High-risk APL: WBC >10k at diagnosis. No clear consensus. In general, chemo (anthracycline or gemtuzumab ozogamicin) added to ATRA + ATO induction and consolidation.</p></li><li><p>Differentiation syndrome (ATRA): ~25% of Pts; fever, pulm. infiltrates, SOB, edema, HoTN, AKI; tx w/ dexamethasone 10 mg bid, supportive care (eg, diuresis) (Blood 2008;113:775)</p></li></ul><p>ACUTE LYMPHOBLASTIC LEUKEMIA (ALL; Lancet 2020;395:1146)</p><p>Classification</p><ul><li><p>Lymphoblastic neoplasms may present as acute leukemia (ALL) w/ >20% BM blasts or as lymphoblastic lymphoma (LBL, more common in T-cell) w/ mass lesion w/ &lt;20% BM blast</p></li><li><p>Morphology: no granules (granules seen in myeloid lineage)</p></li><li><p>Cytochemistry: ⊕ terminal deoxynucleotidyl transferase (TdT) in 95% of ALL, MPO ⊖</p></li><li><p>Immunophenotype</p></li></ul><p>Precursor: CD34, TdT</p><p>B: CD19; variable CD10, CD22, CD79a</p><p>T: CD1a, CD2, cytoplasmic CD3, CD5, CD7</p><p>Treatment</p><ul><li>Induction chemo</li></ul><p>Ph ⊕ t(9;22) (seen in ~25% of B-ALL): tyrosine kinase inhibitor + chemo/steroids</p><p>Ph ⊖: Adolescents & young adults (&lt;40 y): pedi-like regimen typically w/ PEG-asparaginase. Adults (40–60 y): multiagent chemo incl. anthracycline, vincristine, steroids, cyclophosphamide (CYC). Older (>60 y): reduced-intensity chemo.</p><ul><li><p>CNS prophylaxis: intrathecal MTX/cytarabine ± cranial irradiation or systemic MTX</p></li><li><p>Post-remission therapy (choice depends on risk of recurrence)</p></li></ul><ol><li><p>Average risk: consolidation/intensification chemo (~7 mo) → maintenance (~2–3 y)</p></li><li><p>High risk: high-dose chemo w/ allo-HSCT considered for Pts in CR1. High-risk disease includes: Ph ⊕; Ph-like (based on gene expression); MLL translocation t(4;11); complex karyotype; hypodiploid (&lt;44 chromosomes); early T-cell phenotype (ETP; lacks CD1a, CD8, CD5weak, myeloid markers); minimal residual disease (MRD) = morphologic remission but flow cytometry or molec. markers of tumor still detectable.</p></li></ol><ul><li>Relapse/refractory: salvage therapy (below), then allogeneic HSCT if able</li></ul><p>B cell: blinatumomab (CD19 BiTE-bispecific T-cell engager; NEJM 2017;376:836), inotuzumab (CD22 Ab drug conjugate; NEJM 2016;375:740); tisagenlecleucel and brexucabtagene autoleucel (CD19 CAR-T, NEJM 2018;378:449; Lancet 2021;398:491), TKI+chemo/steroids (Ph ⊕t(9;22) only)</p><p>T cell: nelarabine ± cyclophosphamide and etoposide</p><p>Both B & T cell: chemo including high dose cytarabine regimens; clofarabine</p><p>CHRONIC MYELOGENOUS LEUKEMIA (CML; Lancet 2021;398:1914)</p><p>Definition (Blood 2009;114:937)</p><ul><li><p>Myeloproliferative neoplasm with clonal overproduction of hematopoietic myeloid stem cells that can differentiate</p></li><li><p>Philadelphia chromosome (Ph) = t(9;22) → BCR-ABL1 fusion → ↑ Abl kinase activity</p></li></ul><p>BCR-ABL1 required for diagnosis (make via karyotyping or FISH; PCR)</p><p>Epidemiology and risk factors</p><ul><li><p>~6600 new cases/y in U.S.; median age ~64 at presentation; ~15% of adult leukemias</p></li><li><p>↑ risk with irradiation; no clear relation to cytotoxic drugs</p></li></ul><p>Disease classification & manifestations (WHO; NCCN v 2.2022)</p><ul><li><p>Chronic phase (CP): &lt;10% blasts (peripheral or bone marrow). Risk stratification based on Sokal (Blood 1984;63:789) or Euro scores (J Clin Pathol 2001;54:491).</p></li><li><p>Accelerated phase (AP): 10–19% blasts, ≥20% basos, plts &lt;100k, clonal evolution (karyotype changes) not seen at dx</p></li><li><p>Blastic phase (BP): ≥20% blasts (peripheral or marrow) and/or extramedullary leukemia</p></li><li><p>Most Pts asx or may have mild constitutional s/s related to splenomegaly.</p></li><li><p>Worsening constitutional sx, bone pain, rapid ↑ in spleen size herald disease progression</p></li></ul><p>Diagnostic evaluation</p><ul><li><p>Peripheral smear: leukocytosis, left-shifted with all stages of myeloid maturation; thrombocytosis, basophilia</p></li><li><p>Bone marrow w/ karyotype: hypercellular, ↑myeloid:erythroid ratio, micromegakaryocytes</p></li></ul><p>Treatment (Lancet 2015;385:1447; Hematol Oncol Clin North Am 2017;31:577)</p><ul><li>Tyrosine kinase inhibitors (TKI) inhibit abl kinase activity.</li></ul><p>1st gen: imatinib, 1st TKI against BCR-ABL1 (NEJM 2017;376:917)</p><p>2nd gen: nilotinib, dasatinib, bosutinib. ↑ response but ↑ toxicity. No survival difference.</p><p>3rd gen: ponatinib; a/w ↓ risk of disease progress, preferred for int-high risk, but ↑ toxicity</p><p>Imatinib, dasatinib, nilotinib, & bosutinib approved for 1st line Rx. Nilotinib, dasatinib, bosutinib, ponatinib, & asciminib approved for resistant disease; only ponatinib & asciminib effective on T315I mutation (NEJM 2012;367:2075, Blood 2021;138:2031).</p><p>STAMP (allosteric inhibitor): asciminib (NEJM 2019;381:2315); after ≥2 prior TKIs</p><p>Resistance: due to ↑ BCR-ABL1 expression, often 2/2 ABL kinase mutation or amplification</p><p>Side effects: N/V, diarrhea, muscle cramps, cytopenias, ↓ PO4, ↑ QT, rarely CHF; dasatinib: pericardial & pleural effusions and pulm. HTN; nilotinib: ↑ bili & lipase, CV toxicity; ponatinib: pancreatitis and arterial vascular events (cerebral, cardiac, & PAD)</p><ul><li><p>TKI discontinuation: consider if complete molecular response (>4.5 log reduction in BCR-ABL1 transcript) for >2 y. Up to 50% of Pts remain off TKI at 2 y (ie, no molec. recurrence). Success proportional to duration of CMR and risk score at presentation.</p></li><li><p>Consider allogeneic HSCT for AP and BP.</p></li><li><p>CML in pregnancy: hydroxyurea & all TKIs contraind. If Rx needed, IFN (only option).</p></li></ul><p>Milestones of Therapy</p><p>Definition</p><p>Optimal Time</p><p>BCR-ABL1 ratio &lt;10% IS = 1-log reduction by QT- PCR</p><p>3 mo</p><p>BCR-ABL1 ratio &lt;1% IS = 2-log reduction by QT-PCR (CCyR)</p><p>6 mo</p><p>BCR-ABL1 ratio &lt;0.1% IS = 3-log reduction by QT-PCR (MMR)</p><p>12 mo</p><p>BCR-ABL1 ratio: Pt BCR-ABL1 mRNA: ABL mRNA in peripheral blood. International Scale (IS) standardizes across labs by normalizing to BCR-ABL1:ABL1 ratio in a cohort of unRx’d patients.</p><p>Prognosis (NEJM 2017;376:917)</p><ul><li>Chronic phase CML Rx’d w/ imatinib: 89% 5-y overall survival, 95% survival free of CML-related deaths, 7% progression to blast phase at 5 y (NEJM 2006;355:2408). Pts in CCyR (~equal to QT-PCR if 1% IS) have normal life expectancy. QT-PCR >4-log ↓ can consider TKI discontinuation trial (Lancet Onc 2018;19:747).</li></ul><p>CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)</p><p>see “Small Lymphocytic Lymphoma”</p><p>LYMPHOMA AND CLL</p><p>Definition</p><ul><li><p>Malignant disorder of lymphoid cells that reside predominantly in lymphoid tissues</p></li><li><p>Generally characterized as Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL)</p></li></ul><p>Clinical manifestations</p><ul><li>Lymphadenopathy (usually nontender)</li></ul><p>HL: superficial (usually cervical/supraclavicular) ± mediastinal LAN; nodal disease with orderly, anatomic spread to adjacent nodes</p><p>NHL: diffuse; nodal and/or extranodal disease with noncontiguous spread; symptoms reflect involved sites (abdominal fullness, bone pain)</p><ul><li>Constitutional (“B”) symptoms: fever (>38°), drenching sweats, ↓ weight (>10% in 6 mo)</li></ul><p>HL: periodic, recurrent “Pel-Ebstein” fever; 10–15% have pruritus; ~35% “B” symptoms</p><p>NHL: “B” symptoms vary between subtypes, ~15–50%</p><p>Diagnostic and staging evaluation</p><ul><li><p>Physical exam: lymph nodes, liver/spleen size, Waldeyer’s ring, testes (~1% of NHL), skin</p></li><li><p>Pathology: excisional lymph node bx (not FNA b/c need surrounding architecture) with immunophenotyping and cytogenetics (Reed-Sternberg (RS) cells in HL); BM bx if cytopenias; CLL by peripheral flow in patients w/ peripheral disease; LP if CNS involvement clinically suspected</p></li><li><p>Lab tests: CBC, BUN/Cr, LFTs, ESR, LDH, UA, Ca, alb; ✓ HBV & HCV (and must ✓ HBsAg & anti-HBc if planning rituximab Rx due to risk of HBV reactivation); HIV</p></li><li><p>Imaging: PET-CT to assess disease burden and guide biopsy/therapy, especially in HL, DLBCL. Head CT/MRI only if neurologic symptoms.</p></li></ul><p>Ann Arbor Staging System with Cotswolds Modifications</p><p>Stage</p><p>Features</p><p>I</p><p>Single lymph node (LN) region</p><p>II</p><p>≥2 LN regions on the same side of the diaphragm</p><p>III</p><p>LN regions on both sides of the diaphragm</p><p>IV</p><p>Disseminated involvement of one or more extralymphatic organs</p><p>Modifiers: A = no symptoms; B = fever, night sweats or weight loss; X = ”bulky” mediastinal disease or mass >10 cm; E = single contiguous extranodal site; H = hepatic; S = splenic</p><p>HODGKIN LYMPHOMA (HL) (Am J Hematol 2018;93:704; Lancet 2021;398:1518)</p><p>Epidemiology and risk factors</p><ul><li>~9,000 cases/y; bimodal distribution (15–35 & >50 y); ↑ ♂; role of EBV in subsets of HL, esp. immunocompromised patients (eg, HIV)</li></ul><p>Pathology</p><ul><li><p>Affected nodes show RS cells (&lt;1%) in background of non-neoplastic inflammatory cells</p></li><li><p>Classic RS cells: bilobed nucleus & prominent nucleoli with surrounding clear space (“owl’s eyes”). RS cells are clonal B-cells: CD15+, CD30+, CD20– (rarely +).</p></li></ul><p>WHO Histologic Classification of Classical HL</p><p>Nodular sclerosis</p><p>60–80%</p><p>Collagen bands; frequent mediastinal LAN; young adults; female predominance; usually stage I or II at dx</p><p>Mixed cellularity</p><p>15–30%</p><p>Pleomorphic; older age; male predominance; ≥50% stage III or IV at presentation; intermediate prognosis</p><p>Lymphocyte rich</p><p>5%</p><p>Abundant normal-appearing lymphocytes; mediastinal LAN uncommon; male predominance; good prognosis</p><p>Lymphocyte depleted</p><p>&lt;1%</p><p>Diffuse fibrosis and large numbers of RS cells; older, male patients; disseminated at dx; seen in HIV; worst prognosis</p><ul><li>Nonclassical HL (5%): nodular lymphocyte predominant (NLP); involves peripheral LN</li></ul><p>80% present in stages I–II, Rx w/ RT vs. chemoRT w/ 4-yr PFS 88% and OS 96% (JCO 2008;26:434); consider rituximab because most NLP RS cells are CD20+</p><p>Stages III–IV treated with combination chemo (see below)</p><p>Treatment (NCCN Guidelines v5.2021)</p><ul><li>Stages I–II: PET adapted ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) ± RT Favorable: ABVD × 2–4 cycles ± RT (if PET ⊖ after 2 cycles reduce chemo or RT)</li></ul><p>Unfavorable (>50 y, bulky mediastinum, “B” sx, ESR >50, >3 nodal sites): ABVD × 4–6 + RT (stop at 4 cycles if PET ⊖ after 2 cycles)</p><ul><li><p>Stages III–IV: ABVD × 6 cycles (can omit B if PET ⊖ after 2 cycles; NEJM 2016;374:2419); brentuximab (anti-CD30) may replace bleo but more toxic (NEJM 2018;378:331); add RT for select Pts as consolidation</p></li><li><p>Refractory/relapsed disease: salvage chemo + auto HSCT ± RT</p></li></ul><p>brentuximab vedotin post-ASCT yields some long-term remissions (Blood 2016;128:1562)</p><p>PD1/PDL1 blockade (pembrolizumab or nivolumab) (NEJM 2015;372:311, JCO 2017;35:19)</p><ul><li>Late treatment effects include ↑ risk for:</li></ul><p>Second cancers: ~4.6× risk for up to 40 y (NEJM 2015;373:2499)</p><p>breast (if RT), ∴ annual screening at age 40 or 8–10 y post RT; leukemia/MDS; NHL</p><p>Cardiac disease (if RT or anthracycline), ? role of echo/stress at 10 y (controversial)</p><p>Pulmonary toxicity (if bleomycin); Hypothyroidism (if RT), ∴ annual TSH (if neck RT)</p><ul><li>International Prognostic Score (IPS; JCO 2012;30:3383) risk factors: albumin &lt;4 g/dL, Hb &lt;10.5 g/dL, male gender, age >45 y, stage IV, WBC ≥15 k/µL, lymphocytes &lt;600/µL or &lt;8% of diff. 5-yr PFS 62–88% based on # of risk factors.</li></ul><p>NON-HODGKIN LYMPHOMA (NHL)</p><p>Epidemiology and risk factors</p><ul><li><p>79 types of NHL, ~70,000 new cases/y; median age dx 65 y; ♂ predom; 85% B-cell origin</p></li><li><p>Associated conditions: immunodeficiency (eg, HIV, posttransplant); autoimmune</p></li></ul><p>disorders (eg, Sjögren’s, RA, SLE); infection (eg, EBV, HTLV-I, H. pylori)</p><ul><li>Burkitt lymphoma: (1) endemic or African (jaw mass, 80–90% EBV-related); (2) sporadic or American (20% EBV-related); (3) HIV-related</li></ul><p>WHO Classification of Lymphoid Malignancies (Blood 2016;127:2375)</p><p>Type</p><p>Examples</p><p>Associated Abnormalities</p><p>Mature B cell</p><p>aggressiveness</p><p>Burkitt’s lymphoma</p><p>Diffuse large B-cell lymphoma (DLBCL)</p><p>Mantle cell</p><p>Marginal zone lymphoma (nodal, extranodal, splenic)</p><p>Hairy cell leukemia (⊕ TRAP)</p><p>Follicular lymphoma</p><p>CLL/small lymphocytic lymphoma</p><p>8q24, c-MYC</p><p>BCL2, MYC, MLL2, CREBBP, etc.</p><p>t(11;14) BCL1-IgH → cyclin D1</p><p>AP12-MALT1 & BCL-10-Ig enh</p><p>BRAF V600E</p><p>IGH-BCL2, MLL2, CREBBP</p><p>IGHV, TP53, ATM, SF3B1, etc.</p><p>Mature T cell & NK cell</p><p>Peripheral T-cell lymphoma</p><p>Mycosis fungoides (cutaneous lymphoma)/ Sézary syndrome (+ LAN)</p><p>Anaplastic large-cell lymphoma</p><p>Angioimmunoblastic T-cell lymphoma</p><p>TET2 and DNMT3A</p><p>Some ALK1 ⊕</p><p>Treatment (Lancet 2017;390:298)</p><ul><li><p>Treatment and prognosis determined by histopathologic classification rather than stage</p></li><li><p>Rituximab (anti-CD20; NEJM 2012;366:2008) if CD20+</p></li><li><p>Indolent: generally no cure (except allo HSCT), goal sx mgmt (bulky dis, cytopenia, “B” sx)</p></li></ul><p>Follicular Lymphoma Int’l Prog. Index (FLIPI; Blood 2004;104:1258): risk factors = age >60, stage III/IV, Hb &lt;12 g/dL, >4 nodal areas, LDH >nl. 5-yr OS 52–90% based on score.</p><p>Initial: RT if localized, rituximab + chemo (bendamustine, CVP, fludarabine), ibrutinib.</p><p>Obinutuzumab (anti-CD20) + chemo w/ obin maint ↑ PFS but ↑ tox (NEJM 2017;377:1331).</p><p>Maintenance: rituximab in indolent, aggressive, and relapsed disease (Lancet 2011;377:42)</p><p>Hairy cell: cladribine; oral BRAF inhibitor if relapsed/refractory (NEJM 2015;373:1733)</p><p>Gastric MALT: ✓ H. pylori; can cure by treating H. pylori if ⊕; RT for relapsed/refractory</p><ul><li>Aggressive: goal is cure (Am J Hematol 2019;94:604), treatment depends on subtype</li></ul><p>International Prognostic Index (IPI; Blood 2007;109:1857): risk factors = age >60 y, stage III/IV, ≥2 extranodal sites, PS ≥2, LDH >nl. 4-yr OS 55–94% based on score.</p><p>R-CHOP (rituximab, cyclophosphamide, doxorubicin = hydroxydaunorubicin, vincristine = Oncovin, prednisone) (NEJM 2002;346:235 & 2008;359:613) DLBCL 10-y PFS = 45%; overall survival = 55% (Blood 2010;116:2040)</p><ul><li>Radiation for localized or bulky disease</li></ul><p>Consider CNS prophylaxis w/ intrathecal vs. systemic high-dose MTX if paranasal sinus, testicular, breast, periorbital, paravertebral, or bone marrow involved; also w/ ≥2 extranodal sites + ↑ LDH. Controversial (Blood 2021;139:413).</p><p>Refractory/relapsed disease: salvage chemo; high-dose chemo + auto-HSCT (JCO 2001;19:406); allo-HSCT if beyond 2nd relapse (JCO 2011;29:1342)</p><p>CAR-T (qv): axicabtagene (NEJM 2017;377:2531), tisagenlecleucel (NEJM 2019;380:45), lisocabtagene (Lancet 2020;396:839), brexucabtagene (mantle cell; NEJM 2020; 382:1331)</p><p>Mantle cell: ibrutinib for relapsed/refractory disease (Lancet 2016;387:770)</p><ul><li>Highly aggressive</li></ul><p>Burkitt: dose-adjusted EPOCH-R (NEJM 2013;369:1915) or CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate, ifosfamide, etoposide, high-dose cytarabine rituximab) (Blood 2008;112:2248)</p><p>All Pts receive CNS & tumor lysis syndrome prophylaxis</p><p>Rituximab ↑ event-free survival (Lancet 2016;387:2402)</p><p>High-grade B-cell lymphoma w/ rearrangements of MYC and BCL2 and/or BCL6: “double-/triple-hit”, assoc. w/ poor prognosis. Often use DA-R-EPOCH.</p><p>HIV-associated NHL (Blood 2006;107:13)</p><ul><li><p>HIV ⊕ imparts 60–100× relative risk</p></li><li><p>NHL is an AIDS-defining malignancy along with Kaposi’s, cervical CA, anal CA</p></li><li><p>Concurrent HAART & chemotherapy likely provide survival benefit</p></li><li><p>DLBCL & immunoblastic lymphoma (67%): CD4 &lt;100, EBV-associated. Burkitt lymphoma (20%): can occur with CD4 >200. Generally, treat as immunocompetent, but avoid rituximab if CD4 &lt;50 (due to increased risk of death from infection).</p></li><li><p>Primary CNS lymphoma (16%): CD4 &lt;50, EBV-assoc. (also seen in Pts w/o HIV). Rx w/ high-dose MTX-based regimen + steroid ± temozolomide ± RT, consider auto HSCT.</p></li></ul><p>SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)</p><p>Definition (NEJM 2005;352:804; Blood 2008;111:5446)</p><ul><li><p>Monoclonal, functionally incompetent mature B lymphocytes; CLL & SLL = same disease</p></li><li><p>CLL: >5000/µL malignant cells; SLL: &lt;5000/µL malignant cells + LAN ± splenomegaly</p></li><li><p>Monoclonal B lymphocytosis: resembles but does not meet CLL criteria, observe</p></li></ul><p>Epidemiology and risk factors</p><ul><li>~15,000 new cases/y; median age at dx is 71 y; most common adult leukemia</li></ul><p>Clinical manifestations</p><ul><li><p>Often asx & identified by lymphocytosis on CBC; 10–20% p/w “B symptoms”</p></li><li><p>Lymphadenopathy (80%) and hepatosplenomegaly (50%)</p></li><li><p>Autoimmune hemolytic anemia (AIHA) (~10%) or thrombocytopenia (ITP) (~1–2%)</p></li><li><p>Hypogammaglobulinemia ± neutropenia → ↑ susceptibility to infections</p></li><li><p>Bone marrow failure in ~13%; monoclonal gammopathy in ~5%</p></li><li><p>Aggressive Richter’s transformation in ~5% into high-grade lymphoma (poor prognosis)</p></li></ul><p>Diagnostic evaluation</p><ul><li><p>CBC w/ diff: B-cell count</p></li><li><p>Peripheral smear: lymphocytosis (predominantly mature-appearing small cells) “smudge” cells from damage to abnl lymphs from shear stress of making blood smear</p></li><li><p>Flow cytometry: clonality with dim surface Ig; CD5+, CD19+, CD20+, CD23+</p></li><li><p>Bone marrow (not req for dx): normo- or hypercellular; ≥30% small B lymphocytes</p></li><li><p>Genetics: del 11q22-23 & del(17p) unfavorable; trisomy 12 neutral; del 13q14 and mut IGHV favorable. Nine significantly mutated genes, including TP53, NOTCH1, MYD88, and SF3B1. Key role for spliceosome mutations (NEJM 2011;365:2497; JCI 2012;122:3432).</p></li></ul><p>Treatment (NEJM 2020;383:460)</p><ul><li><p>Observation unless “active disease”: Rai stage III/IV, Binet stage C, disease-related sx, progressive disease, AIHA or ITP refractory to steroids, recurrent infections</p></li><li><p>First-line: w/o del(17p)/TP53 use acalabrutinib or ibrutinib (BTK inhibitors) or venetoclax + rituximab; with del(17p)/TP53 use acalabrutinib or venetoclax ± obinutuzumab; ibrutinib + venetoclax w 88% w/ CR but ↑ tox (NEJM 2019;380:2095)</p></li><li><p>Second-line & beyond: in general, choose Rx w/ mechanism different from 1st line Rx. BTK inhibitors (eg, zanubrutinib), venetoclax, chemo including fludarabine, chlorambucil, or bendamustine + rituximab. Consider allo-HSCT in relapse.</p></li><li><p>HSCT is the only curative Rx. Rx choice balances patient/disease characteristics and goals of care. Different rates of complete remission, time to progression, and toxicities.</p></li><li><p>Rx for complications: PCP, HSV, VZV Ppx; AIHA/ITP → steroids; recurrent infxns → IVIg</p></li></ul><p>PLASMA CELL DYSCRASIAS</p><p>Figure 5-6 Spectrum of nonmalignant to malignant clonal plasma cell disorders</p><p>Monoclonal Gammopathy of Uncertain Significance (MGUS) (NEJM 2018;378:241)</p><ul><li><p>✓ CBC, Ca, Cr, SPEP, serum free light chains, UPEP w/ immunofixation (to exclude MM)</p></li><li><p>Close observation: repeat SPEP in 6 mo, then yearly thereafter if stable</p></li><li><p>~1%/y or ~25% lifetime risk → MM, WM, amyloidosis, or malign. lymphoproliferative dis.</p></li><li><p>Abnormal serum free light chain ratio & M protein ≥1.5 g/dL: ↑ risk of progression to MM</p></li></ul><p>Smoldering Multiple Myeloma</p><ul><li><p>Need whole-body MRI or PET-CT to rule out occult bone lesions</p></li><li><p>Risk of prog. 10%/y, depends on [M protein], subtype, FLC ratio. No defined role for Rx yet though trials ongoing (NEJM 2013;369:438; Blood 2019;134:781; JCO 2020;38:1126).</p></li></ul><p>MULTIPLE MYELOMA (MM)</p><p>Definition and epidemiology (Lancet 2021;397:410)</p><ul><li><p>Malignant neoplasm of plasma cells producing a monoclonal Ig = “M protein”</p></li><li><p>~27,000 new cases/y; median age at diagnosis 69 y; more common in African Americans</p></li></ul><p>Clinical manifestations (CRAB criteria and other less common features)</p><ul><li><p>HyperCalcemia due to ↑ osteoclast activity</p></li><li><p>Renal disease: multiple mechanisms include toxic effect of filtered light chains → renal failure (cast nephropathy) or type II RTA; amyloidosis or light chain deposition disease → nephrotic syndrome; hypercalcemia, urate nephropathy, type I cryoglobulinemia</p></li><li><p>Anemia (normocytic) due to bone marrow involvement; rarely, may see AIHA</p></li><li><p>Lytic Bone lesions due to ↑ osteoclast activity → pathologic fx</p></li><li><p>Recurrent infxns due to relative hypogammaglob. (clonal plasma cells suppress nl Ig)</p></li><li><p>Neurologic: cord compression; POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome</p></li><li><p>Hyperviscosity: usually when IgM >4 g/dL, IgG >5 g/dL, or IgA >7 g/dL</p></li><li><p>Coagulopathy: seen in amyloid due to binding & depletion of Factor X</p></li><li><p>AL amyloidosis (see “Amyloidosis”)</p></li></ul><p>Diagnostic and staging evaluation (Lancet Onc 2014;15:e538)</p><ul><li>Dx: BM plasma cells ≥10% or bx-proven plasmacytoma & ≥1 MM-defining event:</li></ul><p>(a) myeloma-related organ or tissue impairment (ROTI) = lytic bone lesions, Ca >11 mg/dL, Cr >2 mg/dL, or Hb &lt;10 g/dL</p><p>(b) any of the following biomarkers: BM plasma cells ≥60%, serum free light chain (FLC) ratio ≥100:1, >1 focal lesion on MRI</p><ul><li>Variants</li></ul><p>Solitary bone or extramedullary plasmacytoma: no periph plasmacytosis or other ROTI</p><p>Plasma cell leukemia: plasma cell count >2000/µL in peripheral blood</p><p>Nonsecretory MM (~2% of MM Pts; MM without M protein)</p><ul><li><p>✓ Peripheral smear for rouleaux (see insert), Ca, alb, Cr; ↓ anion gap, ↑ globulin, ↑ ESR</p></li><li><p>Protein electrophoresis and immunofixation</p></li></ul><p>Serum protein electrophoresis (SPEP): quantitates M component; ⊕ in >80% of Pts</p><p>Ddx of M component: MM, MGUS (vide supra), CLL, lymphoma, sarcoidosis, RA Polyclonal hypergam seen in inflammatory states: HIV, rheumatic diseases, cirrhosis</p><p>Urine protein electrophoresis (UPEP): detects Pts who secrete only light chains (= Bence Jones proteins), which are filtered rapidly from the blood</p><p>Immunofixation: shows component is monoclonal and identifies Ig type → IgG (50%), IgA (20%), IgD (2%), IgM (0.5%), light chain only (20%), nonsecretors (&lt;5%)</p><p>Serum FLC assay: important for dx (esp. light chain-only Pts) and f/up response to Rx</p><ul><li><p>β2-microglobulin (β2M) and LDH levels reflect tumor burden</p></li><li><p>BM bx cytogenetics: normal karyotype better than abnl. Standard risk = hyperdiploidy or t(11;14); high risk = hypodiploidy, del. 17p13 (~10% of Pts), t(4;14) & t(4;16).</p></li><li><p>Skeletal survey (plain X-rays) to identify lytic bone lesions and areas at risk for pathologic fracture. Whole-body PET-CT (scalp to toe) or MRI often used to detect bone lesions.</p></li></ul><p>Multiple Myeloma Staging Systems (OS does not account for cytogenetics)</p><p>Stage</p><p>ISS Criteria*</p><p>Durie-Salmon (DS) Criteria</p><p>ISS Median OS</p><p>I</p><p>β2M &lt;3.5 mg/L</p><p>and</p><p>albumin >3.5 g/dL</p><p>All: Hb >10 g/dL; Ca ≤12 mg/dL; 0–1 lytic bone lesions; IgG &lt;5 g/dL or IgA &lt;3 g/dL or urine light chain &lt;4 g/24 h</p><p>62 mo</p><p>II</p><p>Fulfilling criteria for neither I nor III</p><p>44 mo</p><p>III</p><p>β2M >5.5 mg/L</p><p>Any: Hb &lt;8.5 g/dL; Ca >12 mg/dL; >5 lytic bone lesions; IgG >7 g/dL or IgA >5 g/dL or urine light chain >12 g/24 h</p><p>29 mo (30 mo if Cr &lt;2 mg/dL; 15 mo if Cr ≥2 mg/dL)</p><p>*Consider R-ISS incl chrom abnl & LDH (JCO 2005;23:3412 & 2015;61:2267).</p><p>Treatment and prognosis (NEJM 2016;375:754 & 1319; 2018;378:518 & 379:1811)</p><ul><li><p>Decisions dictated by risk stratification and transplant eligibility; generally incurable. Stratify via ISS criteria; R-ISS which includes chrom abnl & LDH (JCO 2015;61:2267).</p></li><li><p>Rx incl. proteasome inhibitors: bortezomib (V), carfilzomib (K), ixazomib (I); immunomodulators: lenalidomide (R), thalidomide (T), pomalidomide (P); immunotherapy: daratumumab (anti-CD38, Dara), elotuzumab (anti-SLAMF7, Elo)</p></li></ul><p>Other active drugs: dexamethasone (D), melphalan, panobinostat, cyclophosphamide</p><ul><li>Induction Rx w/ best response rate: proteasome inhib (V or K) + immunomod (eg, R). Triplet Rx ↑ OS vs. double (Lancet 2017;389:519). RVD most common regimen in US; KRD if high-risk (NEJM 2014;371:906 & 2016;374:1621). Dara-RD an option (NEJM 2019;380:2104).</li></ul><p>Quad Rx (Dara-RVD) may improve response rates (Blood 2020;136:936).</p><ul><li><p>If not transplant eligible: induction Rx ↑ survival, not curative; consider maint chemo</p></li><li><p>If transplant eligible: after induction chemo then high-dose melphalan + auto-HSCT. Not curative, but ↑ progression-free survival (PFS) vs. chemo alone (NEJM 2014;371:895, Lancet Onc 2015;16:1617). Offer if good perf. status & no prohibitive comorbid. Maint Rx w/ R improves PFS/OS (NEJM 2014;371:10). Timing of HSCT (upfront vs. relapse) debatable.</p></li><li><p>Relapsed/refractory: HSCT (if good prior response, no prior HSCT), Elo-PD, Dara-PD, venetoclax (anti-Bcl-2) + dex in t(11;14); rarely use Allo-SCT. CAR-T w/ idecabtagene vicleucel (anti-B-cell maturation antigen) after >3 prior Rx: response rates >70% (NEJM 2019;380:1726 & 2021;384:705).</p></li><li><p>Local radiation for solitary or extramedullary plasmacytoma</p></li><li><p>Adjunctive Rx: bone: bisphosphonates (JCO 2007;25:2464), XRT for sx bony lesions</p></li></ul><p>renal: avoid NSAIDs & IV contrast; consider plasmapheresis for acute renal failure</p><p>hyperviscosity syndrome: plasmapheresis; infxns: consider IVIg for recurrent infections</p><ul><li>Common toxicities of Rx: melphalan → myelosuppression; lenalidomide → low plts & thromboembolism; bortezomib → periph. neuropathy; steroids → hyperglycemia, infxn</li></ul><p>WALDENSTRÖM’S MACROGLOBULINEMIA (WM)</p><p>Definition (Blood 2009;114:2375; NEJM 2012;367:826)</p><ul><li><p>B-cell neoplasm (lymphoplasmacytic lymphoma) that secretes monoclonal IgM</p></li><li><p>91% w/ MYD88 (NF-κB pathway) L265P mut., may distinguish from MM</p></li><li><p>No evidence of bone lesions (IgM M component + lytic bone lesions = “IgM myeloma”)</p></li></ul><p>Clinical manifestations</p><ul><li><p>Fatigue from anemia is most common sx</p></li><li><p>Tumor infiltration: BM (cytopenias), hepatomegaly, splenomegaly, lymphadenopathy</p></li><li><p>Circulating monoclonal IgM</p></li></ul><p>Hyperviscosity syndrome (~15%): Neurologic: blurred vision (“sausage” retinal veins), HA, dizziness, Δ MS. Cardiopulmonary: congestive heart failure, pulm. infiltrates.</p><p>Type I cryoglobulinemia → Raynaud’s phenomenon</p><p>Platelet dysfxn → mucosal bleeding</p><ul><li><p>IgM deposition (skin, intestine, kidney); amyloidosis and glomerulopathy</p></li><li><p>Autoantibody activity of IgM: Chronic AIHA (prominent rouleaux; 10% Coombs’ ⊕ = AIHA). Peripheral neuropathy: may be due to IgM against myelin-associated glycoprotein.</p></li></ul><p>Diagnostic evaluation</p><ul><li><p>SPEP + immunofixation with IgM >3 g/dL; 24-h urine for UPEP (only 20% have ⊕ UPEP)</p></li><li><p>Bone marrow biopsy: ↑ plasmacytoid lymphocytes; β2-microglobulin for prognostic eval</p></li><li><p>Relative serum viscosity: ratio serum viscosity to H2O (nl 1.8); hyperviscosity when >5–6</p></li></ul><p>Treatment</p><ul><li><p>Hyperviscosity: plasmapheresis; limit transfusions if possible (worsen hyperviscosity)</p></li><li><p>Sx (eg, prog. anemia): ritux ± chemo (eg, bendamustine, Cy, etc.); ritux + ibrutinib (NEJM 2018;378:2399); zanubrutinib (Lancet Haem 2020;7:e837); everolimus or HSCT in salvage</p></li></ul><p>HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)</p><p>Transplantation of donor pluripotent cells that can reconstitute all recipient blood lineages</p><p>Categories of Stem Cell Transplantation</p><p>Feature</p><p>Allogeneic (Allo)</p><p>Autologous (Auto)</p><p>Donor–recipient relationship</p><p>Immunologically distinct</p><p>Donor is also recipient</p><p>Graft-vs.-host disease</p><p>Yes</p><p>No</p><p>Graft-vs.-tumor effect</p><p>Yes</p><p>No</p><p>Risk of graft contam. w/ tumor</p><p>No</p><p>Yes</p><p>Relapse risk (leukemia)</p><p>Lower</p><p>Higher</p><p>Transplant-related mortality</p><p>Higher</p><p>Lower</p><ul><li>Types of Allo HSCT: based on donor/recipient matching of major HLA antigens on Chr. 6 (4 principal genes for serotyping: HLA-A, -B, -C, & -DR; each w/ 2 alleles ∴ 8 major Ag)</li></ul><p>Matched related (MRD, sibling 8/8 major Ag match): lowest GVHD; preferred donor</p><p>Matched unrelated (MUD): ↑ risk of GVHD; ∴ matching of 10 HLA alleles (DQ also) to ↓ risk; chance of match correlates w/ ethnicity (NEJM 2014;371:339)</p><p>Mismatched related (eg, 1/8 Ag mismatch): ↑ available donor pool, but ↑ GVHD, rejection; ∴ need additional immunosuppression</p><p>Haploidentical: typically, between parents and young children or sibs (“half” match); early post-tx cyclophosphamide reduces GVH by destroying proliferating alloreactive T-cells</p><p>Umbilical cord blood: HSC processed at birth & stored. Yields lower cell number. Need 2 cords per adult. Neonatal immune cells: HLA-mismatch tolerated better, ↓ GVHD, slow immune reconstitution → ↑ late viral infections (Blood 2010;116:4693).</p><ul><li><p>Graft-vs.-host disease (GVHD): undesirable side effect of allo HSCT allogeneic T cells view host cells as foreign; ↑ incid. w/ mismatch or unrelated donors</p></li><li><p>Graft-vs.-tumor (GVT): desired effect in allo-SCT; graft T cells attack host tumor cells</p></li></ul><p>Indications (BBMT 2015;21:1863; BMT 2015;50:1037)</p><ul><li>Malignant disease:</li></ul><p>Auto HSCT allows high-dose myeloablative chemo and then rescue what would be otherwise lethal cytopenias with autologous stem cells. Used in chemosensitive diseases such as relapsed/refractory DLBCL, MM, testicular germ cell tumor.</p><p>Allo HSCT produces graft-vs.-tumor (GVT) effect, in addition to hematopoietic rescue (used for AML, ALL, MDS, CML-blast crisis, CLL, lymphoma)</p><ul><li>Nonmalignant disease: allo HSCT replaces abnl lymphohematopoietic system w/ one from nl donor (eg, immunodeficiencies, aplastic anemia, hemoglobinopathies)</li></ul><p>Transplantation procedure (for Allo HSCT)</p><ul><li>Pre-Tx conditioning regimen goal: immunosuppression to allow donor cell engraftment & anti-tumor efficacy to ↓ relapse risk. Type and dose of agents determine this balance.</li></ul><p>Myeloablative conditioning: high-dose chemo and/or total body irradiation. Low relapse rates, high immunosuppression, higher transplant-related morbidity.</p><p>Reduced-intensity conditioning (“RIC”): lower dose of chemo → ↓ transplant-related morbidity/mortality, but ↑ relapse b/c it relies more on GVT effect (Blood 2015;126:23). Allows allo HSCT for older adults (>60) or Pts w/ comorbidities.</p><ul><li>Sources of hematopoietic stem cells (NEJM 2012;367:1487)</li></ul><p>Bone marrow (BM): original source, preferred in non-malignant disease, ↓ GVHD rates</p><p>Peripheral blood stem cells (PBSC): easier to collect, more commonly used. BM vs. PBSC ≈ survival; BM ↓ chronic GVHD, PBSC ↓ graft failure, faster engraftment.</p><p>Umbilical cord blood stem cells (UCB): see above in Types of Allo HSCT</p><ul><li>Engraftment: absolute neutrophil count (ANC) recovers to 500/µL w/in ~2 wk w/ PBSC, ~2.5 wk w/ BM, ~4 wk w/ UCB. G-CSF accelerates recovery by 3–5 d in all scenarios.</li></ul><p>Complications</p><ul><li><p>Either direct chemoradiotoxicities associated with preparative regimen or consequences of interaction between donor and recipient immune systems</p></li><li><p>Engraftment syndrome: fever, rash, noncardiogenic pulm. edema, abnl LFTs, AKI, wt gain. Dx of exclusion: r/o infection, GVHD; Rx w/ 1 mg/kg steroids, rapid taper over 3–4 d.</p></li><li><p>Sinusoidal obstruction syndrome (SOS): incidence ~10%, mortality ~30%</p></li></ul><p>Previously known as veno-occlusive disease (VOD) (BBMT 2016;22:400). Mechanism: direct cytotoxic injury to hepatic venules → in situ thrombosis.</p><p>Symptoms: tender hepatomegaly, ascites, jaundice, fluid retention with severe disease → liver failure, encephalopathy, hepatorenal syndrome</p><p>Diagnosis: ↑ ALT/AST, ↑ bilirubin; ↑ PT with severe disease; Doppler U/S may show reversal of portal vein flow; ↑ hepatic wedge pressure; abnl liver bx</p><p>Treatment: supportive; prophylaxis with ursodiol; treat w/ defibrotide (Blood 2016;127:1656)</p><ul><li>Idiopathic pneumonia syndrome (IPS): 5–25% of Pts, >50% mortality (Blood 2003;102:2777)</li></ul><p>Alveolar injury 2/2 direct toxicity → fever, hypoxia, diffuse infiltrates; occult infxn frequent</p><ul><li><p>Bleeding: incidence ~25%, 2/2 ↓↓ plts; sites: CNS, GI, pulm.; Ppx w plt transfusions</p></li><li><p>Diffuse alveolar hemorrhage (DAH): Dx: bronchoscopy to exclude infection; ↑ bloody lavage fluid. Rx: 500–1000 mg Solu-Medrol × 3 d ± etanercept (BBMT 2015;1:67).</p></li><li><p>Acute GVHD (usually within 6 mo of transplant; NEJM 2017;377:2167)</p></li></ul><p>Clinical grades I–IV based on scores for skin (severity of maculopapular rash), liver (bilirubin level) and GI (volume of diarrhea); bx supports diagnosis</p><p>Prevention: immunosuppression (MTX + cyclosporine, or tacrolimus), T-cell depletion of graft, post-Tx cyclophos. for haploidentical, some high-risk allo (BBMT 2008;14:641)</p><p>Treatment: grade I → topical Rx; grades II–IV → associated with ↓ survival and ∴ treated with immunosuppressants (corticosteroids, CsA, tacrolimus, rapamycin, MMF)</p><ul><li>Chronic GVHD (developing or persisting >3 mo posttransplant; NEJM 2017;377:2565)</li></ul><p>Clinical: malar rash, sicca syndrome, arthritis, obliterative bronchiolitis, bile duct degeneration, cholestasis, and many others. More common w/ PBSC than BM.</p><p>Treatment: immunosuppression; rituximab; photopheresis; ibrutinib (Blood 2017;130:21), ruxolitinib (NEJM 2021; 385:228), belumosudil (Blood 2021;138:2278)</p><ul><li>Graft failure</li></ul><p>Primary = persistent neutropenia without evidence of engraftment</p><p>Secondary = delayed pancytopenia after initial engraftment; either immune mediated via immunocompetent host cells (graft rejection) or non–immune mediated (eg, CMV)</p><ul><li>Infectious complications</li></ul><p>due to regimen-induced pancytopenia and immunosuppression</p><p>auto HSCT recipients: no immunosuppression ∴ at ↑ risk only pre-/postengraftment</p><p>both primary infections and reactivation events occur (eg, CMV, HSV, VZV)</p><p>Timing of Complications Following Allogeneic HSCT</p><p>Time After Transplant and Associated Risk Factors</p><p>Days 0–30 Mucositis; organ dysfunction; neutropenia</p><p>Days 30–90 Acute GVHD; ↓ cell immunity</p><blockquote><p>90 Days Chronic GVHD; ↓ cellular & humoral immunity</p></blockquote><p>Viral infection</p><p>Respiratory and enteral viruses, BK virus</p><p>HSV*</p><p>CMV*, HHV 6 & 7</p><p>EBV-related lymphoma</p><p>VZV*, JC</p><p>Bacterial infection</p><p>Gram ⊕ cocci (Staph., Strep. viridans)</p><p>GNRs (Enterobacteriaceae, Pseudomonas, Legionella, S. maltophilia)</p><p>Encapsulated bacteria</p><p>Fungal infection</p><p>Candida spp.</p><p>Aspergillus spp.</p><p>Parasitic infection</p><p>T. gondii</p><p>P. carinii</p><p>S. stercoralis</p><p>T. gondii</p><p>P. carinii</p><p>Regimen-related</p><p>Pancytopenia</p><p>Growth failure</p><p>Mucositis, rash, alopecia</p><p>Hypogonadism/infertility</p><p>Nausea, vomiting, diarrhea</p><p>Hypothyroidism</p><p>Peripheral neuropathies</p><p>Cataracts</p><p>Hemorrhagic cystitis</p><p>Avascular necrosis of bone</p><p>Veno-occlusive disease</p><p>2nd malignancy</p><p>IPS/Interstitial pneumonitis</p><p>Immune-mediated</p><p>Acute GVHD</p><p>Chronic GVHD</p><p>Primary graft failure</p><p>Secondary graft failure</p><p>*Primarily among persons who are seropositive before transplant.</p><p>Prophylaxis/Supportive Medications During HSCT</p><p>Medication</p><p>Prophylaxis Against</p><p>Duration</p><p>Fluconazole or posaconazole</p><p>Candida</p><p>75 d</p><p>Acyclovir</p><p>HSV/VZV</p><p>365 d</p><p>Valganciclovir, ganciclovir, or letermovir if CMV ⊕</p><p>CMV</p><p>100 d or when no longer immunosuppressed</p><p>Antibiotics (eg, fluoroquinolone)</p><p>Bacterial infxn</p><p>While neutropenic</p><p>TMP-SMX or atovaquone</p><p>PCP</p><p>365 d or when off immunosupp.</p><p>Allopurinol</p><p>Hyperuricemia</p><p>Until d –1</p><p>LUNG CANCER</p><p>Epidemiology and risk factors</p><ul><li><p>Most common cause of cancer-related death for both men and women in the U.S.</p></li><li><p>Two main types: non-small cell (NSCLC, ~85% of cases); small cell (SCLC, ~15%)</p></li><li><p>NSCLC comprised of adeno (40%), squamous cell (SCC, 20%), & large cell (5%) carcinomas, as well as other / not classified (20%)</p></li><li><p>Cigarette smoking: 85% of lung cancers occur in smokers; risk ∝ total pack-yrs, ↓ risk after quitting/reducing but not to baseline (Int J Cancer 2012;131:1210).</p></li></ul><p>SCC & SCLC almost exclusively in smokers, adeno most common type in nonsmokers.</p><ul><li><p>Asbestos: when combined with smoking, synergistic ↑ in risk of lung cancer</p></li><li><p>Other: RT (for other cancer); HIV; environ. toxins (radon, 2nd-hand smoke); pulm. fibrosis</p></li></ul><p>Screening (JAMA 2021;325:962)</p><ul><li><p>Annual low-dose chest CT in ≥20 pack-year current or former (quit w/in 15 y) smokers, age 50–80 y → 20% ↓ lung cancer-related mortality (NEJM 2020;382:503)</p></li><li><p>High rates of screen-detected nodules. Multidisciplinary mgmt recommended (pulm., med onc, thoracic radiology & surgery; NCCN Guidelines: Lung Cancer Screening v.1.2022).</p></li></ul><p>Clinical manifestations</p><ul><li><p>~10% asymptomatic at dx, detected incidentally (only 16% w/ localized dis. at presentation)</p></li><li><p>Endobronchial growth of 1° tumor: cough, hemoptysis, dyspnea, pain, wheezing, post-obstructive pneumonia; more common with squamous or small cell (central location)</p></li><li><p>Regional spread: can cause dysphagia (esophageal compression), stridor (tracheal obstruction), hoarseness (recurrent laryngeal nerve palsy). Pleural effusions & pleural metastases specifically = metastatic disease = Stage IV.</p></li></ul><p>Pancoast’s syndrome: apical tumor → brachial plexus involvement (C8, T1, T2) → Horner’s syndrome, shoulder pain, rib destruction, atrophy of hand muscles</p><p>SVC syndrome (NEJM 2007;356:1862): central tumor → SVC compression → face/arm swelling (>80%), neck/chest vein distention (~60%), SOB/cough (~50%), HA (~10%); Rx = steroids, diuretics, RT ± chemo, SVC stent if severe sx, anticoag if clot</p><ul><li><p>Extrathoracic metastases: brain (~25% of patients at dx), bone, liver, adrenal</p></li><li><p>Paraneoplastic syndromes</p></li></ul><p>Endo: SIADH (SCLC); ACTH (SCLC) → Cushing’s; PTH-rP (SCC) → hyperCa</p><p>Skeletal: digital clubbing (NSCLC), hypertrophic pulm. osteoarthropathy (adenocarcinoma) = symmetric polyarthritis and proliferative periostitis of long bones</p><p>Neuro (SCLC): Eaton-Lambert (anti-P/Q-type voltage-gated Ca2+ channel Abs), peripheral neuropathy (anti-Hu, anti-PCA-2, anti-CRMP5), cerebellar degeneration (anti-Hu, anti-Yo, anti-Ri, anti-Tr), encephalomyelitis (anti-Hu, anti-Ma1/2, anti-CRMP5)</p><p>Hematologic: hypercoagulable state (adenocarcinoma), DIC</p><p>Diagnostic and staging evaluation (NCCN Guidelines v.7.2021)</p><ul><li>Staging: based on tumor size and extent of invasion (T), regional LN involvement [N: N0 (none), N1 (ipsilat. hilar), N2 (ipsilat. mediast.), N3 (contralat., supraclav.)] and presence of metastases (M) (Chest 2017;151:193). Pleural effusions/implants = Stage IV.</li></ul><p>5-y survival: ~70–90% for stage I, 50–60% stage II, 15–35% stage III, 0–10% stage IV (J Thorac Oncol 2016;11:39); survival improving with newer therapies (NEJM 2020;383:640).</p><ul><li>Imaging: CT w/ contrast of chest & abd/pelvis to assess for mets (adrenal, liver, bones).</li></ul><p>PET-CT more Se than CT alone for detecting mediastinal and distant mets as well as</p><p>bone mets (NEJM 2009;361:32). Brain MRI for all Pts except stage IA.</p><ul><li><p>Pathology: via bronchoscopy (central lesions) or CT-guided needle bx (peripheral lesions or accessible sites of suspected metastasis); mediastinoscopy (LN bx / eval), VATS (eval. of pleural peripheral lesions), thoracentesis if pleural effusion (cytology).</p></li><li><p>Genetics (usually just in adv/metastatic disease): ✓ EGFR (include in stage IIA-IIIB), ALK, ROS1, MET, KRAS, RET, BRAF, NTRK fusion for all non-squamous disease (incidence lower in SCC but still consider testing); PD-L1 expression</p></li><li><p>PFTs w/ quant V/Q if Rx includes resection; need 30% nl predicted lung fxn after resection</p></li></ul><p>NSCLC Treatment (NCCN Guidelines v.7.2021; Lancet 2021;398:535)</p><ul><li><p>Localized disease: surgery if possible; RT (eg, stereotactic ablative radiotherapy [SABR]) vs. chemo/RT if not (see Figure 5-7)</p></li><li><p>Metastatic disease: >20 new Rx since 2015. Some targeted Rx substantially improves survival & are better tolerated (see Stage IV Rx table); however, 5-y survival still poor.</p></li></ul><p>First-line immunotherapy (IO) ± chemo for most Pts w/o targetable mutations.</p><p>Pemetrexed + pembrolizumab often continued as maintenance when used.</p><p>Palliative care ↑ survival (NEJM 2010;363:733); palliative RT for local sx from tumor/mets.</p><ul><li><p>Avoid combining IO & targeted Rx, ↑↑ tox (eg, rash/diarrhea, lung/liver injury [can be fatal])</p></li><li><p>Solitary brain metastasis (oligomet): surgical resection + brain radiation may ↑ survival</p></li></ul><p>Figure 5-7 Localized NSCLC treatment algorithm</p><p>(NCCN Guidelines v7.2021; NEJM 2017:377:1919, 2018;378:113, & 2020;383:1711; Lancet 2021;398:1344)</p><p>Stage IV NSCLC Treatment</p><p>Type</p><p>Genetics</p><p>%</p><p>Treatment</p><p>Adeno or Other</p><p>EGFR</p><p>~15</p><p>1st line: osimertinib if L858R, ex19del (NEJM 2018;378:113)</p><p>EGFR ex20 insertion</p><p>2–3</p><p>Subsequent Rx w/ amivantamab (JCO 2021;39:3391) or mobocertinib (JAMA Onc 2021;7:e214761) after platinum chemo</p><p>ALK</p><p>~4</p><p>1st line: alectinib pref. b/c CNS activity (NEJM 2017;377:829)</p><p>ROS1</p><p>2</p><p>Crizotinib pref. (JCO 2017;35:2613); entrectinib (Lancet Onc 2020;21:261)</p><p>MET ex14 skip or amplif.</p><p>3</p><p>Capmatinib (NEJM 2020;383:944) or tepotinib (NEJM 2020;383:931)</p><p>RET</p><p>1</p><p>Selpercatinib (NEJM 2020;383:813) or pralsetinib (Lancet Onc 2021;22: 959-969)</p><p>BRAF V600E</p><p>1–3</p><p>Dabrafenib + trametinib (Lancet Onc 2016;17:984)</p><p>NTRK fusions</p><p>&lt;1</p><p>Larotrectinib (NEJM 2018;378:731)</p><p>KRAS G12C</p><p>~13</p><p>Subsequent Rx w/ sotorasib (NEJM 2021;384:2371)</p><p>PD-L1≥50%</p><p>30</p><p>Pembrolizumab or chemo + pembro (NEJM 2018;378:2078)</p><p>No targets & PD-L1 &lt;50%</p><p>Chemo (carbo/pemetrexed) + pembro (NEJM 2018;378:2078) or carbo/paclitaxel + anti-VEGF Ab (bevacizumab) + atezo (NEJM 2018;378:2288)</p><p>Squam</p><p>PD-L1 ≥50%</p><p>Pembrolizumab or chemo/pembro (NEJM 2016;375:1823)</p><p>PD-L1 &lt;50%</p><p>Chemo [carbo/paclitaxel] + pembro (NEJM 2018;379:2040)</p><p>Many are specific tyrosine kinase inhibitors (‘tinibs) directed against EGFR, ALK, etc. Amivantamab is an EGFR- MET bispecific mAb. Pembrolizumab is a mAb against PD-1 on lymphocytes (ie, an immune checkpoint inhibitor).</p><p>SCLC staging and treatment (NCCN Guidelines v.1.2022)</p><ul><li><p>SCLC usually disseminated at presentation; poor overall survival</p></li><li><p>Can be very responsive to chemotherapy, but rapidly develop resistance</p></li><li><p>Diagnosis: all have Rb & p53 mutations (Nature 2015;524:47); 90% w/ neuroendo markers</p></li><li><p>Treatment: primarily chemo (platinum + etoposide); adding anti-PD-L1 Ab (atezolizumab)</p></li></ul><p>↑ survival (NEJM 2018;379:2220), as does concurrent thoracic RT in limited-stage disease</p><ul><li><p>Prophylactic cranial irradiation (PCI) controversial. Offered to potentially ↑ survival for LS-SCLC in complete remission (NEJM 1999;341:476). Role in ES-SCLC being studied.</p></li><li><p>Second line: low response rates, short survival. Options: lurbinectedin, single-agent chemo (eg, topotecan, docetaxel), reRx w/ platinum doublet, anti-PD-1 (eg, nivo).</p></li></ul><p>BREAST CANCER</p><p>Epidemiology</p><ul><li><p>In U.S., most common cancer in women; 2nd leading cause of cancer death in women</p></li><li><p>Genetic risk: 15–20% ⊕ FHx → 2× ↑ risk; ~45% familial cases a/w germline mutation.</p></li></ul><p>BRCA1/2: 35–85% lifetime risk of breast ca. Germline loss-of-function mutations in PALB2 a/w 35% ↑ risk breast cancer by age 70. Moderate risk mutations CHEK2 and BARD1 a/w 15–30% lifetime risk of breast cancer (NEJM 2021;384:428).</p><ul><li><p>Estrogen: ↑ risk with early menarche, late menopause, late parity or nulliparity (NEJM 2006;354:270); ↑ risk with prolonged HRT (RR = 1.24 after 5.6 y; JAMA 2003;289:3243); OCP use a/w extremely low to no ↑ risk (NEJM 2017:317:2228; JAMA Oncol 2018;4:516)</p></li><li><p>Benign breast conditions: ↑ risk if atypia (atypical ductal or lobular hyperplasia; NEJM 2015;372:78) or proliferative (ductal hyperplasia, papilloma, radial scar, or sclerosing adenosis) features; no ↑ risk w/ cysts, simple fibroadenoma, or columnar changes</p></li><li><p>↑ risk with h/o ionizing radiation to chest for treatment of Hodgkin lymphoma</p></li></ul><p>Prevention (if high-risk: eg, FHx, LCIS, atypical hyperplasia)</p><ul><li><p>Tamoxifen (contraindic. in preg): ↓ risk contralateral breast ca as adjuvant Rx. Approved for 1° prevent. if ↑ risk: ↓ invasive breast cancer, but ↑ DVT & uterine ca.</p></li><li><p>Raloxifene (only if post-menopausal): ↓ risk of invas breast ca, vertebral fx, & uterine ca, ↑ risk stroke & DVT/PE (NEJM 2006;355:125); less effective than tamoxifen for prevention.</p></li><li><p>Aromatase inhib. (post-menopausal): ↓ risk >50% (Lancet 2014;383:1041), ↑ osteoporosis</p></li><li><p>BRCA1/2 ⊕: intensified surveillance vs. prophylactic bilat. mastectomy which ↓ risk ~90%; bilat. salpingo-oophorectomy ↓ risk of ovarian and breast cancer (NEJM 2016;374:454)</p></li></ul><p>Clinical manifestations</p><ul><li><p>Breast mass (hard, irregular, fixed, nontender), nipple discharge (higher risk if unilateral, limited to 1 duct, bloody, associated with mass)</p></li><li><p>Special types: Paget disease → unilateral nipple eczema + nipple discharge; inflammatory breast cancer → skin erythema and edema (peau d’orange)</p></li><li><p>Metastases: lymph nodes, bone, liver, lung, brain</p></li></ul><p>Screening (JAMA 2015;314:1599; Annals 2019;170:547)</p><ul><li><p>Mammography: ~20–30% ↓ in breast cancer mortality, smaller abs. benefit in women &lt;50 y (JAMA 2018;319:1814); digital breast tomosynthesis (3-D) ↑ specificity (JAMA Oncol 2019;5:635); suspicious findings: clustered microcalcifications, spiculated, enlarging</p></li><li><p>ACS: annual mammo starting at 45 (consider biennial after 54), cont. if life expect ≥10 y</p></li><li><p>USPSTF: screen biennially ages 50–75 (some may want to begin at 40)</p></li><li><p>↑ risk: screen earlier w/ exam and mammo (age 25 in BRCA1/2 carrier, 5–10 y before earliest FHx case, 8–10 y after thoracic RT, upon dx of ↑ risk benign disease)</p></li><li><p>MRI: superior to mammo in high-risk and young Pts; consider annually if >20% lifetime risk (eg, ⊕ FHx, BRCA1/2, prior chest RT) (Lancet 2011;378:1804)</p></li><li><p>Germline genetic testing: if metastatic, TNBC, ♂, age ≤45y, or by FHx (NCCN v1.2022)</p></li></ul><p>Diagnostic evaluation</p><ul><li>Palpable breast mass: age &lt;30 y → observe for resolution over 1–2 menstrual cycles; age &lt;30 y, unchanging mass → U/S → aspiration if mass not simple cyst;</li></ul><p>age >30 y or solid mass on U/S or bloody aspirate or recurrence after aspiration → mammo (detect other lesions) and either fine-needle asp. or core-needle bx</p><p>clearly cancerous on exam or indeterminate read or atypia on bx → excisional bx</p><ul><li><p>Suspicious mammogram with normal exam: stereotactically guided bx</p></li><li><p>MRI: detects contralateral cancer in 3% of Pts w/ recently dx breast cancer & contra-lateral mammo (but PPV only 21%) (NEJM 2007;356:1295); utility remains unclear</p></li></ul><p>Staging</p><ul><li><p>Anatomic: tumor size, chest wall invasion, axillary LN mets (strongest prognostic factor)</p></li><li><p>Histopathologic: type (little prognostic relevance) & grade; lymphatic/vascular invasion</p></li></ul><p>In situ carcinoma: no invasion of surrounding stroma</p><p>Ductal (DCIS): ↑ risk of invasive cancer in ipsilateral breast (~30%/10 y)</p><p>Lobular (LCIS): benign entity; marker of ↑ risk of inv. cancer in either breast (~1%/y)</p><p>Invasive carcinoma: infiltrating ductal (70–80%); invasive lobular (5–10%); tubular, medullary and mucinous (10%, better prognosis); papillary (1–2%); other (1–2%)</p><p>Inflammatory breast cancer (see above): not a histologic type but a clinical reflection of tumor invasion of dermal lymphatics; very poor prognosis</p><p>Paget disease (see above): ductal cancer invading nipple epidermis ± associated mass</p><ul><li><p>Tissue biomarkers: estrogen and progesterone receptor (ER/PR), HER2</p></li><li><p>Oncotype DX 21-gene expression recurrence score predicts which ER ⊕, HER2 ⊖ will have minimal benefit from adjuvant chemo in LN ⊖ (NEJM 2018;379:111) and LN ⊕ (1–3) disease (NEJM 2021;385:2336)</p></li></ul><p>Simplified Staging & 5-y Dis. Specific Survival (CA Cancer J Clin 2017;67:290; SEER 2017)</p><p>Stage</p><p>Characteristics</p><p>Description</p><p>5-y DSS</p><p>I</p><p>Tumor ≤2 cm</p><p>Operable</p><p>locoregional</p><p>99%</p><p>IIA</p><p>Tumor >2 cm or mobile axillary nodes</p><p>98%</p><p>IIB</p><p>Tumor >5 cm or 2–5 cm w/ mobile nodes</p><p>96%</p><p>IIIA</p><p>Internal mammary or fixed axillary nodes</p><p>Locally advanced</p><p>95%</p><p>IIIB/C</p><p>Chest wall, skin, infra or supraclavic. nodes</p><p>Inoperable</p><p>80–85%</p><p>IV</p><p>Distant metastases</p><p>Metastatic</p><p>27%</p><p>General Approach to Treatment (JAMA 2019;321:288 & 1716)</p><p>DCIS</p><p>Mastectomy or lumpectomy ± RT ± chemoprevention (Lancet 2016;387:849 & 866)</p><p>I</p><p>Surgery + RT</p><p>II</p><ul><li><p>adjuv. chemo if ↑ risk: tumor >2 cm or ⊕ LN or triple ⊖ or Oncotype DX-guided</p></li><li><p>hormonal Rx for ER/PR ⊕: add ovarian suppression if ↑ risk (NEJM 2018; 379:122)</p></li><li><p>anti-HER2 Rx and chemo if HER2 ⊕ and tumor ≥1 cm or ⊕ LN</p></li></ul><p>III</p><p>Neoadjuvant chemo → surgery + RT ± adjuvant chemotherapy</p><ul><li><p>hormonal Rx for ER/PR ⊕: add ovarian suppression if premenopausal</p></li><li><p>anti-HER2 Rx for HER2 ⊕: usually trastuzumab + pertuzumab</p></li></ul><p>IV</p><p>ER/PR ⊕: combined aromatase & CDK4/6 inhibitors (NEJM 2016; 375:1925)</p><p>ER/PR ⊖/HER2 ⊕: chemo + anti-HER2 therapy</p><p>Triple ⊖: chemo ± immune checkpoint inhibitor</p><p>Bony mets: bisphosphonates & denosumab ↓ fractures (Cochrane 2017;CD003474)</p><p>Surgery and Radiation for Local Control</p><p>Intervention</p><p>Indication</p><p>Breast conserving</p><p>Stage I–II, lumpectomy + sentinel lymph node biopsy* + RT</p><p>Modified radical</p><p>mastectomy</p><p>Large tumor relative to breast, multicentric dis., prior chest</p><p>RT, diffuse microcalcifications, ⊕ margins after lumpectomy</p><p>Post mastectomy</p><p>Radiation</p><p>≥4 ⊕ LN, tumor >5 cm, ⊕ surgical margins, chest wall or skin</p><p>involvement (Lancet 2014;384:1848)</p><p>*Axillary lymph node dissection indicated for palpable axillary LNs</p><p>Systemic Therapy</p><p>Indic.</p><p>Class</p><p>Examples</p><p>ER/PR ⊕</p><p>(Lancet 2017;389: 2403)</p><p>Endo (NEJM 2019;380: 1226)</p><p>Tamoxifen: adjuvant Rx for low-risk pre-meno; ↓ recurrence & ↓ mortality; 10 y superior to 5 y (Lancet 2011;378:771 & 2013;381:805)</p><p>Aromatase inhib (AI; anastrozole, letrozole, exemestane): adjuvant Rx for post-meno; ↑ OS vs. tam. (Lancet 2015;386:1341); 7 y of Rx ↑ DFS vs. 5 y of Rx (NEJM 2021;385:395)</p><p>Adding selective ER degrader (fulvestrant) to AI ↑ OS if mets</p><p>Ovarian suppress.</p><p>LHRH agonists (eg, leuprolide) or oophorectomy: adjuvant Rx for high-risk pre-meno combined with tam. or AI (NEJM 2018;379:122)</p><p>Cell prolif.</p><p>(NEJM 2012;366: 520)</p><p>CDK 4/6 inhib (eg, palbociclib, abemaciclib, ribociclib): + AI (1st-line metastatic Rx) or fulvestrant ↑ PFS (& OS for ribociclib) in stage IV vs. AI alone (NEJM 2018;379:1926; JCO 2017;35:3638); + AI for adjuvant (Ann Onc 2021;32:1571)</p><p>mTOR inhib (everolimus): + AI (exemestane) ↑ OS in stage IV</p><p>PIK3CA ⊕</p><p>PI3K inhib</p><p>Alpelisib + fulvestrant ↑ PFS in met HR⊕ (NEJM 2019;380:1929)</p><p>HER2 ⊕</p><p>(Lancet 2017;389: 2415)</p><p>HER2- targeted</p><p>Trastuzumab (anti-HER2): 1st-line Rx combined w/ chemo</p><p>Trastuzumab emtansine (mAb linked to chemo): ↓ risk of recurrence/death if residual disease post neoadj. Rx (NEJM 2019;380:617); preferred 2nd line Rx for met. disease</p><p>Trastuzumab deruxtecan (mAb linked to chemo): emerging data as 2nd line Rx for met disease, ↓ risk disease progression vs. trastuzumab emtansine, ↑ lung toxicity (NEJM 2022;386:1143)</p><p>Margetuximab (anti-HER2): combined w/ chemo preferred after 2+ lines of Rx (JAMA Oncol 2021;7:573)</p><p>Stage I–III (above)</p><p>Chemo</p><p>Neoadjuvant: to conserve breast & evaluate Rx efficacy, equivalent OS as adjuvant (JCO 2008;26:778)</p><p>Adjuvant: use anthracycline ± taxane. Nb, endocrine only for some ER/PR ⊕ based on oncotype Dx (see staging).</p><p>Triple ⊖</p><p>Immune</p><p>Pembrolizumab (anti-PD-1 mAb) + chemo 1st-line for early stage (NEJM 2020;382:810) & PD-L1 ⊕ met dis. (Lancet 2020;396:1817)</p><p>Ab-drug conjugate</p><p>Sacituzumab govitecan: anti-trop-2 Ab linked to chemo ↑ PFS & OS in heavily pre-Rx’d metastatic disease (NEJM 2019;380:741)</p><p>BRCA ⊕</p><p>PARP inh</p><p>Olaparib & talazoparib (NEJM 2017;377:523 & 2018;379:753)</p><p>DFS, disease-free survival; OS, overall survival; PFS, progression-free survival</p><p>PROSTATE CANCER</p><p>Epidemiology and risk factors (NEJM 2003;349:366)</p><ul><li><p>Most common cancer in U.S. men; 2nd most common cause of cancer death in men</p></li><li><p>Lifetime risk of prostate cancer dx ~16%; lifetime risk of dying of prostate cancer ~3%</p></li><li><p>↑ risk with ↑ age (rare if &lt;45 y), in African Americans, ⊕ FHx, BRCA mutations</p></li></ul><p>Clinical manifestations</p><ul><li><p>Most prostate cancers (78%) are asymptomatic and localized at diagnosis</p></li><li><p>Metastatic dis. sx primarily from bone mets: bone pain, spinal cord compression, cytopenias</p></li></ul><p>Screening (JAMA 2014;311:1143; Lancet 2014;384:2027)</p><ul><li><p>PSA: 4 ng/mL cut point neither Se nor Sp; can ↑ with BPH, prostatitis, acute retention, after bx or TURP, and ejaculation (no significant ↑ after DRE, cystoscopy); 15% of men >62 y w/ PSA &lt;4 & nl DRE have bx-proven T1 cancer (NEJM 2004;350:2239)</p></li><li><p>Digital rectal exam no longer recommended due to limitations, no mortality benefit</p></li><li><p>ACS rec: ≥50 y (or ≥45 y AA or ⊕ FHx) discuss PSA screening, informed decision making</p></li><li><p>USPSTF (JAMA 2018;319:1901) rec discuss pros/cons w/ Pt (no ↓ in prostate ca-related mort.)</p></li></ul><p>Diagnostic evaluation, staging, and treatment (NCCN Guidelines v1.2022)</p><ul><li><p>Transrectal ultrasound (TRUS) guided biopsy (6–12 cores)</p></li><li><p>Multiparametric MRI (± endorectal coil): improves detection (NEJM 2018;378:1767)</p></li><li><p>Gleason score & grade group (histology): Gleason score determines Grade Group. 1 = best → 5 = worst. Group 1: 3+3=6 (most common histologic pattern is 1st #, next is 2nd #), Group 2: 3+4=7, Group 3: 4+3=7, Group 4: 4+4=8, Group 5: all higher.</p></li></ul><p>*In asx Pts w/ life expect ≤5 y & very low-to-intermed risk dis., no w/up or Rx until sx. NCCN Guidelines v1.2022</p><p>†RP more short-term impotence (unless ADT) & incont than RT; over yrs → similar (NEJM 2016;375:1425)</p><p>Treatment of Metastatic Prostate Cancer (NCCN Guidelines v1.2022)</p><p>Androgen deprivation therapy (ADT)</p><p>Prostate ca requires androgen signaling for growth. ADT backbone of Rx.</p><p>Med: 1. Luteinizing hormone-releasing hormone (LHRH) agonist (eg, leuprolide) ± 1st-gen anti-androgen (nilutamide, bicalutamide), or</p><ol start=2><li>LHRH antagonist (degarelix)</li></ol><p>Surgery: bilateral orchiectomy</p><p>Hormone- sensitive prostate cancer (HSPC)</p><p>Def: ADT sensitive (ie, PSA ↓ w/ Rx): all prostate ca initially sensitive</p><p>Workup/testing: PEx & PSA q 3–6 mos; sx-guided imaging</p><p>Rx: 1. ADT alone (only if minimal disease, eg, rising PSA); or</p><ol start=2><li><p>ADT + abiraterone/pred or enza/apalutamide (↑ OS vs. ADT alone); or</p></li><li><p>Docetaxel + ADT (↑ OS vs. ADT alone, espec. in high-volume disease)</p></li></ol><p>Castration-resistant prostate cancer (CRPC)</p><p>Always continue ADT</p><p>Def: All met. HSPC eventually becomes CRPC (ie, progression despite castration androgen levels on ADT), due to re-estab. of androgen signaling via other mech. ∴ more potent anti-androgens are needed.</p><p>Rx: New-gen. anti-androgens: abiraterone (biosynth inhib.) + pred, or enza/daro/apalutamide (receptor blocker) ↑ PFS & OS</p><p>Targeted: BRCA1/2, ATM (homologous recomb genes, ~20%): olaparib; MSI-H/Lynch syndrome (2–5%): pembro; Cancer vaccine: Sipuleucel-T</p><p>Chemo: doce/cabazitaxel +pred/dex+Luetitium-177 (NEJM 2021;385:1091)</p><p>Bone-active agents: 1. denosumab or zoledronic acid ↓ skeletal-related events (SREs); 2. radium-223 used in bone-only dis, ↓ SREs & ↑ OS</p><p>(NEJM 2017;377:338 & 352; 2019;381:121; 2019;381:13; Lancet 2016;387:1163)</p><p>Prognosis and monitoring</p><ul><li><p>PSA level, Gleason score/grade group and age are predictors of metastatic disease</p></li><li><p>In surgically treated Pts, 5-y relapse-free survival >90% (excellent) if disease confined to organ, ~75% if extension through capsule, and ~40% if seminal vesicle invasion</p></li><li><p>PSA q6mo for 5 y if curative Rx; consider PET Axumin scan if ↑ PSA ± equivocal bone scan</p></li></ul><p>COLORECTAL CANCER (CRC)</p><p>Epidemiology and risk factors (CA Cancer J Clin 2018;68:7)</p><ul><li><p>4th most common cancer in U.S. men & women; 2nd leading cause of all cancer death</p></li><li><p>90% of cases occur after age 50. ~75% are sporadic.</p></li><li><p>IBD a/w ~0.3%/y ↑ risk of CRC. ↑ risk w/ ↑ extent and duration of disease.</p></li></ul><p>Heritable Genetic Syndromes</p><p>Disorder</p><p>CRC risk</p><p>Pathophysiology</p><p>Assoc Cancers</p><p>Hereditary nonpolyposis colorectal cancer (HNPCC or Lynch)</p><p>~80%</p><p>lifetime</p><p>Most common hered. CRC (~3%). Mismatch repair mut (eg, MSH2, MLH1). Dx: ≥3 family HNPCC cancer, 1 dx before 50 y, involves 2 gen. Typically right-sided.</p><p>Endometrial, ovarian, stomach, urothelial, small bowel & pancreas</p><p>Familial adeno polyposis (FAP)</p><p>100% lifetime</p><p>Mutation in APC gene → 1000s of polyps at young age</p><p>Thyroid, stomach, small bowel</p><p>MUTYH-assoc. polyposis (MAP)</p><p>40–100% lifetime</p><p>Autosomal recessive; consider if mult. polyps but ⊖ for FAP</p><p>Duodenal, ovarian, bladder, skin</p><ul><li>ASA rec for 1° prev. if 50–59 y & ≥10% 10-y CRC risk. Must take for at least 10 years.</li></ul><p>Screening (JAMA 2021;325:1965)</p><ul><li><p>Average-risk Pts: start at age 45, repeat q1–10y based on screening modality</p></li><li><p>↑ risk Pts: ⊕ FHx: screen age 40 or 10 y before index dx, then q5y. IBD: colo 8–10 y after dx, then q1–2y. Suspect familial syndrome: genetic counsel, screen age 20–25, yearly.</p></li><li><p>Colonoscopy: preferred; 90% Se for lesions >1 cm. If polyp, re ✓ in 3–5 y. Adenomatous polyp removal a/w ↓ CRC mortality (NEJM 2012;366:687). Adenoma: ↑ risk of malig. if >2.5 cm, villous, or sessile; can progress to CRC over ~10 y interval (sporadic & familial).</p></li><li><p>Sigmoidoscopy: benefit w/ 1-time flex-sig (Lancet 2017;389:1299); less Se than colo or CTC</p></li><li><p>CT colonography (CTC): ~90% Se for lesions ≥1 cm but less if smaller (NEJM 2008;359:1207). If high-risk, Se only 85% for neoplasia ≥6 mm (JAMA 2009;301:2453).</p></li><li><p>Combo DNA + Hb immunoassay w/ ~90% Se & Sp (NEJM 2014;370:1287)</p></li><li><p>Occult blood (FOBT): use 3-card home testing (Se 24%) yearly</p></li></ul><p>Clinical manifestations</p><ul><li><p>Distal colon: Δ bowel habits/ caliber, obstruction, colicky abd. pain, hematochezia</p></li><li><p>Proximal colon: iron defic. anemia, dull vague abd pain, liquid stool</p></li><li><p>Associated with Streptococcus bovis bacteremia and Clostridium septicum sepsis</p></li></ul><p>Cancer genetics (Nature 2014;513:382)</p><ul><li><p>Microsatellite stable (MSS) vs. high instability (MSI-H): latter sign of mismatch repair gene failure, accounts for 15% CRC, presents more often as early stage, ~5% of met dis.</p></li><li><p>Mutations: APC (~80%); KRAS (~40%); TP53 (50–70%); DCC, SMAD4, BRAF (~15%), HER2 amplification (&lt;5%)</p></li></ul><p>Staging and treatment (NCCN Clin Pract Guidelines; version 3.2021)</p><ul><li><p>TNM staging, including CT chest and abdomen/pelvis with contrast ± MRI pelvis for rectal</p></li><li><p>Baseline CEA: monitor post resection or follow response; not for screening</p></li><li><p>Chemo options (Lancet 2014;383:1490): 5-FU/leucovorin (LV) foundation. 5-FU/LV + oxaliplatin &/or irinotecan (FOLFOX, FOLFIRI, FOLFOXIRI, resp). Capecitabine oral 5-FU prodrug. TAS102 (trifluridine + tipiracil) in progressive disease (NEJM 2015;372:1909).</p></li></ul><p>Anti-VEGF (bevacizumab) added to chemo ↑ OS in all subsets of mCRC.</p><ul><li><p>Targeted therapy: anti-EGFR mAb (cetuximab or panitumumab) in unmutated KRAS/NRAS/BRAF (NEJM 2013;369:1023), better for L-sided disease; encorafienib + cetuximab + binimetinib in BRAF V600E (NEJM 2019;381:1632)</p></li><li><p>ImmunoRx: anti PD-1 (NEJM 2020;383:2207) ± CTLA-4 in MSI-H/ MMRd met CRC</p></li><li><p>Radiation: loc. adv. rectal (T3/N+) & colon (unresectable); consider for oligo-mets</p></li></ul><p>TNM</p><p>Path. Criteria</p><p>5-y Surv.</p><p>Treatment</p><p>I</p><p>Submucosa/muscularis</p><p>94–97%</p><p>Surgery alone (resect & analyze ≥12 LN)</p><p>IIA</p><p>Serosa</p><p>83%</p><p>Surgery. Consider adjuvant chemo for high-risk Stage II: obstruction, perf, adherence, inadequate LN sampling (&lt;12 LNs).</p><p>IIB</p><p>Peritoneum</p><p>74%</p><p>IIC</p><p>Direct invasion</p><p>56%</p><p>IIIA</p><p>≤6 ⊕ LNs</p><p>86%</p><p>Surgery + FOLFOX (6 mo)</p><p>or CAPOX (3–6 mo) (NEJM 2018;378:13)</p><p>Pre RT ± chemo if rectal (NEJM 2006;355:1114)</p><p>IIIB</p><p>Varying # ⊕ LNs & local invasion</p><p>51–77%</p><p>IIIC</p><p>15–47%</p><p>IV</p><p>Distant metastases* (NEJM 2014;371:1609)</p><p>5%</p><p>Chemo (FOLFOXIRI if high-risk) ± anti-PD-1 (MSI-H only) ± resect isolated mets</p><p>*Oligometastatic dis (few, limited mets) sometimes still curable w/ chemo + metastatectomy/radiation</p><p>PANCREATIC TUMORS</p><p>Genetics and path (Nat Rev Dis Primers 2016;2:16022)</p><ul><li><p>Histologic types: adenocarcinoma (~85%), acinar cell carcinoma, endocrine tumors, cystic neoplasms (&lt;10%); rarely, mets to pancreas (eg, lung, breast, renal cell)</p></li><li><p>Location: ~60% in head, 15% in body, 5% in tail; in 20% diffuse infiltration of pancreas</p></li><li><p>Adeno. mut.: KRAS (>90%), p16 (80–95%), p53 (50–75%), SMAD4 (~55%), BRCA (10%)</p></li></ul><p>Epidemiology and risk factors (Lancet 2016;388:73)</p><ul><li><p>4th leading cause of cancer death in U.S.; 80% panc adeno in ages 60–80 y; M>F (1.3:1)</p></li><li><p>Acquired risk factors: smoking (RR ~1.5; 25% cases), obesity, chronic pancreatitis, T2DM</p></li><li><p>Hereditary (5–10%): familial breast/ovarian CA (BRCA2); hereditary chronic pancreatitis (mutation in cationic trypsinogen gene (PRSS1, SPINK1); familial cancer syndromes: atypical multiple mole melanoma (CDKN2A/p16), Peutz-Jeghers (LKB1), ataxia-telang.</p></li></ul><p>Clinical manifestations</p><ul><li><p>Painless jaundice (w/ pancreatic head mass), pain radiates to back, ↓ weight & appetite</p></li><li><p>New-onset atypical DM (25%); migratory thrombophlebitis (Trousseau’s syndrome)</p></li><li><p>Exam: jaundice, RUQ/epigastric nontender mass, palpable gallbladder (Courvoisier’s sign); hepatomegaly; ascites; L supraclavicular node (Virchow’s)</p></li><li><p>Laboratory tests may show ↑ bilirubin, ↑ alk phos, anemia</p></li></ul><p>Diagnostic and staging evaluation (NCCN Guidelines v.2.2021)</p><ul><li><p>Pancreatic protocol CT scan (I+ w/ arterial & venous phase imaging) or MRI w/ contrast</p></li><li><p>If no lesion seen but concerning signs & sx as above → EUS, ERCP, or MRCP</p></li><li><p>Biopsy pancreatic lesion via EUS-guided FNA (pref. for surgical candidates) or CT-guided (risk of seeding); if possible metastases, biopsy those for staging and dx.</p></li><li><p>✓ CA19-9 preop (nb, can be ↑ in benign liver/biliary dis.); may be useful to trend postop</p></li><li><p>Germline genetic testing for all Pts with pancreatic cancer</p></li></ul><p>Clinical (Radiologic) Staging Pancreatic Adenocarcinoma</p><p>Resectable</p><p>No extrapanc. dis. or bulky LAN; no arterial tumor contact [celiac axis (CA), SMA, common hepatic (CHA)]; and no venous contact [SMV, portal vein (PV)] or ≤180° + patent veins (ie, no tumor thrombus)</p><p>Borderline resectable</p><p>No extrapanc dis. or bulky LAN. Head/uncinate: contact w/ CHA (no extension to CA or HA bifurcation), SMA contact ≤180°, variant anatomy.</p><p>Body/tail: contact CA ≤180° or >180° but w/o gastro-duodenal art. or aortic. Venous: SMV & PV contact ≤180° w/ contour irreg; contact w/ IVC.</p><p>Unresect.</p><p>Distant mets; or head/uncinate: contact >180° SMA, CA; or</p><p>Body/tail: contact >180° SMA or CA; CA & aortic involvement; or</p><p>Venous: SMV/PV involvement/not reconstructible</p><p>Treatment of pancreatic adenocarcinoma (Lancet 2016;388:73)</p><ul><li>Resectable: pancreaticoduodenectomy (Whipple procedure) + adjuvant chemo:</li></ul><p>modified FOLFIRINOX (5-FU + leucovorin, irinotecan, oxaliplatin) if ECOG 0-1</p><p>(NEJM 2018;379:2395), o/w gemcitabine + capecitabine (Lancet 2017;389:1011). Gemcitabine</p><p>monoRx recently standard, but now w/ ↓ role. Role of RT is controversial.</p><ul><li><p>Borderline: goal to ↓ tumor to allow complete resection (R0 – neg margin at histology) using neoadjuvant Rx (various approaches tested). General schema: chemo ± RT → restage & potential resection depending on response. May need vasc. reconstruction during resection. Regimens include: FOLFIRINOX; gemcitabine + nab-paclitaxel.</p></li><li><p>Locally advanced (ie, unresectable): Rx is typically palliative. However, in highly select Pts recent trend toward Rx w/ FOLFIRINOX plus XRT followed by laparotomy for response assessment (imaging can be unreliable) and potential resection.</p></li><li><p>Metastatic: clinical trials preferred; Rx based on performance status (PS)</p></li></ul><p>Good PS: FOLFIRINOX, gemcitabine + nab-paclitaxel (NEJM 2013;369:1691); germline BRCA1/2 mut: maintenance olaparib (NEJM 2019;381:317) also ↑ response to platinum combination chemo (eg, cisplatin w/ gemcitabine), ICI for MSI-high.</p><p>Poor PS: gemcitabine; capecitabine; continuous infusion 5-FU</p><ul><li>Palliative care: Biliary/gastric outlet obstruct.: endoscopic stenting, IR drain, surg bypass. Pain: opiates, celiac plexus neurolysis, XRT. Wt loss: enzyme replacement.</li></ul><p>Prognosis</p><ul><li><p>Resectable: if Rx’d w/ adjuvant FOLFIRINOX, 50+ mos, o/w ~30 mos</p></li><li><p>Unresectable: if locally advanced ~1–2 y; if metastatic, ~1 y</p></li></ul><p>Cystic lesions of the pancreas (Am J Gastroenterol 2018;113:464)</p><ul><li><p>Serous cystadenoma: usually benign; central scar or honeycomb appearance on imaging</p></li><li><p>Mucinous cystic neoplasm (MCN): predominantly young females; multiloculated tumors in body or tail w/ ovarian-type stroma and mucin-rich fluid w/ ↑ CEA levels; precancerous</p></li><li><p>Intraductal papillary mucinous neoplasm (IPMN): arises in main panc duct or branch</p></li></ul><p>OTHER SOLID TUMORS</p><p>HEPATOCELLULAR CARCINOMA (HCC)</p><p>Risk factors (globally, 3rd leading cause of cancer death, espec. in Africa & Asia)</p><ul><li><p>Cirrhosis: present in 70–90% HCC cases</p></li><li><p>Infectious: HCV & HBV (~75%), HBV/HDV coinfection; HBV can cause HCC w/o cirrhosis</p></li><li><p>Toxic: EtOH (⅓ cases in U.S.), tobacco, aflatoxin from Aspergillus</p></li><li><p>Metabolic disorders: NASH, DM, autoimmune hepatitis, hemochromatosis</p></li></ul><p>Screening (screen high-risk Pts: cirrhosis, chronic HBV)</p><ul><li><p>Ultrasonography (U/S) + AFP q 6 mos; if high-risk may alternate U/S w/ MRI</p></li><li><p>If lesion found or increasing AFP, perform 3-phase contrast CT or MRI</p></li></ul><p>Clinical manifestations</p><ul><li><p>Exam: nonspec. c/w liver dysfxn (eg, hepatomegaly, ascites, jaundice, encephalopathy)</p></li><li><p>Labs: coagulopathy, low albumin, elevated LFTs; r/o other etiologies of liver dysfxn</p></li></ul><p>Diagnosis</p><ul><li><p>Can diagnose w/o biopsy in high-risk Pts with 3-phase contrast CT or MRI</p></li><li><p>Only 15% of liver masses are HCC; liver metastases from other 1° more common</p></li></ul><p>Treatment (NEJM 2019;380:1450)</p><ul><li><p>Localized disease (goal = cure) → resection if feasible (preferred), ablation, transarterial chemoembolization, or radiotherapy (SBRT) also options. Inadequate hepatic reserve → liver transplant if able (NEJM 1996;334:693); non-surgical local and/or systemic Rx if not.</p></li><li><p>Systemic Rx: atezolizumab (anti-PD-L1) + bevacizumab preferred (NEJM 2020;382:1894), 2nd line: kinase (lenvatinib, sorafenib) or PD-(L)1 inhib (Lancet 2017;389:2492 & 2018;391:1163)</p></li></ul><p>GASTRIC/ESOPHAGEAL CANCER</p><p>Epidemiology (Lancet 2017;390:2383 & 2020;29:635)</p><ul><li><p>Esophageal: Predominantly adenocarcinoma in U.S. (>60%), squamous cell (SCC) more common globally. Risk factors: GERD → Barrett’s esoph (adeno), smoking/EtOH (SCC)</p></li><li><p>Gastric: Predominantly adenocarcinoma. Risk factors include H. pylori, FHx & cancer syndromes (eg, Lynch syndrome), nitrosamines in diet, smoking/EtOH.</p></li></ul><p>Screening</p><ul><li><p>Esophageal: screen for Barrett’s w/ endoscopy if multiple risk factors (eg, hiatal hernia, age ≥50, male, chronic GERD, obese, smoking, FHx). Repeat q3–5y if Barrett’s.</p></li><li><p>Gastric: typically not screened in U.S. More common in regions w/ higher incidence (eg, Japan, Korea, Chile) w/ endoscopy or barium radiographs.</p></li></ul><p>Clinical manifestations</p><ul><li><p>Dysphagia, wt loss, early satiety, nausea, typically occult GI bleed, vague abd discomfort</p></li><li><p>Exam: diffuse seborrheic keratoses (Leser-Trélat sign, though non-specific)</p></li></ul><p>Diagnosis and staging</p><ul><li><p>Both diagnosed w/ endoscopic biopsy. CT chest/abd/pelvis for staging. If no mets → PET/CT (occult mets). If neg → endoscopic ultrasound for locoregional assessment.</p></li><li><p>Staging laparoscopy needed for gastric cancer</p></li><li><p>Molecular: ✓ HER2, PD-L1, microsatellite instability & mismatch repair</p></li></ul><p>Treatment (NCCN Guidelines v5.2021 Gastric & v4.2021 Esophageal)</p><ul><li><p>If localized disease and good performance status/fit, goal is cure with surgery</p></li><li><p>Localized: resection. Periop or neoadjuvant chemo/chemoRT if stage IB or higher (NEJM 2012;366:2074). Adjuvant nivolumab (NEJM 2021;384:1191).</p></li><li><p>Advanced: sequential chemo w/ platinum/fluoropyrimidine (+ trastuzumab if HER2⊕, + nivolumab if PD-L1⊕), ramucirumab (VEGF, 2nd line), nivolumab/pembrolizumab (PD-1, 3rd line)</p></li><li><p>Supportive care: pain/nausea mgmt. Consider G/G-J tube if obstruction, IVF prn.</p></li></ul><p>MELANOMA</p><p>Clinical presentation and workup (NCCN Guidelines v1.2022)</p><ul><li><p>Suspicious skin lesion (ABCDE: asymm, border, color, diameter >6 mm, evolution) → bx</p></li><li><p>Staging: I & II = no regional/distant mets. III = regional LN ⊕ or in-transit/satellite mets. Ulceration & thickness confer substage within I–III. IV = distant mets.</p></li><li><p>Prognosis: excellent if localized dis., ≤1 mm thickness. Varies widely stage IIIA–IIID based on nodal burden (5yr OS 20–70%; ulceration, mitotic rate, & invasion depth predictive).</p></li><li><p>Molecular diagnostics: check for BRAF V600E (present in ~50% of melanomas)</p></li></ul><p>Treatment (NCCN Guidelines v1.2022; NEJM 2021;384:2229)</p><ul><li>Wide surgical excision + sentinel node mapping (unless in situ or low risk of node ⊕).</li></ul><p>If sentinel node ⊕, nodal dissection vs. observation. No difference in survival w/ observation (Lancet Oncol 2016;17:757, NEJM 2017;376:2211).</p><ul><li><p>Checkpoint inhibitors (CPI = pembrolizumab, nivolumab, nivolumab/ipilimumab)</p></li><li><p>BRAF/MEK inhibitors (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) if activating BRAF V600E mutation present</p></li><li><p>Adjuvant for high-risk node ⊕ disease: CPI (↑ RFS, Lancet Onc 2020;21:1465 & JCO 2020;38:3925) or dabrafenib/trametinib (BRAF ⊕, ↑ OS, NEJM 2020;383:1139)</p></li><li><p>Metastatic: CPI mono vs. dual (ipi+nivo a/w improved response rate especially for intracranial mets, NEJM 2018;379:722). Consider targeted Rx if BRAF ⊕.</p></li></ul><p>OVARIAN CANCER</p><p>Histopathology</p><ul><li><p>Epithelial ovarian carcinoma (EOC, 95%): high-grade serous (most common, often dx at late stage, poor prognosis), low-grade serous, endometroid, clear cell, mucinous</p></li><li><p>Non-epithelial (~5%): germ cell, sex cord-stromal. Rare: small cell, sarcoma.</p></li></ul><p>Risk factors for EOC (Nat Rev Dis Primers 2016;2:16061)</p><ul><li><p>Nulliparity, early menarche, late menopause; EOC risk ↑ 2–7% each additional ovulatory yr</p></li><li><p>Genetics: germline testing / genetics referral for all Pts (25% w/ heritable mutation), can inform Rx (eg, PARPi maintenance, JCO 2020;38:1222). 5% risk if one 1st-degree relative w/ ovarian cancer, 3.5% risk if one 2nd-degree relative (Obstet Gynecol 1992;80:700). ↑↑ risk w/ hereditary syndromes: BRCA1/2 (lifetime risk 17%/44%), Lynch syndrome (non-serous).</p></li><li><p>History of pelvic radiation, endometriosis, or obesity (risk association less clear)</p></li></ul><p>Clinical manifestations</p><ul><li><p>Nonspecific history of bloating, pelvic/abdominal pain, bowel sx, urinary sx</p></li><li><p>Exam may reveal palpable pelvic mass, abdominal distention, or ascites</p></li></ul><p>Diagnosis</p><ul><li><p>No screening modalities have shown survival benefit; no data to support at this time</p></li><li><p>If concerning signs/sx (above), obtain pelvic U/S and/or CT A/P or pelvic MRI, CA-125</p></li><li><p>Pathologic dx based on biopsy of lesion or sampling of ascitic fluid</p></li></ul><p>Treatment</p><ul><li><p>Cytoreductive surgery: survival benefit even for stage IV and relapsed disease (Gynecol Oncol 2013;130:493; NEJM 2021;385:2123). Consider neoadj. chemo to ↑ likelihood of maximal cytoreduction at surgery and reduce surgical morbidity.</p></li><li><p>Chemo: 1st line (neoadj., adj., adv.): carboplatin+paclitaxel (CP). PARPi maintenance (olaparib, niraparib, rucaparib; esp if homologous recombination deficient [eg, BRCA1/2]) or bevacizumab maintenance if homologous recombination proficient.</p></li><li><p>Recurrence at >6 mos = platinum sensitive → Rx w/ platinum doublet. If &lt;6 mos = platinum resistant → single agent chemo (eg, liposomal doxorubicin, gemcitabine) ± bevacizumab.</p></li></ul><p>PRIMARY CNS TUMORS AND BRAIN METASTASES</p><p>Presentation and diagnosis</p><ul><li><p>Suspect if new focal neurologic deficits, seizure, memory or balance issues, or evidence of ↑ intracranial pressure (HA, n/v, vision change)</p></li><li><p>MRI brain for suspected CNS tumors; CT less Se. Consider LP if c/f CNS lymphoma.</p></li></ul><p>Primary CNS tumors</p><ul><li><p>Meningioma: histopath. grading (WHO grades). Grade 1 = benign, asx/small → observe. Large or sx → resection if able, radiation if not. Grade 2–3 → resection + adjuvant RT (defer if risk of RT complication high and tumor totally resected).</p></li><li><p>Glioma: histopath. grading, Grade 1/2/3: astrocytoma, oligodendroglioma most common; Grade 4: glioblastoma. Grade 3/4 = “high grade” (Neuro Oncol 2021;23:1231).</p></li><li><p>Notable testing: 1p/19q, IDH, MGMT methylation (predicts sensitivity to temozolomide)</p></li><li><p>Treatment: max resection as feasible → adjuvant RT + temozolomide → surveillance. Steroids if neuro sx, hold until biopsy if c/f 1° CNS lymphoma. Anti-epileptics if seizures.</p></li><li><p>Prognosis based on grade & histology. For glioblastoma, overall survival 12–15 mos, based on extent of tumor resection (J Neurosurg 2014;120:31).</p></li></ul><p>Metastatic CNS Lesions</p><ul><li><p>↑ incidence than 1° CNS. Most common: lung, breast, melanoma, RCC, gastro-esoph.</p></li><li><p>Surgery if oligomet disease or symptomatic & resectable, steroids if neuro sx</p></li><li><p>Radiation particularly if multiple mets or inoperable. Consider WBRT if many mets.</p></li><li><p>Some systemic therapies (checkpoint inhibitors, targeted Rx in NSCLC) have CNS activity</p></li></ul><p>IMMUNOTHERAPY & CELLULAR THERAPY</p><p>IMMUNE CHECKPOINT INHIBITORS (ICI)</p><p>Overview (Science 2018;359:1350)</p><ul><li><p>Immune checkpoints: co-inhibitory signaling molecules that limit immune responses</p></li><li><p>Cytotoxic T-lymphocyte-assoc. protein 4 (CTLA-4): ↓ T cell activation via negative signals and ligand competition w/ CD28 (activating co-stim. molecule).</p></li><li><p>Programmed cell death protein 1 (PD-1): on activated T cells, turns off T cell responses</p></li><li><p>Prog. death-ligand 1 (PD-L1): PD-1 ligand expressed on tumor and/or immune cells</p></li></ul><p>ICIs (Annals of Oncol 2017;28:2377)</p><p>Target</p><p>Drugs</p><p>Select Indications</p><p>Common Adverse Events</p><p>(approx. incidence, any grade)</p><p>PD-1</p><p>Nivolumab</p><p>Pembrolizumab</p><p>Cemiplimab</p><p>Dostarlimab</p><p>Melanoma, NSCLC, RCC, HNSCC, esoph., endometrial,</p><p>MSI-high tumors</p><p>Rash (12%); hypothyroid (5%); pneumonitis (2%); colitis (&lt;1%); hepatitis (&lt;1%); type 1 DM (&lt;1%)</p><p>PD-L1</p><p>Atezolizumab</p><p>Avelumab</p><p>Durvalumab</p><p>Urothelial carcinoma,</p><p>NSCLC, SCLC,</p><p>HCC (atezo)</p><p>Rash (5%); hypothyroid (2%); adrenal insufficiency (&lt;1%); colitis (&lt;1%); pneumonitis (&lt;1%)</p><p>CTLA-4</p><p>Ipilimumab</p><p>Melanoma, RCC (w/ PD1), mesothelioma (w/ PD1)</p><p>Rash (21%); colitis (5%); hypophysitis (1%); hypothyroid (1%); pneumonitis (&lt;1%); hepatitis (&lt;1%)</p><p>ICI toxicities (Nat Rev Dis Primers 2020;6:38; Curr Cardiol Rep 2021;23:98)</p><ul><li><p>ICIs can cause inflammation of any tissue (lungs, liver, colon, joints, skin, etc.)</p></li><li><p>Common immune-related adverse events (IRAEs) above; ↑ incidence w/ combinations.</p></li><li><p>Rare: myocarditis (can be fulminant), myositis, myelitis, uveitis, diabetes</p></li><li><p>Workup: CT chest for dyspnea; colonoscopy and infectious workup for colitis; TSH, FT4, a.m. cortisol, glucose. Trend comprehensive metabolic panel and TSH while on ICI.</p></li><li><p>IRAEs graded 1 (mild) to 4 (severe) (NCCN Guideline v4.2021)</p></li></ul><p>ICI toxicity treatment (multidisciplinary care)</p><ul><li><p>Most IRAEs reversible with steroids</p></li><li><p>Mild symptoms (grade 1): supportive care, can often continue Rx; moderate symptoms (grade 2): hold ICI, consider steroids; severe symptoms (grades 3–4): often requires admission to hospital, hold ICI, IV steroids, targeted therapies (eg, enteracept)</p></li><li><p>Endocrinopathies (hypophysitis, hypothyroid) are not reversible, Rx hormone replacement</p></li><li><p>Managing IRAEs with steroids likely does not reduce ICI efficacy (J Clin Oncol 2019;37:1927)</p></li><li><p>If ICI is restarted, Pts at increased risk for recurrent IRAE</p></li></ul><p>CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS</p><p>Overview (Nat Rev Cancer 2021;21:145)</p><ul><li><p>Autologous T cells w/ chimeric receptor: antibody variable region fused to T cell co-stimulatory intracellular signaling domains → MHC independent Ag recognition</p></li><li><p>CAR-T cells targeting CD19 used for ALL, DLBCL, FL, MCL. Targeting B-cell maturation antigen (BCMA) for MM. Strategies for solid tumors in development.</p></li></ul><p>Toxicities</p><ul><li><p>Cytokine release syndrome (CRS): fever, HoTN, shock secondary to overwhelming cytokine release from proliferating T cells</p></li><li><p>Immune effector cell-associated neurotoxicitiy synd. (ICANS): cerebral edema → HA, aphasia, delirium, lethargy/obtundation. Graded using ICE score (vide infra).</p></li></ul><p>CAR-T Toxicity (Biol Blood Marrow Transplant 2019;25:625)</p><p>Type</p><p>Grade</p><p>Mechanism & Manifestations</p><p>Treatment</p><p>CRS</p><p>1</p><p>Fever (≥38°C) ± other sx</p><p>Supportive (fluids, O2), ± steroids ± anti-IL-6 (tocilizumab or siltuximab), depending on severity</p><p>2</p><p>Fever + HoTN not needing pressors ± O2 by nasal cannula</p><p>3</p><p>Fever + pressor ± O2 > nasal cannula</p><p>4</p><p>Fever + >1 pressor ± ⊕ pressure vent</p><p>ICANS</p><p>1</p><p>ICE 7–9 pts</p><p>Steroids, anticonvulsants for seizures</p><p>2</p><p>ICE 3–6 pts</p><p>3</p><p>ICE 0–2 pts</p><p>4</p><p>Unarousable & unable to perform ICE</p><p>ICE score: orientation (4 pts), name 3 objects (3 pts), follow commands (1 pt), write sentence (1 pt), count backward from 100 by 10 (1 pt)</p><p>ONCOLOGIC EMERGENCIES</p><p>FEVER AND NEUTROPENIA (FN) (NCCN Guidelines v.1.2021)</p><p>Definition</p><ul><li><p>Fever: single oral temp ≥38.3°C (101°F) or ≥38°C (100.4°F) for ≥1 h</p></li><li><p>Neutropenia: ANC &lt;500 cells/µL or &lt;1000 cells/µL with predicted nadir &lt;500 cells/µL</p></li></ul><p>Pathophysiology and microbiology</p><ul><li><p>Predisposing factors: catheters, skin breakdown, GI mucositis, obstruction (lymphatics, biliary tract, GI, urinary tract), immune defect associated with malignancy</p></li><li><p>Often thought due to seeding of bloodstream by GI flora, eg, GNRs (esp. P. aeruginosa)</p></li><li><p>Neutropenic enterocolitis (typhlitis): RLQ pain, watery/bloody diarrhea, cecal wall thickening</p></li><li><p>Gram ⊕ infections have recently become more common (60–70% of identified organisms)</p></li><li><p>Fungal superinfection often results from prolonged neutropenia & antibiotic use</p></li></ul><p>Prevention (only if intermediate or high-risk)</p><ul><li><p>Bacterial: consider FQ if neutropenic esp steroids+ALL; ↓ mortality (Cochrane 2012 CD004386)</p></li><li><p>Fungal: consider during neutropenia in blood cancers (posa/fluconazole, micafungin)</p></li><li><p>Viral: consider during active Rx in blood cancers (acyclovir, famciclovir, valacyclovir)</p></li></ul><p>Role of hematopoietic growth factors (NCCN Guidelines v.4.2021)</p><ul><li><p>Granulocyte (G-CSF) and granulocyte-macrophage (GM-CSF) colony-stimulating factors can be used (but not in AML) as 1° Ppx when expected FN incidence >20% or as 2° Ppx after FN has occurred in a prior cycle (to maintain dose-intensity for curable tumors)</p></li><li><p>CSFs ↓ rate of FN but have not been shown to affect mortality (Cochrane 2014 CD003039)</p></li></ul><p>Diagnostic evaluation</p><ul><li><p>Exam: skin, oropharynx, lung, perirectal area, surgical & catheter sites; avoid rectal exam</p></li><li><p>Studies: U/A, blood (periph & through each indwelling catheter port), urine, & sputum cx; for localizing s/s → ✓ stool (C. diff, cx), peritoneal fluid, CSF (rare source)</p></li><li><p>Imaging: CXR; for localizing s/s → CNS, sinus, chest or abdomen/pelvis CT</p></li><li><p>Caveats: neutropenia → impaired inflammatory response → exam and radiographic findings may be subtle; absence of neutrophils by Gram stain does not r/o infection</p></li></ul><p>Risk stratification (factors that predict lower risk)</p><ul><li><p>History: outPt, ECOG 0–1, age &lt;60 y, solid tumor, no sx, no major comorbidities, no h/o fungal infection, MASCC Risk Index ≥21 (Support Care Cancer 2013;21:1487)</p></li><li><p>Exam: temp &lt;39 °C, no tachypnea, no HoTN, no Δ MS, no dehydration</p></li><li><p>Labs: ANC >100 cells/µL, anticipated duration of neutropenia ≤100 cells/µL &lt;7 d</p></li></ul><p>Initial antibiotic therapy (NCCN Guidelines v.1.2021)</p><ul><li><p>Empiric regimens should include antipseudomonal activity; consider VRE coverage if ⊕</p></li><li><p>Low risk: PO abx or home IV abx may be considered in select Pts (JCO 2013;31:1149)</p></li></ul><p>PO options: cipro+amoxicillin-clavulanate; levofloxacin; moxifloxacin (avoid if FQ Ppx)</p><ul><li>High risk: hospital admission & IV abx; monotherapy preferred</li></ul><p>options: cefepime, imipenem, meropenem, piperacillin/tazobactam, ceftazidime</p><ul><li>Antifungal Rx added for neutropenic fever ≥4 d despite abx: micafungin, liposomal amphotericin B, caspofungin, anidulafungin, voriconazole, & posaconazole are options</li></ul><p>Modification to initial antibiotic regimen based on site-specific evaluation</p><ul><li><p>Vancomycin only if HoTN, PNA, clinically apparent catheter-related or soft-tissue infxn, gram ⊕ BCx, mucositis + on quinolone Ppx; d/c when BCx ⊖ × 48 h for GPCs</p></li><li><p>Mouth/esoph (ulcer, thrush): anaerobic (if necrotizing), anti-HSV and/or antifungal Rx</p></li><li><p>Sinus/nasal: add vanc if periorbital cellulitis, ampho if concern for Aspergillus/Mucor</p></li><li><p>Abd pain/diarrhea: PO vanc if concern for C. diff; ensure adequate anaerobic coverage</p></li><li><p>Lung infiltrates: consider atypical coverage; vanc/linezolid if c/f MRSA; TMP/SMX if c/f PCP</p></li><li><p>CNS: ID consult; empiric meningitis Rx (incl. Listeria), high-dose acyclovir for encephalitis</p></li></ul><p>Duration of therapy</p><ul><li><p>Known source: complete standard course (eg, 14 d for bacteremia)</p></li><li><p>Unknown source: continue antibiotics until afebrile and ANC >500 cells/µL</p></li><li><p>Less clear when to d/c abx when Pt is afebrile but prolonged neutropenia</p></li></ul><p>SPINAL CORD COMPRESSION</p><p>Clinical manifestations (Lancet Neuro 2008;7:459)</p><ul><li><p>Metastases located in vertebral body extend and cause epidural spinal cord compression</p></li><li><p>Prostate, breast, and lung cancers are most common, followed by RCC, NHL, myeloma</p></li><li><p>Site of involvement: thoracic (60%), lumbar (25%), cervical (15%)</p></li><li><p>Signs and symptoms: pain (>95%, precedes neuro Δs), weakness, autonomic dysfunction (urinary retention, ↓ anal sphincter tone), sensory loss</p></li></ul><p>Diagnostic evaluation</p><ul><li><p>Always take back pain in Pts w/ cancer seriously. Urgent whole-spine MRI; CT if unable.</p></li><li><p>Do not wait for neurologic signs to develop before initiating evaluation b/c duration & severity of neuro dysfunction before treatment are best predictors of neurologic outcome</p></li></ul><p>Treatment (NEJM 2017;376:1358)</p><ul><li>Dexamethasone (10 mg IV × 1 STAT, then 4 mg IV or PO q6h)</li></ul><p>initiate immediately while awaiting imaging if back pain + neurologic deficits</p><ul><li><p>Emergent RT or surgical decompression if confirmed compression/neuro deficits</p></li><li><p>Surgery + RT superior to RT alone for neuro recovery in solid tumors (Lancet 2005;366:643)</p></li><li><p>If pathologic fracture causing compression → surgery; if not surgical candidate → RT</p></li></ul><p>TUMOR LYSIS SYNDROME</p><p>Clinical manifestations (NEJM 2011;364:1844)</p><ul><li><p>Large tumor burden or a rapidly proliferating tumor → spontaneous or chemotherapy-induced release of intracellular electrolytes and nucleic acids</p></li><li><p>Most common w/ treatment of high-grade lymphomas (Burkitt’s) and leukemias (ALL, AML, CML in blast crisis). Very rare w/ solid tumors; rarely due to spont. necrosis.</p></li><li><p>Electrolyte abnormalities: ↑ K, ↑ uric acid, ↑ PO4 → ↓ Ca; renal failure (urate nephropathy)</p></li></ul><p>Prophylaxis</p><ul><li>Allopurinol 300 mg qd to bid PO or 200–400 mg/m2 IV (adjusted for renal fxn) & aggressive hydration prior to beginning chemotherapy or RT</li></ul><p>Treatment</p><ul><li><p>Avoid IV contrast and NSAIDs; treat hyperK, hyperPO4, and only symptomatic hypoCa</p></li><li><p>Allopurinol + aggressive IV hydration ± diuretics to ↑ UOP for goal 80–100 cc/h</p></li><li><p>Rasburicase (0.1–0.2 mg/kg or 6 mg IV fixed dose) for ↑↑ uric acid esp. in aggressive malig (JCO 2003;21:4402; Acta Haem 2006;115:35). Avoid in G6PD def (hemolytic anemia). Consider G6PD testing in Jehovah’s Witnesses especially if Black (12% prevalence).</p></li><li><p>Hemodialysis may be necessary; early renal consultation for renal insufficiency or ARF</p></li></ul><p>CHEMO SIDE EFFECTS</p><p>Nausea & vomiting common (NEJM 2016;374:1356; 375:134 & 177)</p><p>Select Adverse Effects from Chemotherapy*</p><p>Toxicity</p><p>Common Agents</p><p>Comments</p><p>Cardiotoxicity</p><p>(NEJM 2016;375;1457)</p><p>Anthracyclines</p><p>Dose-dependent CMP; ✓ EF pre-Rx</p><p>5-FU</p><p>Spasm → ischemia; CCB may prevent</p><p>Trastuzumab</p><p>CMP, esp w/ anthracycline, TTE’s for EF</p><p>Tyrosine kinase inhib (TKI)</p><p>QTc prolongation, CMP, angina</p><p>Cyclophosphamide</p><p>Myopericarditis (esp. in BMT)</p><p>Cisplatin</p><p>AKI → HypoMg / HyperK → arrhythmia</p><p>Pulmonary</p><p>(Sem Oncol 2006;33:98)</p><p>Busulfan</p><p>~8% fibrosis or DAH; if severe → steroids</p><p>Bleomycin</p><p>~10% IPF; ✓ PFTs pre-Rx; Rx: steroids</p><p>TKI (esp. dasatinib)</p><p>Pleural effusion</p><p>Cyclophosphamide</p><p>Pneumonitis, progressive fibrosis; Rx: d/c</p><p>Bevacizumab</p><p>Pulm. hemorrhage (esp. lung SCC)</p><p>Nephrotoxicity/ urologic toxicity</p><p>Platinum Rx (cisplatin)</p><p>Esp. proximal tubule; pretreat w/ IV saline</p><p>Methotrexate</p><p>Via deposition; Rx: alkalinize urine, IVF</p><p>Cyclophosphamide</p><p>Hemorrhagic cystitis; Rx: Mesna</p><p>Neurotoxicity</p><p>(Sem Oncol 2006;33:324)</p><p>Platinum Rx (cisplatin)</p><p>“Stocking-glove” neuropathy; ototoxicity</p><p>Cytarabine</p><p>Cerebellar toxicity (irreversible 5–10%)</p><p>Methotrexate (esp. intrathecal)</p><p>Late leukoenceph, meningitis; reverse w/ intrathecal glucarpidase, leucovorin</p><p>Ifosfamide</p><p>Enceph; Rx: methylene blue, thiamine</p><p>Taxanes, vincristine</p><p>Sensorimotor long fiber neuropathy</p><p>Hepatotoxicity</p><p>(Sem Oncol 2006;33:50)</p><p>TKI (eg, imatinib, nilotinib)</p><p>↑ LFTs, rarely necrosis; Rx: d/c ± steroids</p><p>Gemcitabine</p><p>Common ↑ ALT/AST; ↓ dose if ↑ bili</p><p>Methotrexate</p><p>↑ ALT/AST, rarely fibrosis</p><p>Dermatologic</p><p>TKI (eg, imatinib)</p><p>Dermatitis, can be severe (eg, SJS)</p><p>*See “ImmunoRx” section for cytokine release and immune effector cell-associated neurotoxicity syndromes</p><p>PNEUMONIA</p><p>Definitions and clinical manifestations</p><ul><li><p>Pneumonia: s/s (fever, cough, purulent sputum, dyspnea) + new infiltrate on chest imaging</p></li><li><p>Community-acquired pneumonia (CAP): pneumonia acquired outside of hospital setting</p></li><li><p>Hospital-acquired pneumonia (HAP): pneumonia acquired ≥48 hrs after hospitalization</p></li><li><p>Ventilator-associated pneumonia (VAP): pneumonia acquired ≥48 hrs after intubation</p></li><li><p>Lung empyema: accumulation of pus in pleural space</p></li><li><p>Lung abscess: parenchymal necrosis with confined cavitation</p></li><li><p>Aspiration pneumonitis: acute lung injury after inhalation of gastric contents without infection, though bacterial infection can occur within 24–72 hrs of injury</p></li></ul><p>Microbiology of Pneumonia</p><p>Clinical Setting</p><p>Etiologies</p><p>CAP (AJRCC 2019;200:7)</p><p>No pathogen identified in 50–60%, virus alone in ~25%, bacteria alone in ~10%, virus-bacteria coinfection in &lt;5%</p><p>Viruses: influenza, RSV, hMPV, parainfluenza, rhinovirus, coronavirus</p><p>S. pneumoniae (most common bacterial cause)</p><p>S. aureus (espec. post-influenza)</p><p>Mycoplasma, Chlamydia (espec. in young & healthy)</p><p>H. influenzae, M. catarrhalis (espec. in COPD)</p><p>Legionella (espec. in elderly, smokers, ↓ immunity, TNF inhibitors)</p><p>Klebsiella & other GNR (espec. in alcoholics & aspiration)</p><p>HAP/VAP</p><p>S. aureus, Pseudomonas, Klebsiella, E. coli, Enterobacter, Acinetobacter, Steno. IV abx w/in 90 d risk factor for MDR. Viral ~20% cases.</p><p>Empyema</p><p>S. pneumo, S. aureus, E. coli, Klebsiella, H. influenzae, anaerobes</p><p>Lung abscess</p><p>Often polymicrobial, incl. oral flora. S. aureus, anaerobes, Strep (anginosus, GAS), GNR (Klebsiella, E. coli, Pseudomonas), Nocardia, Actinomyces, fungi, mycobacteria, Echinococcus</p><p>Immunosupp.</p><p>Above + Pneumocystis, Cryptococcus, Nocardia, non-TB myco- bacteria (NTM), CMV, invasive molds</p><p>Diagnostic studies (AJRCC 2019;200:e45)</p><ul><li><p>Sputum Gram stain/Cx: reliable if high quality (ie, sputum not saliva; &lt;10 squam cells/lpf). If bacterial PNA should be purulent (>25 PMN/lpf). Yield ↓ >10 h after abx (CID 2014;58:1782).</p></li><li><p>Procalcitonin: ↑ in acute bacterial (not viral) PNA. Consider stopping abx if levels &lt;0.25 ng/ml (&lt;0.5 ng/mL in ICU Pts) or ↓ ≥80% from peak. ↓ abx exposure by 2–3 d (Lancet ID 2016;16:819 & 2018;18:95). Not validated in immunosuppressed hosts. Levels harder to interpret in CKD. False ⊕ in cardiac arrest, shock, burns, surgery.</p></li><li><p>CXR (PA & lateral; see Radiology inserts)</p></li><li><p>HIV test (if unknown); MRSA nares swab in HAP/VAP (if ⊖ 96% NPV for MRSA PNA)</p></li><li><p>Consider in severe disease (otherwise not recommended):</p></li></ul><p>Legionella urinary Ag (detects L. pneumophila L1 serotype, 60–70% of clinical disease)</p><p>S. pneumoniae urinary Ag (Se 70%, Sp >90%)</p><p>Blood cultures (before antibiotics!): ⊕ in ~10% of inPts, depending on pathogen</p><ul><li><p>If clinical suspicion for mTB: (induced) sputum AFB stain ×3 q ≥8h (w/ ≥1 early morning). Mycobact. cx (empiric respiratory isolation while pending); MTb DNA PCR if smear ⊕.</p></li><li><p>Viral testing (DFA or PCR) on nasopharyngeal swab or sputum</p></li><li><p>Bronchoscopy: immunosupp., critically ill, failure to respond, suspected PCP, inadequate/ ⊖ sputum cx (send Gram stain/cx, Legionella cx, fungal cx/wet prep, mycobacterial cx/smear, modified AFB stain, galactomannan)</p></li><li><p>Reasons for failure to improve on initial treatment:</p></li></ul><p>Insufficient time: may take ≥72 h to see improvement (fever persists >4 d in ~20%)</p><p>Insufficient drug levels for lung penetration (eg, vanco trough &lt;15–20 μg/mL)</p><p>Resistant organisms or superinfxn: eg, MRSA, Pseudo.; consider bronchoscopy</p><p>Wrong dx: fungal/viral, chemical pneumonitis, PE, CHF, ARDS, DAH, ILD; consider CT</p><p>Parapneumonic effusion/empyema/abscess: if CXR ⊖, consider bedside US or CT. If effusion >1 cm, drain & send fluid pH, gluc, Gram stain & Cx.</p><p>Metastatic infection (eg, endocarditis, septic arthritis)</p><p>Triage</p><ul><li>qSOFA predicts poor outcomes, prolonged ICU stay, and in-hospital mortality if >2 of 3: RR>22, AMS, SBP&lt;100 (JAMA 2016; 315:801)</li></ul><p>Treatment (NEJM 2019;380:651; AJRCC 2019;200:e45)</p><p>Scenario</p><p>Regimen</p><p>CAP (outPt)</p><p>Amoxicillin, azithro, or doxy (avoid latter two if >25% resistance locally)</p><p>CAP (ward)</p><p>[3rd-gen ceph + azithro] or levoflox; omadacycline ≈ FQ (NEJM 2019;380:517)</p><p>CAP (ICU)</p><p>3rd-gen ceph + azithro. Only cover MRSA or Pseudomonas if risk factors (prior PsA PNA, MRSA infection, recent hospitalization, IV abx)</p><p>HAP/VAP</p><p>[Pip-tazo or cefepime or carbapen.] + [vanc or linezolid]. May add resp FQ or azithro if concerned for atypicals. Daptomycin not active in lungs.</p><p>Empyema/ abscess</p><p>[3rd-gen ceph + MNZ] or amp-sulbactam. Only cover Pseudomonas or MRSA if risk factors. Empyema: drain if >1 cm ± chest tube. Abscess: drainage not required. De-escalate to PO abx based on clinical improvement & micro.</p><ul><li><p>Avoid quinolones if suspect TB. When possible, de-escalate abx based on sensitivities.</p></li><li><p>Steroids: not unless indicated for shock or COPD exacerbation; may ↓ mortality, mech vent, & ARDS in severe CAP (Cochrane 2017;12:CD007720). Avoid in influenza.</p></li><li><p>Duration: CAP: 5–7 days, can de-escalate IV abx to PO after clinical improvement. HAP/VAP: 7 days. Empyema/abscess: 2–6 wks based on complexity, drainage.</p></li></ul><p>Prevention</p><ul><li><p>All persons >65 or age 19–64 w/ CHF, lung disease, cirrhosis, DM, EtOH, smoker, immunosupp. (eg, ESRD, organ transplant, HIV, leukemia, lymphoma, asplenia)</p></li><li><p>PCV20 vaccine or PCV15 + PPSV23 1 yr later</p></li></ul><p>VIRAL RESPIRATORY INFECTIONS</p><p>URI, bronchitis, bronchiolitis, pneumonia (Lancet 2011;377:1264)</p><p>Microbiology & epidemiology (
<a href=http://www.cdc.gov/flu/weekly rel=noopener>http://www.cdc.gov/flu/weekly</a>)</p><ul><li>Typical pathogens: Short, mild = rhinovirus, other non-SARS-CoV-2 coronavirus.</li></ul><p>Longer, more severe or complicated = influenza, parainfluenza, RSV, adenovirus, metapneumovirus, COVID-19 (vide infra). Can be esp. severe in immunosupp.</p><p>Diagnosis</p><ul><li><p>Sx: fever, cough, myalgias, SOB, wheezing, sore throat, rhinorrhea, malaise, confusion</p></li><li><p>Respiratory viral panel on nasal swab or sputum/BAL; rapid flu nasopharyngeal swab preferred to nasal swab (Se 50–70%, Sp >90%); RT-PCR for flu A/B (>95% Se & Sp)</p></li></ul><p>Treatment (NEJM 2017;390:697)</p><ul><li><p>Influenza (A & B):</p></li><li><p>Neuraminidase inhib. (eg, oseltamivir); must start w/in 48 h of sx for low-risk; for critically ill or immunosupp., start ASAP even if >48 h. Peramivir IV if unable to tolerate PO.</p></li><li><p>Endonuclease inhib. (baloxavir), superior to oseltamivir in ↓ sx & viral load on 1st day of Rx, but resistance emerging; no data in severe influenza (NEJM 2018; 379:913)</p></li><li><p>RSV: can consider inhaled ribavirin in immunosupp, but very expensive & rarely used</p></li></ul><p>Prevention</p><ul><li><p>Inactivated influenza vaccine: rec for all >6 mo of age.</p></li><li><p>Isolation, droplet precautions for inpatients strongly recommended</p></li><li><p>Ppx for high-risk contacts of confirmed influenza: oseltamivir × 7 d or baloxavir single dose</p></li></ul><p>CORONAVIRUS (COVID-19) / SARS-COV-2 INFECTION</p><p>Microbiology & epidemiology</p><ul><li><p>Person-to-person transmission via respiratory particles; asx & pre-sx transmission can occur</p></li><li><p>Incubation period: up to 14 days, median time of 4–5 days from exposure to sx onset</p></li></ul><p>Presentation</p><ul><li><p>Ranges from asx to severe illness. Of those with sx, 81% mild-to-moderate, 14% severe (hypoxia), 5% critical (ARDS, shock, multiorgan failure) (JAMA 2020:323;13)</p></li><li><p>Common sx: fever, chills, cough, dyspnea, myalgias, HA, N/V, diarrhea, loss of smell/taste</p></li><li><p>Risk factors for severe illness: age ≥65, CVD, DM, stroke, lung dx, CKD, obesity</p></li></ul><p>Diagnosis</p><ul><li><p>RT-PCR testing of nasopharynx, lower respiratory tract, or anterior nares</p></li><li><p>Rapid antigen testing of anterior nares (less Se than PCR)</p></li><li><p>CXR: typically bilateral opacities (esp peripheral), can be nl early; consider CT if dx ?</p></li></ul><p>Treatment (
<a href=https://www.covid19treatmentguidelines.nih.gov/ rel=noopener>https://www.covid19treatmentguidelines.nih.gov/</a>)</p><ul><li><p>Non-hospitalized: mAb, paxlovid and molnupiravir if risk factors for severe disease</p></li><li><p>Hospitalized w/ suppl O2: dexamethasone ± remdesivir (inhibits vRNA polymerase)</p></li><li><p>Hospitalized w/ mechanical ventilation or ECMO: dexamethasone + anti IL6 (tocilizumab/ sarilumab) or anti JAK (baricitinib/tofacitinib) if rapidly ↑ O2 requirement but not intubated</p></li><li><p>Anticoag. due to high rate of thrombosis; Ppx vs. Rx dosing based on severity and risk</p></li></ul><p>Prevention</p><ul><li><p>Vaccines against spike protein highly effective. Infxn may occur but severity much lower.</p></li><li><p>See CDC website for quarantine guidelines (
<a href=https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html rel=noopener>https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html</a>)</p></li></ul><p>FUNGAL INFECTIONS</p><p>Fungal diagnostics</p><ul><li>Antigen detection</li></ul><p>1,3-β-D glucan (Se 75%, Sp 85%): Candida, Aspergillus, Histo, Coccidio, PCP, for invasive infxn in immunocomp host. Cannot detect Mucor, Rhizopus, Blasto, Crypto.</p><p>Galactomannan (Se 71%, Sp 89%): Aspergillus. BAL preferred. Test serum only if heme malig or HSCT. Not for screening or Rx monitoring in solid organ Tx, chronic granulomatous disease (false ⊕ w/ colonization).</p><p>Histo urine/serum Ag: Se of urine Ag 90% (serum 80%) if dissem; Sp limited by X-react</p><p>Crypto Ag (serum, CSF): sAg >90% Se & Sp in invasive, less for pulm. only unless HIV+</p><p>Blastomyces: urine >serum Ag, high Se but modest Sp given X-react w/ other fungi</p><ul><li><p>Culture: Candida grows in blood/urine Cx, but ↓ Se of BCx in deep tissue infection; others (eg, Crypto, Histo) ↓↓ Se of BCx; if suspect Coccidio alert lab (biohazard)</p></li><li><p>Antibody detection: useful for Coccidio (serum IgG and IgM 7–21 days post exposure)</p></li><li><p>Biopsy: no grinding of tissue if Zygomycetes suspected</p></li></ul><p>Candida species</p><ul><li><p>Microbiology: normal GI flora; C. albicans & nonalbicans spp.</p></li><li><p>Epidemiology: neutropenia, immunosupp., broad-spectrum abx, intravascular catheters (esp. if TPN), IVDU, abd surgery, DM, renal failure, age >65</p></li><li><p>Clinical manifestations:</p></li></ul><p>Mucocutaneous: cutaneous (eg, red, macerated lesions in intertriginous zones); oral thrush (exudative, erythematous or atrophic; if unexplained, r/o HIV); esophageal (odynophagia; ± oral thrush); vulvovaginal, balanitis</p><p>Candiduria: typically colonization due to broad-spectrum abx and/or indwelling catheter</p><p>Candidemia: ⊕ blood cx are never a contaminant! R/o retinal involvement (ophtho consult) & endocarditis w/ TTE ± TEE (esp. w/ prosthetic valve) as req ↑ Rx duration. May present w/ erythematous papules or pustules in immunosupp.</p><p>Candida in sputum: usually not a clinically significant pathogen</p><p>Hepatosplenic: typically, after prolonged neutropenia as cell counts are recovering</p><p>Treatment (CID 2016;62:409)</p><p>Mucocutaneous</p><p>Clotrimazole, nystatin, fluconazole, itraconazole</p><p>Candiduria (if pyuria or sx of infxn)</p><p>Fluconazole or intravesical ampho if severe infxn,</p><p>immunosupp. or planned GU procedure.</p><p>Candidemia w/o neutropenia</p><p>Echinocandin (mica 1st line) if stable w/o prior azole exposure can consider fluc; remove CVC; test for azole-resist.</p><p>Candidemia w/ neutropenia</p><p>Echinocandin or ampho; remove CVC; test for azole-resist.</p><p>Aspergillosis (Lancet 2021;397:499)</p><ul><li><p>ABPA: airway hypersensitivity secondary to aspergillus colonization</p></li><li><p>Chronic pulmonary aspergillosis: includes aspergilloma (fungus ball), pulm. nodules, chronic cavitary and chronic fibrotic pulmonary aspergillosis that can present with subacute cough, dyspnea, hemoptysis; aspergilloma/nodules can be asymptomatic</p></li><li><p>Invasive aspergillosis: seen in immunosupp., esp prolonged neutropenia. Primarily pulmonary, ie, PNA w/ chest pain, cough, hemoptysis; CT: solid/cavitary nodules, halo sign. Non-pulm. manifestations: rhinosinusitis (like Zygomycetes), CNS (brain abscesses, mycotic aneurysm), endophthalmitis (eye pain, visual changes), cutaneous, GI (typhlitis)</p></li></ul><p>Rx: voriconazole or posaconazole preferred over ampho. For aspergilloma, ± resection.</p><p>Zygomycetes (eg, Mucor, Rhizopus)</p><ul><li><p>Epidemiology: diabetes (espec. those w/ prior DKA), heme malignancy, neutropenia, transplant, chronic steroids, iron overload, trauma, h/o voriconazole Rx or Ppx</p></li><li><p>Clinical: rhinocerebral = severe periorbital/facial pain, swelling, vision changes, sinusitis, opthalmoplegia, nasal ulcerations/ necrosis, HA. Other: pulm. (PNA w/ infarct & necrosis); cutaneous (indurated painful cellulitis ± eschar); GI (necrotic ulcers); renal (flank pain, fever).</p></li><li><p>Treatment (high mortality): 1st line is debridement + ampho. Can deescalate to posaconazole or isavuconazole if improving after debridement.</p></li></ul><p>ENDEMIC FUNGI</p><p>Cryptococcus (CID 2010;50:291)</p><ul><li><p>Epidemiology: immunosupp. most susceptible (espec. AIDS, transplant recipients, and cirrhosis); can occur in healthy hosts (esp C. gattii)</p></li><li><p>Clinical manifestations</p></li></ul><p>CNS (meningoencephalitis): subacute HA, fever, meningismus, CN abnl, ± stupor</p><p>Other sites: pulm., GU, cutaneous, CNS cryptococcoma. With any crypto dx, LP all Pts.</p><ul><li><p>Dx: CSF cell counts vary in HIV vs. non-HIV; serum/CSF CrAg (Se 99%, Sp 86–100%); cx</p></li><li><p>Treatment</p></li></ul><p>CNS Rx has induction (ampho ± flucytosine × 2 wks), consolidation and maintenance (fluconazole) phases (NEJM 2013;368:1291); if ↑ ICP, may need repeat LP/VP shunt</p><p>Non-CNS disease (pulm., skin, bone, blood) in HIV ⊖ Pts: consider fluconazole</p><p>Histoplasmosis (CID 2007;45:807)</p><ul><li><p>Epidemiology: endemic to central & SE U.S., but sporadic cases throughout U.S.</p></li><li><p>Clinical manifestations</p></li></ul><p>Acute: PNA ± hilar LAN, often subacute, but high inoculum can cause acute severe PNA</p><p>Chronic lung disease: cough + B sx ± cavitary lesions (Ddx TB, blasto)</p><p>Disseminated (seen in immunosupp.): fever, fatigue, wt loss, mucocutaneous lesions, ΔMS, arthritis, pericarditis, interstitial infiltrates HSN, LAN, cytopenias</p><ul><li>Treatment: mild to mod: itraconazole; disseminated/severe: ampho → itraconazole</li></ul><p>Coccidioidomycosis (CID 2016;63:112)</p><ul><li><p>Epidemiology: endemic to SW U.S., Central and South America</p></li><li><p>Clinical manifestations</p></li></ul><p>Acute: subclinical PNA, arthralgias, rash (erythema nodosum)</p><p>Chronic lung disease (seen in immunosupp): dyspnea, chest pain, hemoptysis, “B” sx</p><p>Disseminated (immunosupp, pregnant): meningitis, osteo, monoarthritis, cutaneous</p><ul><li>Treatment: no Rx for mild PNA in immunosupp.; ampho for severe/CNS involvement; azoles for extrathoracic w/o CNS involvement; some cases require debridement</li></ul><p>Blastomycosis (CID 2008;46:1801)</p><ul><li><p>Epidemiology endemic to the eastern ½ of U.S.</p></li><li><p>Clinical manifestations</p></li></ul><p>Acute: PNA w/o hilar LAN that can progress to ARDS</p><p>Chronic: cough + “B” sx, fibronodular infiltrates, masses ± cavitary lesions (Ddx TB, histo)</p><p>Disseminated (seen in immunosupp.): rash (verrucous, ulcerated lesions), subcutaneous nodules, osteo, GU (prostatitis, epididymoorchitis), CNS involvement uncommon</p><ul><li>Treatment: mild to mod: itraconazole; disseminated/severe/CNS: ampho → itraconazole</li></ul><p>INFXNS IN IMMUNOSUPPRESSED HOSTS</p><p>Overview</p><ul><li><p>Many Pts have ≥1 risk (eg, DM, ESRD, transplant, extremes of age)</p></li><li><p>Accurate dx of opportunistic infections and targeted Rx key in this population</p></li><li><p>The following is not an exhaustive list, but a delineation of common or classic etiologies</p></li></ul><p>Predisposition</p><p>Classic Infectious Etiologies</p><p>Humoral immune dysfunction (eg, CVID, myeloma) and asplenia</p><p>Encapsulated bacteria: S. pneumo, H. flu, N. meningitidis (vaccinate against these 3, ideally prior to splenectomy)</p><p>Other bacteria: E. coli and other GNRs, Capnocytophaga</p><p>Parasites: Babesia, Giardia; Viruses: VZV, echovirus, enterovirus</p><p>Granulocytopenia or neutropenia (includes DM, ESRD → functional impairment)</p><p>Bacteria: Gram positive: coag ⊖ staph, S. aureus, viridans strep, S. pneumo, other strep; Corynebacterium spp., Bacillus spp. Gram negative: E. coli, Klebsiella, Pseudomonas</p><p>Fungi: Yeast: Candida albicans and other Candida spp. Molds: Aspergillus, Mucor spp., endemic fungi and others</p><p>Viruses: VZV, HSV1 and 2, CMV</p><p>Impaired cell-mediated immunity (CMI) (eg, HIV/AIDS, chronic steroids, posttransplant, DM, ESRD, autoimmune dis.)</p><p>Bacteria: Salmonella spp., Campylobacter, Listeria, Yersinia, Legionella (Lancet 2016;387:376), Rhodococcus, Nocardia, TB, non-TB mycobacteria</p><p>Fungi: Candida, Crypto, Histo, Coccidio, Aspergillus, Pneumocystis, Zygomycetes spp. and other molds</p><p>Viruses: HSV, VZV, CMV, EBV, JC virus, BK virus</p><p>Parasites: Toxoplasma, Cryptosporidium, Isospora, Microsporidia Babesia; Strongyloides</p><p>Organ dysfunction</p><p>Liver (esp. cirrhosis): Vibrio spp., encapsulated bacteria</p><p>ESRD: impaired granulocyte fxn and CMI as above</p><p>Iron overload (or deferoxamine Rx): Yersinia, Zygomycetes</p><p>Biologics (eg, TNF inhibitors, anti-B- cell Rx; ✓ for TB before starting)</p><p>Bacteria: sepsis, septic arthritis, TB, NTM, Listeria, Legionella</p><p>Fungi: Pneumocystis, Histo, Coccidio, Aspergillus, endemic fungi</p><p>Viruses: JC virus (PML), EBV, HSV, VZV, HBV</p><p>Parasites: Strongyloides reactivation</p><p>(NEJM 2007;357:2601; Am J Med 2007;120:764; CID 2011;53:798)</p><p>URINARY TRACT INFECTIONS</p><p>Definitions</p><ul><li><p>Asymptomatic bacteriuria: presence of bacteria in urine without signs or sx of infection</p></li><li><p>Uncomplicated: confined to bladder. No upper tract or systemic infection signs.</p></li><li><p>Complicated: extends beyond bladder (pyelonephritis, renal/perinephric abscess, prostatitis) with symptoms of fever, rigors, malaise, flank pain, CVA tenderness or pelvic/perineal pain. More likely to develop bacteremia or sepsis. Men, those w/ nephrolithiasis, strictures, stents, urinary diversions, immunosupp, DM, are not automatically complicated. Pregnant & renal Tx are considered complicated.</p></li></ul><p>Microbiology</p><ul><li><p>Uncomplicated: E. coli (80%), Proteus, Klebsiella, S. saprophyticus (CID 2004;39:75). In healthy, nonpregnant women, lactobacilli, enterococci, Group B strep, and coag-neg staph (except S. saprophyticus) are likely contaminants (Annals 2012;156:ITC3).</p></li><li><p>Complicated: as above + PsA, enterococci, staph (uncommon 1º urinary pathogen w/o catheter or recent instrumentation; ? bacteremia w/ hematogenous spread). ↑ MDR.</p></li><li><p>Catheter-associated: E. coli most prevalent, candida, Enterococcus, PsA, other GNR</p></li><li><p>Urethritis: Chlamydia trachomatis, Neisseria gonorrhoeae, Ureaplasma urealyticum, Trichomonas vaginalis, Mycoplasma genitalium, HSV</p></li></ul><p>Clinical manifestations</p><ul><li><p>Cystitis: dysuria, urgency, frequency, hematuria, suprapubic pain; fever absent. R/o vaginitis if symptoms of cystitis & urethritis. Neurogenic bladder Pts may have atypical sx (↑ spasticity, autonomic dysreflexia, malaise).</p></li><li><p>Urethritis: dysuria, urethral discharge (see “STI”)</p></li><li><p>Prostatitis</p></li></ul><p>Chronic: similar to cystitis + symptoms of obstruction (hesitancy, weak stream)</p><p>Acute: perineal pain, fever, tenderness on prostate exam</p><ul><li><p>Pyelonephritis: fever, chills, flank or back pain, nausea, vomiting, diarrhea</p></li><li><p>Renal abscess: pyelonephritis sx + persistent fever on appropriate antibiotics</p></li></ul><p>Diagnostic studies (NEJM 2016;374:562)</p><ul><li><p>Urinalysis: pyuria + bacteriuria ± hematuria ± nitrites</p></li><li><p>Urine Cx (clean-catch midstream or straight-cath)</p></li></ul><p>Obtain cx only if symptoms (although in ill Pts, can include ∆MS, autonomic instability)</p><p>⊕ if: ≥105 CFU/mL, though &lt;105 but ≥102/mL may still indicate UTI in some scenarios</p><p>Pyuria & ⊖ UCx=sterile pyuria. Ddx: prior abx, nephrolithiasis, interstitial nephritis, tumor, TB, urethritis (see “STI”)</p><ul><li><p>Catheter-associated: requires (1) s/s (incl atypical) + (2) urine Cx w/ 1 species ≥103 colonies from clean urine sample (after replacing Foley). Pyuria alone not sufficient to dx</p></li><li><p>Blood cultures: obtain in febrile Pts; consider in complicated UTIs</p></li><li><p>For all men w/ UTI, consider prostatitis: ✓ prostate exam</p></li><li><p>CT A/P: consider in severely ill, obstruction, persistent sx after 48–72 hours of approp abx</p></li></ul><p>Treatment of UTIs (CID 2011;52:e103; JAMA 2014;312:1677)</p><p>Scenario</p><p>Empiric Treatment Guidelines (narrow based on UCx)</p><p>Asymptomatic bacteruria</p><p>Do not treat. Exceptions: pregnant women, renal transplant, prophylaxis prior to invasive urologic procedures (CID 2019;68:1611).</p><p>Cystitis (JAMA 2014;16:1677)</p><p>Uncomp: nitrofurantoin (Macrobid 100 mg PO q12h or Macrodantin 100 mg PO q6h) × 5 d or TMP-SMX DS × 3 d or fosfomycin (3 g × 1). Refer to dosing guidelines for ↑ Cr.</p><p>Complicated: outPt FQ or TMP-SMX PO × 7–14 d</p><p>FQ or TMP-SMX superior to β-lactams (NEJM 2012;366:1028)</p><p>InPt: CTX or FQ; PO if improving, if growing GPC add vancomycin</p><p>If catheterized remove or exchange catheter.</p><p>Prostatitis</p><p>FQ or TMP-SMX PO × 14–28 d (acute) or 6–12 wk (chronic)</p><p>Pyelonephritis</p><p>OutPt: FQ × 7 d or TMP-SMX PO × 14 d (Lancet 2012;380:452)</p><p>InPt: CTX × 14 d; if at risk for MDR pathogen cefepime, pip-tazo, carbapenem, or plazomicin (NEJM 2019;380:729) (Δ IV → PO when clinically improved & afebrile 24–48 h, tailor to Cx)</p><p>Renal abscess</p><p>Drainage + antibiotics as for pyelonephritis</p><p>SEXUALLY TRANSMITTED INFECTIONS</p><p>Risk Factors and Screening (MMWR 2021;70:1)</p><ul><li><p>High risk: >10 lifetime sexual partners, prior STI, MSM, sex workers</p></li><li><p>Screening recommendations: differ based on sexual practices and risk. All adults should have one-time HIV Ag/Ab, HCV Ab. Consider q3mo testing for STIs if high risk.</p></li></ul><p>Genital Lesions (MMWR 2021; 70:1)</p><p>Disease</p><p>Symptoms</p><p>Painless</p><p>Syphilis</p><p>(T. pallidum)</p><p>1°: chancre = firm, indurated, clean base</p><p>2°: fever, LAN, rash palms/soles, uveitis, condylomata lata</p><p>3°: aortitis/aneurysm, gumma, CN palsies (7/8), tabes dorsalis, aseptic meningitis</p><p>Latent = asx; early latent &lt;1yr; late >1yr/unknown</p><p>LGV</p><p>(C. trachomatis, L1–L3)</p><p>1°: transient papule</p><p>2°: 2–6 wks later, painful inguinal LN (buboes)</p><p>3°: Anorectal syndrome w/ proctitis, ulcers</p><p>Donovanosis/GI (K. granulomatis)</p><p>Multiple beefy, firm, irregular ulcers (“granuloma inguinale”), no LAN; in tropics</p><p>Painful</p><p>Genital herpes</p><p>(HSV 2>1)</p><p>Prodrome: multiple painful vesicles</p><p>1° outbreak: more severe ± LAN/fever</p><p>Chancroid (H. ducreyi)</p><p>Multiple ulcers ± LAN, in tropics</p><p>Diagnosis (MMWR 2021;70:1; JAMA 2022;327:161)</p><ul><li>Syphilis: 1st step is treponemal test: IgG to T. pallidum. ⊕ for life.</li></ul><p>2nd step: confirm w/ non-treponemal test (VDRL/RPR titer). Should ↓ 4-fold w/ Rx.</p><p>Neurosyphilis: LP not needed if only ocular or otic sx. CSF VDRL may be ⊖.</p><ul><li><p>LGV: clinical dx + ⊕ rectal C. trachomatis NAAT + r/o other causes of proctitis</p></li><li><p>Donovanosis: bx w/ Donovan bodies (encapsuled GNR) in monocytes/macrophages</p></li><li><p>Genital herpes: clinical dx; confirm w/ PCR, viral cx from lesion</p></li><li><p>Chancroid: clinical dx; r/o syphilis & HSV</p></li></ul><p>Treatment (MMWR 2021;70:1; JAMA 2022;327:161)</p><ul><li>Syphilis</li></ul><p>1°/2°/early latent: PCN G benzathine 2.4 mil U IM × 1</p><p>3°/late latent: PCN G 2.4 mil U IM × 3</p><p>Neuro: IV PCN G 4 mil U q4h 10–14 d (CID 2011; 53:S110)</p><ul><li><p>LGV: doxy 100 mg BID × 21 d + aspiration of buboes</p></li><li><p>Donovanosis: azithro 1g qwk × 3 wks, until healed (MMWR 2015;64)</p></li><li><p>Genital herpes: valacyclovir 1g bid × 7–10 d. Consider suppression if >6 outbreaks/yr.</p></li><li><p>Chancroid: azithro 1g × 1 PO or cipro 500 mg bid × 3 d</p></li></ul><p>Genital Discharge (MMWR 2021;70:1)</p><p>Disease</p><p>Symptoms</p><p>Gonorrhea (N. gonorrhoeae)</p><p>& Chlamydia (C. trachomatis)</p><p>♀: Mucopurulent cervicitis, dysuria, PID; can be asx</p><p>♂: Urethritis, infxn of epididymis/prostate</p><p>All: pharyngitis</p><p>Mycoplasma genitalium</p><p>Suspect in Pts w/ urethritis/cervicitis after Rx for GC/CT</p><p>Trichomoniasis (T. vaginalis)</p><p>♀: Malodorous purulent discharge, dysuria, dyspareunia</p><p>♂: Asymptomatic</p><p>Bacterial vaginosis (Gardnerella vaginalis)</p><p>♀: Malodorous grey/white discharge, no dyspareunia</p><p>♀ denotes all persons with a vagina. ♂ denotes all persons with a penis.</p><p>Diagnosis (MMWR 2021;70:1; JAMA 2022;327:161)</p><ul><li><p>NAAT (vaginal/cervical/urine ♀; urine ♂), mycoplasma testing not widely available</p></li><li><p>For GC/CT, strongly suggest urine + rectal/pharyngeal swab if history of oral or anal sex</p></li><li><p>Trichomoniasis: motile trichomonads on wet mount</p></li><li><p>Bacterial vaginosis: clue cells on wet mount; ⊕ whiff test; vaginal culture</p></li></ul><p>Treatment (MMWR 2021;70:1; JAMA 2022;327:161)</p><ul><li><p>GC: CTX 500 mg IM × 1 (if wt >150 kg, 1 g). CT: doxy 100 mg PO bid × 7 d (preferred) or azithro 1 g PO × 1. Do not need to treat both if neg NAAT. Retest at 3 mos.</p></li><li><p>M. gen.: doxy 100 mg PO bid × 7 d, then: moxifloxacin 400 mg PO qd × 7 d</p></li><li><p>Trich: ♀ → MNZ 500 mg PO bid or tinidazole 2 g PO qd × 7 d. ♂ → MNZ 2 g PO × 1.</p></li><li><p>Bacterial vaginosis: MNZ 500 mg PO bid × 7 d or vaginal Rx w/ MNZ gel daily × 5 d</p></li></ul><p>SKIN AND SOFT TISSUE INFECTIONS</p><p>Definitions</p><ul><li><p>Cellulitis: infection of dermis and subcutaneous tissue characterized by erythema, warmth, tenderness, and swelling; often occurs as a result of skin breaches (JAMA 2016;315:3)</p></li><li><p>Skin abscess: subcutaneous collection of pus</p></li><li><p>Staph toxic shock syndrome: rapid onset fever, rash, hypotension, and multiorgan injury. Staph aureus cx are not necessary for dx. Often associated with packing (tampon, nasal packing). Management may require surgical debridement + abx.</p></li></ul><p>Risk Factors</p><ul><li>Trauma, edema, preceding skin inflammation or infection, obesity, DM, other immunosupp.</li></ul><p>Microbiology (CID 2014;59:e10)</p><ul><li><p>Purulent: MRSA (NEJM 2006;355:666) causes up to 75% of purulent skin/soft tissue infections, followed by MSSA and strep</p></li><li><p>Non-purulent: Strep, MSSA, aerobic GNRs. MRSA less commonly unless significant risk factors (prior MRSA infection, IVDU, HD, recent abx or hospitalization).</p></li><li><p>Bites: skin (Strep, Staph [MRSA only if risk factors]) and oral flora (including anaerobes) + special exposures:</p></li></ul><p>Feature</p><p>Microbiology</p><p>Clinical</p><p>Treatment</p><p>Cat bite*</p><p>Pasturella spp</p><p>Rapid onset erythema, swelling, lymphangitis, fever</p><p>Amox/clav</p><p>Dog bite</p><p>Pasturella & Capnocytophaga spp</p><p>Can cause severe sepsis w/ DIC & gangrene in asplenic/cirrhotics and other immunosupp.</p><p>Amox/clav</p><p>If Capno. suspected: pip/tazo or carbapenem</p><p>Penetrating injury</p><p>Pseudomonas</p><p>Can be a/w deep tissue abscess</p><p>Directed based on suscept.</p><p>Gardening</p><p>Sporothrix</p><p>Ulcerating nodules, lymphatic spread</p><p>Itraconazole</p><p>Salt H2O or raw oysters/fish</p><p>V. vulnificus</p><p>Hemorrhagic bullae & sepsis (esp. in cirrhotics)</p><p>Doxy + Ceftaz/CTX</p><p>Mycobacterium marinum</p><p>Indolent, nodules on extremities/ superficial lymphadenitis</p><p>Macrolide + rifampin/ ethambutol</p><p>Fresh H2O</p><p>Aeromonas</p><p>Myonecrosis/rhabdo can occur.</p><p>FQ, TMP-SMX, or CTX</p><p>*Cat scratch disease caused by Bartonella acquired via cat scratch or bite. Results in lymphadenitis.</p><p>Diagnosis</p><ul><li><p>Clinical diagnosis based on physical examination</p></li><li><p>Cultures from intact skin are not helpful and should not be performed (CID 2014;59:e10)</p></li><li><p>BCx are typically low yield (~5–10%)</p></li><li><p>Ultrasound can be used to identify deep abscesses and facilitate drainage. If abscess is found, incision/drainage is key to treatment.</p></li><li><p>Aspirate from an abscess may provide microbiologic dx</p></li></ul><p>Cellulitis Treatment (NEJM 2014;370:2238; CID 2014;59:e10; JAMA 2016;316:325 & 2017;317:2088)</p><p>Purulent</p><p>Usual Micro</p><p>Severity</p><p>Treatment</p><p>No</p><p>β-hemolytic Strep >S. aureus</p><p>Mild</p><p>Oral: PCN VK, cephalosporin</p><p>Mod</p><p>IV: PCN, ceftriaxone, cefazolin</p><p>Severe</p><p>IV: vanc + pip/tazo (± clinda for toxic shock syndrome)</p><p>Yes</p><p>S. aureus (incl. MRSA) &#187; β-hemolytic Strep</p><p>Mild</p><p>Consider I&D only vs. I&D + clinda or TMP-SMX (NEJM 2017;376:2545)</p><p>Mod</p><p>I&D + TMP-SMX or doxycycline</p><p>Severe</p><p>I&D + IV vanc, daptomycin or linezolid (± clinda for toxic shock syndrome)</p><p>Mild: abscess &lt;2 cm, no systemic signs of infection, immunocompetent, no indwelling hardware; moderate: systemic signs; severe: SIRS or immunosuppressed</p><ul><li><p>Limb elevation; erythema may worsen after starting abx b/c bacterial killing → inflam.</p></li><li><p>In obese Pts, adequate drug dosing important to avoid treatment failure (J Infect 2012;2:128)</p></li><li><p>Duration: 5 to up to 14 d based on severity and response to treatment. Take pictures & draw margins to track progress.</p></li></ul><p>NECROTIZING SOFT-TISSUE INFECTIONS (NEJM 2017;377:2253)</p><p>Definition</p><ul><li><p>Fulminant tissue destruction, systemic toxicity & high mortality. Surgical emergency.</p></li><li><p>May include cellulitis, fasciitis, myositis, myonecrosis (gas gangrene).</p></li></ul><p>Risk factors</p><ul><li>Can affect healthy individuals via skin/mucosal breach or traumatic wound, but ↑ risk w/ DM, PVD, EtOH abuse, IVDU, cirrhosis, or other immunosupp.</li></ul><p>Microbiology</p><ul><li><p>Necrotizing fasciitis</p></li><li><p>Type I: polymicrobial (mixed aerobes & anaerobes), typically in older Pts w/ above RFs. Fournier’s gangrene involves genitalia and/or perineum</p></li></ul><p>Head and neck NSTI evolve from oral flora including anaerobes</p><ul><li><p>Type II: monomicrobial, usually group A strep, less likely Staph, Vibrio, Aero.; a/w TSS</p></li><li><p>Clostridial myonecrosis (gas gangrene): C. perfringens; C. septicum (large Gram ⊕ rods w/ blunt ends on Gram stain). A/w traumatic wounds that create an anaerobic environment ideal for Clostridia.</p></li></ul><p>Clinical manifestations</p><ul><li><p>Erythema, edema, warmth + systemic illness ± crepitus, bullae, necrosis</p></li><li><p>Rapid progression of clinical signs</p></li><li><p>Pain out of proportion to apparent cellulitis; skin hyperesthetic and later anesthetic</p></li></ul><p>Diagnosis</p><ul><li><p>Clinical dx is sufficient to initiate urgent surgical exploration</p></li><li><p>Aspiration of necrotic center; BCx; Gram stain; lactate, AST, & CK for deep tissue necrosis</p></li><li><p>Imaging: noncontrast CT, but do not delay Rx/surgery (Arch Surg 2010;145:452)</p></li><li><p>Microbiologic dx from Gram stain and culture of surgical specimens</p></li></ul><p>Treatment (CID 2014;60:169)</p><ul><li><p>Urgent surgical exploration with debridement of necrotic tissue and ID consultation</p></li><li><p>Empiric antibiotics: [pip/tazo or ceftriaxone + metronidazole or carbapenem] + [vanco or linezolid]. For Group A Strep: penicillin + clindamycin + consideration of IVIG for toxic shock.</p></li></ul><p>DIABETIC FOOT INFECTIONS</p><p>Microbiology and severity (CID 2004;39:885)</p><ul><li><p>Mild (superficial ulcer, no involvement of deeper structures, surrounding erythema &lt;2 cm, and no systemic illness): usually S. aureus or aerobic streptococci</p></li><li><p>Moderate (ulcer with involvement of deeper structures, surrounding erythema >2 cm, or lymphangitic streaking and no systemic illness): more likely to be chronic and polymicrobial (PsA, enterococci, enteric GNR, anaerobes)</p></li><li><p>Severe (moderate + systemic illness or metabolic instability): anaerobic streptococci, enteric GNR, PsA, Bacteroides, Clostridium</p></li></ul><p>Initial evaluation</p><ul><li><p>Cleanse, debride, probe, and obtain deep anaerobic + aerobic cultures</p></li><li><p>Assess for PVD: sensation, pulses, ABIs</p></li></ul><p>Diagnosis</p><ul><li><p>Deep tissue wound cx at time of debridement (ideally prior to antibiotics). Superficial swabs are typically of limited utility due to colonization.</p></li><li><p>For mod/severe: obtain blood cx, ESR, CRP</p></li><li><p>Osteomyelitis should always be ruled out. At ↑ risk if: grossly visible bone or able to probe to bone, ulcer >2 cm, ulcer duration >1–2 wk, ESR >70. If suspicious for osteo, obtain plain films ± MRI (see osteomyelitis below).</p></li></ul><p>Treatment (CID 2012;54:e132)</p><ul><li><p>Mild infxn: oral abx. Target GPCs (diclox, cephalexin, or amox/clav); use TMP-SMX or doxy for MRSA.</p></li><li><p>Mod/severe infxn: IV abx. Target GPCs (vanco, linezolid,dapto) + GNRs (CTX, levo, or amp/sulb) ± anaerobes (metronidazole or clinda). Add PsA coverage (cefepime or pip- tazo) if: macerated wound, significant water exposure, warm climate</p></li><li><p>Elevation, non–weight-bearing status, wound care, glycemic control, Rx for venous insufficiency and arterial ischemia</p></li><li><p>Many require surgery: early, aggressive, and repeated debridement; revascularization or amputation may be necessary</p></li></ul><p>OSTEOMYELITIS</p><p>Infection of bone due to hematogenous seeding or direct spread from contiguous focus</p><p>Etiology (Lancet 2004;364:369)</p><ul><li><p>Hematogenous: S. aureus; mycobacterial infection of vertebral body = Pott’s disease</p></li><li><p>Contiguous focus (may be acute or chronic)</p></li></ul><p>Open fracture, orthopedic surgery, etc.: S. aureus and S. epi</p><p>Skin breakdown + vasc. insuffic. (eg, diabetic foot, pressure ulcer): polymicrobial</p><p>GU source (GNR, Enterococcus)</p><p>Clinical manifestations</p><ul><li><p>Surrounding soft-tissue compromise ± fistula to superficial skin</p></li><li><p>± Fever, malaise, and night sweats (more common in hematogenous than contiguous)</p></li><li><p>Vertebral osteomyelitis (esp. IVDU): unremitting, focal back pain, ± fever (NEJM 2010;362:1022)</p></li></ul><p>Diagnosis (JAMA 2008;299:806)</p><ul><li><p>Crucial to obtain cx data of causative organism to avoid long-term empiric abx</p></li><li><p>Bone biopsy or tissue cx obtained surgically or via percutaneous biopsy (send aerobic, anaerobic, mycobacterial, and fungal cultures + pathology) unless ⊕ blood cx. Do not rely on swabs of ulcers or fistulae drainage.</p></li><li><p>Physical exam: high suspicion in diabetic foot (see above) if can probe ulcer to bone or ulcer >2 cm2 (Sp 83%, 90% PPV)</p></li><li><p>Blood cultures before antibiotics (more often ⊕ w/ acute hematogenous osteomyelitis)</p></li><li><p>CBC, CRP, ESR (>70 greatly ↑ likelihood of osteo)</p></li><li><p>Imaging</p></li></ul><p>Plain radiographs: normal early in disease; lytic lesions seen after 2–6 wk</p><p>MRI: preferred imaging study (overall Se 90%, Sp 82%; Archives 2007;167:125)</p><p>CT: can demonstrate periosteal reaction and cortical and medullary destruction</p><p>CT & MRI very Se but ↓ Sp; false ⊕ if contig focus w/ periosteal reaction, Charcot Δs</p><p>Radionuclide imaging: very Se but non-Sp (false ⊕ if soft-tissue inflammation)</p><p>Treatment</p><ul><li><p>Antibiotics: based on cx data. If clinically stable, consider holding antibiotics until bone bx obtained. Duration depends on Rx strategy/goals of Rx management (eg, 6 wks for vertebral osteo; Lancet 2015;385:875). After ≥7 days from either start of IV abx or surgery, if doing well consider (in consultation with ID!) ∆’ing IV to PO (if good bioavailability and bone penetration) (NEJM 2019;380:425).</p></li><li><p>Surgery should be considered for any of the following: acute osteo that fails to respond to medical Rx, chronic osteo, complications of pyogenic vertebral osteo (eg, neurologic compromise, spinal instability, epidural abscess) or infected prosthesis</p></li></ul><p>EPIDURAL ABSCESS</p><p>Etiology</p><ul><li><p>Hematogenous spread (⅔): skin infection, soft tissue (dental abscess), or endocarditis</p></li><li><p>Direct extension (⅓): vertebral osteo, sacral ulcer, spinal anesthesia or surgery, LP</p></li><li><p>Risk factors: IVDU diabetes, renal failure, alcoholism, immunosuppression</p></li><li><p>S. aureus most common pathogen; in immunosuppressed, consider fungal, TB, and Nocardia</p></li></ul><p>Clinical manifestations</p><ul><li>Back pain with spinal or paraspinal tenderness + fever ± followed by radiculopathy. Sx of cord compression or cauda equina is a surgical emergency.</li></ul><p>Diagnostic studies</p><ul><li><p>MRI with contrast</p></li><li><p>Aspiration of abscess fluid for Gram stain & cx or operative Gram stain & cx</p></li><li><p>Blood cx (frequently ⊖)</p></li></ul><p>Treatment</p><ul><li>Antibiotics (typically MRSA and gram-negative coverage initially then narrowed based on culture data) ± surgery (decompressive laminectomy and debridement) for failure to improve on medical Rx. Emergent surgery for early s/s of cord compression (w/ vertebral osteo and epidural abscess).</li></ul><p>INFECTIONS OF THE NERVOUS SYSTEM</p><p>ACUTE BACTERIAL MENINGITIS</p><p>Definition</p><ul><li><p>Inflammation of tissue around the brain/spinal cord</p></li><li><p>Usually arising from nasopharynx (hematogenous spread), bacteremia, or direct inoculation (surgery, contiguous infection, trauma, foreign body [eg, CSF shunt])</p></li></ul><p>Microbiology in Bacterial Meningitis (NEJM 2011;364:2016)</p><p>S. pneumoniae (30–60%)</p><p>Look for preceding infection (bacteremia, pneumonia, endocarditis)</p><p>Drug-resistant S. pneumoniae:</p><p>~40% PCN-resistant (even intermediate resistance problematic)</p><p>~&lt;10% 3rd-gen. cephalosporin-resistant</p><p>See “Pneumonia” for S. pneumoniae vaccination recs</p><p>N. meningitidis (10–35%)</p><p>Primarily in age &lt;30 y; associated petechiae or purpura</p><p>↑ risk in asplenia, complement defic., HIV, SCT, unvaccinated</p><p>Vaccine rec for all age 11–18 y, HIV infection, asplenia, C5-9 deficiency</p><p>H. influenzae (&lt;5%)</p><p>↑ risk in asplenia, complement defic., HIV, SCT, unvaccinated, CSF leak, trauma/surgery, mastoiditis</p><p>Vaccine rec for all children; markedly ↓ incidence</p><p>L. monocytogenes (5–10%)</p><p>↑ in immunosupp (glucocorticoids, transplant), elderly, malignancy, pregnant, cirrhosis. Outbreaks a/w contaminated dairy & raw veg.</p><p>GNRs (1–10%)</p><p>More common in health care associated meningitis (E. coli, Klebsiella sp., Pseudomonas aeruginosa)</p><p>Staphylococci (5%)</p><p>Preceding infection (endocarditis, bacteremia), post CNS surgery, foreign bodies (CSF shunt, intrathecal pump)</p><p>Mixed infection</p><p>Suspect parameningeal focus or CSF leak, post CNS surgery</p><p>Clinical manifestations (Lancet 2016;339:16)</p><ul><li><p>Headache (84%), fever (74%), stiff neck (74%), photosensitivity, GCS &lt;14 (71%), nausea (62%), seizure (23%); 95% have 2 of 4: HA, fever, stiff neck, ΔMS</p></li><li><p>Presentation may be atypical (eg, lethargy w/o fever) in elderly and immunosupp.</p></li></ul><p>Physical exam (CID 2002;35:46; Am J Emerg Med 2013;31:1601)</p><ul><li><p>Nuchal rigidity (Se 30%, Sp 68%), Kernig’s sign (Se 5%, Sp 95%), Brudzinski’s sign (Se 5%, Sp 95%), jolt sign (HA worsens w/ horizontal rotation) (Se 64%, Sp 43%)</p></li><li><p>± Focal neuro findings (~30%; hemiparesis, aphasia, visual field cuts, CN palsies)</p></li><li><p>± HEENT findings: sinus tenderness, clear rhinorrhea (CSF leak)</p></li><li><p>± Skin and joint findings: petechial rash (N. meningitidis), genital or oral ulcers (HSV), arthritis with joint effusion (N. meningitidis)</p></li></ul><p>Sequential management of bacterial meningitis</p><ol><li><p>Blood cx, initiate empiric antibiotics, consider corticosteroids (vide infra)</p></li><li><p>CT head if indicated (see below)</p></li><li><p>LP ASAP (if not contraindicated); yield of CSF cx unlikely to be changed if obtained w/in ~4 h of initiation of abx</p></li></ol><p>Diagnostic studies (NEJM 2017;388:3036)</p><ul><li><p>Blood cultures ×2 before abx</p></li><li><p>WBC count: >10,000 in >90% of bacterial meningitis in healthy hosts</p></li><li><p>Head CT to r/o mass effect before LP if ≥1 high-risk feature: immunosupp., h/o CNS disease, new-onset seizure, focal neuro findings, papilledema, GCS &lt;15 (CID 2004;39:1267)</p></li><li><p>Lumbar puncture with opening pressure (NEJM 2006;355:e12)</p></li></ul><p>Send CSF for cell count and differential, glucose, protein, Gram stain, bacterial cx</p><p>Additional CSF studies based on clinical suspicion: AFB smear/cx (or MTb PCR), cryptococcal Ag, fungal cx, VDRL, PCR (HSV, VZV, enteroviral), cytology</p><p>CSF Gram stain has 30–90% Se; cx 80–90% Se if LP done prior to abx though abx should not be delayed for LP if there is concern for bacterial meningitis</p><p>Rule of 2s: CSF WBC >2k, gluc &lt;20, TP >200 has >98% Sp for bacterial meningitis</p><p>Repeat LP only if no clinical response after 48 h of appropriate abx or CSF shunt</p><p>Metagenomic next-generation sequencing ↑ dx yield (NEJM 2019;380:2327)</p><p>Empiric Treatment of Bacterial Meningitis (Lancet 2012;380:1693)</p><p>Adults &lt;50 y</p><p>Ceftriaxone + vancomycin (trough 15–20), consider acyclovir IV</p><p>Adults >50 y</p><p>Ceftriaxone + vancomycin + ampicillin, consider acyclovir IV</p><p>Immunosuppressed</p><p>[Cefepime or meropenem] + vanc ± amp (not nec. if on meropenem), consider acyclovir IV & fungal coverage</p><p>Healthcare assoc. infection (eg, surgery, CSF shunt)</p><p>[Cefepime or meropenem or ceftazidime] + vancomycin</p><p>When possible, organism-directed Rx, guided by sensitivities or local patterns of drug resistance should be used</p><p>Confirm appropriate dosing as higher doses are often needed in meningitis (though may need to be adjusted for renal function)</p><p>Corticosteroids: If causative organism is unknown, dexamethasone 10 mg IV q6h × 4 d recommended prior to or with initiation of abx. Greatest benefit in S. pneumoniae and GCS 8-11 (↓ neuro disability & mortality by ~50%). Avoid in crypto (NEJM 2016;374:542).</p><p>Prophylaxis: for close contacts of Pt w/ N. meningitidis; rifampin (600 mg PO bid × 2 d) or ciprofloxacin (500 mg PO × 1) or ceftriaxone (250 mg IM × 1).</p><p>See Microbiology in Bacterial Meningitis Table for available vaccinations.</p><p>Precautions: droplet precautions until N. meningitidis is ruled out</p><p>ASEPTIC MENINGITIS</p><p>Definition</p><ul><li>Clinical/lab evidence of meningeal inflammation with negative bacterial cx (CSF & blood)</li></ul><p>Etiologies (Neurology 2006;66:75)</p><ul><li><p>Viral: enteroviruses are most common cause (summer/fall; rash, GI, URI sx), HIV, HSV, VZV, mumps (parotitis), lymphocytic choriomeningitis virus (rodent exposure), encephalitis viruses, adenovirus, polio, CMV, EBV, WNV</p></li><li><p>Focal bacterial infection: brain/epidural/subdural abscess, CNS septic thrombophlebitis</p></li><li><p>Partially treated bacterial meningitis</p></li><li><p>Other infectious: TB, fungal (cryptococcus, coccidiodes), Lyme, syphilis, leptospirosis</p></li><li><p>Neoplasm: intracranial tumors (or cysts), lymphomatous or carcinomatous meningitis</p></li><li><p>Drug-induced meningitis: NSAIDs, IVIG, antibiotics (TMP-SMX, PCN), anti-epileptics</p></li><li><p>Systemic autoimmune illness: SLE, sarcoidosis, Behçet’s, Sjögren’s syndrome, RA</p></li><li><p>Mollaret’s: recurrent lymphocytic meningitis, spontaneously resolving (often HSV-2)</p></li></ul><p>Diagnosis</p><ul><li><p>Obtain LP for CSF analysis: lymphocytic pleocytosis common in viral etiologies (see Typical CSF Findings in Meningitis table above)</p></li><li><p>Consider CSF cytology and MRI brain/spine to evaluate for malignancy</p></li><li><p>Consider serum autoimmune and serum viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric treatment</p></li></ul><p>Empiric treatment</p><ul><li><p>Suspected bacterial meningitis: see empiric treatment of bacterial meningitis above</p></li><li><p>Suspected viral meningitis: if concern for HSV meningoencephalitis → IV acyclovir</p></li><li><p>Unclear etiology: consider initiation of empiric bacterial meningitis treatment while observing and awaiting CSF studies</p></li></ul><p>ENCEPHALITIS (NEJM 2018;379:557)</p><p>Definition</p><ul><li>Inflammation of brain parenchyma characterized by impaired cerebral function (AMS, neurologic deficits) often due to primary viral infection or post-viral inflammation</li></ul><p>Etiologies (specific etiology found in &lt;20% of cases; Neurology 2006;66:75; CID 2008;47:303)</p><ul><li><p>HSV-1 all ages/seasons. If sxs recur after Rx, consider viral relapse vs. autoimmune encephalitis b/c high rates of autoimmune disease wks later (Lancet Neurol 2018;17:760).</p></li><li><p>VZV 1° or reactivation; ± vesicular rash; all ages (favors elderly), all seasons</p></li><li><p>Arboviruses: evaluate for exposure to vector/geography. Mosquitoes: West Nile, Eastern/Western equine, St. Louis, La Crosse; Ixodes tick: Powassan.</p></li><li><p>Enteroviruses (coxsackie, echo): preceding URI/ GI sx; peaks in late summer/early fall</p></li><li><p>Other infectious: CMV, EBV, HIV, JC, measles, mumps, rabies, adeno, influenza, Lyme</p></li><li><p>Non-infectious: autoimmune/paraneoplastic (anti-NMDAR, anti-Hu, anti-Ma2, anti-CRMP5, anti-mGluR5), post-infxn demyelination (eg, ADEM)</p></li></ul><p>Clinical manifestations</p><ul><li>Fever + ΔMS (subtle to severe), seizure, focal neuro deficit, HA in meningoencephalitis</li></ul><p>Diagnostic studies (CID 2013;57:1114)</p><ul><li><p>CSF analysis: lymphocytic pleocytosis; PCR for HSV (95% Se & Sp), VZV; consider other PCR based on risk factors (CMV/EBV, HIV, JC, adeno/enterovirus, WNV)</p></li><li><p>Consider testing for autoimmune etiologies and serologic viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric HSV/VZV Rx</p></li><li><p>MRI (CT if unavailable); HSV temporal lobe; W. Nile & Powassan thalamic hyperintensity</p></li><li><p>EEG to r/o seizure; findings in encephalitis are nonspecific (temporal lobe focus in HSV)</p></li></ul><p>Treatment</p><ul><li>HSV/VZV: IV acyclovir 10 mg/kg IV q8h; consider empiric treatment given frequency</li></ul><p>BELL’S PALSY</p><p>Definition & clinical manifestations</p><ul><li><p>Acute idiopathic unilat. facial nerve palsy (CN VII), often presumed HSV reactivation</p></li><li><p>P/w unilateral facial muscle weakness, hyperacusis, ↓ taste, lacrimation, & salivation</p></li><li><p>Risk factors: pregnancy (preeclampsia), obesity, HTN, diabetes, preceding URI</p></li></ul><p>Diagnosis (Otol Head Neck Surg 2013;149:656)</p><ul><li><p>Labs, imaging, EMG not needed in routine cases</p></li><li><p>Ddx: Bilateral: Lyme, GBS, sarcoid. Additional neuro sx: stroke, tumor. Rash: herpes zoster. Other: otitis media, HIV, Sjögren.</p></li></ul><p>Treatment and Prognosis (CMAJ 2014;186:917)</p><ul><li><p>70% recover spontaneously w/in 6 mos, >80% recover with glucocorticoid treatment</p></li><li><p>Oral corticosteroids started w/in 72 hrs of sx onset improve odds of recovery; dose varies based on severity (House-Brackmann grading). No conclusive data on antivirals.</p></li><li><p>If eyelid closure is compromised, eye protection is crucial to prevent trauma</p></li></ul><p>HERPES ZOSTER (SHINGLES)</p><p>Definition & etiology</p><ul><li><p>Painful vesicular rash in a peripheral nerve distribution due to reactivation of VZV</p></li><li><p>Spread by contact with active lesion (prior to crusting) in uncomplicated zoster or via airborne transmission in disseminated zoster</p></li></ul><p>Clinical manifestations & complications</p><ul><li><p>Uncomplicated: pain in a dermatomal distribution → dermatomal eruption of erythematous papules → vesicles → crusted plaques in varying stages of evolution</p></li><li><p>Disseminated: vesicles across multiple dermatomes, visceral organ involvement (pneumonia, hepatitis, CNS) seen in immunosupp. (eg, transplant, malignancy)</p></li><li><p>Zoster opthalmicus: ocular involvement (V1 of CN V) requires urgent ophtho eval</p></li><li><p>Post-herpetic neuralgia: neuropathic pain lasting >90 d after dx</p></li></ul><p>Diagnosis</p><ul><li>Clinical diagnosis if uncomplicated. Confirm with PCR (most sensitive), DFA, and viral culture (allows for resistance testing) of vesicular fluid (scrape from unroofed vesicle).</li></ul><p>Treatment & prevention</p><ul><li><p>Uncomplicated: acyclovir, valacyclovir, or famciclovir x 7 d; initiate w/in 72 h of onset for greatest benefit; consider after 72 h if new lesions present; minimal benefit after crusting</p></li><li><p>Superimposed bacterial cellulitis is common; if suspected, treat with appropriate antibiotics</p></li><li><p>Disseminated/immunosupp.: IV acyclovir, eval for visceral spread, droplet precautions</p></li><li><p>Prevention: Shingrix (2 doses) for all Pts >50; consider in younger if immunosupp.</p></li></ul><p>BACTEREMIA & ENDOCARDITIS</p><p>BACTEREMIA</p><p>Definitions</p><ul><li><p>1° bacteremia: bloodstream infection due to direct inoculation of the blood</p></li><li><p>Central line associated bloodstream infection (CLABSI): bacteremia in which the same organism is growing from peripheral and catheter cultures (CID 2009;49:1)</p></li><li><p>2° bacteremia: infection of another site (eg, UTI, PNA, colitis, etc.) spreading to blood</p></li><li><p>Contaminant: bacteria growing in a blood culture that does not represent a true infection</p></li></ul><p>Risk factors for bloodstream infections (JAMA 2012;308:502; CID;2020;71)</p><ul><li>Syndromes with high likelihood of bacteremia:</li></ul><p>Sepsis</p><p>Endovascular infxns: endocarditis, infection of pacemaker, vascular graft or IV catheter</p><p>Vertebral osteomyelitis, epidural abscess, septic arthritis</p><ul><li><p>Risk factors: indwelling lines, IVDU, immunosupp. (neutropenic, transplant)</p></li><li><p>Organisms</p></li></ul><p>More likely pathogenic: S. aureus, β-hemolytic strep, enterococci, GNR, S. pneumo, Neisseria, Candida</p><p>Less likely pathogenic: coag-neg staph, diphtheroids, Cutibacterium</p><ul><li><p>Time to growth: &lt;24 h → higher risk, >72 h → lower risk (except slow-growing, eg, HACEK)</p></li><li><p>Factors increasing likelihood of endocarditis: high-grade bacteremia w/o source, persisting after line removal or drainage of focal source, in hosts at risk for endocarditis or w/ organisms known to cause IE; emboli</p></li></ul><p>Diagnosis</p><ul><li><p>≥2 sets BCx prior to abx (set = aerobic + aneaerobic cx) at separate puncture sites</p></li><li><p>If proven bacteremia, daily surveillance cxs until 48 hrs of ⊖ cxs. May not need for GNRs (ClD 2017;65:1776).</p></li><li><p>TTE/TEE if concern for endocarditis (see IE section)</p></li><li><p>TTE and urgent ophthalmology evaluation if yeast is growing in BCx</p></li></ul><p>Treatment (CID 2009;49:1; JAMA 2020;323:2160)</p><ul><li>Empiric abx based on Gram stain, cx, & clinical syndrome, then tailor based on sensi</li></ul><p>Short-Term Central Venous Catheter-Related Bloodstream Infxns</p><p>S. aureus</p><p>Risk of endocarditis in bacteremia: ~25% (JACC 1997;30:1072).</p><p>ID consult a/w ↓ mortality (ClD 2015;60:1451).</p><p>Remove CVC, evaluate for endocarditis, osteo, hardware infections.</p><p>Preferred abx: MSSA → nafcillin, oxacillin, or cefazolin. MRSA → vancomycin. Duration: 2 wks if normal host, no implants, no e/o endocarditis or metastatic complications. Otherwise 4–6 wks.</p><p>Coag-neg staphylococci</p><p>CVC retention does not ↓ rate of resolution, but a/w ↑ rate of recurrence (CID 2009;49:1187). If CVC left, treat 10–14 d; if removed 5–7d.</p><p>Enterococcus</p><p>Remove CVC & treat for 7–14 d</p><p>GNR</p><p>Remove CVC esp if Pseudomonas. Rx for 14 d (7 if uncomplicated).</p><p>Yeast</p><p>Remove CVC & treat for 14 from first ⊖ BCx. ID consult a/w ↓ mortality.</p><ul><li>Persistently ⊕ BCx: remove CVCs, look for metastatic infxn (endocarditis, septic arthritis, osteo), infected thrombosis, or prosthetic material (vascular graft, PPM)</li></ul><p>BACTERIAL ENDOCARDITIS</p><p>Definition</p><ul><li>Infection of endothelium of heart (including but not limited to the valves) including both prosthetic valve endocarditis (PVE) and native valve endocarditis (NVE)</li></ul><p>Risk Factors</p><ul><li>Abnormal valve (JAMA 1997;277:1794; JACC 2018;72:2443)</li></ul><p>High risk: prior endocarditis, prosthetic valve or ring, some congenital heart disease (unrepaired cyanotic; shunt/conduit; prosthesis in past 6 mos), transplant heart, valvulopathy, VAD</p><p>Medium risk: previous rheumatic fever, non-rheumatic valve disease (including MVP w/ MR or thickened leaflet), HCM, bicuspid AoV</p><ul><li>Risk of bacteremia: IVDU, indwelling venous catheters, hemodialysis, prosthetic material in heart (eg, pacemaker, ICD, graft), poor dentition</li></ul><p>a↑ risk w/ DM, indwelling lines, immunosupp. bCx ⊖ = abiotrophic strep, HACEK (Haemophilus para-influenzae & aphrophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella), T. whipplei, Bartonella, Coxiella, Chlamydia, Legionella, Brucella (JAMA 2007;297:1354; Annals 2007;147:829; J Clin Microbiol 2012;50:216)</p><p>Clinical manifestation (Lancet 2016;387:882)</p><ul><li><p>Persistent bacteremia → fever (80–90%), rigors, night sweats, anorexia, myalgias</p></li><li><p>Valvular or perivalvular infection → HF, conduction abnormalities (eg, AVB)</p></li><li><p>Septic emboli: stroke, embolic MI, renal/splenic/pulmonary infarcts, septic arthritis, osteo</p></li><li><p>Immune complex phenomena: arthritis, glomerulonephritis</p></li><li><p>Subacute endocarditis can present with subacute progressive “B” sx (fatigue, wt loss)</p></li></ul><p>Physical exam</p><ul><li><p>Cardiac murmur (85%), s/s of new HF (pulmonary edema, JVP elevation, edema)</p></li><li><p>Skin/ocular changes (uncommon but highly specific)</p></li></ul><p>Janeway lesions (painless hemorrhagic macules on palms/ soles due to septic emboli)</p><p>Osler’s nodes (painful nodules on pads of digits due to immune complex deposition)</p><p>Splinter hemorrhages in fingernails or toenails</p><p>Roth spots (retinal hemorrhages)</p><ul><li><p>MSK: point tenderness along spine, red/hot joints</p></li><li><p>Neurologic deficits c/f embolic stroke; vertebral tenderness c/f osteo or epidural abscess</p></li><li><p>Devices: evaluate CVCs, PM/ICD pocket, and sites of other hardware/ prosthetics</p></li></ul><p>Diagnosis (CID 2010;51:131; EHJ 2015;36:3075; Circ 2015;132:1435)</p><ul><li><p>Blood cultures (before abx): 3 sets (aerobic & anaerobic bottles) from different sites, ideally spaced ≥1 h apart. ✓ BCx (at least 2 sets) after appropriate abx have been initiated to document clearance; repeat q24–48h until ⊖.</p></li><li><p>Serial ECGs to assess for conduction disease and ↑ PR interval (c/f perivalvular abscess)</p></li><li><p>Echocardiogram: TTE in all Pts. TEE if (i) TTE abnl but nondx, (ii) TTE ⊖ but high suspicion, (iii) complications suspected or present (eg, AVB), (iv) high-risk (prosthetic valve, CIED, prior IE, congenital heart dis.), (v) S. aureus, enterococcus, or fungus, (vi) Δ in signs or sx (eg, new conduction abnl, regurgitation, etc.) (vii) if considering a shortened course (10–14 d) of abx (vide infra)</p></li></ul><p>Sensitivity</p><p>NVE</p><p>PVE</p><p>Abscess</p><p>Transthoracic (TTE)</p><p>39–58%</p><p>33%</p><p>18–63%</p><p>Transesophageal (TEE)</p><blockquote><p>90%</p></blockquote><p>86%</p><p>76–100%</p><p>(Mayo Clin Proc 2014;89:799; Circ 2015;132:1435; Eur Radiol 2015; 25:2125; J Am Soc Echo 2016;29:315)</p><ul><li><p>Gated cardiac CT useful if TTE/TEE equivocal or suspected paravalvular abscess</p></li><li><p>PET/CT using FDG useful for suspected PVE or CIED infxn if TTE/TEE equivocal</p></li><li><p>Brain/spine imaging if concern for CNS spread (mycotic aneurysms, embolic stroke) or spinal involvement (vertebral osteo, epidural abscess)</p></li><li><p>Cx ⊖ endocarditis: may be due to abx prior to BCx. PCR, bacterial 16S ribosomal RNA, serol. may be helpful. Detailed hx: animal exposure, travel, unpast. dairy, etc. ID eval. Consider organisms listed in Cx ⊖ footnote in microbiology table (vide supra).</p></li></ul><p>Modified Duke Criteria</p><p>Definitive: 2 major or 1 major+3 minor or 5 minor; Possible: 1 major+1 minor or 3 minor</p><p>Major</p><p>Minor</p><ul><li><p>BCx with common endocarditis pathogen (grown in 2 separate cx)</p></li><li><p>Coxiella serology ≥1:800</p></li><li><p>Endocardial involvement: vegetation, abscess, prosthetic dehiscence or new valvular regurgitation</p></li><li><p>Predisposing condition (see risk factors)</p></li><li><p>Fever</p></li><li><p>Vascular phenomena: septic arterial or pulmonary emboli, mycotic aneurysms, ICH, Janeway lesions</p></li><li><p>Immune phenomena: ⊕ RF, GN, Osler’s nodes, Roth spots</p></li><li><p>⊕ BCx not meeting major criteria</p></li></ul><p>Se ~90%, Sp >95%, NPV ≥92% (CID 2000;30:633).</p><p>Treatment (ID consult is strongly recommended)</p><p>Treatment (Circ 2015;132:1435)</p><p>Empiric</p><p>NVE or PVE >12 mos post-op: vanc + CTX</p><p>PVE &lt;12 mos post op: vanc + CTX ± gentamicin (if OK renal fxn)</p><p>Strep</p><p>Penicillin, ampicillin, cftx; if PVE consider gentamicin in discussion w/ ID</p><p>Staph (S. aureus and lugdunensis)</p><p>MRSA: vanc or dapto</p><p>MSSA: nafcillin, oxacillin, or cefazolin (avoid if CNS involvement due to poor penetration); vanc inferior to β-lactam for MSSA</p><p>For PCN allergy w/ MSSA consider desensitization</p><p>Consider rifampin / gentamicin in PVE in discussion w/ ID</p><p>Enterococci</p><p>Ampicillin + [CTX or gent]; if VRE: linezolid, dapto, ampicillin if sensitive</p><p>Gram negatives</p><p>HACEK: CTX, ampicillin or FQ. Pseudomonas: 2 anti-Pseudomonal agents [eg, β-lactam + (aminoglycoside or FQ)]</p><p>Fungi (candida, aspergillus)</p><p>Candida: amphotericin B ± flucytosine or micafungin</p><p>Aspergillus: amphotericin B or voriconazole</p><p>Ophtho consult for fungemia to rule out endophthalmitis</p><ul><li><p>De-escalate abx to organism-directed therapy based on speciation and sensitivities</p></li><li><p>If on anticoagulation or antiplatelet, typically can continue unless concern for stroke, intracranial hemorrhage, or need for emergent surgery</p></li><li><p>Monitor for complications of endocarditis (CHF, conduction block, osteomyelitis, new embolic phenomenon) which can occur even on abx</p></li><li><p>Duration is usually 4–6 wks</p></li></ul><p>After ≥10d IV abx can consider ∆’ing to PO if clinically appropriate and available PO abx in consultation with ID (NEJM 2019;380:415)</p><p>Uncomplicated right-sided NVE or PCN-S Strep spp → 2 wks may be adequate</p><ul><li>IVDU-associated best managed by multidisciplinary teams including Addiction Medicine</li></ul><p>Indications for surgery (consult early; JTCS 2017;153:1241; Circ 2021;143:e72)</p><ul><li><p>Emergent if refractory cardiogenic shock</p></li><li><p>Urgent (during initial hospitalization):</p></li></ul><p>Sx HF</p><p>Penetrating infection: periannular abscess, heart block, fistula, worsening conduction</p><p>Persistent infection: ⊕ BCx after >5 d of appropriate abx, ↑ or ? large vegetation</p><p>Emboli: recurrent or w/ residual large (>10 mm) vegetation & severe AR/MR. Cerebral emboli not contraindic. unless severe stroke or hemorrhage (Stroke 2006;37:2094).</p><p>S. aureus, fungal or multiRx-resistant organisms</p><p>PVE (emergent if dysfunction or dehiscence)</p><p>Endocarditis Prophylaxis (Circ 2007;116:1736)</p><p>Cardiac conditions*</p><p>Prosthetic valve; previous endocarditis; congenital heart disease (CHD) including unrepaired or incompletely repaired cyanotic CHD (palliative shunts or conduits), 1st 6 mo after completely repaired CHD using prosthetic material; cardiac transplant recipients w/ valvulopathy.</p><p>(Prophylaxis no longer rec. in acquired valvular dysfxn, bicuspid AoV, MVP with leaflet thickening or regurgitation, HCM.)</p><p>Procedures*</p><p>Dental: manipulation of gingival tissue or periapical region of teeth or perf oral mucosa (eg, extraction, periodontal, implant, root canal, cleaning)</p><p>Regimens</p><p>Oral: amoxicillin 2 g 30–60 min before</p><p>Unable to take PO: amp 2 g IM/IV or cefazolin or CTX 1 g IM/IV</p><p>PCN-allergic: cephalexin or azithro or claritho or doxy</p><p>*Pts should meet both indications (high-risk condition & high-risk procedure) to qualify for Ppx</p><p>TUBERCULOSIS</p><p>Definitions</p><ul><li><p>Primary: new Mycobacterium tuberculosis (TB) in a naïve host; symptomatic or asymptomatic; 90% of infected normal hosts will never develop clinically evident disease</p></li><li><p>Latent: well-controlled infection without clinical or radiographic evidence of active disease; can persist for years to decades</p></li><li><p>Reactivated: activation of latent; more likely in the setting of immunosuppression.</p></li><li><p>Milliary: disseminated lympho-hematogenous spread due to primary or reactivated TB</p></li><li><p>Multidrug-resistant (MDR): resistant to isoniazid (INH) & rifampin. Can occur as 1° infxn.</p></li><li><p>Extensively drug-resistant (XDR): resistant to INH, rifampin (RIF), fluoroquinolones (FQ), and at least one of amikacin, kanamycin, or capreomycin</p></li></ul><p>Epidemiology (NEJM 2016;375:1081)</p><ul><li><p>Transmission via aerosols; untreated active dx requires airborne isolation in healthcare facilities and community isolation measures; must involve local public health authorities</p></li><li><p>Acquisition: residents/travel in TB-endemic area, IVDU, resident/worker in correctional facility or homeless shelter, close contact w/ active TB</p></li><li><p>Reactivation: risk is 5% in first 2 yr, 5–10% overall; ↑ if HIV ⊕, immunosupp. (anti-TNF, steroids), ESRD, DM, cancer, transplant, malnourished, smoker, substance use disorder</p></li></ul><p>Screening for latent TB</p><ul><li><p>Whom to screen: high likelihood of exposure and/or high risk of progression to active disease including HIV ⊕ and prior to immunosuppression (pre-transplant or anti-TNF)</p></li><li><p>Relies on host immune system, so limited Se in immunosuppressed individuals</p></li><li><p>Nb, testing for host exposure & immune response to TB, not whether TB active (vide infra)</p></li><li><p>Screening tests</p></li></ul><p>IFN-γ release assays (IGRA): preferred test; Ag-stimulated IFN-γ release from Pt’s T-cells. ↑ Sp over TST/PPD in BCG vaccinated Pts.</p><p>Tuberculin skin test (TST/ PPD): inject purified protein intradermally, examine for wheal 48–72 hrs later. Interpret based on max diameter of induration, not erythema.</p><p>Size of Reaction</p><p>Persons Considered to Have ⊕ Test (NEJM 2002;347:1860)</p><blockquote><p>5 mm</p></blockquote><p>HIV ⊕ or immunosupp. (eg, prednisone 15 mg/d × >1 mo)</p><p>Close contacts of Pt w/ active TB; CXR c/w prior active TB</p><blockquote><p>10 mm</p></blockquote><p>All other populations with ↑ prevalance/risk. Healthcare workers, recent conversion (↑ induration by >10 mm in 2 y).</p><blockquote><p>15 mm</p></blockquote><p>No risk factors</p><p>False ⊖</p><p>Faulty application, anergy (including from active TB), acute TB</p><p>(2–10 wk to convert), acute non-TB mycobacteria (NTM), malignancy</p><p>False ⊕</p><p>Improper reading, cross-reaction with NTM, BCG vaccination (although usually &lt;10 mm by adulthood)</p><p>Booster effect</p><p>↑ in duration b/c immunologic boost by prior skin test in prev sensitized individual (by TB, NTM, or BCG). Test ⊖ → ⊕ but not true conversion due to recent infxn. 2nd test true baseline. Can be 1 y after initial test.</p><p>Clinical manifestations (Lancet 2016;387:1211)</p><ul><li><p>Constitutional symptoms are common in all manifestations, but may be absent</p></li><li><p>Primary TB pneumonia: middle or lower lobe consolidation, ± effusion, ± cavitation</p></li><li><p>TB pleurisy: pulmonary effusion ± pericardial and peritoneal effusions secondary to granuloma breakdown and local inflammation; can occur in primary or reactivation</p></li><li><p>Reactivation TB pulmonary disease: upper lobe infiltrate ± volume loss ± cavitation</p></li><li><p>Milliary TB: diffuse millet seed-sized lesions, more common in immunosupp.</p></li><li><p>Extrapulmonary TB: lymphadenitis, pericarditis, peritonitis, CNS disease including meningitis, GU tract disease ± sterile pyuria, osteoarticular disease (vertebral = Pott’s disease), granulomatous hepatitis, splenitis, cutaneous disease</p></li><li><p>TB and HIV: HIV ⊕ at ↑ risk infxn, reactivation (8–10%/yr without ART, higher w/ ↓ CD4), and progressive 1° infxn. CXR can be atypical espec. if CD4 ≤200 (JAMA 2005;293:2740).</p></li></ul><p>Diagnostics for active TB (CID 2017;64:11)</p><ul><li><p>Pulmonary TB: common CXR findings discussed above; induced sputum AFB smear & culture (3 samples at least 8 h apart) ± NAAT/ PCR (GeneXpert); consider bronchoscopy + BAL ± transbronchial biopsy. GeneXpert can also detect RIF resistance (non-bloody sputum only). Sp 98%/Se 74%, independent of HIV status.</p></li><li><p>Extrapulmonary TB</p></li></ul><p>Pleural/pericardial effusions or ascites: fluid sampling for AFB cx/smear, NAAT/ PCR, cell counts. Adenosine deaminase (ADA) can be ↑, best validated in ascites. Free INFγ can be elevated in pleural/ascitic fluid (not validated in pericardial effusions). Higher diagnostic yield with pleural/pericardial biopsies for disease at these sites.</p><p>CSF: fluid sampling for AFB cx/smear (submit at least 10 mL), NAAT/PCR, cell count (lymphocyte predominanace), glucose (low), protein (high), ADA (high)</p><p>Soft tissue: tissue biopsy with AFB staining, pathology w/ granulomas</p><p>Treatment of latent TB</p><ul><li><p>If screening test ⊕ and no risk factors, confirm prior to treatment; if ⊕ w/ risk factors, proceed to treatment (CID 2017;64:11).</p></li><li><p>Prior to treatment of latent TB, active TB must be ruled out with, at a minimum, ROS for symptoms (cough, fever, night sweats, weight loss), physical exam, and CXR (though may be normal in immunosupp.)</p></li></ul><p>Scenario</p><p>Prophylaxis Regimen</p><p>PPD/IGRA ⊕ (regardless of HIV status)</p><p>1st line: Rifampin × 4 mo or INH/rifampin daily x 3 mos or INH/rifapentine weekly × 12 wks) (MMWR 2020; 69:1)</p><p>Alternative: INH + vitamin B6 × 6–9 mos</p><p>Contact case known or suspected to have MDR TB</p><p>No proven regimen: ? PZA + EMB, ? PZA + FQ</p><ul><li>✓ LFTs monthly if receiving INH (risk ↑ w/ age; Chest 2005;128:116): if AST/ALT ↑ 5× ULN or sx (nausea, vomiting, abd pain) → stop TB meds & re-eval</li></ul><p>Patient isolation</p><ul><li><p>Decision based on likelihood of active disease. Consider when cough, dyspnea, hemoptysis, ≥1 risk factor (HIV ⊕, foreign born, substance use disorder, homeless, recent incarceration, prior TB or exposure).</p></li><li><p>Discontinue if alternative dx and AFB smear neg ×3, or TB treated for 2 wk & AFB neg ×3</p></li></ul><p>Treatment of active tuberculosis (NEJM 2015;373:2149; Lancet 2016;387:1211)</p><ul><li><p>Prior to treatment, consult ID, check LFTs, Cr, HIV & hepatitis A/B/C screen, DM screen, pregnancy screen, vision testing for acuity and color, EtOH use history</p></li><li><p>Treatment requires several drugs to prevent resistance (see below)</p></li><li><p>Suspect MDR TB if prior TB Rx (esp. if poor adherence), travel to area w/ ↑ rates of MDR (India, China, Eastern Europe including Russia, South Africa), exposure to person w/ likely MDR-TB (NEJM 2008;359:636)</p></li><li><p>“Paradoxical worsening” of sx can occur after starting Rx. More common w/ extrapulm. TB & more frequent/severe w/ concurrent immune reconstitution (eg, HIV ⊕ Pts started on ART, Pts taken off immunosuppression). Must r/o Rx failure (repeat Cx, imaging), consider checking drug levels.</p></li><li><p>Duration of treatment varies based on host, clinical manifestation, and improvement/ progression on treatment</p></li></ul><p>Antituberculous Medications</p><p>Drug</p><p>Adverse Effects*</p><p>Isoniazid (INH)</p><p>Hepatitis (avoid EtOH), periph neuropathy (↓ risk by suppl. vit B6), drug-induced lupus</p><p>Rifampin (RIF)</p><p>Orange tint of body fluids, GI upset, hepatitis (avoid EtOH), hypersensitivity, fever, drug interactions</p><p>Pyrazinamide (PZA)</p><p>Hepatitis (avoid EtOH), hyperuricemia, arthritis</p><p>Ethambutol (EMB)</p><p>Optic neuritis</p><p>Streptomycin (SM)</p><p>Ototoxicity, nephrotoxicity</p><p>Amikacin (AMK)</p><p>Ototoxicity, nephrotoxicity</p><p>Quinolone (moxifloxacin, levofloxacin)</p><p>GI upset, tendinopathy, ↑ QTc</p><p>*Risk of hepatitis ↑ w/ pre-existing liver disease. Consult ID, consider holding/replacing PZA or INH.</p><p>Scenario</p><p>Antituberculous Treatment Regimens</p><p>Pulmonary TB</p><p>≥4% INH-resist. in community (incl. most of U.S.)</p><p>INH + RIF + PZA + EMB until suscept. known</p><p>If sensitive to INH & RIF → INH + RIF + PZA × 2 mo, then → INH + RIF × at least 4 mo</p><p>If resistant, see next row</p><p>Drug-resistant TB (INH-R, RIF-R, or MDR/XDR)</p><p>Consult ID specialist</p><p>(NEJM 2008;359:636)</p><p>Extrapulmonary TB</p><p>Consult ID specialist</p><p>TB in HIV ⊕ patient</p><p>Consult ID specialist</p><p>HIV/AIDS</p><p>Definition & Clinical Manifestations</p><ul><li><p>Acute HIV: rash, lymphadenopathy, fever, oral ulcers, pharyngitis, myalgias, diarrhea Presents ~2–6 wk after exposure; not all HIV infections result in symptoms of acute HIV</p></li><li><p>AIDS: HIV + CD4 &lt;200/mm3 or AIDS-defining opportunistic infection (OI) or malignancy</p></li></ul><p>Epidemiology</p><ul><li><p>~1.2 million Americans living w/ HIV (13% unaware); ~37 million worldwide</p></li><li><p>High risk groups: MSM, transgender women, IVDU, sex worker, partners of high-risk Pts</p></li><li><p>Transmission: sexual (risk 0.1–1% per sex act w/o ARV), needlesticks (occupational or IVDU), vertical (15–40% w/o ARV), transfusions, organ transplant (uncommon in U.S.)</p></li></ul><p>Prophylaxis (NEJM 2015;373:2237; Lancet 2016;387:53; J Infect Dis 2018;218:16; CDC 2021)</p><ul><li><p>Pre-exposure (PrEP): TDF/FTC daily, ↓ transmission >90% if adherent. Consider for serodiscordant partners, condomless sex in high-risk groups, STI w/in 6 mo, IVDU w/ equipment sharing. Rule out HIV prior to initiation, ✓ renal fxn, STIs, & HIV q3 mo.</p></li><li><p>Post-exposure (PEP): start ASAP (within 72 hr) after high-risk exposure from HIV ⊕ source (case-by-case decision if HIV status ?). Test baseline HIV, STIs, HBV, HCV. Rx: 2 NRTIs (usually TDF/FTC) + RAL or DTG × 4 wks. Consider initiating PrEP afterwards.</p></li></ul><p>Screening and Diagnosis (JAMA 2018;320:379)</p><ul><li><p>Screen all 13–64 yo at least once, every preg, if new STI dx; screen high risk annually</p></li><li><p>HIV Ab/p24Ag (ELISA assay): ⊕ 1–12 wk after acute infxn; >99% Se; 1° screening test</p></li><li><p>If ⊕, Ab differentiation assay confirms and differentiates HIV-1 vs. -2 (MMWR 2013;62:489)</p></li><li><p>HIV RNA PCR viral load (VL) in plasma; assay range is 20–10 million copies/mL; false ⊕ can occur, but usually low # copies; in contrast, VL should be high (>750 k) in 1° infxn</p></li><li><p>CD4 count: not a dx test, b/c can be HIV ⊕ w/ normal CD4 or be HIV ⊖ w/ low CD4</p></li></ul><p>Approach to newly diagnosed HIV ⊕ Pt (CID 2020;73:e3572)</p><ul><li><p>Counsel re: excellent prognosis w/adherence to treatment, treatment options, & disclosure</p></li><li><p>Lab evaluation: CD4 count, HIV VL & genotype, CBC w/ diff., BMP, LFTs, HbA1c, lipids, UA, PPD/ IGRA, syphilis Ab, Chlamydia & gonorrhea (3 site), Hep A/B/C, G6PD (if high-risk ethnicity), preg screen, HLA-B*5701 if Rx w/ abacavir. If AIDS: CMV IgG, Toxo IgG.</p></li><li><p>Confirm all vaccinations (including annual flu) are up to date, avoid live vax if CD4 ≤200</p></li><li><p>Initiate ARV early (same day, preferably after labs/genotype and w/ guidance from HIV specialist) regardless of CD4 level because ↓ mortality (NEJM 2015;373:795)</p></li><li><p>Treatment prevents transmission to partners. Risk of transmission w/ unprotected sex w/ undetectable VL >6 months is ~0% (JAMA 2016;316:171; Lancet HIV 2018;5:e438).</p></li><li><p>Regimens include: 2 NRTI (eg, TAF + FTC) + either INSTI or boosted PI (eg, DRV/r)</p></li></ul><p>Common Antiretrovirals (ARVs)</p><p>Common Side Effects</p><p>NRTI</p><p>abacavir (ABC; Ziagen)</p><p>emtricitabine (FTC; Emtriva)</p><p>lamivudine (3TC; Epivir)</p><p>tenofovir (TAF or TDF)</p><p>zidovudine (AZT; Retrovir)</p><p>Class: GI intol, lipoatrophy, lactic acidosis</p><p>ABC: hypersensitivity (3%), ✓ HLA-B*5701</p><p>AZT: BM suppression (esp. macrocytic anemia)</p><p>TDF: renal toxicity, bone density loss</p><p>TAF: minimal renal toxicity</p><p>NNRTI</p><p>efavirenz (EFV; Sustiva)</p><p>etravirine (ETR; Intelence)</p><p>nevirapine (NVP; Viramune)</p><p>rilpivirine (RPV; Edurant)</p><p>Class: rash, hepatitis, mixed CYP450 inducer/inhib</p><p>EFV: CNS effects (incl depression)</p><p>NVP: rash and hypersensitivity [risk factors are female, CD4 >250, pregnancy (∴ avoid)]</p><p>PI</p><p>atazanavir (ATV; Reyataz)</p><p>darunavir (DRV; Prezista)</p><p>lopinavir (LPV; Kaletra)</p><p>PIs given w/boosters ritonavir or cobicistat for ↑ PK</p><p>Class: GI intol; hepatotoxicity; inhibit CYP450 (many DDIs, eg statins, steroids, DOACs); ↑ glc; hyperlipid (less w/ ATV); MI (NEJM 2007;356:1723)</p><p>ATV: crystalluria → nephrolithiasis</p><p>DRV: rash (10%); possible sulfa cross-reactivity</p><p>EI</p><p>maraviroc (MVC; Selzentry)</p><p>Dizziness, hepatotoxicity; ✓ CCR5 tropism assay</p><p>INSTI</p><p>bictegravir (BIC; Biktarvy) dolutegravir (DTG; Tivicay)</p><p>elvitegravir (EVG; Vitekta)</p><p>raltegravir (RAL; Isentress)</p><p>cabotegravir (CAB; Vocabria)</p><p>Class: diarrhea; weight gain; ↑ CPK</p><p>DTG/BIC ↑ metformin levels; monitor glc</p><p>DTG a/w 0.003% risk of neural tube defects (NEJM 2019;381:827)</p><p>CAB/RPV: injection site rxn</p><p>NRTI, nucleoside/tide reverse transcriptase inhib; NNRTI, nonnucleoside RTI; PI, protease inhib; EI, entry inhib (CCR5 antagonist); INSTI, integrase inhib; several multiclass combo pills exist</p><ul><li><p>Initiation of ARVs may transiently worsen existing OIs (TB, MAC, CMV, others) due to immune reconstitution inflammatory syndrome (IRIS). Prednisone during 1st 4 wks of ARVs ↓ risk for TB-associated IRIS, but not routinely given (NEJM 2018;379:1915).</p></li><li><p>Do not start ARVs immediately if c/f cryptococcal or TB meningitis</p></li><li><p>After ARV initiation, check VL q4 wks until undetectable, then monitor q3–4 mos</p></li></ul><p>Approach to previously established HIV ⊕ Pt</p><ul><li><p>H&P (mucocutaneous, neurocognitive, OIs, malignancies, STDs); meds and adherence</p></li><li><p>Review ARVs (past and current); if hospitalized typically continue ARVs, if any must be held, stop all to ↓ risk of resistance</p></li><li><p>Regimen failure: cannot achieve undetectable VL after months on ARVs, viral rebound (VL >200 copies/mL ×2 after prior suppression), ↓ CD4 count or clinical worsening</p></li></ul><p>OI Prophylaxis (
<a href=https://aidsinfo.nih.gov/guidelines rel=noopener>https://aidsinfo.nih.gov/guidelines</a> & JAMA 2018;320:379, HIV.gov:2020)</p><p>OI</p><p>Indication</p><p>1° Prophylaxis</p><p>Tuberculosis</p><p>⊕ PPD (≥5 mm), IGRA,</p><p>or high-risk exposure</p><p>See treatment for latent TB</p><p>Pneumocystis jiroveci (PCP)</p><p>CD4 &lt;200/mm or CD4 &lt;14% or thrush</p><p>TMP-SMX DS qd (first line) or dapsone qd or atovaquone qd or pentamidine inhaled q4wk</p><p>Histoplasmosis</p><p>CD4 &lt;150/mm + endemic/ exposure</p><p>Itraconazole qd</p><p>Toxoplasmosis</p><p>CD4 &lt;100/mm3 and ⊕ Toxo IgG</p><p>TMP-SMX DS qd or dapsone 50 mg qd + pyrimeth. qwk + leucovorin 25 qwk</p><p>MAC</p><p>Ppx no longer rec. if effective ARVs initiated</p><p>When to stop Ppx: PCP and toxo if CD4 >200 × 3 mos; Histo if CD4 >150 × 6 mos</p><p>COMPLICATIONS OF HIV/AIDS</p><p>CD4 Count</p><p>Complications</p><p>Any</p><p>S. pneumo, TB, VZV, HPV complications, Kaposi’s sarcoma, lymphoma, ↑ CVD risk, ↓ bone density.</p><p>&lt;500</p><p>Constitutional sx. Mucocutaneous: seborrheic dermatitis; psoriasis; oral hairy leukoplakia; HSV. Recurrent bacterial infxns.</p><p>&lt;200</p><p>PCP, Toxo, PML, Crypto, candida, Histo/Coccidio (endemic areas)</p><p>&lt;50–100</p><p>CMV, MAC, CNS lymphoma, invasive aspergillosis, bacillary angiomatosis (dissem. Bartonella), death (&lt;50 is medical emergency)</p><p>Fever workup in patient with HIV/AIDS</p><ul><li>Etiologies (Infect Dis Clin North Am 2007;21:1013)</li></ul><p>infxn (82–90%): MAC, TB, CMV, early PCP, Histo, Crypto, Coccidio, Toxo, endocarditis</p><p>noninfectious: lymphoma, drug reaction. Non 1° HIV itself rarely (&lt;5%) cause of fever.</p><ul><li>Workup: guided by CD4 count, s/s, epi, & exposures</li></ul><p>CBC, BMP, LFTs, BCx, CXR, UA, mycobact. & fungal cx, ✓ meds, ? ✓ chest & abd CT</p><p>CD4 &lt;100–200 → serum crypto Ag, urinary Histo Ag, CMV PCR</p><p>pulmonary s/s → CXR; ABG; sputum for bacterial cx, PJ stain, AFB; bronchoscopy</p><p>diarrhea → stool cx, O&P, AFB; direct visualization with bx on colonoscopy</p><p>cytopenias → BM bx for path & cx of aspirate including for mycobacteria & fungi</p><p>headache/visual Δs→ LP; send CSF for bacterial/fungal cx, CrAg, ? MTb PCR; send CMV PCR from serum; dilated eye exam with Ophtho</p><p>Cutaneous</p><ul><li><p>Eosinophilic folliculitis; warts (HPV); HSV & VZV; MRSA SSTI; scabies; candidiasis; eczema; prurigo nodularis; psoriasis; drug eruption; subungual onychomycosis</p></li><li><p>Molluscum contagiosum (poxvirus): 2–5 mm pearly papules w/ central umbilication</p></li><li><p>Kaposi’s sarcoma (KSHV or HHV8): red-purple nonblanching nodular lesions</p></li><li><p>Bacillary angiomatosis (disseminated Bartonella): friable violaceous vascular papules</p></li></ul><p>Oral</p><ul><li><p>Aphthous ulcers; KS; thrush/oral candidiasis (curd-like patches, often painless)</p></li><li><p>Oral hairy leukoplakia: painless proliferation of papillae w/ adherent white coating usually on lateral tongue, caused by EBV but not precancerous</p></li></ul><p>Ophthalmologic</p><ul><li><p>CMV retinitis (CD4 usu &lt;50); Rx: ganciclovir or valganciclovir, foscarnet, or cidofovir</p></li><li><p>HZV, VZV, syphilis (any CD4 count, treat as neurosyphilis) or Toxo (CD4 usually &lt;100)</p></li></ul><p>Endocrine/metabolic</p><ul><li><p>Hypogonadism; adrenal insufficiency (CMV, MAC, TB, HIV, or med-related); sarcopenia; osteopenia/porosis/fragility fractures (at all CD4 counts)</p></li><li><p>Lipodystrophy: central obesity, peripheral lipoatrophy, dyslipidemia, hyperglycemia</p></li></ul><p>Cardiovascular (JACC 2013;61:511)</p><ul><li>Higher rates of CAD, stroke, VTE, dilated CMP; pulm. HTN; pericarditis/effusion</li></ul><p>Pulmonary</p><p>Radiographic Pattern</p><p>Common Causes</p><p>Normal</p><p>Early PCP</p><p>Diffuse interstitial infiltrates</p><p>PCP, TB, viral, or disseminated fungal</p><p>Focal consolidation or masses</p><p>Bacterial or fungal, TB, KS</p><p>Cavitary lesions</p><p>TB, NTM, aspergillus, other fungal, bacterial (incl. Staph aureus, Nocardia, Rhodococcus)</p><p>Pleural effusion</p><p>TB, bacterial or fungal, KS, lymphoma</p><ul><li>Pneumocystis jiroveci (PCP) pneumonia (CD4 &lt;200) (NEJM 1990;323:1444)</li></ul><p>fever, night sweats, dyspnea on exertion, dry (“doorstop”) cough</p><p>CXR w/ interstitial pattern, ↓ PaO2, ↑ A-a ∇, ↑ LDH, ⊕ PCP sputum stain, ⊕ β-glucan</p><p>Rx if PaO2 >70: TMP-SMX 15–20 mg of TMP/kg divided tid, avg dose = DS 2 tabs PO tid</p><p>Rx if PaO2 &lt;70 or A-a gradient >35: prednisone before abx (40 mg PO bid; ↓ after 5 d)</p><p>HIV ⊕ smokers much more likely to die from lung cancer than OI (JAMA 2017;177:1613)</p><p>Gastrointestinal & hepatobiliary</p><ul><li><p>Esophagitis: Candida, CMV (solitary, lg serpiginous), HSV (multiple, small shallow), giant aphthous ulcers, pills; EGD if no thrush or no response to empiric antifungals</p></li><li><p>Enterocolitis: bacterial (esp. if acute: Shigella, Salmonella, C. diff); protozoal (esp. if chronic: Giardia, Isospora, Cryptosporidium, Cyclospora, Microsporidium, Entamoeba); viral (CMV, adeno); fungal (histo); MAC; AIDS enteropathy; TB enteritis</p></li><li><p>GI bleeding: CMV, KS, lymphoma, histo; proctitis: HSV, CMV, LGV, N. gonorrhoeae</p></li><li><p>Hepatitis: HBV, HCV, CMV, MAC, TB, histo, drug-induced</p></li><li><p>AIDS cholangiopathy: often a/w CMV or Cryptosporidium or Microsporidium (at ↓ CD4)</p></li></ul><p>Renal</p><ul><li>HIV-assoc. nephropathy (collapsing FSGS); nephrotoxic drugs (eg, TDF → prox tub dysfxn)</li></ul><p>Hematologic/oncologic (NEJM 2018;378:1029)</p><ul><li><p>Cytopenia: ACD, BM infiltration by tumor/infxn (eg, MAC/TB), drug toxicity, hemolysis, ITP</p></li><li><p>Non-Hodgkin lymphoma: ↑ frequency with any CD4 count, but incidence ↑ with ↓ CD4</p></li><li><p>Hodgkin lymphoma (any CD4; impact of ART unclear)</p></li><li><p>CNS lymphoma: CD4 count &lt;50, EBV-associated</p></li><li><p>Kaposi’s sarcoma (HHV-8): at any CD4 count, incidence ↑ b/c CD4 ↓, usu. MSM</p></li></ul><p>Mucocut. (violacious lesions); pulmonary (nodules, infiltrates, LAN); GI (bleed, obstruct.)</p><ul><li><p>Cervical/anal CA (HPV high risk in MSM)</p></li><li><p>↑ rates of liver CA (a/w HBV/HCV), gastric CA</p></li></ul><p>Neurologic/Psychologic</p><ul><li><p>Meningitis: Crypto (dx w/ CSF; serum CrAg 90% Se), bacterial (inc. Listeria), viral (HSV, CMV, 1° HIV), TB, histo, Coccidio, lymphoma; neurosyphilis (cranial nerve palsies)</p></li><li><p>Space-occupying lesions: may present as HA, focal deficits or Δ MS. Workup: MRI, brain bx only if suspect non-Toxo etiology (Toxo sero ⊖) or no response to 2 wk of empiric anti-Toxo Rx (if Toxo, 50% respond by d3, 91% by d14; NEJM 1993;329:995)</p></li></ul><p>Etiology</p><p>Imaging Appearance</p><p>Diagnostic Studies</p><p>Toxoplasmosis</p><p>Enhancing lesions, typically in basal ganglia (can be multiple)</p><p>⊕ Toxo serology (Se ~85%)</p><p>CNS lymphoma</p><p>Enhancing ring lesion (single 60% of the time)</p><p>⊕ CSF PCR for EBV</p><p>⊕ SPECT or PET scan</p><p>Progressive multifocal leukoencephalopathy (PML)</p><p>Multiple nonenhancing lesions in white matter</p><p>⊕ CSF PCR for JC virus</p><p>Other: abscess, nocardiosis, crypto, TB, CMV, HIV</p><p>Variable</p><p>Biopsy</p><ul><li><p>HIV-assoc. dementia: depressive sx, impaired attention/concentration, psychomotor slowing</p></li><li><p>Depression: ↑ rates of suicide/depression</p></li><li><p>Myelopathy: infxn (CMV, HSV), cord compression (epidural abscess, lymphoma)</p></li><li><p>Peripheral neuropathy: meds (esp 1st gen NRTIs), CMV, diabetes</p></li></ul><p>Disseminated Mycobacterium avium complex (DMAC)</p><ul><li>Fever, night sweats, wt loss, abd pain, diarrhea, pancytopenia. Can cause localized lymphadenitis. Rx: clarithro/azithro + ethambutol ± rifampin/rifabutin.</li></ul><p>Cytomegalovirus (CMV)</p><ul><li>Retinitis, esophagitis, colitis, hepatitis, neuropathies, encephalitis. CMV VL may be ⊖. Consider tissue biopsy. Rx: ganciclovir, valganciclovir, foscarnet, or cidofovir.</li></ul><p>TICK-BORNE DISEASES</p><p>–: &lt;15%, +: 15–25%, ++: 25–50%, +++: 50–75%, ++++: >75%</p><p>Tick prophylaxis: protective clothing, tick ✓ q24h, DEET/picardin, if bitten remove ASAP</p><p>LYME DISEASE</p><p>Microbiology & epidemiology</p><ul><li><p>Spirochete B. burgdorferi transmitted by Ixodes scapularis (deer tick)</p></li><li><p>Humans contact ticks in low brush near wooded areas</p></li><li><p>Infection usually requires tick attached >36–48 h</p></li><li><p>Most common vector-borne illness in U.S.; peak in summer in NE/Mid-Atlantic/Midwest</p></li><li><p>Consider coinfection w/ Anaplasma, Babesia, B. miyamotoi</p></li></ul><p>Clinical Manifestations</p><p>Stage</p><p>Manifestations</p><p>Early localized (w/in 1 month)</p><p>General: flu-like illness. Derm (~80%): erythema migrans (EM) = erythematous patch ± central clearing, ~6–38 cm.</p><p>Early disseminated</p><p>(wks to mos)</p><p>General: fatigue, malaise, LAN, HA</p><p>Derm: multiple EM lesions</p><p>Rheum (~10%): migratory arthralgias & myalgias</p><p>Neurologic (~15%): cranial neuropathies (esp. CN VII), aseptic meningitis, mononeuritis multiplex (± pain), transverse myelitis</p><p>Cardiac (~8%): heart block, myopericarditis</p><p>Late disseminated (mos to yrs)</p><p>Derm (rare in U.S.): acrodermatitis chronica atrophicans, panniculitis</p><p>Rheum (~60%, espec. if not Rx’d): recurrent mono- or oligoarthritis of large joints (classically knee), synovitis</p><p>Neurologic (rare!): subacute encephalomyelitis, polyneuropathy</p><p>(NEJM 2014;370:1724; CID 2020; 72:e1)</p><p>Diagnostic studies (CID 2020; 72:e1)</p><ul><li><p>Avoid testing without signs/symptoms</p></li><li><p>Early localized: clinical dx if EM + possible exposure; no need for testing (often sero ⊖)</p></li><li><p>Early or late disseminated: 2-step testing</p></li></ul><p>1st step: ELISA screen (some false ⊕, false ⊖ w/ early abx or &lt;6 wk after tick bite)</p><p>2nd step: if ⊕ ELISA, confirm with IgM/IgG Western blot (↑ Sp) or 2nd ELISA</p><ul><li>Serum testing is sufficient for diagnosis of Lyme CNS infection or Lyme arthritis, though consider CSF (Ab testing in parallel with serum) or joint fluid sampling (PCR) to rule out other causes and provide a more definitive diagnosis</li></ul><p>Treatment (CID 2020; 72:e1; IDSA 2021)</p><ul><li>Prophylaxis: doxycycline × 1 only if all of the following:</li></ul><ol><li><p>Ixodes scapularis tick attached ≥36 h</p></li><li><p>Local Lyme carriage in ticks ≥20%</p></li><li><p>Abx can be given w/in ≤72 h of tick bite</p></li><li><p>No contraindication to doxycycline (eg, preg, allergy, age &lt;8 y)</p></li></ol><p>Regardless of Ppx, monitor for fever, flu-like sx, rash (erythema migrans) × 30 d</p><ul><li>Treatment</li></ul><p>Isolated EM: doxy × 10 d (alternative: cefurox or amox × 14 d or azithro × 7 d)</p><p>Arthritis: doxy × 28 d (alternative: cefurox or amox × 28 d)</p><p>Carditis/meningitis: CTX IV or doxy PO (based on severity/response) × 14–21 d</p><ul><li><p>Consider coinfection if severe/refractory sx, persistent fever, cytopenias</p></li><li><p>Recurrent sx after abx are likely re-infection, not relapse (NEJM 2012;367:1883)</p></li></ul><p>BABESIOSIS</p><p>Microbiology & epidemiology (MMWR 2012;61:505)</p><ul><li><p>Babesia microti (U.S.) transmitted by Ixodes ticks; also risk from blood transfusion</p></li><li><p>Peak incidence summer in NE U.S. (esp. near coast, “Nantucket fever”), north-central MW</p></li></ul><p>Clinical manifestations</p><ul><li><p>Typically 1–4 wks after tick exposure; &lt;9 wks if transfusion</p></li><li><p>Range: asx/mild flu-like sx to severe DAT ⊖ hemolytic anemia/DIC, multiorgan failure</p></li><li><p>Risk factors for severe dx: asplenia, ↓ cellular immunity, TNF inhib, ↑ age, pregnancy</p></li></ul><p>Diagnosis (CID 2021;72:e49)</p><ul><li><p>Symptoms + blood smear w/ intraerythrocytic parasites (ring forms)</p></li><li><p>Degree of parasitemia = % infected RBC on smear (correlates roughly w/ severity)</p></li><li><p>Repeat smears (q12–24h) if sx persist despite negative initial smear</p></li><li><p>PCR serum if smear ⊖ (or unavailable) and clinical suspicion</p></li></ul><p>Treatment (CID 2021;72:e49)</p><ul><li><p>Atovaquone & azithro preferred; clinda/quinine (more adverse events); call ID if severe</p></li><li><p>Duration depends on host; immunosupp often need longer Rx</p></li><li><p>Consider exchange transfusion if parasitemia >10%, severe hemolysis/ end-organ failure</p></li></ul><p>EHRLICHIOSIS/ANAPLASMOSIS</p><p>Microbiology & epidemiology</p><ul><li><p>Gram ⊖ obligate intracellular bacterium; human monocytic ehrlichiosis (E. chaffeensis, HME); human granulocytic anaplasmosis (A. phagocytophilum, HGA)</p></li><li><p>Transmission: HME by Amblyomma americanum (lone star tick), Dermacentor variabilis (dog tick); HGA by Ixodes; HGA in NE, mid-Atl, MN; HME in SE and south-central U.S.</p></li><li><p>Peak incidence spring and early summer; can be transmitted by blood transfusion</p></li></ul><p>Clinical manifestations (typically w/in 3 wks of tick exposure)</p><ul><li><p>Asx or nonspecific: fever, myalgias, malaise, HA, delirium; onset often acute</p></li><li><p>Laboratory: leukopenia, thrombocytopenia, ↑ aminotransferases, ↑ LDH, ↑ CK</p></li><li><p>Severe disease can be complicated by bacterial superinfection</p></li></ul><p>Diagnosis</p><ul><li>Intraleukocytic morulae on peripheral smear in acute infection; serum PCR ⊕ in acute infection and convalescence</li></ul><p>Treatment (JAMA 2016;315:1767)</p><ul><li><p>Start Rx based on clinical suspicion; definitive dx requires PCR (but not 100% Se)</p></li><li><p>Doxycycline × 10 d; if Pt does not defervesce in ≤48 h, consider co-infection/alt dx</p></li></ul><p>ROCKY MOUNTAIN SPOTTED FEVER (RMSF)</p><p>Microbiology & epidemiology</p><ul><li><p>Infection with Rickettsia rickettsii (Gram ⊖ obligate intracellular bacterium)</p></li><li><p>Transmitted by D. variabilis, D. andersoni (wood tick); peak in spring/early summer</p></li><li><p>Occurs in mid-Atl, SE/south central U.S., mountain west, Mexico, Central & S. America</p></li></ul><p>Clinical manifestations (typically w/in 1–2 wks of tick exposure)</p><ul><li><p>Nonspecific: fever, HA, ΔMS, myalgias, N/V, occasionally abdominal pain</p></li><li><p>Rash (2–5 d after onset of fever) = centripetal: starts on ankles and wrists → trunk, palms, & soles; progresses from macular to maculopapular to petechial</p></li><li><p>Severe cases → vasculitis, multi-organ failure, meningoencephalitis; more likely in elderly</p></li></ul><p>Diagnosis (MMWR 2016;65:1)</p><ul><li><p>Clinical dx (often w/o rash initially); requires high suspicion given risk of delayed Rx</p></li><li><p>Acute illness: skin bx for rickettsiae (Se 70–90%), consider ✓serologies (may be ⊖)</p></li><li><p>Confirm dx: re-check serology 14–21 d later, ⊕ if 4-fold ↑</p></li></ul><p>Treatment (MMWR 2016;65:1)</p><ul><li>Doxy × 7–10 d, empiric Rx if suspicion; if does not defervesce in ≤48 h ? co-infection/alt dx</li></ul><p>TULAREMIA</p><p>Microbiology</p><ul><li>Infxn w/ Francisella tularensis bacteria via arthropod bites, animal contact (bite, scratch, lick), contaminated food or water, aresolized materials</li></ul><p>Clinical manifestations (typically w/in 2–10 d of exposure)</p><ul><li>Fever, chills, malaise, HA, nausea, myalgias; ulcer w/ black eschar at site of entry; LAN; conjunctivitis; pharyngitis; PNA</li></ul><p>Diagnosis & treatment</p><ul><li><p>Serology should be collected at presentation and 2 wks later, bacteria difficult to culture</p></li><li><p>FLQ for mild infection, aminoglycoside for severe infection in consultation with ID</p></li></ul><p>FEVER SYNDROMES</p><p>Temperature ≥100.4°F or ≥38°C</p><p>Diagnostic approach</p><ul><li><p>Thorough history including ROS, PMH/PSH, immunizations, including from childhood</p></li><li><p>Fever curve (holding antipyretics); look at trend/pattern. Less likely to mount fever if: ESRD/ESLD, extremes of age, protein calorie malnutrition, immunosupp., steroid use.</p></li><li><p>Exposures: travel, occupation/hobbies, animals, sexual contacts, TB. Consider geography, season, and incubation time in relation to exposures.</p></li><li><p>Physical exam: look for thrush, dental caries; full eye exam; cardiac murmurs; HSM; abd tenderness; rash/skin lesions; LAN; synovitis; complete neuro exam</p></li></ul><p>FEVER OF UNKNOWN ORIGIN (FUO)</p><p>Definition & etiologies (NEJM 2022;386:463)</p><ul><li><p>Fever (as per above def) on >1 occasion during ≥3 wk & no dx despite 1 wk of evaluation</p></li><li><p>More likely to be unusual manifestation of common disease than an uncommon disease</p></li><li><p>In Pts with HIV: >75% causes are infectious, but rarely due to HIV itself</p></li><li><p>Frequent reassessment needed to identify focal signs and progression of disease</p></li></ul><p>Category</p><p>Etiologies of Classic FUO (Medicine 2007;86:26; AJM 2015;128:1138)</p><p>Infection ~30%</p><p>Tuberculosis: disseminated or extrapulm. disease can have normal CXR, PPD/IGRA, sputum AFB; bx (lung, liver, bone marrow) for granulomas has 80–90% yield in milliary disease</p><p>Endocarditis: if blood cxs neg consider Bartonella, Coxiella, et al.</p><p>Abscess: dental, paraspinal, hepatic, splenic, subphrenic, pancreatic, -perinephric, pelvic, prostatic abscess or prostatitis, appendicitis</p><p>Osteomyelitis, sinusitis, typhoid, 1° CMV or EBV, malaria, Babesia</p><p>Connective tissue disease ~30%</p><p>Giant cell arteritis/PMR: headache, scalp pain, jaw claudication, visual disturbances, myalgias, arthralgias, ↑ ESR</p><p>Adult-onset Still’s: evanescent truncal rash, LAN, pharyngitis, ↑↑ ferritin</p><p>PAN, ANCA ⊕, other vascul.; SLE, RA, psoriatic or reactive arthritis</p><p>Neoplasm ~20%</p><p>Lymphoma: LAN, HSM, ↓ Hct or plt, ↑ LDH; leukemia; myelodysplasia</p><p>Renal cell carcinoma: microscopic hematuria, ↑ Hct</p><p>HCC, pancreatic and colon cancers, sarcomas, mastocytosis</p><p>Atrial myxomas: obstruction, embolism, constitutional symptoms</p><p>Misc ~20%</p><p>Drug fever, factitious, DVT/PE, hematoma</p><p>Thyroiditis or thyroid storm, adrenal insufficiency, pheochromocytoma</p><p>Granulomatous hepatitis (many causes), sarcoidosis, Kikuchi’s, Behçet’s</p><p>Familial Mediterranean fever (peritonitis, episodic fever, pleuritis; ↑ WBC & ESR during attacks); other defects in innate immunity</p><p>More common causes boldfaced</p><p>Workup (Archives 2009;169:2018; AJM 2015;128:1138)</p><ul><li><p>Initial: CBC w/ diff, CMP, ESR, CRP, 3 sets BCx (off abx), U/A, UCx, CXR</p></li><li><p>Additional workup based on sx: ANA, RF, cryoglobulin, LDH, CK/aldolase, SPEP, TFTs, PPD or IGRA, HIV Ag/Ab ± PCR, RPR, EBV serologies, CMV PCR, HBV/HCV serologies</p></li><li><p>Consider imaging: chest & abd CT, tagged WBC scan, FDG-PET, TTE, LE duplex US</p></li><li><p>Tissue dx: consider bx of LN (excisional preferred), liver (especially if ↑ Aϕ), TA (for GCA), BM, kidney (RPGN)</p></li></ul><p>Treatment</p><ul><li><p>Empiric abx not indicated (unless Pt neutropenic or critically ill)</p></li><li><p>Empiric glucocorticoids not indicated unless strong suspicion for specific rheumatologic dx</p></li><li><p>Stop unnecessary meds (only 20% with a med cause have eos or rash)</p></li><li><p>Up to 30% of cases remain undiagnosed, most spontaneously defervesce (wks to mos)</p></li></ul><p>FEVER AND RASH</p><p>Approach to diagnostic workup</p><ul><li><p>Meningococcemia, endocarditis, RMSF, sepsis, & toxic shock need urgent dx & Rx</p></li><li><p>Workup: CBC w/diff, BMP, LFTs, LDH, CK, U/A, HIV Ag/Ab ± PCR, BCx (off abx)</p></li><li><p>To narrow Ddx: characterize time course of rash, progression, & morphology</p></li><li><p>Erythema multiforme: symmetric “target” lesions often of palms, soles, & mucous memb</p></li></ul><p>Infxn etiol: HSV, Mycoplasma, syphilis, VZV, EBV, CMV, adenovirus, etc.</p><p>Non-infxn etiol: most likely meds (eg, NSAIDs, sulfa, AEDs), autoimmune disease</p><ul><li>Erythema nodosum: tender erythematous or violaceous nodules usually symmetric on LE</li></ul><p>Infxn etiol: Strep, TB, EBV, Bartonella, HBV, psittacosis, fungal, L. venereum, etc.</p><p>Non-infxn etiol: sarcoidosis, IBD, Behçet’s, other rheum, pregnancy/OCP use</p><ul><li><p>Pursue specific dx based on exposure hx & exam, including serologies, viral PCRs, possibly skin biopsy ± exam of vesicular or bullae fluid if present</p></li><li><p>Immunosupp. Pts need broad w/u; higher risk of disseminated/rapidly progressive infxns</p></li></ul><p>Variable</p><p>Possible Etiology</p><p>Summer/fall > other seasons</p><p>Enterovirus</p><p>Winter</p><p>Parvovirus, Meningococcemia</p><p>Spring/summer</p><p>Lyme, RMSF, Ehrlichiosis, Anaplasmosis</p><p>Year-round</p><p>Adenovirus, Mycoplasma</p><p>Cat and dog exposure</p><p>Bartonella, Pasteurella, Toxoplasma, Capnocytophaga</p><p>Tick exposure</p><p>Lyme, RMSF, Ehrlichiosis, Anaplasmosis</p><p>Adult &lt;30 y</p><p>Mononucleosis (EBV or CMV)</p><p>Inadequate immunization</p><p>Measles, Rubella, VZV, influenza</p><p>Sexually active</p><p>HIV, syphilis, disseminated gonococcal infection, HSV</p><p>Consider noninfectious causes: allergy/DRESS, DVT, phlebitis, vasculitides, neutrophilic dermatoses, gout, connective tissues dis., malignancy, foreign body rxn</p><p>Treatment</p><ul><li><p>Empiric abx not indicated (unless Pt neutropenic or critically ill)</p></li><li><p>Consider important empiric isolation precautions (ie, varicella → airborne/contact; measles → airborne; meningococcus → droplet) while workup pending</p></li></ul><p>FEVER IN A RETURNED TRAVELER</p><p>See CDC.gov/travel for up to date information on regional risks and recommendations</p><p>Region or Exposure</p><p>Common Etiologies (NEJM 2017;376:548)</p><p>Sub-Saharan Africa</p><p>Malaria &#187; dengue and other arboviruses, rickettsial disease, enteric fever</p><p>South/Southeast Asia</p><p>Dengue > malaria, enteric fever (S. typhi/paratyphi), Chikungunya and other arboviruses</p><p>Central & S. America</p><p>Dengue, enteric fever, malaria</p><p>Caribbean & Mexico</p><p>Dengue &#187; Chikungunya and other arbovirsuses > enteric fever, malaria</p><p>Middle East</p><p>Middle East Respiratory Syndrome, brucellosis</p><p>Freshwater swimming</p><p>Schistosomiasis, leptospirosis</p><p>Unpurified drinking water</p><p>Enteric disease (E. coli &#187; S. typhi, Campylobacter, hepatitis E > Vibrio cholerae), amoebic liver abscess</p><p>Lacking immunizations</p><p>HAV/HBV, S. typhi, influenza, measles, rubella, yellow fever</p><ul><li><p>Pts visiting friends and relatives abroad are most likely to contract illness during travel</p></li><li><p>Also consider domestic infxns, influenza, STIs, & non-infxn causes</p></li></ul><p>Select clinical manifestations</p><ul><li><p>Ebola: fever in traveler from area with active transmission of Ebola w/in 21 d</p></li><li><p>Malaria: nonspecific sx including diarrhea, headache, myalgias, cough, Δ MS</p></li><li><p>Dengue: nonspecific sx including headache, severe myalgias, rash/petechiae</p></li><li><p>Chikungunya: nonspecific sx including joint pain, moderate myalgias</p></li><li><p>Typhoid (Lancet 2015;385:1136): diarrhea/constipation, abd pain, ± rash, relative bradycardia</p></li><li><p>Rickettsial disease: headache, myalgias, lymphadenopathy, ± rash/eschar</p></li><li><p>Zika: rash, arthralgia, headache, conjunctivitis; often less severe than dengue, Chikungunya</p></li></ul><p>Workup</p><ul><li><p>Routine testing: CBC w/ diff, BMP, LFTs, BCx, UA, rapid malaria test</p></li><li><p>Fever in a traveler from a malaria zone is malaria until proven otherwise; consider a medical emergency → hospitalization & empiric Rx. One ⊖ smear does not r/o.</p></li><li><p>Other tests based on s/s, labs, exposure, incubation period, geography, and seasonality. O&P exam, CXR, blood smears for filaria/Babesiosis/Borrelia, serologies, STI & HIV, PPD or IGRA, bone marrow aspirate, bx of lymph nodes or skin lesions, CSF studies.</p></li></ul><p>PITUITARY DISORDERS</p><p>HYPOPITUITARY SYNDROMES (Lancet 2016;388:2403; JCEM 2016;11:3888)</p><p>Etiologies</p><ul><li><p>Primary: surgery, radiation (develops after avg 4–5 y), tumors (primary or metastatic), infection, infiltration (sarcoid, hemochromatosis), autoimmune, ischemia (including Sheehan’s syndrome caused by pituitary infarction intrapartum), carotid aneurysms, cavernous sinus thrombosis, trauma, medications (eg, ipilimumab), apoplexy, empty sella, genetic</p></li><li><p>Secondary: (hypothalamic dysfunction or stalk interruption): tumors (including craniopharyngioma), infection, infiltration, radiation, surgery, trauma</p></li></ul><p>Clinical manifestations</p><ul><li><p>Hormonal deficiencies: ACTH, TSH, FSH and LH, GH, prolactin, and ADH</p></li><li><p>Panhypopituitarism: deficiencies in multiple hormonal axes</p></li><li><p>Mass effect: headache, visual field Δs, cranial nerve palsies</p></li></ul><p>Central adrenal insufficiency: ↓ ACTH</p><ul><li>Sx similar to 1° adrenal insufficiency (see “Adrenal Disorders”) except:</li></ul><p>no salt cravings or hyperkalemia (b/c aldo preserved)</p><p>no hyperpigmentation (b/c ACTH/MSH is not ↑)</p><p>Central hypothyroidism: ↓ TSH</p><ul><li><p>Sx of central hypothyroidism similar to 1° (see “Thyroid Disorders”) except absence of goiter</p></li><li><p>Dx with free T4 in addition to TSH, as TSH may be low or inappropriately normal</p></li></ul><p>Hypoprolactinemia: ↓ prolactin</p><ul><li>Inability to lactate</li></ul><p>Growth hormone deficiency: ↓ GH</p><ul><li><p>↑ chronic risk for osteoporosis, fatigue, decreased lean body mass</p></li><li><p>Dx with failure to ↑ GH w/ appropriate stimulus (eg, insulin tolerance test, glucagon stimulation, and macimorelin stimulation)</p></li><li><p>GH replacement in adults controversial (Annals 2003;35:419; NEJM 2019;380:2551)</p></li></ul><p>Central hypogonadism: ↓ FSH & LH</p><ul><li><p>Clinical manifestations: ↓ libido, impotence, oligomenorrhea or amenorrhea, infertility, ↓ muscle mass, osteoporosis</p></li><li><p>Physical exam: ↓ testicular size; loss of axillary, pubic and body hair</p></li><li><p>Dx with: ↓ a.m. testosterone or estradiol (also assess SHBG, esp. in obese) and ↓ or normal FSH/LH (all levels ↓ in acute illness, ∴ do not measure in hospitalized Pts)</p></li><li><p>Treatment: testosterone or estrogen replacement vs. correction of the underlying cause</p></li></ul><p>Central diabetes insipidus: ↓ ADH</p><ul><li><p>Typically from mass lesion extrinsic to sella; pituitary tumor does not typically present w/ DI</p></li><li><p>Clinical manifestations: severe polyuria, thirst, nl to mild hyperNa (severe if ↓ access to H2O)</p></li><li><p>Diagnostic studies: see “Sodium and Water Homeostasis”</p></li></ul><p>Pituitary apoplexy (Endocr Rev 2015;36:622)</p><ul><li><p>Rapid expansion of pituitary tumor (typically adenoma) due to hemorrhage or infarction</p></li><li><p>Sx include excruciating headache, diplopia, hypopituitarism</p></li><li><p>Rx: immediate high-dose glucocorticoids; prompt surgical decompression if severe neurologic impairment or Δ MS; conservative management if mild</p></li></ul><p>Diagnostic evaluation</p><ul><li>Hormonal studies</li></ul><p>Chronic: ↓ target gland hormone + ↓ or (inappropriately) normal trophic pituitary hormone</p><p>Acute: will develop defic. in target gland hormones, but cortisol normal w/ ACTH stim</p><p>Partial hypopituitarism is more common than panhypopituitarism</p><ul><li>Pituitary MRI: pituitary protocol (contrast enhanced) recommended</li></ul><p>Treatment</p><ul><li><p>Replace deficient target gland hormones</p></li><li><p>Most important deficiencies to recognize and treat in inpatients are adrenal insufficiency and hypothyroidism; if both present, treat with glucocorticoids first, then replace thyroid hormone so as not to precipitate adrenal crisis</p></li></ul><p>HYPERPITUITARY SYNDROMES</p><p>Pituitary tumors (NEJM 2020;382:937)</p><ul><li><p>Pathophysiology: adenoma → excess of trophic hormone (if tumor fxnal, but 30–40% not) and potentially deficiencies in other trophic hormones due to compression; cosecretion of PRL and growth hormone in 10% of prolactinomas</p></li><li><p>Clinical manifestations: specific syndromes due to oversecretion of hormones (see below) ± non-specific mass effect: headache, visual Δs, diplopia, cranial neuropathies</p></li><li><p>Workup: MRI brain pituitary protocol, hormone levels, ± visual field testing if &lt;10 mm, no mass effect, no hormone overproduction, can f/up in 12 mos</p></li></ul><p>Hyperprolactinemia (NEJM 2010;362:1219; JCEM 2011;96:273)</p><ul><li>Etiology</li></ul><p>Prolactinoma (50% of pituitary adenomas)</p><p>Stalk compression due to nonprolactinoma → ↓ inhibitory dopamine → ↑ PRL (mild)</p><ul><li><p>Physiology: PRL induces lactation and inhibits GnRH → ↓ FSH & LH</p></li><li><p>Clinical manifestations: amenorrhea, galactorrhea, infertility, ↓ libido, impotence</p></li><li><p>Diagnostic studies</p></li></ul><p>↑ PRL (✓ fasting levels), but elevated in many situations, ∴ r/o pregnancy or exogenous estrogens, hypothyroidism, dopamine agonists (eg, psych meds, antiemetics), renal failure (↓ clearance), cirrhosis, stress, ↑ carb diet. Watch for hook effect: assay artifact yielding falsely low PRL if very high serum PRL levels; retest with sample dilution.</p><p>MRI brain pituitary protocol</p><ul><li>Treatment</li></ul><p>If asx (no HA, galactorrhea, hypogonadal sx) & microadenoma (&lt;10 mm), follow w/ MRI</p><p>If sx or macroadenoma (10 mm) options include:</p><p>Medical with dopamine agonist such as cabergoline (70–100% success rate) or bromocriptine (not as well tol); side effects include N/V, orthostasis, mental fogginess</p><p>Surgical: transsphenoidal surgery (main indications: failed or cannot tolerate medical Rx, GH cosecretion or neurologic sx not improving); 10–20% recurrence rate</p><p>Radiation: if medical or surgical therapy have failed or are not tolerated</p><p>Acromegaly (↑ GH; 10% of adenomas; Nat Rev Dis Primer 2019;5:1)</p><ul><li><p>Physiology: stimulates secretion of insulin-like growth factor 1 (IGF-1)</p></li><li><p>Clinical manifestations: ↑ soft tissue, arthralgias, jaw enlargement, headache, carpal tunnel syndrome, macroglossia, hoarseness, sleep apnea, amenorrhea, impotence, diabetes mellitus, acanthosis/skin tags, ↑ sweating, HTN/CMP, colonic polyps</p></li><li><p>Diagnostic studies: low utility in checking random GH levels because of pulsatile secretion</p></li></ul><p>↑ IGF-1 (somatomedin C); ± ↑ PRL; OGTT → GH not suppressed to &lt;1 (&lt;0.3 if newer assay) ng/mL; pituitary MRI to evaluate for tumor</p><ul><li><p>Treatment: surgery, octreotide (long- and short-acting preparations), dopamine agonists (if PRL cosecretion), pegvisomant (GH receptor antagonist), radiation</p></li><li><p>Prognosis: w/ and w/o Rx ↑ mortality, risk of pituitary insufficiency, colon cancer</p></li></ul><p>Cushing’s disease (↑ ACTH): 5% of adenomas; see “Adrenal Disorders”</p><p>Central hyperthyroidism (↑ TSH, ↑ α-subunit): extremely rare; see “Thyroid Disorders”</p><p>↑ FSH & LH: often non-fxn, may present as hypopituitarism b/c compression effects</p><p>Multiple Endocrine Neoplasia (MEN) Syndromes</p><p>Type</p><p>Main Features</p><p>1</p><p>(MENIN</p><p>inactiv.)</p><p>Parathyroid hyperplasia/adenomas → hypercalcemia (~100% penetrance)</p><p>Pancreatic islet cell neoplasia (gastrin, VIP, insulin, glucagon)</p><p>Pituitary adenomas (fxn or non-fxn)</p><p>2A</p><p>(RET proto- oncogene)</p><p>Medullary thyroid carcinoma (MTC) (~99%)</p><p>Pheochromocytoma (~50%)</p><p>Parathyroid hyperplasia → hypercalcemia (15–20%)</p><p>2B</p><p>(RET proto- oncogene)</p><p>Medullary thyroid carcinoma (MTC) (~99%)</p><p>Pheochromocytoma (~50%)</p><p>Mucosal and gastrointestinal neuromas, marfanoid habitus</p><p>4</p><p>(CDKN1B)</p><p>Parathyroid hyperplasia/adenomas (~90%)</p><p>Pituitary adenomas (fxnal or non-fxnal)</p><p>Gastroenteropancreatic neuroendocrine tumors (~25%)</p><p>Adrenal, kidney, reproductive organ tumors</p><p>Autoimmune Polyglandular Syndromes (APS) (NEJM 2018;378:1132)</p><p>Type</p><p>Features</p><p>I</p><p>(APECED)</p><p>Child onset, mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency, AIRE mutation</p><p>II</p><p>Adult onset, adrenal insufficiency, autoimmune thyroid disease, diabetes mellitus type 1; polygenic</p><p>THYROID DISORDERS</p><p>Common Diagnostic Tests in Thyroid Disorders</p><p>Test</p><p>Comments</p><p>Thyroid-stimulating</p><p>hormone (TSH)</p><p>Most sensitive test to detect 1° hypo- and hyperthyroidism.</p><p>Used as primary screening test for thyroid disease.</p><p>↓’d by dopamine, glucocorticoids, severe illness, excessive biotin.</p><p>May not be helpful in central hypothyroidism.</p><p>Free T4 (fT4)</p><p>Unbound T4, not influenced by TBG. Checked in a variety of thyroid states including hyperthyroidism & central hypothyroidism</p><p>Total T3</p><p>Total serum concentrations of T3 (liothyronine). Useful when evaluating for hyperthyroidism.</p><p>Antithyroid peroxidase Ab (anti-TPO)</p><p>Antithyroid peroxidase (TPO) seen in Hashimoto’s (high titer), painless subacute thyroiditis and Graves’ disease (low titer)</p><p>(Lancet 2001;357:619 & Thyroid 2003;13:19)</p><p>Specialized Diagnostic Tests in Thyroid Disorders</p><p>Test</p><p>Comments</p><p>Total T4</p><p>Total serum concentrations (∴ influenced by TBG). Checked if concern that TSH and free T4 are not accurate.</p><p>Free T3</p><p>Unbound T3, low clinical utility</p><p>Reverse T3</p><p>Inactive, ↑’d in sick euthyroid syndrome. Rarely used clinically.</p><p>Thyroid stimulating Abs</p><p>Thyroid-stimulating Ig (TSI) and thyrotropin-binding inhibitory immunoglobulin (TBII) seen in Graves’ disease. Diagnostic of Graves’ disease in high titer.</p><p>Thyroglobulin</p><p>↑’d in goiter, hyperthyroidism and thyroiditis</p><p>↓’d in factitious ingestion of thyroid hormone</p><p>Tumor marker for thyroid cancer only after total thyroidectomy and radioiodine therapy</p><p>Thyroxine-binding globulin (TBG)</p><p>↑ TBG (∴ ↑ T4): estrogen (OCP, preg.), hepatitis, opioids, hereditary</p><p>↓ TBG (∴ ↓ T4): androgens, glucocorticoids, nephrotic syndrome, cirrhosis, acromegaly, antiepileptics, hereditary</p><p>Radioactive iodine uptake (RAIU) scan</p><p>Useful to differentiate causes of hyperthyroidism</p><p>↑ uptake: Graves’ disease, toxic multinodular goiter or hot nodule</p><p>no uptake: subacute painful (de Quervain’s) or silent thyroiditis, exogenous thyroid hormone, recent iodine load, struma ovarii or antithyroid drugs</p><p>Figure 7-1 Approach to TSH levels</p><p>HYPOTHYROIDISM (Annals 2020;173:ITC1)</p><p>Etiologies</p><ul><li>Primary (>90% of cases of hypothyroidism; ↓ free T4, ↑ TSH)</li></ul><p>Goitrous: Hashimoto’s thyroiditis (after hyperthyroid phase of thyroiditis), iodine deficiency, lithium, amiodarone</p><p>Nongoitrous: surgical destruction, s/p radioactive iodine or XRT, amiodarone</p><ul><li>Secondary (central): ↓ free T4; TSH low, inappropriately nl, or slightly high (although functionally inactive due to abnormal glycosylation); due to hypothalamic or pituitary failure</li></ul><p>Hashimoto’s thyroiditis</p><ul><li><p>Autoimmune destruction with diffuse lymphocytic infiltration</p></li><li><p>Associated with other autoimmune disease and may be part of APS Type II</p></li><li><p>⊕ antithyroid peroxidase (anti-TPO) and antithyroglobulin (anti-Tg) Abs in >90%</p></li></ul><p>Clinical manifestations (Annals 2020;173:ITC1)</p><ul><li><p>Early: weakness, fatigue, arthralgias, myalgias, headache, depression, cold intolerance, weight gain, constipation, menorrhagia, dry skin, coarse brittle hair, brittle nails, carpal tunnel syndrome, delayed DTRs (“hung up” reflexes), diastolic HTN, hyperlipidemia</p></li><li><p>Late: slow speech; hoarseness; loss of outer third of eyebrows; myxedema (nonpitting skin thickening due to ↑ glycosaminoglycans); periorbital puffiness; bradycardia; pleural, pericardial, & peritoneal effusions; atherosclerosis</p></li><li><p>Myxedema crisis: vide infra</p></li></ul><p>Diagnostic studies (Lancet 2017;390:1550)</p><ul><li><p>↓ free T4; ↑ TSH in 1º hypothyroidism; ⊕ antithyroid Ab (TPO) in Hashimoto’s thyroiditis</p></li><li><p>May see hyponatremia, hypoglycemia, anemia, ↑ LDL, ↓ HDL and ↑ CK</p></li><li><p>Screening recommended for pregnant women</p></li></ul><p>Treatment of overt hypothyroidism (Endocrine 2019;66:18)</p><ul><li><p>Levothyroxine (1.5–1.7 µg/kg/d), re ✓ TSH q5–6wk, titrate q8-12 wks if TSH not in range</p></li><li><p>Lower starting dose (0.3–0.5 µg/kg/d) if at risk for ischemic heart disease or elderly</p></li><li><p>↑ dose typically needed if:</p></li></ul><p>poor GI absorption: meds that ↓ absorption (iron, calcium, cholestyramine, sucralfate, PPI), celiac disease, IBD</p><p>meds that accelerate T4 catabolism (eg, phenytoin, phenobarbital)</p><p>initiation of estrogen replacement; pregnancy (~30% ↑ by wk 8): TSH goals change by trimester: 1st = 0.1–4.0 mIU/L, 2nd & 3rd = gradual return of TSH to nonpregnant nl range (Thyroid 2017;3:315)</p><p>Subclinical hypothyroidism (NEJM 2017;376:2556; JAMA 2019;322:153)</p><ul><li><p>Mild ↑ TSH and normal free T4 with only subtle or no sx</p></li><li><p>If TSH &lt;7 or ⊖ anti-TPO Ab, ~½ resolve after 2 y (JCEM 2012;97:1962) if ↑ titers of antithyroid Abs, progression to overt hypothyroidism is ~4%/y</p></li><li><p>No clear benefit to Rx (NEJM 2017;376:2534). In practice, follow expectantly or Rx to improve mild sx or dyslipidemia. Experts often Rx if TSH >10 mU/L, goiter, pregnancy or infertility.</p></li></ul><p>Myxedema coma (ie, profound hypothyroidism; Thyroid 2014;24:1670)</p><ul><li><p>Presentation: hypothermia, hypotension, hypoventilation, Δ MS (coma rare), hyponatremia, hypoglycemia; often precipitated by infxn or major cardiopulmonary or neurologic illness</p></li><li><p>Treatment: supportive care most important. Slow metabolism of drugs can lead to coma. Correction of hypothyroidism takes time. Load 200-400 µg T4 IV, then 50–100 µg IV qd; b/c peripheral conversion impaired, may also give 5–20 µg T3 IV q8h if unstable w/ bradycardia and/or hypothermia (T3 more arrhythmogenic); must give empiric adrenal replacement therapy first as ↓ adrenal reserves in myxedema coma.</p></li></ul><p>HYPERTHYROIDISM (Annals 2020;172:ITC49)</p><p>Etiologies (Lancet 2016;388:906)</p><ul><li><p>Graves’ disease (60–80% of thyrotoxicosis)</p></li><li><p>Thyroiditis: thyrotoxic phase of subacute (granulomatous) or painless (lymphocytic)</p></li><li><p>Toxic adenomas (single or multinodular goiter)</p></li><li><p>Extremely rare: TSH-secreting pituitary tumor or pituitary resistant to thyroid hormone (↑ TSH, ↑ free T4)</p></li><li><p>Misc: amiodarone, iodine-induced, thyrotoxicosis factitia, struma ovarii (3% of ovarian dermoid tumors and teratomas), tumors (eg, choriocarcinoma) secreting hCG (weak bioactivity against TSH-R), large deposits of metastatic follicular thyroid cancer</p></li></ul><p>Clinical manifestations</p><ul><li><p>Restlessness, sweating, tremor, moist warm skin, fine hair, tachycardia, AF, weight loss, ↑ frequency of stools, menstrual irregularities, hyperreflexia, osteoporosis, stare and lid lag (due to sympathetic overactivity)</p></li><li><p>Apathetic thyrotoxicosis: seen in elderly who can present with lethargy as only sx</p></li></ul><p>Laboratory testing</p><ul><li><p>↑ free T4 and total T3; ↓ TSH (except in TSH-secreting tumors)</p></li><li><p>RAIU scan is very useful study to differentiate causes (see table on page 7-3); cannot do if recent IV contrast or amio load b/c iodine blocks uptake, so ✓ autoantibodies instead</p></li><li><p>Rarely need to ✓ for autoantibodies except in pregnancy (to assess risk of fetal Graves’)</p></li><li><p>May see hypercalciuria ± hypercalcemia, ↑ Aϕ, anemia</p></li></ul><p>Figure 7-2 Workup of primary hyperthyroidism</p><p>Graves’ disease (NEJM 2016;375:1552)</p><ul><li><p>♀:♂ ratio is 5–10:1, most Pts between 40 and 60 y at dx</p></li><li><p>⊕ thyroid antibodies: TSI or TBII (⊕ in 80%), anti-TPO, antithyroglobulin; ANA</p></li><li><p>Clinical manifestations in addition to those of hyperthyroidism (see above):</p></li></ul><p>Goiter: diffuse, nontender, w/ thyroid bruit</p><p>Ophthalmopathy (NEJM 2010;362:726): seen in 50%; up to 90% if formally tested. Periorbital edema, lid retraction, proptosis, conjunctivitis, diplopia (EOM infiltration); associated w/ smoking. Stare and lid lag seen in any type of hyperthyroidism.</p><p>Pretibial myxedema (3%): infiltrative dermopathy</p><p>Thyroiditis (NEJM 2003;348:2646; Med Clin North Am 2012;96:223)</p><ul><li><p>Acute: bacterial infection (very rare in U.S. except postsurgical), typically Staph/Strep spp.</p></li><li><p>Subacute: transient thyrotoxicosis → transient hypothyroidism → normal thyroid fxn</p></li></ul><p>Painful (viral, granulomatous or de Quervain’s): fever, ↑ ESR; Rx = NSAIDs, ASA, steroids</p><p>Silent (postpartum, autoimmune including Hashimoto’s, or lymphocytic): painless, ⊕ TPO Abs; if postpartum, can recur with subsequent pregnancies</p><p>Other: meds (amiodarone, lithium, TKIs, ICIs), palpation thyroiditis, post-radiation</p><p>Treatment (Thyroid 2016;26:1343; JCEM 2020;105:3704)</p><ul><li><p>β-blockers: control tachycardia (propranolol also ↓ T4 → T3 conversion)</p></li><li><p>Graves’ disease: either antithyroid drugs or radioactive iodine (NEJM 2016;375:1552)</p></li></ul><p>methimazole: 60% chance of recurrence after 1 y; side effects include pruritus, rash, arthralgia, fever, N/V and agranulocytosis in 0.5%. PTU: 2nd line (risk of hepatocellular necrosis; TID dosing; slower effect; JCEM 2007;92:2157). For both, need to ✓ LFTs, WBC, TSH at baseline and in follow-up.</p><p>radioactive iodine (RAI) (NEJM 2011;364:542): typically done as outPt; preRx w/ antithyroid drugs in selected Pts w/ CV disease or elderly to prevent ↑ thyrotoxicosis, stop 3 d before to allow RAI uptake; >75% of treated Pts become hypothyroid</p><p>surgery: less commonly chosen for Graves’, usually for Pts w/ obstructive goiter or ophthalmopathy. Adverse effects hypoparathyroidism, recurrent laryngeal nerve injury.</p><ul><li><p>Ophthalmopathy: can worsen after RAI; prophylax w/ prednisone in high-risk Pts; can be Rx’d w/ selenium, glucocorticoids, teprotumumab (IGF-1R inhibitor), radiation and/or surgical decompression of orbits (NEJM 2009;360:994)</p></li><li><p>Toxic adenoma or toxic multinodular goiter: RAI or surgery (methimazole preRx for surgery, in selected patients before RAI)</p></li></ul><p>Subclinical hyperthyroidism (NEJM 2018;378:2411)</p><ul><li><p>Mild ↓ TSH and normal free T4 with only subtle or no sx</p></li><li><p>~15% → overt hyperthyroidism in 2 y; ↑ risk of AF, CHD, fracture (JAMA 2015;313:2055)</p></li><li><p>Rx controversial: consider if TSH &lt;0.1 mU/L and ↑ risk for CV disease or osteopenic</p></li></ul><p>Thyroid storm (extremely rare; JCEM 2015;2:451)</p><ul><li><p>Presentation: delirium, fever, tachycardia, systolic HTN w/ wide pulse pressure and ↓ MAP, GI symptoms; 20–30% mortality</p></li><li><p>Diagnosis: no universally accepted criteria. Biochemical hyperthyroidism + severe sx, consider additional dx that may explain/contribute to sx.</p></li><li><p>Treatment: β-blocker, PTU or methimazole, iopanoic acid or iodide (for Wolff-Chaikoff effect) >1 h after PTU, ± steroids (↓ T4 → T3)</p></li></ul><p>NONTHYROIDAL ILLNESS (SICK EUTHYROID SYNDROME) (J Endocrinol 2010;205:1)</p><ul><li><p>TFT abnormalities in Pts w/ severe nonthyroidal illness (∴ in acute illness, ✓ TFTs only if ↑ concern for thyroid disease); may have acquired transient central hypothyroidism</p></li><li><p>If thyroid dysfxn suspected in critically ill Pt, TSH alone not reliable; must measure total T4, free T4, & T3</p></li><li><p>Mild illness: ↓ T4 → T3 conversion, ↑ rT3 → ↓ T3; in severe illness: ↓ TBG & albumin, ↑↑ rT3 → ↓↓ T3, ↑ degradation of T4, central ↓ TSH → ↓↓ T3, ↓↓ T4, ↓ free T4, ↓ TSH</p></li><li><p>Recovery phase: ↑ TSH followed by recovery of T4 and then T3</p></li><li><p>Replacement thyroxine not helpful or recommended for critically ill Pts w/ ↓ T3 and T4 unless other s/s of hypothyroidism</p></li></ul><p>AMIODARONE AND THYROID DISEASE</p><p>Overview (JCEM 2021;106:226)</p><ul><li><p>6 mg iodine per 200-mg tablet; risk of thyroid dysfunction lower with lower doses</p></li><li><p>✓ TSH prior to therapy, at 4-mo intervals on amio, and for 1 y after if amio d/c’d</p></li></ul><p>Hypothyroidism (occurs in ~10%; more common in iodine-replete areas)</p><ul><li>Pathophysiology</li></ul><p>(1) Wolff-Chaikoff effect: iodine load ↓ I– uptake, organification and release of T4 & T3</p><p>(2) inhibits T4 → T3 conversion</p><p>(3) ? direct/immune-mediated thyroid destruction</p><ul><li><p>Normal individuals: ↓ T4; then escape Wolff-Chaikoff effect and have ↑ T4, ↓ T3, ↑ TSH; then TSH normalizes (after 1–3 mo)</p></li><li><p>Susceptible individuals (eg, subclinical Hashimoto’s, ∴ ✓ anti-TPO) do not escape effects</p></li><li><p>Treatment: thyroxine to normalize TSH; may need larger than usual dose</p></li></ul><p>Hyperthyroidism (3% of Pts on amio; ~10–20% of Pts in iodine-deficient areas)</p><ul><li>Type 1 = underlying multinodular goiter or autonomous thyroid tissue</li></ul><p>Jod-Basedow effect: iodine load → ↑ synthesis of T4 and T3 in autonomous tissue</p><ul><li>Type 2 = destructive thyroiditis</li></ul><p>↑ release of preformed T4 & T3 → hyperthyroidism → hypothyroidism → recovery</p><ul><li><p>Doppler U/S: type 1 w/ ↑ thyroid blood flow; type 2 w/ ↓ flow</p></li><li><p>Treatment: not absolutely necessary to d/c amio b/c amio ↓ T4 → T3 conversion methimazole for type 1; steroids (eg, 40 mg prednisone qd) for type 2 often difficult to distinguish, so Rx for both typically initiated (JCEM 2001;86:3) consider thyroidectomy in severely ill patient</p></li></ul><p>THYROID CANCER (Thyroid 2016;26:1; Endo Metab Clin NA 2019;48:23)</p><p>Thyroid nodules (JAMA 2018;319:914)</p><ul><li><p>Prevalence 5–10% (50–60% if screen with U/S), ♀ > ♂, ~7–15% malignant</p></li><li><p>Screening U/S recommended if FHx of MEN2 or medullary thyroid cancer, personal h/o neck XRT, palpable nodules or multinodular goiter</p></li><li><p>Features a/w ↑ risk of malig: age &lt;30 y, h/o neck XRT, family history of thyroid cancer</p></li><li><p>U/S features a/w benign dx: cystic nodules, “spongiform” sonographic pattern</p></li><li><p>Worrisome findings: hypoechoic, solid, irregular borders, microCa2+, height>width, >20 mm</p></li><li><p>Indications for FNA: >10-mm nodule w/ suspicious features</p></li></ul><p>Papillary thyroid cancer</p><ul><li><p>Most common form (85% of differentiated thyroid cancers); peak incidence 30 to 50 y</p></li><li><p>Risk factors: childhood radiation exposure, FHx in 1° relative, familial syndrome</p></li><li><p>Low-risk, mort. 1–2% at 20 y; mets to neck LN common, but prognosis remains good</p></li><li><p>Rx is surgery; after surgical resection, RAI in select intermediate-risk or high-risk</p></li></ul><p>Follicular thyroid cancer</p><ul><li><p>Peak incidence 40 to 60 y, ♀:♂ 3:1; RFs: childhood radiation; FHx; familial syndrome</p></li><li><p>Mortality 10–20% at 20 y; mets frequently distal due to hematogenous spread</p></li><li><p>Hurthle cell carcinoma: pathologic dx; variant a/w poorer prognosis and ↑ recurrence rate</p></li></ul><p>Anaplastic thyroid cancer (Endo Metab Clin NA 2019;48:269)</p><ul><li><p>♀:♂ 1.5–2:1; poorly differentiated, extremely aggressive, mortality 90% at 5 y</p></li><li><p>P/w rapidly growing fixed & hard neck mass, regional or distant spread in 90% at dx</p></li><li><p>Rx options include surgery, radiation, trach, chemo, investigational clinical trials</p></li></ul><p>Medullary thyroid cancer (Endo Metab Clin NA 2019;48:285)</p><ul><li><p>Neuroendocrine tumor of C cells, peak incidence 40 to 60 y, a/w MEN2A and MEN2B</p></li><li><p>Most commonly solitary nodule; calcitonin production (presents with diarrhea, flushing) and level used to trend dz progression, dx w/ FNA (Se 50–80%); mortality 25–50% at 5 y</p></li><li><p>Surgery first-line treatment</p></li></ul><p>ADRENAL DISORDERS</p><p>Cushing’s Syndrome (Hypercortisolism)</p><p>Cushing’s syndrome = cortisol excess</p><p>Cushing’s disease = Cushing’s syndrome 2° to pituitary ACTH hypersecretion</p><p>Etiologies of hypercortisolism</p><ul><li><p>Most commonly iatrogenic caused by exogenous glucocorticoids (though underreported)</p></li><li><p>Cushing’s disease (60–70% of non-iatrogenic CS): ACTH-secreting pituitary adenoma (usually microadenoma) or hyperplasia</p></li><li><p>Adrenal tumor (10–15%): adenoma or (rarely) carcinoma</p></li><li><p>Ectopic ACTH (10–15%): SCLC, carcinoid, islet cell tumors, medullary thyroid ca, pheo</p></li></ul><p>Clinical manifestations (Lancet 2006;367:1605)</p><ul><li><p>Nonspecific: glucose intolerance or DM, HTN, obesity, oligo- or amenorrhea, osteoporosis</p></li><li><p>More specific: central obesity w/ extremity wasting, dorsocervical fat pads, spont. bruising</p></li><li><p>Most specific: proximal myopathy, rounded facies, facial plethora, wide purple striae</p></li><li><p>Other: depression, insomnia, psychosis, impaired cognition, hypokalemia, acne, hirsutism, hyperpigmentation (if ↑ ACTH), fungal skin infxns, nephrolithiasis, polyuria</p></li></ul><p>Diagnosis</p><ul><li><p>Typically performed in outPt setting</p></li><li><p>Very difficult as inPt b/c hypercortisolism from acute illness and hosp.</p></li></ul><p>Figure 7-3 Approach to suspected Cushing’s syndrome (NEJM 2017;376:1451)</p><p>CRH, corticotropin-releasing hormone; DST, dexamethasone suppression test; UFC, urinary free cortisol</p><p>Overnight 1 mg DST = give 1 mg at 11 p.m.; ✓ 8 a.m. serum cortisol (suppression if &lt;1.8 µg/dL); &lt;5% false ⊕ (primarily used to evaluate subclinical Cushing’s in adrenal “incidentalomas”)</p><p>11 p.m. salivary cortisol × 2 = abnl if level ↑; 24-h UFC × 2 = abnl if level ↑, >4× ULN virtually diagnostic</p><p>48-h LD DST + CRH = 0.5 mg q6h × 2 d, then IV CRH 2 h later; ✓ serum cortisol 15 min later (⊕ = >1.4 µg/dL)</p><p>48-h LD DST = 0.5 mg q6h × 2 d; ✓ 8 a.m. serum cortisol (suppression if &lt;1.8 µg/dL);</p><p>48-h HD DST = 2 mg q6h × 2 d; ✓ 24-h UFC at baseline & during last 24 h of dex (suppressed if &lt;80–90% of base)</p><p>O/N HD DST = 8 mg at 11 p.m.; ✓ 9 a.m. serum cortisol (suppression if &lt;50% from day prior)</p><p>CRH stim test = 1 µg/kg IV; ✓ cortisol and ACTH (⊕ if > 35% ↑ in ACTH or >20% ↑ in cortisol above baseline)</p><p>BIPSS, bilat. Inferior petrosal sinus vein sampling; ✓ petrosal:peripheral ACTH ratio (⊕ ≥2 basal, ≥3 after CRH)</p><p>Treatment of Cushing’s syndrome (JCEM 2015;100:2807. J Intern Med 2019;286:526)</p><ul><li><p>Surgical: resection of pituitary adenoma, adrenal tumor or ectopic ACTH-secreting tumor, or bilateral surgical adrenalectomy if unable to control source of ACTH</p></li><li><p>Medical: ketoconazole, metyrapone, osilodrostat, cabergoline, pasireotide, or mitotane to ↓ cortisol, and/or mifepristone to block cortisol action at glucocorticoid receptor; frequently used as bridge to surgery or when surgery contraindicated</p></li><li><p>Radiation: can do pituitary XRT, but not effective immediately (takes 6 mo to 2 y)</p></li><li><p>Glucocorticoid replacement therapy × 6–36 mo after TSS (lifelong glucocorticoid + mineralocorticoid replacement if medical or surgical adrenalectomy)</p></li></ul><p>HYPERALDOSTERONISM</p><p>Etiologies</p><ul><li><p>Primary (adrenal disorders, renin-independent increase in aldosterone; JCEM 2015;100:1) adrenal hyperplasia (60–70%), adenoma (Conn’s syndrome, 30–40%), adrenocortical cancer, glucocorticoid-remediable aldosteronism (GRA; ACTH-dep. rearranged promoter)</p></li><li><p>Secondary (extra-adrenal disorders, ↑ aldosterone is renin-dependent)</p></li></ul><p>Primary reninism: renin-secreting tumor (very rare)</p><p>Secondary reninism: renovascular disease: RAS, malignant hypertension; edematous states w/ ↓ effective arterial volume: CHF, cirrhosis, nephrotic syndrome;</p><p>hypovolemia, diuretics, T2D, Bartter’s (defective Na/K/2Cl transporter ≈ receiving loop</p><p>diuretic), Gitelman’s (defective renal Na/Cl transporter ≈ receiving thiazide diuretic)</p><ul><li>Nonaldosterone mineralocorticoid excess mimics hyperaldosteronism</li></ul><p>11β-HSD defic. (→ lack of inactivation of cortisol, which binds to mineralocorticoid recept.)</p><p>Black licorice (glycyrrhizic acid inhibits 11β-HSD), extreme hypercortisolism (overwhelming 11β-HSD), exogenous mineralocorticoids</p><p>Liddle’s syndrome (constitutively activated/overexpressed distal tubular renal Na channel)</p><p>Clinical manifestations</p><ul><li><p>Mild-to-moderate HTN: 16-22% of all HTN, 11% of refractory cases (Annals 2020;173:10)</p></li><li><p>Headache, muscle weakness, polyuria, polydipsia; no peripheral edema because of “escape” from Na retention; malignant HTN is rare</p></li><li><p>Classically hypokalemia (but often normal), metabolic alkalosis, mild hypernatremia</p></li></ul><p>Diagnosis (JCEM 2016;101:1889; Endo Metab Clin 2019;48:681; J Clin Endo Met 2021;106:2423)</p><ul><li><p>5–10% of Pts w/ HTN; ∴ screen if HTN + hypoK, adrenal mass, refractory/early onset HTN</p></li><li><p>Screening: ↓↓ renin, aldo >15–20 ng/dL, plasma aldo:renin ratio (>20 if 1°); obtain 8 a.m. paired values (off spirono & eplerenone for 6 wk); cut-offs arbitrary; Se var., Sp >70%</p></li><li><p>ACEI/ARB, diuretics, CCB can ↑ renin activity → ↓ PAC/PRA ratio and βBs may ↑ PAC/PRA ratio; ∴ avoid. α-blockers generally best to control HTN during dx testing.</p></li><li><p>Confirm with sodium suppression test (fail to suppress aldo after sodium load) oral salt load (+ KCl) × 3 d, ✓ 24-h urine (⊕ if urinary aldo >12 µg/d while urinary Na >200 mEq/d) or 2L NS over 4 h, measure plasma aldo at end of infusion (⊕ if aldo >5 ng/dL)</p></li></ul><p>Figure 7-4 Approach to suspected hyperaldosteronism</p><p>Treatment (SCNA 2014;94:643)</p><ul><li><p>Adenoma → adrenalectomy vs. medical Rx w/ spironolactone or eplerenone</p></li><li><p>Hyperplasia → spironolactone or eplerenone; GRA → glucocorticoids ± spironolactone</p></li><li><p>Carcinoma → adrenalectomy</p></li></ul><p>ADRENAL INSUFFICIENCY</p><p>Etiologies</p><ul><li>Primary = adrenocortical disease = Addison’s disease</li></ul><p>autoimmune: isolated or in assoc w/ APS (see table on page 7-2)</p><p>infection: TB, CMV, histoplasmosis, paracoccidioidomycosis</p><p>vascular: hemorrhage (usually in setting of sepsis), adrenal vein thrombosis, HIT, trauma</p><p>metastatic disease: (90% of adrenals must be destroyed to cause insufficiency)</p><p>deposition diseases: hemochromatosis, amyloidosis, sarcoidosis</p><p>drugs: azole antifungals, etomidate (even after single dose), rifampin, anticonvulsants</p><ul><li>Secondary = pituitary failure of ACTH secretion (but adrenal aldosterone intact b/c RAA axis) any cause of primary or secondary hypopituitarism (see “Pituitary Disorders”)</li></ul><p>glucocorticoid therapy (can occur after ≤2 wk of “suppressive doses”; dose effect variable; even &lt;10 mg of prednisone daily chronically can be suppressive)</p><p>megestrol (a progestin with some glucocorticoid activity)</p><p>Clinical manifestations (Lancet 2021;397:613)</p><ul><li><p>Primary or secondary: weakness and fatigability (95%), weight loss (70%), orthostatic hypotension (60%), nausea (50%), vomiting (50%), hyponatremia (75%)</p></li><li><p>Primary only (extra s/s due to lack of aldosterone and ↑ ACTH): marked orthostatic hypotension (because volume depleted), salt craving, hyperpigmentation (seen in creases, mucous membranes, pressure areas, nipples), hyperkalemia</p></li><li><p>Secondary only: ± other manifestations of hypopituitarism (see “Pituitary Disorders”)</p></li></ul><p>Diagnostic studies (JCEM 2016;101:364)</p><ul><li><p>Early a.m. serum cortisol: &lt;3 µg/dL virtually diagnostic; ≥18 µg/dL generally consistent with intact adrenal function, lower cutoff w/ modern specific assays (see Appendix)</p></li><li><p>Standard (250 µg) cosyntropin stimulation test (testing ability of ACTH → ↑ cortisol)</p></li></ul><p>normal = 60-min (or 30-min) post-ACTH cortisol ≥18 µg/dL</p><p>abnormal in primary b/c adrenal gland diseased and unable to give adequate output</p><p>abnormal in chronic secondary b/c adrenals atrophied and unable to respond</p><p>(very rarely, may be normal in acute pituitary injury b/c adrenals still able to respond → use early a.m. cortisol instead)</p><p>All glucocorticoids (incl creams, inh. & drops) affect test. Must know exposure to interpret.</p><ul><li><p>Other tests (w/ guidance by endocrinologist): renin, aldosterone, insulin-induced hypoglycemia (measure serum cortisol response); metyrapone (blocks cortisol synthesis and therefore stimulates ACTH, measure plasma 11-deoxycortisol and urinary 17-hydroxycorticosteroid levels)</p></li><li><p>Other lab abnormalities: hypoglycemia, eosinophilia, lymphocytosis, ± neutropenia</p></li><li><p>ACTH: ↑ in 1°, ↓ or low-normal in 2°</p></li><li><p>Imaging studies to consider</p></li></ul><p>pituitary MRI to detect anatomical abnormalities</p><p>adrenal CT: small, noncalcified adrenals in autoimmune, enlarged in metastatic disease, hemorrhage, infection or deposition (although they may be normal-appearing)</p><p>Treatment</p><ul><li><p>Acute insufficiency: volume resusc. w/ normal saline + hydrocortisone IV (see below)</p></li><li><p>Chronic insufficiency: (1) prednisone ~4–5 mg PO qam or hydrocortisone 15–25 mg PO qd (2/3 a.m., 1/3 early p.m.); (2) fludrocortisone (not needed in 2° adrenal insufficiency) 0.05–0.2 mg PO qam (JCEM 2018;103:376); (3) backup dexamethasone 4-mg IM prefilled syringe given to Pt for emergency situations</p></li></ul><p>Adrenal insufficiency & critical illness (NEJM 2003;348:727; JAMA 2009;301:2362)</p><ul><li><p>Low cortisol binding proteins; ∴ dx of adrenal insufficiency problematic (NEJM 2013;368:1477)</p></li><li><p>Adrenal insufficiency rare in most cases of shock unless adrenal infarction or bleed, Waterhouse-Friderichson, CNS or pituitary bleed</p></li><li><p>Reasonable to collect cortisol level in HoTN Pt w/ suspicion for adrenal insufficiency</p></li><li><p>Can consider above dx criteria, but decision for Rx should also be based on clinical assessment due to risk of false ⊖ and ⊕ results in context of altered physiology</p></li><li><p>If concerned, initiate corticosteroids early: use hydrocortisone 100 mg IV followed by 50 mg IV q6h</p></li><li><p>Controversial data for empiric steroids in all critically ill Pts (see “Sepsis”)</p></li></ul><p>Adrenal crisis in adrenal insufficiency (NEJM 2019;381;852)</p><ul><li><p>Precipitants: preexisting adrenal insufficiency + serious infection or GI illness, bilateral adrenal hemorrhage or infarction, pituitary infarction</p></li><li><p>Presentation: shock + anorexia, N/V, abd pain, weakness, fatigue, confusion, coma, fever</p></li><li><p>Lab findings: hyponatremia, hyperkalemia (1°)</p></li><li><p>Rx: hydrocortisone 100 mg IV followed by 50 mg IV q6 + IVF; do not delay for dx tests</p></li></ul><p>PHEOCHROMOCYTOMA & PARAGANGLIOMA</p><p>Clinical manifestations (NEJM 2019;381:552)</p><ul><li><p>Neuroendocrine neoplasm leads to inappropriate and paroxysmal release of adrenergic agents including epinephrine, norepinephrine, and rarely dopamine</p></li><li><p>Classic triad: episodic headaches, palpitations and profuse sweating; only 50% have paroxysmal hypertension and most Pts do not have three classic sx</p></li><li><p>Paroxysms can be triggered by meds (eg, β-blockers), abdominal manipulation</p></li><li><p>Up to 40% of pheos/paragangliomas thought to have underlying genetic etiology; genetic testing frequently recommended</p></li><li><p>Associated with MEN2A/2B, von Hippel Lindau, NF1, familial paraganglioma (mutations in succinate dehydrogenase gene B, C and D), MAX or TMEM127 mutations</p></li></ul><p>Diagnostic studies (JCEM 2014;99:1915)</p><ul><li><p>24° urinary fractionated metanephrines: 98% Se, 98% Sp. Screening test of choice if low-risk (b/c false ⊕ with severe illness, renal failure, OSA, labetalol due to assay interference, acetaminophen, TCAs, medications containing sympathomimetics).</p></li><li><p>Plasma fractionated metanephrines: 97% Se, 91% Sp. Screening test of choice if high risk, but ↑ rate of false ⊕ in low-prevalence population. False ⊕ rate lower if patient supine for 30 min (estimated 2.8× ↑ false ⊕ if seated).</p></li><li><p>Adrenal CT or T2-weighted MRI; PET for known metastatic disease or to localize nonadrenal mass but usually easy to find; consider MIBG scintigraphy if CT/MRI ⊖</p></li><li><p>Consider genetic testing in all Pts (J Intern Med 2019;285:187)</p></li></ul><p>Treatment</p><ul><li><p>α-blockade first (usually phenoxybenzamine) ± β-blockade (often propranolol) → surgery</p></li><li><p>Preoperative volume expansion is critical due to possible hypotension after tumor excision</p></li></ul><p>ADRENAL INCIDENTALOMAS</p><p>Epidemiology</p><ul><li>4% of Pts undergoing abdominal CT scan have incidentally discovered adrenal mass; prevalence ↑ with age</li></ul><p>Differential diagnosis</p><ul><li><p>Nonfunctioning mass: adenoma, cysts, abscesses, granuloma, hemorrhage, lipoma, myelolipoma, primary or metastatic malignancy</p></li><li><p>Functioning mass: pheochromocytoma, adenoma (cortisol, aldosterone, sex hormones), other endocrine tumor, carcinoma</p></li></ul><p>Hormonal workup (EJE 2016;175:G1; NEJM 2021;384:1542)</p><ul><li><p>Rule out subclinical Cushing’s syndrome in all Pts using 1 mg overnight DST (Sp 91%). Abnormal results require confirmatory testing.</p></li><li><p>Rule out hyperaldosteronism if hypertensive w/ plasma aldo & renin (see above)</p></li><li><p>Rule out pheochromocytoma in ALL Pts (b/c of morbidity unRx’d pheo) using 24-h urine fractionated metanephrines or plasma fractionated metanephrines</p></li></ul><p>Malignancy workup</p><ul><li>CT and MRI characteristics may suggest adenoma vs. carcinoma</li></ul><p>Benign features: unenhanced CT &lt;10 Hounsfield units or CT contrast-medium washout >50% at 10 min; size &lt;4 cm; smooth margins, homogenous and hypodense appearance; can follow such incidentalomas w/ periodic scans</p><p>Suspicious features: size ≥4 cm or ↑ size on repeat scan; >10 Hounsfield units on CT, irregular margins, heterogeneous, dense or vascular appearance; h/o malignancy or young age. Such incidentalomas warrant resection or repeat scan at short interval.</p><ul><li>Rule out metastatic cancer (and infection) in Pts w/ h/o cancer; ~50% of adrenal incidentalomas are malignant</li></ul><p>Follow-up</p><ul><li>If hormonal workup ⊖ and appearance benign, no further follow-up imaging needed, but controversial (Annals 2019;171:107)</li></ul><p>CALCIUM DISORDERS</p><p>Pitfalls in measuring calcium</p><ul><li><p>Physiologically active Ca is free or ionized (ICa). Serum Ca reflects total calcium (bound + unbound) and ∴ influenced by albumin (main Ca-binding protein).</p></li><li><p>Corrected Ca (mg/dL) = measured Ca (mg/dL) + {0.8 × [4 – albumin (g/dL)]}</p></li><li><p>Alkalosis will cause more Ca to be bound to albumin (∴ total Ca may be normal but ↓ ICa)</p></li><li><p>Best to measure ionized Ca directly (but accuracy is lab dependent)</p></li></ul><p>HYPERCALCEMIA</p><p>Etiologies of Hypercalcemia</p><p>Category</p><p>Etiologies</p><p>Hyperparathyroidism (HPT)</p><p>(NEJM 2018;379:1050; Lancet 2018;391:168)</p><p>1°: adenoma (85%), hyperplasia (15–20%; spont. vs. MEN1/2A), carcinoma (&lt;1%), meds (Lithium → ↑ PTH)</p><p>3°: after long-standing 2° hyperparathyroidism (as in renal failure) → autonomous nodule develops, requires surgery</p><p>Familial hypocalciuric hypercalcemia (FHH)</p><p>Inact. mut. in Ca-sensing receptor (FHH1), Gα11 (FHH2), AP2S1 (FHH3) → ↑ Ca set point; ± mild ↑ PTH</p><p>Acquired form due to autoAb vs. Ca-sensing receptor (rare)</p><p>FECa [(24-h UCa/serum Ca) / (24-h UCr/serum Cr)] &lt;0.01</p><p>Malignancy</p><p>(NEJM 2022;386:1443)</p><p>PTH-related peptide (PTHrP) → humoral ↑ Ca of malignancy (eg, squamous cell cancers, renal, breast, bladder)</p><p>Cytokines → ↑ osteoclast activity (eg, hematologic malig)</p><p>↑ 1,25-(OH)2D (eg, rare lymphomas)</p><p>Local osteolysis (eg, breast cancer, myeloma)</p><p>Vitamin D excess</p><p>Granulomas (sarcoid, TB, histo, GPA) → ↑ 1-OHase → ↑ 1,25-(OH)2D. Vitamin D intoxication.</p><p>↑ Bone turnover</p><p>Hyperthyroidism, immobilization + Paget’s disease, vitamin A</p><p>Miscellaneous</p><p>Thiazides; Ca-based antacids or massive dairy consumption (milk-alkali syndrome); adrenal insufficiency</p><p>Among inPts w/ hypercalcemia: 45% have cancer, 25% 1° HPT, 10% CKD → 3° HPT</p><p>(JCEM 2005;90:6316; NEJM 2013;368:644)</p><p>Clinical manifestations (“bones, stones, abdominal groans, and psychic moans”)</p><ul><li>Hypercalcemic crisis (usually when Ca >13–15): polyuria, dehydration, ΔMS</li></ul><p>Ca toxic to renal tubules → blocks ADH activity, causes vasoconstriction and ↓ GFR → polyuria but Ca reabsorption → ↑ serum Ca → ↑ nephrotoxicity and CNS sx</p><ul><li><p>Osteopenia, fractures, and osteitis fibrosa cystica (latter seen in severe hyperpara. only → ↑ osteoclast activity → cysts, fibrous nodules, salt & pepper appearance on X-ray)</p></li><li><p>Nephrolithiasis, nephrocalcinosis, nephrogenic DI</p></li><li><p>Abdominal pain, anorexia, nausea, vomiting, constipation, pancreatitis, PUD</p></li><li><p>Fatigue, weakness, depression, confusion, coma, ↓ DTRs, short QT interval</p></li><li><p>1° HPT: 80% asx, 20% nephrolithiasis, osteoporosis, etc.</p></li></ul><p>Diagnostic studies</p><ul><li><p>Hyperparathyroidism (HPT) and malignancy account for 90% of cases of ↑ Ca; HPT more likely if asx or chronic; malignancy (usually overt) more likely if acute or sx</p></li><li><p>Ca, alb, ICa, PTH (may be inapprop. normal in 1° HPT & FHH; JAMA 2014;312:2680), PO4</p></li></ul><p>↑ or high nl PTH: Ca/Cr clearance ratio &lt;0.01 → FHH</p><p>↓ PTH: ✓ PTHrP, Aϕ, & search for malig (eg, CT, mammogram, SPEP/UPEP) and ✓ vit D: ↑ 25-(OH)D → meds; ↑ 1,25-(OH)2D → granuloma (✓ CXR, ACE, r/o lymph)</p><p>Acute Treatment of Hypercalcemia (BMJ 2015;350:h2723)</p><p>Treatment</p><p>Onset</p><p>Duration</p><p>Comments</p><p>Normal saline</p><p>(4–6 L/d)</p><p>h</p><p>during Rx</p><p>Natriuresis → ↑ renal Ca excretion</p><p>∙ Furosemide</p><p>h</p><p>during Rx</p><p>Use cautiously, only if volume overloaded</p><p>Bisphosphonates</p><p>1–2 d</p><p>var.</p><p>Inhibit osteoclasts, useful in malignancy; caution in renal failure; risk of jaw osteonecrosis; monitor for hypocalcemia</p><p>Calcitonin</p><p>h</p><p>~48 hrs</p><p>Bridging Rx, quickly develop tachyphylaxis</p><p>Glucocorticoids</p><p>days</p><p>days</p><p>Useful in some malig, granulomatous disorders & vitamin D intox.</p><p>Denosumab (JCEM 2014;99:3144)</p><p>days</p><p>months</p><p>Monoclonal Ab against RANKL; typically used in hyperCa of malignancy; not renally cleared</p><p>Hemodialysis</p><p>min</p><p>during Rx</p><p>If other measures ineffective or contraindicated</p><p>Treatment of asymptomatic 1° HPT (JCEM 2014;99:3561; JAMA 2020;323:1186)</p><ul><li><p>Surgery if: age &lt;50 y; serum Ca >1 mg/dL >ULN; CrCl &lt;60 mL/min, DEXA T score &lt;–2.5</p></li><li><p>If surgery declined/deferred, can Rx with cinacalcet (↓ Ca & PTH but may not ↑ BMD)</p></li><li><p>If not yet candidate for surgery: ✓ serum Ca & Cr annually and BMD q2y</p></li></ul><p>HYPOCALCEMIA</p><p>Etiologies of Hypocalcemia</p><p>Category</p><p>Etiologies</p><p>Hypoparathyroidism</p><p>(NEJM 2019;380:1738; JCEM 2020;105:1722)</p><p>Iatrogenic (s/p thyroidectomy, rarely after parathyroidectomy); sporadic; familial (APS1, activating Ca-sensing receptor mutations; see page 7-2); Wilson’s, hemochromatosis; hypoMg (↓ secretion and effect); activating Ca-sensing receptor autoAb</p><p>Pseudo- hypoparathyroidism</p><p>(Endo Metab Clin North Am 2018;47:865)</p><p>1a, 1b, & 1c: PTH end-organ resistance (∴ ↑ serum PTH)</p><p>1a & 1c: + skeletal abnormalities, short stature & developmental delay</p><p>1b: w/o extra features</p><p>Pseudopseudohypoparathyroidism = 1a mutation inherited from father, no hormonal abnormalities</p><p>Vit D defic. or resist</p><p>(NEJM 2011;364:248; JCEM 2012;97:1153)</p><p>Nutritional/sunlight deprivation; GI disease/fat malabs.; drugs (anticonvulsants, rifampin, ketoconazole, 5-FU/leucovorin); genetic (1α-hydroxylase, VDR mutations). Deficiency more common.</p><p>Chronic renal failure</p><p>↓ 1,25-(OH)2D production from elevated FGF23, ↑ PO4 from ↓ clearance</p><p>Accelerated net bone formation</p><p>Postparathyroidectomy, Paget’s disease (JBMR 2019;34:579), osteoblastic metastases</p><p>Calcium sequestration</p><p>Pancreatitis, citrate excess (after blood transfusions), acute ↑↑ PO4 (ARF, rhabdomyolysis, tumor lysis), bisphosphonates</p><p>Clinical manifestations</p><ul><li><p>Neuromuscular irritability: perioral paresthesias, cramps, ⊕ Trousseau’s (inflation of BP cuff ≥3 min → carpal spasm), ⊕ Chvostek’s (tapping facial nerve → contraction of facial muscles), laryngospasm; irritability, depression, psychosis, seizures, ↑ QT</p></li><li><p>Rickets and/or osteomalacia: chronic ↓ vit D → ↓ Ca, ↓ PO4 → ↓ bone/cartilage mineralization, growth failure, bone pain, muscle weakness</p></li><li><p>Renal osteodystrophy: osteomalacia [↓ mineralization of bone due to ↓ Ca and 1,25-(OH)2D] & osteitis fibrosa cystica (due to ↑ PTH), adynamic bone disease or mixed uremic osteodystrophy; dx by bone biopsy</p></li></ul><p>Diagnostic studies</p><ul><li>Ca, alb, ICa, PTH, 25-(OH)D, 1,25-(OH) 2D (if renal failure or rickets), Cr, Mg, PO4, Aϕ, UCa</li></ul><p>Treatment (also treat concomitant vitamin D deficiency; Endocrine 2020;69:485)</p><ul><li><p>Severely symptomatic: Ca gluconate (1–2 g IV over 20 min) + oral Ca + calcitriol (but takes hrs to work) ± Mg (50–100 mEq/d); 10% CaCl2 in codes or via CVL</p></li><li><p>Consider Ca gtt or PO to follow b/c effect of IV bolus typically lasts only a few hours</p></li><li><p>Chronic (depends on etiol.): oral Ca (1–3 g/d; citrate better absorbed than carbonate, esp. if achlorhydria or on PPI) and typically calcitriol (0.25–2 mcg/d), and replete vit. D defic. Consider thiazide to ↓ urinary Ca or recombinant PTH 1-84 (if hypopara).</p></li><li><p>Chronic renal failure: phosphate binder(s), oral Ca, calcitriol or analogue</p></li></ul><p>DIABETES MELLITUS</p><p>Definition (Diabetes Care 2022;45:S256)</p><ul><li><p>Either HbA1c ≥6.5, fasting glc ≥126 mg/dL, or glc 2 h after OGTT ≥200 mg/dL × 2 (for any test) or single random glc ≥200 mg/dL w/ classic sx of hyperglycemia; all tests equally reasonable (nb, may be ⊕ on one test but not another); OGTT preferred during preg</p></li><li><p>Blood glc higher than normal, but not frank DM (“prediabetics,” ~40% U.S. population)</p></li></ul><p>HbA1c 5.7–6.4%, impaired fasting glc (IFG) 100–125 mg/dL, or 2 h prandial glc 140–199.</p><p>Preventing progression to DM: diet/exercise (58% ↓), metformin (31% ↓; NEJM 2002;346:393)</p><p>Categories</p><ul><li><p>Type 1 (Lancet 2018;391:2449): islet cell destruction; absolute insulin deficiency; ketosis in absence of insulin; prevalence 0.4%; usual onset in childhood but can occur throughout adulthood; ↑ risk if ⊕ FHx; HLA associations; anti-GAD, anti-islet cell & anti-insulin autoAb</p></li><li><p>Type 2 (Lancet 2017;389:2239): insulin resistance + relative insulin ↓; prevalence 6%; onset generally later in life; no HLA assoc.; risk factors: age, ⊕ FHx, obesity, sedentary lifestyle</p></li><li><p>Type 2 DM p/w DKA (“ketosis-prone diabetes” or “Flatbush diabetes”): most often seen in nonwhite, ± anti-GAD Ab, eventually may not require insulin (Endo Rev 2008;29:292)</p></li><li><p>Mature-Onset Diabetes of the Young (MODY): autosomal dom. forms of DM due to defects in insulin secretion genes; genetically and clinically heterogeneous (JCEM 2021;106:237)</p></li><li><p>Secondary causes of diabetes: exogenous glucocorticoids, glucagonoma (3 Ds = DM, DVT, diarrhea), pancreatic (pancreatitis, hemochromatosis, CF, resection), endocrino-pathies (Cushing’s, acromegaly), gestational, drugs (protease inhibitors, atypical antiψ)</p></li></ul><p>Clinical manifestations</p><ul><li>Polyuria, polydipsia, polyphagia with unexplained weight loss; may be asymptomatic</li></ul><p>Diabetes Treatment Approach for Pt w/ ASCVD, HF, or CKD</p><p>Med (↓ HbA1C)</p><p>Comments</p><p>GLP-1 receptor agonists (~1–2%)</p><p>↑ glc-depend. insulin secretion. Delay gastric emptying. Wt ↓, N/V.</p><p>↓ CVD/MI/stroke, esp. if ASCVD. ↓ prog of albuminuria.</p><p>1st line if est. ASCVD or high ASCVD risk (age >55, LVH, arterial stenosis >50%), regardless of A1c.</p><p>SGLT-2 inhibitors (~0.5–1%)</p><p>↑ glucosuria. Wt ↓. ↑ genital infxn. ? caution if PAD.</p><p>↓ CVD/HHF. ↓ prog. of renal disease. ± ↓ MI if ASCVD.</p><p>1st line if HF, proteinuric CKD, regardless of A1c.</p><p>Metformin (~1–1.5%)</p><p>↓ hepatic gluconeogenesis. Mild wt ↓. Rare lactic acidosis. Caution if GFR 30–45; contra. if &lt;30. Poss CV benefit.</p><p>Historically 1st line Rx, although some debate given benefit of GLP1RA & SGLT2i.</p><p>Additional Diabetes Treatment Options</p><p>DPP-4 inhibitors</p><p>(~0.5–1%)</p><p>Block degrad. GLP-1 & GIP → ↑ insulin.</p><p>↑ risk of HF w/ saxagliptin (NEJM 2013;369:1317), not w/ others.</p><p>Sulfonylureas (SU) (~1.5%)</p><p>↑ insulin secretion. Hypoglycemia; wt gain.</p><p>Thiazolidinediones (TZD) (~1%)</p><p>↑ insulin sens. in adipose & muscle. Wt ↑, fluid retention & CHF. Hepatox. ↑ MI w/ rosiglitazone? Contraindic. in HF & liver dysfxn.</p><p>Glinides (~1%)</p><p>↑ insulin secretion; hypoglycemia; wt gain</p><p>α-gluc. inhib (~0.5%)</p><p>↓ intestinal CHO absorption. Abd pain, flatulence.</p><p>Pramlintide (~0.5%)</p><p>Delays gastric emptying & ↓ glucagon. N/V</p><p>Insulin</p><p>(variable)</p><p>↓↓ glc; wt gain. Mandatory in T1D; consider in T2D if oral Rx inadeq. Weekly vs. daily w/ similar glycemic ctrl (NEJM 2020;383:2107).</p><p>Tirzepatide (~2–2.5%)</p><p>Dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Greater ↓ in A1C & wt vs. semaglutide (NEJM 2021;385:503). Not yet FDA approved.</p><p>Gastric bypass</p><p>Wt ↓↓↓; can cause remission DM (NEJM 2014;370:2002)</p><p>Lifestyle changes including weight management are foundational. Diabetes Care 2022;45:S256; NEJM 2021; 385:896. NEJM 2019;381:1995; Lancet 2019;393:31; Circ 2019;139:2022; NEJM 2019;380:2295.</p><p>Complications (NEJM 2004;350:48; 2016;374:1455; CJASN 2017;12:1366)</p><ul><li>Retinopathy</li></ul><p>nonproliferative: “dot & blot” and retinal hemorrhages, cotton-wool/protein exudates</p><p>proliferative: neovascularization, vitreous hemorrhage, retinal detachment, blindness</p><p>treatment: photocoagulation, surgery, intravitreal bevacizumab injections</p><ul><li><p>Nephropathy: microalbuminuria → proteinuria ± nephrotic syndrome → renal failure. Strict BP control using ACEI or ARB; SGLT-2 inhib (NEJM 2016;375:323 & 2019;380:2295); finerenone (NEJM 2020;383:2219); low-protein diet; dialysis or transplant.</p></li><li><p>Neuropathy: peripheral: symmetric distal sensory loss, paresthesias, ± motor loss</p></li></ul><p>autonomic: gastroparesis, constipation, neurogenic bladder, erectile dysfxn, orthostasis</p><p>mononeuropathy: sudden-onset peripheral or CN deficit (footdrop, CN III >VI >IV)</p><ul><li><p>Accelerated atherosclerosis: coronary, cerebral and peripheral arterial beds</p></li><li><p>Infections: UTI, osteomyelitis of foot, candidiasis, mucormycosis, necrotizing external otitis</p></li><li><p>Dermatologic: necrobiosis lipoidica diabeticorum, lipodystrophy, acanthosis nigricans</p></li></ul><p>Outpatient screening and treatment goals (Diabetes Care 2022;45;S83 & S144)</p><ul><li><p>✓ HbA1C q3–6mo, goal &lt;7% for most Pts. Goal &lt;6.5% if low-risk hypoglycemia; ≤8% if h/o severe hypoglycemia, elderly or other comorbid.</p></li><li><p>Microvascular complications (nephropathy, retinopathy, neuropathy) ↓↓ by strict glycemic control (NEJM 1993;329:977).</p></li><li><p>Effect of strict glycemic control on macrovascular complications (ASCVD) more nuanced. Benefit in T1D (NEJM 2005;353:2643) & T2D, but emerged after a decade (NEJM 2015;372:2197). In shorter-term trials (~5 yrs), modest ↓ in risk of MI, but no effect on death and even ↑ in some studies, potentially because of hypoglycemia (Lancet 2009;373:1765).</p></li><li><p>Microalbuminuria screening yearly with spot microalbumin/Cr ratio, goal &lt;30 mg/g</p></li><li><p>Wt loss (dietary/drugs) can regress or resolve DM (Endo Rev 2018;39:79; NEJM 2018;379:1107)</p></li><li><p>BP ≤130/80 if high CV risk, ≤140/90 if lower risk; benefit of ACEI/ARB</p></li><li><p>Lipids: statin initiation in all diabetics age 40–75 if LDL-C >70 (see “Lipid Disorders”)</p></li><li><p>ASA in 2° prevention; ? role in 1°, balancing ↓ MACE & ↑ bleeding (NEJM 2018;379:1529)</p></li><li><p>Dilated retinal exam and comprehensive foot exam</p></li></ul><p>Management of hyperglycemia in inPts (for ICU: see “Sepsis”) (Clin Ther 2013;35:724)</p><ul><li><p>Identify reversible causes/precipitants (dextrose IVF, glucocorticoids, postop, ↑ carb diet)</p></li><li><p>Dx studies: BG fingersticks (fasting, qAC, qHS; or q6h if NPO), HbA1C</p></li><li><p>Treatment goals: avoid hypoglycemia, extreme hyperglycemia (>180 mg/dL)</p></li><li><p>Transition to inPt:</p></li></ul><p>T1D: do not stop basal insulin (can → DKA)</p><p>T2D: stopping oral DM meds generally preferred to avoid hypoglycemia or med interaction (except if short stay, excellent outPt cntl, no plan for IV contrast, nl diet). If Pt on insulin as outpt do not rely on sliding scale alone (Diabetes Care 2022;45:S244).</p><ul><li>Starting new insulin regimen</li></ul><p>Basal = 0.2–0.4 U/kg/d NPH Q12h or detemir or glargine + correction insulin for BG >150 mg/dL + prandial insulin if eating: 0.05–0.1 U/kg/meal lispro, aspart, or regular</p><ul><li>When NPO</li></ul><p>T1D: continue basal insulin at current dose or 75% depending on BG control</p><p>T2D: continue basal insulin at 25–75% depending on BG control and level of insulin resistance. Hold all prandial insulin.</p><ul><li>Discharge regimen: similar to admission regimen unless poor outPt cntl or strong reason for Δ. Arrange early insulin and glucometer teaching, prompt outPt follow-up.</li></ul><p>DIABETIC KETOACIDOSIS (DKA)</p><p>Precipitants (the I’s)</p><ul><li><p>Insulin defic. (ie, failure to take enough insulin); Iatrogenesis (glucocorticoids; SGLT2 inhibitors—can be w/o marked hyperglycemia; Diabetes Care 2016;39:532)</p></li><li><p>Infection (pneumonia, UTI) or Inflammation (pancreatitis, cholecystitis)</p></li><li><p>Ischemia or Infarction (myocardial, cerebral, gut); Intoxication (alcohol, drugs)</p></li></ul><p>Pathophysiology (NEJM 2015;372:546)</p><ul><li><p>Occurs in T1D (and in ketosis-prone T2D); ↑ glucagon and ↓ insulin</p></li><li><p>Hyperglycemia due to: ↑ gluconeogenesis, ↑ glycogenolysis, ↓ glucose uptake into cells</p></li><li><p>Ketosis due to: insulin deficiency → mobilization and oxidation of fatty acids,</p></li></ul><p>↑ substrate for ketogenesis, ↑ ketogenic state of the liver, ↓ ketone clearance</p><p>Clinical manifestations (Diabetes Care 2009;32:1335 & 2016;39:S99)</p><ul><li><p>Polyuria, polydipsia, & dehydration → ↑ HR, HoTN, dry mucous membranes, ↓ skin turgor</p></li><li><p>N/V, abdominal pain (either due to intra-abdominal process or DKA), ileus</p></li><li><p>Kussmaul’s respirations (deep) to compensate for metabolic acidosis with odor of acetone</p></li><li><p>Δ MS → somnolence, stupor, coma; mortality ~1% even at tertiary care centers</p></li></ul><p>Diagnostic studies</p><ul><li><p>↑ Anion gap metabolic acidosis (pH &lt;7.3 & HCO3 &lt;18): can later develop nonanion gap acidosis due to urinary loss of ketones (HCO3 equiv.) & fluid resuscitation w/ chloride</p></li><li><p>Ketosis: ⊕ urine and serum ketones (predominant ketone is β-OH-butyrate, but acetoacetate measured by assay; urine ketones may be ⊕ in fasting normal Pts)</p></li><li><p>↑ Serum glc usually >250 mg/dL (but can be euglycemic if on SGLT-2i);↑ BUN & Cr</p></li><li><p>Hyponatremia: corrected Na = measured Na + [2.4 × (measured glc – 100)/100]</p></li><li><p>↓ or ↑ K (but even if serum K is elevated, usually total body K depleted); ↓ total body phos</p></li><li><p>Leukocytosis & ↑ amylase (even if no pancreatitis)</p></li></ul><p>Treatment of DKA (BMJ 2019;365:1114)</p><p>R/o possible precipitants</p><p>Infection, intra-abdominal process, MI, etc. (see above)</p><p>Aggressive hydration</p><p>1L NS then ~250 cc/hr, tailor to dehydration & CV status</p><p>Insulin</p><p>0.1 U/kg bolus followed by 0.1 U/kg/h IV</p><p>Continue insulin drip until AG normal</p><p>If glc &lt;250 and AG still high → add dextrose to IVF and ↓ insulin drip to 0.02—0.05 U/kg/hr</p><p>AG nl & can eat → SC insulin (overlap IV & SC 2–3 h)</p><p>Electrolyte repletion</p><p>K: add 20–40 mEq/L IVF if serum K &lt;5.4; insulin</p><p>promotes K entry into cells → hold insulin if K &lt;3.3. Careful K repletion in Pts with renal failure.</p><p>HCO3: consider repletion if pH &lt;6.9 or if cardiac instability</p><p>HYPEROSMOLAR HYPERGLYCEMIC STATE</p><p>Definition, precipitants, pathophysiology (Med Clin North Am 2017;101:587)</p><ul><li><p>Extreme hyperglycemia (w/o ketoacidosis) + hyperosm. + Δ MS in T2D (typically elderly)</p></li><li><p>Precip same as for DKA, but also include dehydration and renal failure</p></li><li><p>Hyperglycemia → osmotic diuresis → vol depletion → prerenal azotemia → ↑ glc, etc.</p></li></ul><p>Clinical manifestations & dx studies (Diabetes Care 2014;37:3124)</p><ul><li><p>Volume depletion and Δ MS</p></li><li><p>↑ serum glc (usually >600 mg/dL) and ↑ meas. serum osmolality (>320 mOsm/L) effective Osm = 2 × Na (mEq/L) + glc (mg/dL)/18</p></li><li><p>pH >7.3, no ketoacidosis; usually ↑ BUN & Cr; [Na] depends on glucose & dehydration</p></li></ul><p>Treatment</p><ul><li><p>Rule-out possible precipitants; ~15% mortality due to precipitating factors</p></li><li><p>Aggressive hydration: initially NS, then ½ NS, average fluid loss up to 8–10 L</p></li><li><p>Insulin (eg, 10 U IV followed by 0.05–0.1 U/kg/h), target glucose ~250 until Pt alert</p></li></ul><p>HYPOGLYCEMIA</p><p>Clinical manifestations (glucose &lt;~55 mg/dL)</p><ul><li><p>CNS: headache, visual Δs, Δ MS, weakness, seizure, LOC (neuroglycopenic sx)</p></li><li><p>Autonomic: diaphoresis, palpitations, tremor (adrenergic sx)</p></li></ul><p>Etiologies</p><ul><li><p>Pts w/ diabetes: excess insulin, oral hypoglycemics, missed meals, renal failure (↓ insulin & SU clearance); β-blockers can mask adrenergic symptoms of hypoglycemia</p></li><li><p>Pt without diabetes: low fasting glucose w/o sx can be normal</p></li><li><p>↑ insulin: exogenous insulin, sulfonylureas, insulinoma, anti-insulin antibodies</p></li><li><p>↓ glucose production: hypopituitarism, adrenal insufficiency, glucagon deficiency, hepatic failure, renal failure, CHF, alcoholism, sepsis, severe malnutrition</p></li></ul><p>Postprandial, esp. postgastrectomy or gastric bypass: excessive response to glc load</p><p>↑ IGF-II: non-islet tumor (rare)</p><p>Evaluation in patients without diabetes (JCEM 2009;94:709)</p><ul><li><p>If clinically ill: take measures to avoid recurrent hypoglycemia; ✓ BUN, Cr, LFTs, TFTs, prealbumin; IGF-I/IGF-II ratio when appropriate</p></li><li><p>If otherwise healthy: 72-h fast w/ monitored blood glc; stop for neuroglycopenic sx</p></li><li><p>At time of hypoglycemia: insulin, C peptide (↑ w/ insulinoma and sulfonylureas, ↓ w/ exogenous insulin), β-OH-butyrate, sulfonylurea levels</p></li><li><p>At end of fast, give 1 mg glucagon IV and measure response of plasma glc before feeding</p></li></ul><p>Treatment</p><ul><li><p>Glucose tablets, paste, & fruit juice are first-line Rx for Pts who can take POs</p></li><li><p>25–50 g of D50 IV; if no access, glucagon 0.5–1 mg IM or SC (side effect: N/V)</p></li></ul><p>LIPID DISORDERS</p><p>Measurements</p><ul><li><p>Lipoproteins = lipid core (cholesteryl esters & triglycerides) + phospholipid surface + proteins. Include: chylomicrons, VLDL, IDL, LDL, HDL, Lp(a)</p></li><li><p>Measure after 12-h fast; LDL typically calculated: LDL-C = TC – HDL-C – (TG/5) underestim. if TG >400 or LDL-C &lt;70 mg/dL; ∴ directly measure LDL-C levels stable up to 24 h after ACS, then ↓ and may take 6 wk to return to nl</p></li><li><p>PEx clues: tendon xanthomas (eg, Achilles), imply LDL >300 mg/dL; eruptive xanthomas on extensor surfaces imply TG >1500 mg/dL; xanthelasma (yellowish streaks on eyelids)</p></li><li><p>Metabolic syndrome (≥3 of following): waist ≥40″ (♂) or ≥35″ (♀); TG ≥150 mg/dL; HDL&lt;40 (♂) or &lt;50 mg/dL (♀); BP ≥130/85 mmHg; fasting glc ≥100 mg/dL (Circ 2009;120:1640)</p></li><li><p>Lp(a) = LDL particle + apo(a); concentration genetically determined; a/w CAD & AS</p></li></ul><p>Dyslipidemias</p><ul><li><p>1° (inherited causes): familial hyperchol. (1:250): defective LDL receptor; ↑↑ chol; ↑ CAD; familial hyperTG: ↑ TG & pancreatitis; familial combined hyperlipid.: ↑ chol & TG; etc.</p></li><li><p>2°: DM (↑ TG, ↓ HDL), hypothyroidism (↑ LDL, ↑ TG), nephrotic syndrome (↑ LDL, ↑ TG), liver failure (↓ LDL), alcohol (↑ TG, ↑ HDL), thiazides (↑ LDL, ↑ TG), protease inhib (↑ TG)</p></li></ul><p>Drug Treatment</p><p>Drug</p><p>↓ LDL</p><p>↓ TG</p><p>Side Effects/Comments</p><p>Statins</p><p>30–60%</p><p>10–25%</p><p>↑ ALT in 0.5–3%; ✓ before starting and then prn</p><p>Myalgias &lt;10%, rhabdo &lt;0.1%, dose-dependent</p><p>↑ risk of DM; screen if risk factors (ATVB 2019;39:e38)</p><p>Ezetimibe</p><p>~24%</p><p>—</p><p>Well tolerated</p><p>Bempedoic acid</p><p>~16%</p><p>—</p><p>Hyperuricemia/gout; ↓ eGFR. CVOT under way.</p><p>PCSK9i</p><p>50–60%</p><p>15–25%</p><p>mAb inj SC q2-4w or siRNA inj SC q6mo</p><p>Fibrates</p><p>5–15%</p><p>35–50%</p><p>Myopathy risk ↑ w/ statin. ↑ Cr; ✓ renal fxn q6mo.</p><p>Ω-3 FA</p><p>5% ↑</p><p>25–50%</p><p>EPA & DHA at doses of up to 4 g/d</p><p>No benefit to low-dose supplementation</p><p>Resins ↓ LDL-C by ~20%, but not well tolerated; niacin ↑ HDL-C and ↓ TG & LDL-C; no effect on CV outcomes.</p><p>Treatment of LDL-C (Lancet 2014;384:607)</p><ul><li><p>Statins: every 1 mmol (39 mg/dL) ↓ LDL-C → 22% ↓ major vascular events (CV death, MI, stroke, revasc) in individuals w/ & w/o CAD (Lancet 2010;376:1670)</p></li><li><p>Ezetimibe: ↓ major vascular events incl MI & stroke when added to statin post-ACS, w/ magnitude of benefit consistent w/ LDL-statin relationship (IMPROVE-IT, NEJM 2015;372:2387)</p></li><li><p>PCSK9 inhibitors: ~60% ↓ LDL-C on top of statin, as monoRx, and in FH (EHJ 2014;35:2249); ↓ CV outcomes (NEJM 2017;376:1713 & 2018;379:2097)</p></li><li><p>In homozygous FH: apheresis; evinacumab (ANGPTL3 inhib) ↓ LDL-C by ~50% (NEJM 2020;383:711)</p></li></ul><p>Treatment of other lipid fractions (Lancet 2014;384:618 & 626)</p><ul><li><p>HDL-C: low levels a/w ↑ risk of MI, but no clinical benefit shown by raising</p></li><li><p>Triglycerides: reasonable to treat levels >500 mg/dL w/ fibrates or Ω-3 FA to ↓ risk of pancreatitis. May be a/w CAD (NEJM 2014;371:22). 4 g/d of EPA ↓ CV risk, but 2 g/d EPA + 2 g/d DHA did not despite similar ↓ TG (NEJM 2019;380:11; JAMA 2020;324:2268)</p></li><li><p>Lp(a): PCKS9i ↓ ~25%. siRNA that ↓ ≥75% under study (NEJM 2020;382:244).</p></li></ul><p>2018 ACC/AHA Cholesterol Guidelines (Circ 2019;139:e1082)</p><p>Population</p><p>Recommendation</p><p>Very high-risk ASCVD*</p><p>High-intensity statin; add EZE then PCSK9i if LDL-C ≥70</p><p>Clinical ASCVD</p><p>High-intensity statin (? mod if >75 y), add EZE if LDL-C ≥70</p><p>LDL-C ≥190 mg/dL</p><p>High-intensity statin; add EZE or PCKS9i if LDL-C ≥100</p><p>DM, age 40–75 y</p><p>High-intensity statin (? moderate if no CV RFs)</p><p>Age 40–75 y (and none of above); calc 10-y risk</p><p>≥20%</p><p>High-intensity statin</p><p>7.5%–&lt;20%</p><p>Moderate-intensity statin; if uncertain consider CAC</p><p>5–&lt;7.5%</p><p>Moderate-intensity statin reasonable</p><p>&lt;5%</p><p>Emphasize lifestyle</p><p>ASCVD incl h/o ACS, stable angina, art. revasc, stroke, TIA, PAD. *Multiple major ASCVD events (MI, stroke, sx PAD) or 1 major event + multiple high-risk conditions (age ≥65, DM, HTN, CKD, smoking, FH, prior PCI/CABG). 10-y CV Risk Score:
<a href=http://my.americanheart.org/cvriskcalculator rel=noopener>http://my.americanheart.org/cvriskcalculator</a>. Additional risk factors to consider: LDL-C ≥160 mg/dL, met. synd.,CKD, FHx premature ASCVD, hsCRP ≥2 mg/l, Lp(a) ≥50 mg/dL, ABI &lt;0.9, high-risk ethnic groups.</p><p>APPROACH TO RHEUMATIC DISEASE</p><p>Major categories of inflammatory rheumatic disease</p><ul><li><p>Inflammatory arthritis: crystalline (gout, CPPD), RA, spondyloarthritis, adult-onset Still’s</p></li><li><p>Connective tissue disease: SLE, Sjögren’s, scleroderma, myositides (DM, PM), MCTD</p></li><li><p>Vasculitis: large (GCA, Takayasu’s); medium (PAN); small (ANCA, IgA, cryo); Behçet’s</p></li><li><p>Other: IgG4-related disease, autoinflammatory disease (familial Mediterranean fever, TNF receptor-associated periodic syndrome, VEXAS = vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic), sarcoid (see “ILD”), HLH/MAS, relapsing polychondritis</p></li></ul><p>Approach to patient with joint pain</p><ul><li><p>Articular vs. periarticular (bursitis, tendinitis) source of pain: typically active ROM more painful than passive ROM in periarticular process</p></li><li><p>Inflammatory vs. noninflammatory pain: features of inflammatory arthropathy include joint swelling, warmth or redness, prolonged morning stiffness (>30 min), improvement of pain/stiffness w/ motion/exercise. Assess for extra-articular features.</p></li><li><p>Physical exam: localize complaint, identify signs of inflammation, and assess number and pattern of affected joints.</p></li></ul><p>aMay initially present as arthralgia w/o overt arthritis. bRange of motion of joint or joint a/w bursa or tendon.</p><p>Figure 8-1 Approach to arthritis</p><p>*WBC count of aspirated fluid in septic bursitis often &lt; WBC count in septic arthritis.</p><p>Imaging features of major arthritides</p><ul><li><p>OA: plain films: asym joint space narrowing (JSN), osteophytes, subchondral sclerosis & cysts; subchondral “gull-wing” erosions may be seen in less-common erosive OA; MRI may show early disease not seen on plain films; U/S ≈ MRI for structural damage ⊖</p></li><li><p>RA: plain films: symmetric JSN, early = periarticular osteopenia; late = marginal erosions; subluxations; MRI & U/S can detect early and subclinical disease; MRI ≈ U/S for erosions</p></li><li><p>Gout: plain films: early = nonspec swelling; late = tophus, joint erosions w/ overhanging edges; U/S for detection of microtophi (double-contour sign); dual-energy CT (DECT): identify articular/periarticular UrA deposits vs. calcium deposits; MRI ≈ U/S for erosions</p></li><li><p>Spondyloarthritis: e/o sacroiliitis: plain films: early = pseudo-widening SI joint space, late = sclerosis, erosions, ankylosis; SI MRI ↑ Se for early Δ; U/S ≈ MRI to detect enthesitis</p></li></ul><p>INFLAMMATORY MARKER & AUTOANTIBODY TESTING</p><p>Inflammatory markers (Mod Rheumatol 2009;19:469; NEJM 1999;340:448)</p><ul><li><p>ESR: indirect measure of inflammation [↑ RBC aggregation due to acute-phase proteins (fibrinogen, Ig)]; slow to rise; may ↑ w/ age, preg., anemia, obesity, ESRD. Ddx for >100: malig. esp. MM, lymphoma; GCA or other vasculitis; endocarditis, TB, osteomyelitis.</p></li><li><p>CRP: direct measure of inflammation (protein produced by liver, part of innate immune system); typically rises and falls before the ESR w/ treatment/resolution of process</p></li></ul><p>Autoantibody testing (Best Pract Res Clin Rheumatol 2014;28:907)</p><ul><li><p>ANA (anti-nuclear Ab): screening test for Ab directed against nuclear proteins.</p></li><li><p>Order ANA only when clinical suspicion for CTD b/c nonspecific: 1:40 (very low ⊕, 25–30% of healthy Pts); 1:80 (low ⊕, 10–15% of healthy Pts); ≥1:160 (⊕, 5% of healthy Pts). May be ⊕ in Pts prior to clin manifest (NEJM 2003;349:1526; Arthritis Res Ther 2011;13:1).</p></li><li><p>If ANA ⊕ and high clinical suspicion for CTD, consider testing for Ab against dsDNA, Smith, Ro/La, RNP, Scl-70 and myositis-specific Abs (highly specific for various CTD)</p></li><li><p>ANA does not correlate well w/ disease activity, ∴ no clinical value in serial testing</p></li><li><p>ANA also ⊕ in: AIH, PBC, thyroid disease, certain infxns and malignancies, IBD, IPF</p></li><li><p>RF and anti-CCP (see “Rheumatoid Arthritis”)</p></li></ul><p>DDX & APPROACH TO COMMON INPATIENT RHEUM PRESENTATIONS</p><p>Feature</p><p>Rheum Ddx</p><p>Rheum Lab w/up (+ ANA)</p><p>FUO</p><p>GCA/PMR, AOSD, SLE, inflamm arthr, Taka- yasu, PAN, ANCA ⊕ vasc, cryo, HSP, VEXAS</p><p>ESR, CRP, RF, ANCA, ± cryo</p><p>Pulm HTN</p><p>Scleroderma (limited >diffuse), MCTD, SLE, PM/DM (less common)</p><p>Scl-70, centromere, RNA Pol III, RNP</p><p>DAH</p><p>ANCA ⊕ vasc, Goodpasture’s, SLE, APS</p><p>ANCA, GBM, C3/C4, APLA</p><p>ILD</p><p>Scleroderma (diffuse >limited), sarcoid, RA, DM, PM, antisynthetase syndrome, Sjögren’s, MCTD, SLE (esp. pleura), ANCA ⊕ vasc (esp. MPA)</p><p>Scl-70, RF/CCP, CK, aldolase, ± myositis specific Abs, Jo-1, Ro/La, ANCA</p><p>Pleuro- pericarditis</p><p>SLE, scleroderma, RA, MCTD, DM/PM, ANCA ⊕ vasc, Sjögren’s, AOSD, PAN</p><p>dsDNA, RF/CCP, Sm, Ro/La, Scl-70, RNP, ANCA</p><p>AKI + active sed. or CTD s/s</p><p>SLE (GN or nephrotic), ANCA ⊕ vasc (GN), scleroderma renal crisis, Sjögren’s (RTA/TIN), PAN (infarct), HSP, Goodpasture’s, cryo, APS</p><p>dsDNA, Sm, Ro/La, RNP, C3/C4, Scl-70, RNA Pol III, ANCA, GBM, cryos, APLA</p><p>Neuropathy</p><p>ANCA ⊕ vasc, SLE, Sjögren’s, cryo, sarcoid, RA, PAN</p><p>Ro/La, ANCA, cryo RF/CCP, HCV, HBV</p><p>RHEUMATOID ARTHRITIS (RA)</p><p>Definition & epidemiology (Lancet 2016;388:2023)</p><ul><li><p>Chronic, symmetric, and potentially destructive inflammatory polyarthritis characterized by proliferative synovial tissue (pannus) formation in affected joints</p></li><li><p>Pathogenesis involves overproduction of TNF, IL-1, and IL-6 (∴ used as drug targets)</p></li><li><p>Risk stems from combination of genetics (~50% of risk), environmental influences (eg, smoking, silica dust), and Pt factors (periodontal disease, Δs in gut microbiome)</p></li><li><p>HLA-DRB1 haplotype a/w disease suscept., severity, & response to Rx (JAMA 2015;313:1645)</p></li><li><p>Prevalence = 1/100 adults and 1/20 ♀ >70 y; ♀ to ♂ ratio = 3:1; peak incidence 50–75 y</p></li></ul><p>Clinical manifestations (JAMA 2018;320:1360)</p><ul><li><p>Usually insidious onset pain, swelling, & impaired function of joints w/ prolonged morning stiffness for ≥6 wk (typically PIPs, MCPs, wrists, knees, ankles, MTPs, cervical spine)</p></li><li><p>Typically polyarticular (60% small joints, 30% large joints, 10% both), may be monoarticular (knee, shoulder, wrist) early in course; rheumatoid joints more susceptible to infection</p></li><li><p>Joint deformities: ulnar deviation, swan neck (MCP flexion, PIP hyperextension, DIP flexion), boutonnière (PIP flexion, DIP hyperextension), cock-up deformities (toes)</p></li><li><p>C1–C2 instability → myelopathy, ∴✓ C-spine flex/ext films prior to elective intubation</p></li><li><p>Constitutional symptoms: low-grade fever, weight loss, malaise</p></li><li><p>Extra-articular manifestations (18–41% of Pts) can occur at any time; ↑ frequency in seropositive (⊕ RF or anti-CCP) and w/ active disease (Autoimmun Rev 2021;20:102776)</p></li></ul><p>Extra-Articular Manifestations</p><p>Skin</p><p>Rheumatoid nodules (20–30%, usually sero ⊕): extensor surface, bursae; can be in lung, heart, sclera</p><p>Raynaud’s, pyoderma gangrenosum, cutan. vasculitis (ulcers, purpura, etc.)</p><p>Pulm</p><p>ILD (a/w MUC5B mutations), airway disease, pleuritis, effusions (low glc), nodules, pulm HTN; precedes joint sx in 20% of cases; RA med toxicity (MTX, ? anti-TNF, & anti-CD20) (Semin Arthritis Rheum 2014;43:613)</p><p>CV</p><p>Accel. athero w/ ↑ risk of MI & CV death, AF, pericarditis (effusions in ⅓ of sero ⊕), myocarditis, coronary/systemic vasculitis (Nat Rev Rheum 2020;16:361)</p><p>Nervous</p><p>Nerve entrapment (eg, carpal tunnel), stroke, mononeuritis multiplex, CNS vasculitis</p><p>Ocular</p><p>Scleritis, episcleritis, keratoconjunctivitis sicca (2° Sjögren’s)</p><p>Heme</p><p>Anemia of chronic disease, neutropenia (Felty’s syndrome: 1%, typically long- standing RA + splenomegaly; large granular lymphocyte leukemia: bone marrow infiltrated w/ lymphocytes ± myeloid hypoplasia), NHL, amyloidosis</p><p>Renal</p><p>Glomerulonephritis (usually mesangial), nephrotic syndrome (2° amyloidosis), nephrotoxicity from RA meds</p><p>Vasculitis</p><p>Small & medium vessels (usually ↑ RF titer, long-standing RA); pericarditis, ulcers, scleritis, & neuropathy most common</p><p>Laboratory & radiologic studies</p><ul><li><p>RF (IgM/IgA/IgG anti-IgGAb) ⊕ in ~70%; also seen in other rheumatic diseases (SLE, Sjögren’s), cryoglobulinemia, infection (SBE, hepatitis, TB), ~5% of healthy pop.</p></li><li><p>Anti-CCP (Ab to cyclic citrullinated peptide): ⊕ in ~70% of Pts w/ RA, similar Se, but more Sp (>90%) than RF particularly for early RA (Arth Rheum 2009;61:1472); a/w increased joint damage and low remission rates</p></li><li><p>~20% are seronegative (RF and anti-CCP negative)</p></li><li><p>↑ ESR/CRP but nl in ~30%; ⊕ ANA in ~40%; ↑ globulin during periods of active disease</p></li><li><p>Radiographs of hands and wrists: periarticular osteopenia, bone erosions, joint subluxation</p></li><li><p>Increasing use of MSK U/S to diagnose synovitis, tenosynovitis, and erosive disease</p></li></ul><p>ACR/EULAR classification criteria (Arth Rheum 2010;62:2569)</p><ul><li><p>Used in clinical research, but not in clinical practice</p></li><li><p>Relevant for Pts with ≥1 joint with synovitis not better explained by another disease</p></li><li><p>Likelihood of RA ↑ w/ higher # (espec. ≥4) of small joints involved, ⊕ RF or anti-CCP (espec. high titer), ↑ ESR or CRP, and duration ≥6 wk</p></li></ul><p>Management (Lancet 2017;389:2328 & 2338; JAMA 2018;320:1360)</p><ul><li><p>Early dx and Rx (esp DMARD) w/ frequent follow-up and escalation of Rx as needed with goal to achieve clinical remission or low disease activity</p></li><li><p>↓ time to remission ≈ ↑ length of sustained remission (Arthritis Res Ther 2010;12:R97)</p></li><li><p>Sero ⊕ (eg, RF or anti-CCP) a/w aggressive joint disease & extraarticular disease</p></li><li><p>At dx, start both rapid-acting agent (to acutely ↓ inflammation) and Disease-Modifying Anti- Rheumatic Drug (DMARD) (typically take 1–3 mo to have max effect)</p></li><li><p>Rapid-acting drugs:</p></li></ul><p>NSAIDs or COX-2 inhibitors: ↑ CV risk, GI adverse events, AKI; consider starting w/ PPI</p><p>glucocorticoids: low dose (&lt;20 mg/d oral) or joint injection</p><p>NSAIDs + glucocorticoids: ↑↑ GI events; give PPI and minimize long-term concurrent use</p><ul><li>DMARDs (see RA therapeutics below):</li></ul><p>Methotrexate (1st line unless CKD, hepatitis, EtOH, or lung disease), alternatives include sulfasalazine (SSZ) or leflunomide; consider HCQ if mild disease</p><p>If inadequate response after 3 mo (despite DMARD dose escalation) consider:</p><p>combination Rx w/ other DMARDs (eg, “triple therapy” w/ MTX, SSZ, and HCQ) or</p><p>adding biologic (anti-TNF typically 1st line unless contraindication)</p><p>MTX/SSZ/HCQ non-inferior to etanercept/MTX (NEJM 2013;369:307)</p><p>JAKi: if fail biologics vs. initial DMARD, but ↑ serious side effect risk over abatacept or TNFi (see below) (Lancet 2018;391:2503 & 2513; NEJM 2020;383:1511; NEJM 2022;386:316)</p><ul><li>Given a/w CV morbidity/mortality, try to ↓ risk w/ lifestyle mgmt, lipid & DM screening</li></ul><p>RA Therapeutics (Arth Care Res 2021;73:924)</p><p>Class</p><p>Drug</p><p>Side Effects</p><p>Traditional DMARDs</p><p>Methotrexate (MTX)</p><p>Leflunomide</p><p>Sulfasalazine (SSZ)</p><p>MTX: GI distress, stomatitis, ILD, myelosuppression, hepatotoxicity</p><p>Supplement MTX ± SSZ w/ folate</p><p>✓ G6PD prior to SSZ</p><p>Biologic DMARDs</p><p>(all anti-TNF ≈ efficacy; if inadequate resp to anti- TNF try non-TNF)</p><p>Anti-TNF: etanercept, infliximab, adali- mumab, certolizumab, golimumab</p><p>CTLA4-Ig: abatacept</p><p>Anti-IL-6R Ab: tocilizumab (studied as mono-Rx w/o MTX); sarilumab</p><p>Anti-CD20: rituximab</p><p>Anti-IL-1R: anakinra</p><p>Never use 2 biologics together</p><p>↑ risk bacterial/fungal/viral infxn</p><p>✓ TB, Hep B/C before starting</p><p>Immunize against Zoster + Pneumococcus</p><p>Anti-TNF: ? risk for CHF & CNS demyelinating disease</p><p>Anti-IL-6R: risk of GI perf.</p><p>Rituximab: infusion reaction</p><p>Other</p><p>Hydroxychloroquine (HCQ)</p><p>JAKi: tofacitinib, baricitinib; upadacitinib (JAK1 selective)</p><p>Rare: cyclosporine, azathioprine, gold</p><p>HCQ: retinopathy, rash</p><p>JAKi: infxn, ↑ LFTs, HTN, VTE, CV events, malignancy, death</p><p>CsA: ↑ Cr, HTN, gum hyperplasia</p><p>ADULT-ONSET STILL’S DISEASE (AOSD) & RELAPSING POLYCHONDRITIS</p><p>Adult-onset Still’s disease (J Autoimmun 2018;93:24)</p><ul><li><p>Rare autoinflammatory syndrome, &lt;4/million per y incidence; ♂ = ♀ w/ bimodal typical onset 15–25 or 36–46 y; sx evolve over wks to mos</p></li><li><p>Dx if 5 criteria are present & ≥2 major; exclude infxn, malig, other rheumatic, drug rxn</p></li></ul><p>Major: fever ≥39°C for ≥1 wk (usually daily or twice daily high-spiking fever); arthralgias/ arthritis ≥2 wk; Still’s rash (qv); ↑ WBC w/ 80% PMN</p><p>Minor: sore throat; LAN; HSM; ↑ AST/ALT/LDH; negative ANA & RF</p><ul><li><p>Still’s rash (>85%): nonpruritic macular or maculopapular salmon-colored rash; usually trunk or extremities; may be precipitated by trauma (Koebner phenomenon), warm water</p></li><li><p>Plain films: soft tissue swelling (early) → cartilage loss, erosions, carpal ankylosis (late)</p></li><li><p>Treatment: NSAIDs; steroids; steroid-sparing (MTX, anakinra, anti-TNF, tocilizumab)</p></li><li><p>Variable clinical course: 20% w/ long-term remission; 30% remit-relapse; ~50% chronic (esp. arthritis); ↑ risk of macrophage activation syndrome (life threatening)</p></li></ul><p>Relapsing polychondritis (Rheumatology 2018;57:1525)</p><ul><li><p>Inflammatory destruction of cartilaginous structures; typical onset age 40–60, ♂=♀, &lt;1/million per y incidence</p></li><li><p>Subacute onset of red, painful, and swollen cartilage; ultimately atrophic & deformed</p></li><li><p>Multiple sites of cartilaginous inflammation: bilateral auricular chondritis, nonerosive inflammatory arthritis, nasal chondritis, laryngeal or tracheal chondritis, valvulopathy. Ocular inflammation and cochlear/vestibular dysfxn also common.</p></li><li><p>40% of cases a/w immunologic disorder (eg, RA, SLE, vasc., Sjögren’s), cancer or MDS (including VEXAS; NEJM 2020;383:2628)</p></li><li><p>Labs: ↑ ESR & CRP, leukocytosis, eosinophilia, anemia of chronic inflammation</p></li><li><p>Bx (not req for dx): proteoglycan depletion, perichondrial inflammation and replacement with granulation tissue and fibrosis; immunofluorescence with Ig and C3 deposits</p></li><li><p>Screen for pulm (PFTs, CXR/CT, ± bronch) and cardiac (ECG, TTE) involvement</p></li><li><p>Rx guided by disease activity/severity: steroids 1st line; NSAIDs/dapsone for arthralgias, mild disease; MTX, AZA, or biologics steroid-sparing; cyclophosph if organ-threatening</p></li></ul><p>CRYSTAL DEPOSITION ARTHRITIDES</p><p>Comparison of Gout and Pseudogout</p><p>Gout (Rheumatology 2018;58:27)</p><p>Pseudogout (NEJM 2016;374:2575)</p><p>Acute clinical</p><p>Sudden onset painful mono- articular arthritis (classically podagra [MTP of great toe]) or bursitis; frequently nocturnal</p><p>May be polyarticular in subseq flares</p><p>Can mimic cellulitis (esp in foot)</p><p>Mono- or asymmetric oligoarthritis (esp knees, wrists, and MCP joints); rare axial involvement (eg, crowned dens syndrome)</p><p>Chronic clinical</p><p>Solid crystal deposition (tophus) in joints (esp. toes, fingers, wrists, knees) & tissue (esp. olecranon bursa, pinna, Achilles)</p><p>“Pseudo-RA” w/ polyarticular arthritis w/ morning stiffness or “Pseudo-OA”</p><p>Assoc. conditions</p><p>Metabolic syndrome; CKD; CHF</p><p>3 H’s: Hyper-PTH, Hypo-Mg, Hemochromatosis</p><p>Crystal</p><p>Monosodium urate (MSU)</p><p>Calcium pyrophosphate dihydrate</p><p>Polarized microscopy*</p><p>Needle-shaped, negatively birefringent</p><p>Rhomboid-shaped, weakly positively birefringent</p><p>Radio- graphic findings</p><p>Early = nonspecific tissue swelling</p><p>Late = tophus, joint erosions w/ overhanging edges</p><p>“Double contour sign” on MSK US</p><p>DECT: UrA vs. Ca deposits</p><p>Chondrocalcinosis: linear densities within articular cartilage; often found in menisci, fibrocartilage of wrist, hands, symphysis pubis</p><p>Other</p><p>a/w uric acid stones; urate nephropathy</p><p>✓ Ca, Mg, Fe, ferritin, TIBC, UrA, PTH in young or severe cases</p><p>*Crystals should be intracellular; infection can coexist with acute attacks, ∴ always ✓ Gram stain & Cx</p><p>GOUT</p><p>Definition & epidemiology (Rheumatology 2018;58:27; Lancet 2021;397:1843)</p><ul><li><p>Humans lack enzyme (uricase) to metabolize urate (end-product of purine metabolism)</p></li><li><p>MSU crystal deposition promotes inflammation in joints and peri-articular tissue;</p></li><li><p>Prev >1/30 American adults, ♂ >♀; peak incidence 5th decade; most common inflamm arthritis in ♂ over 30 y; rare in premenopausal ♀ (estrogens ↑ renal urate excretion)</p></li></ul><p>Etiologies</p><ul><li><p>UrA underexcretion (85–90%): meds (eg, diuretics); idiopathic; ↓ renal function; obesity</p></li><li><p>Uric acid (UrA) overproduction (10–15%): ↑ meat, seafood, EtOH, psoriasis, idiopathic, myelo- and lymphoproliferative disease, chronic hemolytic anemia, cytotoxic drugs, rare inherited enzyme defic, genetic variants (Nature Rev Rheumatol 2018;14:341)</p></li></ul><p>Diagnosis</p><ul><li><p>↑ UrA is not diagnostic; 25% of measurements nl during flare; ± ↑ WBC & ESR</p></li><li><p>Arthrocentesis is gold standard: intracellular negatively birefringent needle-shaped MSU crystal. U/S w/ double-contour sign or dual-energy CT can aid non-invasive dx.</p></li><li><p>2015 ACR/EULAR Classification Criteria (Ann Rheum Dis 2015;74:1789) used 1° in research</p></li></ul><p>Acute treatment (Arthritis Care Res 2020;72:744)</p><ul><li><p>Colchinine, NSAIDs, & steroids all 1st-line; choice guided by side effect profile/comorbidities. IL-1i (J Rheum 2019;46:1345) or ACTH if these contraindicated. Start Rx ASAP; continue until acute flare resolves; consider combo Rx if severe; rest/ice; self-limited w/in 3–21+ d w/o Rx.</p></li><li><p>Continue urate-lowering therapy during attack if already taking</p></li></ul><p>Acute Treatment for Gout</p><p>Drug</p><p>Initial Dose</p><p>Comments</p><p>NSAIDs (nonsel or COX-2 inhib)</p><p>Full anti-inflammatory dose → tapering</p><p>Gastritis & GIB risk. Avoid in CKD & CVD.</p><p>≈ efficacy among NSAIDs.</p><p>Colchicine (PO; IV no longer available in U.S.)</p><p>1.2 mg then 0.6 mg 1 h later → 0.6 mg bid</p><p>N/V/diarrhea (w/ ↑ dose), marrow suppression, myopathy, neuropathy. ↓ dose in CKD (however, not nephrotoxic).</p><p>Corticosteroids (PO, IA, IV, IM)</p><p>eg, prednisone 0.5 mg/kg/d × 5–10 d ± taper</p><p>Rule out joint infection 1st.</p><p>Corticosteroid injection if &lt;3 joints.</p><p>ACTH (IM)</p><p>eg, 100 IU IM ×1–2 doses</p><p>↑ cost, ↓ s/e, limited data (Semin Arthritis Rheum 2014;43:648)</p><p>IL-1 inhibitors</p><p>(J Rheumatol 2019;46:1345)</p><p>anakinra (100 mg SC qd × 3 d); canakinumab (150 mg SC × 1)</p><p>↑↑ cost; anakinra a/w injection site pain</p><p>Canakinumab approved in EU (Ann Rheum Dis 2012;71:1839; Arth Rheum 2010;62:3064)</p><p>Chronic treatment (Arthritis Care Res 2020;72:744)</p><ul><li><p>Approach: if ≥2 attacks/y, polyarticular attack, tophus, joint erosions, GFR &lt;60, or urolithiasis → start urate-lowering therapy + pharmacologic Ppx to ↓ risk of acute attacks</p></li><li><p>Urate-lowering therapy (ULT): goal UrA &lt;6 mg/dL; when starting ULT, always give with pharm Ppx as below; do NOT d/c during acute attack or due to AKI</p></li><li><p>Pharmacologic prophylaxis: continue 6 mos w/ above Rx or longer if frequent attacks:</p></li></ul><p>low-dose colchicine (~50% ↓ risk of acute flare; J Rheum 2004;31:2429), NSAIDs (less evidence; Ann Rheum Dis 2006;65:1312), low-dose steroids, IL-1 inhibitors</p><ul><li>Lifestyle Δs: ↓ intake of meat, EtOH, & seafood, ↑ low-fat dairy, wt loss, avoid dehydration</li></ul><p>Urate-Lowering Therapy (Chronic Treatment for Gout)</p><p>Drug (route)</p><p>Mechanism</p><p>Comments</p><p>Allopurinol (PO)</p><p>Xanthine oxidase</p><p>inhibitor</p><p>1st line; adjust starting dose in CKD; titrate ↑ q2–5wk;</p><p>a/w rash, hypersensitivity syndrome (see below), BM suppression (avoid w/ AZA/6-MP), diarrhea, N/V, hepatitis; monitor CBC, LFT’s; not nephrotoxic</p><p>max dose = 800 mg/d</p><p>Febuxostat (PO)</p><p>Nonpurine xanthine oxidase inhib</p><p>2nd line; use if allopurinol intolerant;</p><p>a/w ↑ LFT, rash, arthralgias, N/V;</p><p>avoid w/ AZA/6-MP (BM suppress);</p><p>start 40 mg, max dose = 120 mg/d</p><p>Pegloticase (IV)</p><p>Recombinant uricase</p><p>For refractory tophaceous gout; infusion reactions (including anaphylaxis); Ab formation may limit use (JAMA 2011;306:711); avoid w/ G6PD deficiency</p><p>Probenecid (PO)</p><p>Uricosuric</p><p>Rarely used; risk of urolithiasis</p><ul><li>Allopurinol hypersensitivity syndrome: 10–25% mortality; incidence ~5/1000. ↓ risk w/ starting dose 100 mg/d if eGFR >40 or 50 mg/d if eGFR ≤40. Titrate by 100 mg/d (eGFR >40) or 50 mg/d (eGFR ≤40) q2–5 wk until UrA &lt;6 mg/dL (dose can be >300 mg/d even in CKD). A/w HLA-B5801, esp. Han Chinese, Koreans, Thai; screen in these high-risk populations prior to initiating (Arthritis Care Res 2020;72:744; JAMA Intern Med 2015;175:1550).</li></ul><p>CALCIUM PYROPHOSPHATE DIHYDRATE (CPPD) DEPOSITION DISEASE/PSEUDOGOUT</p><p>Definition (NEJM 2016;374:2575)</p><ul><li>Deposition of CPPD crystals w/in tendons, ligaments, articular capsules, synovium, cartilage; frequently asymptomatic</li></ul><p>Etiologies (Nat Rev Rheumatol 2018;14:592)</p><ul><li><p>Most cases idiopathic; consider further metabolic eval in young (&lt;50 y) and florid forms</p></li><li><p>Metabolic (3 H’s): hemochromatosis; hyperparathyroidism; hypomagnesemia (esp. in Gitelman’s or Bartter’s syndromes)</p></li><li><p>Joint trauma (incl. previous surgery); intra-articular hyaluronate can precipitate attacks</p></li><li><p>Familial chondrocalcinosis (autosomal dominant disorder); early-onset, polyarticular dis.</p></li></ul><p>Clinical manifestations</p><ul><li>Chondrocalcinosis: calcification of cartilage, resulting from CPPD crystal deposition in articular cartilage, fibrocartilage, or menisci</li></ul><p>↑ incidence w/ age; can be asymptomatic; chondrocalcinosis in 20% >60 y at autopsy</p><ul><li>Pseudogout: acute CPPD crystal-induced mono- or asymmetric oligoarticular arthritis, indistinguishable from gout except through synovial fluid exam for crystals</li></ul><p>location: knees, wrists, and MCP joints; rarely, axial (eg, crowned dens syndrome due to CPPD deposition at C1–C2)</p><p>precipitants: surgery, trauma, or severe illness</p><ul><li>Chronic forms: “pseudo-RA” and pyrophosphate arthropathy (resembles OA, can involve axial skeleton)</li></ul><p>Diagnostic studies</p><ul><li><p>Arthrocentesis is gold standard: rhomboid shaped, weakly positively birefringent crystals (yellow perpendicular & blue parallel to axis on polarizer; see table above)</p></li><li><p>Radiographs: see table above</p></li></ul><p>Treatment (NEJM 2016;374:2575)</p><ul><li><p>Asymptomatic chondrocalcinosis requires no treatment</p></li><li><p>Acute therapy for pseudogout: no RCTs, extrapolated from practice in gout; ∴ same as for gout, though colchicine not as effective</p></li><li><p>If associated metabolic disease, Rx of underlying disorder may improve arthritis sx</p></li><li><p>Low-dose daily colchicine or NSAID may be effective for prophylaxis or chronic arthropathy</p></li></ul><p>SERONEGATIVE SPONDYLOARTHRITIS</p><p>Definition and classification system (NEJM 2016;374:2563)</p><ul><li><p>Spondyloarthritis (SpA): group of inflammatory disorders that share common clinical manifestations: inflammatory spine disease, peripheral arthritis, enthesitis (see below), and extra-articular manifestations (primarily ocular and skin disease)</p></li><li><p>Seronegative = absence of autoantibodies</p></li><li><p>Subtypes: ankylosing spondylitis (AS), psoriatic (PsA), reactive (ReA), IBD-assoc, juvenille SpA, and undifferentiated. Distinguished by axial vs. peripheral predominant involvement.</p></li></ul><p>Epidemiology & pathogenesis (Nat Rev Rheumatol 2015;11:110)</p><ul><li><p>Prevalence 1/200 to 1/50 worldwide; AS and non-radiographic axial SpA most common</p></li><li><p>HLA-B27 accounts for ~30% of attributable genetic risk but not required for diagnosis</p></li><li><p>Environmental factors likely critical for disease, esp reactive arthritis (ie, infection)</p></li></ul><p>Spondyloarthritis (SpA) Epidemiology and Key Presentation Features</p><p>Disease</p><p>Epidemiology</p><p>Key Features</p><p>Ankylosing spondylitis (AS)</p><p>♂:♀ = 3:1; onset in teens to mid-20s (rare after 40 y)</p><p>Progressive limitation of spinal motion, a.m. stiffness, buttock pain, “bamboo spine,” ⊕ Schober test</p><p>Psoriatic arthritis (PsA)</p><p>♂ = ♀; peak incidence 45–54 y; seen in 20–30% of Pts w/ psoriasis</p><p>In 13–17% arthritis precedes skin findings by yrs; does not correlate with psoriasis activity; a/w HIV</p><p>Reactive arthritis (ReA)</p><p>♂ &#187; ♀; 20–40 y; 10–30 d after</p><p>GI or GU infxn* in genetically susceptible host</p><p>Arthritis, urethritis, and conjunctivitis.</p><p>Most resolve w/in 12 mo.</p><p>IBD- associated</p><p>arthritis</p><p>♂ = ♀; seen in 20% of IBD Pts; Crohn’s >UC</p><p>Type I &lt;5 joints: correlates w/ IBD activ.</p><p>Type II >5 joints or axial disease: does not correlate w/ IBD activity</p><p>*GU: Chlamydia, Ureaplasma urealyticum; GI: Shigella, Salmonella, Yersinia, Campylobacter, C. diff.</p><p>Major clinical manifestations (Lancet 2017;390:73)</p><ul><li>Inflammatory back pain: SI joints (sacroiliitis), apophyseal joints of spine</li></ul><p>characterized by IPAIN (Insidious onset, Pain at night, Age of onset &lt;40 y, Improves w/ exercise/hot water, No improvement w/ rest), a.m. stiffness, responsive to NSAIDs</p><ul><li><p>Peripheral arthritis: typically asymmetric, oligoarticular, large joints, lower >upper limbs; however, can be symmetric & polyarticular (thus, mimic RA), espec. in psoriatic arthritis</p></li><li><p>Enthesitis: inflammation at site of tendon/ligament insertion into bone, esp Achilles, plantar fascia (calcaneal insertion), pre-patellar, elbow epicondyles</p></li><li><p>Rigidity of spine: bamboo spine by X-ray, ankylosis due to progressive growth of bony spurs that bridge intervertebral disc</p></li><li><p>Dactylitis: “sausage digit,” inflammation of entire digit (joint + tenosynovial inflamm)</p></li><li><p>Uveitis: anterior uveitis most common extra-articular manifestation in seronegative SpA; usually unilateral and p/w pain, red eye, blurry vision, photophobia</p></li></ul><p>Clinical assessment (Nat Rev Rheumatol 2021;17:109)</p><ul><li><p>Seronegative: rheumatoid factor and other autoantibodies usually ⊖; ± ↑ ESR/CRP</p></li><li><p>HLA-B27: nonspecific, b/c common in general population (6–8%); most useful when high clinical suspicion but nl imaging; ⊕ 90% of Pts w/ AS, but only 20–80% in other SpA</p></li><li><p>Axial disease physical exam</p></li></ul><p>The following are not specific PEx findings but useful in monitoring disease during Rx:</p><p>Lumbar flexion deformity assessed by modified Schober’s test (⊕ if &lt;5 cm ↑ in distance between a point 5 cm below the lumbosacral jxn and another point 10 cm above, when going from standing to maximum forward flexion)</p><p>T-spine mobility (extension) and kyphosis severity measured by occiput-to-wall distance (although occiput-to-wall distance also increased in osteoporotic kyphosis)</p><ul><li>Infectious evaluation for reactive arthritis (⊖ studies do not r/o)</li></ul><p>GU: U/A, PCR of urine and/or genital swab for Chlamydia; urethritis usually due to Chlamydia infxn preceding arthritis, but can also see sterile urethritis post dysentery</p><p>GI: stool Cx, C. diff toxin. Consider HIV in workup for reactive or psoriatic arthritis.</p><ul><li>Radiology</li></ul><p>MRI preferred for early detection of inflammation (sacroiliitis)</p><p>Plain films detect late structural changes (SI erosions/sclerosis)</p><p>Calcification of spinal ligaments w/ bridging symm syndesmophytes (“bamboo spine”)</p><p>Squaring and generalized demineralization of vertebral bodies (“shiny corners”)</p><p>Descriptions of skin manifestations</p><ul><li><p>Psoriasis: erythematous plaques with sharply defined margins often w/ thick silvery scale</p></li><li><p>Circinate balanitis: shallow, painless ulcers of glans penis and urethral meatus</p></li><li><p>Keratoderma blennorrhagica: hyperkeratosis of palms/soles, scrotum, trunk, scalp</p></li><li><p>Erythema nodosum: red tender nodules in subcutan. fat (panniculitis), typically on shins Ddx includes idiopathic, infxn, sarcoid, drug rxn, vasculitis, IBD, lymphoma</p></li><li><p>Pyoderma gangrenosum: neutrophilic dermatosis → painful ulcers w/ violaceous border Ddx incl. idiopathic, IBD, RA, heme and solid malignancies, MGUS, MDS, polycyth. vera</p></li></ul><p>Psoriatic arthritis subtypes (Lancet 2018;391:2273 & 2285; Nat Rev Dis Primers 2021;7:59)</p><ul><li><p>Mono/oligoarticular (large or DIP joint, dactylitic digit): most common initial manifestation</p></li><li><p>Polyarthritis (small joints of the hands/feet, wrists, ankles, knees, elbows): indistinguishable from RA, but often asymmetric</p></li><li><p>Arthritis mutilans: severe destructive arthritis with bone resorption, esp. hands</p></li><li><p>Axial disease: unilateral/asymmetric sacroiliitis</p></li><li><p>DIP-limited: good correlation with nail pitting and onycholysis</p></li></ul><p>Treatment approach (Arthritis Care Res 2019;71:2 & 2019;71:1285; NEJM 2021;385:628)</p><ul><li><p>Untreated disease may lead to irreversible structural damage and associated ↓ function</p></li><li><p>Early physiotherapy beneficial</p></li><li><p>Tight control of inflammation may improve outcomes (eg, in PsA; Lancet 2015;386:2489)</p></li><li><p>NSAIDs: 1st line; rapidly ↓ stiffness and pain; prolonged, continuous administration may modify disease course but associated w/ GI and CV toxicity (Cochrane Database Syst Rev 2015;17:CD010952); may exacerbate IBD</p></li><li><p>Intra-articular corticosteroids in mono- or oligoarthritis; limited role for systemic steroids, esp. for axial disease</p></li><li><p>Conventional DMARDs (eg, MTX, SSZ, leflunomide): no efficacy for axial disease or enthesitis; may have role in peripheral arthritis, uveitis, and extra-articular manifestations</p></li><li><p>Anti-TNFs: effective for both axial and peripheral SpA, improves function and may slow progression of structural changes; adalimumab or infliximab preferred if eyes involved</p></li><li><p>Anti-IL17A (secukinumab, ixekizumab): for both AS and axial and peripheral PsA (NEJM 2015;373:1329 & 2534; Lancet 2015;386:1137)</p></li><li><p>Anti-IL12/23 (ustekinumab) and anti-IL23 (guselkumab) for both axial & peripheral PsA (Lancet 2020;395:1115) but not axial SpA (Arthritis Rheumatol 2019;71:258)</p></li><li><p>PDE-4 inhibitor (apremilast): effective in PsA refractory to conventional DMARD or as first-line (Rheumatology 2018;7:1253); a/w GI side effects and wt loss</p></li><li><p>JAK inhibitor: for conventional DMARD- or anti-TNF-resistant peripheral and/or axial SpA (NEJM 2017;377:1525 & 1537; 2021;384:1227)</p></li><li><p>Other:</p></li></ul><p>Abx indicated in ReA if active GU infxn but not typically needed for uncomplicated enteric infx. Can consider prolonged abx for refractory Chlamydia ReA (Arthritis Rheum 2010;62:1298), but controversial.</p><p>Involve ophtho if suspect eyes affected (may need steroid drops or intravitreal injection)</p><p>Treat underlying IBD when appropriate</p><p>INFECTIOUS ARTHRITIS & BURSITIS</p><p>ETIOLOGIES & DIAGNOSIS OF INFECTIOUS ARTHRITIS</p><p>Etiologies (Curr Rheumatol Rep 2013;15:332)</p><ul><li><p>Bacterial (nongonococcal): early diagnosis and treatment essential</p></li><li><p>Gonococcal (N. gonorrhea): consider in sexually active young adults</p></li><li><p>Viral: parvovirus, HCV, HBV, acute HIV, Chikungunya; mainly polyarticular, may mimic RA</p></li><li><p>Mycobacterial: monoarticular or axial (Pott’s disease)</p></li><li><p>Fungal: Candida (esp. prosthetic joints), coccidiomycosis (valley fever), histoplasmosis</p></li><li><p>Other: Lyme, Mycoplasma, Salmonella, Brucellosis, T. whipplei</p></li></ul><p>Diagnosis (JAMA 2007;297:1478)</p><ul><li><p>H&P w/ poor sensitivity and specificity for septic arthritis</p></li><li><p>Arthrocentesis in acute onset inflammatory monoarthritis to r/o septic arthritis; if possible, obtain fluid sample prior to starting antibiotics</p></li><li><p>Do not tap through overlying infected area to prevent introducing infxn into joint space</p></li><li><p>✓ Fluid cell count w/ diff, Gram stain, bacterial culture, crystal analysis; WBC >50k</p></li></ul><p>w/ PMN predominance suspicious for bact. infxn; crystals do not r/o septic arthritis!</p><p>BACTERIAL (NONGONOCOCCAL) ARTHRITIS</p><p>Epidemiology & risk factors (Infect Dis Clin North Am 2017;31:203)</p><ul><li><p>1/50,000 incidence per year</p></li><li><p>Immunocompromised host: DM, EtOH use, HIV, age >80, SLE, cancer, steroid use, etc.</p></li><li><p>Damaged joints: RA, OA, gout, trauma, prior surgery/prosthetic, prior arthrocentesis (rare)</p></li><li><p>Bacterial seeding: bacteremia especially secondary to IVDU or endocarditis; direct inoculation or spread from contiguous focus (eg, cellulitis, septic bursitis, osteomyelitis)</p></li></ul><p>Clinical manifestations (JAMA 2007;297:1478; Lancet 2010;375:846)</p><ul><li><p>Acute onset monoarticular arthritis (>80%) w/ pain (Se 85%), swelling (Se 78%), warmth</p></li><li><p>Location: knee (most common), hip, wrist, shoulder, ankle. In IVDU, tends to involve other areas including axial joints (eg, SI, symphysis pubis, sternoclavicular, manubrial joints).</p></li><li><p>Constit. sx: fevers (Se 57%), rigors (Se 19%), sweats (Se 27%), malaise, myalgias</p></li><li><p>Infection can track from initial site to form fistulae, abscesses, or osteomyelitis</p></li><li><p>Septic bursitis must be differentiated from septic arthritis (intra-articular infection)</p></li></ul><p>Additional diagnostic studies (JAMA 2007;297:1478)</p><ul><li><p>Synovial fluid: WBC usually >50k (Se 62%, Sp 92%) but can be &lt;10k, >90% polys; Gram stain ⊕ in ~75% of Staph, ~50% of GNR; Cx ⊕ in >90%; synovial bx most sens.</p></li><li><p>Leukocytosis (Se 90%, Sp 36%); elevated ESR/CRP (Se >90%)</p></li><li><p>Blood cultures ⊕ in >50% of cases, ~80% when more than 1 joint involved</p></li><li><p>X-rays of joints should be obtained but usually normal until after ~2 wk of infection when may see bony erosions, joint space narrowing, osteomyelitis, and periostitis</p></li><li><p>CT & MRI useful esp. for suspected hip infection or epidural abscess</p></li></ul><p>Treatment for native joints (IDCNA 2017;31:203)</p><ul><li>Prompt empiric antibiotics guided by Gram stain after surgical drainage. If Gram stain ⊖, empiric Rx w/ vancomycin; add anti-pseudomonal agent if IVDU or immunocompromised.</li></ul><p>Common Microbes (by Gram stain)</p><p>Population</p><p>Initial Antibiotic Regimen (tailor based on Gram stain, cx, clin course)</p><p>GPC clusters</p><p>S. aureus</p><p>(most common)</p><p>Normal joints</p><p>Prosthetic joints</p><p>Damaged joints</p><p>Vancomycin.</p><p>Can later Δ to antistaphylococcal penicillin or cefazolin based on sensitivities.</p><p>S. epidermidis</p><p>Prosthetic joints</p><p>Postprocedure</p><p>GPC chains</p><p>Streptococci</p><p>Healthy adults</p><p>Splenic dysfunction</p><p>PCN-G or ampicillin</p><p>GN</p><p>Diplococci:</p><p>N. gonorrhea</p><p>Sexually active young adults</p><p>Ceftriaxone or cefotaxime</p><p>Rods: E. coli,</p><p>Pseudomonas,</p><p>Serratia</p><p>IVDU, GI infection</p><p>immunosupp, trauma</p><p>elderly</p><p>Cefepime or piperacillin/tazobactam + antipseudomonal aminoglycoside in IVDU</p><ul><li><p>IV antibiotics × ≥2 wk followed by oral antibiotics; varies by clinical course & microbiology</p></li><li><p>Joint must be drained, often serially w/ arthroscopy (larger joints, initial Rx) or arthrocentesis. Serial synovial fluid analyses should demonstrate ↓ in WBC and sterility.</p></li><li><p>10–15% mortality (up to 50% w/ polyarticular); depends on virulence, time to Rx, host</p></li></ul><p>Prosthetic joint infections (Infect Dis Clin North Am 2012;26:29; CID 2013;56:e1)</p><ul><li><p>↑ risk in first 2 y s/p procedure; rate generally low (0.5–2.4%); risk factors include obesity, RA, immunocompromised state, steroids, & superficial surgical site infxn</p></li><li><p>Staphylococci (coag negative & S. aureus) in >50%; polymicrobial in 10–20%</p></li><li><p>Early (&lt;3 mo s/p surgery) or delayed (3–24 mo) onset of sx from microbe typically acquired during implantation; early w/ virulent (eg, MRSA) and delayed w/ less virulent organisms (eg, P. acnes, coag negative Staph) & more indolent presentation</p></li><li><p>Late (>24 mo) onset typically related to secondary hematogenous seeding</p></li><li><p>Diagnosis requires arthrocentesis; ESR & CRP (CRP Se 73–91%, Sp 81– 86%; NEJM 2009;361:787) can be helpful</p></li><li><p>Requires prolonged abx (initial empiric regimen: vanc + 3rd/4th gen cephalosporin) for 6 wks (NEJM 2021;384:1991) & 2-stage joint replacement (retention a/w ~40% failure; CID 2013;56:182) or life-long suppressive abx. Consult ID & orthopedics.</p></li></ul><p>DISSEMINATED GONOCOCCAL INFECTION (DGI)</p><p>Epidemiology (Infect Dis Clin North Am 2005;19:853)</p><ul><li><p>N. gonorrhea; most frequent type of infectious arthritis in sexually active young adults</p></li><li><p>Normal host as well as Pts w/ deficiencies of terminal components of complement</p></li><li><p>♀:♂ = 4:1 historically, but now ↑ in ♂. Occurs in &lt;3% of N. gonorrhea infxn; ↑ incidence w/ menses, pregnancy, postpartum, SLE; ↑ incidence in MSM.</p></li></ul><p>Clinical manifestations</p><ul><li><p>Preceded by mucosal infection (eg, cervix, urethra, anus, or pharynx) that is often asx</p></li><li><p>Two distinct syndromes, although Pts can have both:</p></li></ul><p>Joint-localized: purulent arthritis (40%), usually 1–2 joints (knees >wrists >ankles)</p><p>Arthritis-dermatitis syndrome: triad of polyarthralgias, tenosynovitis, skin lesions</p><ol><li><p>polyarthralgias: migratory joint pain, can affect small or large joints</p></li><li><p>tenosynovitis: pain/inflammation of tendon and its sheath in wrists, fingers, ankles, toes</p></li><li><p>skin lesions: gunmetal gray pustules with erythematous base on extremities & trunk</p></li></ol><ul><li>Rare complications: Fitz-Hugh-Curtis syndrome (perihepatitis), pericarditis, meningitis, myocarditis, osteomyelitis from direct extension of joint-localized infection</li></ul><p>Additional diagnostic studies</p><ul><li>Synovial fluid: WBC >50k (but can be &lt;10k), poly predominant</li></ul><p>Gram stain ⊕ in ~25%; culture ⊕ in up to 50% if done w/ Thayer-Martin media</p><ul><li><p>Blood culture: more likely ⊕ in arthritis-dermatitis syndrome; rarely in joint-localized disease</p></li><li><p>Gram stain and culture of skin lesions occasionally ⊕</p></li><li><p>Cervical, urethral, pharyngeal, rectal PCR or cx on Thayer-Martin media; ✓ Chlamydia</p></li></ul><p>Treatment</p><ul><li><p>Ceftriaxone × 7–14 d w/ empiric doxycycline × 7 d for Chlamydia if co-infection has not been excluded (see STI)</p></li><li><p>Joint arthroscopy/lavage may be required for purulent arthritis; rarely >1 time</p></li></ul><p>OLECRANON & PREPATELLAR BURSITIS</p><p>Epidemiology & risk factors (Joint Bone Spine 2019;86:583)</p><ul><li><blockquote><p>150 bursae in the body; 2 most commonly infected are olecranon and prepatellar</p></blockquote></li><li><p>Most commonly (esp. superficial bursae) due to direct trauma, percutaneous inoculation, or contiguous spread from adjacent infection (eg, cellulitis)</p></li><li><p>Other risk factors: recurrent noninfectious inflammation (eg, gout, RA), diabetes</p></li><li><p>S. aureus (80%) most common, followed by streptococci</p></li></ul><p>Diagnosis</p><ul><li><p>Physical exam: discrete bursal swelling, erythema, maximal tenderness at center of bursa with preserved joint range of motion</p></li><li><p>Aspirate bursa if concern for infxn, ✓ cell count, Gram stain, bacterial cx, crystals</p></li></ul><p>WBC >20k w/ poly predominance suspicious for bacterial infection, but lower counts very common (crystals do not rule out septic bursitis!)</p><ul><li><p>Assess for adjacent joint effusion, which can also be septic</p></li><li><p>Do not tap through infected skin to avoid introducing infxn into bursa</p></li></ul><p>Initial therapy</p><ul><li><p>Prompt empiric coverage for staphylococci and streptococci: PO abx acceptable for mild presentation; vancomycin if ill appearing; broaden spectrum based on risk factors</p></li><li><p>Modify antibiotics based on Gram stain, culture results, & clinical course. Duration of Rx is 1–3 wks. Serial aspirations every 1–3 d until sterile or no reaccumulation of fluid.</p></li><li><p>Surgery if unable to drain bursa through aspiration, evidence of foreign body or necrosis, recurrent/refractory bursitis w/ concern for infxn of adjacent structures</p></li></ul><p>CONNECTIVE TISSUE DISEASES</p><p>Centr, centromere; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, limited cSSc; IM, inflammatory myopathies; RF, rheumatoid factor; Sm, Smith (Primer on the Rheumatic Diseases, 12th ed., 2001; Lancet 2013;382:797; J Rheumatol 2015;42:558)</p><ul><li><p>Only order auto-Ab testing if clinical suspicion for CTD, the presence of auto-Ab without characteristic clinical findings ≠ diagnosis, and auto-Ab do not define a particular CTD</p></li><li><p>Overlap syndromes may be reflected by multiple autoantibodies</p></li></ul><p>see “Systemic Lupus Erythematosus” and “Rheumatoid Arthritis” for those diseases</p><p>SYSTEMIC SCLEROSIS AND SCLERODERMA DISORDERS</p><p>Definition & epidemiology (Best Pract Res Clin Rheumatol 2018;32:223)</p><ul><li><p>Scleroderma refers to the presence of tight, thickened skin</p></li><li><p>Localized scleroderma: morphea (plaques of fibrotic skin), linear (fibrotic bands), “en coup de sabre” (linear scleroderma on one side of scalp and forehead ≈ saber scar)</p></li><li><p>Systemic sclerosis (SSc) = scleroderma + internal organ involvement. High-mortality.</p></li></ul><p>SSc w/ limited cutaneous disease (lcSSc): formerly CREST syndrome (see below)</p><p>SSc w/ diffuse cutaneous disease (dcSSc): often rapidly progressive skin thickening</p><p>SSc sine scleroderma (visceral disease without skin involvement, rare)</p><ul><li><p>Peak onset age 30–50; ♀ >♂ (8:1). Earlier/more severe disease in African Americans</p></li><li><p>&lt;6/100,000 annual SSc incidence wordwide; lcSSc incidence ~2× that of dcSSc</p></li><li><p>Pathogenesis: unclear. Endothelial injury → ROS/oxidative stress → perivascular inflammation → fibrosis. Cytokines, growth factors, genetics, environ. factors + antibodies (against PDGFR, endo. cells, fibroblasts) may contribute (NEJM 2009;360:1989).</p></li></ul><p>ACR/EULAR SSc classification criteria (Ann Rheum Dis 2013;72:1747)</p><ul><li><p>Sufficient for dx: skin thickening of fingers of both hands extending proximal to MCPs</p></li><li><p>Other items considered in criteria: Raynaud’s, SSc-related auto-Ab, pulm hypertension (PHT) and/or ILD, abnormal nailfold capillaries, telangiectasia, fingertip lesions (ulcers, scars), skin thickening distal to MCPs</p></li><li><p>Rule out other causes of thickened skin: diabetes (scleredema), scleromyxedema, toxin, hypothyroidism, nephrogenic systemic fibrosis, eosinophilic fasciitis, amyloidosis, GVHD</p></li></ul><p>Clinical Manifestations of Systemic Sclerosis (Lancet 2017;390:1685)</p><p>Skin</p><p>Tightening and thickening of extremities, face, trunk (bx not req for dx)</p><p>“Puffy” hands, carpal tunnel syndrome, sclerodactyly</p><p>Nailfold capillary dilatation & dropout</p><p>Immobile, pinched, “mouse-like” facies and “purse-string” mouth</p><p>Calcinosis cutis (subcutaneous calcification), telangiectasias</p><p>Arteries</p><p>Raynaud’s phenomenon (80%); digital or visceral ischemia</p><p>Renal</p><p>Scleroderma renal crisis (SRC) = abrupt onset of HTN (relative to Pt’s baseline), MAHA. Urine sediment typically bland. Renal bx not required but would show “onion-skin” hypertrophy of arteries & arterioles.</p><p>Affects 5–10%. ACEI effective (see below) but 40% still progress to ESRD and 5y-mortality is 40% (QJM 2007;100:485). Risks: dcSSc, early disease (⅔ of cases in 1st yr), >15 mg/d prednisone, RNA Pol III Ab.</p><p>GI (>80% of Pts)</p><p>GERD and erosive esophagitis, esophageal dysmotility (dysphagia, odynophagia, aspiration), gastric dysmotility, small intestinal dysmotility (malabsorption, bact overgrowth, bloating)</p><p>Musculoskel</p><p>Arthralgias/arthritis; myositis; joint contractures; tendon friction rubs</p><p>Cardiac</p><p>Myocardial fibrosis; pericardial effusion; conduction abnormalities; CAD</p><p>Pulmonary</p><p>Pulmonary fibrosis (typically develops w/in 4 y); pulmonary arterial hypertension (typically develops after many yrs); #1 cause of mortality</p><p>Endocrine</p><p>Amenorrhea and infertility common; thyroid fibrosis ± hypothyroidism</p><p>SSc Subgroup Comparison</p><p>Limited (lcSSc)</p><p>Diffuse (dcSSc)</p><p>General</p><p>Fatigue, weight loss</p><p>Skin</p><p>Thickening on extremities distal to elbows/knees and face only</p><p>Thickening of distal and proximal ext, face and trunk</p><p>Pulmonary</p><p>PAH (rapidly progressive) >fibrosis</p><p>Fibrosis >PAH</p><p>GI</p><p>Primary biliary cirrhosis</p><p>Renal</p><p>SRC later in disease course</p><p>SRC earlier & more common</p><p>Cardiac</p><p>Restrictive cardiomyopathy</p><p>Other</p><p>CREST syndrome = Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, Telangiectasias</p><p>Raynaud’s</p><p>Antibodies</p><p>Centromere (10–40%)</p><p>Scl 70, RNA-Pol III (40%)</p><p>Prognosis</p><p>Survival >70% at 10 y</p><p>Survival 40–60% at 10 y</p><p>Diagnostic studies & monitoring (Lancet 2017;390:1685)</p><ul><li>Autoantibodies: >95% Pts w/ auto-Ab; generally mutually exclusive</li></ul><p>⊕ anti-Scl-70 (anti-topoisomerase 1): a/w diffuse SSc; ↑ risk pulm fibrosis</p><p>⊕ anticentromere: a/w limited SSc; ↑ risk of severe digit ischemia and PHT</p><p>⊕ anti-RNA-Pol III: a/w diffuse SSc; ↑ risk renal crisis; a/w cancer</p><p>⊕ ANA (>90%), ⊕ RF (30%), ⊕ anti-U1-RNP a/w overlap syndrome</p><p>Other: anti-Th/To (a/w limited SSc), U3-RNP (a/w ILD), PmScl (polymyositis-SSc overlap)</p><ul><li><p>CXCL4 levels reported to correlate w/ degree of fibrosis (NEJM 2014;370:433)</p></li><li><p>At baseline: ✓ BUN/Cr & UA for proteinuria, PFTs (spirometry, lung volumes, DLCO), high- res chest CT (if diffuse disease), TTE (RVSP for PHT), RHC if ↑ RVSP or suspect PHT</p></li><li><p>Annual PFTs; TTE q1–2y</p></li><li><p>Skin bx not routine, but helpful to assess other possible causes for skin thickening</p></li><li><p>↑ risk of malignancy (esp. lung cancer) compared to general population</p></li><li><p>Frequent (eg, daily) BP ✓ to monitor for HTN suggestive of scleroderma renal crisis</p></li></ul><p>Treatment (Ann Rheum Dis 2017;76:1327; Arthritis Rheumatol 2018;70:1820)</p><ul><li><p>Minimize steroid exposure to reduce risk of renal crisis</p></li><li><p>Interstitial lung disease: tocilizumab (Lancet Respir Med 2020;8:963), MMF (↓ toxicity vs. cyclophosphamide; Lancet Respir Med 2020;8:304); nintedanib (multikinase inhibitor/antifibrotic) a/w ↓ FVC decline (NEJM 2019; 380:2518).</p></li></ul><p>PAH: pulmonary vasodilators (see “Pulm Hypertension”); early Rx a/w better outcomes</p><ul><li><p>Renal crisis: ACEI (not ARB) for Rx, not prophylaxis (Semin Arthritis Rheum 2015;44:687)</p></li><li><p>GI: PPI/H2-blockers for GERD; promotility agents & antibx for bacterial overgrowth</p></li><li><p>Cardiac: NSAIDs ± colchicine superior to steroids for pericarditis</p></li><li><p>Arthritis: acetaminophen, NSAIDs, hydroxychloroquine, MTX</p></li><li><p>Myositis: MTX, AZA, steroids</p></li><li><p>Skin: PUVA for morphea. Pruritus: emollients, topical/oral steroids. Fibrosis: MTX; MMF? (Ann Rheum Dis 2017;76:1207; Int J Rheum Dis 2017;20:481). CYC if severe (NEJM 2006;354:2655).</p></li><li><p>Auto-HSCT promising for severe disease (NEJM 2018;378:35)</p></li></ul><p>RAYNAUD’S PHENOMENON</p><p>Clinical manifestations & diagnosis (NEJM 2016;375:556; Nat Rev Rheum 2020;16:208)</p><ul><li>Episodic, reversible digital ischemia, triggered by cold temp, or stress, classically: blanching (white, ischemia) → cyanosis (blue, hypoxia) → rubor (red, reperfusion); color Δ usually well demarcated; affects fingers, toes, ears, nose</li></ul><p>Primary vs. Secondary Raynaud’s Phenomenon</p><p>Primary (80–90%)</p><p>Secondary (10–20%)</p><p>Vessel wall</p><p>Functionally abnl</p><p>Structurally abnl</p><p>Etiologies</p><p>Idiopathic; however, can be exacerbated by comorbid conditions, including HTN, athero, CAD, DM</p><p>SSc, SLE, PM-DM, MCTD, Sjögren’s, RA</p><p>Arterial disease (athero, Buerger’s), trauma</p><p>Heme (cyro, Waldenström’s, APS)</p><p>Drugs (ergopeptides, estrogens, cocaine)</p><p>Epidem.</p><p>20–40 y; ♀ > ♂ (5:1)</p><blockquote><p>35 y</p></blockquote><p>Clinical</p><p>Mild, symm. episodic attacks.</p><p>No tissue injury, PVD, or systemic sx; spares thumb.</p><p>Severe, asymm. attacks; tissue ischemia & injury (eg, digital ulcers); can be assoc w/ systemic sx; may affect thumb or prox limbs</p><p>Auto Ab</p><p>⊖ CTD antibodies</p><p>Depends on etiology, CTD Ab often ⊕</p><p>Nailfold</p><p>Normal capillaroscopy</p><p>Dropout and enlarged or distorted loops</p><p>Treatment (Curr Opin Rheumatol 2021;33:453; Clin Rheumatol 2019;38:3317)</p><ul><li><p>All: avoid cold, maintain warmth of digits & body; avoid cigarettes, sympathomimetics, caffeine, & trauma; abx for infected ulceration</p></li><li><p>Mild–mod: long-acting CCB, topical nitrates, SSRI, ARB, α-blockers, ASA/clopidogrel</p></li><li><p>Severe: PDE inhibitors, anti-ET-1 receptor (if ulcers esp. w/ PHT), digital sympathectomy</p></li><li><p>Digit-threatening: IV prostaglandins, digital sympathectomy, ± anticoagulation</p></li></ul><p>INFLAMMATORY MYOPATHIES</p><p>Definition & epidemiology (NEJM 2015;372:1734; Lancet Neurol 2018;17:816)</p><ul><li><p>All lead to skeletal muscle inflammation & weakness, variable extramuscular involvement</p></li><li><p>Polymyositis (PM): incidence &lt;1/million/y; onset typically 40s–50s; ♀ >♂</p></li><li><p>Dermatomyositis (DM): similar to PM but w/ skin manifestations; incidence ~1/million/y; also occurs in childhood; malignancy a/w PM (10%) and DM (24%)</p></li><li><p>Necrotizing autoimmune myositis (NM): usually adults; risk factors: statin exposure (⊕ anti-HMGCR; NEJM 2016;374:664), CTD, cancer, rarely viral infection; incidence unclear</p></li><li><p>Inclusion body myositis (IBM): age >50; ♂ >♀; incidence ~5/million/y; often misdiagnosed as PM</p></li><li><p>Ddx: drug-induced toxic myopathy (statins, cocaine, steroids, colchicine); infxn (HIV, EBV, CMV); metabolic (hypothyroid, hypo-K, hypo-Ca); neuromuscular dis. (eg, myasthenia gravis); glycogen storage disease; mitochondrial cytopathy; muscular dystrophy</p></li></ul><p>Clinical manifestations</p><ul><li>Muscle weakness: typically gradual onset (wks to mos) but often accelerated in NM (days to wks) and more insidious (yrs) in IBM; progressive and painless</li></ul><p>DM/PM/NM: proximal and symmetric; difficulty climbing stairs, arising from chairs, brushing hair; fine motor skills (eg, buttoning) lost late</p><p>IBM: weakness may be asymmetric, distal, and involve facial muscles</p><ul><li>Skin findings in dermatomyositis: may precede myositis by mos to yrs</li></ul><p>Gottron’s papules: seen in >80% of Pts & pathognomonic; violaceous, often scaly, areas symmetrically over dorsum of PIP and MCP joints, elbows, patellae, medial malleoli</p><p>Heliotrope rash: purplish discoloration over upper eyelids ± periorbital edema</p><p>Poikiloderma: red or purple rash w/ areas of hyper and hypopigmentation mostly on sun- exposed areas; upper back (shawl sign), neck & chest (V sign), and hips (Holster sign)</p><p>Mechanic’s hands: cracking, fissuring radial side of digits and can include pigmentation along palmar crease; a/w antisynthetase syndrome; also seen in PM</p><ul><li>Pulmonary: acute alveolitis, interstitial lung disease; resp muscle weakness; aspiration</li></ul><p>Antisynthetase syndrome: acute onset DM or PM w/ rapidly progressive ILD, fever, weight loss, Raynaud’s, mechanic’s hands, arthritis; most commonly anti-Jo-1 ⊕</p><p>MDA5-assoc. DM: ↑ amyopathic, ↑ rapidly progressive ILD, palmar papules, skin ulcers</p><ul><li><p>Cardiac: (33%): often asx; conduction abnl; myo/pericarditis; HF uncommon; ↑ CK-MB/Tn</p></li><li><p>GI: dysphagia, aspiration</p></li><li><p>Polyarthralgias or polyarthritis: usually early, nonerosive; small joints >large joints</p></li><li><p>Raynaud’s (30%, DM and overlap CTD) w/ dilatation & dropout of nail bed capillaries</p></li></ul><p>Diagnostic studies (Ann Rheum Dis 2017;76:1955)</p><ul><li><p>↑ CK (rarely >100,000 U/L, can be ↑↑↑ in NM), aldolase, SGOT, LDH; ± ↑ ESR & CRP</p></li><li><p>Autoantibodies: ⊕ ANA (>75%)</p></li></ul><p>⊕ anti-Jo-1 (25%): most common specific Ab; a/w antisynthetase syndrome</p><p>⊕ anti-Mi-2 (DM >PM 15–20%) is a/w disease that responds well to steroids</p><p>⊕ anti-SRP is a/w NM, poor Rx response; ⊕ anti-HMGCR in NM a/w statin exposure</p><p>Multiple others (Best Pract Res Clin Rheumatol 2018;32:887). Often ordered as an Ab panel.</p><ul><li><p>Consider EMG (↑ spontaneous activity, ↓ amplitude, polyphasic potentials w/ contraction) or MRI (muscle edema, inflammation, atrophy) for evaluation; may guide biopsy</p></li><li><p>Pathology and muscle biopsy: all with interstitial mononuclear infiltrates, muscle fiber necrosis, degeneration, & regeneration (required for definitive diagnosis)</p></li></ul><p>PM: CD8 T cell-mediated muscle injury; perivascular and endomysial inflammation surrounds MHC class I-expressing non-necrotic fibers</p><p>DM: immune complex deposition in blood vessels with complement activation; perifascicular atrophy w/ interfascicular and perivascular inflam (B & CD4 T cells)</p><p>NM: necrotic fibers w/ macrophages</p><p>IBM: T cell-mediated injury, vacuole formation; same as PM w/ eosinophilic inclusions and rimmed vacuoles and chronic myopathic changes (variable fiber size)</p><p>Treatment (Nat Rev Rheum 2018;14:279)</p><ul><li><p>Immunosuppression not effective for IBM. For all others:</p></li><li><p>Steroids (prednisone 1 mg/kg); MTX or AZA early if mod/severe or taper fails (2–3 mo)</p></li><li><p>For resistant (30–40%) or severe disease: AZA/MTX combo, IVIg (NM, DM ± PM), rituximab, MMF, cyclophosphamide (esp. if ILD or vasculitis)</p></li><li><p>IVIg w/ pulse steroids acutely for life-threatening esophageal or resp muscle involvement</p></li><li><p>✓ for occult malignancy (esp. if DM); monitor respiratory muscle strength with spirometry</p></li><li><p>NM: stop statin; steroids + MTX, RTX, or IVIg</p></li></ul><p>SJÖGREN’S SYNDROME (NEJM 2018;378:931)</p><p>Definition & epidemiology</p><ul><li><p>Chronic dysfxn of exocrine glands (eg, salivary/lacrimal) due to lymphoplasmacytic infiltration, extraglandular manifestations common in primary form</p></li><li><p>Can be primary or secondary (a/w RA, scleroderma, SLE, PM, hypothyroidism, HIV)</p></li><li><p>~1/1000 prevelance with 9:1 ♀:♂ ratio; typically presents between age 40 & 60</p></li></ul><p>Clinical manifestations</p><ul><li><p>Dry eyes (keratoconjunctivitis sicca): ↓ tear production; burning, scratchy sensation</p></li><li><p>Dry mouth (xerostomia): difficulty speaking/swallowing, dental caries, xerotrachea, thrush</p></li><li><p>Parotid gland enlargement: intermittent, painless, typically bilateral</p></li><li><p>Vaginal dryness and dyspareunia</p></li><li><p>Recurrent nonallergic rhinitis/sinusitis due to upper airway gland involvement</p></li><li><p>Extraglandular manifestations: arthritis, interstitial nephritis (40%), type I RTA (20%), cutaneous vasculitis (25%), PNS >CNS neurological disease (20%), ILD, PBC</p></li><li><p>↑ risk of lymphoproliferative disorders (~50× ↑ risk of lymphoma and WM in 1° Sjögren’s)</p></li><li><p>Neonatal lupus, including fetal skin rash or heart block (a/w SSA and/or SSB antibodies)</p></li></ul><p>Diagnostic studies</p><ul><li>Autoantibodies: ⊕ ANA (95%), ⊕ RF (75%)</li></ul><p>Primary Sjögren’s: ⊕ anti-Ro (anti-SSA, ~50%) ± anti-La (anti-SSB, ~30%)</p><ul><li><p>Schirmer test: filter paper in palpebral fissures to assess tear production</p></li><li><p>Rose-Bengal staining: dye that reveals devitalized epithelium of cornea/conjunctiva</p></li><li><p>Ocular staining score: substitute for Rose-Bengal staining to determine degree of keratoconjunctivitis sicca using fluorescein and lissamine green</p></li><li><p>Biopsy (minor salivary, labial, lacrimal, or parotid gland): lymphocytic infiltration</p></li></ul><p>Classification criteria (≥4 points 96% Se & 95% Sp; Arthritis Rheumatol 2017;69:35)</p><ul><li><p>3 points: ⊕ anti-Ro; labial saliv. gland bx w/ lymphocytic sialadenitis & score ≥1 foci/4 mm2</p></li><li><p>1 point: abnormal ocular staining score ≥5; Schirmer’s test ≤5 mm/5 min; unstimulated salivary flow rate of ≤0.1 mL/min</p></li></ul><p>Treatment (Ann Rheum Dis 2020;79:3)</p><ul><li><p>Ocular: artificial tears, cyclosporine eyedrops, autologous tears</p></li><li><p>Oral: sugar-free gum, lemon drops, saliva substitute, hydration, pilocarpine, cevimeline</p></li><li><p>Systemic: depends on extraglandular manifest.; NSAIDs, steroids, DMARDs, rituximab</p></li></ul><p>MIXED CONNECTIVE TISSUE DISEASE (MCTD)</p><p>Definition (Best Pract Res Clin Rheumatol 2016;30:95)</p><ul><li><p>Features of SLE, systemic sclerosis, and/or polymyositis that appear gradually over years and often evolve to a dominant phenotype of SLE or systemic sclerosis</p></li><li><p>Different from undifferentiated CTD (UCTD): nonspecific symptoms that fail to meet criteria for any CTD; 30% go on to develop CTD over 3–5 y (usually SLE)</p></li></ul><p>Clinical & laboratory manifestations (Rheumatology 2018;57:255)</p><ul><li><p>Raynaud’s phenomenon (qv) typical presenting symptom (75–90%)</p></li><li><p>Hand edema (“puffy hands”), sclerodactyly, RA-like arthritis w/o erosions, polyarthralgias</p></li><li><p>Pulmonary involvement (85%) with pulmonary hypertension, fibrosis</p></li><li><p>Pericarditis most frequent cardiovascular manifestation; GI: dysmotility (70%)</p></li><li><p>Membranous & mesangial GN common (25%); low risk for renal HTN crisis or severe GN</p></li><li><p>⊕ ANA (>95%); ⊕ RF (50%); requires ⊕ anti-U1-RNP but not specific (seen in ~50% SLE)</p></li></ul><p>Treatment: as per specific rheumatic diseases detailed above</p><p>SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)</p><p>Definition and epidemiology (Nat Rev Rheumatol 2021;17:515)</p><ul><li><p>Multisystem inflammatory autoimmune disease with a broad spectrum of clinical manifestations in association with antinuclear antibody (ANA) production</p></li><li><p>Prevalence 5–35/10,000 in U.S.; predominantly affects women 2nd to 4th decade</p></li><li><p>♀:♂ ratio = 8:1; African Americans affected 2–4× as often as Caucasians</p></li><li><p>Complex genetics; some HLA association; rarely C1q & C2 deficiency</p></li></ul><p>Classification Criteria (Ann Rheum Dis 2019;78:1151) for research/classification not dx</p><p>Required criteria: ANA titer ≥1:80 AND ≥10 points (at least one clinical):</p><p>Clinical domains (points*)</p><p>Renal</p><ul><li><p>proteinuria >0.5 g/d (4)</p></li><li><p>class II or V nephritis (8)</p></li><li><p>class III or IV nephritis (10)</p></li></ul><p>Hematologic</p><ul><li><p>leukopenia (3)</p></li><li><p>thrombocytopenia (4)</p></li><li><p>autoimm. hemolytic anemia (4)</p></li></ul><p>Neuropsychiatric</p><ul><li><p>delirium (2)</p></li><li><p>psychosis (3)</p></li><li><p>seizure (5)</p></li></ul><p>Mucutaneous</p><ul><li><p>non-sclarring alopecia (2)</p></li><li><p>oral ulcers (2)</p></li><li><p>discoid lupus (4); subacute (4) or acute (6) cutaneous lupus</p></li></ul><p>Serosal</p><ul><li><p>pleural/pericardial effusion (5)</p></li><li><p>acute pericarditis (6)</p></li></ul><p>Musculoskeletal</p><ul><li>joint involvement (6)</li></ul><p>Constitutional</p><ul><li>fever (2)</li></ul><p>Immunology domains (points*)</p><p>Antiphospholipid antibodies</p><ul><li>anti-CL, anti-B2GP1, or a lupus anticoagulant (2)</li></ul><p>Complement proteins</p><ul><li><p>low C3 or C4 (3)</p></li><li><p>low C3 and C4 (4)</p></li></ul><p>SLE-specific Abs</p><ul><li>anti-dsDNA or anti- Smith (6)</li></ul><p>*Within each domain, only the highest weighted criterion is counted toward the total score.</p><p>Autoantibodies in SLE (Nat Rev Rheumatol 2020;16:565)</p><p>Auto-Ab</p><p>Frequency (approx)</p><p>Clinical Associations</p><p>Timeline</p><p>ANA</p><p>95–99% if active disease</p><p>90% if in remission</p><p>Homogeneous or speckled</p><p>Any or all of broad spectrum of clinical manifestations</p><p>Sensitive but not specific</p><p>May appear yrs before overt disease</p><p>Ro</p><p>La</p><p>15–35%</p><p>⊕ anti-Ro may be seen w/ ⊖ or low titer ANA</p><p>Sjögren’s/SLE overlap</p><p>Neonatal lupus; photosens.; subacute cutaneous lupus</p><p>ds-DNA</p><p>70%; ~95% Sp; titers may parallel dis. activity, esp. renal</p><p>Lupus nephritis</p><p>Vasculitis</p><p>Appears mos before or at dx, but may become ⊕ after dx</p><p>Sm</p><p>30%; very specific for SLE</p><p>Lupus nephritis</p><p>U1-RNP</p><p>40%</p><p>MCTD; Raynaud’s;</p><p>Tend not to have nephritis</p><p>Histone</p><p>90% in DLE; 60–80% in SLE</p><p>Mild arthritis and serositis</p><p>At diagnosis</p><p>Workup</p><ul><li><p>Autoantibodies: ANA, if ⊕ → ✓ anti-ds-DNA, anti-Sm, anti-Ro, anti-La, anti-U1-RNP</p></li><li><p>CBC, APLA (⊕ in 20–40%; ACL, B2GP1, lupus anticoagulant), total complement, C3 & C4</p></li><li><p>Lytes, BUN, Cr, U/A, urine sed, spot microalb:Cr ratio or 24-h urine for CrCl and protein</p></li><li><p>If ↓ GFR, active sediment, hematuria, or proteinuria (>0.5 g/dL) → renal bx to guide Rx</p></li></ul><p>Treatment (Ann Rheum Dis. 2019;78:736; Lancet 2019;393:2332; Nat Rev Rheumatol 2019;15:30)</p><p>Drug</p><p>Indication</p><p>Adverse Effects</p><p>Hydroxychloroquine (HCQ)</p><p>All Pts b/c ↓ flares (NEJM 1991;324:150); monoRx for arthritis, serositis, skin disease</p><p>Retinal tox (&lt;1%), Stevens- Johnson; myopathy. Not immunosuppressive.</p><p>NSAIDs</p><p>Arthritis, myalgias, serositis</p><p>Gastritis, UGIB, renal failure</p><p>Corticosteroids</p><p>Low dose for arthritis, serositis; high-dose (1 mg/kg) ± pulse (1 g × 3 d) for major dis. (eg, renal, CNS, heme). Minimize as able.</p><p>Adrenal suppression, diabetes, cataracts, osteopenia, avascular necrosis of bone, myopathy</p><p>Mycophenolate (MMF)</p><p>Nephritis (induction/maint);</p><p>nonrenal refractory to HCQ</p><p>Cytopenias, ↑ LFTs, diarrhea, teratogen</p><p>Cyclophosphamide (CYC)</p><p>Severe organ-threatening nephritis or CNS disease (induction, minimize exposure)</p><p>Cytopenias, infertility/teratogen, myeloprolif. dis., hemorrhagic cystitis, bladder cancer</p><p>Azathioprine (AZA)</p><p>Nephritis (maintenance)</p><p>Non-renal dis. refractory to HCQ</p><p>Myelosuppr. (✓TPMT), ↑ LFTs, teratogen, lymphoprolif. dis.</p><p>Methotrexate (MTX)</p><p>Arthritis (preferred over MMF/AZA)</p><p>Skin disease & serositis</p><p>Myelosuppression, alopecia, hepatotoxicity, stomatitis,</p><p>pneumonitis, teratogen</p><p>Cyclosporine (CsA)</p><p>Renal disease</p><p>Hyperplastic gums, HTN,</p><p>hirsutism, CKD, anemia</p><p>Voclosporin (calcineurin inhibitor Lancet 2021;397:2070)</p><p>Nephritis (induction). Added to MMF+steroids; ↑ complete renal response w/ ↓ steroid.</p><p>HTN, ↓ GFR, diarrhea.</p><p>(Stable PK, ∴ does not require levels like other calcineurin inhibitors)</p><p>Belimumab</p><p>(NEJM 2013;368:1528 & 2020;383:1117)</p><p>Arthritis, serositis, skin disease (esp. if ⊕ ds-DNA or ↓ C3/C4).</p><p>Nephritis (induction). ↑ renal response when added.</p><p>B-cell depletion by binding BLyS (less immunosuppressive than RTX)</p><p>Rituximab (RTX)</p><p>ITP, AIHA, refractory SLE</p><p>Infusion reaction / serum sickness, PML, infection</p><p>Baricitinib (Lancet 2018;392:222)</p><p>Prelim data: 4 mg w/ efficacy in arthritis, skin disease</p><p>Infections (zoster), ↑ LFTs, cytopenias, dyslipidemia</p><p>Anifrolumab (anti- IFN receptor)</p><p>Moderate to severe disease (NEJM 2020;382:211)</p><p>Infection (PNA, zoster), hypersensitivity reaction</p><p>Lupus Nephritis – 40% affected (Nat Rev Rheumatol 2020;16:255)</p><p>Class</p><p>Presentation</p><p>Treatment (all benefit from HCQ)</p><p>I: Min. mesangial</p><p>Normal U/A & eGFR</p><p>No specific treatment</p><p>II: Mesangial prolif</p><p>Micro hematuria/proteinuria</p><p>No specific treatment ± ACEI</p><p>III: Focal prolif</p><p>Hematuria/proteinuria, ± HTN, ↓ GFR, ± nephrotic</p><p>Induce: MMF or CYC + steroids</p><p>Maintenance: MMF >AZA</p><p>(NEJM 2004;350:971 & 2005;353:2219 & 2011;365:1886)</p><p>IV: Diffuse prolif</p><p>Hematuria/proteinuria and HTN, ↓ GFR, ± nephrotic</p><p>V: Membranous</p><p>(can coexist with class III or IV)</p><p>Proteinuria, nephrotic</p><p>ACEI</p><p>If nephrotic-range proteinuria, induce w/ MMF + steroids</p><p>Maintenance: MMF superior to AZA</p><p>VI: Adv. Sclerotic</p><p>ESRD</p><p>Renal replacement therapy</p><p>Prognosis (Nat Rev Rheumatol 2021;17:515)</p><ul><li><p>Overall mortality 2–3× higher than general population, higher in Blacks.</p></li><li><p>Leading causes of morbidity/mortality: infection, CV events, renal failure (nephritis remission achieved in &lt;50%; >10% end up w/ ESRD), neurologic events, thrombosis</p></li></ul><p>Drug-induced lupus (DLE) (Drug Saf 2017;16:1255; Autoimmun Rev 2018;17:912)</p><ul><li><p>Many drugs: procainamide, hydralazine, penicillamine, minocycline, INH, methyldopa, quinidine, chlorpromazine, diltiazem, anti-TNF (esp. infliximab), interferons</p></li><li><p>Abrupt onset; generally mild disease with arthritis, serositis, skin disease; renal dx, malar and discoid rash rare; prevalence ♀:♂ = 1:1</p></li><li><p>⊕ Anti-histone (95%) (may be ⊖ in anti-TNF); ⊖ anti-ds-DNA (often ⊕ in anti-TNF cases, even w/o manifestations of DLE) & ⊖ anti-Sm; normal complement levels</p></li><li><p>Usually reversible w/in 4–6 wk after stopping medication</p></li></ul><p>IGG4-RELATED DISEASE</p><p>Definition & etiology (NEJM 2012;366:539; Nat Rev Rheumatol 2020;16:702)</p><ul><li><p>Characterized by tumor-like inflammatory lesions that can affect nearly any organ</p></li><li><p>Etiology: ? autoimmune; unclear role of IgG4; may have h/o atopy</p></li><li><p>♂ >♀, mean age ~ 60. Incidence ~1/100,000 per y in Japan, but elsewhere unknown.</p></li></ul><p>Clinical manifestations (Arthritis Rheumatol 2015;67:2466 & 2020;72:7)</p><ul><li><p>Commonly pancreatitis, aortitis, cholangitis, sialadenitis, thyroiditis, dacroadenitis, orbital myositis ± pseudotumor, retroperitoneal fibrosis, renal and lung involvement</p></li><li><p>Insidious progression; multiple lesions may be present synchronously or metachronously</p></li></ul><p>Diagnosis and management (Lancet Rheumatol 2019;1:e55)</p><ul><li><p>Biopsy w/ specific findings: lymphoplasmacytic infiltrate w/ significant IgG4+ plasma cell infiltrate, storiform fibrosis, obliterative phlebitis</p></li><li><p>↑ serum IgG4 (Se 90%, Sp 60%); may have low C3, C4</p></li><li><p>Highly responsive to steroids but relapse common. Efficacy of DMARDs in maintenance remains unclear but B-cell depleting agents appear promising (Eur J Intern Med 2020;74:92).</p></li></ul><p>VASCULITIS</p><p>OVERVIEW</p><ul><li><p>Inflammation w/in blood vessel walls causing end-organ damage often a/w systemic sx; may be primary or secondary (eg, infection, malignancy) in etiology</p></li><li><p>Classified by size of predominant vessel affected (Arthritis Rheum 2013;65:1); overlap of vessel size affected is common</p></li><li><p>Clinical manifestations based on size of vessels involved; constitutional sx (low-grade fever, fatigue, weight loss, myalgias, anorexia) common to all</p></li></ul><p>TAK, Takayasu’s arteritis; GCA, giant cell arteritis; PAN, polyarteritis nodosa; ANCA-assoc. is GPA, EGPA, & MPA; IC, immune complex small-vessel vasculitis (eg, IgA, cryoglobulinemia); GN, glomerulonephritis.</p><p>LARGE-VESSEL VASCULITIS</p><p>Takayasu’s arteritis (“pulseless disease”)</p><ul><li><p>Arteritis of aorta and its branches → stenosis/aneurysm → claudication. Most often subclavian & innominate arteries (>90%); carotid, coronary, renal, or pulm a. (~50%)</p></li><li><p>Epidemiology: most common in Asia; ♀:♂ ~9:1 in Japan but lower elsewhere; age &lt;50 y. Prev 8/million in U.S. w/ ~4:1 ♀:♂ (J Rheumatol 2021;48:952).</p></li><li><p>Clinical manifestations: systemic inflamm with fever, arthralgias, wt loss</p></li></ul><p>Vessel inflamm w/ pain & tenderness, ↓ & unequal pulses/BPs in extremities, bruits, limb claudication, renovascular HTN (>50%), neurogenic syncope, Ao aneurysm ± AI</p><p>“Burnt out” or fibrotic period (eg, vascular stenosis)</p><ul><li><p>Dx studies: ↑ ESR (75%), CRP; arteriography (MRA, CTA) → occlusion, stenosis, irregularity, and aneurysms; carotid U/S Doppler studies; PET-CT; pathology → focal panarteritis, cellular infiltrate with granulomas and giant cells (bx not required for dx)</p></li><li><p>Rx: steroids ± MTX, AZA, or anti-TNF; tocilizumab 2nd line (Ann Rheum Dis. 2020;79:19); ASA if critical cerebral stenosis; if surgical/endovascular revasc, preferably done in remission</p></li><li><p>Monitoring: MRA, CTA, or PET-CT; ESR/CRP</p></li></ul><p>Giant cell arteritis (GCA) (JAMA 2016;315:2442)</p><ul><li><p>Granulomatous arteritis typically involving aorta/branches; predilection for extracranial branches of carotid a., particularly temporal a. (thus also called temporal arteritis).</p></li><li><p>Epidemiology: 90% >60 y, peak incidence at 70–80 y, extremely rare &lt;50 y; ♀:♂ = 3:1. Prev 2/1000 of those age ≥50 (Semin Arthritis Rheum 2017;47:253).</p></li><li><p>Clinical manifestations (NEJM 2014;371:50): constitutional sx: fevers, fatigue, wt loss</p></li></ul><p>Temporal artery (TA) → headache, tender TAs and scalp, absent TA pulse</p><p>Ophthalmic artery (20%) → optic neuropathy, diplopia, amaurosis fugax, blindness</p><p>Facial arteries → jaw claudication</p><p>Large vessel vasculitis → intermittent claudication of extremities; thoracic aorta aneurysm</p><p>Strong association w/ PMR; ~50% of Pts w/ GCA ultimately received PMR diagnosis</p><ul><li>Dx: ↑ ESR (Se 84%, Sp 30%), ↑ CRP (Se 86%, Sp 30%), anemia.</li></ul><p>Temporal artery bx (shows vasculitis & granulomas) whenever GCA suspected (Se ≤85%); consider bilat to ↑ yield (3–7% discordant). If bx ⊖ or suspect aortitis/large vessel involvement: U/S (halo sign) or MRA of temporal/cranial arteries, or CTA, MRA, or PET of aorta/large arteries (Arthritis Rheumatol 2021;73:1349). Some advocate imaging upfront to r/o, but requires imaging expertise (Ann Rheum Dis 2018;77:636 & 2020;79:19).</p><ul><li><p>Rx: steroids: do not await bx/path! Have >2 wks to bx w/o Δ. Pred 40–60 mg/d w/ slow taper; ASA if critical cerebral narrowing; consider IV steroids if vision threatened (Arthritis Rheumatol 2021;73:1349). Adding tocilizumab ↑ sustained remission (NEJM 2017;377:317).</p></li><li><p>Polymyalgia rheumatica (JAMA 2016;315:2442; Lancet 2017;390:1700)</p></li></ul><p>Prev 7/1000 of age ≥50. In 50% of GCA Pts; 15% of PMR Pts develop GCA. ♀:♂ ≈ 2.</p><p>ESR >40 mm/h (and/or ↑ CRP); bilateral pain & morning stiffness (>30 min), involving 2 of 3 areas: neck or torso, shoulders or prox. arms, hips or prox. thighs; nighttime pain; ± subdeltoid bursitis on U/S; exclude other causes of sx (eg, RA); nl CK</p><p>Rx: pred 12.5–25 mg/d; if clinical response, initiate slow taper. If not, consider alternate dx or ↑ dose. Consider MTX if at ↑ risk of steroid side effects (Ann Rheum Dis 2015;74:1799).</p><ul><li>Follow clinical status & ESR/CRP; ~⅓relapse over 2 y (J Rheum 2015;42:1213)</li></ul><p>MEDIUM-VESSEL VASCULITIS</p><p>Polyarteritis nodosa (“classic” PAN) (Nat Rev Rheumatol 2017;13:381)</p><ul><li><p>Necrotizing nongranulomatous vasculitis of medium & small arteries (w/in muscular media) w/o glomerulonephritis or capillary involvement (ie, no DAH), not a/w ANCA</p></li><li><p>Incidence ~2/million/y; ↑ in HBV-endemic areas; ♂ >♀; av. age ~50; 10% HBV-assoc</p></li><li><p>Clinical manifestations (Arth Rheum 2010;62:616): const. sx (80%): wt loss, fever, fatigue</p></li></ul><p>Neuro (79%): mononeuritis multiplex, peripheral neuropathies, stroke</p><p>Musculoskeletal (64%): extremity pain, myalgias, arthralgias, arthritis</p><p>Renal (51%): HTN, hematuria, proteinuria, renal failure; glomerulonephritis unusual</p><p>GI (38%): abd pain, GIB/infarction, cholecystitis; GU (25%): ovarian or testicular pain</p><p>Skin (50%): livedo reticularis, purpura, nodules, ulcers, Raynaud’s</p><p>Ophthalmic (9%): retinal vasculitis, retinal exudates, conjunctivitis, uveitis</p><p>Cardiac (22%): coronary arteritis, cardiomyopathy, pericarditis</p><p>Pulmonary: rare; if lung involvement, suspect other vasculitis</p><ul><li>Dx (Arthritis Care Res 2021;73:1061): ↑ ESR/CRP; r/o ANCA, HBV; ↓ C3/C4 if HBV-assoc.</li></ul><p>Angiogram (mesenteric or renal vessels) → microaneurysms & focal vessel narrowing</p><p>CTA or MRA may be adequate for dx, but conventional angiogram is most sensitive</p><p>Biopsy (nerve, deep-skin, or affected organ) → vasculitis of small and medium a. w/ fibrinoid necrosis w/o granulomas</p><ul><li>Rx: based on severity; steroids ± DMARD (MTX, AZA; CYC if severe); antivirals if HBV. Most dis. monophasic so consider stopping DMARD if in steroid-free remission at 18 m.</li></ul><p>ANCA-ASSOCIATED SMALL-VESSEL VASCULITIS</p><p>Microvascular vasculitis (eg, capillaries, postcapillary venules, & arterioles)</p><p>aPredominant type, can see either type (NEJM 2012;367:214). bGPA is formerly Wegener’s granulomatosis, EGPA is formerly Churg-Strauss. Microscopic polyangiitis (MPA).</p><p>Differential diagnosis of ANCA (Nat Rev Dis Primers 2020;6:71)</p><ul><li><p>anti-PR3: GPA, EGPA, microscopic polyangiitis (rarely), levamisole (contam. in cocaine)</p></li><li><p>anti-MPO: microscopic polyangiitis, EGPA, GPA, drug-induced vasculitis, nonvasculitic rheumatic dis., levamisole (contaminant in cocaine)</p></li><li><p>Atypical ANCA patterns: drug-induced vasculitis, nonvasculitic rheumatic diseases, ulcerative colitis, primary sclerosing cholangitis, endocarditis, cystic fibrosis</p></li></ul><p>Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis)</p><ul><li><p>Necrotizing granulomatous systemic vasculitis frequently affecting upper respiratory tract (nose, sinuses) in addition to kidneys, lower resp tract (lungs), and other organs</p></li><li><p>Epi: incidence 12/million/y; any age but ↑ in young/middle-aged adults; ♂=♀</p></li><li><p>Clinical manifestations</p></li></ul><p>Constitutional: fever, fatigue, malaise, anorexia, weight loss</p><p>Respiratory (90%): Upper: recurrent sinusitis, rhinitis, oral/nasal ulcers, nasal crusting, saddle-nose deformity, otitis, hearing loss, subglottic stenosis Lower: infiltrates, nodules, & hemorrhage → cough, dyspnea, hemoptysis, pleurisy</p><p>Renal (80%): RPGN, microscopic hematuria (dysmorphic RBCs and casts)</p><p>Skin (50%): palpable purpura, livedo reticularis</p><p>Ocular (50%): episcleritis, scleritis, uveitis, orbital granulomas → proptosis, corneal ulcer</p><p>Neuro: cranial + peripheral neuropathies, mononeuritis multiplex.</p><p>Heme: ↑ incidence DVT/PE (20×) when disease active (Ann Intern Med 2005;142:620)</p><ul><li>Dx studies: 90% ⊕ ANCA (80% PR3, 20% MPO), less Se in limited upper-airway disease</li></ul><p>CXR or CT → nodules, infiltrates, cavities; sinus CT → sinusitis ± bone erosions</p><p>↑ BUN & Cr, proteinuria, hematuria; sediment w/ RBC casts, dysmorphic RBCs</p><p>Biopsy → necrotizing granulomatous inflammation of arterioles, capillaries, veins. Renal bx w/ pauci-immune (minimal immune deposition) necrotizing and crescentic GN.</p><ul><li>Treatment: assess severity w/ BVAS/GPA score (Arth Rheum Dis 2009;68:1827)</li></ul><p>Mild disease (no end-organ dysfxn; BVAS 0–3): MTX + steroids (Arth Rheum 2012;64:3472)</p><p>Severe disease (end-organ damage incl. pulm hemorrhage, RPGN etc.; BVAS >3):</p><p>Induction: [RTX 375 mg/m2/wk × 4 wk or 1000 mg on d1 + d15 or CYC 2 mg/kg/d × 3–6 mo or pulse 15 mg/kg q2–3 wk] + steroids 1 g IV × 3 d → ~1 mg/kg/d (Ann Rheum Dis 2015;74:1178). RTX preferred as ↓ toxicity (Arth Rheum 2021;73:1366).</p><p>Plasma exchange (PLEX) may ↓ risk of ESRD in those most at risk (NEJM 2020;382:622; Arth Rheum 2021;73:1366).</p><p>Adding avacopan (oral C5a receptor inhibitor) increases remission rate and allows ↓ steroids (NEJM 2021;384:599)</p><p>Maintenance: RTX q6mo superior to AZA or observ. (Ann Intern Med 2020;173:179)</p><p>Relapse: mild → steroids ± MTX or AZA; severe → reinduce w/ steroids + RTX or CYC</p><p>↑ ANCA w/o clinical evidence of flare should not prompt Δ Rx (Annals 2007;147:611)</p><p>Microscopic polyangiitis (MPA) (Rheum Dis Clin North Am 2010;36:545)</p><ul><li><p>Similar to GPA, but w/o ENT/upper airway involvement & nongranulomatous</p></li><li><p>Epidemiology: incidence 4/million/y. ♂ = ♀; avg onset 50–60 y</p></li><li><p>Clinical manifestations</p></li></ul><p>Constitutional, neuro sx similar to GPA</p><p>Renal (80–100%): glomerulonephritis</p><p>Skin lesions (eg, palpable purpura) in 30–60%</p><p>Pulmonary (25–50%): pulmonary capillary alveolitis, pulmonary fibrosis</p><ul><li>Dx studies: 70% ⊕ ANCA (almost all anti-MPO)</li></ul><p>Biopsy → necrotizing, nongranulomatous inflammation of small vessels, pauci-immune</p><p>Urine sediment and CXR findings similar to those seen in GPA</p><ul><li>Treatment: as for GPA (Arth Rheum 2021;73:1366); ↓ relapse rate compared to GPA</li></ul><p>Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss)</p><ul><li><p>Similar to GPA w/ more frequent cardiac involvement, a/w asthma and eosinophilia</p></li><li><p>Epi: rare (incidence 2/million/y); any age (typically 30–40 y); ♂ = ♀; a/w HLA-DRB4</p></li><li><p>Clinical manifestations (Rheumatol 2020;59:iii84)</p></li></ul><p>Initial sx: asthma, sinusitis, allergic rhinitis (new asthma in adult raises suspicion)</p><p>Eosinophilic infiltrative disease: transient pulm infiltrates, gastroenteritis, or esophagitis</p><p>Systemic small-vessel vasculitis: neuropathy (mononeuritis multiplex), renal (glomerulonephritis), skin (palpable purpura, petechial, nodules)</p><p>Cardiac: coronary arteritis, myocarditis, CHF, valvular insufficiency (Medicine 2009;88:236)</p><ul><li>Dx studies: 50% ⊕ ANCA (MPO >PR3), eosinophilia (>1500/uL or 10%, often >60%),</li></ul><p>biopsy → microgranulomas, fibrinoid necrosis, small artery/vein thromboses w/ eosinophilic infiltrate</p><ul><li>Treatment: high-dose steroids + mepolizumab (anti-IL-5) (if nonsevere) or RTX or CYC (if severe) (Arth Rheum 2021;73:1366); mepolizumab for relapse/refractory (NEJM 2017;376:1921)</li></ul><p>Renal-limited vasculitis</p><ul><li><p>Small vessel pauci-immune vasculitis causing RPGN w/o other organ involvement</p></li><li><p>Dx studies: 80% ⊕ ANCA (MPO >PR3); biopsy with pauci-immune GN ± granulomas</p></li><li><p>Treatment identical to that for GPA/MPA</p></li></ul><p>IMMUNE COMPLEX (IC)–ASSOCIATED SMALL-VESSEL VASCULITIS</p><p>IgA vasculitis (formerly Henoch-Schönlein purpura [HSP]) (Rheumatol 2019;58:1607)</p><ul><li><p>IgA-mediated small-vessel vasculitis w/ predilection for skin, GI tract, and kidneys</p></li><li><p>Epidemiology: incidence 140/million/y; ♂ >♀, children >adults, winter >summer</p></li><li><p>May develop ~10 d after onset of upper resp infx or after drug exposure</p></li><li><p>Clinical manifestations</p></li></ul><p>Palpable purpura on extensor surfaces (lower extremity first) & buttocks</p><p>Polyarthralgias (nondeforming) esp. involving hips, knees, & ankles</p><p>Colicky abdominal pain ± GIB or intussusception</p><p>Nephritis ranging from microscopic hematuria & proteinuria to ESRD</p><ul><li>Dx studies: skin bx w/ immunofluorescence → leukocytoclastic vasculitis w/ IgA</li></ul><p>and C3 deposition in vessel wall; renal bx → mesangial IgA deposition</p><ul><li>Treatment: often self-limiting over 4 wk; steroids ± DMARDs for renal or severe disease</li></ul><p>Cryoglobulinemic vasculitis (Lancet 2012;379:348; Nat Rev Dis Primers 2018;4:11)</p><ul><li><p>Cryoglobulins: proteins that precipitate from serum or plasma on exposure to cold and redissolve on rewarming, characterized by their composition; a/w chronic immune stimulation and/or lymphoproliferation</p></li><li><p>Distinguish from cryofibrinogenemia = proteins (eg, fibrin, fibrinogen) that precipitate only from plasma; found in autoimmune dis, malignancies, infxns; unclear clinical significance</p></li></ul><p>Types of Cryoglobulinemia (J Autoimmun 2019;105:102313)</p><p>Feature</p><p>Type I (monoclonal)</p><p>Type II (mixed)</p><p>Type III (mixed)</p><p>Frequency</p><p>10–15%</p><p>50–60%</p><p>25–30%</p><p>Cryoglobulin composition</p><p>Monoclonal Ig (usually IgM or IgG)</p><p>Monoclonal IgM w/ RF activity + polyclonal IgG</p><p>Polyclonal IgG and IgM</p><p>Common etiologies</p><p>Plasma cell</p><p>dyscrasias</p><p>Infection, malignancy, autoimmune syndromes</p><p>Autoimmune synd., infxn</p><p>Primary manifestations</p><p>Hyperviscosity</p><p>± thrombosis → ischemia</p><p>IC-mediated vasculitis, w/ multiorgan involvement. Can be asx.</p><ul><li><p>Epidemiology: ~1/100,000, but prevalence varies with HCV rates; ♀ >♂</p></li><li><p>Etiologies (idiopathic in ~10%)</p></li></ul><p>Hematologic diseases: multiple myeloma, MGUS, Waldenström’s, chronic lymphocytic leukemia in type I; B-cell lymphomas or solid-organ malignancies in type II</p><p>Infxns (types II & III): viral (HCV [>80% RNA ⊕], HBV, HIV, HAV, EBV, CMV), bacterial (endocarditis, strep, etc.), fungal (coccidiomycosis, etc.), parasitic (malaria, amoebiasis)</p><p>Autoimmune syndromes (type III >II): Sjögren’s syndrome, SLE, RA, PAN</p><p>Renal transplant recipients (Clin Nephrol 2008;69:239)</p><ul><li>Pathophysiology</li></ul><p>Type I: cryo precipitation in microcirculation → hyperviscosity & vascular occlusion</p><p>Types II/III: defective/insufficient immune complex (IC) clearance → IC-mediated inflammation of blood vessels w/ complement activation → vasculitis</p><ul><li>Clinical manifestations (most Pts w/o sx)</li></ul><p>Type I: hyperviscosity (cold worsens sx) → HA, visual Δ, livedo, digital ischemia</p><p>Type II/III: vasculitis (not affected by cold) → fever, derm (54–80%; purpura, livedo reticularis, ulcers), arthralgia (44–70%; symmetric migratory, small/med joints), glomerulonephritis (50%; MPGN), neurologic (17–60%; peripheral neuropathy (polyneuropathy >mononeuritis multiplex), ↓ Hgb, ↓ plt, ↑ B-cell lymphoma risk, GI (5%; pain, HSM, ↑ LFTs). “Meltzer’s triad”: purpura, arthralgias, weakness in 25–30%.</p><ul><li>Dx studies</li></ul><p>✓ Cryoglobulins (keep blood warmed to 37°C en route to lab to avoid false ⊖, loss of RF and ↓↓ C3, C4). Cryocrit quantifies cryoprotein but not always indicative of disease activity. May see false ↑ in WBC or plt on automated CBC due to precipitation.</p><p>Type I: ✓ serum viscosity, symptomatic if ≥4.0 centipoise; complement normal.</p><p>Type II: ↓ C4, variable C3, ↑ ESR, ⊕ RF. ✓ HCV, HBV, HIV in mixed cryoglobulinemia. Bx: hyaline thrombi; small vessel leukocytoclastic vasculitis w/ mononuclear infiltrate.</p><ul><li>Treatment (Blood 2017;129:289; J Inflamm Res 2017;10:49): Rx underlying disorder. Heme malig → chemoradiation; HCV → antivirals; CTD → DMARD/steroids ± RTX. Type I: plasma exchange if hyperviscosity; steroids, alkylating agents, RTX, chemo. For mixed cryo, steroids and RTX; CYC or plasma exchange for major organ involvement.</li></ul><p>Connective tissue disease–associated vasculitis</p><ul><li><p>Small-vessel vasculitis a/w RA, SLE, or Sjögren’s syndrome</p></li><li><p>Clinical sx: distal arteritis (digital ischemia, livedo reticularis, palpable purpura, cutaneous ulceration); visceral arteritis (pericarditis, mesenteric ischemia); peripheral neuropathy</p></li><li><p>Dx studies: skin/sural nerve bx, EMG, angiography; ↓ C3, C4 in SLE; ⊕ RF, anti-CCP in RA</p></li><li><p>Treatment: steroids, cyclophosphamide, MTX (other DMARDs)</p></li></ul><p>Cutaneous leukocytoclastic angiitis (Arthritis Rheumatol 2018;70:171)</p><ul><li><p>Most common type of vasculitis; heterogeneous group of clinical syndromes due to IC deposition in capillaries, venules, and arterioles; includes hypersensitivity vasculitis</p></li><li><p>Etiol: drugs (PCN, ASA, amphetamines, levamisole, thiazides, chemicals, immunizations, etc.); infection (Strep, Staph, endocarditis, TB, hepatitis); malignancy (paraneoplastic)</p></li><li><p>Clinical manifestations: abrupt onset of palpable purpura and transient arthralgias after exposure to the offending agent; visceral involvement rare but can be severe</p></li><li><p>Dx studies: ↑ ESR, ↓ complement levels, eosinophilia; ✓ U/A; skin biopsy → leukocytoclastic vasculitis w/o IgA deposition in skin (to distinguish from IgA vasculitis); if etiology not clear, consider ANCA, cryoglobulins, hepatitis serologies, ANA, RF</p></li><li><p>Treatment: withdrawal of offending agent ± rapid prednisone taper</p></li></ul><p>VARIABLE-VESSEL VASCULITIS</p><p>Behçet’s syndrome (Nat Rev Dis Primers 2021;7:67)</p><ul><li><p>Systemic vasculitis affecting all vessel sizes, venous and arterial, a/w painful oral and/or genital ulcers</p></li><li><p>Epi: usually young adults (25–35 y); ♂ = ♀, ↑ severity in ♂; a/w HLA-B51; ↑ prev on old Silk Road (Turkey, Middle East, Asia) w/ 5 vs. 370/100,000 in U.S. vs. Turkey</p></li><li><p>Classification criteria (#1 + ≥2 others is 91% Se & 96% Sp; Lancet 1990;335:1078)</p></li></ul><ol><li><p>Recurrent oral aphthous ulceration (≥3× in 1 y, usually 1st manifestation)</p></li><li><p>Recurrent genital ulceration (labia in females, scrotum in males)</p></li><li><p>Eye lesions: uveitis, scleritis, retinal vasculitis, optic neuritis; may threaten vision</p></li><li><p>Skin lesions: pustules, papules, folliculitis, erythema nodosum (scarring)</p></li><li><p>⊕ pathergy test (prick forearm w/ sterile needle → pustule) (not sensitive in Caucasians)</p></li></ol><ul><li>Other clinical manifestations: most recur but are not chronic</li></ul><p>Arthritis: mild, ± symmetric, nondestructive, involving knees and ankles</p><p>Neurologic: usually involvement of midbrain parenchyma; peripheral neuropathy rare</p><p>Vascular: superficial or deep vein thrombosis (25%); arterial stenosis, occlusion, and aneurysm can also occur; low incidence of thromboembolism</p><ul><li><p>Dx studies: ↑ ESR/CRP; ulcer swab to r/o HSV; ulcer bx nonspecific; ophtho eval if sx</p></li><li><p>Treatment (Ann Rheum Dis 2018;77:808)</p></li></ul><p>Mucocutaneous: Mild: topical steroids, colchicine (esp. for erythema nodosum), dapsone, apremilast (PDE-4 inhib) for oral ulcers and ? genital ulcers (NEJM 2019;381:1918). Severe: oral steroids, steroid-sparing agents.</p><p>Arthritis: NSAIDs, colchicine, steroids, steroid-sparing agents</p><p>Ocular: topical and/or systemic steroids ± steroid-sparing agents</p><p>Steroid-sparing: AZA, anti-TNF, CYC (large vessel and CNS ds), CsA, MTX, IFNα-2A</p><p>Venous thrombosis: steroids and anticoagulation (careful if aneurysm present)</p><p>AUTOINFLAMMATORY SYNDROMES</p><p>Immune-mediated diseases thought to result from overactivation of innate immunity</p><p>Familial Mediterranean fever (FMF) (Ann Rhem Dis 2016;75:644)</p><ul><li><p>Recessive MEFV mutations (activating pyrin, upstream of inflammasome)</p></li><li><p>Febrile episodes for 1–3 d w/ abd pain (serositis, can mimic acute abdomen), pleurisy, lg joint monoarthritis/arthralgia, erysipelas-like skin lesions. Variable time between attacks.</p></li><li><p>Epidemiology: ↑ prev in Armenians (1/500), Sephardic Jews, North Africans, Turks, Arabs; onset usually as child</p></li><li><p>Risk of ESRD due to amyloidosis (AA), peritoneal adhesions, or infertility if untreated</p></li><li><p>Colchicine effective prophylactic and ↓ amyloid; anti-IL1 is alternative (NEJM 2018;378:1908)</p></li></ul><p>TNF receptor-associated periodic syndrome (TRAPS)</p><ul><li><p>TNF receptor mutations → febrile episodes q 5–6 wks each lasting >7 d w/ myalgia, abd pain/nausea, migratory rash, periorbital edema; risk of amyloidosis (AA)</p></li><li><p>Epidemiology: autosomal dom. w/ variable penetr.; prev 1/million; onset usually as child</p></li><li><p>Rx: steroid taper; NSAID alone if mild flare. If freq or severe flares, anti-IL1 (canakinumab) induction and maintenance (NEJM 2018;378:1908) appears more effective than anti-TNF</p></li></ul><p>VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome</p><ul><li><p>Acquired/mosaic UBA1 (ubiquitylation enzyme on X chr) mutation in HSCs → myeloid + erythroid cytoplasmic vacuoles → heterogeneous but fever, cytopenias, chondritis, vasculitis, thrombosis, aveolitis, neutrophilic dermatoses common (NEJM 2020;383:2628)</p></li><li><p>Epidemiology: ♂, mean onset age >60</p></li><li><p>Steroids reduce symptoms but Rx otherwise unclear</p></li></ul><p>Hemophagocytic lymphohistiocytosis (HLH)</p><ul><li><p>↑↑ immune activity; failure to ↓ activated macrophages by NK cells/CTLs → ↑ cytokines (IFNλ, IL18) → macrophages phagocytize other blood cells, cytokine storm, organ failure</p></li><li><p>Triggered by disruption of immune homeostasis: immune activation (infxn, autoimmune flare) or immunodeficiency; ~25% familial (mutations in perforin-mediated cytotoxicity)</p></li><li><p>HLH 2/2 rheumatologic disease termed macrophage activation syndrome (MAS)</p></li><li><p>Fever, ↑ spleen, cytopenias, ↑ TG, ↓ fibrinogen, ↑ LFTs, hemophagocytosis, ↓ NK cell activity, ↑ ferritin, ↑ soluble IL2R; H-score for HLH likelihood (Arthritis Rheum 2014;66:2613)</p></li><li><p>Rx trigger (eg, rheum flare w steroids/biologics); if insufficient, HLH-04 protocol (etoposide + steroids ± CsA ± intrathecal MTX; BMT if genetic or relapsed/refractory; Blood 2017;130:2728), anti-IL1/IVIg/steroids (Lancet Rheumatol 2020:2:e358), or emapalumab (anti-IFNγ) (NEJM 2020;382:1811); high mortality if no Rx (Blood 2019;133:2465)</p></li></ul><p>AMYLOIDOSIS</p><p>Deposition of misfolded proteins as insoluble fibrils (β-pleated sheets) in normal tissues</p><p>(NEJM 2007;356:2361; 2020;282:1567; Circulation 2020;142:e7; Nat Rev Dis Primers 2018;4:38)</p><p>Clinical Manifestations of Amyloidosis (Lancet 2016;387:2641; JAMA 2020;324:79)</p><p>System</p><p>Manifestations</p><p>Amyloid</p><p>Renal</p><p>Proteinuria or nephrotic syndrome</p><p>AL, AA</p><p>Cardiac</p><p>Restrictive CMP (↓ EF late), thick walls but ↓ QRS amplitude, conduction abnl, AF, syncope</p><p>AL, mATTR, wt ATTR</p><p>GI</p><p>Diarrhea, malabsorption, protein loss; ulcers, hemorrhage, obstruction; macroglossia (dysphonia/dysphagia)</p><p>All systemic</p><p>Neuro</p><p>Periph neuropathy w/ painful paresthesia; carpal tunnel;</p><p>Autonomic neuro → impotence, dysmotility, ↓ BP</p><p>mATTR, Aβ2M, AL, localized</p><p>Skin</p><p>Waxy, nonpruritic papules; periorbital ecchymoses; “pinch purpura” = skin bleeds with minimal trauma</p><p>AL</p><p>HSM</p><p>Hepatosplenomegaly w/o hepatic dysfnx or cytopenias</p><p>All systemic</p><p>Endo</p><p>Deposition with rare hormonal insufficiency</p><p>localized</p><p>MSK</p><p>Arthralgias and arthritis (especially shoulder)</p><p>AL, Aβ2M</p><p>Pulm</p><p>Airway obstruction; pleural effusions</p><p>AL, AA</p><p>Heme</p><p>Factor X deficiency</p><p>AL</p><p>Diagnostic studies</p><ul><li><p>Biopsy (abd fat pad, rectal, etc.): apple-green birefring w/ Congo red (Se &lt;85% Sp >90%)</p></li><li><p>If suspect AL: SPEP & UPEP + immunofixation, free light chains, ± BM biopsy</p></li><li><p>If suspect renal involvement: U/A for proteinuria</p></li><li><p>If suspect CMP: ECG (↓ volt, conduction abnl), TTE (↓ longitudinal strain, LVH, valve & septal thickening, myocard. speckling), MRI (late gad. enhancement). R/o plasma cell dyscrasia; if ⊖ → (99m)Tc-pyrophosphate (PYP) SPECT for TTR. ± Cardiac bx.</p></li><li><p>Mass spec of biopsy to ID fibril type. Genetic testing to distinguish wt vs. hereditary ATTR.</p></li></ul><p>Treatment of Amyloidosis</p><p>AL</p><p>Limited involvement: high-dose melphalan → auto HSCT (NEJM 2007;357:1083)</p><p>Not HSCT candidate: dara-CyBorD [daratumumab + CYC + bortezomib + dexameth.] (NEJM 2021;385:46). [Low-dose melphalan + D] if Bor not tolerated.</p><p>Relapse: dara, ixazomib, Bor, or lenalidomide (Blood 2020;136:2620)</p><p>AA</p><p>Rx underlying disease. Colchicine for FMF, esp. to ↓ renal dis. ? Anti-cytokine Rx (anakinra or tocilizumab) (Clin Exp Rheumatol 2015;33:46; Amyloid 2017;24:189).</p><p>ATTR</p><p>Stabilize TTR tetramers: diflunisal slows neuropathy; tafamidis ↑ QoL, ↓ CV hosp/mortality (JAMA 2013;310:2658; NEJM 2018;379:1007)</p><p>↓ hepatic mut TTR production: siRNA (patisiran) or anti-sense oligo (inotersen) -improve neuropathy (NEJM 2018;379:11 & 22); CRISPR in trials (NEJM 2021;385;493)</p><p>Liver transplant can benefit some mATTR forms (Muscle Nerve 2013;47:157)</p><ul><li><p>Clearance of amyloid by Ab under study (NEJM 2015;373:1106; Br J Haematol 2020;189:228)</p></li><li><p>Cardiac: diuretics; avoid CCB; ↑ dig toxicity risk (? amyloid binding); anticoag all AF</p></li><li><p>Heart, kidney, and liver transplant may be considered in those w/ advanced disease</p></li><li><p>Median survival: 5y AL (~6 m if CM); 11y AA; 4y wt ATTR & 2.5y ATTR V122I CM w/o Rx</p></li></ul><p>CHANGE IN MENTAL STATUS</p><p>Consciousness/Arousal (description of patient & timing is most helpful)</p><ul><li><p>Arousal: spectrum from awake/alert → drowsy → stupor → coma. Terms vague & subjective, so most useful to describe response to increasing stimulation (eg, voice → noxious).</p></li><li><p>Coma: lack of response to external stimuli. Degree formalized in Glasgow Coma Scale. Caused by focal lesions in brainstem (reticular activating system), thalamus, or diffuse dysfxn of both cerebral hemispheres. Mimics: locked-in synd., akinetic mutism, catatonia.</p></li><li><p>Delirium/acute confusional state: altered attention & awareness, develops over hrs to days, often fluctuating, accompanied by cognitive Δs (eg, disorientation, memory loss, perceptual Δs); sometimes w/ sleep–wake dysregulation, autonomic Δs, emotionality</p></li><li><p>Dementia: progressive cognitive impairment developing over mos to yrs; often affects memory, language, visuospatial, and executive function; attention often spared</p></li></ul><p>Etiologies of Decreased Responsiveness</p><p>1° Neurologic (usually with focal signs)</p><p>Systemic (esp. in elderly or prior CNS injury)</p><p>Vasc: ischemic stroke/TIA, ICH, VST, PRES, vasculitis, pituitary apoplexy</p><p>Seizure: postictal, status, nonconvulsive</p><p>Infxn: meningitis, encephalitis, abscess</p><p>Trauma: TBI, concussion, diffuse axonal injury</p><p>↑ intracranial pressure: mass, edema, hydrocephalus, herniation</p><p>Autoimmune/paraneoplastic enceph.</p><p>Neurodeg: late-stage (eg, Alzheimer’s) or rapidly progressive (eg, CJD)</p><p>Cardiac: global ischemia, HoTN, HTN enceph</p><p>Pulmonary: ↓ PaO2, ↑ PaCO2</p><p>GI: liver failure, ↑ NH3</p><p>Renal: uremia, dialysis, ↓ or ↑ Na, ↓ or ↑ Ca</p><p>Heme: TTP/HUS, DIC, hyperviscosity</p><p>Endo: ↓ glc, DKA/HHNS, hypothyr., Addisonian</p><p>ID: pneumonia, UTI, endocarditis, sepsis</p><p>Hypothermia & hyperthermia</p><p>Meds: anticholin., anti-hist., psychotrop., digoxin</p><p>Toxins/withdrawal: EtOH, sedative, opiate, CO</p><p>Psychiatric: catatonia, serotonin synd., NMS</p><p>Initial evaluation</p><ul><li><p>History (witness & background crucial): tempo, premorbid sx (eg, focal neuro deficits, HA, infxn, pain, falls), medical conditions (eg, dementia, epilepsy, onc, cardiac, psych, infection/immune status), accompanied by head trauma, current meds (eg, sedatives, opioids, anticoag, anticonvulsants, immunosuppressants), drug/alcohol use</p></li><li><p>General exam: VS, breathing pattern (eg, Cheyne-Stokes), tongue bite (seizure), nuchal rigidity (meningitis, SAH; do not test if c/f trauma/cervical spine fx), ecchymoses, rash, signs of head trauma (eg, Battle sign, raccoon eyes, hemotympanum, CSF rhinorrhea), asterixis, liver disease stigmata, embolic phenomena/endocarditis, s/s drug use</p></li><li><p>Neuro exam (see below): perform off sedatives/paralytics if possible, look for focal deficits suggesting structural cause (eg, stroke, herniation), s/s of ↑ ICP (eg, HA, vomiting, papilledema, abducens nerve palsy, unilateral dilated pupil, ↑ BP/↓ HR, fixed downgaze)</p></li></ul><p>Neuro Exam in Patients with Decreased Responsiveness</p><p>Mental status</p><p>Arousal (behavioral response to ↑ intensity of stimulation, GCS)</p><p>Cranial nerves</p><p>Pupils: pinpoint → opiates, pontine lesion; midposition & fixed → midbrain lesion; fixed & dilated → severe anoxic injury, herniation, anti-cholin.</p><p>Extraocular movements / vestibulo-ocular reflex tests:</p><p>Oculocephalic maneuver (“doll’s eyes”): nl = eyes move opposite head movement (do not test if possible cervical spine trauma)</p><p>Vestibular (cold) caloric stimulation: in coma, nl = eyes move slowly to lavaged ear, then quickly away (do not test w tymp memb perf)</p><p>Corneal reflex, facial grimace to nasal tickle</p><p>Gag & cough reflexes (with ET tube manipulation if necessary)</p><p>Motor</p><p>Tone, spont movements, flexor/extensor posturing of arms/legs, strength</p><p>Sensory</p><p>Response to painful stimuli: purposeful vs. reflexive/posturing</p><p>Reflexes</p><p>Deep tendon reflexes, Babinski, “triple” flexion (ankle, knee, & hip flexion to noxious stimulation → not suggestive of intact cortical function)</p><p>Glasgow Coma Scale (sum points from each of 3 categories to calculate score)</p><p>Eye Opening</p><p>Best Verbal Response</p><p>Best Motor Response</p><p>Points</p><p>Follows commands</p><p>6</p><p>Oriented</p><p>Localizes pain</p><p>5</p><p>Spontaneous</p><p>Confused</p><p>Withdraws from pain</p><p>4</p><p>To voice</p><p>Inappropriate words</p><p>Flexor posturing</p><p>3</p><p>To painful stimuli</p><p>Unintelligible sounds</p><p>Extensor posturing</p><p>2</p><p>None</p><p>None (intubated = 1T)</p><p>None</p><p>1</p><p>Initial treatment</p><ul><li><p>Empiric antibiotics if c/f CNS infection: vancomycin/CTX, consider acyclovir and ampicillin</p></li><li><p>Immobilization of C-spine if concern for cervical trauma</p></li><li><p>Thiamine 100 mg IV → dextrose 50 g IVP (this order to prevent exacerbation of Wernicke’s)</p></li><li><p>If opiates suspected: naloxone 0.01 mg/kg; if BDZ suspected, consider flumazenil 0.2 mg IV</p></li><li><p>If concern for ↑ ICP ↑ herniation: ↑ head of bed; osmotherapy w/ mannitol or hypertonic saline; ↑ ventilation; dexamethasone for tumor edema; c/s neurosurgery (? decompress)</p></li></ul><p>Diagnostic studies (Lancet 2014;384:2064)</p><ul><li><p>All patients: check fingerstick glucose, electrolytes, BUN/Cr, LFTs, CBC, tox screen, U/A</p></li><li><p>Based on clinical suspicion:</p></li></ul><p>Labs: NH3, TSH, cort stim, B12, ABG, HIV, ESR, ANA, TPO/anti-TG, BCx, drug levels</p><p>Imaging: head CT, then MRI; CTA if c/f stroke/SAH; radiographs to r/o C-spine fracture</p><p>Lumbar puncture to r/o meningitis, SAH, or noninfectious inflammation (eg, autoimmune)</p><p>EEG to evaluate for nonconvulsive seizures, toxic/metabolic encephalopathy</p><p>Further treatment of delirium (NEJM 2017;377:1456)</p><ul><li><p>Treat underlying acute illness, eliminate precipitating factors, & provide supportive care</p></li><li><p>Address sensory & cognitive impairments (frequent reorientation, glasses/hearing aids, etc.)</p></li><li><p>Decrease/prevent infection/restraints if possible, remove lines/catheters if unnecessary</p></li><li><p>Promote good sleep: reduce noise & nighttime interventions; sedative med if necessary</p></li><li><p>Meds: consider antipsychotics (but neither haloperidol nor ziprasidone ↓ delirium duration in ICU Pts; NEJM 2018;379:2506); avoid benzos except in EtOH withdrawal or seizures</p></li></ul><p>ANOXIC BRAIN INJURY (at risk if ≥5 min cerebral hypoxia)</p><p>Initial evaluation (Circulation 2010:S768)</p><ul><li><p>Neuro exam: arousal/verbal, eyes & other cranial nerves, motor response to pain</p></li><li><p>Imaging: CT usually not informative w/in first day after arrest, but should be done prior to initiating targeted temp management if patient found down or has had head trauma</p></li></ul><p>Targeted temperature management (Circulation 2015;132:2448)</p><ul><li><p>Indications: comatose (GCS &lt;8) w/in 6 h after cardiac arrest (not isolated resp. arrest). Beneficial in both VT/VF and PEA/asystole. Also consider 6–12 h post-arrest.</p></li><li><p>Relative contraindic.: major head trauma, coagulopathy/bleeding, major surgery &lt;14 d; CV instability no longer viewed as contraindication, but rather something to be managed.</p></li><li><p>Target temp: 32–37.8°C × ≥24 h, rewarm, then maintain normothermia (37°C) for ~24 hrs.</p></li><li><p>Initial studies showing benefit w/ 32–34°C, but subsequent studies showed ≈ outcomes for 36°C or 37.8°C vs. 33°C (NEJM 2013;369:2197 & 2021;384:2283)</p></li><li><p>∴ prevent hyperthermia, but need for hypothermia vs. normothermia unclear</p></li><li><p>Method: ice packs to head/neck/torso; cooling blankets; cooling vest or endovascular catheter. Goal to achieve target temp &lt;6 h. Pts should be sedated/paralyzed while cooled. Start rewarming 24 h after cooling initiated (rewarm ≤0.5°C per h).</p></li><li><p>Can consider higher MAP goal of >70 mmHg</p></li><li><p>Complications</p></li></ul><p>Dysrhythmias (brady most common): if significant or hemodynamic instability → rewarm</p><p>Coagulopathy (can receive lytics, GP IIb/IIIa inhibitors, etc.); monitor PT & PTT</p><p>Infection: monitor surveillance blood cultures during cooling</p><p>Hyperglycemia during cooling, hypoglycemia w/ rewarming; stop insulin if glc &lt;200 mg/dL</p><p>Hypokalemia during cooling, hyperkalemia w/ rewarming; keep K 4–5 mEq/L</p><p>Ongoing evaluation</p><ul><li><p>Neuro exam: daily focus on coma exam. No exam finding is reliable &lt;24 h or on sedation. Should be off sedation for adequate time (depends on dose, duration, Pt’s metabolism).</p></li><li><p>Labs: daily CBC, PT/PTT, electrolytes. Serum neuron-specific enolase (NSE) on days 1–3.</p></li><li><p>Imaging: noncontrast CT 24 h after arrest; if unrevealing, consider MRI around days 3–5</p></li><li><p>EEG: consider in all to exclude seizures; greatest risk during rewarming. Unreactive background or abundant rhythmic or episodic discharges may convey poor prognosis.</p></li><li><p>Somatosensory evoked potentials (SSEP): helpful for prediction of poor outcome if cortical responses are absent bilaterally; perform 48 h after arrest (72 h if cooled)</p></li></ul><p>Prognosis (Nat Rev Neuro 2014;10:190)</p><ul><li><p>Prior to cooling era, poor prognosis at 72 h if absent pupillary & corneal reflexes and no motor response to pain; or absent SSEPs at 48 h. With cooling, unclear if prior measures as reliable. Overall ~12% survive to hosp. d/c; VT/VF 25-40%, PEA ~10%, asystole ~2%.</p></li><li><p>Prognosis requires multifactorial assessment based on age, exam, comorbidities, ancillary data. Poor signs: absent brainstem reflexes, Rx-resistant myoclonus, EEG w/ absent background/reactivity, NSE >101, MRI w/ diffuse hypoxic injury. If doubt, err on more time.</p></li></ul><p>SEIZURES</p><p>Definitions & clinical manifestations (Epilepsia 2017;58:522)</p><ul><li><p>Seizure: transient neurologic symptoms due to excessive synchronous neuronal activity; may be provoked by a reversible factor lowering the seizure threshold, or unprovoked</p></li><li><p>Epilepsy: ≥2 unprovoked seizures occurring >24 h apart or 1 unprovoked seizure w/ ≥60% probability of further seizures over the next 10 y (see below for prognostication)</p></li><li><p>Generalized seizures (involves brain diffusely)</p></li></ul><p>Tonic-clonic (grand mal):</p><p>Aura (sec to mins): premonition with paresthesias, focal motor contractions, abnormal smells/tastes, fear, depersonalization, déjà vu, autonomic changes, automatisms</p><p>Ictal period (sec to mins): lateral gaze and head deviation, tonic contraction of muscles → intermittent relaxing and tensing of muscles, tongue biting, urinary incontinence, pooling of secretions</p><p>Postictal period (mins to h): slowly resolving period of confusion, disorientation, and lethargy. May be accompanied by focal neurologic deficits (Todd’s paralysis).</p><p>Absence (petit mal): transient lapse of consciousness w/o loss of postural tone, usu pedi</p><p>Myoclonic (infantile spasms & juvenile myoclonic epilepsy): sudden, brief contraction</p><ul><li>Focal seizures (involves discrete brain area, often associated with a structural lesion)</li></ul><p>w/o impaired awareness: focal motor/autonomic sx (formerly “simple partial seizure”) or focal sensory/psychic symptoms (eg, aura)</p><p>w/ impaired awareness: dyscognitive features (formerly “complex partial seizure”)</p><p>evolving to bilateral, convulsive seizure (formerly “secondarily generalized seizure”)</p><ul><li><p>Status epilepticus: continuous convulsive seizure ≥5 min or >2 seizures w/o resolution of postictal encephalopathy; life threatening</p></li><li><p>Nonconvulsive status epilepticus: alteration of awareness (ranging from confusion to coma) w/o motor manifestations of seizure; dx with EEG</p></li></ul><p>Differential diagnosis</p><ul><li>Syncope (Lancet Neurol 2006;5:171)</li></ul><p>Feature</p><p>Seizure</p><p>Syncope</p><p>Aura</p><p>Unusual behavior/automatisms</p><p>Diaphoresis, nausea, tunnel vision</p><p>Convulsions</p><p>Variable duration</p><p>Usually &lt;10 sec</p><p>Postictal state</p><p>Yes; can be ≥30 min</p><p>None or short</p><p>Other clues</p><p>Tongue biting, incontinence</p><p>Skin pallor, clamminess</p><ul><li><p>Nonepileptic seizure (aka “psychogenic”): may see side-to-side head turning, asymmetric large-amplitude limb movements, hip thrusting, diffuse shaking w/o LOC, crying/talking during event; diagnosis requires spell capture on EEG with no EEG correlate</p></li><li><p>Other: metabolic disorders (eg, alcoholic blackouts, hypoglycemia), migraine, TIA, transient global amnesia, narcolepsy (cataplexy), nonepileptic myoclonus, tics, asterixis</p></li></ul><p>Etiologies of seizures (vary strongly by age)</p><ul><li><p>Without focal lesion: genetic predisposition to seizures or epilepsy syndrome; alcohol withdrawal, illicit drugs; meds (eg, β-lactams, bupropion, fluoroquinolones, tramadol, MNZ, meperidine, CsA); electrolyte (hyponatremia) & other metabolic (eg, uremia, liver failure, hypoglycemia); autoimmune encephalitis, idiopathic (~60%)</p></li><li><p>With focal lesion: tumor, trauma, stroke, subdural hematomas, posterior reversible encephalopathy syndrome, mesial temporal sclerosis, abscess, focal cortical dysplasia</p></li></ul><p>Clinical evaluation (JAMA 2016;316:2657)</p><ul><li><p>History key in differentiating seizure from other causes of transient loss of consciousness. Must talk to witnesses. Ask about prodrome, unusual behavior before spell, type & pattern of abnl movements incl. head turning & eye deviation (gaze preference usually away from seizure focus), loss of responsiveness.</p></li><li><p>Recent events: illnesses/fevers, head trauma, sleep deprivation, stressors</p></li><li><p>PMH: prior seizures or ⊕ FHx; prior CNS infection, stroke or head trauma; dementia</p></li><li><p>Medications (new or noncompliance), alcohol and illicit drug use</p></li><li><p>General physical exam should include the skin, looking for neuroectodermal disorders (eg, neurofibromatosis, tuberous sclerosis) that are a/w seizures</p></li><li><p>Neurologic exam should look for focal abnormalities → underlying structural abnormality</p></li></ul><p>Diagnostic studies (Neurology 2007;69:1996)</p><ul><li><p>Lab: full lytes, BUN, Cr, glc, LFTs, CK, lactate, tox screen, AED levels (except levetiracetam level rarely useful unless ? noncompliance), illicit drug screen, prolactin if drawn immediately after event (w/in 10–20 min)</p></li><li><p>Routine EEG (~30 min): may help determine risk of seizure recurrence after 1st-time unprovoked seizure. Caveat: interictal EEG nl in 50% of Pts w/ epilepsy, and interictal epileptiform activity (spikes or sharp waves) seen in up to 2% of nl population; EEG w/in 24 h, sleep deprivation and repeated studies ↑ dx yield of EEG.</p></li><li><p>Long-term EEG monitoring (hrs to days): if suspicion for nonconvulsive status or non-epileptic seizures; video monitoring may help w/ nonepileptic seizures</p></li><li><p>MRI to r/o structural abnormalities; ↑ Se w/ fine coronal imaging of frontal & temporal lobes</p></li><li><p>LP (if no space-occupying lesion on imaging): if suspect meningoencephalitis (eg, fever, ↑ WBC, nuchal rigidity), autoimmune encephalitis, and in all HIV ⊕ Pts</p></li></ul><p>Treatment (Neurology 2015;84:1705; Lancet 2015;385:884)</p><ul><li><p>Treat any underlying precipitants, including CNS infections, intoxication, withdrawal, discontinuing provoking med, etc.</p></li><li><p>Antiepileptic drug (AED) Rx usually reserved for Pts w/ ≥2 unprovoked seizures, single seizure w/ high risk of recurrence (see below), or underlying structural abnormality. Provoked seizures generally treated by addressing underlying cause; consider AED if status epilepticus on presentation, focal neuro exam, postictal Todd’s paralysis.</p></li><li><p>After 1st unprovoked sz, weigh risks of recurrence vs. AED. ↑ risk of recurrence if abnl EEG, MRI, or nocturnal sz. If EEG & MRI nl → 65% sz-free at 5 y (Lancet Neurol 2006;5:317).</p></li><li><p>Immediate treatment w/ AED after 1st unprovoked seizure ↓ risk of recurrence over 2 y, but does not Δ long-term prognosis</p></li><li><p>If AED Rx indicated, choice dependent on type of seizure, side effects, cost, mechanism of elimination (if hepatic or renal insufficiency), teratogenesis, and drug interactions</p></li><li><p>Introduce gradually, monitor carefully</p></li><li><p>Individual state laws mandate seizure-free duration before being allowed to drive</p></li></ul><p>Antiepileptic Drugs and Side Effects</p><p>Medication</p><p>Avg Daily Dose</p><p>Common Side Effects</p><p>Systemic</p><p>Neurologic</p><p>(all: sedation)</p><p>Carbamazepine</p><p>400–1600 mg</p><p>Aplastic anemia, ↓ WBC, rash, hepatotoxicity, ↓ Na</p><p>Diplopia, confusion, ataxia</p><p>Ethosuximide</p><p>500–1500 mg</p><p>Rash, BM suppression</p><p>Behavioral Δs</p><p>Gabapentin</p><p>900–3600 mg</p><p>GI upset, wt gain</p><p>Nystagmus, ataxia</p><p>Lacosamide</p><p>200–400 mg</p><p>Prolonged PR interval</p><p>Dizziness, diplopia</p><p>Lamotrigine</p><p>100–300 mg</p><p>Rash (Stevens-Johnson)</p><p>Tremor, HA, blurred vision, insomnia</p><p>Levetiracetam</p><p>1000–3000 mg</p><p>GI upset (rare)</p><p>Emotional lability</p><p>Oxcarbazepine</p><p>600–2400 mg</p><p>Hyponatremia, rash</p><p>Diplopia, dizziness</p><p>Phenobarbital</p><p>50–200 mg</p><p>Rash</p><p>Cognitive slowing</p><p>Phenytoin</p><p>200–400 mg</p><p>Gum hyperplasia</p><p>Dizziness, ataxia</p><p>Topiramate</p><p>100–400 mg</p><p>↓ wt, hypohidrosis, kidney stones, glaucoma, met acid</p><p>Cognitive slowing</p><p>Valproic acid</p><p>500–2500 mg</p><p>Hepatotox, ↑ NH3, ↑ wt, ↓ hair</p><p>Tremor</p><p>Zonisamide</p><p>200–600 mg</p><p>↓ wt, hypohidrosis, nephrolith</p><p>Cog slowing, fatigue</p><p>(NEJM 2008;359:166; Lancet Neurol 2011;10:446)</p><p>Status epilepticus (Epilepsy Curr 2016;16:48)</p><ul><li><p>ABCs: vital signs, oral airway or endotracheal intubation. Place Pt in semiprone position to ↓ risk of aspiration. Obtain IV access. Give thiamine, dextrose, IV normal saline.</p></li><li><p>STAT POC glc, metabolic panel, CBC, tox screen, CK, lactate, AED levels, consider head CT, LP</p></li><li><p>Start standing AED after loading dose.</p></li></ul><p>Treatment of Status Epilepticus</p><p>Time (min)</p><p>Antiepileptic</p><p>Dosing Regimen</p><p>Typical Adult Dose</p><p>5–20</p><p>Lorazepam or</p><p>Midazolam or</p><p>Diazepam*</p><p>0.1 mg/kg IV>IM</p><p>0.2 mg/kg IM</p><p>0.2 mg/kg IV or 0.2–0.5 mg/kg PR</p><p>2–4 mg IV pushes, up to 8 mg Up to 10 mg x1</p><p>Up to 10 mg IV; up to 20 mg PR</p><p>20–40</p><p>Phenytoin or Fosphenytoin or Valproate or</p><p>Levetiracetam</p><p>20 mg/kg</p><p>20 mg PE/kg</p><p>40 mg/kg</p><p>20–40 mg/kg</p><p>1.0–1.5 g IV (max 1.5 g) over 20 min</p><p>1.0–1.5 g PE IV over 5–10 min</p><p>1.0–1.5 g IV (max 3 g) over 5–10 min</p><p>2g IV (max 4.5 g) over 10–15 min</p><p>Subsequent steps mandate intubation, EEG monitoring, and ICU admission</p><p>40–60</p><p>General anesthesia with continuous midazolam, pentobarbital, or propofol</p><p>PE, phenytoin equivalents. *Consider PR diazepam if no IV access and IM midazolam is contraindicated.</p><p>ALCOHOL WITHDRAWAL</p><p>Clinical manifestations</p><ul><li><p>Minor withdrawal: 6–48 h after last drink; mild anxiety, tremulousness, HA</p></li><li><p>Withdrawal seizures: typically w/in 48 h after last drink; if unRx’d, 1/3 → delirium tremens</p></li><li><p>Alcoholic hallucinosis: isolated hallucinations (typically visual) 12–48 h after last drink</p></li><li><p>Delirium tremens (DT): disorientation, agitation, hallucinations, ↑ HR & BP, fever, diaphoresis; begins 48–96 h after last drink, lasts 5–7 d</p></li><li><p>Consider other dx: CNS infxn or bleed, sz, drug O/D, co-ingestions, acute liver failure, GIB</p></li><li><p>Ten-item scale (CIWA-Ar) used to assess and manage alcohol withdrawal (see Appendix)</p></li></ul><p>Treatment (J Addict Med 2020;14:1)</p><ul><li>Benzodiazepines:</li></ul><p>Drug: diazepam preferred (long-acting; ↓ risk of recurrent withdrawal), lorazepam (short-acting), chlordiazepoxide, oxazepam (no active metab; good if cirrhosis)</p><p>Dosing: typically start w/ diazepam 10–15 mg IV q10–15min (or lorazepam 2–4 mg IV q15–20min) until appropriate sedation achieved, then titrate to CIWA-Ar scale, evaluating q1–4 h until score &lt;10 × 24 h, then q4–8 h × 24 h, and if stable, then q4 h</p><ul><li><p>Phenobarbital: adjunctive use in severe withdrawal may ↓ hospital stay, mech ventilation</p></li><li><p>Avoid βB (mask sx)</p></li><li><p>Mechanical restraints as needed until chemical sedation achieved</p></li><li><p>Volume resuscitation as needed; thiamine then glc to prevent Wernicke’s encephalopathy (ataxia, ophthalmoplegia, short-term memory loss); replete K, Mg, PO4</p></li><li><p>Ppx: if min sx or asx (ie, CIWA score &lt;8) but prolonged heavy EtOH consumption or h/o withdrawal seizures or DTs → chlordiazepoxide 25–100 mg q6 h × 24 h, then taper</p></li></ul><p>DIZZINESS</p><p>Differential diagnosis</p><ul><li><p>Includes a variety of sx. Disequilibrium: sense of imbalance, gait disturbance; vertigo: perception of spinning; near syncope: lightheadedness due to cerebral hypoperfusion.</p></li><li><p>Dizziness can occur with PNS & CNS injury (vide infra) or in hematologic (eg, anemia), CV (eg, arrhythmia, orthostasis) & endocrine (eg, ↓ glc, thyroid) disorders, or due to meds</p></li><li><p>Vertigo Ddx:</p></li></ul><p>Peripheral (inner ear/CNVIII)</p><p>BPPV: dislodged canaliths in semicircular canal; episodic rotatory vertigo (&lt;1 min episodes), triggered by changes in position; Rx: Epley/BBQ roll maneuver</p><p>Meniere’s disease: ↑ endolymphatic pressure in inner ear; episodic rotatory vertigo (min-hrs), N/V, aural fullness, hearing loss, tinnitus; Rx: diuretics, ↓ salt</p><p>Vestibular neuritis: sudden-onset w/ gait ataxia; severe for 24–48 hrs followed by gradual improvement, often post-viral; w/ hearing loss = labyrinthitis</p><p>Central (brainstem/cerebellum)</p><p>Posterior circulation stroke/TIA: “5 Ds” of dizziness, diplopia, dysarthria, dysphagia, dystaxia; sudden onset (resolves after mins in TIA, persists in stroke)</p><p>Other: migraine, Chiari, epilepsy, MS, tumors, drugs/meds, concussion</p><p>Initial evaluation</p><ul><li>Hx: ask open-ended questions (description by Pt may be unreliable), pace of illness, episodic vs. chronic, meds, other sx of posterior circ including diplopia, dysarthria, ataxia</li></ul><p>Exam</p><p>Peripheral Causes</p><p>Central Causes</p><p>Orthostatics</p><p>⊕ in orthostatic syncope</p><p>Typically absent</p><p>Eye movements</p><p>Nystagmus unidirectional if present, never vertical, suppressed w/ fixation</p><p>Nystagmus bidirectional, often vertical, not suppressed w/ fixation</p><p>Hearing</p><p>May be impaired in some peripheral causes of vertigo</p><p>Normal (rarely unilat. hearing loss in AICA-territory stroke)</p><p>Coord./gait</p><p>Normal</p><p>May reveal limb, trunk, gait ataxia</p><ul><li>HINTS testing (Stroke 2009;40:3504)</li></ul><p>Head Impulse test: Pt fixates on examiner’s nose during rapid passive head turn of ~10–20°; presence of “catch-up saccade” supports peripheral dysfunction to side of turn</p><p>Nystagmus (see table above)</p><p>Test of Skew: vertical refixation saccade on alternating eye cover supports central cause</p><ul><li><p>Dix-Hallpike test: Pt sitting → lying back w/ 45º head tilt; elicits rotatory nystagmus after delay of secs; fatigues if repeated; ⊕ suggests BPPV w/ affected ear down</p></li><li><p>Supine Roll test: nystagmus elicited by head turn while patient supine; when ⊕ suggests BPPV w/ affected ear down (lateral canal, 8% of cases)</p></li><li><p>Studies: orthostatic VS, basic labs, ECG; if concerning s/s HINTS → MRI brain</p></li><li><p>Rx: Epley for BPP; vestib. PT; anti-hist., sedative or anti-emetic, steroid for vestib. neuritis</p></li></ul><p>STROKE</p><p>ISCHEMIC STROKE</p><p>Etiologies</p><ul><li><p>Embolic: artery → artery, cardioembolic (~30% due to AF; NEJM 2014;370:2478), paradoxical</p></li><li><p>Thrombotic: large vessel (atherosclerosis) vs. small vessel (“lacunar,” lipohyalinosis of small arteries, often related to smoking, HTN, hyperlipidemia, & DM)</p></li><li><p>Other: hypoperfusion, dissection, vasculopathy (vasculitis, radiation), vasospasm, hypercoag, hematologic (sickle cell, hyperviscosity), endocarditis, venous</p></li></ul><p>Clinical manifestations</p><ul><li>Timing: embolic → sudden onset; thrombotic → may have stuttering course</li></ul><p>Stroke Syndromes by Vascular Territory</p><p>Artery</p><p>Deficits</p><p>ICA → Ophth</p><p>Amaurosis fugax (transient monocular blindness)</p><p>ACA</p><p>Hemiplegia (leg >arm), abulia, urinary incontinence, primitive reflexes</p><p>MCA</p><p>Hemiplegia (face & arm >leg); hemianesthesia; homonymous hemianopia</p><p>Aphasia if dom. hemisphere: sup. div. → expressive; inf. div → receptive</p><p>Apraxia & neglect if nondom. hemisphere.</p><p>PCA</p><p>Macular-sparing homonymous hemianopia; alexia w/o agraphia</p><p>Thalamic syndromes with contralateral hemisensory disturbance</p><p>Vertebral, PICA</p><p>Wallenberg syndrome = numbness of ipsilateral face and contralateral limbs, diplopia, dysarthria, dysphagia, ipsilateral Horner’s, hiccups</p><p>Basilar</p><p>Pupillary Δs (midbrain=dilated, pons=pinpoint), long tract signs (quadriplegia, sensory loss), CN abnl, cerebellar dysfxn. Top of basilar → ”locked in” synd.</p><p>Cerebellar</p><p>Vertigo, N/V, diplopia, dysarthria, nystagmus, ipsilateral limb ataxia</p><p>Lacunar (arterioles)</p><p>5 major syndromes: pure hemiplegia, pure hemianesthesia, ataxic hemiparesis, dysarthria + clumsy hand, mixed sensorimotor</p><p>Transient ischemic attack (TIA)</p><ul><li><p>Sudden deficit due to cerebral ischemia; no stroke on imaging; most resolve in &lt;1 h</p></li><li><p>Ddx: seizure, migraine, hypoglycemia, amyloid spells, TGA, anxiety</p></li><li><p>Risk of subsequent stroke ~2% by 1 wk (NEJM 2016;374:1533). Can stratify based on ABCD2: Age ≥60 y (+1); BP ≥140/90 (+1); Clin features: unilat. weak. (+2), speech impair. w/o weakness (+1); Duration ≥60 (+2) or 10–59 min (+1); DM (+1)</p></li></ul><p>Physical exam</p><ul><li><p>General: murmurs, carotid & subclavian bruits, peripheral emboli, endocarditis stigmata</p></li><li><p>Neurologic exam, NIH stroke scale (
<a href=http://www.stroke.nih.gov/documents/NIH rel=noopener>http://www.stroke.nih.gov/documents/NIH</a> Stroke Scale 508C.pdf)</p></li></ul><p>Acute workup</p><ul><li><p>Electrolytes, Cr (relevant for contrast); glc, CBC, coags (see exclusion criteria for lysis)</p></li><li><p>Cardiac biomarkers, 12-lead ECG, tox screen</p></li><li><p>STAT CT to r/o ICH prior to lysis (Se ICH ≈ MRI, CT faster). Early signs of stroke: hyperdense artery, loss of gray-white differentiation, edema, insular ribbon. CT can be nl initially, & not Se for small or brainstem stroke. CTA if possible endovascular Rx.</p></li></ul><p>Acute treatment of ischemic stroke (Stroke 2019;50:e344; JAMA 2021;325:1088)</p><ul><li>Thrombolysis (IV): tPA 0.9 mg/kg (max 90 mg), w/ 10% as bolus over 1 min, rest over 1 h</li></ul><p>consider if onset w/in 4.5 h, Ø contraindic. (incl. current/prior ICH; head trauma or stroke w/in 3 mo; intracranial neoplasm, AVM or aneurysm; recent intracranial/intraspinal surgery; active internal bleeding; noncompressible arterial puncture; ↑ BP; multilobar infarct; plt &lt;100k, INR >1.7, on Xa inhib, PTT >40, glc &lt;50)</p><p>0–3 h: 12% absolute ↑ in good neuro outcome (min/no disability), 5.8% absolute ↑ in ICH, trend toward 4% absolute ↓ mortality</p><p>3–4.5 h: 7.4% absolute ↑ in good neuro outcome, 1.8% absolute ↑ in ICH, Ø mortality benefit (nb, trial excluded patients with previous strokes + DM)</p><p>Data for tenecteplase (TNK), Rx up to 9 h or unknown timing, and for MRI imaging to guide Rx (NEJM 2018;378:1573 & 379:611; 2019;380:1795; Lancet 2020;396:1574)</p><ul><li><p>BP: lower to &lt;185/110 to consider lysis; if lyse keep &lt;180/105 × 24 h (consider IV labetalol or nicardipine), o/w permissive HTN unless >220/120 or sx; if sx HoTN consider vasopressors</p></li><li><p>Initiate ASA w/in 24–48 h; avoid anticoagulation w/in 24 h of lysis; see below for long-term Rx</p></li><li><p>Cerebral edema → herniation: 1–5 d post large MCA or cerebellar strokes, ↑ risk in young. Elevate HOB >30°; mannitol ± 23% NaCl. Hemicraniectomy ↓ mortality (NEJM 2014;370:1091). Neurosurgery consult in select MCA and all large cerebellar strokes.</p></li><li><p>Endovascular thrombectomy if w/in 6 h of sx onset, pre mRS 0-1, occlusion in ICA or MCA, NIHSS ≥6, ASPECTS ≥6 (CT-based likelihood of recovery). May extend to 6–24 h if mismatch between infarct size and clinical deficits or stroke penumbra (NEJM 2018;378:11 & 708).</p></li></ul><p>Workup to assess for etiology/modifiable risk factors</p><ul><li><p>Cardiac: monitor for AF (inPt and extended outPt); TTE to r/o thrombus/veg, w/ bubble study to r/o PFO/atrial septal aneurysm if suspect embolic</p></li><li><p>Vessel imaging: CTA or MRA head/neck; carotid U/S w/ Doppler if contraindic to CTA/MRA</p></li><li><p>Labs: lipids, HbA1c, TSH, homocysteine, Lp(a), hypercoag w/u (if &lt;65 y or cryptogenic stroke; ideally drawn before starting anticoag), ESR/CRP, blood cx if s/s systemic infection</p></li><li><p>MRI helpful if dx of stroke unclear (esp. post circ) or to define stroke subtype, age, exact size</p></li></ul><p>DWI bright/ADC dark = earliest finding in acute ischemia (~w/in mins, up to days)</p><p>T2-FLAIR: hyperintense w/in about 6 hrs, persists for wks; PWI differentiates irreversibly infarcted core vs. viable penumbra; T1 fat-sat (neck vessels) if suspicious for dissection</p><p>Secondary stroke prevention (Stroke 2021;52:e364)</p><ul><li>Antiplatelet therapy: different agents likely have similar efficacy</li></ul><p>ASA ↓ death & repeat stroke; equal to warfarin in nonembolic stroke (NEJM 2001;345:1444)</p><p>clopidogrel: marginally superior to ASA, slightly ↑ ICH (Lancet 1996;348:1329)</p><p>P2Y12 (clopi or ticag) + ASA (vs. ASA alone): Rx for 1–3 mos in minor strokes or TIA w/ high ABCD2 → ↓ risk of ischemic stroke, ↑ ICH (NEJM 2018;379:215 & 2020;383:207). Rx for 90 d if stroke due to intracranial athero (NEJM 2011;365:993).</p><ul><li>Anticoagulation (AC): consider for AF (qv), cardiac/paradoxical emboli (except bacterial endocard); large extra-dural dissections; hypercoag; bridge to CEA in sx carotid stenosis</li></ul><p>Hold off on AC in large strokes for ~2–4 wk given risk of hemorrhagic conversion</p><ul><li><p>Long-term SBP target &lt;130/80 mmHg</p></li><li><p>↓ LDL-C (&#171; 70 mg/dL): ↓ recurrence w/ statin PCSK9i added to statin (NEJM 2017;376:1713)</p></li><li><p>Carotid revascularization (NEJM 2013;369:1143)</p></li></ul><p>CEA (if surgical morbidity & mortality ≤6%) indicated for:</p><p>sx stenosis 70–99% (benefit ↑ for males, >75 y, ≤2 wk from stroke) → 65% ↓ RR of repeat stroke, slight benefit for 50–69% stenosis (NEJM 1991;325:445; Lancet 2004;363:915)</p><p>asx stenosis 70–90%, &lt;79 y: 50% ↓ RR of repeat stroke (Lancet 2010;376:1074)</p><p>Stenting: c/w CEA, ↑ periprocedural stroke (esp. in elderly) & ↓ MI (but many asx); subseq. ≈ rates of fatal or disabling stroke, but ↑ non-disabling stroke (Lancet 2021;398:1065)</p><p>Patent foramen ovale (PFO; in ~25% of population) (NEJM 2005;353:2361)</p><ul><li><p>↑ stroke risk: ≥4 mm separation, R→L shunting at rest, ↑ septal mobility, atrial septal aneurysm</p></li><li><p>Risk scores assess likelihood stroke related to PFO. RoPE score: age (+1 for each decade &lt;70); cortical stroke on imaging (+1); HTN, DM, h/o stroke/TIA, smoker (+1 for each absent risk factor). PASCAL classification also includes large shunt or atrial septal aneurysm.</p></li><li><p>If PFO & stroke/TIA: no benefit of warfarin vs. ASA, but consider if high risk for or has DVT/PE</p></li><li><p>Closure ↓ recurrence by ≥50%, with magnitude of benefit dependent on risk classification (RoPE ≥7 or PASCAL classification of possible or probable) (JAMA 2021;326:2277)</p></li></ul><p>INTRACRANIAL HEMORRHAGE (ICH)</p><p>Classification by location</p><ul><li><p>Hemorrhagic strokes: intraparenchymal hemorrhage (IPH) & subarachnoid hemorrhage (SAH)</p></li><li><p>Other ICH: epidural hematoma (EDH) & subdural hematoma (SDH)</p></li></ul><p>Etiologies</p><ul><li><p>AVM, aneurysm, cerebral venous sinus thrombosis → IPH or SAH</p></li><li><p>HTN (basal ganglia, cerebellum, brainstem), cerebral amyloid (lobar), tumor (esp. w/ melanoma, renal cell CA, chorio-CA, thyroid CA) → IPH</p></li><li><p>Trauma → all locations (nb, IPH or SAH caused by trauma technically not a stroke)</p></li></ul><p>Clinical manifestations (Lancet 2017;389:655 & NEJM 2017;377:257)</p><ul><li><p>↓ consciousness, N/V, HA, progressive focal neurologic deficits</p></li><li><p>SAH: thunderclap HA, onset w/ exertion; nuchal pain/rigidity; LOC. EDH: initial lucid interval.</p></li></ul><p>Workup (Acad Emerg Med 2016;23:963)</p><ul><li><p>STAT CT brain, angio (CT-A or conventional) if suspicious for vascular source</p></li><li><p>? LP for xanthochromia if no evid of ICH on CT (although ⊖ LR 0.01) & suspicious for SAH</p></li><li><p>Coags (PT, PTT, INR)</p></li></ul><p>Management (Crit Care Med 2016;44:2251; JAMA 2019;321:1295)</p><ul><li><p>Reverse coagulopathy, INR &lt;1.4. Plt >100k, no need for plt tfn if on antiplt Rx (? if ↑ ICH), DDAVP if uremic. 2–3 mo after recovers, can restart antiplt mono Rx (Lancet 2019;393:2013).</p></li><li><p>BP control w/ art line, nicardipine or labetalol gtt. SBP goal &lt;140 for 1st 24 h, then &lt;160 (NEJM 2013;368:2355 & 2016;375:1033), though BP goals controversial (NEJM 2016;375:1033)</p></li><li><p>SAH: endovasc coiling vs. surg clipping (depends on location, comorbid.; Lancet 2015;385:691) of aneurysm/AVM; nimodipine to ↓ risk of vasospasm (monitor w/ TCDs), seizure Ppx</p></li><li><p>Surg evac: EDH; SDH if >1 cm or rapid ↑, Rx-resistant epilepsy; IPH: no obvious benefit</p></li><li><p>Venous sinus thrombosis: start anticoagulation, manage ↑ ICP and seizures as needed</p></li></ul><p>WEAKNESS & NEUROMUSCULAR DYSFUNCTION</p><p>PERIPHERAL NEUROPATHIES</p><p>Etiologies based on presentation</p><ul><li><p>Mononeuropathy (1 nerve): acute → trauma; chronic → entrapment, compression, DM, Lyme. Common: median nerve (carpal tunnel); ulnar (elbow or wrist); radial (spiral groove); com. peroneal (fibular head w/ leg crossing); lat. femoral cutan. (inguinal lig)</p></li><li><p>Mononeuropathy multiplex (axonal loss of multiple, noncontig. nerves): vasculitic synd. (eg, PAN, EGPA, GPA, SLE, RA, Sjögren’s, cryo, HCV), DM, Lyme, HIV, leprosy, hereditary neurop. w/ pressure palsies, infiltrative (sarcoid, lymphoma, leukemia)</p></li><li><p>Polyneuropathy (multiple symmetric nerves, generally length dependent): 30% idiopathic;</p></li></ul><p>W/ autonomic features: DM, EtOH, paraneoplastic, B12 def, amyloid, chemo, 1° dysauto</p><p>Painful (small fiber nerves): DM, EtOH, amyloid, chemo, sarcoid, heavy metals, porphyria</p><p>Demyelinating. Acute: AIDP (Guillain-Barré), diphtheria. Subacute: meds (taxanes), paraneoplastic. Chronic: idiopathic, DM, CIDP, anti-MAG, HIV, hypothyroidism, toxins, paraproteinemia, hereditary (eg, CMT).</p><p>Axonal. Acute: acute motor axonal neuropathy, porphyria, vasculitis, uremia, critical illness. Subacute: EtOH, sepsis, paraneoplastic, meds (cisplatin, paclitaxel, vincristine, INH, ddI, amio). Chronic: DM, uremia, lead, arsenic, HIV, paraproteinemia, B12 defic.</p><p>Clinical manifestations</p><ul><li><p>Weakness, fasciculations, cramps, numbness, dysesthesias (burning/tingling), allodynia</p></li><li><p>↑ Autonomic dysfxn (orthostasis, constipation, urinary retention, impotence, abnl sweating)</p></li><li><p>Depressed or absent DTRs (may be normal in small fiber neuropathy)</p></li></ul><p>Diagnostic studies</p><ul><li><p>Distal symmetric polyneuropathy: CBC, lytes, BUN/Cr, HbA1C, B12, ESR, SPEP + IF</p></li><li><p>EMG/NCS (often no change in 1st 10–14 d or in small-fiber neuropathy)</p></li><li><p>Based on H&P: LFTs, celiac Abs, ANA, anti-Ro/La, HIV, Cu, Lyme, RPR, UA, UPEP+IF, ACE, ANCA, heavy metals, LP (AIDP/CIDP), cryo, paraneoplastic Abs, genetic testing. Autonomic testing/skin bx (small fiber), nerve bx (mononeuropathy multiplex), fat pad bx (amyloid).</p></li><li><p>MRI if possible radiculopathy or plexopathy (after EMG)</p></li></ul><p>Pharmacologic treatment of neuropathic pain (Lancet Neurol 2015;14:162)</p><ul><li><p>Gabapentin, pregabalin, TCAs (nortriptyline, amitriptyline), SNRIs (duloxetine, venlafaxine)</p></li><li><p>2nd line: tramadol, topicals (lido, capsaicin); 3rd line: nerve block, botulinum toxin A</p></li></ul><p>GUILLAIN-BARRE SYNDROME (GBS)</p><p>Definition & epidemiology (Lancet 2021;397:1214)</p><ul><li><p>AIDP (60–80%); acute motor axonal neuropathy (AMAN; 7–30%; a/w anti-GM1, anti-GD1a Abs; worse prognosis); Miller Fisher synd. (ophthalmoplegia & ataxia; a/w anti-GQ1b Ab)</p></li><li><p>Incidence 1–2 per 100,000; most common acute/subacute paralysis</p></li><li><p>Precipitants in 60%: viral illness (influenza, CMV, EBV, HIV, Zika, COVID-19), URI (Mycoplasma), gastroenteritis (Campylobacter), Lyme, immunizations, immune checkpoint inhibitors, surgery</p></li></ul><p>Clinical manifestations (Nat Rev Neurol 2019;15:671)</p><ul><li><p>Pain (55–90%), distal sensory dysesthesias & numbness often 1st sx, back pain common</p></li><li><p>Progressive symmetric paralysis in legs and arms over hrs to days; plateau in 1–4 wk</p></li><li><p>Hypoactive then absent reflexes. &lt;10% w/ reflexes on presentation, but all develop hypo/areflexia during course. Minority of AMAN w/ preserved reflexes throughout.</p></li><li><p>Resp failure requiring mech vent occurs in 25%; autonomic instability & arrhythmias in 60%</p></li></ul><p>Diagnostic studies (results may be normal in first several days)</p><ul><li><p>LP: albuminocytologic dissociation = ↑ protein w/o pleocytosis (&lt;10 WBCs) seen in up to 64% of Pts. ↑ protein in ½ in 1st wk, ¾ by 3rd wk of sx. Unlikely to be GBS if WBC >50</p></li><li><p>EMG/NCS: ↓ conduction velocity, conduction block, abnl F-waves; can be nl in 1st 2 wk</p></li><li><p>FVC & NIF: to assess for risk of resp. failure (cannot rely on PaO2 or SaO2 alone)</p></li></ul><p>Treatment</p><ul><li><p>Plasma exchange or IVIg of equal efficacy (Neuro 2012;78:1009); steroids not beneficial</p></li><li><p>Supportive care with monitoring in ICU setting if rapid progression or resp. failure</p></li><li><p>Watch for autonomic dysfunction: labile BP, dysrhythmias, urinary retention, ileus</p></li><li><p>Erasmus GBS outcome score can help w/ prognostication (Lancet Neurol 2007;6:589). Most recover near baseline in 1 y; 3–5% mortality. Residual deficits: pain, fatigue.</p></li></ul><p>MYASTHENIA GRAVIS (MG)</p><p>Definition & epidemiology (Lancet Neurol 2015;14:1023; NEJM 2016;375:2570)</p><ul><li><p>Autoimmune disorder with Ab against acetylcholine receptor (AChR, 80%), muscle-specific kinase (MusK, 4%), lipoprotein-related protein 4 (LRP4, 2%), or other NMJ proteins</p></li><li><p>Prevalence: 150–250 per million; all ages, peak incidence 20s–30s (F), 60s–70s (M)</p></li><li><p>15% of AchR MG a/w thymoma; 30% of pts w/ thymoma develop AchR MG</p></li></ul><p>Clinical manifestations</p><ul><li><p>Fluctuating weakness w/ fatigability (worse w/ repetitive use, relieved by rest)</p></li><li><p>Cranial muscles involved early → 60% present initially w/ ocular sx (ptosis, diplopia); 15% confined to ocular sx; 15% w/ bulbar (difficulty chewing, dysarthria, dysphagia)</p></li><li><p>Limb weakness proximal >distal; DTRs preserved; minimal/no atrophy</p></li><li><p>MusK MG (F &#187;M): more severe limb/facial/bulbar weakness, muscle atrophy</p></li><li><p>Exacerb. triggers: URI, surgery, preg/postpartum, meds (eg, Mg, AG, macrolides, FQ, procainamide, phenytoin, D-penicillamine, β-blocker). Prednisone can worsen sx acutely.</p></li><li><p>Myasthenic crisis = sx exacerbation, risk of respiratory compromise</p></li><li><p>Cholinergic crisis = excessive Rx with anticholinesterases: salivation, cramping, diarrhea</p></li></ul><p>Diagnostic studies</p><ul><li><p>Bedside: ptosis, worse after >45 sec of sustained upgaze; improved with ice pack over eyes for 2–5 min (Se 77%, Sp 98%), ophthalmoplegia, weakness</p></li><li><p>Neostigmine test: temporary ↑ strength; false ⊕ & ⊖ occur; premedicate w/ atropine</p></li><li><p>EMG: ↓ response with repetitive nerve stimulation (vs. ↑ response in Lambert-Eaton)</p></li><li><p>Anti-AChR Ab (Se 80%, 50% if ocular disease only, Sp >90%); muscle specific receptor tyrosine kinase (MuSK) Ab; AchR modulating Ab</p></li><li><p>CT or MRI of thorax to evaluate thymus (65% hyperplasia, 10% thymoma)</p></li></ul><p>Treatment (Neurology 2021;96:114)</p><ul><li><p>Thymectomy if thymoma and in Ab ⊕ Pts w/o thymoma (NEJM 2016;375:511)</p></li><li><p>Cholinesterase inhibitor (eg, pyridostigmine) is most rapid acting (30–60 min). Less effective for MusK MG. Side effects: cholinergic stim (brady, diarrhea, drooling).</p></li><li><p>Immunosuppression: prednisone (benefit in wks; don’t start during crisis) + steroid-sparing agent: AZA (benefit in 6–15 mo), MMF. Refractory: rituximab, MTZ, eculizumab.</p></li><li><p>Myasthenic crisis: treat precipitant; d/c cholinesterase inhibitor if suspect cholinergic crisis. IVIg or plasmapheresis; if no response, high-dose glucocorticoids (monitor for initial worsening). ICU if rapid or severe (follow FVC, NIF).</p></li></ul><p>MYOPATHIES</p><p>Etiologies (Front Neurol 2011;2:49)</p><ul><li><p>Hereditary: Duchenne, Becker, limb-girdle, myotonic, metabolic, mitochondrial</p></li><li><p>Endocrine: hypothyroidism, hyperparathyroidism, Cushing syndrome</p></li><li><p>Toxic: statins, fibrates, steroids, zidovudine, EtOH, cocaine, colchicine, penicillamine</p></li><li><p>Infectious: HIV, HTLV-1, trichinosis, toxoplasmosis, COVID-19</p></li><li><p>Inflammatory: polymyositis, dermatomyositis, inclusion body myositis, anti-HMGCR</p></li></ul><p>Clinical manifestations</p><ul><li><p>Progressive or episodic weakness (not fatigue)</p></li><li><p>Weakness most often symmetric, proximal >distal (stairs, rising from sitting, etc.)</p></li><li><p>↑ Myalgias (though not prominent or frequent), cramps, myotonia (impaired relaxation)</p></li><li><p>May develop either pseudohypertrophy (dystrophies) or mild muscle atrophy</p></li><li><p>Assoc. organ dysfxn: cardiac (arrhythmia, CHF), pulmonary (ILD), dysmorphic features</p></li></ul><p>Diagnostic studies</p><ul><li><p>CK, aldolase, LDH, electrolytes, ALT/AST, PTH, TSH, ESR, HIV</p></li><li><p>Autoantibodies: ANA, RF, anti-Jo1, antisynthetase, anti-Mi-2, anti-SRP, anti-HMGCR, 5TN1CA (in inclusion body myositis)</p></li><li><p>EMG/NCS: low-amplitude, polyphasic units w/ early recruitment, ↑ fibrillation potentials</p></li><li><p>Muscle biopsy, molecular genetic testing (where indicated)</p></li><li><p>Age-appropriate cancer screening if polymyositis or dermatomyositis suspected</p></li></ul><p>HEADACHE</p><p>Primary headache syndromes (Cephalgia 2018;38:1)</p><ul><li><p>Tension-type: bilateral, pressure-like pain of mild–mod intensity, not throbbing or aggravated by physical activity. A/w photophobia or phonophobia, not N/V. Freq a/w myofascial sensitivity in neck/head. Triggers: stress, sleep deprivation, dehydration, hunger. Episodic HA Rx: NSAIDs, acetaminophen (risk of med overuse HA); chronic HA Rx: TCAs.</p></li><li><p>Cluster HA and other trigeminal autonomic cephalalgias (TACs) (Continuum 2018;24:1137)</p></li></ul><p>Characterized by unilateral headache a/w ipsilateral autonomic sx (rhinorrhea, red/tearing eye, miosis, ptosis, lid edema, sweating), subtypes differentiated by timing.</p><p>Cluster: ♂ >♀, unilateral pain w/ autonomic sx & restlessness; attacks 15 min–3 h, up to 8/d (circadian). Rx: high-flow O2 (12–15 L/min), sumatriptan. Ppx: CCB (verapamil).</p><p>Paroxysmal hemicrania: similar to cluster, but ♀ >♂, attacks 2–30 min. Rx: indomethacin.</p><p>Hemicrania continua: ♀ >♂, ice pick–like pain lasting >3 mo. Rx: indomethacin.</p><p>Short-lasting unilateral neuralgiform HA (SUNA/SUNCT): ♂ >♀, excruciating, stabbing, electrical pain, 5 sec–4 min, up to 200×/d. Rx: lamotrigine, gabapentin, topiramate.</p><ul><li>Migraine: see below</li></ul><p>Secondary causes of headaches (Neurology 2019;92:134)</p><ul><li><p>Traumatic: post-concussion, SAH, SDH, postcraniotomy</p></li><li><p>↑ ICP: mass (tumor, abscess, vascular malformations, ICH), hydrocephalus, idiopathic intracranial hypertension (pseudotumor cerebri), altitude-associated cerebral edema</p></li><li><p>↓ ICP: post-LP headache, CSF leak/dural tear, overshunting</p></li><li><p>Vascular: stroke (esp. posterior circ), dissection, vasculitis (incl. temporal arteritis), reversible cerebral vasoconstriction syndrome (RCVS), ICH, venous sinus thrombosis</p></li><li><p>Meningeal irritation: meningitis, SAH</p></li><li><p>Extracranial: sinusitis, TMJ syndrome, glaucoma</p></li><li><p>Systemic: hypoxia (OSA), hypercapnia, dialysis, HTN, cardiac cephalalgia, hypoglycemia, ↓ TSH, pheo, medication overuse (analgesics), withdrawal (caffeine, opioids, estrogen)</p></li></ul><p>Clinical evaluation (Neurology 2019;92:134 & JAMA 2021;325:1874)</p><ul><li><p>Hx: onset (sudden vs. gradual), quality, evolution (progressive), severity, location, duration, triggers, alleviating factors, positional, hormonal (menstruation), preceding trauma, assoc. sx (visual Δs, “floaters,” N/V, photophobia, focal neuro sx), meds (new, analgesics), substance abuse (opioids, caffeine), personal/family hx of HA; neoplasm, preg</p></li><li><p>General and neurologic exam (including funduscopic exam, visual fields). Headache diary.</p></li><li><p>Warning signs (should prompt neuroimaging)</p></li></ul><p>Explosive onset (vasc); “worst HA of life” (SAH, RCVS); meningismus (SAH, infxn)</p><p>Positional: lying >standing (↑ ICP); N/V (↑ ICP; migraines); coughing/bearing down (↑ ICP)</p><p>Visual sx: diplopia, blurring, ↓ acuity (GCA, glaucoma, ↑ ICP); eye pain (glaucoma, trigeminal autonomic cephalalgia, optic neuritis)</p><p>Abnl exam (struct. lesion, poss. in migraine); ↓ consciousness; systemic sx (fever)</p><p>Age >65 y; immunosuppression (CNS infections, PRES)</p><ul><li><p>Imaging: CT or MRI; consider CTA (beading in vasculitis/RCVS/vasospasm), CTV/MRV</p></li><li><p>LP if ? SAH (✓ for xanthochromia), idiopathic intracranial HTN (✓opening press); image first!</p></li></ul><p>MIGRAINE (NEJM 2017;377:553)</p><p>Definition & clinical manifestations (Lancet 2018;391:1315 & Continuum 2021;27:586)</p><ul><li><p>Epidemiology: affects 15% of women and 6% of men; onset usually by 30 y</p></li><li><p>Migraine w/o aura (most common): ≥5 attacks lasting 4–72 h with both (a) N/V or photophobia & phonophobia, and (b) ≥2 of following: unilateral, pulsating, mod–severe intensity, or aggravated by routine activity</p></li><li><p>Migraine w/ aura: ≥2 attacks w/: (a) aura defined as ≥1 fully reversible sx: visual Δs (flickering spots, visual loss), sensory sx (paresthesias, numbness), speech disturbance; and (b) unilateral progression of sx over ≥5 but ≤60 min; and (c) HA w/in 60 min of aura</p></li><li><p>Aura may occur w/o HA (“acephalgic migraine”), must r/o TIA/stroke (typically rapid onset)</p></li><li><p>If motor weakness, consider sporadic or familial hemiplegic migraine: aura of reversible motor weakness (up to 24 h), a/w CACNA1A, ATP1A2, or SCN1A mutations</p></li><li><p>Precipitants: stress, foods (cheese, chocolate, MSG), fatigue, EtOH, menses, exercise</p></li></ul><p>Treatment (Lancet 2021;397:1505 & Continuum 2021;27:613)</p><ul><li><p>Abortive Rx: 5-HT1 agonists (triptans) effective if given early in migraine attack; contraindicated if motor aura, CAD, prior stroke. Also consider acetaminophen, caffeine, NSAIDs (ketorolac), steroids, Mg, metoclopramide, prochlorperazine, valproate, dihydroergotamine (caution if CAD, recent triptan use). Avoid butalbital, opioids.</p></li><li><p>Prophylaxis: AEDs (topiramate, VPA), β-blockers (propranolol first-line), TCAs (amitriptyline), Mg, B2, botox, anti-CGRP, & receptor mAbs (Lancet 2021;397:51)</p></li></ul><p>BACK AND SPINAL CORD DISEASE</p><p>Differential diagnosis of back pain</p><ul><li><p>Musculoskeletal: involving spine (vertebra, facet joints), paraspinal muscles & ligaments, sacroiliac joint, or hip joint. Spondylolisthesis, vertebral fx, OA, inflam. spondyloarthritis (qv), musculoligamentous “strain,” myofascial pain syndrome, trochanteric bursitis.</p></li><li><p>Spinal cord (myelopathy)/nerve root (radiculopathy):</p></li></ul><p>Degenerative/traumatic: disc herniation, foraminal or lumbar stenosis, spondylolisthesis</p><p>Neoplastic: lung, breast, prostate, RCC, thyroid, colon, multiple myeloma, lymphoma</p><p>Infectious: osteomyelitis/discitis, epidural abscess, zoster, Lyme, CMV, HIV, spinal TB</p><p>Vascular: spinal cord ischemia, dural AV fistula</p><ul><li>Referred pain from visceral disease:</li></ul><p>GI: PUD, cholelithiasis, pancreatitis, pancreatic cancer</p><p>GU: pyelonephritis, nephrolithiasis, uterine or ovarian cancer, salpingitis</p><p>Vascular: aortic dissection, leaking aortic aneurysm</p><p>Initial evaluation (Lancet 2017;389:736 & Continuum 2021;27:12)</p><ul><li><p>History: location, timing (acute/subacute/chronic), worse w/ Valsalva, radiation, trauma, wt loss, cancer, fever, immunocompromised, IVDU, neurologic sx, saddle anesthesia, Lhermitte phenomenon, bowel/bladder/sexual sx (retention, incontinence)</p></li><li><p>General physical exam: local tenderness, ROM, signs of infection or malignancy; paraspinal tenderness or spasm in musculoskeletal strain</p></li><li><p>Signs of radiculopathy (sharp/lancinating pain radiating into limb):</p></li></ul><p>Spurling sign (cervical radiculopathy): radicular pain w/ downward force to extended & ipsilaterally rotated head; 30% Se, 93% Sp</p><p>Straight leg raise (sciatica or lumbosacral radiculopathy): radicular pain at 30–70°; ipsilateral: 92% Se, 28% Sp; crossed (contralateral leg raised): 28% Se, 90% Sp</p><p>Patrick/FABER test (SI joint synd): severe pain on hip ext rotation; 70% Se, 100% Sp</p><p>Neurogenic claudication in lumbar stenosis (see table on next page)</p><ul><li><p>Neuro exam: full motor (incl. sphincter tone); gait; sensory (temp/pain, position, vibration; ↑ perineal; ? dermatomal); reflexes incl. bulbocavernous, anal wink (S4), cremasteric (L2)</p></li><li><p>Red flags: acute change (pain, weakness), upper motor neuron signs (hyperreflexia, upgoing toes), cauda equina or conus medullaris syndromes (saddle anesthesia, bowel/bladder or sexual dysfunction, reduced rectal tone, loss of sacral reflexes), dyspnea when flat (C3–C5), pain at rest or at night</p></li><li><p>Laboratory (depending on suspicion): CBC w/ diff, ESR/CRP, Ca, PO4, CSF, BCx</p></li><li><p>Neuroimaging: low yield if nonradiating pain, high false ⊕ rate (incidental spondylosis); depending on suspicion: X-rays, CT or CT myelography, MRI, bone scan</p></li><li><p>EMG/NCS: may be useful to distinguish root/plexopathies from peripheral neuropathies</p></li></ul><p>SPINAL CORD COMPRESSION</p><p>Clinical features (Continuum 2021;27:163)</p><ul><li><p>Etiologies: tumor (vertebral mets, intradural meningioma/neurofibroma), epidural abscess/ hematoma, vascular malformation (dural AV fistula), degen. dis. (spondylosis), trauma</p></li><li><p>Acute: flaccid paraparesis and absent reflexes (“spinal shock”)</p></li><li><p>Subacute–chronic: spastic paraparesis and hyperreflexia (upgoing toes ± ankle clonus)</p></li><li><p>Posterior column dysfunction in legs (loss of vibratory and/or proprioceptive sense)</p></li><li><p>Sensory loss below level of lesion (truncal level ↑ bilateral leg sx is clue for cord process)</p></li></ul><p>Evaluation & treatment</p><ul><li><p>Empiric spine immobilization (collar, board) for all trauma patients</p></li><li><p>STAT MRI (at and above clinical spinal level, with gadolinium) or CT myelogram</p></li><li><p>Emergent neurosurgical and/or neurology consultation. Urgent radiation therapy ↑ surgery for compression if due to metastatic disease (Lancet Oncol 2017;18:e720).</p></li><li><p>Empiric broad-spectrum antibiotics ± surgery if c/f epidural abscess</p></li><li><p>High-dose steroids depending on cause:</p></li></ul><p>Tumor: dexamethasone 16 mg/d IV (usually 4 mg q6 h) with slow taper over wks</p><p>Trauma: methylprednisolone 30 mg/kg IV over 15 min then 5.4 mg/kg/h × 24 h (if started w/in 3 h of injury) or × 48 h (if started 3–8 h after injury) (Cochrane 2012:CD001046)</p><p>NERVE ROOT COMPRESSION</p><p>Clinical features (NEJM 2015;372:1240 & Continuum 2021;27:163)</p><ul><li><p>Radicular pain aggravated by activity (esp. bending, straining, coughing), relieved by lying</p></li><li><p>Sciatica = radicular pain radiating from buttocks down lateral aspect of leg, often to knee or lateral calf ± numbness and paresthesias radiating to lateral foot. Caused by compression of nerve roots, plexus, or sciatic nerve.</p></li></ul><p>Pathophysiology</p><ul><li><p>&lt;65 y: 90% from disc herniation. ≥65 y also w/ more degenerative contributors: ligamentous hypertrophy, osteophyte formation, facet arthropathy, neural foraminal narrowing</p></li><li><p>Spinal stenosis: central canal narrowing → root compression via direct impingement, CSF flow obstruction, vascular compromise</p></li></ul><p>Nb, lumbar disc protrusion tends to compress the nerve root that exits 1 vertebral level below the protrusion.</p><p>Neurogenic vs. Vascular Claudication</p><p>Features</p><p>Neurogenic Claudication</p><p>Vascular Claudication</p><p>Cause</p><p>Lumbar spinal stenosis (with nerve root compression)</p><p>Peripheral artery disease</p><p>(with limb ischemia)</p><p>Pain</p><p>Radicular back/buttock pain</p><p>Radiating down legs</p><p>Cramping leg pain</p><p>Mostly in calves; radiating up legs</p><p>Worse with</p><p>Walking & standing</p><p>Hyperextension/lying prone</p><p>Walking</p><p>Biking</p><p>Better with</p><p>Bending forward, sitting</p><p>Rest (standing or sitting)</p><p>Other sx</p><p>Numbness/paresthesias</p><p>Pale, cool extremity</p><p>Exam</p><p>± Focal weakness, ↓ reflexes</p><p>↓ Lumbar extension</p><p>Preserved pulses</p><p>Diminished/absent pulses</p><p>(dorsalis pedis/posterior tibialis) Pallor</p><p>Diagnostic studies</p><p>MRI lumbar spine</p><p>CT myelogram (if no MRI)</p><p>EMG/NCS</p><p>Arterial Doppler studies</p><p>Ankle-brachial index (ABI) Arteriography</p><p>Treatment</p><p>PT (flexion exercise), NSAIDs,</p><p>epidural steroid injections (ESI)</p><p>Surgery (if other Rx fails)</p><p>Modify vascular risk factors, exercise rehab, antiplatelet Rx, revascularization</p><p>Nb, diagnosis complicated by overlap between presentations & possibility of both diagnoses in the same patient.</p><p>Evaluation & treatment of nerve root compression (NEJM 2016;374:1763)</p><ul><li><p>MRI if sx not improved after 6 wk of conservative tx; if nondiagnostic, consider EMG/NCS</p></li><li><p>Conservative: avoid bending/lifting; soft collar (cervical radiculopathy); NSAIDs; muscle relaxants; lidocaine patch/ointment; Rx neuropathic pain (see “Peripheral Neuropathies”); physical/occup therapy. Insufficient evidence for oral steroids.</p></li><li><p>Avoid opiates when possible; risks outweigh benefits in noncancerous back pain</p></li><li><p>Spinal epidural steroid injections (ESI): limited short-term relief of refractory radicular pain</p></li><li><p>Surgery: cord compression or cauda equina syndrome; progressive motor dysfunction/EMG/NCS pathologic findings; bowel/bladder dysfunction; intractable pain w/ failure to respond to conservative Rx after 3 mo</p></li></ul><p>SURGICAL ISSUES</p><p>ABDOMINAL PAIN</p><p>Visceral Pain</p><p>Anatomic Division</p><p>Viscera</p><p>Area to Which Pain Referred</p><p>Foregut</p><p>Esophagus & duodenum</p><p>Epigastrium</p><p>Midgut</p><p>Jejunum to mid-transverse colon</p><p>Umbilicus</p><p>Hindgut</p><p>Mid-transverse colon to rectum</p><p>Hypogastrium</p><p>Pain due to pancreatitis and nephrolithiasis commonly radiates to the back</p><p>Figure 10-1 Etiologies of abdominal pain based on location</p><p>Initial evaluation</p><ul><li><p>History: onset of pain, location, exacerbating/relieving factors</p></li><li><p>Assoc. sx: fevers/chills, N/V, Δ in bowel habits (diarrhea/constipation, stool diam. or color, hematochezia, melena), flatus, jaundice, Δ in urine color, Δ in wt, menstrual hx in women</p></li><li><p>PMHx: previous incisions or abdominal surgeries; Ob/Gyn hx</p></li><li><p>Exam: VS; general posture of Pt; comprehensive abdominal exam looking for signs of peritonitis, which include rebound tenderness and involuntary guarding, abdominal wall rigidity, pain w/ percussion/minimal palpation; presence of hernias; rectal/pelvic</p></li><li><p>Labs: CBC, electrolytes, LFTs, amylase/lipase, pregnancy test</p></li><li><p>Imaging: depends on suspected etiology, may include RUQ U/S for biliary/hepatic disease, KUB for intestinal obstruction, CT for pancreatitis or intestinal disease. Do not delay resuscitation or surgical consultation for ill Pt while waiting for imaging.</p></li></ul><p>ACUTE ABDOMEN</p><p>Definition</p><ul><li>Acute onset abdominal pain that portends need for urgent surgery</li></ul><p>Etiologies</p><ul><li><p>Perforated viscus → peritonitis (perforated ulcer, complicated diverticulitis, trauma)</p></li><li><p>Intraperitoneal or retroperitoneal bleed (also see “Acute Aortic Syndromes”)</p></li><li><p>Bowel obstruction (adhesions from previous surgeries, malignancies, hernias, volvulus)</p></li><li><p>Acute mesenteric ischemia (esp. if AF, low flow states, “pain out of proportion to exam”)</p></li><li><p>Mimics: severe pancreatitis can resemble peritonitis; renal colic causes severe abdominal pain but not abdominal rigidity</p></li></ul><p>Initial evaluation</p><ul><li><p>H&P as above</p></li><li><p>Labs as above plus: PT/INR, PTT, lactate, type & screen (crossmatch if active bleeding)</p></li><li><p>Imaging: upright CXR/KUB; if stable, CT A/P w/ IV contrast (IV/PO if suspect obstruction)</p></li></ul><p>Initial management</p><ul><li><p>Immediate surgical consultation for suspected acute abdomen</p></li><li><p>NPO, start IV fluids (NS or LR), Foley, NGT placement if obstruction suspected</p></li><li><p>Broad spectrum abx if perforation suspected</p></li></ul><p>EXTREMITY EMERGENCIES</p><p>Acute limb ischemia (see “Peripheral Artery Disease” for details)</p><ul><li><p>Definition: sudden ↓ in perfusion causing threat to limb viability</p></li><li><p>Eval: detailed vascular exam (incl. pulses & Doppler signals, motor/sensory function); CTA</p></li><li><p>Initial management: anticoag for embolism/thrombosis (heparin dose 80 U/kg bolus, then 18 U/kg drip); immediate surgical consultation</p></li></ul><p>Compartment syndrome (Clin Orthop Relat Res 2010;468:940)</p><ul><li><p>Definition: ↑ intracompartmental pressure w/ compressive closure of venules → ↑ hydrostatic force resulting in further increases in compartment pressure</p></li><li><p>Etiologies: orthopedic (fracture), vascular (ischemia-reperfusion), iatrogenic (eg, vascular injury in anticoagulated Pt), soft-tissue injury (eg, prolonged limb compression)</p></li><li><p>Clinical manifestations: pain espec. on passive movement, swollen/tense compartment, paraesthesia, pallor, pulselessness, paralysis (late)</p></li><li><p>Evaluation: surgical evaluation of compartment pressures; intracompartment pressure >30 or difference between diastolic & intracompartment pressure of >10–30 is diagnostic</p></li><li><p>Treatment: fasciotomy</p></li></ul><p>SURGICAL TUBES, DRAINS, WOUNDS</p><p>Tracheostomy (Otolaryngol Head Neck Surg 2013;148:6)</p><ul><li><p>Typically a cuffed tube, which creates a tight seal to facilitate ventilation throughout tube</p></li><li><p>Speaking valve (eg, Passy-Muir): 1-way valve that allows inhalation through tube, but exhalation around tube through vocal cords (nb, cuff should not be inflated)</p></li><li><p>1st routine tube Δ for percutaneously placed tubes should be ~10 d postop; surgically placed tubes can be Δ’d >5 d postop; first Δ should be overseen by experienced person</p></li><li><p>Accidental dislodgement: intubate from above (if airway/vent nec & anatomically possible)</p></li></ul><p>w/in 7 d of placement: emergent surgical consultation</p><blockquote><p>7 d after placement: replace with a similar size tube or smaller</p></blockquote><p>Chest tubes (Eur J Cardiothorac Surg 2011;40:291)</p><ul><li><p>Inserted for PTX, chest trauma or after thoracic surg for drainage of air/fluid from thoracic cavity. Range from small (8–10 Fr for spont. PTX) to large (28–32 Fr after pulm. resections)</p></li><li><p>Connected to 3-chamber chest drainage system:</p></li></ul><p>1st: collection chamber for pleural fluid</p><p>2nd: water seal chamber used to allow air to exit pleural space on exhalation and prevent air from entering on inhalation</p><p>3rd: suction control chamber which regulates suction transmitted to pleural space</p><ul><li><p>Monitor for output and presence of air leak (indicated by bubbling in water seal chamber)</p></li><li><p>Removal determined by overall daily outputs and absence of air leak</p></li><li><p>If accidentally removed or dislodged, tube should be completely removed and an occlusive dressing (eg, 4 × 4 covered w/ Tegaderm or silk tape) should be placed rapidly over site. CXR STAT; new tube should be placed if persistent PTX.</p></li></ul><p>Gastrostomy/jejunostomy tubes (Paediatr Child Health 2011;16:281)</p><ul><li><p>Placed for tube feedings, hydration, and delivery of medications</p></li><li><p>Should not be removed for ≥6–8 wk to allow establishment of mature gastrocutaneous tract</p></li><li><p>Obstructed tubes can be cleared by flushing with agents such as carbonated water, meat tenderizer, & pancreatic enzymes. ↓ obstruction by flushing before & after meds and flushing q4–6h when receiving continuous feeds.</p></li><li><p>Inadvertent removal: place Foley catheter of similar size or smaller into tract immediately to prevent stoma from closing. Tube then replaced and confirmed via fluoro study.</p></li></ul><p>Suture/staple removal</p><ul><li><p>Should be done in consultation w/ surgical team; timing depends on location of wound</p></li><li><p>Should not be removed if there is evidence of wound separation during removal!</p></li><li><p>After removal, wound should be reapproximated w/ Steri-Strips</p></li></ul><p>Decubitus ulcers (J Wound Ostomy Continence Nurs 2012;39:3)</p><ul><li><p>Sores in dependent areas exposed to repeated pressure (commonly sacrum, heels)</p></li><li><p>Risk factors: immobility, poor nutritional status</p></li><li><p>Stage I (non-blanchable erythema); Stage II (partial thickness); Stage III (full-thickness skin loss); Stage IV (full-thickness tissue loss)</p></li><li><p>Treatment: offload area, air mattress, pillows and/or support boots, nutritional support</p></li><li><p>Surgical consultation for debridement of ulcers with necrotic or infected tissue, may require plastic surgical reconstruction for advanced ulcers once clean</p></li></ul><p>MAXIMIZING A SURGICAL CONSULT</p><ul><li><p>For ill Pt, call surgical consult early, do not wait for labs & imaging results</p></li><li><p>If potential surgical emergency, make Pt NPO, start IVF, ✓ coags, type, & screen</p></li><li><p>Have appropriate-level MD who knows & has examined Pt call consult</p></li></ul><p>OB/GYN ISSUES</p><p>VAGINAL BLEEDING</p><p>Bleeding from lower (vulva, vagina, cervix) or upper genital tract (uterus)</p><p>Etiologies</p><ul><li>Premenopausal</li></ul><p>Not pregnant: menses, lower tract (trauma, STI, cervical dysplasia/cancer), & abnormal uterine bleeding (polyp, adenomyosis, leiomyoma, hyperplasia/cancer, coagulopathy, ovulatory dysfunction, endometrial, & iatrogenic)</p><p>Pregnant</p><p>1st trimester: threatened abortion, spont. abortion (missed, incomplete, or complete), ectopic preg, molar preg (partial/complete hydatidiform mole)</p><p>2nd or 3rd trimester: preterm labor/labor, placenta previa, placental abruption</p><ul><li>Postmenopausal: atrophy, polyp, leiomyoma, endometrial hyperplasia/cancer</li></ul><p>History & exam</p><ul><li><p>Age, menopausal status, gestational age if preg, volume & duration of current bleeding</p></li><li><p>If premenopausal: menstrual hx including age of onset, interval between & duration of menses, any assoc. sx & LMP to assess timing of menstrual cycle</p></li><li><p>Past Ob/Gyn hx: incl. any structural abnl, STI, & contraception</p></li><li><p>Health maint.: Pap smear, HPV screening, domestic violence, anticoag/antiplt meds</p></li><li><p>General physical & abdominal exam (incl. tenderness, masses)</p></li><li><p>Pelvic exam: external (quantity of bleeding seen on vulva, any lesions, any trauma), speculum exam (quantity of bleeding, cervical os open/close; & if open, dilation, any polyps), & bimanual exam (cervical dilation, uterine size/tenderness, adnexal mass/tenderness)</p></li></ul><p>Laboratory evaluation & imaging</p><ul><li><p>Urine (rapid test) & serum preg test (βhCG), Hct/hemoglobin</p></li><li><p>Pelvic U/S: visualize leiomyoma & if preg, intrauterine preg & placental position to r/o placenta previa/abruption</p></li><li><p>If preg & intrauterine preg not seen, must r/o ectopic as life-threatening dx (βHCG > discrim. zone → ? ectopic; if βHCG &lt;discrim. zone → follow βHCG) (JAMA 2013;309:1722)</p></li></ul><p>VAGINAL DISCHARGE</p><p>Fluid or mucus from vagina, cervix, or uterus</p><p>Etiologies</p><ul><li><p>Infectious: bacterial vaginosis, candida vulvovaginitis, trichomoniasis</p></li><li><p>Noninfectious: physiologic (in preg/non-preg), rupture of membranes, foreign-body rxn</p></li></ul><p>Initial evaluation</p><ul><li><p>Age, LMP, gestational age if preg or menopausal status</p></li><li><p>Discharge quantity, color, consistency, odor, assoc. sx (itchiness, redness, abd/pelvic pain)</p></li><li><p>Past Gyn hx: incl. STI and contraception usage (condoms ↓ STI risk)</p></li><li><p>Tampon or condom use as risk factors for retained foreign body</p></li><li><p>Pelvic exam: external (quantity & quality of discharge on vulva, any lesions), speculum (discharge, appearance of cervix), bimanual (cervical motion tenderness)</p></li><li><p>Laboratory: pH of discharge, microscopy (saline & KOH wet mounts), urine preg test</p></li></ul><p>Treatment</p><ul><li><p>Bacterial vaginosis: oral/vaginal metronidazole or clindamycin</p></li><li><p>Candida vulvovaginitis: oral/topical antimycotic medications</p></li><li><p>Trichomoniasis: oral metronidazole</p></li></ul><p>ADNEXAL MASS IN NON-PREGNANT WOMAN</p><p>Mass arising from ovary, fallopian tube, or surrounding connective tissue</p><p>Etiologies</p><ul><li><p>Ovarian: functional cyst (follicular/corpus luteum), hemorrhagic cyst, endometriomas, ovarian torsion, tubo-ovarian abscess, benign & malignant ovarian tumors</p></li><li><p>Fallopian tube: paratubal cyst, hydrosalpinx, ovarian torsion, tubo-ovarian abscess</p></li></ul><p>Initial evaluation</p><ul><li><p>LMP/menopausal status, assoc. sx of abd/pelvic pain, FHx of gyn cancers</p></li><li><p>Abd exam (distension, tenderness, masses), bimanual (uterine or adnexal masses)</p></li><li><p>Preg test if premenopausal (if ⊕, then mass likely preg), CA-125 if postmenopausal</p></li><li><p>Pelvic U/S (even if mass 1st identified on CT, because U/S is best modality), U/S appearance of mass important factor to determine risk of malignancy</p></li></ul><p>OPHTHALMIC ISSUES</p><p>INITIAL EVALUATION</p><ul><li><p>Ocular symptom: onset (sudden or progressive) & duration of sx; unilateral vs. bilateral; pain; photophobia; discharge; Δ in near (eg, book) or far (eg, TV across room) vision</p></li><li><p>Preexisting ocular conditions, eye meds (incl any Δs), recent h/o ocular surgery, trauma</p></li><li><p>Ocular exam: vision (✓ with Pt’s correction [glasses/contacts]) w/ each eye; pupillary exam; EOM; confrontation visual fields (important if suspect CNS problem)</p></li><li><p>Overall: VS, immunocomp., s/s of infxn, h/o malig, CNS issues, Δ in meds, CBC, coags</p></li></ul><p>COMMON VISUAL SYMPTOMS</p><ul><li><p>Fluctuation in vision (ie, blurry): med-induced refractive error (eg, systemic steroids, chemoRx), hyperglycemia, dry eye (common). Visual defect may p/w “blurred vision.” Bilateral: glaucoma (common), homonymous contral. CNS lesion; bitemporal: pituitary, toxic/nutritional. Unilateral: ipsilateral orbital, retinal, or optic nerve lesion.</p></li><li><p>Red eye:</p></li></ul><p>Bilateral: viral conjunct. (starts in 1 eye; also w/ lid swelling, discharge); chronic inflammation (dry eyes, rosacea, autoimmune disease)</p><p>Unilateral: subconj. hemorrhage, infxn, or inflam (eg, episcleritis, iritis, uveitis, scleritis); acute angle closure (qv). Scleritis & acute angle closure p/w severe pain, H/A, nausea.</p><ul><li><p>Double vision (diplopia): fixed double vision w/ ophthalmoplegia from orbital process or cranial nerve palsy (III, IV, VI). Transient “diplopia” due to fatigue or sedation.</p></li><li><p>Flashing lights/floaters: vitreous detach. (common, benign); retinal detach. (unilateral visual field defect; urgent ophthalmology consult); hemorrhage; intraocular lymphoma</p></li></ul><p>ACUTE VISUAL CHANGES</p><p>Etiologies of Acute Vision Loss (italics indicates a/w pain)</p><p>Unilateral</p><p>Bilateral</p><p>Transient</p><p>(&lt;24 h, often &lt;1 h)</p><p>Ret. art. embolism, impending retinal artery or vein occlusion (amaurosis fugax), vasospasm, carotid disease</p><p>Ocular surface dis. (dry eye), bilat. carotid dis., TIA, migraine, high ICP (papilledema)</p><p>Prolonged</p><p>(>24 h)</p><p>Retinal art/vein occl, retinal detach., retina/vitreous heme, retinitis, ant. optic neurop./corneal ulcer, GCA, acute angle closure glaucoma</p><p>Visual cortex stroke, post. ischemic neuropathy (profound hypotension during surgery), post. reversible enceph. synd., GCA</p><p>COMMON OCULAR CONDITIONS (FRONT TO BACK)</p><ul><li><p>Orbit: orbital cellulitis (fever, proptosis, ↓ EOM; emergent abx, scan, & referral)</p></li><li><p>Lids: hordeolum or chalazion (stye); preseptal cellulitis; ptosis (age; Horner’s; CN III palsy: EOM restricted in all directions except laterally (eye is “down & out”), a/w ptosis & mydriasis, seen w/ uncal herniation, aneurysm of post com art., GCA, HTN, DM); incomplete lid closure (CN 7th palsy)</p></li><li><p>Conjunctiva: conjunctivitis (red eye); subconj. hemorrhage (HTN, blood thinner); ocular surface disease (dry eyes); episcleritis/scleritis (deep vessels of sclera)</p></li><li><p>Cornea: contact lens-related ulcer; herpetic keratitis/scarring/neurotropic ulcers (CN V paresis); pterygium; keratoconus; corneal dystrophy</p></li><li><p>Ant. chamber: iritis (inflam. cells); hyphema (blood, post trauma); hypopyon (inflam./infxn)</p></li><li><p>Pupil: Anisocoria (physiologic asymmetry); Horner’s, CN III</p></li><li><p>Lens: cataract (age, trauma, medication, radiation, congenital); post cataract surgery infxn</p></li><li><p>Vitreous/Retina/Macula: diabetic retinopathy; macular degen; retinal detachment; retinal ± vitreous hemorrhage; retinitis (infectious)</p></li><li><p>Optic nerve (CN II): ischemic neuropathy p/w acute unilat. visual loss, altitudinal field defect; a/w GCA; nonarteritic a/w HTN, hyperchol., DM, thrombophilia. Optic neuritis: often p/w unilat. central scotoma, pain w/ EOM, ↑ visual loss over days; a/w demyelinating disease (eg, MS), also seen w/ sarcoidosis & CTD. Optic neuropathy (glaucoma common).</p></li></ul><p>OCULAR EMERGENCIES</p><ul><li><p>Chemical splash: alkali worse than acid; immediate eye flush; pH 7.3–7.4 normal</p></li><li><p>Acute angle closure glaucoma: fixed mid-dilated pupil, corneal edema, high intraocular pressure (typically >50; normal 8–21). Rx w/ topical drops; may require AC tap/laser.</p></li><li><p>Penetrating eye injury: protect eye (no patching), IV abx, tetanus, NPO, surgical prep</p></li></ul><p>ICU MEDICATIONS</p><p>Drug</p><p>Class</p><p>Dose</p><p>per kg</p><p>average</p><p>Pressors, Inotropes, and Chronotropes</p><p>Phenylephrine</p><p>α1</p><p>10–300 μg/min</p><p>Norepinephrine</p><p>α1 >β1</p><p>1–40 μg/min</p><p>Vasopressin</p><p>V1</p><p>0.01–0.1 U/min (usually &lt;0.04)</p><p>Epinephrine</p><p>α1, α2, β1, β2</p><p>2–20 μg/min</p><p>Isoproterenol</p><p>β1, β2</p><p>0.1–10 μg/min</p><p>Dopamine</p><p>D</p><p>β, D</p><p>α, β, D</p><p>0.5–2 μg/kg/min</p><p>2–10 μg/kg/min</p><blockquote><p>10 μg/kg/min</p></blockquote><p>50–200 μg/min</p><p>200–500 μg/min</p><p>500–1000 μg/min</p><p>Dobutamine</p><p>β1 >β2</p><p>2–20 μg/kg/min</p><p>50–1000 μg/min</p><p>Milrinone</p><p>PDE</p><p>± 50 μg/kg over 10 min then 0.25–0.75 μg/kg/min</p><p>3–4 mg over 10 min then 20–50 μg/min</p><p>Vasodilators</p><p>Nitroglycerin</p><p>NO</p><p>5–500 μg/min</p><p>Nitroprusside</p><p>NO</p><p>0.25–10 μg/kg/min</p><p>10–800 μg/min</p><p>Labetalol</p><p>α1, β1, and β2 blocker</p><p>20–80 mg q10min or 10–120 mg/h</p><p>Fenoldopam</p><p>D</p><p>0.1–1.6 μg/kg/min</p><p>10–120 μg/min</p><p>Clevidipine</p><p>CCB</p><p>1–32 mg/h</p><p>Epoprostenol</p><p>vasodilator</p><p>2–20 ng/kg/min</p><p>Antiarrhythmics</p><p>Amiodarone</p><p>K et al. (Class III)</p><p>150 mg over 10 min, then 1 mg/min × 6 h, then 0.5 mg/min × 18 h</p><p>Lidocaine</p><p>Na channel (Class IB)</p><p>1–1.5 mg/kg then</p><p>1–4 mg/min</p><p>100 mg then</p><p>1–4 mg/min</p><p>Procainamide</p><p>Na channel (Class IA)</p><p>17 mg/kg over 60 min</p><p>then 1–4 mg/min</p><p>1 g over 60 min then 1–4 mg/min</p><p>Ibutilide</p><p>K channel (Class III)</p><p>1 mg over 10 min,</p><p>may repeat × 1</p><p>Propranolol</p><p>β blocker</p><p>0.5–1 mg q5min then 1–10 mg/h</p><p>Esmolol</p><p>β1 >β2 blocker</p><p>500–1000 μg/kg</p><p>then 50–200 μg/kg/min</p><p>20–40 mg over 1 min then 2–20 mg/min</p><p>Verapamil</p><p>CCB</p><p>2.5–5 mg over 1–2′, repeat 5–10 mg in 15–30′ prn 5–20 mg/h</p><p>Diltiazem</p><p>CCB</p><p>0.25 mg/kg over 2 min reload 0.35 mg/kg × 1 prn then 5–15 mg/h</p><p>20 mg over 2 min reload 25 mg × 1 prn then 5–15 mg/h</p><p>Adenosine</p><p>purinergic</p><p>6 mg rapid push; if no response: 12 mg → 12–18 mg</p><p>Sedation</p><p>Morphine</p><p>opioid</p><p>1–30 (in theory, unlimited) mg/h</p><p>Fentanyl</p><p>opioid</p><p>50–100 μg then 50–800 (? unlimited) μg/h</p><p>Propofol</p><p>anesthetic</p><p>1–3 mg/kg then</p><p>0.3–5 mg/kg/h</p><p>50–200 mg then 20–400 mg/h</p><p>Dexmedetomidine</p><p>α2 agonist</p><p>1 μg/kg over 10 min → 0.2–0.7 μg/kg/h</p><p>Diazepam</p><p>BDZ</p><p>1–5 mg q1–2h then q6h prn</p><p>Midazolam</p><p>BDZ</p><p>0.5–2 mg q5min prn; 0.02–0.1 mg/kg/h or 1–10 mg/h</p><p>Lorazepam</p><p>BDZ</p><p>0.01–0.1 mg/kg/h</p><p>Naloxone</p><p>opioid antag.</p><p>0.4–2 mg q2–3min to total of 10 mg</p><p>Flumazenil</p><p>BDZ antag.</p><p>0.2 mg over 30 sec then 0.3 mg over 30 sec prn may repeat 0.5 mg over 30 sec to total of 3 mg</p><p>Miscellaneous</p><p>Aminophylline</p><p>PDE</p><p>5.5 mg/kg over 20 min then 0.5–1 mg/kg/h</p><p>250–500 mg</p><p>then 10–80 mg/h</p><p>Octreotide</p><p>somatostatin analog</p><p>50 μg then 50 μg/h</p><p>Glucagon</p><p>hormone</p><p>3–10 mg IV slowly over 3–5 min then 3–5 mg/h</p><p>Mannitol</p><p>osmole</p><p>1.5–2 g/kg over 30–60 min repeat q6–12h to keep osm 310–320</p><p>Figure 11-1 ACLS pulmonary edema, hypotension or shock algorithm</p><p>(Adapted from ACLS 2005 Guidelines)</p><p>ANTIBIOTICS</p><p>The following tables of spectra of activity for different antibiotics are generalizations.</p><p>Sensitivity data at your own institution should be used to guide therapy.</p><p>Penicillins</p><p>Generation</p><p>Properties</p><p>Spectrum</p><p>Natural (penicillin)</p><p>Active vs. many GPC, GPR, anaerobes (not Bacteroides), some Gram ⊖ coccobacilli & Gram ⊖ diplococci</p><p>Most streptococci, many enterococci, Listeria, C. acnes, Pasteurella, Actinomyces, syphilis</p><p>Anti-staph (eg, nafcillin)</p><p>Active vs. PCNase-producing Staph Little activity vs. Gram ⊖</p><p>Staphylococci (except MRSA) Streptococci</p><p>Amino (eg, ampicillin)</p><p>Penetrate porin channel of Gram ⊖</p><p>Not stable against PCNases</p><p>PCN plus E. coli, Proteus, H. influenzae, Salmonella, Shigella</p><p>Extended (eg, piperacillin)</p><p>Penetrate porin channel of Gram ⊖ More resistant to PCNases</p><p>Most GNR incl. Enterobacter, Pseudomonas, Serratia</p><p>β-lact. inhib. (eg, sulbactam, clavulanate) with PCN derivative</p><p>Inhibits some plasma-mediated β-lactamases</p><p>Adds staph (not MRSA), most PCN-R anaerobes, & some GNR (H. flu, M. cat, some enterics); intrinsic activity against Acinetobacter</p><p>Cephalosporins</p><p>Resistant to most penicillin b-lactamases. No activity vs. enterococci.</p><p>Generation</p><p>Spectrum</p><p>Indications</p><p>1st (eg, cefazolin)</p><p>Most GPC (incl. staph & strep, not MRSA); some GNR (incl. E. coli, Proteus, Klebsiella)</p><p>Used for surgical Ppx & skin infxns</p><p>2nd (eg, cefuroxime, cefotetan)</p><p>↓ activity vs. GPC, ↑ vs. GNR. 2 subgroups:</p><p>Resp: H. influenzae & M. catarrhalis</p><p>GI/GU: ↑ activity vs. B. fragilis</p><p>PNA/COPD flare</p><p>Abdominal infxns</p><p>3rd (eg, ceftriaxone, ceftazidime)</p><p>Broad activity vs. GNR (not ESBL), streptococci, & some anaerobes. Ceftazidime active vs. Pseudomonas, less vs. strep</p><p>PNA, sepsis, meningitis</p><p>4th (eg, cefepime)</p><p>↑ resistance to β-lactamases (incl. Enterobacter)</p><p>Similar to 3rd gen. MonoRx for nonlocalizing febrile neutropenia</p><p>5th (eg, ceftaroline)</p><p>Only class of cephalosporin with MRSA activity. GN activity similar to ceftriaxone. NOT active vs. Pseudomonas.</p><p>MRSA. Not 1st line for MRSA bacteremia.</p><p>Combination (eg, ceftolozane-tazobactam, ceftazidime- avibactam)</p><p>MDR GNRs, incl. Pseudomonas. Ceftaz-avi has activity vs. some carbapenemases.</p><p>Complicated UTIs, complicated intra-abdominal infections.</p><p>Other Beta-Lactams</p><p>Class</p><p>Properties</p><p>Spectrum</p><p>Carbapenems (eg, imipenem)</p><p>Resistant to most β-lactamases</p><p>Most Gram ⊕ & ⊖, incl. anaerobes; not MRSA or VRE</p><p>Monobactams (aztreonam)</p><p>Active vs. Gram ⊖ but not Gram ⊕</p><p>Gram ⊖ bacterial infxn in Pt w/ PCN or Ceph allergy</p><p>Other Antibiotics</p><p>Antibiotic</p><p>Spectrum</p><p>Vancomycin</p><p>Gram ⊕ bacteria incl. MRSA, PCNase-producing pneumococci and enterococci (except VRE)</p><p>Linezolid</p><p>GPC incl. MRSA & VRE (check susceptibility for VRE)</p><p>Daptomycin</p><p>Quinolones</p><p>GNR & atypicals. Levo and esp moxi ↑ activity vs. Gram ⊕.</p><p>Aminoglycosides</p><p>GNR. Synergy w/ cell-wall active abx (β-lactam, vanco) vs. GPC. ↓ activity in low pH (eg, abscess). No activity vs. anaerobes.</p><p>Macrolides</p><p>GPC, some respiratory Gram ⊖, atypicals</p><p>TMP/SMX</p><p>Most enteric GNR, Staph incl CA-MRSA, Stenotrophomonas, Nocardia, Toxo, Pneumocystis</p><p>Clindamycin</p><p>Most Gram ⊕ (except enterococci) & anaerobes (increasing resistance, especially GI)</p><p>Metronidazole</p><p>Almost all anaerobic Gram ⊖, most anaerobic Gram ⊕, some protozoa (Entamoeba, Trichomonas, et al.)</p><p>Doxycycline</p><p>Rickettsia, Ehrlichia, Anaplasma, Chlamydia, Mycoplasma, Nocardia, Lyme; many Staph and GNR</p><p>Tigecycline</p><p>Many GPC incl. MRSA & VRE; most GNR incl. ESBL but not Pseudomonas or Proteus; most anaerobes</p><p>FORMULAE AND QUICK REFERENCE</p><p>CARDIOLOGY</p><p>Hemodynamic Parameters</p><p>Normal Value</p><p>Mean arterial pressure</p><p>70–100 mmHg</p><p>Heart rate (HR)</p><p>60–100 bpm</p><p>Right atrial pressure (RA)</p><p>≤6 mmHg</p><p>Right ventricular (RV)</p><p>systolic 15–30 mmHg</p><p>diastolic 1–8 mmHg</p><p>Pulmonary artery (PA)</p><p>systolic 15–30 mmHg</p><p>mean 9–18 mmHg</p><p>diastolic 6–12 mmHg</p><p>Pulmonary capillary wedge pressure (PCWP)</p><p>≤12 mmHg</p><p>Cardiac output (CO)</p><p>4–8 L/min</p><p>Cardiac index</p><p>2.6–4.2 L/min/m2</p><p>Stroke volume</p><p>60–120 mL/contraction</p><p>Stroke volume index</p><p>40–50 mL/contraction/m2</p><p>Systemic vascular resistance (SVR)</p><p>800–1200 dynes × sec/cm5</p><p>Pulmonary vascular resistance (PVR)</p><p>120–250 dynes × sec/cm5</p><p>“Rule of 6s” for PAC: RA ≤6, RV ≤30/6, PA ≤30/12, WP ≤12. Nb 1 mmHg = 1.36 cm water or blood.</p><p>Fick cardiac output</p><p>Oxygen consumption (L/min) = CO (L/min) × arteriovenous (AV) oxygen difference</p><p>CO = oxygen consumption/AV oxygen difference</p><p>Oxygen consumption must be measured (can estimate w/ 125 mL/min/m2, but inaccurate)</p><p>AV oxygen difference = Hb (g/dL) × 10 (dL/L) × 1.36 (mL O2/g of Hb) × (SaO2–SMVO2)</p><p>SaO2 is measured in any arterial sample (usually 93–98%)</p><p>SMVO2 (mixed venous O2) is measured in RA, RV, or PA (assuming no shunt) (nl ~75%)</p><p>Assessment of RV function (Circ 2017;136:314)</p><p>PAPi = Pulmonary artery pulsatility index = [PA systolic – PA diastolic] / RA pressure ≤0.9 predicts RV failure in acute MI; &lt;1.85 predicts RV failure after LVAD</p><p>Shunts</p><p>Valve equations</p><p>Simplified Bernoulli: Pressure gradient (∇P) = 4 × v2 (where v = peak flow velocity)</p><p>Continuity (conservation of flow): Area1 × Velocity1 = A2 × V2 (where 1 & 2 different points)</p><p>PULMONARY</p><p>Chest Imaging (CXR & CT) Patterns</p><p>Pattern</p><p>Pathophysiology</p><p>Ddx</p><p>Consolidation</p><p>Radiopaque material in air space & interstitium patent airway → “air bronchograms”</p><p>Acute: water (pulm. edema), pus (PNA), blood</p><p>Chronic: neoplasm (BAC, lymphoma), aspiration, inflammatory (COP, eosinophilic PNA), PAP, granuloma (TB/fungal, alveolar sarcoid)</p><p>Ground glass (CT easier than CXR)</p><p>Interstitial thickening or partial filling of alveoli (but vessels visible)</p><p>Acute: pulm. edema, infxn (PCP, viral, resolving bact. PNA)</p><p>Chronic: ILD</p><p>w/o fibrosis: acute hypersens., DIP/RB, PAP</p><p>w/ fibrosis: IPF</p><p>Septal lines Kerley A & B</p><p>Radiopaque material in septae</p><p>Cardiogenic pulm. edema, interstitial PNA viral, mycoplasma, lymphangitic tumor</p><p>Reticular</p><p>Lace-like net (ILD)</p><p>ILD (esp. IPF, CVD, bleomycin, asbestos)</p><p>Nodules</p><p>Tumor</p><p>Granulomas</p><p>Abscess</p><p>Cavitary: Primary or metastatic cancer, TB (react. or miliary), fungus, Wegener’s, RA septic emboli, PNA</p><p>Noncavitary: any of above + sarcoid, hypersens. pneum., HIV, Kaposi’s sarcoma</p><p>Wedge opac.</p><p>Peripheral infarct</p><p>PE, cocaine, angioinv. aspergillus, Wegener’s</p><p>Tree-in-bud (best on CT)</p><p>Inflammation of small airways</p><p>Bronchopneumonia, endobronchial TB/MAI, viral PNA, aspiration, ABPA, CF, asthma, COP</p><p>Hilar fullness</p><p>↑ LN or pulm. arteries</p><p>Neoplasm (lung, mets, lymphoma)</p><p>Infxn (AIDS); Granuloma (sarcoid/TB/fungal)</p><p>Pulmonary hypertension</p><p>Upper lobe</p><p>n/a</p><p>TB, fungal, sarcoid, hypersens. pneum., CF, XRT</p><p>Lower lobe</p><p>n/a</p><p>Aspiration, bronchiect., IPF, RA, SLE, asbestos</p><p>Peripheral</p><p>n/a</p><p>COP, IPF & DIP, eos PNA, asbestosis</p><p>CXR in heart failure</p><ul><li><p>↑ cardiac silhouette (in systolic dysfxn, not in diastolic)</p></li><li><p>Pulmonary venous hypertension: cephalization of vessels (vessels size >bronchi in upper lobes), peribronchial cuffing (fluid around bronchi seen on end → small circles), Kerley B lines (horizontal 1- to 2-cm lines at bases), ↑ vascular pedicle width, loss of sharp vascular margins, pleural effusions (~75% bilateral)</p></li><li><p>Pulmonary edema: ranges from ground glass to consolidation; often dependent and central, sparing outer third (“bat wing” appearance)</p></li></ul><p>Dead space = lung units that are ventilated but not perfused</p><p>Intrapulmonary shunt = lung units that are perfused but not ventilated</p><p>A-a gradient = PAO2 – PaO2 [normal A-a gradient ≈ 4 + (age/4)]</p><p>Minute ventilation (VE) = tidal volume (VT) × respiratory rate (RR) (nl 4–6 L/min)</p><p>Tidal volume (VT) = alveolar space (VA) + dead space (VD)</p><p>GASTROENTEROLOGY</p><p>Modified Child-Turcotte-Pugh (CPS) Scoring System</p><p>Points Scored</p><p>1</p><p>2</p><p>3</p><p>Ascites</p><p>None</p><p>Easily controlled</p><p>Poorly controlled</p><p>Encephalopathy</p><p>None</p><p>Grade 1 or 2</p><p>Grade 3 or 4</p><p>Bilirubin (mg/dL)</p><p>&lt;2</p><p>2–3</p><blockquote><p>3</p></blockquote><p>Albumin (g/dL)</p><blockquote><p>3.5</p></blockquote><p>2.8–3.5</p><p>&lt;2.8</p><p>PT (sec >control)</p><p>or INR</p><p>&lt;4</p><p>&lt;1.7</p><p>4–6</p><p>1.8–2.3</p><blockquote><p>6</p></blockquote><blockquote><p>2.3</p></blockquote><p>Classification</p><p>A</p><p>B</p><p>C</p><p>Total points</p><p>5–6</p><p>7–9</p><p>10–15</p><p>1-y survival</p><p>100%</p><p>80%</p><p>45%</p><p>NEPHROLOGY</p><p>Anion gap (AG) = Na – (Cl + HCO3) (normal = [alb] × 2.5; typically 12 ± 2 mEq)</p><p>Delta-delta (ΔΔ) = [Δ AG (ie, calc. AG – expected) / Δ HCO3 (ie, 24 – measured HCO3)]</p><p>Urine anion gap (UAG) = (UNa + UK) – UCl</p><p>HEMATOLOGY</p><p>Peripheral Smear Findings (also see Photo Inserts)</p><p>Feature</p><p>Abnormalities and Diagnoses</p><p>Size</p><p>normocytic vs. microcytic vs. macrocytic → see below</p><p>Shape</p><p>Anisocytosis → unequal RBC size; poikilocytosis → irregular RBC shape acanthocytes = spur cells (irregular sharp projections) → liver disease</p><p>Bite cells (removal of Heinz bodies by phagocytes) → G6PD deficiency echinocytes = burr cells (even, regular projections) → uremia, artifact</p><p>Pencil cell → long, thin, hypochromic–very common in adv. iron deficiency</p><p>Rouleaux → hyperglobulinemia (eg, multiple myeloma)</p><p>Schistocytes, helmet cells → MAHA (eg, DIC, TTP/HUS), mechanical valve</p><p>Spherocytes → HS, AIHA; sickle cells → sickle cell anemia</p><p>Stomatocyte → central pallor appears as curved slit → liver disease, EtOH</p><p>Target cells → liver disease, hemoglobinopathies, splenectomy</p><p>Tear drop cells = dacryocytes → myelofibrosis, myelophthisic anemia, megaloblastic anemia, thalassemia</p><p>Intra- RBC findings</p><p>Basophilic stippling (ribosomes) → abnl Hb, sideroblastic, megaloblastic</p><p>Heinz bodies (denatured Hb) → G6PD deficiency, thalassemia</p><p>Howell-Jolly bodies (nuclear fragments) → splenectomy or functional asplenia (eg, advanced sickle cell)</p><p>Nucleated RBCs → hemolysis, extramedullary hematopoiesis</p><p>WBC findings</p><p>Blasts → leukemia, lymphoma; Auer rods → acute myelogenous leukemia</p><p>Hypersegmented (>5 lobes) PMNs: megaloblastic anemia (B12/folate def.)</p><p>Pseudo-Pelger-Huët anomaly (bilobed nucleus, “pince-nez”) → MDS</p><p>Toxic granules (coarse, dark blue) and Döhle bodies (blue patches of dilated endoplasmic reticulum) → (sepsis, severe inflammation)</p><p>Platelet</p><p>Clumping → artifact, repeat plt count</p><a href=#-periph-blood-plt-count-10000-plt-for-every-1-plt-seen-at-hpf-100><h1 id=-periph-blood-plt-count-10000-plt-for-every-1-plt-seen-at-hpf-100><span class=hanchor arialabel=Anchor># </span>→ periph blood plt count ~10,000 plt for every 1 plt seen at hpf (100×)</h1></a><p>Size → MPV (mean platelet volume) enlarged in ITP</p><p>(NEJM 2005;353:498)</p><p>Heparin for Thromboembolism</p><p>80 U/kg bolus</p><p>18 U/kg/h</p><p>PTT</p><p>Adjustment</p><p>&lt;40</p><p>bolus 5000 U, ↑ rate 300 U/h</p><p>40–49</p><p>bolus 3000 U, ↑ rate 200 U/h</p><p>50–59</p><p>↑ rate 150 U/h</p><p>60–85</p><p>no Δ</p><p>86–95</p><p>↓ rate 100 U/h</p><p>96–120</p><p>hold 30 min, ↓ rate 100 U/h</p><blockquote><p>120</p></blockquote><p>hold 60 min, ↓ rate 150 U/h</p><p>(Modified from Chest 2008;133:141S)</p><p>Heparin for ACS</p><p>60 U/kg bolus (max 4000 U)</p><p>12 U/kg/h (max 1000 U/h)</p><p>PTT</p><p>Adjustment</p><p>&lt;40</p><p>bolus 3000 U, ↑ rate 100 U/h</p><p>40–49</p><p>↑ rate 100 U/h</p><p>50–75</p><p>no Δ</p><p>76–85</p><p>↓ rate 100 U/h</p><p>86–100</p><p>hold 30 min, ↓ rate 100 U/h</p><blockquote><p>100</p></blockquote><p>hold 60 min, ↓ rate 200 U/h</p><p>(Modified from Circ 2007;116:e148 & Chest 2008;133:670)</p><p>✓ PTT q6h after every Δ (t. of heparin ~90 min) and then qd or bid once PTT is therapeutic</p><p>✓ CBC qd (to ensure Hct and plt counts are stable)</p><p>(Annals 1997;126:133; Archives 1999;159:46) or, go to
<a href=https://www.warfarindosing.org rel=noopener>www.warfarindosing.org</a></p><p>Warfarin-heparin overlap therapy</p><ul><li><p>Indications: when failure to anticoagulate carries ↑ risk of morbidity or mortality (eg, DVT/PE, intracardiac thrombus)</p></li><li><p>Rationale: (1) Half-life of factor VII (3–6 h) is shorter than half-life of factor II (60–72 h);</p></li></ul><p>∴ warfarin can elevate PT before achieving a true antithrombotic state</p><p>(2) Protein C also has half-life less than that of factor II;</p><p>∴ theoretical concern of hypercoagulable state before antithrombotic state</p><ul><li>Method: (1) Therapeutic PTT is achieved using heparin</li></ul><p>(2) Warfarin therapy is initiated</p><p>(3) Heparin continued until INR therapeutic for ≥2 d and ≥4–5 d of warfarin (roughly corresponds to ~2 half-lives of factor II or a reduction to ~25%)</p><p>Common Warfarin-Drug Interactions</p><p>Drugs that ↑ PT</p><p>Drugs that ↓ PT</p><p>Amiodarone</p><p>Antimicrobials: erythromycin, ? clarithro, ciprofloxacin, MNZ, sulfonamides</p><p>Antifungals: azoles</p><p>Acetaminophen, cimetidine, levothyroxine</p><p>Antimicrobials: rifampin</p><p>CNS: barbiturates, carbamazepine, phenytoin (initial transient ↑ PT)</p><p>Cholestyramine</p><p>ENDOCRINOLOGY</p><p>Examples of Various Cosyntropin Stimulation Test Results</p><p>0′</p><p>30′</p><p>60′</p><p>Interpretation</p><p>5.3</p><p>15.5</p><p>23.2</p><p>Normal stimulation test</p><p>1.5</p><p>13.3</p><p>21.1</p><p>Acute central AI (eg, apoplexy or CNS bleed). Can look normal.</p><p>1.2</p><p>1.5</p><p>2.0</p><p>1° AI (eg, Addisons or adrenal bleed). Flat or minimal stim.</p><p>0.8</p><p>10.0</p><p>19.7</p><p>Acute effect of glucocorticoids: low initial value but stims >threshold</p><p>5.3</p><p>7.2</p><p>8.9</p><p>Chronic 2° AI: some cortisol production and stim, but evidence of adrenal atrophy</p><p>6.7</p><p>19.5</p><p>17.2</p><p>“Early peak” (fast metab): ~5% of Pts peak at 30’ rather than 60’</p><p>6.3</p><p>11.5</p><p>16.2</p><p>Equivocal test. Can occur due to mild AI, acute illness, liver disease, low cortisol binding protein, renal disease, etc.</p><p>NEUROLOGY</p><p>OTHER</p><p>NOTES</p><p>ABBREVIATIONS</p><p>5′-NT 5′-nucleotidase</p><p>6-MP 6-mercaptopurine</p><p>AAA abdominal aortic aneurysm</p><p>AAD antiarrhythmic drug</p><p>Ab antibody</p><p>ABE acute bacterial endocarditis</p><p>ABG arterial blood gas</p><p>abnl abnormal</p><p>ABPA allergic bronchopulmonary aspergillosis</p><p>abx antibiotics</p><p>a/c anticoagulation</p><p>AC assist control</p><p>ACE angiotensin-converting enzyme</p><p>ACEI ACE inhibitor</p><p>ACI anemia of chronic inflammation</p><p>ACL anticardiolipin antibody</p><p>ACLS advanced cardiac life support</p><p>ACS acute coronary syndrome</p><p>ACTH adrenocorticotrophic hormone</p><p>ACV acyclovir</p><p>ADA adenosine deaminase</p><p>ADH antidiuretic hormone</p><p>ADL activities of daily living</p><p>AF atrial fibrillation</p><p>AFB acid-fast bacilli</p><p>AFL atrial flutter</p><p>AFP α-fetoprotein</p><p>AFTP ascites fluid total protein</p><p>AG aminoglycoside anion gap</p><p>Ag antigen</p><p>AGN acute glomerulonephritis</p><p>AI adrenal insufficiency</p><p>aortic insufficiency aromatase inhibitor</p><p>AIDS acquired immunodefic. synd.</p><p>AIH autoimmune hepatitis</p><p>AIHA autoimmune hemolytic anemia</p><p>AIN acute interstitial nephritis</p><p>AIP acute interstitial pneumonia</p><p>AKI acute kidney injury</p><p>ALF acute liver failure</p><p>ALL acute lymphoblastic leukemia</p><p>ALS amyotrophic lateral sclerosis</p><p>ALT alanine aminotransferase</p><p>AMA anti-mitochondrial antibody</p><p>AMI anterior myocardial infarction</p><p>AML acute myelogenous leukemia</p><p>amy amylase</p><p>ANA antinuclear antibody</p><p>ANCA antineutrophilic cytoplasmic Ab</p><p>AoD aortic dissection</p><p>AoV aortic valve</p><p>APAP acetyl-para-aminophenol</p><p>APC activated protein C</p><p>APL acute promyelocytic leukemia</p><p>APLA antiphospholipid Ab</p><p>APS antiphospholipid Ab synd.</p><p>ARB angiotensin receptor blocker</p><p>ARDS acute resp distress synd.</p><p>ARV antiretroviral</p><p>ARVC arrhythmogenic RV CMP</p><p>AS aortic stenosis</p><p>ASA aspirin</p><p>ASD atrial septal defect</p><p>AST aspartate aminotransferase</p><p>asx asymptomatic</p><p>AT atrial tachycardia</p><p>ATII angiotensin II</p><p>ATIII antithrombin III</p><p>ATN acute tubular necrosis</p><p>ATRA all-trans-retinoic acid</p><p>AV atrioventricular</p><p>AVA aortic valve area</p><p>AVB atrioventricular block</p><p>AVNRT AV nodal reentrant tachycardia</p><p>AVR aortic valve replacement</p><p>AVRT AV reciprocating tachycardia</p><p>a/w associated with</p><p>AZA azathioprine</p><p>Aϕ alkaline phosphatase</p><p>BAL bronchoalveolar lavage</p><p>βB beta-blocker</p><p>BBB bundle branch block</p><p>b/c because</p><p>BCx blood culture</p><p>BD bile duct</p><p>BDZ benzodiazepines</p><p>bili. bilirubin</p><p>BiPAP bilevel positive airway pressure</p><p>BiV biventricular</p><p>BM bone marrow</p><p>bowel movement</p><p>BMD bone mineral density</p><p>BMI body mass index</p><p>BMS bare metal stent</p><p>BNP B-type natriuretic peptide</p><p>BP blood pressure</p><p>BPH benign prostatic hypertrophy</p><p>BRBPR bright red blood per rectum</p><p>BS breath sounds</p><p>BT bleeding time</p><p>BUN blood urea nitrogen</p><p>bx biopsy</p><p>BYCE buffered charcoal yeast extract</p><p>C′ complement</p><p>CABG coronary artery bypass grafting</p><p>CAD coronary artery disease</p><p>CAH congenital adrenal hyperplasia</p><p>CALLA common ALL antigen</p><p>CAPD chronic ambulatory peritoneal dialysis</p><p>CBC complete blood count</p><p>CBD common bile duct</p><p>CCB calcium channel blocker</p><p>CCl4 carbon tetrachloride</p><p>CCP cyclic citrullinated peptide</p><p>CCS Canadian Cardiovascular Society</p><p>CCY cholecystectomy</p><p>CD Crohn’s disease</p><p>CEA carcinoembryonic antigen</p><p>carotid endarterectomy</p><p>ceph. cephalosporin</p><p>c/f concern for</p><p>CF cystic fibrosis</p><p>CFU colony forming units</p><p>CHB complete heart block</p><p>CHD congenital heart disease</p><p>CHF congestive heart failure</p><p>CI cardiac index</p><p>CIAKI contrast-induced AKI</p><p>CIDP chronic inflammatory demyelinating polyneuropathy</p><p>CJD Creutzfeldt-Jakob disease</p><p>CK creatine kinase</p><p>CKD chronic kidney disease</p><p>CLL chronic lymphocytic leukemia</p><p>CMC carpometacarpal (joint)</p><p>CML chronic myelogenous leukemia</p><p>CMML chronic myelomonocytic leukemia</p><p>CMP cardiomyopathy</p><p>CMV cytomegalovirus</p><p>CN cranial nerve</p><p>CNI calcineurin inhibitor</p><p>CNS central nervous system</p><p>coagulase-negative Staphylococci</p><p>CO carbon monoxide</p><p>cardiac output</p><p>COP cryptogenic organizing PNA</p><p>COPD chronic obstructive pulm. dis.</p><p>COX cyclo-oxygenase</p><p>CP chest pain</p><p>CPAP continuous positive airway pressure</p><p>CPP cerebral perfusion pressure</p><p>CPPD calcium pyrophosphate dihydrate</p><p>Cr creatinine</p><p>CrAg cryptococcal antigen</p><p>CRC colorectal cancer</p><p>CrCl creatinine clearance</p><p>CRP C-reactive protein</p><p>CRT cardiac resynchronization therapy</p><p>c/s consult</p><p>CsA cyclosporine A</p><p>CSF cerebrospinal fluid</p><p>CSM carotid sinus massage</p><p>CT computed tomogram</p><p>CTA CT angiogram</p><p>CTD connective tissue disease</p><p>CTX ceftriaxone</p><p>CV cardiovascular</p><p>CVA cerebrovascular accident</p><p>CVD cerebrovascular disease</p><p>collagen vascular disease</p><p>CVID common variable immunodefic.</p><p>CVP central venous pressure</p><p>CVVH continuous veno-venous hemofiltration</p><p>c/w compared with</p><p>consistent with</p><p>CW chest wall</p><p>cx culture</p><p>CXR chest radiograph</p><p>CYC cyclophosphamide</p><p>d day</p><p>D death</p><p>ΔMS change in mental status</p><p>DA dopamine</p><p>DAD diffuse alveolar damage</p><p>DAH diffuse alveolar hemorrhage</p><p>DAT direct antiglobulin test</p><p>DBP diastolic blood pressure</p><p>d/c discharge</p><p>discontinue</p><p>DCCV direct current cardioversion</p><p>DCIS ductal carcinoma in situ</p><p>DCMP dilated cardiomyopathy</p><p>DCT distal collecting tubule</p><p>Ddx differential diagnosis</p><p>DES drug-eluting stent</p><p>DFA direct fluorescent antigen detection</p><p>DI diabetes insipidus</p><p>DIC disseminated intravascular coagulation</p><p>diff. differential</p><p>DIP desquamative interstitial pneumonitis</p><p>distal interphalangeal (joint)</p><p>DKA diabetic ketoacidosis</p><p>DLCO diffusion capacity of the lung</p><p>DLE drug-induced lupus</p><p>DM dermatomyositis</p><p>diabetes mellitus</p><p>DMARD disease-modifying anti-rheumatic drug</p><p>DOE dyspnea on exertion</p><p>DRE digital rectal exam</p><p>DRESS drug reaction w/ eosinophilia & systemic symptoms</p><p>DSE dobutamine stress echo</p><p>DST dexamethasone suppression test</p><p>DTRs deep tendon reflexes</p><p>DU duodenal ulcer</p><p>DVT deep vein thrombosis</p><p>dx diagnosis</p><p>EAD extreme axis deviation</p><p>EAV effective arterial volume</p><p>EBV Epstein-Barr virus</p><p>ECG electrocardiogram</p><p>ECMO extracorporeal membrane oxygenation</p><p>ED emergency department</p><p>EDP end-diastolic pressure</p><p>EDV end-diastolic volume</p><p>EEG electroencephalogram</p><p>EF ejection fraction</p><p>EGD esophagogastroduodenoscopy</p><p>EGFR epidermal growth factor receptor</p><p>EGPA eosinophilic granulomatosis with polyangiitis</p><p>EI entry inhibitor</p><p>EIA enzyme-linked immunoassay</p><p>ELISA enzyme-linked immunosorbent assay</p><p>EM electron microscopy</p><p>EMB ethambutol</p><p>ENaC epithelial Na channel</p><p>ENT ears, nose, & throat</p><p>e/o evidence of</p><p>EOM extraocular movement/muscles</p><p>EP electrophysiology</p><p>Epo erythropoietin</p><p>EPS electrophysiology study</p><p>ERCP endoscopic retrograde cholangiopancreatography</p><p>ERV expiratory reserve volume</p><p>ESA erythropoiesis-stimulating agents</p><p>ESBL extended spectrum beta-lactamase</p><p>ESP end-systolic pressure</p><p>ESR erythrocyte sedimentation rate</p><p>ESRD end-stage renal disease</p><p>ESV end-systolic volume</p><p>ET endotracheal tube</p><p>essential thrombocythemia</p><p>EtOH alcohol</p><p>ETT endotracheal tube</p><p>exercise tolerance test</p><p>EUS endoscopic ultrasound</p><p>EVAR endovascular aneurysm repair</p><p>FDP fibrin degradation product</p><p>FEV1 forced expir. vol in 1 sec</p><p>FFP fresh frozen plasma</p><p>FHx family history</p><p>FI fusion inhibitor</p><p>FMD fibromuscular dysplasia</p><p>FMF familial Mediterranean fever</p><p>FNA fine-needle aspiration</p><p>FOB fecal occult blood</p><p>FOBT fecal occult blood testing</p><p>FQ fluoroquinolone</p><p>FRC functional residual capacity</p><p>FSGS focal segmental glomerulosclerosis</p><p>FSH follicle-stimulating hormone</p><p>FTI free thyroxine index</p><p>FUO fever of unknown origin</p><p>f/up follow-up</p><p>FVC forced vital capacity</p><p>G6PD glc-6-phosphate dehydrogenase</p><p>GB gallbladder</p><p>GBM glomerular basement membrane</p><p>GBS Guillain-Barré syndrome</p><p>GCA giant cell arteritis</p><p>GCS Glasgow coma scale</p><p>G-CSF granulocyte colony-stimulating factor</p><p>GE gastroesophageal</p><p>gen. generation</p><p>GERD gastroesophageal reflux disease</p><p>GFR glomerular filtration rate</p><p>GGT γ-glutamyl transpeptidase</p><p>GH growth hormone</p><p>GIB gastrointestinal bleed</p><p>GIST gastrointestinal stromal tumor</p><p>glc glucose</p><p>GMCSF granulocyte-macrophage colony-stimulating factor</p><p>GN glomerulonephritis</p><p>GNR gram-negative rods</p><p>GnRH gonadotropin-releasing hormone</p><p>GPA granulomatosis w/ polyangiitis</p><p>GPC gram-positive cocci</p><p>GPI glycoprotein IIb/IIIa inhibitor</p><p>GRA glucocorticoid-remediable aldosteronism</p><p>GU gastric ulcer</p><p>GVHD graft-versus-host disease</p><p>h hour</p><p>H2RA H2-receptor antagonist</p><p>HA headache</p><p>HACA human antichimeric antibody</p><p>HAV hepatitis A virus</p><p>Hb hemoglobin</p><p>HBIG hepatitis B immunoglobulin</p><p>HBV hepatitis B virus</p><p>HCC hepatocellular carcinoma</p><p>HCMP hypertrophic cardiomyopathy</p><p>Hct hematocrit</p><p>HCV hepatitis C virus</p><p>HCW health care worker</p><p>HD hemodialysis</p><p>HDL high-density lipoprotein</p><p>HDV hepatitis D virus</p><p>HELLP hemolysis, abnl LFTs, low plts</p><p>HEV hepatitis E virus</p><p>HF heart failure</p><p>HGPRT hypoxanthine-guanine phosphoribosyl transferase</p><p>HHS hyperosmolar hyperglycemic state</p><p>HIT heparin-induced thrombocytopenia</p><p>HK hypokinesis</p><p>HL Hodgkin lymphoma</p><p>h/o history of</p><p>HOB head of bed</p><p>HoTN hypotension</p><p>hpf high-power field</p><p>HPT hyperparathyroidism</p><p>HR heart rate</p><p>HRT hormone replacement therapy</p><p>HS hereditary spherocytosis</p><p>HSCT hematopoietic stem cell transplantation</p><p>HSM hepatosplenomegaly</p><p>HSP Henoch-Schönlein purpura</p><p>HSV herpes simplex virus</p><p>HTN hypertension</p><p>HUS hemolytic uremic syndrome</p><p>hx history</p><p>I&D incision & drainage</p><p>IABP intra-aortic balloon pump</p><p>IBD inflammatory bowel disease</p><p>IBS irritable bowel syndrome</p><p>IC inspiratory capacity</p><p>ICa ionized calcium</p><p>ICD implantable cardiac defibrillator</p><p>ICH intracranial hemorrhage</p><p>ICP intracranial pressure</p><p>ICU intensive care unit</p><p>IE infective endocarditis</p><p>IGF insulin-like growth factor</p><p>IGRA interferon-γ release assay</p><p>II integrase inhibitor</p><p>IIP idiopathic interstitial PNA</p><p>ILD interstitial lung disease</p><p>IMI inferior myocardial infarction</p><p>infxn infection</p><p>inh inhaled</p><p>INH isoniazid</p><p>INR international normalized ratio</p><p>IPAA ileal pouch-anal anastomosis</p><p>IPF idiopathic pulmonary fibrosis</p><p>ITP idiopathic thrombocytopenic purpura</p><p>IVB intravenous bolus</p><p>IVC inferior vena cava</p><p>IVDU intravenous drug use(r)</p><p>IVF intravenous fluids</p><p>IVIg intravenous immunoglobulin</p><p>JVD jugular venous distention</p><p>JVP jugular venous pulse</p><p>KS Kaposi’s sarcoma</p><p>KUB kidney-ureter-bladder (radiography)</p><p>LA left atrium</p><p>long-acting</p><p>lupus anticoagulant</p><p>LABA long-acting β2-agonist</p><p>LAD left anterior descending coronary artery</p><p>left axis deviation</p><p>LAE left atrial enlargement</p><p>LAN lymphadenopathy</p><p>LAP left atrial pressure</p><p>leukocyte alkaline phosphatase</p><p>LBBB left bundle branch block</p><p>LCA left coronary artery</p><p>LCIS lobular carcinoma in situ</p><p>LCx left circumflex cor. art.</p><p>LDH lactate dehydrogenase</p><p>LDL low-density lipoprotein</p><p>LE lower extremity</p><p>LES lower esophageal sphincter</p><p>LFTs liver function tests</p><p>LGIB lower gastrointestinal bleed</p><p>LGV lymphogranuloma venereum</p><p>LH luteinizing hormone</p><p>LLQ left lower quadrant</p><p>LM left main coronary artery</p><p>LMWH low-molecular-weight heparin</p><p>LN lymph node</p><p>LOC loss of consciousness</p><p>LOS length of stay</p><p>LP lumbar puncture</p><p>lpf low-power field</p><p>LQTS long QT syndrome</p><p>LR lactated Ringer’s</p><p>LUSB left upper sternal border</p><p>LV left ventricle</p><p>LVAD LV assist device</p><p>LVEDP LV end-diastolic pressure</p><p>LVEDV LV end-diastolic volume</p><p>LVESD LV end-systolic diameter</p><p>LVH left ventricular hypertrophy</p><p>LVOT left ventricular outflow tract</p><p>LVSD LV systolic dimension</p><p>mAb monoclonal antibody</p><p>MAC mitral annular calcification</p><p>Mycobacterium avium complex</p><p>MAHA microangiopathic hemolytic anemia</p><p>MALT mucosa-assoc. lymphoid tissue</p><p>MAO monoamine oxidase</p><p>MAP mean arterial pressure</p><p>MAT multifocal atrial tachycardia</p><p>MCD minimal change disease</p><p>MCP metacarpal phalangeal (joint)</p><p>MCS mechanical circulatory support</p><p>MCTD mixed connective tissue dis.</p><p>MCV mean corpuscular volume</p><p>MDI metered dose inhaler</p><p>MDMA 3,4-methylenedioxymetham- phetamine (Ecstasy)</p><p>MDR multidrug resistant</p><p>MDS myelodysplastic syndrome</p><p>MEN multiple endocrine neoplasia</p><p>MG myasthenia gravis</p><p>MGUS monoclonal gammopathy of uncertain significance</p><p>MI myocardial infarction</p><p>min minute</p><p>min. minimal</p><p>MM multiple myeloma</p><p>MMEFR max. mid-expir. flow rate</p><p>MMF mycophenolate mofetil</p><p>MN membranous nephropathy</p><p>MNZ metronidazole</p><p>mo month</p><p>mod. moderate</p><p>MODS multiple organ dysfxn synd.</p><p>MPA microscopic polyangiitis</p><p>MPGN membranoproliferative glomerulonephritis</p><p>MPN myeloproliferative neoplasm</p><p>MR magnetic resonance</p><p>mitral regurgitation</p><p>MRA magnetic resonance angiography</p><p>MRCP MR cholangiopancreatography</p><p>MRI magnetic resonance imaging</p><p>MRSA methicillin-resistant S. aureus</p><p>MS mitral stenosis</p><p>MSA multisystem atrophy</p><p>MSK musculoskeletal</p><p>MTb Mycobacterium tuberculosis</p><p>mTOR mechanistic target of rapamycin</p><p>MTP metatarsal phalangeal (joint)</p><p>MTX methotrexate</p><p>MV mitral valve</p><p>MVA mitral valve area</p><p>MVP mitral valve prolapse</p><p>MVR mitral valve replacement</p><p>Mϕ macrophage</p><p>NAC N-acetylcysteine</p><p>NAFLD non-alcoholic fatty liver disease</p><p>NASH non-alcoholic steatohepatitis</p><p>NG nasogastric</p><p>NGT nasogastric tube</p><p>NHL non-Hodgkin lymphoma</p><p>niCMP non-ischemic CMP</p><p>NIF negative inspiratory force</p><p>NJ nasojejunal</p><p>nl normal</p><p>NM neuromuscular</p><p>NMJ neuromuscular junction</p><p>NNRTI non-nucleoside reverse transcriptase inhibitor</p><p>NNT number needed to treat</p><p>NO nitric oxide</p><p>NPJT nonparoxysmal junctional tachycardia</p><p>NPO nothing by mouth</p><p>NPPV noninvasive positive pressure ventilation</p><p>NPV negative predictive value</p><p>NRTI nucleoside reverse transcriptase inhibitor</p><p>NS normal saline</p><p>NSAID nonsteroidal anti-inflam. drug</p><p>NSCLC non-small cell lung cancer</p><p>NSF nephrogenic systemic fibrosis</p><p>NTG nitroglycerin</p><p>N/V nausea and/or vomiting</p><p>NVE native valve endocarditis</p><p>NYHA New York Heart Association</p><p>O/D overdose</p><p>o/w otherwise</p><p>O&P ova & parasites</p><p>OA osteoarthritis</p><p>OCP oral contraceptive pill</p><p>OG osmolal gap</p><p>OGT orogastric tube</p><p>OGTT oral glucose tolerance test</p><p>OI opportunistic infection</p><p>OM obtuse marginal cor. art.</p><p>OS overall survival</p><p>OSA obstructive sleep apnea</p><p>OTC over-the-counter</p><p>p/w present(s) with</p><p>PA pulmonary artery</p><p>PAC pulmonary artery catheter</p><p>PAD peripheral artery disease</p><p>PAN polyarteritis nodosa</p><p>PASP PA systolic pressure</p><p>PAV percutaneous aortic valvuloplasty</p><p>pb problem</p><p>PBC primary biliary cholangitis</p><p>PCI percutaneous coronary intervention</p><p>PCN penicillin</p><p>PCP Pneumocystis jiroveci pneumonia</p><p>PCR polymerase chain reaction</p><p>PCT porphyria cutanea tarda</p><p>PCWP pulmonary capillary wedge pressure</p><p>PD Parkinson’s disease</p><p>peritoneal dialysis</p><p>PDA patent ductus arteriosus</p><p>posterior descending cor. art.</p><p>PE pulmonary embolism</p><p>PEA pulseless electrical activity</p><p>PEEP positive end-expiratory pressure</p><p>PEF peak expiratory flow</p><p>PET positron emission tomography</p><p>PEx physical examination</p><p>PFO patent foramen ovale</p><p>PFS progression-free survival</p><p>PFT pulmonary function test</p><p>PGA polyglandular autoimmune syndrome</p><p>PHT pulmonary hypertension</p><p>PI protease inhibitor</p><p>PID pelvic inflammatory disease</p><p>PIF prolactin inhibitory factor</p><p>PIP peak inspiratory pressure</p><p>proximal interphalangeal (joint)</p><p>PKD polycystic kidney disease</p><p>PM polymyositis</p><p>PMF primary myelofibrosis</p><p>PMHx past medical history</p><p>PMI point of maximal impulse</p><p>PML progressive multifocal leukoencephalopathy</p><p>PMN polymorphonuclear leukocyte</p><p>PMR polymyalgia rheumatica</p><p>PMV percutaneous mitral valvuloplasty</p><p>PMVT polymorphic ventricular tachycardia</p><p>PNA pneumonia</p><p>PND paroxysmal nocturnal dyspnea</p><p>PNH paroxysmal nocturnal hemoglobinuria</p><p>PNS peripheral nervous system</p><p>PO oral intake</p><p>POTS postural orthostatic tachycardia syndrome</p><p>PPD purified protein derivative</p><p>PPH primary pulmonary HTN</p><p>PPI proton pump inhibitors</p><p>Pplat plateau pressure</p><p>PPM permanent pacemaker</p><p>PPV positive predictive value</p><p>Ppx prophylaxis</p><p>PR PR segment on ECG</p><p>pulmonary regurgitation</p><p>PRBCs packed red blood cells</p><p>PRL prolactin</p><p>PRPP phosphoribosyl-I-pyrophosphate</p><p>PRWP poor R wave progression</p><p>PS pressure support</p><p>pulmonic stenosis</p><p>PSA prostate specific antigen</p><p>PsA Pseudomonas aeruginosa</p><p>PSC primary sclerosing cholangitis</p><p>PSGN post streptococcal glomerulonephritis</p><p>PSHx past surgical history</p><p>PSV pressure support ventilation</p><p>Pt patient</p><p>PT prothrombin time</p><p>PTA percutaneous transluminal angioplasty</p><p>PTH parathyroid hormone</p><p>PTH-rP PTH-related peptide</p><p>PTT partial thromboplastin time</p><p>PTU propylthiouracil</p><p>PTX pneumothorax</p><p>PUD peptic ulcer disease</p><p>PUVA psoralen + ultraviolet A</p><p>PV polycythemia vera</p><p>portal vein</p><p>PVD peripheral vascular disease</p><p>PVE prosthetic valve endocarditis</p><p>PVR pulmonary vascular resistance</p><p>PZA pyrazinamide</p><p>qac before every meal</p><p>qhs every bedtime</p><p>QoL quality of life</p><p>Qw Q wave</p><p>RA refractory anemia</p><p>rheumatoid arthritis</p><p>right atrium</p><p>RAA renin-angiotensin-aldosterone</p><p>RAD right axis deviation</p><p>RAE right atrial enlargement</p><p>RAI radioactive iodine</p><p>RAIU radioactive iodine uptake</p><p>RAS renal artery stenosis</p><p>RAST radioallergosorbent test</p><p>RBBB right bundle branch block</p><p>RBC red blood cell</p><p>RBF renal blood flow</p><p>RBV ribavirin</p><p>RCA right coronary artery</p><p>RCMP restrictive cardiomyopathy</p><p>RCT randomized controlled trial</p><p>RDW red cell distribution width</p><p>RE reticuloendothelial</p><p>RF rheumatoid factor</p><p>risk factor</p><p>RFA radiofrequency ablation</p><p>RHD rheumatic heart disease</p><p>r/i rule in</p><p>RI reticulocyte index</p><p>RIBA recombinant immunoblot assay</p><p>RMSF Rocky Mountain spotted fever</p><p>r/o rule out</p><p>ROS review of systems</p><p>RPGN rapidly progressive glomerulonephritis</p><p>RR respiratory rate</p><p>RRT renal replacement therapy</p><p>RT radiation therapy</p><p>RTA renal tubular acidosis</p><p>RTX rituximab</p><p>RUQ right upper quadrant</p><p>RUSB right upper sternal border</p><p>RV residual volume</p><p>right ventricle</p><p>RVAD RV assist device</p><p>RVH right ventricular hypertrophy</p><p>RVOT RV outflow tract</p><p>RVSP RV systolic pressure</p><p>Rx therapy</p><p>RYGB roux-en-Y gastric bypass</p><p>SA sinoatrial</p><p>SAAG serum-ascites albumin gradient</p><p>SAH subarachnoid hemorrhage</p><p>SB small bowel</p><p>SBE subacute bacterial endocarditis</p><p>SBO small bowel obstruction</p><p>SBP spontaneous bacterial peritonitis</p><p>systolic blood pressure</p><p>SBT spontaneous breathing trial</p><p>SC subcutaneous</p><p>SCD sudden cardiac death</p><p>SCID severe combined immunodefic.</p><p>SCLC small-cell lung cancer</p><p>s/e side effect</p><p>Se sensitivity</p><p>sec second</p><p>SERM selective estrogen receptor modulator</p><p>sev. severe</p><p>SHBG steroid hormone binding globulin</p><p>SIADH synd. of inappropriate ADH</p><p>SIBO small intestine bacterial overgrowth</p><p>SIEP serum immunoelectrophoresis</p><p>SIHD stable ischemic heart disease</p><p>SIMV synchronized intermittent mandatory ventilation</p><p>SIRS systemic inflammatory response syndrome</p><p>SJS Stevens-Johnson syndrome</p><p>SLE systemic lupus erythematosus</p><p>SMA superior mesenteric artery</p><p>SMV superior mesenteric vein</p><p>SMX sulfamethoxazole</p><p>SOS sinusoidal obstructive synd.</p><p>s/p status post</p><p>Sp specificity</p><p>SPEP serum protein electrophoresis</p><p>SR sinus rhythm</p><p>s/s signs and symptoms</p><p>SSCY Salmonella, Shigella, Campylobacter, Yersinia</p><p>SSRI selective serotonin reuptake inhibitor</p><p>SSS sick sinus syndrome</p><p>SSZ sulfasalazine</p><p>ST sinus tachycardia</p><p>STD ST-segment depression</p><p>STE ST-segment elevation</p><p>STI sexually transmitted infection</p><p>SV stroke volume</p><p>SVC superior vena cava</p><p>SVR systemic vascular resistance</p><p>SVT supraventricular tachycardia</p><p>sx symptom(s) or symptomatic</p><p>T1D type 1 diabetes mellitus</p><p>T2D type 2 diabetes mellitus</p><p>T3RU T3 resin uptake</p><p>TAA thoracic aortic aneurysm</p><p>TAVI transcatheter aortic valve implantation</p><p>TB tuberculosis</p><p>TBG thyroid binding globulin</p><p>TCA tricyclic antidepressant</p><p>TCD transcranial Doppler</p><p>TCN tetracycline</p><p>Tdap tetanus, diphtheria, pertussis</p><p>TdP torsades de pointes</p><p>TdT terminal deoxynucleotidyl transferase</p><p>TEE transesophageal echo</p><p>tfn transfusion</p><p>TFTs thyroid function tests</p><p>TG triglycerides</p><p>TGA transposition of the great arteries</p><p>TIA transient ischemic attack</p><p>TIBC total iron binding capacity</p><p>TINU tubulointerstitial nephritis and uveitis</p><p>TIPS transjugular intrahepatic portosystemic shunt</p><p>TKI tyrosine kinase inhibitor</p><p>TLC total lung capacity</p><p>TLS tumor lysis syndrome</p><p>TMP trimethoprim</p><p>Tn troponin</p><p>TP total protein</p><p>TPMT thiopurine methyltransferase</p><p>TPN total parenteral nutrition</p><p>Tpo thrombopoietin</p><p>TPO thyroid peroxidase</p><p>TR tricuspid regurgitation</p><p>TRALI transfusion-related acute lung injury</p><p>TRH thyrotropin-releasing hormone</p><p>TRS TIMI risk score</p><p>TRUS transrectal ultrasound</p><p>TS tricuspid stenosis</p><p>TSH thyroid-stimulating hormone</p><p>TSI thyroid-stimulating immunoglobulin</p><p>TSS toxic shock syndrome</p><p>transsphenoidal surgery</p><p>TTE transthoracic echo</p><p>TTKG transtubular potassium gradient</p><p>TTP thrombotic thrombocytopenic purpura</p><p>TV tricuspid valve</p><p>Tw T wave</p><p>TWF T-wave flattening</p><p>TWI T-wave inversion</p><p>Tx transplant</p><p>TZD thiazolidinediones</p><p>U/A urinalysis</p><p>UA unstable angina</p><p>UAG urine anion gap</p><p>UC ulcerative colitis</p><p>UCx urine culture</p><p>UES upper esophageal sphincter</p><p>UFH unfractionated heparin</p><p>UGIB upper gastrointestinal bleed</p><p>UIP usual interstitial pneumonitis</p><p>ULN upper limit of normal</p><p>UOP urine output</p><p>UPEP urine protein electrophoresis</p><p>UR urgent revascularization</p><p>UrA uric acid</p><p>URI upper resp. tract infxn</p><p>U/S ultrasound</p><p>UTI urinary tract infection</p><p>V/Q ventilation-perfusion</p><p>VAD ventricular assist device</p><p>VAP ventilator-associated PNA</p><p>VATS video-assisted thoracoscopic surgery</p><p>VBI vertebrobasilar insufficiency</p><p>VC vital capacity</p><p>VD vessel disease</p><p>VDRL venereal disease research laboratory (test for syphilis)</p><p>VEGF vascular endothelial growth factor</p><p>VEXAS vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic</p><p>VF ventricular fibrillation</p><p>VLDL very-low-density lipoproteins</p><p>VOD veno-occlusive disease</p><p>VS vital signs</p><p>VSD ventricular septal defect</p><p>Vt tidal volume</p><p>VT ventricular tachycardia</p><p>VTE venous thromboembolus</p><p>vWD von Willebrand’s disease</p><p>vWF von Willebrand’s factor</p><p>VZV varicella zoster virus</p><p>w/ with</p><p>WBC white blood cell (count)</p><p>WCT wide-complex tachycardia</p><p>WHO World Health Organization</p><p>wk week</p><p>WM Waldenström’s macroglobulinemia</p><p>WMA wall motion abnormality</p><p>w/o without</p><p>WPW Wolff-Parkinson-White syndrome</p><p>w/u workup</p><p>XRT radiation therapy</p><p>INDEX</p><p>A</p><p>A-a gradient, 2-18, 11-6</p><p>abdominal CT scan, P-7</p><p>abdominal pain, 10-1</p><p>accessory pathway, 1-34</p><p>acetaminophen</p><p>as cause of metabolic acidosis, 4-2</p><p>hepatotoxicity, 3-19</p><p>achalasia, 3-1</p><p>acid-base disturbances, 4-1</p><p>acquired immunodeficiency syndrome (AIDS), 6-18</p><p>acromegaly, 7-2</p><p>activated protein C resistance, 5-11</p><p>acute abdomen, 10-1</p><p>acute aortic syndrome, 1-32</p><p>acute coronary syndromes, 1-7</p><p>acute interstitial nephritis, 4-12, 4-13</p><p>acute kidney injury, 4-12</p><p>acute respiratory distress syndrome (ARDS), 2-22</p><p>acute tubular necrosis, 4-12</p><p>Addison’s disease, 7-9</p><p>adnexal mass, non-pregnant woman, 10-3</p><p>adrenal disorders, 7-7</p><p>adrenal incidentalomas, 7-10</p><p>adrenal insufficiency, 7-9</p><p>adrenal mass, 7-10</p><p>advanced cardiac life support, ACLS-1</p><p>albuminuria, 4-14</p><p>alcohol withdrawal, 9-5</p><p>allergic bronchopulmonary aspergillosis, 2-10</p><p>alpha1-antitrypsin deficiency</p><p>as cause of cirrhosis, 3-24</p><p>as cause of COPD, 2-5</p><p>alveolar gas equation, 11-6</p><p>amaurosis fugax, 9-6</p><p>amiodarone, thyroid disease and, 7-6</p><p>amyloidosis, 8-22</p><p>cardiac manifestations, 1-20</p><p>anaphylaxis, 2-4</p><p>anaplasmosis, 6-22</p><p>anemia, 5-1</p><p>aplastic, 5-3</p><p>autoimmune hemolytic, 5-5, P-13</p><p>of chronic inflammation, 5-2</p><p>Cooley’s, 5-2</p><p>Fanconi’s, 5-3</p><p>folate deficiency, 5-3</p><p>hemolytic, 5-4</p><p>iron deficiency, 5-1, P-13</p><p>macrocytic, 5-3</p><p>megaloblastic, 5-3, P-13</p><p>microangiopathic hemolytic, 5-5</p><p>microcytic, 5-1</p><p>myelophthisic, 5-4</p><p>normocytic, 5-2</p><p>pernicious, 5-3</p><p>sickle cell, 5-4, P-14</p><p>sideroblastic, 5-2</p><p>vitamin B12 deficiency, 5-3</p><p>angina, 1-3, 1-7</p><p>angioectasia, 3-4</p><p>angioedema, 2-4</p><p>angioplasty, 1-5</p><p>animal bites, 6-7</p><p>anion gap, 4-2, 11-7</p><p>ankylosing spondylitis, 8-7</p><p>anoxic brain injury, 9-2</p><p>antibiotics, 11-3</p><p>antibodies</p><p>anticardiolipin, 5-11, 8-16</p><p>anti-centromere, 8-11</p><p>anti-cyclic citrullinated peptide (CCP), 8-3</p><p>anti-ds-DNA, 8-15</p><p>anti-GBM, 4-17</p><p>anti-histone, 8-15</p><p>anti-Jo-1, 8-13</p><p>anti-La, 8-14, 8-15</p><p>anti-Mi-2, 8-13</p><p>antimitochondrial, 3-24</p><p>anti-MPO, 4-17, 8-18</p><p>antineutrophil cytoplasmic (ANCA), 4-17, 8-18</p><p>antinuclear (ANA), 8-2, 8-15</p><p>antiphospholipid, 5-11</p><p>anti-PR3, 4-17, 8-18</p><p>anti-Ro, 8-14, 8-15</p><p>anti-Scl-70, 8-12</p><p>anti-Sm, 8-15</p><p>anti-smooth muscle, 3-19</p><p>anti-SRP, 8-13</p><p>anti-TPO, 7-4, 7-5</p><p>anti-U1-RNP, 8-14, 8-15</p><p>autoantibodies, 8-2</p><p>in connective tissue diseases, 8-11</p><p>anticoagulants, 5-6, 5-10</p><p>anti-GBM disease, as cause of glomerulonephritis, 4-17</p><p>antiphospholipid syndrome, 5-11</p><p>aortic aneurysm, 1-31</p><p>aortic dissection, 1-32</p><p>aortic regurgitation, 1-22</p><p>aortic stenosis, 1-21</p><p>aortoenteric fistula, 3-4</p><p>arrhythmias, 1-33</p><p>arthralgias, 8-1</p><p>arthritis, 8-1</p><p>IBD-associated (enteropathic), 8-7</p><p>infectious, 8-9</p><p>osteoarthritis, 8-1</p><p>psoriatic, 8-7</p><p>reactive, 8-7</p><p>rheumatoid, 8-3</p><p>asbestosis, 2-10</p><p>ascites, 3-26</p><p>treatment of, in cirrhotics, 3-21</p><p>aspergillosis, 6-3</p><p>asplenia, 6-4</p><p>asthma, 2-2</p><p>atrial fibrillation, 1-33, 1-36</p><p>atrial flutter, 1-33, 1-37</p><p>Auer rod, 5-17</p><p>autoimmune polyglandular syndromes (APS), 7-2</p><p>auto-PEEP, 2-20</p><p>AV block, 1-33</p><p>AV dissociation, 1-33</p><p>B</p><p>babesiosis, 6-21</p><p>bacillary angiomatosis, 6-19</p><p>back pain, 9-11</p><p>bacteremia, 6-13</p><p>Barrett’s esophagus, 3-2</p><p>Bartter’s syndrome, 4-5, 4-10, 7-8</p><p>basophilia, 5-12</p><p>basophilic stippling, 5-2, 11-8</p><p>Beck’s triad, 1-27</p><p>Behçet’s syndrome, 8-21</p><p>Bell’s palsy, 6-12</p><p>Bernard-Soulier disease, 5-9</p><p>berylliosis, 2-10</p><p>bilevel positive airway pressure (BiPAP), 2-19</p><p>biliary tract disease, 3-27</p><p>bite cells, 5-4, 11-7</p><p>biventricular pacing; see cardiac resynchronization therapy</p><p>blastomycosis, 6-4</p><p>body surface area, 11-9</p><p>Boerhaave syndrome, 1-3</p><p>bone marrow transplantation, 5-25</p><p>bradycardia, 1-33</p><p>breast cancer, 5-29</p><p>Brockenbrough sign, 1-19</p><p>bronchiectasis, 2-8</p><p>bronchitis, chronic, 2-5</p><p>Brudzinski’s sign, 6-10</p><p>Brugada syndrome, 1-35</p><p>B-type natriuretic peptide, 1-15, 2-1</p><p>Budd-Chiari syndrome, 3-25</p><p>bundle branch blocks, 1-1</p><p>burr cells, 11-7</p><p>bursitis, 8-1, 8-10</p><p>C</p><p>calciphylaxis, 4-14</p><p>calcium disorders, 7-11</p><p>calcium pyrophosphate dehydrate deposition disease, 8-6</p><p>Cameron’s lesions, 3-4</p><p>Candida species, 6-3</p><p>carbon monoxide poisoning, 2-18</p><p>carcinoid, 3-7</p><p>cardiac output, 1-13, 11-5</p><p>cardiac resynchronization therapy, 1-17, 1-40</p><p>cardiac shunt, 11-5</p><p>cardiomyopathy, 1-18</p><p>arrhythmogenic RV, 1-18, 1-35</p><p>dilated, 1-18</p><p>hypertrophic, 1-19</p><p>peripartum, 1-18</p><p>restrictive, 1-20</p><p>Takotsubo, 1-18</p><p>vs. constrictive pericarditis, 1-28</p><p>cardiorenal syndrome, 4-13</p><p>carotid revascularization, 9-7</p><p>cat scratch disease, 6-7</p><p>cauda equina syndrome, 9-11</p><p>celiac disease, 3-7</p><p>cellulitis, 6-7</p><p>central line associated</p><p>bloodstream infection, 6-13</p><p>cerebrovascular disease, 9-6</p><p>Chagas, 1-18</p><p>chancroid, 6-6</p><p>Charcot’s triad, 3-28</p><p>Chediak-Higashi syndrome, 5-9</p><p>chemotherapy side effects, 5-38</p><p>chest pain, 1-3</p><p>chest tubes, 10-2</p><p>Chikungunya, 6-24</p><p>Child-Turcotte-Pugh scoring system, 11-7</p><p>chimeric antigen receptor (CAR)-T cells, 5-36</p><p>cholangitis, 3-28</p><p>cholecystitis, 3-27</p><p>choledocholithiasis, 3-28</p><p>cholelithiasis, 3-27</p><p>cholera, 3-5</p><p>cholestasis, 3-16</p><p>cholesterol emboli syndrome, 1-5</p><p>chronic kidney disease, 4-13</p><p>chronic obstructive pulmonary disease (COPD), 2-5, P-1</p><p>Churg-Strauss syndrome; see eosinophilic granulomatosis with polyangiitis</p><p>Chvostek’s sign, 7-12</p><p>cirrhosis, 3-21</p><p>claudication, neurogenic vs. vascular, 9-12</p><p>clinical institute withdrawal assessment for alcohol (CIWA-Ar), 11-9</p><p>clostridial myonecrosis, 6-8</p><p>Clostridioides difficile infection, 3-6</p><p>CNS tumors, 5-35</p><p>coagulation cascade, 5-6</p><p>coagulopathies, 5-10</p><p>coarctation of aorta, 1-29</p><p>coccidioidomycosis, 6-4</p><p>cold caloric, 9-1</p><p>colonic polyps, 3-9</p><p>colonic pseudo-obstruction, 3-8</p><p>colonoscopy, screening, 5-32</p><p>colorectal cancer (CRC), 5-32</p><p>coma, 9-1</p><p>compartment syndrome, 10-2</p><p>confusion, 9-1</p><p>connective tissue diseases, 8-11</p><p>Conn’s syndrome, 7-8</p><p>constipation, 3-8</p><p>constrictive pericarditis, 1-28</p><p>continuous positive airway pressure (CPAP), 2-19, 2-20</p><p>continuous veno-venous hemofiltration, 4-16</p><p>contrast-induced acute kidney injury, 4-13</p><p>conus medullaris syndrome, 9-11</p><p>cord compression, 5-37, 9-11</p><p>coronary angiography, 1-5, P-13</p><p>computed tomographic, 1-4</p><p>coronary arteries, P-13</p><p>coronary artery bypass grafting (CABG), 1-6</p><p>coronary artery calcium score, 1-4</p><p>coronary revascularization, 1-5, 1-6</p><p>Courvoisier’s sign, 5-33</p><p>COVID-19, 6-2</p><p>creatinine clearance, 11-7</p><p>CREST syndrome, 8-12</p><p>Crohn’s disease, 3-10</p><p>cryoglobulinemia, 8-20</p><p>Cryptococcus, 6-3</p><p>crystal deposition arthritides, 8-5</p><p>Cullen’s sign, 3-13</p><p>Cushing’s reflex, 3-20</p><p>Cushing’s syndrome, 7-7</p><p>cutaneous leukocytoclastic angiitis, 8-20</p><p>CXR/chest CT scan, P-1, P-5</p><p>cyanide poisoning, 2-18</p><p>cyanosis, 2-18</p><p>cyclic vomiting syndrome, 3-8</p><p>cystic fibrosis, 2-8</p><p>cystitis, 6-5</p><p>cytomegalovirus, 6-20</p><p>D</p><p>dactylitis, 8-7</p><p>decubitus ulcer, 10-2</p><p>deep venous thrombosis, 2-13</p><p>delirium, 9-1</p><p>delirium tremens, 9-5</p><p>delta-delta, 4-2, 11-7</p><p>dementia, 9-1</p><p>dengue, 6-24</p><p>dermatomyositis, 8-13</p><p>diabetes insipidus, 4-8, 4-9</p><p>diabetes mellitus, 7-13</p><p>diabetic foot, 6-8</p><p>diabetic ketoacidosis (DKA), 7-14</p><p>diarrhea, 3-5</p><p>Dieulafoy’s lesion, 3-4</p><p>diffuse alveolar damage, 2-22</p><p>diffuse alveolar hemorrhage, 2-10, 5-26</p><p>diplopia, 10-4</p><p>direct oral anticoagulants (DOACs), 5-10</p><p>disc herniation, 9-12</p><p>discriminant function, 3-19</p><p>disseminated gonococcal arthritis, 8-10</p><p>disseminated intravascular coagulation (DIC), 5-10</p><p>diuresis, 4-15</p><p>diverticular disease, 3-9</p><p>dizziness, 9-5</p><p>Döhle bodies, 5-12, 11-8</p><p>doll’s eyes, 9-1</p><p>donovanosis; see granuloma inguinale</p><p>Dressler’s syndrome, 1-12, 1-26</p><p>Duke treadmill score, 1-4</p><p>duodenal ulcer, 3-2</p><p>dyslipidemias, 7-16</p><p>dysphagia, 3-1</p><p>dyspnea, 2-1</p><p>E</p><p>Eaton-Lambert syndrome, 5-27, 9-9</p><p>Ebola, 6-24</p><p>echocardiography, P-9</p><p>Ehlers-Danlos syndrome, 1-31, 1-32</p><p>ehrlichiosis, 6-22</p><p>electrocardiography, 1-1</p><p>emphysema, 2-5</p><p>encephalitis, viral, 6-12</p><p>endocarditis, 6-13</p><p>endomyocardial fibrosis, 1-20</p><p>enthesitis, 8-7</p><p>eosinophilia, 5-12</p><p>eosinophilic granulomatosis with polyangiitis, 8-19</p><p>as cause of asthma, 2-2</p><p>as cause of glomerulonephritis, 4-17</p><p>as cause of interstitial lung disease, 2-10</p><p>epidural abscess, 6-9</p><p>epidural hematoma, 9-7</p><p>epilepsy, 9-3</p><p>erosive gastropathy, 3-3</p><p>erythema migrans, 6-21</p><p>erythema multiforme, 6-23</p><p>erythema nodosum, 2-9, 6-24, 8-8</p><p>erythrocyte sedimentation rate, 8-2</p><p>erythromelalgia, 5-15</p><p>esophageal cancer, 5-34</p><p>esophageal reflux, 3-1</p><p>esophageal ring, 3-1</p><p>esophageal spasm, 1-3</p><p>esophageal web, 3-1</p><p>esophagitis, 3-1, 3-4</p><p>essential thrombocythemia, 5-16</p><p>ethylene glycol intoxication, 4-2</p><p>exercise tolerance test, 1-4</p><p>F</p><p>factor V Leiden, 5-11</p><p>familial adenomatous polyposis, 5-32</p><p>familial hypocalciuric hypercalcemia, 7-11</p><p>familial Mediterranean fever, 6-23, 8-21</p><p>Fanconi’s syndrome, 4-3</p><p>Felty’s syndrome, 8-3</p><p>fever</p><p>neutropenia and, 5-37</p><p>Pel-Ebstein, 5-20</p><p>syndromes, 6-23</p><p>fibromyalgia, 8-14</p><p>Fitz-Hugh-Curtis syndrome, 8-10</p><p>focal segmental glomerulosclerosis, 4-18</p><p>folate deficiency, 5-3</p><p>food poisoning, 3-5</p><p>Fournier’s gangrene, 6-8</p><p>fractional excretion of Na, 4-12, 11-7</p><p>fractional flow reserve (FFR), 1-5</p><p>free H2O deficit, 4-8, 11-7</p><p>fungal infections, 6-3</p><p>G</p><p>Gaisböck’s syndrome, 5-15</p><p>Gallavardin effect, 1-21</p><p>gallstone ileus, 3-27</p><p>gas gangrene, 6-8</p><p>gastric antral vascular ectasia, 3-4</p><p>gastric cancer, 5-34</p><p>gastric ulcer, 3-2</p><p>gastroesophageal reflux disease (GERD), 3-1</p><p>gastrointestinal bleeding, 3-3</p><p>gastroparesis, 3-8</p><p>gastrostomy tubes, 10-2</p><p>genital herpes, 6-6</p><p>giant cell arteritis, 8-17</p><p>Gitelman’s syndrome, 4-5, 4-10, 7-8</p><p>Glanzmann’s thromboasthenia, 5-9</p><p>Glasgow Coma Scale, 9-1</p><p>glaucoma, 10-4</p><p>glomerulonephritis, 4-17</p><p>glucose-6-phosphate dehydrogenase (G6PD) deficiency, 5-4</p><p>glycemic control, in critical care, 2-23</p><p>goiter, 7-3, 7-5</p><p>Goodpasture’s syndrome</p><p>as cause of alveolar hemorrhage, 2-10</p><p>as cause of glomerulonephritis, 4-17</p><p>Gottron’s papules, 8-13</p><p>gout, 8-5</p><p>graft-versus-host disease (GVHD), 5-25, 5-26</p><p>granuloma inguinale, 6-6</p><p>granulomatosis with polyangiitis, 8-18</p><p>as cause of glomerulonephritis, 4-17</p><p>as cause of interstitial lung disease, 2-10</p><p>Graves’ disease, 7-5</p><p>Grey Turner’s sign, 3-13</p><p>Guillain-Barré syndrome, 9-8</p><p>H</p><p>Hamman-Rich syndrome, 2-10</p><p>headache, 9-10</p><p>heart failure, 1-15</p><p>with preserved EF, 1-17</p><p>with reduced EF, 1-16</p><p>Heinz bodies, 5-4, 11-8</p><p>Helicobacter pylori infection, 3-2</p><p>heliotrope rash, 8-13</p><p>hematemesis, 3-3</p><p>hematochezia, 3-3</p><p>hematopoietic stem cell transplantation, 5-25</p><p>hematuria, 4-20</p><p>hemochromatosis</p><p>as cause of cirrhosis, 3-23</p><p>as cause of DCM, 1-18</p><p>as cause of RCM, 1-20</p><p>hemodialysis, 4-16</p><p>hemolytic-uremic syndrome, 5-9</p><p>hemophagocytic lymphohistiocytosis, 8-21</p><p>hemophilia, 5-10</p><p>hemoptysis, 2-7</p><p>hemostasis disorders, 5-6</p><p>Henoch-Schönlein purpura, 8-19</p><p>as cause of glomerulonephritis, 4-17</p><p>heparin</p><p>nomograms, 11-8</p><p>reversal, 5-10</p><p>heparin-induced thrombocytopenia, 5-8</p><p>hepatic encephalopathy, 3-22</p><p>hepatic hydrothorax, 2-12, 3-22</p><p>hepatitis, 3-17</p><p>alcoholic, 3-19</p><p>autoimmune, 3-19</p><p>ischemic, 3-19</p><p>viral, 3-17</p><p>hepatocellular carcinoma, 3-23, 5-34</p><p>hepatopulmonary syndrome, 3-23</p><p>hepatorenal syndrome, 3-22</p><p>hereditary nonpolyposis colorectal cancer, 5-32</p><p>hereditary spherocytosis, 5-5</p><p>Hermansky-Pudlak syndrome, 5-9</p><p>herpes zoster, 6-12</p><p>Heyde syndrome, 3-4, 5-9</p><p>histoplasmosis, 6-4</p><p>Howell-Jolly bodies, 5-5, 11-8</p><p>human immunodeficiency virus (HIV), 6-18</p><p>hyperaldosteronism, 7-8</p><p>as cause of hypokalemia, 4-10</p><p>as cause of metabolic alkalosis, 4-4</p><p>hyperbilirubinemia, 3-15</p><p>hypercalcemia, 7-11</p><p>hypercapnia, 2-18</p><p>hypercholesterolemia, 7-16</p><p>hypercoagulable states, 5-11</p><p>hypercortisolism, 7-7</p><p>hyperhomocysteinemia, 5-11</p><p>hyperkalemia, 4-11</p><p>hypernatremia, 4-8</p><p>hyperosmolar hyperglycemic state, 7-15</p><p>hyperparathyroidism, 7-11</p><p>secondary, 4-14</p><p>hyperpituitary syndrome, 7-1</p><p>hyperprolactinemia, 7-2</p><p>hypertension, 1-29</p><p>hypertensive crisis, 1-30</p><p>hyperthyroidism, 7-4</p><p>hypertriglyceridemia, 7-16</p><p>hypertrophic pulmonary</p><p>osteoarthropathy, 5-27</p><p>hypoaldosteronism, 7-9</p><p>as cause of hyperkalemia, 4-11</p><p>as cause of metabolic acidosis, 4-3</p><p>hypocalcemia, 7-12</p><p>hypoglycemia, 7-15</p><p>hypokalemia, 4-10</p><p>hypomagnesemia, 4-11</p><p>hyponatremia, 4-6</p><p>hypoparathyroidism, 7-12</p><p>hypopituitary syndromes, 7-1</p><p>hypothyroidism, 7-3</p><p>hypoxemia, 2-18</p><p>I</p><p>ICU medications, 11-1</p><p>ideal body weight, 11-9</p><p>IgA nephropathy, 4-18</p><p>IgG4-related disease, 8-16</p><p>ileus, 3-8</p><p>immune checkpoint inhibitors, 5-36</p><p>immune thrombocytopenic purpura, 5-7</p><p>immunotherapy side effects, 5-37</p><p>implantable cardiac defibrillator, 1-17, 1-40</p><p>infections in susceptible hosts, 6-4</p><p>inflammatory bowel disease, 3-10</p><p>inflammatory markers, 8-2</p><p>influenza, 6-2</p><p>instantaneous wave-free ratio (iFR), 1-5</p><p>interstitial lung disease, 2-9</p><p>intestinal ischemia, 3-12</p><p>intracranial hemorrhage (ICH), 9-7</p><p>intraductal papillary mucinous neoplasm, 5-33</p><p>intramural hematoma (aortic), 1-32</p><p>iron deficiency, 5-1</p><p>irritable bowel syndrome (IBS), 3-7, 3-8</p><p>ischemic colitis, 3-12</p><p>isopropyl alcohol intoxication, 4-3</p><p>J</p><p>Janeway lesions, 6-14</p><p>jaundice, 3-15</p><p>Jod-Basedow effect, 7-6</p><p>joint fluid, analysis, 8-1</p><p>K</p><p>Kaposi’s sarcoma, 6-20</p><p>keratoderma blennorrhagica, 8-8</p><p>Kernig’s sign, 6-10</p><p>ketoacidosis, 4-2</p><p>kidney transplantation, 4-16</p><p>koilonychia, 5-1</p><p>Kussmaul’s sign, 1-28</p><p>L</p><p>lactic acidosis, 4-2</p><p>lactose intolerance, 3-6</p><p>Lady Windermere syndrome, 2-8</p><p>Langerhans cell granulomatosis, 2-10</p><p>left ventricular hypertrophy, 1-1</p><p>left ventricular noncompaction, 1-18</p><p>left ventricular thrombus, 1-12</p><p>leukemia, 5-17, P-14</p><p>acute lymphoblastic, 5-18</p><p>acute myelogenous, 5-17</p><p>acute promyelocytic, 5-18</p><p>chronic lymphocytic, 5-22</p><p>chronic myelogenous, 5-19</p><p>hairy cell, 5-21</p><p>leukostasis, 5-17</p><p>Liddle’s syndrome, 4-5, 4-10, 7-8</p><p>Light’s criteria, 2-11</p><p>limb ischemia, acute, 1-42, 10-1</p><p>lipodystrophy, 6-19</p><p>liver failure, 3-20</p><p>liver tests, abnormal, 3-15</p><p>liver transplantation, 3-23</p><p>Loeys-Dietz syndrome, 1-31, 1-32</p><p>Löffler’s endocarditis, 1-20</p><p>Löffler’s syndrome, 2-10</p><p>Löfgren’s syndrome, 2-9</p><p>long QT syndrome, 1-1, 1-35</p><p>lung cancer, 5-27</p><p>lung transplantation, 2-24</p><p>lupus anticoagulant, 5-11</p><p>lupus pernio, 2-9</p><p>Lyme disease, 6-21</p><p>lymphadenopathy, 5-12</p><p>lymphangioleiomyomatosis, 2-10</p><p>lymphocytosis, 5-12</p><p>lymphogranuloma venereum, 6-6</p><p>lymphoma, 5-20</p><p>CNS, 6-20</p><p>Hodgkin, 5-20</p><p>non-Hodgkin, 5-21</p><p>small lymphocytic, 5-22</p><p>M</p><p>macro-ovalocytes, 5-3</p><p>malabsorption, 3-7</p><p>malaria, 6-24</p><p>Mallory-Weiss tear, 1-3, 3-4</p><p>mammography, 5-29</p><p>Marfan syndrome, 1-31, 1-32</p><p>mechanical circulatory support, 1-16</p><p>mechanical ventilation, 2-19</p><p>mechanic’s hands, 8-13</p><p>Meckel’s diverticulum, 3-4</p><p>Meigs’ syndrome, 2-11, 3-26</p><p>melanoma, 5-34</p><p>MELD score, 3-21</p><p>melena, 3-3</p><p>membranoproliferative glomerulonephritis, 4-18</p><p>membranous nephropathy, 4-18</p><p>Meniere’s disease, 9-5</p><p>meningitis</p><p>acute bacterial, 6-10</p><p>aseptic, 6-11</p><p>mental status, change in, 9-1</p><p>mesenteric ischemia, acute, 3-12</p><p>metabolic acidosis, 4-2</p><p>metabolic alkalosis, 4-4</p><p>metabolic syndrome, 7-16</p><p>methanol intoxication, 4-2</p><p>methemoglobinemia, 2-18</p><p>microscopic colitis, 3-7</p><p>microscopic polyangiitis, 8-19</p><p>as cause of glomerulonephritis, 4-17</p><p>as cause of interstitial lung disease, 2-10</p><p>migraine headache, 9-10</p><p>milk-alkali syndrome, 7-11</p><p>minimal change disease, 4-18</p><p>Mirizzi syndrome, 3-27</p><p>mitral regurgitation, 1-23</p><p>mitral stenosis, 1-24</p><p>mitral valve prolapse, 1-24</p><p>mixed connective tissue disease (MCTD), 8-14</p><p>molluscum contagiosum, 6-19</p><p>monoclonal gammopathy of uncertain significance, 5-23</p><p>monocytosis, 5-12</p><p>mucinous cystic neoplasm of pancreas, 5-33</p><p>Mucor infection, 6-3</p><p>multiple endocrine neoplasia (MEN) syndromes, 7-2</p><p>multiple myeloma, 5-23</p><p>murmurs, eponymous</p><p>Austin Flint, 1-22</p><p>Graham Steel, 2-14, 2-16</p><p>Murphy’s sign, 3-27</p><p>myalgias, 8-14</p><p>myasthenia gravis, 9-9</p><p>Mycobacterium avium complex, disseminated, 6-20</p><p>mycosis fungoides, 5-21</p><p>myelodysplastic syndromes, 5-14</p><p>myelofibrosis, primary, 5-16</p><p>myeloid neoplasms, 5-14</p><p>myeloproliferative neoplasms, 5-15</p><p>myocardial infarction (MI)</p><p>non-ST elevation, 1-8</p><p>ST elevation, 1-10</p><p>myocardial viability, 1-4</p><p>myocarditis, 1-18</p><p>myopathies, 8-13, 9-9</p><p>myositis, 8-12</p><p>myxedema, 7-4</p><p>N</p><p>necrotizing fasciitis, 6-8</p><p>nephrogenic systemic fibrosis, 4-13</p><p>nephrolithiasis, 4-20</p><p>nephrotic syndrome, 4-18</p><p>nerve root compression, 9-11</p><p>neuropathies, 9-8</p><p>neutropenia, 5-12, 5-37, 6-4</p><p>neutropenic enterocolitis, 5-37</p><p>neutrophilia, 5-12</p><p>New York Heart Association classification, 1-15</p><p>nonalcoholic fatty liver disease (NAFLD), 3-19</p><p>noninvasive ventilation, 2-19</p><p>non-TB mycobacterium, 2-8</p><p>nutrition, in hospitalized Pt, 3-8</p><p>O</p><p>ocular motor palsies, 10-4</p><p>oculocephalic maneuver, 9-1</p><p>Ogilvie’s syndrome, 3-8</p><p>optic neuritis, 10-4</p><p>optic neuropathy, ischemic, 10-4</p><p>oral hairy leukoplakia, 6-19</p><p>orbital cellulitis, 10-4</p><p>orthostatic hypotension, 1-38</p><p>Osler’s nodes, 6-14</p><p>osmolal gap, 4-3, 11-7</p><p>osteoarthritis, 8-1</p><p>osteomyelitis, 6-9</p><p>ovarian cancer, 5-35</p><p>P</p><p>pacemakers, 1-40</p><p>Paget’s disease</p><p>of bone, 7-11</p><p>of breast, 5-29</p><p>Pancoast’s syndrome, 5-27</p><p>pancreatic cancer, 5-33</p><p>pancreatic insufficiency, 3-7</p><p>pancreatitis, 3-13</p><p>pancytopenia, 5-3</p><p>panhypopituitarism, 7-1</p><p>papillary muscle rupture, 1-11</p><p>Pappenheimer bodies, 5-2</p><p>paroxysmal nocturnal hemoglobinuria, 5-4</p><p>patent foramen ovale, 9-7</p><p>PEEP, 2-20, 2-22</p><p>peptic ulcer disease (PUD), 1-3, 3-2, 3-3</p><p>percutaneous coronary intervention (PCI), 1-5, 1-6</p><p>pericardial effusion, 1-26</p><p>pericardial tamponade, 1-27</p><p>pericarditis, 1-26</p><p>periodic paralysis</p><p>hyperkalemic, 4-11</p><p>hypokalemic, 4-10</p><p>peripheral arterial disease, 1-42</p><p>peripheral smear, findings in, 11-7</p><p>peritoneal dialysis, 4-16</p><p>peritonitis, 3-26</p><p>petechiae, 5-6</p><p>pheochromocytoma, 7-10</p><p>phlegmasia cerulea dolens, 2-13</p><p>pica, 5-1</p><p>pituitary disorders, 7-1</p><p>pituitary tumors, 7-1</p><p>plasma cell dyscrasias, 5-23</p><p>platelet disorders, 5-7</p><p>pleural effusion, 2-11, P-4</p><p>pleuritis, 1-3</p><p>Plummer-Vinson syndrome, 5-1</p><p>pneumoconioses, 2-10</p><p>Pneumocystis jiroveci pneumonia, 6-20</p><p>pneumonia, 6-1, P-2</p><p>cryptogenic organizing, 2-10</p><p>eosinophilic, 2-10</p><p>hypersensitivity, 2-10</p><p>interstitial, 2-10</p><p>pneumothorax, 1-3, P-4</p><p>POEMS syndrome, 5-23</p><p>polyarteritis nodosa, 8-18</p><p>polycystic kidney disease, 4-13</p><p>polycythemia vera, 5-15</p><p>polydipsia, 4-9</p><p>polymyalgia rheumatica, 8-13, 8-18</p><p>polymyositis, 8-12</p><p>polyuria, 4-9</p><p>porphyria cutanea tarda, 3-18</p><p>portal hypertension, 3-21, 3-26</p><p>portal vein thrombosis (PVT), 3-25</p><p>portopulmonary hypertension, 2-16, 3-23</p><p>postural orthostatic tachycardia syndrome (POTS), 1-38</p><p>Pott’s disease, 6-9, 6-16</p><p>preexcitation, 1-34</p><p>pregnancy, ectopic, 10-3</p><p>preoperative risk assessment, 1-41</p><p>prerenal azotemia, 4-12</p><p>primary biliary cholangitis, 3-24</p><p>primary sclerosing cholangitis, 3-24</p><p>Prinzmetal’s angina, 1-7</p><p>progressive multifocal leukoencephalopathy, 6-20</p><p>prolactinoma, 7-1, 7-2</p><p>propofol infusion syndrome, 2-21</p><p>propylene glycol intoxication, 4-2</p><p>prostate cancer, 5-31</p><p>prostate-specific antigen (PSA) testing, 5-31</p><p>prostatitis, 6-5</p><p>prosthetic heart valves, 1-25</p><p>proteinuria, 4-19</p><p>prothrombin mutation, 5-11</p><p>pseudogout, 8-6</p><p>pseudo-hypoparathyroidism, 7-12</p><p>pseudo-Pelger-Huët cells, 5-14, 11-8</p><p>pseudotumor cerebri, 9-10</p><p>pulmonary alveolar proteinosis, 2-10</p><p>pulmonary artery catheter, 1-13, 11-5</p><p>pulmonary edema</p><p>CXR pattern in, P-2</p><p>treatment of, 1-16, 11-2</p><p>pulmonary embolism, 2-14, P-6</p><p>pulmonary fibrosis, idiopathic, 2-10, P-6</p><p>pulmonary function tests, 2-1</p><p>pulmonary hypertension, 2-16</p><p>pulmonary infiltrates with eosinophilia, 2-10</p><p>pulsus paradoxus, 1-27</p><p>pure red cell aplasia, 5-2</p><p>purified protein derivative (PPD) test, 6-16</p><p>purpura, 5-6</p><p>pyelonephritis, 6-5</p><p>pyoderma gangrenosum, 3-10, 8-8</p><p>Q</p><p>QT interval, 1-1</p><p>R</p><p>radiculopathies, 9-11</p><p>radioactive iodine uptake scan, 7-3</p><p>Raynaud’s phenomenon, 8-14</p><p>red eye, 10-4</p><p>Reed-Sternberg cells, 5-20</p><p>refeeding syndrome, 3-8</p><p>Reiter’s syndrome, 8-7</p><p>relapsing polychondritis, 8-4</p><p>renal abscess, 6-5</p><p>renal artery stenosis, 1-29</p><p>renal failure, 4-12</p><p>renal osteodystrophy, 7-12</p><p>renal replacement therapy, 4-15</p><p>renal tubular acidosis, 4-3</p><p>respiratory acidosis, 4-5</p><p>respiratory alkalosis, 4-5</p><p>respiratory bronchiolitis-associated interstitial lung disease, 2-10</p><p>respiratory failure, 2-18</p><p>reticulocyte index, 5-1</p><p>Reynolds’ pentad, 3-28</p><p>rhabdomyolysis, 4-13</p><p>rheumatoid factor, 8-3</p><p>Rhizopus infection, 6-3</p><p>Richter’s syndrome, 5-22</p><p>Rocky Mountain spotted tick fever (RMSF), 6-22</p><p>Roth spots, 6-14</p><p>S</p><p>salicylate intoxication, 4-2</p><p>Samter’s syndrome, 2-2</p><p>sarcoidosis, 2-9, P-6</p><p>cardiac manifestations of, 1-20</p><p>schistocytes, 5-5, 11-7, P-14</p><p>sciatica, 9-11</p><p>scleroderma, 8-11</p><p>seizures, 9-3</p><p>sepsis, 2-23</p><p>Sequential Organ Failure Assessment (SOFA), 2-23</p><p>seronegative spondyloarthritis, 8-7</p><p>serum-ascites albumin gradient, 3-26</p><p>sexually transmitted infections, 6-6</p><p>Sézary syndrome, 5-21</p><p>Sheehan’s syndrome, 7-1</p><p>shock, 1-14, 11-2</p><p>cardiogenic, 1-14</p><p>septic, 2-23</p><p>sicca syndrome, 8-14</p><p>sick euthyroid syndrome, 7-6</p><p>silicosis, 2-10</p><p>sinusoidal obstruction syndrome, 3-25, 5-25</p><p>Sjögren’s syndrome, 8-14</p><p>small intestinal bacterial overgrowth, 3-7</p><p>smudge cells, 5-22</p><p>soft tissue infections, 6-7</p><p>solitary pulmonary nodule, 2-7</p><p>spinal cord compression, 5-37, 9-11</p><p>spinal stenosis, 9-12</p><p>splenic vein thrombosis, 3-25</p><p>splenomegaly, 5-5</p><p>spontaneous bacterial peritonitis, 3-26</p><p>treatment of in cirrhosis, 3-22</p><p>spur cells, 11-7, P-14</p><p>ST depression, 1-2</p><p>ST elevation, 1-2</p><p>stable ischemic heart disease, 1-6</p><p>statistics, 11-9</p><p>status epilepticus, 9-4</p><p>stent thrombosis, 1-5</p><p>steroids, in critical care, 2-23</p><p>Still’s disease, adult onset, 6-23, 8-4</p><p>stool osmotic gap, 3-7</p><p>stress test, 1-4</p><p>stroke, 9-6</p><p>struma ovarii, 7-4</p><p>subarachnoid hemorrhage, 9-7</p><p>subdural hematoma, 9-7</p><p>superior vena cava syndrome, 5-27</p><p>syncope, 1-38</p><p>syndrome of inappropriate antidiuretic hormone (SIADH), 4-7</p><p>syphilis, 6-6</p><p>systemic lupus erythematosus (SLE), 8-15</p><p>systemic sclerosis, 8-11</p><p>T</p><p>tachycardia-bradycardia syndrome, 1-33</p><p>tachycardias, 1-33</p><p>atrial, 1-32</p><p>atrioventricular reciprocating, 1-33, 1-34</p><p>AV nodal reentrant tach, 1-33</p><p>multifocal atrial, 1-33</p><p>nonparoxysmal junctional, 1-33</p><p>sinus, 1-33</p><p>supraventricular, 1-33</p><p>ventricular, 1-35</p><p>wide-complex, 1-35</p><p>Takayasu’s arteritis, 8-17</p><p>target cells, 11-7</p><p>targeted temperature management, 9-2</p><p>teardrop cells, 5-16, P-14</p><p>temporal arteritis, 8-17</p><p>thalassemias, 5-2</p><p>thrombocytopenia, 5-7</p><p>thrombotic microangiopathies, 5-9</p><p>thrombotic thrombocytopenic purpura, 5-9</p><p>thrush, 6-19</p><p>thyroid cancer, 7-6</p><p>thyroid disorders, 7-3</p><p>thyroid function tests, 7-3</p><p>thyroid nodules, 7-6</p><p>thyroid storm, 7-5</p><p>thyroiditis, 7-5</p><p>Hashimoto’s, 7-4</p><p>TIMI risk score for UA/NSTEMI, 1-9</p><p>TNF receptor-associated periodic syndrome, 8-21</p><p>Todd’s paralysis, 9-3</p><p>torsades de pointes, 1-35</p><p>total body water, 11-7</p><p>toxic megacolon, 3-6, 3-10</p><p>toxic shock syndrome, 6-8</p><p>toxicology, 2-24</p><p>toxoplasmosis, 6-20</p><p>tracheostomy, 10-2</p><p>transfusion-related acute lung injury, 2-22, 5-13</p><p>transfusion therapy, 5-13</p><p>transient ischemic attack (TIA), 9-6</p><p>trans-tubular potassium gradient, 4-10, 11-7</p><p>tricuspid regurgitation, 1-25</p><p>troponin, 1-3, 1-6</p><p>Trousseau’s sign (hypocalcemia), 7-12</p><p>Trousseau’s syndrome (malignancy), 5-33</p><p>tuberculosis, 6-16</p><p>tularemia, 6-22</p><p>tumor lysis syndrome, 5-38</p><p>T wave inversion, 1-2</p><p>typhlitis, 5-37</p><p>typhoid fever, 6-24</p><p>U</p><p>ulcerative colitis, 3-10</p><p>unstable angina, 1-8</p><p>uremia, 4-14</p><p>uremic bleeding, 5-9</p><p>urethritis, 6-5</p><p>urinalysis, 4-19</p><p>urinary tract infection (UTI), 6-5</p><p>urine anion gap, 4-3</p><p>urine osmolality, 4-6</p><p>urine sediment, 4-19, P-15</p><p>uveitis, 8-7</p><p>V</p><p>vaginal bleeding, 10-3</p><p>vaginal discharge, 10-3</p><p>varices, 3-4, 3-22</p><p>vasculitis, 8-17</p><p>veno-occlusive disease, pulmonary, 2-16</p><p>venous thromboembolism, 2-13</p><p>ventricular aneurysm, 1-12</p><p>ventricular pseudoaneurysm, 1-12</p><p>ventricular septal defect, 1-11</p><p>Verner-Morrison syndrome, 3-7</p><p>vertigo, 9-5</p><p>vestibular caloric stimulation, 9-1</p><p>VEXAS syndrome, 8-21</p><p>Virchow’s node, 5-33</p><p>visual changes, 10-4</p><p>visual field defect, 10-4</p><p>vitamin B12 deficiency, 5-3</p><p>vitamin D deficiency, 7-12</p><p>vitamin K deficiency, 5-10</p><p>von Willebrand’s disease, 5-9</p><p>V/Q mismatch, 2-18</p><p>W</p><p>Waldenström’s macroglobulinemia, 5-24</p><p>warfarin loading nomogram, 11-8</p><p>warfarin overdose, 5-10</p><p>Wegener’s granulomatosis; see granulomatosis with polyangiitis</p><p>Wernicke’s encephalopathy, 9-5</p><p>Whipple’s disease, 3-7</p><p>Wilson disease, 3-24</p><p>Wolff-Chaikoff effect, 7-6</p><p>Wolff-Parkinson-White syndrome, 1-34</p><p>X</p><p>xanthelasma, 7-16</p><p>xanthomas, 7-16</p><p>Y</p><p>yellow-nail syndrome, 2-11</p><p>Z</p><p>Zenker’s diverticulum, 3-1</p><p>Zika, 6-24</p><p>Zollinger-Ellison syndrome, 3-2, 3-7</p><p>zygomycetes, 6-3</p><p>Radiology</p><p>1 Normal PA CXR. The convex right cardiac border is formed by the right atrium (straight arrows), and the curved arrows indicate the location of the superior vena cava. The left cardiac and great vessels border what might be considered as 4 skiing moguls. From cephalad to caudad, the moguls are the aortic arch, the main and left pulmonary arteries, the left atrial appendage, and the left ventricle. (Radiology 101, 3rd ed, 2009.)</p><p>2 Normal lateral CXR. (Radiology 101, 3rd ed, 2009.)</p><p>3 COPD: with hyperlucent, overinflated lungs and flat diaphragms. (Radiology 101, 3rd ed, 2009.)</p><p>4 Interstitial pulmonary edema: with Kerley A, B, and C lines and cephalization of the vascular markings. (Fund. Diag. Radiology, 3rd ed, 2006.)</p><p>5 Alveolar pulmonary edema. (Fund. Diag. Radiology, 3rd ed, 2006.)</p><p>6 Right upper lobe pneumonia. (Radiology 101, 3rd ed, 2009.)</p><p>7 Right middle lobe pneumonia. (Radiology 101, 3rd ed, 2009.)</p><p>8 Right lower lobe pneumonia (PA). (Radiology 101, 3rd ed, 2009.)</p><p>9 Right lower lobe pneumonia (lateral). (Radiology 101, 3rd ed, 2009.)</p><p>10 Bilateral pleural effusions (curved arrows) and enlarged azygous vein (straight arrow). (PA). (Radiology 101, 3rd ed, 2009.)</p><p>11 Bilateral pleural effusions (curved arrows) (lateral). (Radiology 101, 3rd ed, 2009.)</p><p>12 Pneumothorax. (Radiology 101, 3rd ed, 2009.)</p><p>13 Normal chest CT at level of pulmonary arteries (parenchymal windows). (Radiology 101, 3rd ed, 2009.)</p><p>14 Bilateral PE (mediastinal windows). (Radiology 101, 3rd ed, 2009.)</p><p>15 Sarcoidosis with perilymphatic nodules. (Fund. Diag. Radiology, 3rd ed, 2006.)</p><p>16 Idiopathic pulmonary fibrosis. (Fund. Diag. Radiology, 3rd ed, 2006.)</p><p>17 Normal abdomen CT at level of liver & spleen. (Radiology 101, 3rd ed, 2009.)</p><p>18 Normal abdomen CT at level of pancreas. (Radiology 101, 3rd ed, 2009.)</p><p>Echocardiography</p><p>1 Parasternal long-axis view allows visualization of the right ventricle (RV), ventricular septum (VS), posterior wall (PW) aortic valve cusps, left ventricle (LV), mitral valve, left atrium (LA), and ascending thoracic aorta (Ao). *Pulmonary artery. (Top: From Mayo Clinic Proceedings [Tajik AJ, Seward JB, Hagler DJ, et al. Two-dimensional real-time ultrasonic imaging of the heart and great vessels: Technique, image orientation, structure identification, and validation. Mayo Clinic Proceedings, 1978;53:271–303], with permission. Bottom: From Oh JK, Seward JB, Tajik AJ. The Echo Manual, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2006. By permission of Mayo Foundation for Medical Education and Research. All rights reserved.)</p><p>2 Parasternal short-axis view at the level of the aorta: LA, left atrium; PV, pulmonary valve; RA, right atrium; RVOT, right ventricular outflow tract. (Top: From Mayo Clinic Proceedings [Tajik AJ, Seward JB, Hagler DJ, et al. Two-dimensional real-time ultrasonic imaging of the heart and great vessels: Technique, image orientation, structure identification, and validation. Mayo Clinic Proceedings, 1978;53:271–303], with permission. Bottom: From Oh JK, Seward JB, Tajik AJ. The Echo Manual, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2006. By permission of Mayo Foundation for Medical Education and Research. All rights reserved.)</p><p>3 Parasternal short-axis view at the level of the papillary muscles: AL, anterolateral papillary muscle; LV, left ventricle; PM, posteromedial papillary muscle; RV, right ventricle; VS, ventricular septum. (Top: From Mayo Clinic Proceedings [Tajik AJ, Seward JB, Hagler DJ, et al. Two-dimensional real-time ultrasonic imaging of the heart and great vessels: Technique, image orientation, structure identification, and validation. Mayo Clinic Proceedings, 1978;53:271–303], with permission. Bottom: From Oh JK, Seward JB, Tajik AJ. The Echo Manual, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2006. By permission of Mayo Foundation for Medical Education and Research. All rights reserved.)</p><p>4 Apical four-chamber view: Note that at some institutions the image is re- versed so that the left side of the heart appears on the right side of the screen. LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. (Top: From Mayo Clinic Proceedings [Tajik AJ, Seward JB, Hagler DJ, et al. Two-dimensional real-time ultrasonic imaging of the heart and great vessels: Technique, image orientation, structure identification, and validation. Mayo Clinic Proceedings, 1978;53:271–303], with permission. Bottom: From Oh JK, Seward JB, Tajik AJ. The Echo Manual, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2006. By permission of Mayo Foundation for Medical Education and Research. All rights reserved.)</p><p>Coronary Angiography</p><p>Coronary arteries. (From Grossman WG. Cardiac Catheterization and Angiography, 4th ed. Philadelphia: Lea & Febiger, 1991, with permission.)</p><p>Peripheral Blood Smears</p><p>1 Normal smear.</p><p>2 Hypochromic, microcytic anemia due to iron-deficiency.</p><p>3 Macrocytic anemia due to pernicious anemia; note macro-ovalocytes and hypersegmented neutrophils.</p><p>4 Spherocytes due to autoimmune hemolytic anemia.</p><p>5 Sickle cell anemia.</p><p>6 Schistocytes.</p><p>7 Teardrop shaped RBC (dacrocyte).</p><p>8 Acanthocytes.</p><p>9 Nucleated RBC.</p><p>10 Rouleaux.</p><p>Leukemias</p><p>1 AML with Auer rod.</p><p>2 ALL.</p><p>3 CML.</p><p>4 CLL.</p><p>All photos excluding Leukemias Fig. 4: From Wintrobe’s Clin. Hematol. 12th ed, 2009: Leukemias. Fig. 4: From Devita, Hellman, and Rosenberg’s Cancer: Princip. & Prac. of Oncol. 8th ed, 2008.</p><p>Urinalysis</p><p>1 “Muddy brown” or granular cast (courtesy Nicholas Zwang, MD)</p><p>2 Hyaline cast (courtesy Nicholas Zwang, MD)</p><p>3 “Waxy broad” cast (courtesy Nicholas Zwang, MD)</p><p>4 Renal tubular epithelial cell (courtesy Nicholas Zwang, MD)</p><p>5 RBC cast (courtesy Harish Seethapathy, MBBS)</p><p>6 WBC cast (courtesy Harish Seethapathy, MBBS)</p><p>7 Calcium oxalate crystals (courtesy Mallika Mendu, MD). Calcium dihydrate (arrow), calcium monohydrate (dashed arrow), and amorphous calcium crystals (arrow-head)</p><p>8 “Struvite” magnesium ammonia phosphate crystals (courtesy Brett Carroll, MD)</p><p>9 Cystine crystals (Clin. Lab. Medicine, 1994.)</p><p>10 Sulfadiazine “shock of wheat” crystals (courtesy Nicholas Zwang, MD)</p><p>11a Uric acid crystals under polarized light (courtesy Harish Seethapathy, MBBS)</p><p>11b Uric acid crystals under normal light (courtesy Harish Seethapathy, MBBS)</p><p>12 Acyclovir needle crystals (courtesy Yuvaram Reddy, MBBS)</p><p>NOTES</p><p>ACLS ALGORITHMS</p><p>Figure ACLS-1 ACLS Tachycardia Algorithm</p><p>(Adapted from ACLS 2020 Guidelines, Circ 2020;142(Suppl 2):S366)</p><p>Figure ACLS-2 ACLS Bradycardia Algorithm</p><p>(Adapted from ACLS 2020 Guidelines, Circ 2020;142(Suppl 2):S366)</p><p>Figure ACLS-3 VF/Pulseless VT, Asystole, & PEA Algorithms</p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li>No backlinks found</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://htlin222.github.io/garden/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div id=contact_buttons><footer><p>Made by htlin222 using <a href=https://github.com/jackyzha0/quartz>Quartz</a>, © 2023</p><ul><li><a href=https://htlin222.github.io/garden/>Home</a></li><li><a href=https://twitter.com/_jzhao>Twitter</a></li><li><a href=https://github.com/jackyzha0>GitHub</a></li></ul></footer></div></div></body></html>